WO2004074270A2 - Inhibitors of hepatitis c virus rna-dependent rna polymerase, and compositions and treatments using the same - Google Patents

Inhibitors of hepatitis c virus rna-dependent rna polymerase, and compositions and treatments using the same Download PDF

Info

Publication number
WO2004074270A2
WO2004074270A2 PCT/IB2004/000493 IB2004000493W WO2004074270A2 WO 2004074270 A2 WO2004074270 A2 WO 2004074270A2 IB 2004000493 W IB2004000493 W IB 2004000493W WO 2004074270 A2 WO2004074270 A2 WO 2004074270A2
Authority
WO
WIPO (PCT)
Prior art keywords
ethyl
cyclopentyl
pyran
hydroxy
dihydro
Prior art date
Application number
PCT/IB2004/000493
Other languages
French (fr)
Other versions
WO2004074270A3 (en
WO2004074270B1 (en
Inventor
Allen John Borchardt
Javier Gonzalez
Hui Li
Maria Angelica Linton
John Howard Tatlock
Original Assignee
Pfizer Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Inc. filed Critical Pfizer Inc.
Priority to EP04709301A priority Critical patent/EP1597246A2/en
Priority to JP2006502472A priority patent/JP3940430B2/en
Priority to BR0407699-0A priority patent/BRPI0407699A/en
Priority to CA002516235A priority patent/CA2516235A1/en
Priority to MXPA05007133A priority patent/MXPA05007133A/en
Priority to AU2004213247A priority patent/AU2004213247A1/en
Publication of WO2004074270A2 publication Critical patent/WO2004074270A2/en
Publication of WO2004074270A3 publication Critical patent/WO2004074270A3/en
Publication of WO2004074270B1 publication Critical patent/WO2004074270B1/en
Priority to IS7896A priority patent/IS7896A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/06—1,2,3-Thiadiazoles; Hydrogenated 1,2,3-thiadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
    • C07D263/58—Benzoxazoles; Hydrogenated benzoxazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/32—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/28—Oxygen atom
    • C07D473/30—Oxygen atom attached in position 6, e.g. hypoxanthine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/36—Sulfur atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Definitions

  • the invention relates to agents that inhibit hepatitis C virus (HCV) RNA-dependent RNA polymerase (RdRp).
  • HCV hepatitis C virus
  • RdRp RNA-dependent RNA polymerase
  • HCV is an enveloped RNA virus containing a single-stranded positive-sense RNA genome approximately 9.5 kb in length (Choo et al., Science 244:359-362 (1989)).
  • the RNA genome contains a 5'-nontranslated region (5' NTR) of 341 nucleotides (Brown et al., Nucl. Acids Res. 20:5041-5045 (1992); Bukh et al., Proc. Natl. Acad. Sci. USA 89:4942-4946 (1992)), a large open reading frame (ORF) encoding a single polypeptide of 3,010 to 3,040 amino acids (Choo et al.
  • the 5' NTR is one of the most conserved regions of the viral genome and plays a pivotal role in the initiation of translation of the viral polyprotein (Bartenschlager (1997), supra).
  • a single ORF encodes a polyprotein that is co- or post-translationally processed into structural (core, E1, and E2) and nonstructural (NS2, NS3, NS4A, NS4B, NS5A, and NS5B) viral proteins by either cellular or viral proteinases (Bartenschlager (1997), supra).
  • the 3' NTR consists of three distinct regions: a variable region of about 38 nucleotides following the stop codon of the polyprotein, a polyuridine tract of variable length with interspersed substitutions of cystines, and 98 nucleotides (nt) at the very 3' end which are highly conserved among various HCV isolates.
  • Hepatitis C virus is a member of the hepacivirus genus in the family Flaviviridae. It is the major causative agent of non-A, non-B viral hepatitis and is the major cause of transfusion- associated hepatitis and accounts for a significant proportion of hepatitis cases worldwide. Although acute HCV infection is often asymptomatic, nearly 80% of cases resolve to chronic hepatitis.
  • HCV polyprotein is first cleaved by a host signal peptidase generating the structural proteins C/E1, E1/E2, E2/p7, and p7/NS2 (Hijikata et al., Proc. Natl. Acad. Sci. USA 88:5547-5551 (1991); Lin et al., J. Virol. 68:5063-5073 (1994)).
  • NS2-3 proteinase which is a metalloprotease, then cleaves at the NS2/NS3 junction.
  • the NS3/4A proteinase complex (NS3 serine protease/NS4A cofactor), then at all the remaining cleavage sites (Bartenschlager et al., J. Virol. 67:3835-3844 (1993); Bartenschlager (1997), supra).
  • RNA helicase and NTPase activities have also been identified in the NS3 protein.
  • NS5A may be phosphorylated and act as a putative cofactor of NS5B.
  • the fourth viral enzyme, NS5B is an RNA-dependent RNA polymerase (RdRp) and a key component responsible for replication of the viral RNA genome (Lohmann et al., J. Virol. 71:8416- 8428 (1997)).
  • RNA-dependent RNA polymerase activity RdRp
  • NS5B While the role of NS3 in RNA replication is less clear, NS5B apparently is the key enzyme responsible for synthesis of progeny RNA strands.
  • baculoviruses to express NS5B in insect cells and a synthetic nonviral RNA as a substrate, two enzymatic activities have been identified as being associated with NS5B. The two activities include a primer-dependent RdRp and a terminal transferase (TNTase) activity.
  • TNTase terminal transferase
  • the present invention relates to compounds of the formula 1
  • R 2 is selected from the group of R 1 substituents, -(CR 8 R 9 ) t (C 6 -C 10 aryl), -(CR 8 R 9 ) t (4-10 membered heterocyclic), -(CR 8 R 9 ) q C(O)(CR 8 R 9 ) t (C 6 -C 10 aryl), -(CR 8 R 9 ) q C(O)(CR 8 R 9 ) t (4-10 membered heterocyclic), -(CR 8 R 9 ) t O(CR 8 R 9 ) q (C 6 -C 10 aryl), -(CR 8 R 9 ) t O(CR 8 R 9 ) q (4-10 membered heterocyclic), -(CR 8 R 9 ) q SO n (CR 8 R 9 )t(C 6 -C 10 aryl), and -(CR 8 R 9 ) q SO n (CR 8 R 9 ) t (4-10 membered heterocyclic), wherein
  • R 3' is selected from the group of R 3 substituents except R 3' is not H; each R 4 is independently selected from halo, cyano, nitro, trifluoromethoxy, trifluoromethyl, azido, C r C ⁇ 0 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, -C(0)R 6 , -C(0)OR 6 , -OC(0)R 6 , -NR 6 C(0)R 7 , -NR 6 C(0)NR 7 , -C(0)NR 6 R 7 , -NR 6 R 7 , -NR 6 OR 7 , -S0 2 NR 6 R 7 , -NR 6 S0 2 R 7 , -(CR 8 R 9 ) t (C 6 -C 10 aryl)(wherein t is an integer from 0 to 5), -(CR 8 R 9 ) t (4-10 membered heterocyclic)(wherein t is an integer from 0 to 5),
  • each R 8 and R 9 is independently selected from H and C C alkyl; and each R 10 is independently selected from halo, cyano, trifluoromethyl, trifluoromethoxy, -C(0)0-R 6 , -OR 6 , -C(0)(CR 8 R 9 ) p C(0)OR 6 , wherein p is an integer from
  • R 2 is selected from the group of R 1 substituents, -(CR 8 R 9 ) (C 3 -C 10 cycloalkyl), - (CR 8 R 9 ) t (C 6 -C 10 aryl), -(CR 8 R 9 ) t (4-10 membered heterocyclic), -(CR 8 R 9 ) q C(O)(CR 8 R 9 ) t (C 6 -C 10 aryl), -(CR 8 R 9 ) q C(O)(CR 8 R 9 ) t (4-10 membered heterocyclic), -(CR 8 R 9 ),O(CR 8 R 9 ) q (C 6 -C 10 aryl), -(CR 8 R 9 ) t O(CR 8 R 9 ) q (4-10 membered heterocyclic), -(CR 8 R 9 ) q SO n (CR 8 R 9 ) t (C 6 -C 10 aryl), and
  • R 3 is hydrogen, -OR 6 , -SR 8 , -NR 6 R 7 , and the group of R 2 substituents;
  • R 3' is selected from the group of R 3 substituents; each R 4 is independently selected from halo, cyano, nitro, trifluoromethoxy, trifluoromethyl, azido, C C ⁇ 0 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 3 -C 10 cycloalkyl, - (CR 8 R 9 ),N(R 5 ) 2 , -(CR 8 R 9 ) t NR 6 C(0)R 6 , -(CR 8 R 9 ) t OR 6 , -(CR 8 R 9 ) t C(0)R 6 , -(CR 8 R 9 ) t C(0)OR 6 , - (CR 8 R 9 ) t C(0)R 6 , -(CR 8 R 9 ), NR 6 C(0)R 7 , -(CR 8 R 9 ) t NR 6 C(0)OR 6 -(CR 8 R 9 ) t NR 6 C(0)NR 7
  • R 1 is cyclopentyl
  • R 2 is -(CR 8 R 9 ) t (C 6 -C 10 aryl) or -(CR 8 R 9 ) t (4-10 membered heterocyclic), wherein t is an integer from 0 to 5, and the aryl and heterocyclic moieties of said R 2 groups are optionally substituted by 1 to 5 R 4 groups, and with the proviso that R 2 is not H;
  • R 3 is hydrogen, -OR 6 , -SR 6 , -NR 6 R 7 , and the group of R 2 substituents; each R 4 is independently selected from halo, cyano, nitro, trifluoromethoxy, trifluoromethyl, azido, C r C 10 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, -C(0)R 6 , -C(0)OR 6 , -OC(0)R 8 , -NR 6 C(0)R 7 , -NR 6 C(0)NR 7 , -C(0)NR
  • the present invention further relates to a compound of the formula (3)
  • R 1 is cyclopentyl;
  • R 2 is -(CR 8 R 9 ) t (C 6 -C 10 aryl) or -(CR 8 R 9 ),(4-10 membered heterocyclic), wherein t is an integer from 0 to 5, and the aryl and heterocyclic moieties of said R 2 groups are optionally substituted by 1 to 5 R 4 groups, and with the proviso that R 2 is not H;
  • R 3 is hydrogen;
  • each R 4 is independently selected from halo, cyano, nitro, trifluoromethoxy, trifluoromethyl, azido, C r C 10 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, -C(0)R 6 , -C(0)OR 6 , -OC(0)R 6 ,
  • R 2 is - (CR 8 R 9 ) t (C 6 -C 10 aryl), wherein t is an integer from 2 to 5, and the aryl moiety of said R 2 group is optionally substituted by 1 to 5 R 4 groups, and with the proviso that R 2 is not H; optionally each R 4 is independently selected from halo, nitro, C C 10 alkyl, -C(0)R 6 , -C(0)OR 6 , -OC(0)R 6 ,
  • R 1 is cyclopentyl
  • R 3 is -(CR 8 R 9 ) t (C 6 -C 10 aryl) or -(CR 8 R 9 ) t (4-10 membered heterocyclic), wherein t is an integer from 0 to 5, and the aryl and heterocyclic moieties of said R 3 groups are optionally substituted by 1 to 5 R 4 groups; each R 4 is independently chosen from halo, C r C 10 alkyl, and R 6 -0-, and each C r C 10 alkyl may be optionally substituted by at least one substituent chosen from halo, trifluoromethyl, trifluoromethoxy, C C ⁇ 0 alkyl, and cyano; or when two adjacent R 4 groups are both C C ⁇ o alkyl, they, together with the atoms to which they are attached, form a 3- to 7-membered ring, wherein in said ring any carbon atom may be replaced by a heteroatom chosen from N, 0, and S, provided that two adjacent carbons are not both replaced by heteroatoms
  • R 8 and R 9 are independently chosen from hydrogen and C C 10 alkyl; z is an integer from 1 to 5; and y is an integer from 0 to 5.
  • R 1 is cyclopentyl
  • R 3 is -(CR 8 R 9 )t(4-10 membered heterocyclic), wherein t is an integer from 0 to 5, and the heterocyclic moiety is optionally substituted by 1 to 5 R 4 groups; each R 4 is independently chosen from halo, C C ⁇ 0 alkyl, and R 6 -0-, and each C C 10 alkyl may be optionally substituted by at least one substituent chosen from halo, trifluoromethyl, trifluoromethoxy, C C 10 alkyl, and cyano; or when two adjacent R 4 groups are both C C 10 alkyl, they, together with the atoms to which they are attached, form a 3- to 7-membered ring, wherein in said ring any carbon atom may be replaced by a heteroatom chosen from N, O, and S, provided that two adjacent carbons are not both replaced by heteroatoms;
  • R 6 is hydrogen or C C 10 alkyl
  • R 8 and R 9 are hydrogen
  • z is an integer from 1 to 5
  • y is an integer from 0 to 5.
  • R 1 is cyclopentyl;
  • R 3 is -(CH 2 ) t ([1 ,2,4]triazolo[1 ,5-a]pyrimidyl), optionally substituted by 1 to 3 R 4 groups;
  • t is an integer from 1-3;
  • each R 4 is independently chosen from halo, C C ⁇ alkyl, and R 6 -0-, and each CrC 10 alkyl may be optionally substituted by at least one substituent chosen from halo, trifluoromethyl, trifluoromethoxy, C C 10 alkyl, and cyano; or when two adjacent R 4 groups are both C C ⁇ o alkyl, they, together with the atoms to which they are attached, form a 3- to 7-membered ring, wherein in said ring any carbon atom may be replaced by a heteroatom chosen from N, O, and S, provided that two adjacent carbons are not both replaced by heteroatoms;
  • R 6 is hydrogen or C C 10 alkyl;
  • R is cyclopentyl
  • R 3 is -(CH 2 )([1,2,4]triazolo[1,5-a]pyrimidyl), substituted by 1 to 3 R 4 groups; each R 4 is independently chosen from halo and C ⁇ -C 10 alkyl optionally substituted with cyano; or two adjacent R 4 groups are both C C ⁇ 0 alkyl and, together with the atoms to which they are attached, form a 3- to 7-membered ring, wherein a carbon atom is replaced by a heteroatom chosen from N, O, and S; z is an integer from 2 to 3; and y is 2.
  • R 1 is cyclopentyl
  • R 3 is -(CH 2 )([1,2,4]triazolo[1,5-a]pyrimidyl), substituted by 2 R 4 groups; each R 4 is independently chosen from halo, -CH 3 , and -C(CH 3 ) 2 CN; and y is 2.
  • R 3 is -(CH 2 )([1,2,4]triazolo[1,5-a]pyrimidyl), substituted by at least one substituent chosen from halo and methyl; two adjacent R 4 groups, together with the atoms to which they are attached form a 5- membered ring, wherein in said ring one carbon atom is replaced by O; z is an integer from 2 to 3; and y is 2.
  • R 3 is -(CH 2 )([1 ,2,4]triazolo[1 ,5-a]pyrimidyl), substituted by at least one substituent chosen from halo and methyl;
  • Q is chosen from N, O, and S;
  • R 4a , R 4 , and R 4c are independently chosen from hydrogen, halo, C C 10 alkyl, and R 6 -0-;
  • R 6 is chosen from hydrogen and C C 10 alkyl.
  • Another aspect of the present invention provides compounds of formula (5),
  • R 4a , R 4b , and R c are independently chosen from halo and C C 10 alkyl;
  • R 4d , R e , and R 4f are independently chosen from halo, R 6 -0-, and C C ⁇ o alkyl, wherein said C 1 -C 10 alkyl is optionally substituted with at least one substituent chosen from halo and cyano; and
  • R 6 is C C 10 alkyl or hydrogen.
  • Another aspect of the present invention provides compounds of formula (6),
  • R is halo
  • Another aspect of the present invention provides compounds of formula (8),
  • R 4 is halo
  • Still a further aspect of the present invention provides compounds of formulas (6), (7), and (8), wherein R 4 is chosen from fluorine and chlorine. In yet another aspect of the present invention are provided compounds of formulas (6), (7), and (8), wherein R 4 is fluorine. In still a further aspect are provided those compounds of formula (6), (7), and (8), wherein R 4 is chlorine.
  • Another aspect of the present invention provides compounds of formula (4), wherein:
  • R 1 is cyclopentyl
  • R 3 is -(CH 2 )([1,2,4]triazolo[1,5-a]pyrimidyl), optionally substituted by 1 to 3 R 4 groups; each R 4 is independently chosen from halo, C ⁇ -C 10 alkyl, and R 6 -0-, and each C 1 -C 10 alkyl may be optionally substituted by at least one substituent chosen from halo, trifluoromethyl, trifluoromethoxy, C r C 10 alkyl, and cyano;
  • R 6 is hydrogen or C C 10 alkyl; z is an integer from 1 to 3; and y is 2.
  • R >1 ; is, cyclopentyl
  • R 3 is -(CH 2 )([1 ,2,4]triazolo[1,5-a]pyrimidyI), optionally substituted by 1 to 3 R 4 groups; each R 4 is independently chosen from halo, C ⁇ -C 10 alkyl, and R 6 -0-, and each C r C 10 alkyl may be optionally substituted by at least one substituent chosen from halo, trifluoromethyl, trifluoromethoxy, C C 10 alkyl, and cyano; R 6 is hydrogen or methyl; z is an integer from 2-3; and y is 2.
  • R 4a is halo or C C 10 alkyl
  • R 4 , R c , and R 4d are independently chosen from C C 10 alkyl and R 6 -0-;
  • R 6 is hydrogen or methyl.
  • R 4a is halo
  • R b and R c are each R 6 -0-;
  • R 4d is C C ⁇ o alkyl
  • R 6 is hydrogen or methyl.
  • R ,a is fluorine or chlorine
  • R" D is -OCH 3 ;
  • R ,c is -OH; and a d
  • R w is -CH 2 CH 3 .
  • R 4a is chlorine
  • R 40 is -OH
  • R 4d is -CH 2 CH 3 .
  • Another aspect of the present invention provides compounds of formula (10),
  • Still a further aspect of the present invention provides compounds of formula (11),
  • the invention relates to a compound selected from the group consisting of:
  • the present invention also provides compounds chosen from:
  • compounds chosen from: (+)-2-(2-fluoro-4- ⁇ 2-[2-cyclopentyl-5-(5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-ylmethyl)-4- hydroxy-6-oxo-3,6-dihydro-2H-pyran-2-yl]-ethyl ⁇ -phenyl)-2-methyl-propionitrile;
  • the invention also relates to a method for the treatment of Hepatitis C virus (HCV) in a mammal, such as a human, comprising administering to said mammal an amount of a compound of the present invention or a salt or solvate thereof that is effective in treating HCV.
  • HCV Hepatitis C virus
  • a mammal such as a human, suffering from infection with Hepatitis C virus
  • methods for the treatment of a mammal comprising administering to said mammal a Hepatitis C virus-inhibiting amount of a compound of the present invention, or a pharmaceutically acceptable salt, prodrug, pharmaceutically active metabolite, or solvate thereof.
  • the present invention also relates to a method of inhibiting Hepatitis C polymerase, comprising contacting said polymerase with a polymerase-inhibiting amount of a compound of the present invention, or a pharmaceutically acceptable salt, prodrug, pharmaceutically active metabolite, or solvate thereof.
  • the present invention is also directed to a pharmaceutical composition for the treatment of Hepatitis C virus (HCV) in a mammal, such as a human, comprising an amount of a compound the present invention, or a pharmaceutically acceptable salt, prodrug, pharmaceutically active metabolite, or solvate thereof, that is effective in treating HCV, and a pharmaceutically acceptable carrier.
  • HCV Hepatitis C virus
  • the present invention is also directed to inhibition of Hepatitis C virus replication in a mammal, such as a human, comprising administering to said mammal a Hepatitis C virus replication-inhibiting amount of a compound of the present invention.
  • the present invention is further directed to a method of inhibiting HCV RdRp activity, comprising contacting the protein with an effective amount of a compound of the present invention, or a pharmaceutically acceptable salt, prodrug, pharmaceutically active metabolite, or solvate thereof.
  • HCV activity may be inhibited in mammalian tissue by administering an HCV-inhibiting agent according to the invention.
  • the present invention also relates to the use of the compounds of the invention in the preparation of a medicament for the treatment of a mammal suffering from infection with Hepatitis C virus.
  • the medicament may comprise a Hepatitis C virus-inhibiting amount of a compound or compounds of the invention and a pharmaceutically acceptable carrier or carriers.
  • a pharmaceutically acceptable carrier or carriers As used herein, the terms “comprising” and “including” are used in their open, non- limiting sense.
  • the compounds of the present invention may exist in several tautomeric forms.
  • a compound of the invention may exist in a form in which two ketones are present on a ring of the compound, as shown in (A) below.
  • the compounds of the present invention may exist in at least two different enol forms, as shown in compounds (B) and (C) below. These three forms may be in equilibrium and the compounds of the invention may exist in more than one of these forms at the same time.
  • a certain percentage of the molecules may be present in form (A) while the remainder are present in form (B) or form (C).
  • C C 6 alkyl includes saturated monovalent hydrocarbon radicals having straight, branched, or cyclic moieties (including fused and bridged bicyclic and spirocyclic moieties), or a combination of the foregoing moieties, and containing from 1-6 carbon atoms.
  • the group For an alkyl group to have cyclic moieties, the group must have at least three carbon atoms.
  • a "lower alkyl” is intended to mean an alkyl group having from 1 to 4 carbon atoms in its chain.
  • heteroalkyl refers to a straight- or branched-chain alkyl group having from 2 to
  • heteroalkyls include alkyl ethers, secondary and tertiary amines, alkyl sulfides and the like.
  • C 2 -C 6 alkenyl includes alkyl moieties having at least one carbon-carbon double bond wherein alkyl is as defined above and including E and Z isomers of said alkenyl moiety, and having from 2 to 6 carbon atoms.
  • C 2 -C 6 alkynyl includes alkyl moieties having at least one carbon-carbon triple bond wherein alkyl is as defined above, and containing from 2-6 carbon atoms.
  • carbocycle refers to a saturated, partially saturated, unsaturated, or aromatic, monocyclic or fused or non-fused polycyclic, ring structure having only carbon ring atoms (no heteroatoms, i.e., non-carbon ring atoms).
  • exemplary carbocycles include cycloalkyl, aryl, and cycloalkyl-aryl groups.
  • C 3 -C 10 cycloalkyl group is intended to mean a saturated or partially saturated, monocyclic, or fused or spiro polycyclic, ring structure having a total of from 3 to 10 carbon ring atoms (but no heteroatoms).
  • exemplary cycloalkyls include cyclopropyl, cyclobutyl, cyclopentyl, cyclopentenyl, cyclohexyl, cycloheptyl, adamantyl, and like groups.
  • heterocycloalkyl group is intended to mean a monocyclic, or fused or spiro polycyclic, ring structure that is saturated or partially saturated, and has a total of from 3 to 18 ring atoms, including 1 to 5 heteroatoms selected from nitrogen, oxygen, and sulfur.
  • heterocycloalkyl groups include pyrrolidinyl, tetrahydrofuryl, piperidinyl, piperazinyl, morpholinyl, thiomorpholinyl, aziridinyl, and like groups.
  • C 6 -C 10 aryl as used herein, unless otherwise indicated, includes an organic radical derived from an aromatic hydrocarbon by removal of one hydrogen, such as phenyl or naphthyl.
  • Non-aromatic heterocyclic groups include groups having only 4 atoms in their ring system, but aromatic heterocyclic groups must have at least 5 atoms in their ring system.
  • the heterocyclic groups include benzo-fused ring systems.
  • An example of a 4 membered heterocyclic group is azetidinyl (derived from azetidine).
  • An example of a 5 membered heterocyclic group is thiazolyl and an example of a 10 membered heterocyclic group is quinolinyl.
  • non- aromatic heterocyclic groups are pyrrolidinyl, tetrahydrofuranyl, dihydrofuranyl, tetrahydrothiehyl, tetrahydropyranyl, dihydropyranyl, tetrahydrothiopyranyl, piperidino, morpholino, thiomorpholino, thioxanyl, piperazinyl, azetidinyl, oxetanyl, thietanyl, homopiperidinyl, oxepanyl, thiepanyl, oxazepinyl, diazepinyl, thiazepinyl, 1 ,2,3,6-tetrahydropyridinyl, 2-pyrrolinyl, 3-pyrrolinyl, indolinyl, 2H-pyranyl, 4H-pyranyl, dioxanyl, 1,3-dioxolanyl, pyrazolinyl, di
  • aromatic heterocyclic groups are pyridinyl, imidazolyl, pyrimidinyl, pyrazolyl, triazolyl, pyrazinyl, tetrazolyl, furyl, thienyl, isoxazolyl, thiazolyl, oxazolyl, isothiazolyl, pyrrolyl, quinolinyl, isoquinolinyl, indolyl, benzimidazolyl, benzofuranyl, cinnolinyl, indazolyl, indolizinyl, phthalazinyl, pyridazinyl, triazinyl, isoindolyl, pteridinyl, purinyl, oxadiazolyl, thiadiazolyl, furazanyl, benzofurazanyl, benzothiophenyl, benzothiazolyl, benzoxazolyl, quinazolinyl, quinox
  • a group derived from pyrrole may be pyrrol-1-yl (N-attached) or pyrrol-3-yl (C-attached).
  • a group derived from imidazole may be imidazol-1-yl (N-attached) or imidazol-3-yl (C-attached).
  • heteroaryl group is intended to mean a monocyclic or fused or spiro polycyclic, aromatic ring structure having from 4 to 18 ring atoms, including from 1 to 5 heteroatoms selected from nitrogen, oxygen, and sulfur.
  • heteroaryl groups include pyrrolyl, thienyl, oxazolyl, pyrazolyl, thiazolyl, furyl, pyridinyl, pyrazinyl, triazolyl, tetrazolyl, indolyl, quinolinyl, quinoxalinyl, benzthiazolyl, benzodioxinyl, benzodioxolyl, benzooxazolyl, and the like.
  • alkoxy as used herein, unless otherwise indicated, includes O-alkyl groups wherein alkyl is as defined above.
  • amino is intended to mean the -NH 2 radical.
  • halogen and halo, as used herein represent chlorine, fluorine, bromine or iodine.
  • trifluoromethyl is meant to represent a group -CF 3 .
  • trifluoromethoxy is meant to represent a group -OCF 3 .
  • cyano as used herein, is meant to represent a group -CN.
  • substituted means that the specified group or moiety bears one or more substituents.
  • unsubstituted means that the specified group bears no substituents.
  • optionally substituted means that the specified group is unsubstituted or substituted by one or more substituents.
  • HCV refers to Hepatitis C virus.
  • the term "inhibiting Hepatitis C virus” means inhibiting Hepatitis C virus replication in a mammal, such as a human, by administering to the mammal a Hepatitis C virus-inhibiting amount of a compound of the invention.
  • the amount of inhibition of Hepatitis C virus replication in a mammal can be measured using methods known to those of ordinary skill in the art. For example, an amount of a compound of the invention may be administered to a mammal, either alone or as part of a pharmaceutically acceptable formulation. Blood samples may then be withdrawn from the mammal and the amount of Hepatitis C virus in the sample may be quantified using methods known to those of ordinary skill in the art.
  • a reduction in the amount of Hepatitis C virus in the sample compared to the amount found in the blood before administration of a compound of the invention would represent inhibition of the replication of Hepatitis C virus in the mammal.
  • the administration of a compound of the invention to the mammal may be in the form of single dose or a series of doses over successive days.
  • HCV-inhibiting agent means a compound of the present invention or a pharmaceutically acceptable salt, hydrate, prodrug, active metabolite or solvate thereof.
  • HCV-inhibiting amount refers to an amount of a compound of the present invention that is sufficient to inhibit the replication of the Hepatitis C virus when administered to a mammal, such as a human.
  • HCV polymerase-inhibiting amount means an amount of a compound of the present invention that is sufficient to inhibit the function of the Hepatitis C virus polymerase enzyme when the compound is placed in contact with the enzyme.
  • a “prodrug” is a compound that may be converted under physiological conditions or by solvolysis to the specified compound or to a pharmaceutically acceptable salt of such compound.
  • a prodrug containing such a moiety may be prepared according to conventional procedures by treatment of a hydroxamate derivative of this invention containing, for example, an amido, carboxylic acid, or hydroxyl moiety with a suitable reagent.
  • an "active metabolite” is a pharmacologically active product produced through metabolism in the body of a specified hydroxamate derivative or salt thereof.
  • Prodrugs and active metabolites of the hydroxamate derivative may be identified using routine techniques known in the art. See, e.g., Bertolini et al., J. Med. Chem., 40:2011-2016 (1997); Shan et al., J. Pharm. Sci., 86 (7):765-767 (1997); Bagshawe, Drug Dev.
  • a “solvate” is intended to mean a pharmaceutically acceptable solvate form of a specified compound that retains the biological effectiveness of such compound.
  • solvates include compounds of the invention in combination with solvents such as, but not limited to, water, isopropanol, ethanol, methanol, DMSO, ethyl acetate, acetic acid, or ethanolamine.
  • solvents such as, but not limited to, water, isopropanol, ethanol, methanol, DMSO, ethyl acetate, acetic acid, or ethanolamine.
  • a “pharmaceutically acceptable salt” is intended to mean a salt that retains the biological effectiveness of the free acids and bases of the specified derivative and that is not biologically or otherwise undesirable.
  • Examples of pharmaceutically acceptable salts include sulfates, pyrosulfates, bisulfates, sulfites, bisulfites, phosphates, monohydrogenphosphates, dihydrogenphosphates, metaphosphates, pyrophosphates, chlorides, bromides, iodides, acetates, propionates, decanoates, caprylates, acrylates, formates, isobutyrates, caproates, heptanoates, propiolates, oxalates, malonates, succinates, suberates, sebacates, fumarates, maleates, butyne-1 ,4-dioates, hexyne-1,6-dioates, benzoates, chlorobenzoates, methylbenzoates, dinitrobenzoates, hydroxybenzoates, methoxybenzoates, phthalates, sulfonates, xylenesulfonates, phenylacetates, phen
  • treating means reversing, alleviating, inhibiting the progress of, or preventing the disorder or condition to which such term applies, or one or more symptoms of such disorder or condition.
  • treatment refers to the act of treating as “treating” is defined immediately above.
  • phrases "pharmaceutically acceptable salt(s)", as used herein, unless otherwise indicated, includes salts of acidic or basic groups, which may be present in the compounds of the present invention.
  • the compounds of the present invention that are basic in nature are capable of forming a wide variety of salts with various inorganic and organic acids.
  • acids that may be used to prepare pharmaceutically acceptable acid addition salts of such basic compounds of the present invention are those that form non-toxic acid addition salts, e , salts containing pharmacologically acceptable anions, such as the acetate, benzenesulfonate, benzoate, bicarbonate, bisulfate, bitartrate, borate, bromide, calcium edetate, camsylate, carbonate, chloride, clavulanate, citrate, dihydrochloride, edetate, edislyate, estolate, esylate, ethylsuccinate, fumarate, gluceptate, gluconate, glutamate, glycollylarsanilate, hexylresorcinate, hydrabamine, hydrobromide, hydrochloride, iodide, isothionate, lactate, lactobionate, laurate, malate, maleate, mandelate, mesylate, methylsulfate
  • terapéuticaally effective amount is intended to mean the amount of an inventive agent that, when administered to a mammal in need of treatment, is sufficient to effect treatment for injury or disease conditions alleviated by the inhibition of HCV RNA replication such as for potentiation of anti-cancer therapies or inhibition of neurotoxicity consequent to stroke, head trauma, and neurodegenerative diseases.
  • the amount of a given HCV-inhibiting agent used in the method of the invention that will be therapeutically effective will vary depending upon factors such as the particular HCV- inhibiting agent, the disease condition and the severity thereof, the identity and characteristics of the mammal in need thereof, which amount may be routinely determined by artisans.
  • the compounds of the present invention may have asymmetric carbon atoms.
  • the carbon-carbon bonds of the compounds of the present invention may be depicted herein using a solid line ( ), a solid wedge ( """ ⁇ — m ), or a dotted wedge ( '"" ).
  • the use of a solid line to depict bonds to asymmetric carbon atoms is meant to indicate that all possible stereoisomers at that carbon atom are included.
  • the use of either a solid or dotted wedge to depict bonds to asymmetric carbon atoms is meant to indicate that only the stereoisomer shown is meant to be included. It is possible that compounds of the invention may contain more than one asymmetric carbon atom.
  • a solid line to depict bonds to asymmetric carbon atoms is meant to indicate that all possible stereoisomers are meant to be included.
  • the use of a solid line to depict bonds to one or more asymmetric carbon atoms in a compound of the invention and the use of a solid or dotted wedge to depict bonds to other asymmetric carbon atoms in the same compound is meant to indicate that a mixture of diastereomers is present.
  • Solutions of individual stereoisomeric compounds of the present invention may rotate plane-polarized light.
  • the use of either a "(+)" or “(-)” symbol in the name of a compound of the invention indicates that a solution of a particular stereoisomer rotates plane-polarized light in the (+) or (-) direction, as measured using techniques known to those of ordinary skill in the art.
  • Diastereomeric mixtures can be separated into their individual diastereomers on the basis of their physical chemical differences by methods known to those skilled in the art, for example, by chromatography or fractional crystallization.
  • Enantiomers can be separated by converting the enantiomeric mixtures into a diastereomeric mixture by reaction with an appropriate optically active compound (e.g., alcohol), separating the diastereomers and converting (e.g., hydrolyzing) the individual diastereomers to the corresponding pure enantiomers. All such isomers, including diastereomeric mixtures and pure enantiomers are considered as part of the invention. Alternatively, individual stereoisomeric compounds of the present invention may be prepared in enantiomerically enriched form by asymmetric synthesis.
  • an appropriate optically active compound e.g., alcohol
  • converting e.g., hydrolyzing
  • Asymmetric synthesis may be performed using techniques known to those of skill in the art, such as the use of asymmetric starting materials that are commercially available or readily prepared using methods known to those of ordinary skill in the art, the use of asymmetric auxiliaries that may be removed at the completion of the synthesis, or the resolution of intermediate compounds using enzymatic methods.
  • the choice of such a method will depend on factors that include, but are not limited to, the availability of starting materials, the relative efficiency of a method, and whether such methods are useful for the compounds of the invention containing particular functional groups. Such choices are within the knowledge of one of ordinary skill in the art.
  • the derivative salts, prodrugs and solvates may exist as single stereoisomers, racemates, and/or mixtures of enantiomers and/or diastereomers. All such single stereoisomers, racemates, and mixtures thereof are intended to be within the scope of the present invention.
  • an optically pure compound is one that is enantiomerically pure.
  • the term "optically pure” is intended to mean a compound comprising at least a sufficient activity.
  • an optically pure amount of a single enantiomer to yield a compound having the desired pharmacological pure compound of the invention comprises at least 90% of a single isomer (80% enantiomeric excess), more preferably at least 95% (90% e.e.), even more preferably at least 97.5% (95% e.e.), and most preferably at least 99% (98% e.e.).
  • a desired salt may be prepared by any suitable method known to the art, including treatment of the free base with an inorganic acid, such as hydrochloric acid; hydrobromic acid; sulfuric acid; nitric acid; phosphoric
  • ⁇ acid and the like, or with an organic acid, such as acetic acid; maleic acid; succinic acid; mandelic acid; fumaric acid; malonic acid; pyruvic acid; oxalic acid; glycolic acid; salicylic acid; pyranosidyl acid, such as glucuronic acid or galacturonic acid; alpha-hydroxy acid, such as citric acid or tartaric acid; amino acid, such as aspartic acid or glutamic acid; aromatic acid, such as benzoic acid or cinnamic acid; sulfonic acid, such as p-toluenesulfonic acid or ethanesulfonic acid; and the like.
  • organic acid such as acetic acid; maleic acid; succinic acid; mandelic acid; fumaric acid; malonic acid; pyruvic acid; oxalic acid; glycolic acid; salicylic acid; pyranosidyl acid, such as glucuronic acid or galacturonic
  • a desired salt may be prepared by any suitable method known to the art, including treatment of the free acid with an inorganic or organic base, such as an amine (primary, secondary, or tertiary); an alkali metal or alkaline earth metal hydroxide; or the like.
  • suitable salts include organic salts derived from amino acids such as glycine and arginine; ammonia; primary, secondary, and tertiary amines; and cyclic amines, such as piperidine, morpholine, and piperazine; as well as inorganic salts derived from sodium, calcium, potassium, magnesium, manganese, iron, copper, zinc, aluminum, and lithium.
  • derivatives, prodrugs, salts, or solvates that are solids
  • the derivatives, prodrugs, salts, and solvates used in the method of the invention may exist in different polymorph or crystal forms, all of which are intended to be within the scope of the present invention and specified formulas.
  • the derivative, salts, prodrugs and solvates used in the method of the invention may exist as tautomers, all of which are intended to be within the broad scope of the present invention.
  • the compounds of the present invention that are basic in nature are capable of forming a wide variety of different salts with various inorganic and organic acids. Although such salts must be pharmaceutically acceptable for administration to animals, it is often desirable in practice to initially isolate the compound of the present invention from the reaction mixture as a pharmaceutically unacceptable salt and then simply convert the latter back to the free base compound by treatment with an alkaline reagent and subsequently convert the latter free base to a pharmaceutically acceptable acid addition salt.
  • the acid addition salts of the base compounds of this invention are readily prepared by treating the base compound with a substantially equivalent amount of the chosen mineral or organic acid in an aqueous solvent medium or in a suitable organic solvent, such as methanol or ethanol. Upon careful evaporation of the solvent, the desired solid salt is readily obtained.
  • the desired acid salt can also be precipitated from a solution of the free base in an organic solvent by adding to the solution an appropriate mineral or organic acid.
  • Those compounds of the present invention that are acidic in nature are capable of forming base salts with various pharmacologically acceptable cations.
  • such salts include the alkali metal or alkaline-earth metal salts and particularly, the sodium and potassium salts. These salts are all prepared by conventional techniques.
  • the chemical bases which are used as reagents to prepare the pharmaceutically acceptable base salts of this invention are those which form nontoxic base salts with the acidic compounds of the present invention.
  • Such non-toxic base salts include those derived from such pharmacologically acceptable cations as sodium, potassium calcium and magnesium, etc.
  • salts can easily be prepared by treating the corresponding acidic compounds with an aqueous solution containing the desired pharmacologically acceptable cations, and then evaporating the resulting solution to dryness, preferably under reduced pressure.
  • they may also be prepared by mixing lower alkanolic solutions of the acidic compounds and the desired alkali metal alkoxide together, and then evaporating the resulting solution to dryness in the same manner as before.
  • stoichiometric quantities of reagents are preferably employed in order to ensure completeness of reaction and maximum yields of the desired final product.
  • the activity of the compounds as inhibitors of HCV activity may be measured by any of the suitable methods available in the art, including in vivo and in vitro assays.
  • An Example of a suitable assay for activity measurements is the HCV replicon assay described herein.
  • Administration of the compounds and their pharmaceutically acceptable prodrugs, salts, active metabolites, and solvates may be performed according to any of the accepted modes of administration available to those skilled in the art.
  • suitable modes of administration include oral, nasal, parenteral, topical, transdermal, and rectal. Oral and intravenous deliveries are preferred.
  • An HCV-inhibiting agent of the present invention may be administered as a pharmaceutical composition in any suitable pharmaceutical form.
  • suitable pharmaceutical forms include solid, semisolid, liquid, or lyopholized formulations, such as tablets, powders, capsules, suppositories, suspensions, liposomes, and aerosols.
  • the HCV-inhibiting agent may be prepared as a solution using any of a variety of methodologies.
  • the HCV-inhibiting agent can be dissolved with acid (e.g., 1 M HCl) and diluted with a sufficient volume of a solution of 5% dextrose in water (D5W) to yield the desired final concentration of HCV-inhibiting agent (e.g., about 15 mM).
  • a solution of D5W containing about 15 mM HCl can be used to provide a solution of the HCV-inhibiting agent at the appropriate concentration.
  • the HCV- inhibiting agent can be prepared as a suspension using, for example, a 1% solution of carboxymethylcellulose (CMC).
  • compositions are known or may be routinely determined by those skilled in the art.
  • pharmaceutical preparations may be prepared following conventional techniques of the pharmaceutical chemist involving steps such as mixing, granulating, and compressing when necessary for tablet forms, or mixing, filling, and dissolving the ingredients as appropriate, to give the desired products for oral, parenteral, topical, intravaginal, intranasal, intrabronchial, intraocular, intraaural, and/or rectal administration.
  • compositions of the invention may also include suitable excipients, diluents, vehicles, and carriers, as well as other pharmaceutically active agents, depending upon the intended use.
  • Solid or liquid pharmaceutically acceptable carriers, diluents, vehicles, or excipients may be employed in the pharmaceutical compositions.
  • Illustrative solid carriers include starch, lactose, calcium sulfate dihydrate, terra alba, sucrose, talc, gelatin, pectin, acacia, magnesium stearate, and stearic acid.
  • Illustrative liquid carriers include syrup, peanut oil, olive oil, saline solution, and water.
  • the carrier or diluent may include a suitable prolonged-release material, such as glyceryl monostearate or glyceryl distearate, alone or with a wax.
  • a suitable prolonged-release material such as glyceryl monostearate or glyceryl distearate, alone or with a wax.
  • the preparation may be in the form of a syrup, elixir, emulsion, soft gelatin capsule, sterile injectable liquid (e.g., solution), or a nonaqueous or aqueous liquid suspension.
  • a dose of the pharmaceutical composition may contain at least a therapeutically effective amount of an HCV-inhibiting agent and preferably is made up of one or more pharmaceutical dosage units.
  • the selected dose may be administered to a mammal, for example, a human, in need of treatment mediated by inhibition of HCV activity, by any known or suitable method of administering the dose, including topically, for example, as an ointment or cream; orally; rectally, for example, as a suppository; parenterally by injection; intravenously; or continuously by intravaginal, intranasal, intrabronchial, intraaural, or intraocular infusion.
  • the composition When the composition is administered in conjunction with a cytotoxic drug, the composition can be administered before, with, and/or after introduction of the cytotoxic drug. However, when the composition is administered in conjunction with radiotherapy, the composition is preferably introduced before radiotherapy is commenced.
  • a dose that may be employed is from about 0.001 to about 1000 mg/kg body weight, preferably from about 0.1 to about 100 mg/kg body weight, and even more preferably from about 1 to about 50 mg/kg body weight, with courses of treatment repeated at appropriate intervals.
  • the subject invention also includes isotopically-labelled compounds, which are identical to those recited in the compounds of the present invention, but for the fact that one or more atoms are replaced by an atom having an atomic mass or mass number different from the atomic mass or mass number usually found in nature.
  • isotopes that can be incorporated into compounds of the invention include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorous, fluorine and chlorine, such as 2 H, 3 H, 13 C, 14 C, 15 N, 1 ⁇ O, 17 0, 31 P, 32 P, 35 S, 18 F, and 36 Ci, respectively.
  • Compounds of the present invention, prodrugs thereof, and pharmaceutically acceptable salts of said compounds or of said prodrugs which contain the aforementioned isotopes and/or other isotopes of other atoms are within the scope of this invention.
  • isotopically-labelled compounds of the present invention for example those into which radioactive isotopes such as 3 H and 1 C are incorporated, are useful in drug and/or substrate tissue distribution assays. Tritiated, i.e., 3 H, and carbon-14, i.e., 14 C, isotopes are particularly preferred for their ease of preparation and detectability. Further, substitution with heavier isotopes such as deuterium, i.e., 2 H, can afford certain therapeutic advantages resulting from greater metabolic stability, for example increased in vivo half-life or reduced dosage requirements and, hence, may be preferred in some circumstances.
  • Isotopically labelled compounds of the present invention and prodrugs thereof can generally be prepared by carrying out the procedures disclosed in the Schemes and/or in the Examples and Preparations below, by substituting a readily available isotopically labelled reagent for a non-isotopically labelled reagent.
  • Et2 ⁇ diethyl ether
  • DMF N,N- dimethylformamide
  • DMSO dimethylsulfoxide
  • MeOH methanol
  • EtOH ethanol
  • EtOAc ethyl acetate
  • Ac acetyl
  • Hex hexane
  • Me Me
  • Et (ethyl); Ph phenyl
  • DIEA diisopropylethylamine
  • TFA trifluoroacetic acid
  • DTT dithiothreitol
  • THF tetrahydrofuran
  • Solid-phase syntheses were performed by immobilizing reagents with Rink amide linkers (Rink, Tetrahedron Letters (1987) 28:3787), which are standard acid-cleavable linkers that upon cleavage generate a free carboxamide group.
  • Rink amide linkers Rink, Tetrahedron Letters (1987) 28:3787
  • Small-scale solid-phase syntheses e.g., about 2 - 5 ⁇ mole, were performed using Chiron SynPhase® polystyrene O-series crowns (pins) derivatized with Fmoc-protected Rink amide linkers.
  • the Rink amide linkages were formed to Argonaut Technologies Argogel® resin, a grafted polystyrene-poly(ethylene glycol) copolymer.
  • Any suitable resin may be used as the solid phase, selected from resins that are physically resilient and that, other than with regard to the linking and cleavage reactions, are inert to the synthetic reaction conditions.
  • Example A(2) 6-[2-(3-tert-Butyl-4-hydroxy-phenyl)-ethyl]-6-cyclopentyl-dihydro-pyran-2,4- dione.
  • Example A(82) The title compound was prepared analogously to Example A(82), where 4-Bromo-1- ethoxy-2-methyl-benzene was substituted in place of 2-Bromopyridine in Step 1 of that example.
  • Example A(4) 6-Cyclopentyl-6-[2-(4-isopropoxy-3-methyl-phenyl)-ethyl]-dihydro-pyran-2,4- dione.
  • Example A(6) 6-Cyclopentyl-6-(4-methoxy-phenylsulfanylmethyl)-dihydro-pyran-2,4-dione.
  • Step 1 2-Chloro-1-cyclopentyl-et anone.
  • Step 2 1-Cyclopentyl-2-(4-methoxy-phenylsulfanyl)-ethanone.
  • Example A(7) N- ⁇ 4-[2-(2-Cyclopentyl-4,6-dioxo-tetrahydro-pyran-2-yl)-ethyl]-2-fluoro- phenyl ⁇ -acetamide.
  • Example A(64) The title compound was prepared analogously to Example A(64), where ⁇ /-(4-Bromo-2- fluoro-phenyi)-acetamide was substituted in place of 4-bromo-2-fluoro-1-isopropylbenzene of that example.
  • Step 1 2-(4-Bromo-2-fluoro-phenyl)-benzo[b]thiophene
  • Methyl acetoacetate (0.66g, 5.7mmol) was added to a cooled 0 °C suspension of NaH (0.23 g, 5.7 mmol, 60% dispersion in mineral oil) in THF (10ml). After 30 min n-BuLi (2.3mL,
  • Step 1 3-Cyclohex-1-enyl-propionic acid ethyl ester.
  • Step 3 3-Cyclohex-1-enyl-thiopropionic acid S-pyridin-2-yl ester.
  • Step 4 3-Cyclohex-1-enyl-1-cyclopentyl-propan-1-one. ⁇ TB-4059-095 ⁇
  • Example A(14) 6-Cyclopentyl-6-[2-(2-oxo-pyrrolidin-1-yl)-ethyl]-dihydro-pyran-2,4-dione.
  • Step 2 1-(3-Cyclopentyl-3-oxo-propyl)-pyrrolidin-2-one.
  • the solid was suspended in pyridine (20mL) and treated with acetic anhydride (4.24mL, 45mmol). The mixture was refluxed for 2 h and then stirred at rt for 15h. The reaction mixture was partitioned between 2N HCl and EtOAc. The organic layer was washed with 1 N HCl, saturated NaHC0 3 , brine, dried over Na 2 S0 4 and concentrated. The residue was purifed by silica gel chromatography (5% hexanes in EtOAc), to give the title compound as a white solid, (1.1g, 29% yield).
  • Example A(64) The title compound was prepared analogously to Example A(64), where 4-Bromo- ⁇ /- ethyl-2-fluoro-benzamide (described below), was substituted in place of 4-bromo-2-fluoro-1- isopropylbenzene of that example.
  • Stepl 4-Bromo-W-ethyl-2-fluoro-benzamide.
  • Example A(64) The title compound was prepared analogously to Example A(64), where 4-(4-Bromo- phenyl)-3,5-dimethyl-isoxazole (described below) was substituted in place of 4-bromo-2-fluoro-1- isopropylbenzene of that example.
  • Step 1 4-(4-Bromo-phenyl)-3,5-dimethyl-isoxazole
  • Step 1 [3(1 "R),4R]-3-[2'-(5"-Methoxy-1 "-indanyl)acetyl]-4-(phenylmethyl)-2-oxazolidinone (A) and [3(1 "S),4R]-3-[2'-(5"-Methoxy-1 "-indanyl)acetyl]-4-(phenylmethy l)-2-oxazolidinone (B):
  • Step 3 (5-Methoxy-indan-1-yl)-thioacetic acid S-pyridin-2-yl ester.
  • Methoxy-indan-1-yl)-acetic acid (from Step 2 below) was substituted in place of 3-Cyclohex-1- enyl-propionic acid.
  • Step 4 1-Cyclopentyl-2-(5-methoxy-indan-1-yl)-ethanone.
  • Example A(22) 6-Cyclopentyl-6-[2-(3-ethyl-4-hydroxy-phenyl)-ethyl]-dihydro-pyran-2,4- dione.
  • Step 3 Acetic acid 4-[2-(2-cyclopentyl-4,6-dioxo-tetrahydro-pyran-2-yl)-ethyl]-2-ethyl- phenyl ester.
  • Step 1 N-Methoxy ⁇ 3-(4 ⁇ methoxy-phenyl)-N-methyl-propionamide.
  • N.O-dimethylhydroxylamine hydrochloride (5.41g, 55.5mmol), EDC (12.77g, 66.6mmol), followed by triethylamine (17mL, 122mmol) were added to a cooled 0°C solution of 3-(4- methoxyphenyl)propionic acid (10g, 55.5mmol).
  • the reaction mixture was stirred for 15h under N 2 and then concentrated.
  • the residue was partitioned between 1 N HCl and EtOAc.
  • the organic layers were washed with saturated NaHC0 3 , brine, dried over Na 2 S0 4 and concentrated to an oil.
  • the oil was purified by silica gel chromatography (40% EtOAc in hexanes) to give a clear oil (10.6g, 85%).
  • Step 2 1-(4-Methoxy-phenyl)-pentan-3-one.
  • Step 1 3-(4-Methoxy-phenyl)-thiopropionic acid S-pyridin-2-yl ester.
  • Step 2 1-(4-Methoxy-phenyl)-5-methyl-hexan-3-one.
  • Example A(23) The title compound was prepared analogously to Example A(23), where allyl magnesium chloride was substituted in place of ethylmagnesium bromide in Step 2 of that Example.
  • Step 1 4-Bromo-2-chloro-thiobenzoic acid S-pyridin-2-yl ester.
  • Step 2 1-(4-Bromo-2-chloro-phenyl)-ethanone.
  • Step 3 3-(4-Acetyl-3-chloro-phenyl)-1-cyclopentyl-propan-1-one.
  • Example A(27) The title compound was prepared analogously to Example A(27), where 3-Bromo acetophenone was substituted in place of 1-(4-Bromo-2-chloro-phenyl)-ethanone in Step 3 of that example.
  • Step 1 5-(3-Bromo-phenyl)-5-methyl-dihydro-furan-2-one
  • Example A(27) The title compound was prepared analogously to Example A(27), where (4-Bromo- phenyl)-cyclopropyl-methanone was substituted in place of 1-(4-Bromo-2-chloro-phenyl)- ethanone in Step 3 of that example.
  • Example A(27) The title compound was prepared analogously to Example A(27), where (4-Bromo- phenyl)-cyclopropyI-methanone was substituted in place of 1-(4-Bromo-2-chloro-phenyl)- ethanone in Step 3 of that example.
  • the title compound was obtained side product previously described Example A(31).
  • This compound was prepared as described in the following reference: Tetrahedron 2001 , 57, 5027-5038.
  • This compound was prepared as described in the following reference: Tetrahedron 2001 , 57, 5027-5038.
  • Step 1 (R) W-[1-(4-Bromo-phenyl)-ethyl]-malonamic acid ethyl ester.
  • Step 1 (R) 1-[1-(4-Bromo-phenyl)-ethyl]-3-methyl-urea
  • Step 1 (R) W-[1-(4-Bromo-phenyl)-ethyl]-methanesulfonamide.
  • Step 1 (R)-5-Methyl-isoxazole-3-carboxylic acid [1-(4-bromo-phenyl)-ethyl]-amide.
  • Step 1 4'-Bromo-biphenyl-3-carbonitrile.
  • Step 1 2-(4-Bromo-phenyl)-W-methyl-isobutyramide.
  • Step 1 2-(4-Bromo-phenyl)-W-ethyl-isobutyramide
  • Step 1 2-(4-Bromo-2-fluoro-phenoxy)-2-rnethyl-propionic acid methyl ester.
  • Step 1 2-[2-Chloro-4-(3-cyclopentyl-3-oxo-propyl)-phenoxy]-2-methyl-propionic acid methyl ester.
  • Example A(53) The title compound was prepared analogously to Example A(53), where [2-Chloro-4-(3- cyclopentyl-3-oxo-propyl)-phenoxy]-acetic acid methyl ester (described in Step 1 below) was substituted in place of 2-[2-Chloro-4-(3-cyclopentyl-3-oxo-propyl)-phenoxy]-2-methyl-propionic acid methyl ester) of that example.
  • Step 1 [2-Chloro-4-(3-cyclopentyl-3-oxo-propyl)-phenoxy]-acetic acid methyl ester.
  • Example A(27) The title compound was prepared analogously to Example A(27), where 2-(4-Bromo-2- fluoro-phenoxy)-2-methyl-propionic acid methyl ester (described in Step 1 of Example A(52), was substituted in place of 1-(4-Bromo-2-chloro-phenyl)-ethanone in Step 3 of that example.
  • Step 1 3-[1 -(4-Bromo-phenyl)-1 -methyl-ethyl]-5-methyl-[1 ,2,4]oxadiazole
  • Example A(58) 6-Cyclopentyl-6-[2-(4-difluoromethoxy-phenyl)-ethyl]-dihydro-pyran-2,4- dione.
  • Step l 3-(4-Propoxy-phenyl)-propionic acid.
  • Step 1 2-(4-bromo-2-fluorophenyl)propan-2-ol
  • Step 2 4-bromo-2-fluoro-1 -isopropylbenzene
  • Step 3 6-[2-cyclopentyl-4-(3-fluoro-4-isopropylphenyl)-2-hydroxybut-3-ynyl]-2,2-dimethyl- 4H-1 ,3 ⁇ dioxin-4-one.
  • Step 1 4-bromo-2-ethyl-1 -f luorobenzene
  • Example A(66) 6-Cyclopentyl-6-[2-(3-ethyl-phenyl)-ethyl]-dihydro-pyran-2,4-dione.
  • Example A(86) The title compound was prepared analogously to Example A(86), where 3-Bromo- ethylbenzene was substituted in place of 1-(4-Bromo-phenyl)-cyclopropanecarboxylic acid methyl ester in Step 3 of that example.
  • Example A(86) The title compound was prepared analogously to Example A(86), where (3-Bromo- phenyl)-acetic acid methyl ester was substituted in place of 1-(4-Bromo-phenyl)- cyclopropanecarboxylic acid methyl ester in Step 3 of that example.
  • Step 1 1-(3-Bromo-phenyl)-cyclopropanecarboxylic acid methyl ester.
  • HATU 169.6 mg, 0.4464 mmol
  • 6- ⁇ 2-[3-(2-Amino-1,1- dimethyl-ethyl)-phenyl]-ethyl ⁇ -6-cyclopentyl-dihydro-pyran-2,4-dione trifluoroacetic acid salt (175 mg, 0.372 mmol), Et 3 N (207 ⁇ L, 1.488 mmol), 1H-Pyrazole-3-carboxylic acid (50.0 mg, 0.4464 mmol), dissolved in DMF (2 mL). The reaction was stirred overnight, then purified directly by
  • Step 1 [2-(3-Bromo-phenyl)-2-methyl-propyl]-carbamic acid tert-butyl ester
  • Step 2 (2- ⁇ 3-[2-(2-Cyclopentyl-4,6-dioxo-tetrahydro-pyran-2-yl)-ethyl]-phenyl ⁇ -2-methyl- propyl)-carbamic acid tert-butyl ester
  • Step 3 6- ⁇ 2-[3-(2-Amino-1,1-dimethyl-ethyl)-phenyl]-ethyl ⁇ -6-cyclopentyl-dihydro-pyran- 2,4-dione trifluoroacetic acid salt
  • the desired product was prepared analogously to Step 5 of Example A(86), substituting 2- ⁇ 4-[3-Cyclopentyl-4-(2,2-dimethyl-6-oxo-6H-t1,3]dioxin-4-yl)-3-hydroxy-butyl]-2-fluoro-phenyl ⁇ -2- methyl-propionitrile (1.23 g, 2.9 mmol) from Step 3 below in place of 1- ⁇ 4-[3-Cyclopentyl-4-(2,2- dimethyl-6-oxo-6H-[1,3]dioxin-4-yl)-3-hydroxy-butyl]-2-fluoro-phenyl ⁇ -cyclopropanecarbonitrile. Yield: 0.614 g, 56 %.
  • Step 2 2- ⁇ 4-[3-Cyclopenty!-4-(2,2-dimethyl-6-oxo-6H-[1 ,3]dioxin-4-yl)-3-hydroxy-but-1- ynyl]-2-fluoro-phenyl ⁇ -2-methyl-propionitrile
  • Step 3 2- ⁇ 4-[3-Cyclopentyl-4-(2,2-dimethyl-6-oxo-6H-[1 ,3]dioxin-4-yl)-3-hydroxy-butyl]-2- fluoro-phenyl ⁇ -2-methyl-propionitrile
  • the desired product was prepared analogously to example A(86), Step 6, substituting 2- ⁇ 4-[3-Cyclopentyl-4-(2,2-dimethyi-6-oxo-6H-[1,3]dioxin-4-yl)-3-hydroxy-but-1-ynyl]-2-fluoro- phenyl ⁇ -2-methyl-propionitrile (1.25 g, 2.9 mmol) from Step 2 above in place of 1- ⁇ 4-[3- Cyclopentyl-4-(2,2-dimethyl-6-oxo-6H-[1,3]dioxin-4-yl)-3-hydroxy-but-1-ynyl]-2-fluoro-phenyl ⁇ - cyclopropanecarbonitrile. Yield: 1.23 g, 99%.
  • the aqueous layer was extracted with 2 x 100 mL CH 2 CI 2 and the organic layers were combined. After drying the organic with MgS0 4l and filtering to remove the solids, the solvent was removed by rotary evaporation. The remaining oil was purified by flash chromatography to yield the desired product (0.367 g, 47%).
  • Step 4 6-(2-Cyclopentyl-2-hydroxy-4-trimethylsilanyl-but-3-ynyl)-2,2-dimethyl-[1,3]dioxin- 4-one
  • Step 5 1- ⁇ 4-[3-Cyclopentyl-4-(2,2-dimethyl-e-oxo-6H-[1,3]dioxin-4-yl)-3 hydroxy-but-1- ynyl]-2-fluoro-phenyl ⁇ -cyclopropanecarbonitrile
  • the desired product was prepared analogously to example F(7), Step 5, substituting 1-(4- bromo-2-fluoro-phenyl)-cyclopropanecarbonitrile (0.96 g, 4.0 mmol), from Step 2 above in place of 3-iodophenol, and 6-(2-cyclopentyl-2-hydroxy-but-3-ynyl)-2,2-dimethyl-[1,3]dioxin-4-one (1.06 g, 4.0 mmol; from Step 4 above) in place of 6-but-3-ynyl-3-chloro-6-cyclopentyl-dihydro-pyran-
  • Step 6 1- ⁇ 4-[3-Cyclopentyl-4-(2,2-dimethyl-6-oxo-6H-[1,3]dioxin-4-yl)-3-hydroxy-butyl]-2- fluoro-phenyl ⁇ -cyclopropanecarbonitrile
  • Methane sulfonyl chloride (1.93ml, 0.025M) was added to a solution of 4-bromo-2-ethylaniline (5.0g, 0.025M) and pyridine (2.02ml, 0.025M) ⁇ dichloromethane (100ml) at 0°C.
  • the reaction mixture was stirred for lhr, after which time it was partitioned between dichloromethane (100ml) and IN hydrochloric acid (100ml). The organics were separated and dried over magnesium sulfate, filtered and concentrated in vacuuo to afford the title compound as a clear oil (4.77g).
  • Step 2 ⁇ /-(4-bromo-2-ethylphenyl)- ⁇ /-methylmethanesulfonamide
  • Methyl iodide (1.6g, 0.0256M) was added to a mixture ofN-(4-bromo-2- ethylphenyl)methanesulfonamide (4.77g, 0.0171M) and potassium carbonate (3.5g, 0.0256M) in dimethylformamide (50ml) at room temperature under an atmosphere of nitrogen.
  • the reaction mixture was stirred for a further 24hrs after which time it was partitioned between diethylether (100ml) and water (100ml). The aqueous was extracted further with diethyl ether (2x100ml). The combined organics were dried over magnesium sulfate, filtered and the solvent concentrated in vacuuo to afford the title compound as a brown oil (3.6g).
  • Step 2 /-(4-bromophenyl)-N-methylmethanesulfonamide
  • Methyl iodide (2.38g, 0.0382yi) was added to a mixture of ⁇ /-(4- bromophenyl)methanesulfonamide 6.37g, 0.0255M) and potassium carbonate (5.21 g, 0.0382M in dimethylformamide (50ml) at room temperature under an atmosphere of nitrogen.
  • the reaction mixture was stirred for a further 24(jrs after which time it was partitioned between diethylether (100ml) and water (100ml). The aqueous was extracted further with diethyl e her (2x100ml). The combined organics were dried over magnesium sulfate, filtered and the solvent" concentrated in vacuuo to afford the title compound as a white solid (5.6g).
  • Example A(22) The title compound was prepared analogously to Example A(22): where 4-bromo-2- cyclopentylphenol, from step 1 , was used in place of 4-Bromo-2-ethyl-phenol in step 2 of that example.
  • Step 2 2- ⁇ 4-[3-Cyclopentyl-4-(2,2-dimethyl-6-oxo-6H-[1,3]dioxin-4-yl)-3-hydroxy-but-1- ynyl]-2-fluoro-phenyl ⁇ -2-ethyl-butyronitrile
  • the desired product was prepared analogously to Example A(86) step 5, substituting 2- (4-Bromo-2-fluoro-phenyl)-2-ethyl-butyronitrile (1.01 g, 4.0 mmol) from step 1 above in place of 1- (4-bromo-2-fluoro-phenyl)-cyclopropanecarbonitrile. Yield: 0.953 g, 53 %.
  • the desired product was prepared analogously to example A(86) step 6, substituting 1- ⁇ 4-[3-Cyclopentyl-4-(2,2-dimethyl-6-oxo-6H-[1,3]dioxin-4-yl)-3-hydroxy-but-1-ynyl]-2-fluoro- phenyl ⁇ -2-ethyl-butyronitrile (0.900 g, 2.0 mmol) from step 2 above in place of 1- ⁇ 4-[3- Cyclopentyl-4-(2,2-dimethyl-6-oxo-6H-[1,3]dioxin-4-yl)-3-hydroxy-but-1-ynyl]-2-fluoro-phenyl ⁇ - cyclopropanecarbonitrile. Yield: 0.841 g, 92%.
  • the desired product was prepared analogously to Example A(86) step 5 substituting 1- ⁇ 4- [3-Cyclopentyl-4-(2,2-dimethyl-6-oxo-6H-[1,3]dioxin-4-yl)-3-hydroxy-butyl]-2-fluoro-phenyl ⁇ - cyclobutanecarbonitrile (1.00 g, 2.2 mmol) from step 3 below in place of 1- ⁇ 4-[3-Cyclopentyl-4- (2,2-dimethyl-6-oxo-6H-[1,3]dioxin-4-yl)-3-hydroxy-butyl]-2-fluoro-phenyl ⁇ - cyclopropanecarbonitrile. Yield: 0.477 g, 57 %.
  • the desired product was prepared analogously to Example A(86) step 5, substituting 1- (4-Bromo-2-fluoro-phenyl)-cyclobutanecarbonitriie (1.06 g, 4.0 mmol) from step 1 above in place of 1-(4-bromo-2-fluoro-phenyl)-cyclopropanecarbonitrile. Yield: 1.226 g, 70 %.
  • Step 3 1- ⁇ 4-[3-Cyclopentyl-4-(2,2-dimethyl-6-oxo-6H-[1 ,3]dioxin-4-yl)-3-hydroxy-butyl]-2- fluoro-phenylj-cyclobutanecarbonitrile
  • the desired product was prepared analogously to Example A(86) step 6, substituting 1- ⁇ 4-[3-Cyclopentyl-4-(2,2-di ⁇ f ⁇ ethyl-6-oxo-6H-[1,3]dioxin-4-yl)-3-hydroxy-but-1-ynyl]-2-fluoro- phenyl ⁇ -cyclobutanecarborjjtrile (1.200 g, 2.7 mmol) from' step 2 above in place of 1- ⁇ 4-[3- Cyclopentyl-4-(2,2-dimethyJ-6-oxo-6H-[1,3]dioxin-4-yl)-3-hydroxy-but-1-ynyl]-2-fluoro-phenyl ⁇ - cyclopropanecarbonitrile. Yield: 1.00 g, 84%.
  • Example A(94) The title compotl ⁇ d was prepared analogously to Example A(22)where Acetic acid 4-[2- (2-cyclopentyl-4,6-diox ⁇ tetrahydro-pyran-2-yl)-ethyl]-2-isopropyl-phenyl ester (Example A(94) ) was substituted in place Jj ⁇ f acetic acid 4-[2-(2-cyclopentyl-4,6-dioxo-tetrahydro-pyran-2-yl)-ethyl]- 2-ethyl-phenyl ester.
  • Step 4 Preparation of compound 2- ⁇ 4-[2-(2-cyclopentyl-4,6-dioxotetrahydro-2W-pyran-2- yl)ethyl]-2-fluorophenyl ⁇ -2-methylpropanenitrile.
  • the crude mixture was dissolved in anhydrous MeOH (100 mL) and treated with K 2 C0 3 (2.8 g, 10 mmol). The reaction was heated at 45 °C for 40 min before it was cooled down to room temperature. The crude mixture was diluted with aqueous NH CI and extracted with EtOAc (3 x 100 mL). The combined organic layers were washed with brine, dried over Na 2 S0 4 . The solvent was removed and the mixture was purified by flash column chromatography (EtOAc in hexanes, 10-40 % gradient) to give the desired product (1.4 g, 35% for two steps).
  • Step 3 Preparation of compound 2- ⁇ 4-[3-cyclopentyl-4-(2,2-dimethyl-4-oxo-4H-1,3-dioxin-6- yl)-3-hydroxybut-1-ynyl]-2-fluorophenyl ⁇ -2-methylpropanenitrile
  • Step 1 4-chloro-/V 1 -methylbenzene-1,2-diamine

Abstract

The invention relates to compounds of the formula (I) and to pharmaceutically acceptable salts, solvates, prodrugs and metabolites thereof, wherein W, Z, R1 and R2, are as defined herein. The invention also relates to methods of treating Hepatitis C virus in mammals by administering the compounds of formula (I), and to pharmaceutical compositions for treating such disorders, which contain the compounds of formula (I). The invention also relates to methods of preparing the compounds of formula (I).

Description

INHIBITORS OF HEPATITIS C VIRUS RNA-DEPENDENT RNA POLYMERASE. AND COMPOSITIONS AND TREATMENTS USING THE SAME Background of the Invention The invention relates to agents that inhibit hepatitis C virus (HCV) RNA-dependent RNA polymerase (RdRp). The invention also relates to the use of such compounds in pharmaceutical compositions and therapeutic treatments useful for inhibition of HCV replication.
HCV is an enveloped RNA virus containing a single-stranded positive-sense RNA genome approximately 9.5 kb in length (Choo et al., Science 244:359-362 (1989)). The RNA genome contains a 5'-nontranslated region (5' NTR) of 341 nucleotides (Brown et al., Nucl. Acids Res. 20:5041-5045 (1992); Bukh et al., Proc. Natl. Acad. Sci. USA 89:4942-4946 (1992)), a large open reading frame (ORF) encoding a single polypeptide of 3,010 to 3,040 amino acids (Choo et al. (1989), supra;), and a 3'-nontranslated region (3'-NTR) of variable length of about 230 nucleotides (Kolykhalov et al., J. Virol. 70:3363-3371 (1996); Tanaka et al., J. Virol. 70:3307-3312 (1996)). The 5' NTR is one of the most conserved regions of the viral genome and plays a pivotal role in the initiation of translation of the viral polyprotein (Bartenschlager (1997), supra). A single ORF encodes a polyprotein that is co- or post-translationally processed into structural (core, E1, and E2) and nonstructural (NS2, NS3, NS4A, NS4B, NS5A, and NS5B) viral proteins by either cellular or viral proteinases (Bartenschlager (1997), supra). The 3' NTR consists of three distinct regions: a variable region of about 38 nucleotides following the stop codon of the polyprotein, a polyuridine tract of variable length with interspersed substitutions of cystines, and 98 nucleotides (nt) at the very 3' end which are highly conserved among various HCV isolates. The order of the genes within the genome is: NH2-C-E1-E2-p7-NS2-NS3-NS4A-NS4'B-NS5A-NS5B-COOH (Grakoui et al., J. Virol. 67:1385-1395 (1993)). Hepatitis C virus (HCV) is a member of the hepacivirus genus in the family Flaviviridae. It is the major causative agent of non-A, non-B viral hepatitis and is the major cause of transfusion- associated hepatitis and accounts for a significant proportion of hepatitis cases worldwide. Although acute HCV infection is often asymptomatic, nearly 80% of cases resolve to chronic hepatitis. The persistent property of the HCV infection has been explained by its ability to escape from the host immune surveillance through hypermutability of the exposed regions in the envelope protein E2 (Weiner et al., Virology 180:842-848 (1991); Weiner et al. Proc. Natl. Acad. Sci. USA 89:3468-3472 (1992).
Processing of the structural proteins core (C), envelope protein 1 and (E1, E2), and the p7 region is mediated by host signal peptidases. In contrast, maturation of the nonstructural (NS) region is accomplished by two viral enzymes. The HCV polyprotein is first cleaved by a host signal peptidase generating the structural proteins C/E1, E1/E2, E2/p7, and p7/NS2 (Hijikata et al., Proc. Natl. Acad. Sci. USA 88:5547-5551 (1991); Lin et al., J. Virol. 68:5063-5073 (1994)). The NS2-3 proteinase, which is a metalloprotease, then cleaves at the NS2/NS3 junction. The NS3/4A proteinase complex (NS3 serine protease/NS4A cofactor), then at all the remaining cleavage sites (Bartenschlager et al., J. Virol. 67:3835-3844 (1993); Bartenschlager (1997), supra). RNA helicase and NTPase activities have also been identified in the NS3 protein. The N- terminal one-third of the NS3 protein functions as a protease, and the remaining two-thirds of the molecule acts as a helicase/ATPase, which is thought to be involved in HCV replication (Bartenschlager (1997), supra). NS5A may be phosphorylated and act as a putative cofactor of NS5B. The fourth viral enzyme, NS5B, is an RNA-dependent RNA polymerase (RdRp) and a key component responsible for replication of the viral RNA genome (Lohmann et al., J. Virol. 71:8416- 8428 (1997)).
Replication of HCV is thought to occur in membrane-associated replication complexes. Within these, the genomic plus-strand RNA is transcribed into minus-strand RNA, which in turn can be used as a template for synthesis of progeny genomic plus strands. Two viral proteins appear to be involved in this reaction: the NS3 protein, which carries in the carboxy terminal two- thirds a nucleoside triphosphatase/ RNA helicase, and the NS5B protein, which is a membrane- associated phosphoprotein with an RNA-dependent RNA polymerase activity (RdRp) (Hwang et al., J. Virol. 227:439-446 (1997)). While the role of NS3 in RNA replication is less clear, NS5B apparently is the key enzyme responsible for synthesis of progeny RNA strands. Using recombinant baculoviruses to express NS5B in insect cells and a synthetic nonviral RNA as a substrate, two enzymatic activities have been identified as being associated with NS5B. The two activities include a primer-dependent RdRp and a terminal transferase (TNTase) activity. NS5B's activity was confirmed and further characterized through the use of the HCV RNA genome as a substrate (Lohmann et al., Virology 249: 108-118 (1998)). Recent studies have shown that NS5B with a C-terminal 21 amino-acid truncation expressed in Escherichia coli is also active for in vitro RNA synthesis (Ferrari et al., J. Virol. 73:1649-1654 (1999); Yamashita et al., J. Biol. Chem. 273:15479-15486 (1998)). Since persistent infection of HCV is related to chronic hepatitis and eventually to hepatocarcinogenesis, HCV replication is one of the targets to eliminate HCV reproduction and to prevent hepatocellular carcinoma. Unfortunately, present treatment approaches for HCV infection are characterized by relatively poor efficacy and an unfavorable side-effect profile. Therefore, intensive effort is directed at the discovery of molecules to treat this disease, including the discovery of drugs designed to inhibit HC replication, as there is a persistent need for non- peptide, small-molecule compounds that are HCV RdRp inhibitors having desirable or improved physical and chemical properties appropriate for pharmaceutical applications.
SUMMARY OF THE INVENTION
The present invention relates to compounds of the formula 1
Figure imgf000004_0001
and to pharmaceutically acceptable salts, hydrates, metabolites, prodrugs and solvates thereof, wherein:
W-Z is -C(=0)-C(-R3)(H)- or -C(-OR6)=C(-R3')-, wherein when W-Z is -C(- OR6)=C(-R3')-; each R1 is independently selected from hydrogen, C C6 alkyl, C2-C6 alkenyl, C2- C6 alkynyl, (C3-C10) cycloalkyl, 4- to 10-membered heterocyclic, and C6-C10 aryl, wherein the foregoing R1 groups, except H, are optionally substituted by 1 to 4 substituents selected from R4;
R2 is selected from the group of R1 substituents, -(CR8R9)t(C6-C10 aryl), -(CR8R9)t(4-10 membered heterocyclic), -(CR8R9)qC(O)(CR8R9)t(C6-C10 aryl), -(CR8R9)qC(O)(CR8R9)t(4-10 membered heterocyclic), -(CR8R9)tO(CR8R9)q(C6-C10 aryl), -(CR8R9)tO(CR8R9)q(4-10 membered heterocyclic), -(CR8R9)qSOn(CR8R9)t(C6-C10 aryl), and -(CR8R9)qSOn(CR8R9)t(4-10 membered heterocyclic), wherein q and t are each independently an integer from 0 to 5, n is an integer from 0 to 2, the alkyl, aryl and heterocyclic moieties of said R2 groups are optionally substituted by 1 to 5 R4 groups, and with the proviso that R2 is not H; R3 is hydrogen, -OR6, -SR6, -NR6R7, and the group of R2 substituents;
R3' is selected from the group of R3 substituents except R3' is not H; each R4 is independently selected from halo, cyano, nitro, trifluoromethoxy, trifluoromethyl, azido, CrCι0 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, -C(0)R6, -C(0)OR6, -OC(0)R6, -NR6C(0)R7, -NR6C(0)NR7, -C(0)NR6R7, -NR6R7, -NR6OR7, -S02NR6R7, -NR6S02R7, -(CR8R9)t(C6-C10 aryl)(wherein t is an integer from 0 to 5), -(CR8R9)t(4-10 membered heterocyclic)(wherein t is an integer from 0 to 5), C3-C10 cycloalkyl, R6-0-, R6- SOn- (wherein n is an integer from 0 to 2), and oxo (=0), and wherein the alkyl, aryl, and heterocyclic moieties of said R4 groups are optionally substituted by 1 to 4 substituents selected from R5; each R5 is independently selected from halo, trifluoromethyl, trifluoromethoxy, cyano, CrC6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, -OR8, C3-C10 cycloalkyl, C6-C10 aryl, 4- to
10-membered heterocyclic, oxo (=0), -C(0)R6, -C(0)OR6, -OC(0)R6, -NR6C(0)R6, -NR6C(0)NR7, -C(0)NR6R7, -NR6R7, -NR6OR7, -NR6S02R7and -S02NR6R7, wherein the alkyl, aryl and heterocyclic moieties of the foregoing R5 groups are optionally substituted by 1 to 3 R10; each R6 and R7 is independently selected from H, C C6 alkyl, C3-C10 cycloalkyl,
-(CR8R9)t(C6-C10 aryl), and -(CR8R9)t(4-10 membered heterocyclic), wherein t is an integer from 0 to 5, 1 or 2 ring carbon atoms of the heterocyclic group are optionally substituted with an oxo (=0) moiety, and the alkyl, aryl and heterocyclic moieties of the foregoing R6 and R7 groups are optionally substituted with 1 to 3 halo, cyano, trifluoromethyl, trifluoromethoxy, C C6 alkyl, C C6 alkoxy, C2-C6 alkenyl, C2-C6 alkynyl,
-(CR8R9)t(C6-Cιo aryl), and -(CR8R9)t(4-10 membered heterocyclic), wherein t is an integer from 0 to 5; each R8 and R9 is independently selected from H and C C alkyl; and each R10 is independently selected from halo, cyano, trifluoromethyl, trifluoromethoxy, -C(0)0-R6, -OR6, -C(0)(CR8R9)pC(0)OR6, wherein p is an integer from
1 to 5, C C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, and -NR6R7. The present invention also relates to compounds of formula (1 ), wherein: W-Z is -C(=0)-C(-R3)(H)- or -C(-OR6)=C(-R3')-; each R1 is independently selected from hydrogen, C C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, (C3-C10) cycloalkyl, 4- to 10-membered heterocyclic, and C6-C10 aryl, wherein the foregoing R1 groups, except H, are optionally substituted by 1 to 4 substituents selected from R4;
R2 is selected from the group of R1 substituents, -(CR8R9) (C3-C10 cycloalkyl), - (CR8R9)t(C6-C10 aryl), -(CR8R9)t(4-10 membered heterocyclic), -(CR8R9)qC(O)(CR8R9)t(C6-C10 aryl), -(CR8R9)qC(O)(CR8R9)t(4-10 membered heterocyclic), -(CR8R9),O(CR8R9)q(C6-C10 aryl), -(CR8R9)tO(CR8R9)q(4-10 membered heterocyclic), -(CR8R9)qSOn(CR8R9)t(C6-C10 aryl), and
-(CR8R9)qSOn(CR8R9),(4-10 membered heterocyclic), wherein q and t are each independently an integer from 0 to 5, n is an integer from 0 to 2, the alkyl, cycloalkyl, aryl and heterocyclic moieties of said R2 groups are optionally substituted by 1 to 5 R4 groups, and with the proviso that R2 is not H; R3 is hydrogen, -OR6, -SR8, -NR6R7, and the group of R2 substituents;
R3' is selected from the group of R3 substituents; each R4 is independently selected from halo, cyano, nitro, trifluoromethoxy, trifluoromethyl, azido, C Cι0 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C10 cycloalkyl, - (CR8R9),N(R5)2, -(CR8R9)tNR6C(0)R6, -(CR8R9)tOR6, -(CR8R9)tC(0)R6, -(CR8R9)t C(0)OR6, - (CR8R9)tC(0)R6, -(CR8R9), NR6C(0)R7, -(CR8R9)tNR6C(0)OR6 -(CR8R9)tNR6C(0)NR7, - (CR8R9)tC(0)NR6R7, -(CR8R9)tNR6R7, -(CR8R9)tNR6OR7, -(CR8R9)tS02NR6R7, - (CR8R9)tNR6S02R7, -(CR8R9)t(C6-C10 aryl)(wherein t is an integer from 0 to 5), -(CR8R9)t(4-10 membered heterocyclic)(wherein t is an integer from 0 to 5), C3-C10 cycloalkyl, R6-0-, R6-SOn- (CR8R9)r (wherein n is an integer from 0 to 2), and oxo (=0), and wherein the alkyl, aryl, and heterocyclic moieties of said R4 groups are optionally substituted by 1 to 4 substituents selected from R5; each R5 is independently selected from halo, trifluoromethyl, trifluoromethoxy, cyano, C C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, -OR8, C3-C10 cycloalkyl, C6-C10 aryl, 4- to 10-membered heterocyclic, oxo (=0), -C(0)R6, -C(0)OR6, -OC(0)R6, -NR6C(0)R6, -NR6C(0)NR7, -C(0)NR6R7, -NR6R7, -NR6OR7, -NR6S02R7 and -S02NR6R7, wherein the alkyl, aryl and heterocyclic moieties of the foregoing R5 groups are optionally substituted by 1 to 3 R10; each R6 and R7 is independently selected from H, cyano, C C6 alkyl, C3-C10 cycloalkyl, -(CR8R9)t(C6-C10 aryl), and -(CR8R9)t(4-10 membered heterocyclic), -(CR8R9)tC(0)R8 wherein t is an integer from 0 to 5, 1 or 2 ring carbon atoms of the heterocyclic group are optionally substituted with an oxo (=0) moiety, and the alkyl, aryl and heterocyclic moieties of the foregoing R6 and R7 groups are optionally substituted with 1 to 3 halo, cyano, C3-C10 cycloalkyl, -C(0)OR8 - NR8C(0)R9, -(CR8R9),NR8R9, -OR8, -NC(0)R9, trifluoromethyl, trifluoromethoxy, C C6 alkyl, CrC6 alkoxy, C2-C6 alkenyl, C2-C6 alkynyl, -(CR8R9)t(C6-C10 aryl), and -(CR8R9),(4-10 membered heterocyclic), wherein t is an integer from 0 to 5; each R8 and R9 is independently selected from H and C C4 alkyl; and each R10 is independently selected from halo, cyano, trifluoromethyl, trifluoromethoxy, - C(0)OR6, -C(0)0-R6, -OR6, -C(0)(CR8R9)pC(0)OR6, wherein p is an integer from 1 to 5, CrC6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, and -NR6R7.
The present futher relates to a comound of the formula 2
Figure imgf000007_0001
and pharmaceutically acceptable salts, solvates, metabolites, prodrugs and solvates thereof, wherein: W-Z is -C(-OR6)=C(-R3')-;
R1 is cyclopentyl;
R2 is -(CR8R9)t(C6-C10 aryl) or -(CR8R9)t(4-10 membered heterocyclic), wherein t is an integer from 0 to 5, and the aryl and heterocyclic moieties of said R2 groups are optionally substituted by 1 to 5 R4 groups, and with the proviso that R2 is not H; R3 is hydrogen, -OR6, -SR6, -NR6R7, and the group of R2 substituents; each R4 is independently selected from halo, cyano, nitro, trifluoromethoxy, trifluoromethyl, azido, CrC10 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, -C(0)R6, -C(0)OR6, -OC(0)R8, -NR6C(0)R7, -NR6C(0)NR7, -C(0)NR6R7, -NR6R7, -NR6OR7, -S02NR6R7, -NR6S02R7, -(CR8R9)t(C6-C10 aryl)(wherein t is an integer from 0 to 5), -(CR8R9)t(4-10 membered heterocyclic)(wherein t is an integer from 0 to 5), C3-C10 cycloalkyl, R6-0-, R6-SOn- (wherein n is an integer from 0 to 2), and oxo (=0), and wherein the alkyl, aryl, and heterocyclic moieties of said R4 groups are optionally substituted by 1 to 4 substituents selected from R5; each R5 is independently selected from halo, trifluoromethyl, trifluoromethoxy, cyano, C C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, -OR8, C3-C10 cycloalkyl, C6-C10 aryl, 4- to 10-membered heterocyclic, oxo (=0), -C(0)R6, -C(0)OR6, -OC(0)R6, -NR6C(0)R6, -NR6C(0)NR7, -C(0)NR6R7, -NR6R7, -NR6OR7, -NR6S02R7 and -S02NR6R7, wherein the alkyl, aryl and heterocyclic moieties of the foregoing R5 groups are optionally substituted by 1 to 3 R10; each R6 and R7 is independently selected from H, CrC6 alkyl, C3-C10 cycloalkyl, - (CR8R9)t(C6-C10 aryl), and -(CR8R9)t(4-10 membered heterocyclic), wherein t is an integer from 0 to 5, 1 or 2 ring carbon atoms of the heterocyclic group are optionally substituted with an oxo (=0) moiety, and the alkyl, aryl and heterocyclic moieties of the foregoing R6 and R7 groups are optionally substituted with 1 to 3 halo, cyano, trifluoromethyl, trifluoromethoxy, C C6 alkyl, CrC6 alkoxy, C2-C6 alkenyl, C2-C6 alkynyl, (CR8R9)t(C6-C10 aryl), and -(CR8R9)t(4-10 membered heterocyclic), wherein t is an integer from 0 to 5; each R8 and R9 is independently selected from H and C C alkyl; and each R10 is independently selected from halo, cyano, trifluoromethyl, trifluoromethoxy, - C(0)0-R6, -OR6, -C(0)(CR8R9)pC(0)OR6, wherein p is an integer from 1 to 5, CrCβ alkyl, C2-C6 alkenyl, C2-C6 alkynyl, and NR6R7.
The present invention further relates to a compound of the formula (3)
Figure imgf000008_0001
and to pharmaceutically acceptable salts, solvates, prodrugs, and metabolites thereof, wherein: W-Z is -C(=0)-C(-R3)(H)-; R1 is cyclopentyl; R2 is -(CR8R9)t(C6-C10 aryl) or -(CR8R9),(4-10 membered heterocyclic), wherein t is an integer from 0 to 5, and the aryl and heterocyclic moieties of said R2 groups are optionally substituted by 1 to 5 R4 groups, and with the proviso that R2 is not H; R3 is hydrogen; each R4 is independently selected from halo, cyano, nitro, trifluoromethoxy, trifluoromethyl, azido, CrC10 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, -C(0)R6, -C(0)OR6, -OC(0)R6, -NR6C(0)R7, -NR6C(0)NR7, -C(0)NR6R7, -NR6R7, -NR6OR7, -S02NR6R7, -NR6S02R7, -(CR8R9)t(C6-C10 aryl)(wherein t is an integer from 0 to 5), -(CR8R9)t(4-10 membered heterocyclic)(wherein t is an integer from 0 to 5), C3-C10 cycloalkyl, R6-0-, R6-SOn- (wherein n is an integer from 0 to 2), and oxo (=0), and wherein the alkyl, aryl, and heterocyclic moieties of said R4 groups are optionally substituted by 1 to 4 substituents selected from R5; each R5 is independently selected from halo, trifluoromethyl, trifluoromethoxy, cyano, Cr C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, -OR8, C3-C10 cycloalkyl, C6-C10 aryl, 4- to 10-membered heterocyclic, oxo (=0), -C(0)R6, -C(0)OR6, -OC(0)R6, -NR6C(0)R6, -NR6C(0)NR7, -C(0)NR6R7, -NR6R7, -NR8OR7, -NR6S02R7and -S02NR6R7, wherein the alkyl, aryl and heterocyclic moieties of the foregoing R5 groups are optionally substituted by 1 to 3 R10; each R6 and R7 is independently selected from H, C C6 alkyl, C3-C10 cycloalkyl, -(CR8R9)t(C6-C10 aryl), and -(CR8R9)t(4-10 membered heterocyclic), wherein t is an integer from 0 to 5, 1 or 2 ring carbon atoms of the heterocyclic group are optionally substituted with an oxo (=0) moiety, and the alkyl, aryl and heterocyclic moieties of the foregoing R6 and R7 groups are optionally substituted with 1 to 3 halo, cyano, trifluoromethyl, trifluoromethoxy, C C6 alkyl, d-C6 alkoxy, C2-C6 alkenyl, C2-C6 alkynyl, (CR8R9),(C6-C10 aryl), and -(CR8R9)t(4-10 membered heterocyclic), wherein t is an integer from 0 to 5; each R and R9 is independently selected from H and C C4 alkyl; and each R10 is independently selected from halo, cyano, trifluoromethyl, trifluoromethoxy, - C(0)0-R6, -OR6, -C(0)(CR8R9)pC(0)OR6, wherein p is an integer from 1 to 5, CrC6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, and NR6R7.
In a specific embodiment of the present invention, according to formula 1 , R2 is - (CR8R9)t(C6-C10 aryl), wherein t is an integer from 2 to 5, and the aryl moiety of said R2 group is optionally substituted by 1 to 5 R4 groups, and with the proviso that R2 is not H; optionally each R4 is independently selected from halo, nitro, C C10 alkyl, -C(0)R6, -C(0)OR6, -OC(0)R6,
36o7
-C(0)NR R , -(CR R )t(4-10 membered heterocyclic)(wherein t is an integer from 0 to 5), C3-C10 cycloalkyl, R6-0-, and wherein the alkyl, aryl, and heterocyclic moieties of said R4 groups are optionally substituted by 1 to 4 substituents selected from R5, optionally each R5 is independently selected from halo, trifluoromethyl, CrC6 alkyl, -OR8, C3-C10 cycloalkyl, C6-C10 aryl, oxo (=0), - C(0)R6, -C(0)OR6, -OC(0)R6, -NR6C(0)R6, -NR6C(0)NR7, -C(0)NR6R7, -NR6R7, -NR6OR7, -NR6S02R7 and -S02NR6R7, wherein the alkyl and aryl moieties of the foregoing R5 groups are optionally substituted by 1 to 3 R10; optionally each R10 is independently selected from halo, trifluoromethyl, -C(0)0-R6, -OR6, CrC6 alkyl and NR6R7; optionally R3 is -OR6, -SR6, -NR6R7, and -(CR8R9)t(C6-Cιo aryl), wherein t is an integer from 2 to 5, and the aryl moiety of said R2 group is optionally substituted by 1 to 5 R4 groups.
In yet another aspect of the present invention are provided compounds of formula (4),
Figure imgf000009_0001
wherein:
R1 is cyclopentyl;
R3 is -(CR8R9)t(C6-C10 aryl) or -(CR8R9)t(4-10 membered heterocyclic), wherein t is an integer from 0 to 5, and the aryl and heterocyclic moieties of said R3 groups are optionally substituted by 1 to 5 R4 groups; each R4 is independently chosen from halo, CrC10 alkyl, and R6-0-, and each CrC10 alkyl may be optionally substituted by at least one substituent chosen from halo, trifluoromethyl, trifluoromethoxy, C Cι0 alkyl, and cyano; or when two adjacent R4 groups are both C Cιo alkyl, they, together with the atoms to which they are attached, form a 3- to 7-membered ring, wherein in said ring any carbon atom may be replaced by a heteroatom chosen from N, 0, and S, provided that two adjacent carbons are not both replaced by heteroatoms; R6 is hydrogen or CrC10 alkyl;
R8 and R9 are independently chosen from hydrogen and C C10 alkyl; z is an integer from 1 to 5; and y is an integer from 0 to 5.
In a further aspect of the present invention are provided compounds of formula (4), wherein:
R1 is cyclopentyl;
R3 is -(CR8R9)t(4-10 membered heterocyclic), wherein t is an integer from 0 to 5, and the heterocyclic moiety is optionally substituted by 1 to 5 R4 groups; each R4 is independently chosen from halo, C Cι0 alkyl, and R6-0-, and each C C10 alkyl may be optionally substituted by at least one substituent chosen from halo, trifluoromethyl, trifluoromethoxy, C C10 alkyl, and cyano; or when two adjacent R4 groups are both C C10 alkyl, they, together with the atoms to which they are attached, form a 3- to 7-membered ring, wherein in said ring any carbon atom may be replaced by a heteroatom chosen from N, O, and S, provided that two adjacent carbons are not both replaced by heteroatoms;
R6 is hydrogen or C C10 alkyl; R8 and R9 are hydrogen; z is an integer from 1 to 5; and y is an integer from 0 to 5.
In yet another aspect of the present invention are provided compounds of formula (4), wherein:
R1 is cyclopentyl; R3 is -(CH2)t([1 ,2,4]triazolo[1 ,5-a]pyrimidyl), optionally substituted by 1 to 3 R4 groups; t is an integer from 1-3; each R4 is independently chosen from halo, C C^ alkyl, and R6-0-, and each CrC10 alkyl may be optionally substituted by at least one substituent chosen from halo, trifluoromethyl, trifluoromethoxy, C C10 alkyl, and cyano; or when two adjacent R4 groups are both C Cιo alkyl, they, together with the atoms to which they are attached, form a 3- to 7-membered ring, wherein in said ring any carbon atom may be replaced by a heteroatom chosen from N, O, and S, provided that two adjacent carbons are not both replaced by heteroatoms; R6 is hydrogen or C C10 alkyl; z is an integer from 1 to 5; and y is an integer from 1 to 3.
In still a further aspect of the present invention are provided compounds of formula (4), wherein:
R is cyclopentyl;
R3 is -(CH2)([1,2,4]triazolo[1,5-a]pyrimidyl), substituted by 1 to 3 R4 groups; each R4 is independently chosen from halo and Cι-C10 alkyl optionally substituted with cyano; or two adjacent R4 groups are both C Cι0 alkyl and, together with the atoms to which they are attached, form a 3- to 7-membered ring, wherein a carbon atom is replaced by a heteroatom chosen from N, O, and S; z is an integer from 2 to 3; and y is 2.
In yet another aspect of the present invention are provided compounds of formula (4), wherein:
R1 is cyclopentyl;
R3 is -(CH2)([1,2,4]triazolo[1,5-a]pyrimidyl), substituted by 2 R4 groups; each R4 is independently chosen from halo, -CH3, and -C(CH3)2CN; and y is 2.
In still a further aspect of the present invention are provided compounds of formula (4), wherein: R1 is cyclopentyl;
R3 is -(CH2)([1,2,4]triazolo[1,5-a]pyrimidyl), substituted by at least one substituent chosen from halo and methyl; two adjacent R4 groups, together with the atoms to which they are attached form a 5- membered ring, wherein in said ring one carbon atom is replaced by O; z is an integer from 2 to 3; and y is 2.
In yet another aspect of the present invention are provided compounds of formula (4b),
Figure imgf000012_0001
wherein:
R3 is -(CH2)([1 ,2,4]triazolo[1 ,5-a]pyrimidyl), substituted by at least one substituent chosen from halo and methyl;
Q is chosen from N, O, and S;
R4a, R4 , and R4c are independently chosen from hydrogen, halo, C C10 alkyl, and R6-0-; and
R6 is chosen from hydrogen and C C10 alkyl.
Another aspect of the present invention provides compounds of formula (5),
wherein:
R4a, R4b, and R c are independently chosen from halo and C C10 alkyl; R4d, R e, and R4f are independently chosen from halo, R6-0-, and C Cιo alkyl, wherein said C1-C10 alkyl is optionally substituted with at least one substituent chosen from halo and cyano; and R6 is C C10 alkyl or hydrogen.
Another aspect of the present invention provides compounds of formula (6),
Figure imgf000013_0001
wherein R is halo.
In still a further aspect of the present invention are provided compounds of formula (7),
Figure imgf000013_0002
wherein R is halo
Another aspect of the present invention provides compounds of formula (8),
Figure imgf000014_0001
wherein R4 is halo.
Still a further aspect of the present invention provides compounds of formulas (6), (7), and (8), wherein R4 is chosen from fluorine and chlorine. In yet another aspect of the present invention are provided compounds of formulas (6), (7), and (8), wherein R4is fluorine. In still a further aspect are provided those compounds of formula (6), (7), and (8), wherein R4 is chlorine.
Another aspect of the present invention provides compounds of formula (4), wherein:
R1 is cyclopentyl;
R3 is -(CH2)([1,2,4]triazolo[1,5-a]pyrimidyl), optionally substituted by 1 to 3 R4 groups; each R4 is independently chosen from halo, Cι-C10 alkyl, and R6-0-, and each C1-C10 alkyl may be optionally substituted by at least one substituent chosen from halo, trifluoromethyl, trifluoromethoxy, CrC10 alkyl, and cyano;
R6 is hydrogen or C C10 alkyl; z is an integer from 1 to 3; and y is 2.
In still a further aspect of the present invention are provided compounds of formula (4),' wherein:
R >1 ; is, cyclopentyl;
R3 is -(CH2)([1 ,2,4]triazolo[1,5-a]pyrimidyI), optionally substituted by 1 to 3 R4 groups; each R4 is independently chosen from halo, Cι-C10 alkyl, and R6-0-, and each CrC10 alkyl may be optionally substituted by at least one substituent chosen from halo, trifluoromethyl, trifluoromethoxy, C C10 alkyl, and cyano; R6 is hydrogen or methyl; z is an integer from 2-3; and y is 2.
In still a further aspect of the present invention are provided compounds of formula (9),
Figure imgf000015_0001
wherein:
R4a is halo or C C10 alkyl;
R4 , R c, and R4d are independently chosen from C C10 alkyl and R6-0-; and
R6 is hydrogen or methyl.
Also provided in the present invention are compounds of formula (9), wherein:
R4a is halo;
R b and R c are each R6-0-;
R4d is C Cιo alkyl; and
R6 is hydrogen or methyl.
In another aspect of the present invention are provided compounds of formula (9), wherein:
R,a is fluorine or chlorine;
,4b
R"D is -OCH3;
-.4c
R,c is -OH; and a d
Rw is -CH2CH3.
Another aspect provides compounds of formula (9), wherein: R4a is chlorine;
Figure imgf000016_0001
R40 is -OH; and R4d is -CH2CH3.
Another aspect of the present invention provides compounds of formula (10),
Figure imgf000016_0002
Still a further aspect of the present invention provides compounds of formula (11),
Figure imgf000016_0003
In another embodiment of the present invention, the invention relates to a compound selected from the group consisting of:
6-Cyclopentyl-3-(5,7-dimethyl-[1 ,2,4]triazolo[1,5-a-pyrimidin-2-ylmethyl)-6-[2-(3-fluoro-4-methoxy- phenyl)-ethyl]-4-hydroxy-5,6-dihydro-pyran-2-one;
6-[2-(3-tert-Butyl-phenyl)-ethyl]-6-cyclopentyl-3-(5,7-dimethyl-[1,2,4]triazolo[1 ,5-a]pyrimidin-2- ylmethyl)-4-hydroxy-5,6-dihydro-pyran-2-one; 6-Cyclopentyl-3-(5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-ylmethyl)-6-[2-(3-ethyl-4-hydroxy- phenyl)-ethyl]-4-hydroxy-5,6-dihydro-pyran-2-one;
6-[2-(3-tert-Butyl-4-hydroxy-phenyl)-ethyl]-6-cyclopentyl-3-(5,7-dimethyl-[1,2,4]triazolo[1 ,5- a]pyrimidin-2-ylmethyl)-4-hydroxy-5,6-dihydro-pyran-2-one; 6-[2-(3-Chloro-4-isopropoxy-phenyl)-ethyl]-6-cyclopentyl-3-(5,7-dimethyl-[1,2,4]triazolo[1,5- a]pyrimidin-2-ylmethyl)-4-hydroxy-5,6-dihydro-pyran-2-one;
6-Cyclopentyl-6-[2-(3,5-dichloro-4-ethoxy-phenyl)-ethyl]-3-(5,7-dimethyl-[1 ,2,4]triazolo[1 ,5- a]pyrimidin-2-ylmethyl)-4-hydroxy-5,6-dihydro-pyran-2-one;
6-cyclopentyI-3-[(5,7-dimethyl [1 ,2,4]triazolo[1 ,5-a]pyrimidin-2-yl)methyl]-6-[2-(3- isopropylphenyl)ethyl]dihydro-2/-/-pyran-2,4(3H)-dione;
7-({6-[2-(5-Chloro-2,4-dimethoxyphenyl)ethyl]-6-cyclopentyl-4-hydroxy-2-oxo-5,6-dihydro-2H- pyran-3-yl}methyl)-3-methyl-5H-[1,3]thiazolo[3,2-a]pyrimidin-5-one;
2-(4-{2-[2-Cyclopentyl-5-(5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-ylmethyl)-4-hydroxy-6-oxo-
3,6-dihydro-2H-pyran-2-yl]-ethyl}-2-fluoro-phenyl)-2-methyl-propionitrile; 1-(4-{2-[2-CycIopentyl-5-(5,7-dimethyl-[1 ,2,4]triazolo[1 ,5-a]pyrimidin-2-ylmethyl)-4-hydroxy-6-oxo-
3,6-dihydro-2H-pyran-2-yl]-ethyl}-2-fluoro-phenyl)-cyclopropanecarbonitrile;
6-[2-(5-chloro-2,4-dimethoxyphenyl)ethyl]-6-cyclopentyl-4-hydroxy-3-(imidazo[1 ,2-a]pyrimidin-2- ylmethyl)-5,6-dihydro-2H-pyran-2-one;
6 Λ/-[4-(2-{2-cyclopentyl-5-[(5,7-dimethyl[1 ,2,4]triazolo[1 ,5-a]pyrimidin-2-yl)methyl]-4,6- dioxotetrahydro-2 -/-pyran-2-yl}ethyl)-2-ethylphenyl]-Λ/-methylmethanesulfonamide;
2-[4-(2-{2-cyclopentyl-4-hydroxy-5-[(1-methyl-1H-indol-5-yl)methyl]-6-oxo-3,6-dihydro-2 -/-pyran-
2-yl}ethyl)-2-fluorophenyl]-2-methylpropanenitrile;
6-[2-(3-Chloro-4-hydroxy-phenyl)-ethyl]-6-cyclopentyl-3-(5,7-dimethyl-[1,2,4]triazolo[1,5- a]pyrimidin-2-ylmethyl)-4-hydroxy-5,6-dihydro-pyran-2-one; 6-Cyclopentyl-3-(5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-ylmethyl)-6-[2-(3-ethyl-4-methoxy- phenyl)-ethyl]-4-hydroxy-5,6-dihydro-pyran-2-one;
3-(5-Chloro-1-isopropyl-1-benzoimidazol-2-ylsulfanyl)-6-cyclopentyl-6-[2-(3-fluoro-4-isopropoxy- phenyl)-ethyl]-4-hydroxy-5,6-dihydro-pyran-2-one;
5-{6-Cyclopentyl-6-[2-(3-fluoro-4-isopropoxy-phenyl)-ethyl]-4-hydroxy-2-oxo-5,6-dihydro-2H- pyran-3-ylsulfanyl}-4-methyl-4H-[1 ,2,4]triazole-3-carboxylic acid methyl ester;
3-(5-Chloro-1-methyl-1H-benzoimidazol-2-ylsulfanyl)-6-cyclopentyl-6-{2-[4-(3,5-dimethyl-isoxazol-
4-yl)-phenyl]-ethyl}-4-hydroxy-5,6-dihydro-pyran-2-one;
6-[2-(3-chloro-4-methoxyphenyl)ethyl]-6-cyclopentyl-3-{[5-(2-furyl)-4-methyl-4H-1,2,4-triazol-3- yl]thio}-4-hydroxy-5,6-dihydro-2H-pyran-2-one; 6-[2-(3-chIoro-4-methoxyphenyl)ethyl]-6-cyclopentyl-4-hydroxy-3-[(5-pyridin-4-yl-4W-1,2,4-triazol-
3-yl)thio]-5,6-dihydro-2H-pyran-2-one;
6-[2-(3-chloro-4-methoxyphenyl)ethyl]-3-[(5-chloro-1-methyl-1H-benzimidazol-2-yl)thio]-6- cyclopentyl-4-hydroxy-5,6-dihydro-2H-pyran-2-one; 6-[2-(5-chloro-2,4-dimethoxyphenyl)ethyl]-3-[(5-chloro-1-methyl-1H-benzimidazol-2-yl)thio]-6- cyclopentyl-4-hydroxy-5,6-dihydro-2H-pyran-2-one;
6-[2-(3-chloro-4-isopropoxyphenyl)ethyl]-3-[(5-chloro-1-methyl-1H-benzimidazol-2-yl)thio]-6- cyclopentyl-4-hydroxy-5,6-dihydro-2H-pyran-2-one;
8-({6-[2-(5-chloro-2,4-dimethoxyphenyl)ethyl]-6-cyclopentyl-4-hydroxy-2-oxo-5,6-dihydro-2/-/- pyran-3-yl}thio)-1 ,7-dihydro-6H-purin-6-one;
6-[2-(5-chlor-2,4-dimethoxyphenyl)ethyl]-6-cyclopentyl-4-hydroxy-3-{[5-(4-hydroxyphenyl)-4H-
1,2,4-triazol-3-yl]thio}-5,6-dihydro-2A7-pyran-2-one; ethyl 2-({6-[2-(5-chloro-2,4-dimethoxyphenyl)ethyl]-6-cyclopentyl-4-hydroxy-2-oxo-5,6-dihydro-
2H-pyran-3-yl}thio)[1,2,4]triazolo[1,5-a]pyrimidine-6-carboxylate; 6-cyclopentyl-3-t(5,7-dimethyl[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-6-[2-(3-fluoro-4- isopropoxyphenyl)ethyl]-4-hydroxy-5,6-dihydro-2fV-pyran-2-one;
6-Cyclopentyl-3-(5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-ylmethyl)-6-[2-(3-ethyl-phenyl)- ethyl]-4-hydroxy-5,6-dihydro-pyran-2-one;
6-Cyclopentyl-3-(5,7-dimethyI-[1,2,4]triazolo[1,5-a]pyrimidin-2-ylmethyl)-6-[2-(3-ethyl-phenyl)- ethyl]-4-hydroxy-5,6-dihydro-pyran-2-one;
2-[4-(2-{5-[(4-chloro-1-methyl-1H-pyrazol-3-yl)methyl]-2-cyclopentyl-4-hydroxy-6-oxo-3,6-dihydro-
2H-pyran-2-yl}ethyl)-2-fluorophenyl]-2-methylpropanenitrile;
2-{4-[2-(2-Cyclopentyl-4,6-dioxo-5-[1,2,4]triazolo[1,5-a]pyrimidin-2-ylmethyl-tetrahydro-pyran-2- yl)-ethyl]-2-fluoro-phenyl}-2-methyl-propionitrile; 2-(4-{2-[2-Cyclopentyl-5-(6-methyl-t1,2,4]triazolo[1,5-a]pyrimidin-2-ylmethyl)-4,6-dioxo-tetrahydro- pyran-2-yl]-ethyl}-2-fluoro-phenyl)-2-methyl-propionitrile;
(+)-2-(4-{2-[2-Cyclopentyl-5-(6-methyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-ylmethyl)-4,6-dioxo- tetrahydro-pyran-2-yl]-ethyl}-2-fluoro-phenyl)-2-methyl-propionitrile;
(-)-2-(4-{2-[2-Cyclopentyl-5-(6-methyl-[1,2,4]triazolo[1 ,5-a]pyrimidin-2-ylmethyl)-4,6-dioxo- tetrahydro-pyran-2-yl]-ethyl}-2-fluoro-phenyl)-2-methyl-propionitrile;
2-(4-{2-[5-(6-Chloro-[1,2,4]triazolo[1,5-a]pyrimidin-2-ylmethyl)-2-cyclopentyl-4,6-dioxo-tetrahydro- pyran-2-yl]-ethyl}-2-fluoro-phenyl)-2-methyl-propionitrile;
2-(4-{2-[2-CyclopentyI-5-(5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-ylmethyl)-4,6-dioxo- tetrahydro-pyran-2-yl]-ethyl}-2-fluoro-phenyl)-2-ethyl-butyronitrile; 1-(4-{2-[2-CycIopentyl-5-(6-methyl-t1,2,4]triazolo[1,5-a]pyrimidin-2-ylmethyI)-4,6-dioxo-tetrahydro- pyran-2-yl]-ethyl}-2-fluoro-phenyl)-cyclopropanecarbonitrile;
1-(4-{2-[5-(6-Chloro-t1,2,4]triazolo[1,5-a]pyrimidin-2-ylmethyl)-2-cyclopentyl-4,6-dioxo-tetrahydro- pyran-2-yl]-ethyl}-2-fluoro-phenyl)-cyclopropanecarbonitrile; 6-Cyclopentyl-6-[2-(3-ethyl-4-hydroxy-phenyl)-ethyl]-4-hydroxy-3-(6-methyl-[1,2,4]triazolo[1,5- a]pyrimidin-2-ylmethyl)-5,6-dihydro-pyran-2-one;
3-(6-Chloro-[1,2,4]triazolo[1 ,5-a]pyrimidin-2-ylmethyl)-6-cyclopentyl-6-[2-(3-ethyl-4-hydroxy- phenyl)-ethyl]-4-hydroxy-5,6-dihydro-pyran-2-one;
6-cyclopentyl-3-[(5,7-diethyl[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-4-hydroxy-6-[2-(4-hydroxy- 3-propylphenyl)ethyl]-5,6-dihydro-2H-pyran-2-one;
6-cyclopentyl-3-[(5,7-diethyl[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-6-[2-(3-ethyl-4- hydroxyphenyl)ethyl]-4-hydroxy-5,6-dihydro-2W-pyran-2-one;
Λ/-{2-[4-(2-{2-cyclopentyl-5-[(5,7-dimethyl[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-4-hydroxy-6- oxo-3, 6-dihydro-2 V-pyran-2-yl}ethyl)-2-ethylphenoxy]ethyl}acetamide; 2-(4-{2-[2-Cyclopentyl-5- 5,7-dimethyl- [1,2,4] triazolo[1 ,5-a]pyrimidin-2-ylmethyl]-4-hydroxy-6- oxo-3,6-dihydro-2H-pyran-2-yl}-ethyl)-2,6-difluoro-phenyl)-2-methyl-propionitrile;
2-(4-{2-[2-Cyclopentyl-4-hydroxy-5-(6-methyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-ylmethyl)-6-oxo-3,6- dihydro-2H-pyran-2-yl]-ethyl}-2,6-difluoro-phenyl)-2-methyl-propionitrile;
2-(2-Chloro-4-{2-[2-cyclopentyl-5-(5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-ylmethyl)-4- hydroxy-6-oxo-3,6-dihydro-2H-pyran-2-yl]-ethyl}-phenyl)-2-methyl-propionitrile;
1-(2-Chloro-4-{2-[2-cyclopentyl-5-(5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-ylmethyl)-4- hydroxy-6-oxo-3,6-dihydro-2H-pyran-2-yl]-ethyl}-phenyl)-cyclopropanecarbonitrile;
6-Cyclopentyl-3-(5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-ylmethyl)-6-[2-(5-ethyl-4-hydroxy-2- methoxy-phenyl)-ethyl]-4-hydroxy-5,6-dihydro-pyran-2-one; (+)-2-(2-chloro-4-{2-[2-cyclopentyl-5-(5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-ylmethyl)-4- hydroxy-6-oxo-3,6-dihydro-2/-/-pyran-2-yl]-ethyl}-phenyl)-2-methyl-propionitrile;
(-)-2-(2-chloro-4-{2-[2-cyclopentyl-5-(5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-ylmethyl)-4- hydroxy-6-oxo-3,6-dihydro-2H-pyran-2-yl]-ethyl}-phenyl)-2-methyl-propionitrile
(+)-2-(2-fluoro-4-{2-[2-cyclopentyl-5-(5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-ylmethyl)-4- hydroxy-6-oxo-3,6-dihydro-2W-pyran-2-yl]-ethyl}-phenyl)-2-methyl-propionitrile;
(-)-2-(2-fluoro-4-{2-[2-cyclopentyl-5-(5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-ylmethyl)-4- hydroxy-6-oxo-3,6-dihydro-2H-pyran-2-yl]-ethyl}-phenyl)-2-methyl-propionitrile;
(+)-3-[(6-chloro[1,2,4]triazolo[1,5-a]pyrlmidin-2-yl)methyi]-6-cyclopentyl-6-[2-(5-ethyl-4-hydroxy-2- methoxyphenyl)ethyl]-4-hydroxy-5,6-dihydro-2H-pyran-2-one (-)-3-[(6-chloro[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-6-cyclopentyl-6-[2-(5-ethyl-4-hydroxy-2- methoxyphenyl)ethyl]-4-hydroxy-5,6-dihydro-2H-pyran-2-one
6-Cyclopentyl-3-(5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-ylmethyl)-6-[2-(5-ethyl-4-hydroxy-2- methoxy-phenyl)-ethyl]-4-hydroxy-5,6-dihydro-pyran-2-one; (-)-6-Cyclopentyl-3-(5,7-dimethyl-[1,2,4]triazolo[1,5-ajpyrimidin-2-ylmethyl)-6-[2-(5-ethyl-4- hydroxy-2-methoxy-phenyl)-ethyl]-4-hydroxy-5,6-dihydro-pyran-2-one;
6-[2-(3-Chloro-5-ethyl-4-methoxy-phenyl)-ethyl]-6-cyclopentyl-3-(5,7-dimethyl-[1,2,4]triazolo[1,5- a]pyrimidin-2-ylmethyl)-4-hydroxy-5,6-dihydro-pyran-2-one;
6-Cyclopentyl-3-(5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-ylmethyl)-6-[2-(5-ethyl-2-methoxy- phenyl)-ethyI]-4-hydroxy-5,6-dihydro-pyran-2-one;
6-[2-(3-Chloro-5-ethyl-4-hydroxy-phenyl)-ethyl]-6-cyclopentyl-3-(5,7-dimethyl-[1,2,4]triazolo[1,5- a]pyrimidin-2-ylmethyl)-4-hydroxy-5,6-dihydro-pyran-2-one;
6-Cyclopentyl-3-(5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-ylmethyl)-6-{2-[3-ethyl-4-(2- hydroxy-ethoxy)-phenyl]-ethyl}-4-hydroxy-5,6-dihydro-pyran-2-one; 6-Cyclopentyl-6-[2-(3-cyclopropyl-4-methoxy-phenyl)-ethyl]-3-(5,7-dimethyl-[1,2,4]triazolo[1,5- a]pyrimidin-2-ylmethyl)-4-hydroxy-5,6-dihydro-pyran-2-one;
6-Cyclopentyl-3-(5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-ylmethyl)-6-[2-(5-ethyl-4-hydroxy-
2,3-dihydro-benzofuran-7-yl)-ethyl]-4-hydroxy-5,6-dihydro-pyran-2-one;
(+)-6-Cyclopentyl-3-(5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-ylmethyl)-6-[2-(5-ethyl-4- hydroxy-2,3-dihydro-benzofuran-7-yl)-ethyl]-4-hydroxy-5,6-dihydro-pyran-2-one;
(-)-6-Cyclopentyl-3-(5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-ylmethyl)-6-[2-(5-ethyl-4- hydroxy-2,3-dihydro-benzofuran-7-yl)-ethyl]-4-hydroxy-5,6-dihydro-pyran-2-one;
6-CycIopentyl-3-(5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-ylmethyl)-6-[2-(5-ethyl-pyridin-3-yl)- ethyl]-4-hydroxy-5,6-dihydro-pyran-2-one; and pharmaceutically acceptable salts, solvates and prodrugs of the foregoing compounds. The present invention also provides compounds chosen from:
2-[4-(2-{5-[(4-chloro-1-methyl-1rV-pyrazol-3-yl)methyl]-2-cyclopentyl-4-hydroxy-6-oxo-3,6-dihydro-
2H-pyran-2-yl}ethyl)-2-fluorophenyl]-2-methylpropanenitrile;
2-(4-{2-[2-Cyclopentyl-5-(6-methyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-ylmethyl)-4,6-dioxo-tetrahydro- pyran-2-yl]-ethyl}-2-fluoro-phenyl)-2-methyl-propionitrile;
(+)-2-(4-{2-[2-Cyclopentyl-5-(6-methyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-ylmethyl)-4,6-dioxo- tetrahydro-pyran-2-yl]-ethyl}-2-fluoro-phenyl)-2-methyl-propionitrile;
(-)-2-(4-{2-[2-Cyclopentyl-5-(6-methyl-[1,2,4]triazolo[1,5-ajpyrimidin-2-ylmethyI)-4,6-dioxo- tetrahydro-pyran-2-yl]-ethyl}-2-fluoro-phenyl)-2-methyl-propionitrile; 2-(4-{2-[5-(6-Chloro-[1,2,4]triazolo[1,5-a]pyrimidin-2-ylmethyl)-2-cyclopentyl-4,6-dioxo-tetrahydro- pyran-2-yl]-ethyl}-2-fluoro-phenyl)-2-methyl-propionitrile;
3-(6-Chloro-[1,2,4]triazolo[1,5-a]pyrimidin-2-ylmethyl)-6-cyclopentyl-6-[2-(3-ethyl-4-hydroxy- phenyl)-ethyl]-4-hydroxy-5,6-dihydro-pyran-2-one; Λ/-{2-[4-(2-{2-cyclopentyl-5-[(5,7-dimethyl[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-4-hydroxy-6- oxo-3,6-dihydro-2H-pyran-2-yl}ethyl)-2-ethylphenoxy]ethyl}acetamide;
2-(4-{2-[2-Cyclopentyl-5- 5,7-dimethyl- [1 ,2,4] triazolo[1 ,5-a]pyrimidin-2-ylmethyI]-4-hydroxy-6- oxo-3,6-dihydro-2H-pyran-2-yl}-ethyl)-2,6-difluoro-phenyl)-2-methyl-propionitrile;
(+)-2-(2-chloro-4-{2-[2-cyclopentyl-5-(5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-ylmethyl)-4- hydroxy-6-oxo-3,6-dihydro-2/-/-pyran-2-yl]-ethyl}-phenyl)-2-methyl-propionitrile;
(-)-2-(2-chloro-4-{2-[2-cyclopentyl-5-(5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-ylmethyl)-4- hydroxy-6-oxo-3,6-dihydro-2/-/-pyran-2-yl]-ethyl}-phenyl)-2-methyl-propionitrile;
(+)-2-(2-fluoro-4-{2-[2-cyclopentyl-5-(5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-ylmethyl)-4- hydroxy-6-oxo-3,6-dihydro-2H-pyran-2-yl]-ethyl}-phenyl)-2-methyl-propionitrile; (-)-2-(2-fluoro-4-{2-[2-cyclopentyl-5-(5,7-dimethyl-[1,2,4]triazolo[1 ,5-a]pyrimidin-2-ylmethyl)-4- hydroxy-6-oxo-3,6-dihydro-2/-/-pyran-2-yl]-ethyl}-phenyl)-2-methyl-propionitrile;
(+)-3-[(6-chloro[1 ,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-6-cyclopentyl-6-[2-(5-ethyl-4-hydroxy-2- methoxyphenyl)ethyl]-4-hydroxy-5,6-dihydro-2/-/-pyran-2-one
(-)-3-[(6-chloro[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-6-cyclopentyl-6-[2-(5-ethyl-4-hydroxy-2- methoxyphenyl)ethyl]-4-hydroxy-5,6-dihydro-2/--pyran-2-one
1-(2-Chloro-4-{2-[2-cyclopentyl-5-(5,7-dimethyl-[1 ,2,4]triazolo[1,5-a]pyrimidin-2-ylmethyl)-4- hydroxy-6-oxo-3,6-dihydro-2/-/-pyran-2-yl]-ethyl}-phenyl)-cyclopropanecarbonitrile;
6-Cyclopentyl-3-(5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-ylmethyl)-6-[2-(5-ethyl-4-hydroxy-2- methoxy-phenyl)-ethyl]-4-hydroxy-5,6-dihydro-pyran-2-one; (-)-6-Cyclopentyl-3-(5,7-dimethyl-[1,2,4]triazolo[1 ,5-a]pyrimidin-2-ylmethyl)-6-[2-(5-ethyl-4- hydroxy-2-methoxy-phenyl)-ethyl]-4-hydroxy-5,6-dihydro-pyran-2-one;
6-[2-(3-Chloro-5-ethyl-4-hydroxy-phenyl)-ethyl]-6-cyclopentyl-3-(5,7-dimethyI-[1,2,4]triazolo[1,5- a]pyrimidin-2-ylmethyl)-4-hydroxy-5,6-dihydro-pyran-2-one;
6-Cyclopentyl-3-(5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-yimethyl)-6-{2-[3-ethyl-4-(2- hydroxy-ethoxy)-phenyl]-ethyl}-4-hydroxy-5,6-dihydro-pyran-2-one;
6-Cyclopentyl-3-(5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-ylmethyl)-6-[2-(5-ethyl-4-hydroxy-
2,3-dihydro-benzofuran-7-yl)-ethyl]-4-hydroxy-5,6-dihydro-pyran-2-one;
(+)-6-Cyclopentyl-3-(5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-ylmethyl)-6-[2-(5-ethyl-4- hydroxy-2,3-dihydro-benzofuran-7-yl)-ethyl]-4-hydroxy-5,6-dihydro-pyran-2-one; (-)-6-Cyclopentyl-3-(5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-ylmethyl)-6-[2-(5-ethyl-4- hydroxy-2,3-dihydro-benzofuran-7-yl)-ethyl]-4-hydroxy-5,6-dihydro-pyran-2-one;
6-Cyclopentyl-3-(5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-ylmethyl)-6-[2-(5-ethyl-pyridin-3-yl)- ethyl]-4-hydroxy-5,6-dihydro-pyran-2-one; and the pharmaceutically acceptable salts, solvates and prodrugs of the foregoing compounds. In a further aspect, the invention relates to compounds chosen from:
6-[2-(3-tert-Butyl-phenyl)-ethyl]-6-cyclopentyl-3-(5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2- ylmethyl)-4-hydroxy-5,6-dihydro-pyran-2-one;
6-Cyclopentyl-3-(5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-ylmethyl)-6-[2-(3-ethyl-4-hydroxy- phenyl)-ethyl]-4-hydroxy-5,6-dihydro-pyran-2-one;
6-[2-(3-Chloro-4-isopropoxy-phenyl)-ethyl]-6-cycIopentyl-3-(5,7-dimethyl-[1,2,4]triazolo[1,5- a]pyrimidin-2-ylmethyl)-4-hydroxy-5,6-dihydro-pyran-2-one;
6-Cyclopentyl-6-[2-(3,5-dichloro-4-ethoxy-phenyl)-ethyl]-3-(5,7-dimethyl-[1,2,4]triazolo[1,5- a]pyrimidin-2-ylmethyl)-4-hydroxy-5,6-dihydro-pyran-2-one; 7-({6-[2-(5-Chloro-2,4-dimethoxyphenyl)ethyl]-6-cyclopentyl-4-hydroxy-2-oxo-5,6-dihydro-2/-/- pyran-3-yl}methyl)-3-methyl-5/-/-[1,3]thiazolo[3,2-a]pyrimidin-5-one;
2-(4-{2-[2-CyclopentyI-5-(5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-ylmethyl)-4-hydroxy-6-oxo-
3,6-dihydro-2H-pyran-2-yl]-ethyl}-2-fluoro-phenyl)-2-methyl-propionitrile;
1-(4-{2-[2-Cyclopentyl-5-(5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-ylmethyl)-4-hydroxy-6-oxo- 3,6-dihydro-2H-pyran-2-yl]-ethyl}-2-fluoro-phenyl)-cyclopropanecarbonitrile;
6-[2-(5-chloro-2,4-dimethoxyphenyl)ethyl]-6-cyclopentyl-4-hydroxy-3-(imidazo[1,2-a]pyrimidin-2- ylmethyl)-5,6-dihydro-2H-pyran-2-one;
2-[4-(2-{2-cyclopentyl-4-hydroxy-5-[(1-methyl-1/-/-indol-5-yl)methyl]-6-oxo-3,6-dihydro-2/-/-pyran-
2-yl}ethyI)-2-fluorophenyl]-2-methylpropanenitrile; 6-Cyclopentyl-3-(5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-ylmethyl)-6-[2-(3-ethyl-4-methoxy- phenyl)-ethyl]-4-hydroxy-5,6-dihydro-pyran-2-one;
6-[2-(5-chloro-2,4-dimethoxyphenyl)ethyl]-3-[(5-chloro-1-methyl-1/-/-benzimidazoI-2-yl)thio]-6- cyclopentyl-4-hydroxy-5,6-dihydro-2H-pyran-2-one;
6-cyclopentyl-3-[(5,7-dimethyl[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-6-[2-(3-fluoro-4- isopropoxyphenyl)ethyl]-4-hydroxy-5,6-dihydro-2/-/-pyran-2-one;
(+)-2-(2-fluoro-4-{2-[2-cyclopentyl-5-(5,7-dimethyl-[1 ,2,4]triazolo[1,5-a]pyrimidin-2-ylmethyl)-4- hydroxy-6-oxo-3,6-dihydro-2H-pyran-2-yl]-ethyl}-phenyl)-2-methyl-propionitrile;
(-)-2-(2-fluoro-4-{2-[2-cyclopentyl-5-(5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-ylmethyl)-4- hydroxy-6-oxo-3,6-dihydro-2rV-pyran-2-yl]-ethyl}-phenyl)-2-methyl-propionitrile; (+)-2-(2-chloro-4-{2-[2-cyclopentyl-5-(5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-ylmethyl)-4- hydroxy-6-oxo-3,6-dihydro-2H-pyran-2-yl]-ethyl}-phenyl)-2-methyl-propionitrile; (-)-2-(2-chloro-4-{2-[2-cyclopentyl-5-(5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-ylmethyl)-4- hydroxy-6-oxo-3,6-dihydro-2H-pyran-2-yl]-ethyl}-phenyl)-2-methyl-propionitrile; (+)-3-t(6-chloro[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-6-cyclopentyl-6-[2-(5-ethyl-4-hydroxy-2- methoxyphenyl)ethyl]-4-hydroxy-5,6-dihydro-2H-pyran-2-one;
(-)-3-[(6-chloro[1,2,4]triazolot1,5-a]pyrimidin-2-yl)methyl]-6-cyclopentyl-6-[2-(5-ethyl-4-hydroxy-2- methoxyphenyl)ethyl]-4-hydroxy-5,6-dihydro-2H-pyran-2-one; 6-Cyclopentyl-3-(5,7-dimethyI- [1,2,4]triazolo[1,5-a]pyrimidin-2-ylmethyl)-6-[2-(5-ethyl-4-hydroxy-2,3-dihydro-benzofuran-7-yl)- ethyl]-4-hydroxy-5,6-dihydro-pyran-2-one;
(+)-6-Cyclopentyl-3-(5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-ylmethyl)-6-[2-(5-ethyl-4- hydroxy-2,3-dihydro-benzofuran-7-yl)-ethyl]-4-hydroxy-5,6-dihydro-pyran-2-one; (-)-6-Cyclopentyl-3-(5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-ylmethyl)-6-[2-(5-ethyl-4- hydroxy-2,3-dihydro-benzofuran-7-yl)-ethyl]-4-hydroxy-5,6-dihydro-pyran-2-one; 6-Cyclopentyl-3-(5,7-dimethyl-t1 ,2,4]triazolo[1 ,5-a]pyrimidin-2-ylmethyI)-6-[2-(5-ethyl-pyridin-3-yl)- ethyl]-4-hydroxy-5,6-dihydro-pyran-2-one; and pharmaceutically acceptable salts, solvates and prodrugs of the foregoing compounds.
In yet another aspect of the present invention are provided compounds chosen from: (+)-2-(2-fluoro-4-{2-[2-cyclopentyl-5-(5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-ylmethyl)-4- hydroxy-6-oxo-3,6-dihydro-2H-pyran-2-yl]-ethyl}-phenyl)-2-methyl-propionitrile;
(-)-2-(2-fluoro-4-{2-[2-cyclopentyl-5-(5,7-dimethyl-[1,2,4]triazolo[1 ,5-a]pyrimidin-2-ylmethyl)-4- hydroxy-6-oxo-3,6-dihydro-2H-pyran-2-yI]-ethyl}-phenyl)-2-methyl-propionitrile; (+)-2-(2-chloro-4-{2-[2-cyclopentyl-5-(5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-ylmethyl)-4- hydroxy-6-oxo-3,6-dihydro-2H-pyran-2-yl]-ethyl}-phenyl)-2-methyl-propionitrile; (-)-2-(2-chloro-4-{2-[2-cyclopentyl-5-(5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-ylmethyl)-4- hydroxy-6-oxo-3,6-dihydro-2f/-pyran-2-yl]-ethyl}-phenyl)-2-methyl-propionitrile; (+)-3-[(6-chloro[1,2,4]triazoIo[1,5-a]pyrimidin-2-yl)methyl]-6-cyclopentyl-6-t2-(5-ethyl-4-hydroxy-2- methoxyphenyl)ethyl]-4-hydroxy-5,6-dihydro-2H-pyran-2-one; (-)-3-[(6-chIoro[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-6-cyclopentyl-6-[2-(5-ethyl-4-hydroxy-2- methoxyphenyl)ethyl]-4-hydroxy-5,6-dihydro-2W-pyran-2-one;
6-Cyclopentyl-3-(5,7-dimethyl-t1,2,4]triazolo[1,5-a]pyrimidin-2-ylmethyl)-6-[2-(5-ethyl-4-hydroxy- 2,3-dihydro-benzofuran-7-yl)-ethyl]-4-hydroxy-5,6-dihydro-pyran-2-one; (+)-6-Cyclopentyl-3-(5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-ylmethyl)-6-[2-(5-ethyl-4- hydroxy-2,3-dihydro-benzofuran-7-yl)-ethyl]-4-hydroxy-5,6-dihydro-pyran-2-one; (-)-6-Cyclopentyl-3-(5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-ylmethyl)-6-[2-(5-ethyl-4- hydroxy-2,3-dihydro-benzofuran-7-yl)-ethyl]-4-hydroxy-5,6-dihydro-pyran-2-one; 6-Cyclopentyl-3-(5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-ylmethyl)-6-[2-(5-ethyl-pyridin-3-yl)- ethyl]-4-hydroxy-5,6-dihydro-pyran-2-one;and pharmaceutically acceptable salts, solvates and prodrugs of the foregoing compounds.
The invention also relates to a method for the treatment of Hepatitis C virus (HCV) in a mammal, such as a human, comprising administering to said mammal an amount of a compound of the present invention or a salt or solvate thereof that is effective in treating HCV.
In a further aspect of the present invention are provided methods for the treatment of a mammal, such as a human, suffering from infection with Hepatitis C virus, comprising administering to said mammal a Hepatitis C virus-inhibiting amount of a compound of the present invention, or a pharmaceutically acceptable salt, prodrug, pharmaceutically active metabolite, or solvate thereof.
The present invention also relates to a method of inhibiting Hepatitis C polymerase, comprising contacting said polymerase with a polymerase-inhibiting amount of a compound of the present invention, or a pharmaceutically acceptable salt, prodrug, pharmaceutically active metabolite, or solvate thereof.
The present invention is also directed to a pharmaceutical composition for the treatment of Hepatitis C virus (HCV) in a mammal, such as a human, comprising an amount of a compound the present invention, or a pharmaceutically acceptable salt, prodrug, pharmaceutically active metabolite, or solvate thereof, that is effective in treating HCV, and a pharmaceutically acceptable carrier.
The present invention is also directed to inhibition of Hepatitis C virus replication in a mammal, such as a human, comprising administering to said mammal a Hepatitis C virus replication-inhibiting amount of a compound of the present invention.
The present invention is further directed to a method of inhibiting HCV RdRp activity, comprising contacting the protein with an effective amount of a compound of the present invention, or a pharmaceutically acceptable salt, prodrug, pharmaceutically active metabolite, or solvate thereof. For Example, HCV activity may be inhibited in mammalian tissue by administering an HCV-inhibiting agent according to the invention.
The present invention also relates to the use of the compounds of the invention in the preparation of a medicament for the treatment of a mammal suffering from infection with Hepatitis C virus. The medicament may comprise a Hepatitis C virus-inhibiting amount of a compound or compounds of the invention and a pharmaceutically acceptable carrier or carriers. As used herein, the terms "comprising" and "including" are used in their open, non- limiting sense.
In accordance with a convention used in the art, the symbol ^ is used in structural formulas herein to depict the bond that is the point of attachment of the moiety or substituent to the core or backbone structure. In accordance with another convention, in some structural formulae herein the carbon atoms and their bound hydrogen atoms are not explicitly depicted,
e.g., represents a methyl group,
Figure imgf000025_0001
represents a cyclopentyl group, etc.
The compounds of the present invention may exist in several tautomeric forms. For example, a compound of the invention may exist in a form in which two ketones are present on a ring of the compound, as shown in (A) below. Alternatively, the compounds of the present invention may exist in at least two different enol forms, as shown in compounds (B) and (C) below. These three forms may be in equilibrium and the compounds of the invention may exist in more than one of these forms at the same time. For example, in a particular compound of the invention, a certain percentage of the molecules may be present in form (A) while the remainder are present in form (B) or form (C). Which form predominates in a particular compound of the invention depends on several factors that include, but are not limited to, whether the compound is in solid, liquid, or crystalline form, whether the compound is dissolved in a solvent and the identity of the solvent, the environmental temperature, and the relative humidity. It is specifically contemplated that when the compounds of the present invention are drawn in a particular form, form (A) for example, all the tautomeric forms, forms (B) and (C) for example, are included as well.
Figure imgf000025_0002
(B) (A) (C)
The term "C C6 alkyl", as used herein, unless otherwise indicated, includes saturated monovalent hydrocarbon radicals having straight, branched, or cyclic moieties (including fused and bridged bicyclic and spirocyclic moieties), or a combination of the foregoing moieties, and containing from 1-6 carbon atoms. For an alkyl group to have cyclic moieties, the group must have at least three carbon atoms. A "lower alkyl" is intended to mean an alkyl group having from 1 to 4 carbon atoms in its chain. The term "heteroalkyl" refers to a straight- or branched-chain alkyl group having from 2 to
12 atoms in the chain, one or more of which is a heteroatom selected from S, O, and N.
Exemplary heteroalkyls include alkyl ethers, secondary and tertiary amines, alkyl sulfides and the like.
The term "C2-C6 alkenyl", as used herein, unless otherwise indicated, includes alkyl moieties having at least one carbon-carbon double bond wherein alkyl is as defined above and including E and Z isomers of said alkenyl moiety, and having from 2 to 6 carbon atoms.
The term "C2-C6 alkynyl", as used herein, unless otherwise indicated, includes alkyl moieties having at least one carbon-carbon triple bond wherein alkyl is as defined above, and containing from 2-6 carbon atoms.
The term "carbocycle" refers to a saturated, partially saturated, unsaturated, or aromatic, monocyclic or fused or non-fused polycyclic, ring structure having only carbon ring atoms (no heteroatoms, i.e., non-carbon ring atoms). Exemplary carbocycles include cycloalkyl, aryl, and cycloalkyl-aryl groups.
A "C3-C10 cycloalkyl group" is intended to mean a saturated or partially saturated, monocyclic, or fused or spiro polycyclic, ring structure having a total of from 3 to 10 carbon ring atoms (but no heteroatoms). Exemplary cycloalkyls include cyclopropyl, cyclobutyl, cyclopentyl, cyclopentenyl, cyclohexyl, cycloheptyl, adamantyl, and like groups. A "heterocycloalkyl group" is intended to mean a monocyclic, or fused or spiro polycyclic, ring structure that is saturated or partially saturated, and has a total of from 3 to 18 ring atoms, including 1 to 5 heteroatoms selected from nitrogen, oxygen, and sulfur. Illustrative Examples of heterocycloalkyl groups include pyrrolidinyl, tetrahydrofuryl, piperidinyl, piperazinyl, morpholinyl, thiomorpholinyl, aziridinyl, and like groups. The term "C6-C10 aryl", as used herein, unless otherwise indicated, includes an organic radical derived from an aromatic hydrocarbon by removal of one hydrogen, such as phenyl or naphthyl.
The term "4-10 membered heterocyclic", as used herein, unless otherwise indicated, includes aromatic and non-aromatic heterocyclic groups containing one to four heteroatoms each selected from O, S and N, wherein each heterocyclic group has from 4-10 atoms in its ring system, and with the proviso that the ring of said group does not contain two adjacent O or S atoms. Furthermore, the sulfur atoms contained in such heterocyclic groups may be oxidized with one or two sulfur atoms. Non-aromatic heterocyclic groups include groups having only 4 atoms in their ring system, but aromatic heterocyclic groups must have at least 5 atoms in their ring system. The heterocyclic groups include benzo-fused ring systems. An example of a 4 membered heterocyclic group is azetidinyl (derived from azetidine). An example of a 5 membered heterocyclic group is thiazolyl and an example of a 10 membered heterocyclic group is quinolinyl. Examples of non- aromatic heterocyclic groups are pyrrolidinyl, tetrahydrofuranyl, dihydrofuranyl, tetrahydrothiehyl, tetrahydropyranyl, dihydropyranyl, tetrahydrothiopyranyl, piperidino, morpholino, thiomorpholino, thioxanyl, piperazinyl, azetidinyl, oxetanyl, thietanyl, homopiperidinyl, oxepanyl, thiepanyl, oxazepinyl, diazepinyl, thiazepinyl, 1 ,2,3,6-tetrahydropyridinyl, 2-pyrrolinyl, 3-pyrrolinyl, indolinyl, 2H-pyranyl, 4H-pyranyl, dioxanyl, 1,3-dioxolanyl, pyrazolinyl, dithianyl, dithiolanyl, dihydropyranyl, dihydrothienyl, dihydrofuranyl, pyrazolidinyl, imidazolinyl, imidazolidinyl, 3- azabicyclo[3.1.0]hexanyl, 3-azabicyclo[4.1.0]heptanyl, 3H-indolyl and quinolizinyl. Examples of aromatic heterocyclic groups are pyridinyl, imidazolyl, pyrimidinyl, pyrazolyl, triazolyl, pyrazinyl, tetrazolyl, furyl, thienyl, isoxazolyl, thiazolyl, oxazolyl, isothiazolyl, pyrrolyl, quinolinyl, isoquinolinyl, indolyl, benzimidazolyl, benzofuranyl, cinnolinyl, indazolyl, indolizinyl, phthalazinyl, pyridazinyl, triazinyl, isoindolyl, pteridinyl, purinyl, oxadiazolyl, thiadiazolyl, furazanyl, benzofurazanyl, benzothiophenyl, benzothiazolyl, benzoxazolyl, quinazolinyl, quinoxalinyl, naphthyridinyl, and furopyridinyl. The foregoing groups, as derived from the groups listed above, may be C-attached or N-attached where such is possible. For instance, a group derived from pyrrole may be pyrrol-1-yl (N-attached) or pyrrol-3-yl (C-attached). Further, a group derived from imidazole may be imidazol-1-yl (N-attached) or imidazol-3-yl (C-attached). An example of a heterocyclic group wherein 2 ring carbon atoms are substituted with oxo (=0) moieties is 1,1-dioxo- thiomorpholinyl.
A "heteroaryl group" is intended to mean a monocyclic or fused or spiro polycyclic, aromatic ring structure having from 4 to 18 ring atoms, including from 1 to 5 heteroatoms selected from nitrogen, oxygen, and sulfur. Illustrative Examples of heteroaryl groups include pyrrolyl, thienyl, oxazolyl, pyrazolyl, thiazolyl, furyl, pyridinyl, pyrazinyl, triazolyl, tetrazolyl, indolyl, quinolinyl, quinoxalinyl, benzthiazolyl, benzodioxinyl, benzodioxolyl, benzooxazolyl, and the like.
The term "alkoxy", as used herein, unless otherwise indicated, includes O-alkyl groups wherein alkyl is as defined above.
The term "amino" is intended to mean the -NH2 radical. The terms "halogen" and "halo," as used herein represent chlorine, fluorine, bromine or iodine.
The term "trifluoromethyl," as used herein, is meant to represent a group -CF3.
The term "trifluoromethoxy," as used herein, is meant to represent a group -OCF3.
The term "cyano," as used herein, is meant to represent a group -CN. The term "substituted" means that the specified group or moiety bears one or more substituents. The term "unsubstituted" means that the specified group bears no substituents. The term "optionally substituted" means that the specified group is unsubstituted or substituted by one or more substituents. The term "HCV," as used herein, refers to Hepatitis C virus.
The term "inhibiting Hepatitis C virus" means inhibiting Hepatitis C virus replication in a mammal, such as a human, by administering to the mammal a Hepatitis C virus-inhibiting amount of a compound of the invention. The amount of inhibition of Hepatitis C virus replication in a mammal can be measured using methods known to those of ordinary skill in the art. For example, an amount of a compound of the invention may be administered to a mammal, either alone or as part of a pharmaceutically acceptable formulation. Blood samples may then be withdrawn from the mammal and the amount of Hepatitis C virus in the sample may be quantified using methods known to those of ordinary skill in the art. A reduction in the amount of Hepatitis C virus in the sample compared to the amount found in the blood before administration of a compound of the invention would represent inhibition of the replication of Hepatitis C virus in the mammal. The administration of a compound of the invention to the mammal may be in the form of single dose or a series of doses over successive days.
An "HCV-inhibiting agent" means a compound of the present invention or a pharmaceutically acceptable salt, hydrate, prodrug, active metabolite or solvate thereof. The term "HCV-inhibiting amount," as used herein, refers to an amount of a compound of the present invention that is sufficient to inhibit the replication of the Hepatitis C virus when administered to a mammal, such as a human.
The term "HCV polymerase-inhibiting amount," as used herein, means an amount of a compound of the present invention that is sufficient to inhibit the function of the Hepatitis C virus polymerase enzyme when the compound is placed in contact with the enzyme.
A "prodrug" is a compound that may be converted under physiological conditions or by solvolysis to the specified compound or to a pharmaceutically acceptable salt of such compound. A prodrug may be a derivative of one of the compounds of the present invention that contains a moiety, such as for example-C02R,-PO(OR)2 or-C=NR, that may be cleaved under physiological conditions or by solvolysis. Any suitable R substituent may be used that provides a pharmaceutically acceptable solvolysis or cleavage product. A prodrug containing such a moiety may be prepared according to conventional procedures by treatment of a hydroxamate derivative of this invention containing, for example, an amido, carboxylic acid, or hydroxyl moiety with a suitable reagent. An "active metabolite" is a pharmacologically active product produced through metabolism in the body of a specified hydroxamate derivative or salt thereof. Prodrugs and active metabolites of the hydroxamate derivative may be identified using routine techniques known in the art. See, e.g., Bertolini et al., J. Med. Chem., 40:2011-2016 (1997); Shan et al., J. Pharm. Sci., 86 (7):765-767 (1997); Bagshawe, Drug Dev. Res., 34:220-230 (1995); Bodor, /Advances in Drug Res., 13:224-331 (1984); Bundgaard, "Design of Prodrugs" (Elsevier Press, 1985); Larsen, Design and Application of Prodrugs, Drug Design and Development (Krogsgaard-Larsen et al. eds., Harwood Academic Publishers, 1991); Dear et al., Chromatogr. B, 748:281-293 (2000); Spraul et al., J. Pharmaceutical & Biomedical Analysis, 10 (8):601-605 (1992); and Prox et al., Xenobiol, 3(2):103-112 (1992). A "solvate" is intended to mean a pharmaceutically acceptable solvate form of a specified compound that retains the biological effectiveness of such compound. Examples of solvates include compounds of the invention in combination with solvents such as, but not limited to, water, isopropanol, ethanol, methanol, DMSO, ethyl acetate, acetic acid, or ethanolamine. A "pharmaceutically acceptable salt" is intended to mean a salt that retains the biological effectiveness of the free acids and bases of the specified derivative and that is not biologically or otherwise undesirable. Examples of pharmaceutically acceptable salts include sulfates, pyrosulfates, bisulfates, sulfites, bisulfites, phosphates, monohydrogenphosphates, dihydrogenphosphates, metaphosphates, pyrophosphates, chlorides, bromides, iodides, acetates, propionates, decanoates, caprylates, acrylates, formates, isobutyrates, caproates, heptanoates, propiolates, oxalates, malonates, succinates, suberates, sebacates, fumarates, maleates, butyne-1 ,4-dioates, hexyne-1,6-dioates, benzoates, chlorobenzoates, methylbenzoates, dinitrobenzoates, hydroxybenzoates, methoxybenzoates, phthalates, sulfonates, xylenesulfonates, phenylacetates, phenylpropionates, phenylbutyrates, citrates, lactates, γ-hydroxybutyrates, glycollates, tartrates, methane-sulfonates, propanesulfonates, naphthalene-1 -sulfonates, naphthalene-2-sulfonates, and mandelates.
The term "treating", as used herein, unless otherwise indicated, means reversing, alleviating, inhibiting the progress of, or preventing the disorder or condition to which such term applies, or one or more symptoms of such disorder or condition. The term "treatment", as used herein, unless otherwise indicated, refers to the act of treating as "treating" is defined immediately above.
The phrase "pharmaceutically acceptable salt(s)", as used herein, unless otherwise indicated, includes salts of acidic or basic groups, which may be present in the compounds of the present invention. The compounds of the present invention that are basic in nature are capable of forming a wide variety of salts with various inorganic and organic acids. The acids that may be used to prepare pharmaceutically acceptable acid addition salts of such basic compounds of the present invention are those that form non-toxic acid addition salts, e , salts containing pharmacologically acceptable anions, such as the acetate, benzenesulfonate, benzoate, bicarbonate, bisulfate, bitartrate, borate, bromide, calcium edetate, camsylate, carbonate, chloride, clavulanate, citrate, dihydrochloride, edetate, edislyate, estolate, esylate, ethylsuccinate, fumarate, gluceptate, gluconate, glutamate, glycollylarsanilate, hexylresorcinate, hydrabamine, hydrobromide, hydrochloride, iodide, isothionate, lactate, lactobionate, laurate, malate, maleate, mandelate, mesylate, methylsulfate, mucate, napsylate, nitrate, oleate, oxalate, pamoate (embonate), palmitate, pantothenate, phospate/diphosphate, polygalacturonate, salicylate, stearate, subacetate, succinate, tannate, tartrate, teoclate, tosylate, triethiodode, and valerate salts.
The phrases "therapeutically effective amount," "effective amount," and "HCV-inhibiting amount," are intended to mean the amount of an inventive agent that, when administered to a mammal in need of treatment, is sufficient to effect treatment for injury or disease conditions alleviated by the inhibition of HCV RNA replication such as for potentiation of anti-cancer therapies or inhibition of neurotoxicity consequent to stroke, head trauma, and neurodegenerative diseases. The amount of a given HCV-inhibiting agent used in the method of the invention that will be therapeutically effective will vary depending upon factors such as the particular HCV- inhibiting agent, the disease condition and the severity thereof, the identity and characteristics of the mammal in need thereof, which amount may be routinely determined by artisans.
DETAILED DESCRIPTION OF THE INVENTION
The compounds of the present invention may have asymmetric carbon atoms. The carbon-carbon bonds of the compounds of the present invention may be depicted herein using a solid line ( ), a solid wedge ( """■ — m ), or a dotted wedge ( '"" ). The use of a solid line to depict bonds to asymmetric carbon atoms is meant to indicate that all possible stereoisomers at that carbon atom are included. The use of either a solid or dotted wedge to depict bonds to asymmetric carbon atoms is meant to indicate that only the stereoisomer shown is meant to be included. It is possible that compounds of the invention may contain more than one asymmetric carbon atom. In those compounds, the use of a solid line to depict bonds to asymmetric carbon atoms is meant to indicate that all possible stereoisomers are meant to be included. The use of a solid line to depict bonds to one or more asymmetric carbon atoms in a compound of the invention and the use of a solid or dotted wedge to depict bonds to other asymmetric carbon atoms in the same compound is meant to indicate that a mixture of diastereomers is present.
Solutions of individual stereoisomeric compounds of the present invention may rotate plane-polarized light. The use of either a "(+)" or "(-)" symbol in the name of a compound of the invention indicates that a solution of a particular stereoisomer rotates plane-polarized light in the (+) or (-) direction, as measured using techniques known to those of ordinary skill in the art. Diastereomeric mixtures can be separated into their individual diastereomers on the basis of their physical chemical differences by methods known to those skilled in the art, for example, by chromatography or fractional crystallization. Enantiomers can be separated by converting the enantiomeric mixtures into a diastereomeric mixture by reaction with an appropriate optically active compound (e.g., alcohol), separating the diastereomers and converting (e.g., hydrolyzing) the individual diastereomers to the corresponding pure enantiomers. All such isomers, including diastereomeric mixtures and pure enantiomers are considered as part of the invention. Alternatively, individual stereoisomeric compounds of the present invention may be prepared in enantiomerically enriched form by asymmetric synthesis. Asymmetric synthesis may be performed using techniques known to those of skill in the art, such as the use of asymmetric starting materials that are commercially available or readily prepared using methods known to those of ordinary skill in the art, the use of asymmetric auxiliaries that may be removed at the completion of the synthesis, or the resolution of intermediate compounds using enzymatic methods. The choice of such a method will depend on factors that include, but are not limited to, the availability of starting materials, the relative efficiency of a method, and whether such methods are useful for the compounds of the invention containing particular functional groups. Such choices are within the knowledge of one of ordinary skill in the art. When the compounds of the present invention contain asymmetric carbon atoms, the derivative salts, prodrugs and solvates may exist as single stereoisomers, racemates, and/or mixtures of enantiomers and/or diastereomers. All such single stereoisomers, racemates, and mixtures thereof are intended to be within the scope of the present invention.
As generally understood by those skilled in the art, an optically pure compound is one that is enantiomerically pure. As used herein, the term "optically pure" is intended to mean a compound comprising at least a sufficient activity. Preferably, an optically pure amount of a single enantiomer to yield a compound having the desired pharmacological pure compound of the invention comprises at least 90% of a single isomer (80% enantiomeric excess), more preferably at least 95% (90% e.e.), even more preferably at least 97.5% (95% e.e.), and most preferably at least 99% (98% e.e.).
If a derivative used in the method of the invention is a base, a desired salt may be prepared by any suitable method known to the art, including treatment of the free base with an inorganic acid, such as hydrochloric acid; hydrobromic acid; sulfuric acid; nitric acid; phosphoric
\ acid; and the like, or with an organic acid, such as acetic acid; maleic acid; succinic acid; mandelic acid; fumaric acid; malonic acid; pyruvic acid; oxalic acid; glycolic acid; salicylic acid; pyranosidyl acid, such as glucuronic acid or galacturonic acid; alpha-hydroxy acid, such as citric acid or tartaric acid; amino acid, such as aspartic acid or glutamic acid; aromatic acid, such as benzoic acid or cinnamic acid; sulfonic acid, such as p-toluenesulfonic acid or ethanesulfonic acid; and the like.
If a derivative used in the method of the invention is an acid, a desired salt may be prepared by any suitable method known to the art, including treatment of the free acid with an inorganic or organic base, such as an amine (primary, secondary, or tertiary); an alkali metal or alkaline earth metal hydroxide; or the like. Illustrative Examples of suitable salts include organic salts derived from amino acids such as glycine and arginine; ammonia; primary, secondary, and tertiary amines; and cyclic amines, such as piperidine, morpholine, and piperazine; as well as inorganic salts derived from sodium, calcium, potassium, magnesium, manganese, iron, copper, zinc, aluminum, and lithium. In the case of derivatives, prodrugs, salts, or solvates that are solids, it is understood by those skilled in the art that the derivatives, prodrugs, salts, and solvates used in the method of the invention, may exist in different polymorph or crystal forms, all of which are intended to be within the scope of the present invention and specified formulas. In addition, the derivative, salts, prodrugs and solvates used in the method of the invention may exist as tautomers, all of which are intended to be within the broad scope of the present invention.
The compounds of the present invention that are basic in nature are capable of forming a wide variety of different salts with various inorganic and organic acids. Although such salts must be pharmaceutically acceptable for administration to animals, it is often desirable in practice to initially isolate the compound of the present invention from the reaction mixture as a pharmaceutically unacceptable salt and then simply convert the latter back to the free base compound by treatment with an alkaline reagent and subsequently convert the latter free base to a pharmaceutically acceptable acid addition salt. The acid addition salts of the base compounds of this invention are readily prepared by treating the base compound with a substantially equivalent amount of the chosen mineral or organic acid in an aqueous solvent medium or in a suitable organic solvent, such as methanol or ethanol. Upon careful evaporation of the solvent, the desired solid salt is readily obtained. The desired acid salt can also be precipitated from a solution of the free base in an organic solvent by adding to the solution an appropriate mineral or organic acid.
Those compounds of the present invention that are acidic in nature are capable of forming base salts with various pharmacologically acceptable cations. Examples of such salts include the alkali metal or alkaline-earth metal salts and particularly, the sodium and potassium salts. These salts are all prepared by conventional techniques. The chemical bases which are used as reagents to prepare the pharmaceutically acceptable base salts of this invention are those which form nontoxic base salts with the acidic compounds of the present invention. Such non-toxic base salts include those derived from such pharmacologically acceptable cations as sodium, potassium calcium and magnesium, etc. These salts can easily be prepared by treating the corresponding acidic compounds with an aqueous solution containing the desired pharmacologically acceptable cations, and then evaporating the resulting solution to dryness, preferably under reduced pressure. Alternatively, they may also be prepared by mixing lower alkanolic solutions of the acidic compounds and the desired alkali metal alkoxide together, and then evaporating the resulting solution to dryness in the same manner as before. In either case, stoichiometric quantities of reagents are preferably employed in order to ensure completeness of reaction and maximum yields of the desired final product.
The activity of the compounds as inhibitors of HCV activity may be measured by any of the suitable methods available in the art, including in vivo and in vitro assays. An Example of a suitable assay for activity measurements is the HCV replicon assay described herein.
Administration of the compounds and their pharmaceutically acceptable prodrugs, salts, active metabolites, and solvates may be performed according to any of the accepted modes of administration available to those skilled in the art. Illustrative Examples of suitable modes of administration include oral, nasal, parenteral, topical, transdermal, and rectal. Oral and intravenous deliveries are preferred.
An HCV-inhibiting agent of the present invention may be administered as a pharmaceutical composition in any suitable pharmaceutical form. Suitable pharmaceutical forms include solid, semisolid, liquid, or lyopholized formulations, such as tablets, powders, capsules, suppositories, suspensions, liposomes, and aerosols. The HCV-inhibiting agent may be prepared as a solution using any of a variety of methodologies. For Example, the HCV-inhibiting agent can be dissolved with acid (e.g., 1 M HCl) and diluted with a sufficient volume of a solution of 5% dextrose in water (D5W) to yield the desired final concentration of HCV-inhibiting agent (e.g., about 15 mM). Alternatively, a solution of D5W containing about 15 mM HCl can be used to provide a solution of the HCV-inhibiting agent at the appropriate concentration. Further, the HCV- inhibiting agent can be prepared as a suspension using, for example, a 1% solution of carboxymethylcellulose (CMC).
Acceptable methods of preparing suitable pharmaceutical forms of the pharmaceutical compositions are known or may be routinely determined by those skilled in the art. For Example, pharmaceutical preparations may be prepared following conventional techniques of the pharmaceutical chemist involving steps such as mixing, granulating, and compressing when necessary for tablet forms, or mixing, filling, and dissolving the ingredients as appropriate, to give the desired products for oral, parenteral, topical, intravaginal, intranasal, intrabronchial, intraocular, intraaural, and/or rectal administration.
Pharmaceutical compositions of the invention may also include suitable excipients, diluents, vehicles, and carriers, as well as other pharmaceutically active agents, depending upon the intended use. Solid or liquid pharmaceutically acceptable carriers, diluents, vehicles, or excipients may be employed in the pharmaceutical compositions. Illustrative solid carriers include starch, lactose, calcium sulfate dihydrate, terra alba, sucrose, talc, gelatin, pectin, acacia, magnesium stearate, and stearic acid. Illustrative liquid carriers include syrup, peanut oil, olive oil, saline solution, and water. The carrier or diluent may include a suitable prolonged-release material, such as glyceryl monostearate or glyceryl distearate, alone or with a wax. When a liquid carrier is used, the preparation may be in the form of a syrup, elixir, emulsion, soft gelatin capsule, sterile injectable liquid (e.g., solution), or a nonaqueous or aqueous liquid suspension.
A dose of the pharmaceutical composition may contain at least a therapeutically effective amount of an HCV-inhibiting agent and preferably is made up of one or more pharmaceutical dosage units. The selected dose may be administered to a mammal, for example, a human, in need of treatment mediated by inhibition of HCV activity, by any known or suitable method of administering the dose, including topically, for example, as an ointment or cream; orally; rectally, for example, as a suppository; parenterally by injection; intravenously; or continuously by intravaginal, intranasal, intrabronchial, intraaural, or intraocular infusion. When the composition is administered in conjunction with a cytotoxic drug, the composition can be administered before, with, and/or after introduction of the cytotoxic drug. However, when the composition is administered in conjunction with radiotherapy, the composition is preferably introduced before radiotherapy is commenced.
Methods of preparing various pharmaceutical compositions with a specific amount of active compound are known, or will be apparent, to those skilled in this art. For examples, see Remington's Pharmaceutical Sciences. Mack Publishing Company, Easter, Pa., 15th Edition (1975). It will be appreciated that the actual dosages of the HCV-inhibiting agents used in the pharmaceutical compositions of this invention will be selected according to the properties of the particular agent being used, the particular composition formulated, the mode of administration and the particular site, and the host and condition being treated. Optimal dosages for a given set of conditions can be ascertained by those skilled in the art using conventional dosage- determination tests. For oral administration, e.g., a dose that may be employed is from about 0.001 to about 1000 mg/kg body weight, preferably from about 0.1 to about 100 mg/kg body weight, and even more preferably from about 1 to about 50 mg/kg body weight, with courses of treatment repeated at appropriate intervals. The subject invention also includes isotopically-labelled compounds, which are identical to those recited in the compounds of the present invention, but for the fact that one or more atoms are replaced by an atom having an atomic mass or mass number different from the atomic mass or mass number usually found in nature. Examples of isotopes that can be incorporated into compounds of the invention include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorous, fluorine and chlorine, such as 2H, 3H, 13C, 14C, 15N, 1δO, 170, 31P, 32P, 35S, 18F, and 36Ci, respectively. Compounds of the present invention, prodrugs thereof, and pharmaceutically acceptable salts of said compounds or of said prodrugs which contain the aforementioned isotopes and/or other isotopes of other atoms are within the scope of this invention. Certain isotopically-labelled compounds of the present invention, for example those into which radioactive isotopes such as 3H and 1 C are incorporated, are useful in drug and/or substrate tissue distribution assays. Tritiated, i.e., 3H, and carbon-14, i.e., 14C, isotopes are particularly preferred for their ease of preparation and detectability. Further, substitution with heavier isotopes such as deuterium, i.e., 2H, can afford certain therapeutic advantages resulting from greater metabolic stability, for example increased in vivo half-life or reduced dosage requirements and, hence, may be preferred in some circumstances. Isotopically labelled compounds of the present invention and prodrugs thereof can generally be prepared by carrying out the procedures disclosed in the Schemes and/or in the Examples and Preparations below, by substituting a readily available isotopically labelled reagent for a non-isotopically labelled reagent.
EXAMPLES Specific Examples of various compounds according to the invention may be advantageously prepared as set out in the Examples above. These examples and the compounds contained therein are not meant to limit the scope of the present invention in any way. The structures of the compounds of the following Examples were confirmed by one or more of the following: proton magnetic resonance spectroscopy, infrared spectroscopy, elemental microanalysis, mass spectrometry, thin layer chromatography, melting point, boiling point, and HPLC. Proton magnetic resonance (1H NMR) spectra were determined using a 300 megahertz
Tech-Mag, Bruker Avance 300DPX, or Bruker Avance 500 DRX spectrometer operating at a field strength of 300 or 500 megahertz (MHz). Chemical shifts are reported in parts per million (ppm, δ) downfield from an internal tetramethylsilane standard. Alternatively, 1H NMR spectra were referenced to residual protic solvent signals as follows: CHCI3 = 7.26 ppm; DMSO = 2.49 ppm; CβHDδ = 7.15 ppm. Peak multiplicities are designated as follows: s = singlet; d = doublet; dd = doublet of doublets; t = triplet; q = quartet; br = broad resonance; and m = multiplet. Coupling constants are given in Hertz. Infrared absorption (IR) spectra were obtained using a Perkin- Elmer 1600 series FTIR spectrometer. Elemental microanalyses were performed by Atlantic Microlab Inc. (Norcross, GA) and gave results for the elements stated within ±0.4% of the theoretical values. Flash column chromatography was performed using Silica gel 60 (Merck Art 9385). Analytical thin layer chromatography (TLC) was performed using precoated sheets of Silica 60 F254 (Merck Art 5719). HPLC chromatographs were run on a Hewlett Packard Model 1100 system fitted with a Zorbax SB-C18 4.6 mm x 150 mm column having 3.5 micron packing material. Unless otherwise stated, a ramp of 5% CH3CN/H20 to 95% CH3CN/H20 over 7.5 minutes then holding at 95% CH3CN/H20 for 2.5 minutes (both solvents contained 0.1 % v/v TFA) at a flow of 1 mL/min was used. Retention times (Rt) are given in minutes. Semi-preparative HPLC samples were run on a Gilson LC3D system fitted with a 21.2 mm x 250 mm C8 column. Ramps were optimized for each compound with a CH3CN/H20 solvent system. Melting points were determined on a Mel-Temp apparatus and are uncorrected. All reactions were performed in septum-sealed flasks under a slight positive pressure of argon, unless otherwise noted. All commercial reagents were used as received from their respective suppliers with the following exceptions: tetrahydrofuran (THF) was distilled from sodium-benzophenone ketyl prior to use; dichloromethane (CH2CI2) was distilled from calcium hydride prior to use; anhydrous lithium chloride was prepared by heating at 110°C under vacuum overnight. Mass spectra, both low and high resolution, were measured using either electrospray (El) or fast atom bombardment (FAB) ionization techniques.
The following abbreviations are used herein: Et2θ (diethyl ether); DMF (N,N- dimethylformamide); DMSO (dimethylsulfoxide); MeOH (methanol); EtOH (ethanol); EtOAc (ethyl acetate); Ac (acetyl); Hex (hexane); Me (methyl); Et (ethyl); Ph (phenyl); DIEA (diisopropylethylamine); TFA (trifluoroacetic acid); DTT (dithiothreitol); and THF (tetrahydrofuran); and (precipitate); min. or min (minutes); h (hours).
Solid-phase syntheses were performed by immobilizing reagents with Rink amide linkers (Rink, Tetrahedron Letters (1987) 28:3787), which are standard acid-cleavable linkers that upon cleavage generate a free carboxamide group. Small-scale solid-phase syntheses, e.g., about 2 - 5 μmole, were performed using Chiron SynPhase® polystyrene O-series crowns (pins) derivatized with Fmoc-protected Rink amide linkers. For larger scale (e.g., greater than about 100 μmole) syntheses, the Rink amide linkages were formed to Argonaut Technologies Argogel® resin, a grafted polystyrene-poly(ethylene glycol) copolymer. Any suitable resin may be used as the solid phase, selected from resins that are physically resilient and that, other than with regard to the linking and cleavage reactions, are inert to the synthetic reaction conditions. Example A(1): 6-Cyclopentyl-6-[2-(1-ethyl-6-oxo-1,6-dihydro-pyridin-3-yl)-ethyl]-dihydro- pyran-2,4-dione.
Figure imgf000037_0001
The title compound was prepared analogously to Example A(82), where 5-Bromo-1-ethyl- 1 H-pyridin-2-one was substituted in place of 2-Bromopyridine in Step 1 of that example.
lH NMR (CDC13): δ 1.35 (t, J= 7.2 Hz, 3H), 1.52-1.81 (brm, 8H), 1.87 (m, 2H), 2.28 (m, IH), 2.45 (t; J= 8.5 Hz, 2H), 2.72 (d, = 16 Hz, IH), 2.80 (d, J= 16 Hz, IH), 3.43 (s, 2H), 3.96 (q, = 7.2 Hz, 2H), 6.54 (d, J= 9.2 Hz, IH), 7.06 (s, IH), 7.14 (d, J= 9.2 Hz, IH). Anal. Calcd. For C19H25N104: C, 68.86; H, 7.60; N, 4.23. Found: C, 68.74; H, 7.42; N, 4.34.
Example A(2): 6-[2-(3-tert-Butyl-4-hydroxy-phenyl)-ethyl]-6-cyclopentyl-dihydro-pyran-2,4- dione.
Figure imgf000038_0001
The title compound was prepared analogously to Example A(22), where 4-Bromo-2-tert- butyl-phenol from Step 1 , was used in place of 4-Bromo-2-ethyl-phenol in Step 2 of that example.
'H NMR (CDC13): δ 1.39 (s, 9H,), 1.43-1.85 (br m, 8H), 1.87 - 2.01 (m, 2H), 2.27 (m, 1 H), 2.60 (t, J= 8.4 Hz, 2H), 2.77 (s, 2H), 3.42 (s, 2H), 4.74 (s, IH), 6.60 (d, J= 8.1 Hz IH)), 6.84 (d, J= 8.1 Hz, IH), 7.00 (s, IH).
Step l. 4-Bromo-2-tert-butyl-phenol
Figure imgf000038_0002
2-tert-Butyl-phenol (5 g, 0.033 mol) was dissolved in CHCI3 (100 mL) and magnetically stirred at room temperature. To this solution was added a solution of Tetrabutyl ammonium tribromide (16.05 g, 0.033 mol) in CHCI3 (100mL). The resulting yellow solution was allowed to stir at room temperature for 1 hour. The reaction was quenched with a 5% solution of sodium thiosulfate (200 mL). The biphasic mixture was stirred for 15 min. The organics were separated and concentrated. The residue was dissolved in EtOAc (100 mL) and washed with water (2 x 100 mL) and brine (1 x 100mL). The organics were dried over Na2S04, filtered and concentrated. The residue was purified by flash chromatography (silica gel) eluting with 3% EtOAc in Hexanes. The result was a clear oil (6.8 g, 89%)
'HNMR CDClj): δ 1.39 (s, 9H), 4.95 (s, 1 H), 6.59 (d, J= 8.5 Hz IH), 7.19 (d, J= 8.5 Hz, IH), 7.24 (s, IH). Example A(3): 6-Cyclopentyl-6-[2-(4-ethoxy-3-methyl-phenyl)-ethyl]-dihydro-pyran-2,4- dione.
Figure imgf000039_0001
The title compound was prepared analogously to Example A(82), where 4-Bromo-1- ethoxy-2-methyl-benzene was substituted in place of 2-Bromopyridine in Step 1 of that example.
Η NMR (CDC13): δ 1.40 (t, J= 7 Hz, 3H), 1.52-1.81 (brm, 8H), 1.99 (m, 2H), 2.19 (s, 3H), 2.30 (m, IH), 2.58 (t, J= 8.6 Hz, 2H), 2.76 (s, 2H), 3.41 (s, 2H), 4.00 (q, J= 7Hz, 2H), 6.71 (d, = 8.8 Hz, IH), 6.89 (m, 2H). Anal. Calcd. For C21H28O4: C, 73.23; H, 8.19. Found: C, 73.12; H, 8.22.
Example A(4): 6-Cyclopentyl-6-[2-(4-isopropoxy-3-methyl-phenyl)-ethyl]-dihydro-pyran-2,4- dione.
Figure imgf000039_0002
The title compound was prepared analogously to Example A(82), where 4-Bromo-1- isopropoxy-2-methyl-benzene was substituted in place of 2-Bromopyridine in Step 1 of that example.
Η NMR (CDCI3): δ 1.30 (d, J= 6.2 Hz, 6H), 1.52-1.81 (brm, 8H), 1.99 (m, 2H), 2.15 (s, 3H), 2.37 (m, IH), 2.58 (t, J= 8.6 Hz, 2H), 2.74 (s, 2H), 3.42 (s, 2H), 4.43 (m, IH), 6.71 (d, J= 8.2 Hz, IH), 6.88 (m,
2H). Anal. Calcd. For C22H3o04: C, 73.71; H, 8.44. Found: C, 73.64; H, 8.22. Example A(5): 6-{2-[3-Chloro-4-(2,2,2-trifluoro-ethoxy)-phenyl]-ethyl}-6-cyclopentyl- dihydro-pyran-2,4-dione.
Figure imgf000040_0001
The title compound was prepared analogously to Example A(82), where was 4-Bromo-2- chloro-1-(2,2,2-trifluoro-ethoxy)-benzene substituted in place of 2-Bromopyridine in Step 1 of that example.
Η NMR (CDCI3): δ 1.44-1.77 (brm, 8H), 1.92 (m, 2H), 2.27 (m, IH), 2.63 (m, 2H), 2.74 (d, J= 15.8 Hz, IH), 2.79 (d, J= 15.8 Hz, IH), 3.43 (s, 2H), 4.35 (d, = 8.1 Hz, IH), 4.40 (d, J= 8.1 Hz, IH), 6.90 (d, J= 8.5 Hz, IH), 7.02 (d, = 8.5 Hz, IH), 7.19 (s, IH). Anal. Calcd. For C2oH22ClF3θ4: C, 57.35; H, 5.29. Found: C, 57.55; H, 5.12.
Example A(6): 6-Cyclopentyl-6-(4-methoxy-phenylsulfanylmethyl)-dihydro-pyran-2,4-dione.
Figure imgf000040_0002
1-CyclopentyI-2-(4-methoxy-phenylsulfanyl)-ethanone (from Step 2 below) was subjected to the methyl acetoacetate dianion addition reaction described in the synthesis of Example A(82), to yield the title compound as a white solid.
lR NMR (CDCI3): δ 1.35-1.86 (brm, 8H), 2.35 (m, IH), 2.61-3.62 (m, 6H), 3.85 (s, 3H), 6.82 (d, = 8.2 Hz, 2H), 7.44 (d; = 8.2 Hz, 2H).
Step 1: 2-Chloro-1-cyclopentyl-et anone.
Figure imgf000041_0001
Cyclopentanecarbonyl chloride (5.0 g, 0.038 mol) was dissolved in THF (100 mL) and cooled to 0 °C. The solution was treated with a 2M solution of TMS-Diazomethane in hexanes (56.56 mL, 0.113 mol) over 10 min. The resulting yellow solution was allowed to stand at room temperature for 12 hours. The solution was then concentrated and the residue was dissolved in THF (100 mL) and treated slowly with a 4N HCl in Dioxane solution (28.28 mL, 0.113 mol). The result was allowed to stir at 24 °C for 2 hours. The solution was concentrated to an oil which was chromatographed on silica gel eluting with 5% EtOAc in Hexanes to give the intermediate depicted below (4.9 g, 88%)
'HNMR CCDCls): δ 1.62-1.98 (m, 8H), 3.12-3.25 (m, IH), 4.21 (s, 2H).
Step 2: 1-Cyclopentyl-2-(4-methoxy-phenylsulfanyl)-ethanone.
Figure imgf000041_0002
The intermediate 2-Chloro-l-cyclopentyl-ethanone from Step 1 (1 g, 6.81 mmol), was combined with 4- methoxy-benzenethiol (1.05 g, 7.50 mmol), in THF (20 mL) and treated with Triethylamine (1.05 mL, 7,50 mmol). The mixture was stirred for 1 hour at room temperature then poured into water (50 mL) and extracted with EtOAc (2X 50 mL). The organics were then washed with 0.5N HCl (2x 50 mL), 2N NaOH (2x 50 mL), water (2 x 50 mL) and brine (lx 50 mL) the organics were dried over Na2S04, filtered and concentrated. The residue was used without further purification (1.65 g, 97%).
Example A(7): N-{4-[2-(2-Cyclopentyl-4,6-dioxo-tetrahydro-pyran-2-yl)-ethyl]-2-fluoro- phenyl}-acetamide.
Figure imgf000042_0001
The title compound was prepared analogously to Example A(64), where Λ/-(4-Bromo-2- fluoro-phenyi)-acetamide was substituted in place of 4-bromo-2-fluoro-1-isopropylbenzene of that example.
'H N IKCDCla): δ 1.55-1.77 (br m, 8H), 1.94 (m, 2H), 2.21 (s, 3H), 2.26 (m, 1H), 2.65 (m, 2H), 2.76 (s, 2H), 3.43 (s, 2H), 6.90 (m, 2H), 8.19 (t, IH, J= 8.3 Hz). ESIMS: (M + H)+ 384.05.
Example A(8): 6-Cyclopentyl-6-[2-(3-fluoro-4-methoxymethyl-phenyl)-et yl]-dihydro-pyran- 2,4-dione
Figure imgf000042_0002
The title compound was prepared analogously to Example A(64), where 4-Bromo-2-fluoro-1- methoxymethyl-benzene was substituted in place of 4-bromo-2-fluoro-1-isopropylbenzene of that example.
Η NMR (CDC13): δ 1.55-1.80 (br m, 8H), 1.95 (m, 2H), 2.27 (m, IH), 2.68 (m, 2H); 2.76 (s, 2H), 3.40 (s, 3H), 3.43 (s, 2H), 4.48 (s, 2H), 6.85 (d, IH, J= 9.6 Hz), 6.93 (d, IH, J= 6.2 Hz), 7.32 (t, IH, J= 1.1 Hz). Anal. Calcd. For C20H25O4F: C, 68.77; H, 7.11; Found: C, 68.90; H, 7.23.
Example A(9): 6-Cyclopentyl-6-t2-(2-fluoro-biphenyl-4-yl)-ethyl]-dihydro-pyran-2,4-dione
Figure imgf000043_0001
The title compound was prepared analogously to Example A(64), where 4-Bromo-2-fluoro- biphenyl was substituted in place of 4-bromo-2-fluoro-1-isopropylbenzene of that example.
'H NMR CDCls): δ 1.55-1.83 (br m, 8H), 2.0 (m, 2H), 2.30 (m, 1 H), 2.72 (m, 2H), 2.79 (s, 2H), 3.45 (s, 2H), 6.96 (d, 1 H, J= 11.7 Hz), 7.0 (d, IH, J= 7.9 Hz), 7.36 (m, 2H), 7.44 (m, 2H), 7.52 (m, 2H). Anal. Calcd. For C24H2503F: C, 75.76; H, 6.62; Found: C, 75.56; H, 6.66.
Example A(10): 6-[2-(4-Benzo[b]thiophen-2-yl-3-fluoro-phenyl)-ethyl]-6-cyclopentyl- dihydro-pyran-2,4-dione
Figure imgf000043_0002
The title compound was prepared analogously to Example A(64), where 2-(4-Bromo-2- fluoro-phenyl)-benzo[6]thiophene (described below) was substituted in place of 4-bromo-2-fluoro- 1-isopropylbenzene of that example.
Η NMR (CDC13): δ 1.55-1.83 (br m, 8H), 2.0 (m, 2H), 2.29 (m, 1 H), 2.73 (m, 2H), 2.79 (s, 2H), 3.45 (s, 2H), 6.98 (d, 1 H, J= 6.0 Hz), 7.0 (s, IH), 7.34 (m, 2H), 7.62 (t, IH, J= 10.5 Hz), 7.70 (s, IH), 7.82 (m, 2H). ESIMS: Mff 435.05.
Step 1 : 2-(4-Bromo-2-fluoro-phenyl)-benzo[b]thiophene
Figure imgf000044_0001
A mixture of Benzo[b]thiophene-2-boronic acid ( 0.71 g, 4mmol), 1-bromo-3-fluoro-4- iodobenzene (1g, 3.3mmol), bis(triphenylphospine)palladium(ll) chloride (46mg, 2mol%), NaHC03 (0.83g, 9.9mmol) in DME (4mL) and H20 (4mL) was heated to 80°C under N2 for 72h. The reaction mixture was partitioned between 1N HCl and EtOAc. The organic layer was washed with saturated NaHC03, brine, dried over Na2S0 and concentrated. The residue was purified by silica gel chromatography (hexanes) to give the title compound as a white solid (0.13g, 13%).
'H NMR CDCls): δ 7.33 - 7.41 (m, 4H), 7.57 (m, 1 H), 7.72 (s, 1 H), 1.80 - 7.86 (m, 2H).
Example A(11): 4-[2-(2-Cyclopentyl-4,6-dioxo-tetrahydro-pyran-2-yl)-ethyl]-2-fluoro-N- methyl-benzamide
Figure imgf000044_0002
The title compound was prepared analogously to Example A(64), where 4-Bromo-2- fluoro-Λ/-methyl-benzamide (described below), was substituted in place of 4-bromo-2-fluoro-1- isopropylbenzene of that example.
'H NMR CDCy: δ 1.46-1.80 (br m, 8H), 1.96 (m, 2H), 2.27 (m, 1 H), 2.73 (m, 2H), 2.77 (d, 2H, J = 5.3 Hz), 3.03 (d, 3H, = 4.5 Hz), 3.44 (s, 2H), 6.71 (br s, IH), 6.91 (d, IH, J= 12.8 Hz), 7.05 (d, IH, J= 9.2 Hz), 8.10 (t, IH, = 8.0 Hz). Anal. Calcd. For C20H24NO4FO.3 H20: C, 65.48; H, 6.76; N, 3.82. Found: C, 65.29; H, 6.48; N, 3.56. Step 1 : 4-Bromo-2-fluoro-/V-methyl-benzamide
Figure imgf000045_0001
A solution of 4-bromo-2-fluorobenzoic acid (0.8g, 3.7mmol), methylamine (3.65mL, 7.3mmol), EDC (1.4g, 7.3mmol), triethylamine (LOmL, 7.3mmol) dissolved in CH2CI2(15mL) was stirred under N2 for 24h. The reaction mixture was partitioned between 1 N HCl and EtOAc. The organic layers were washed with saturated NaHC03, brine, dried over dried over Na2S0 and concentrated. The residue was purified by silica gel chromatography (40% EtOAc in hexanes) to give the title compound as a white solid (0.27g, 32%).
Η NMR (CDC13): δ 3.03 (d, 3H, J= 6.0 Hz), 6.68 (br s, IH), 7.32 (d, IH, J= 11.3 Hz), 7.42 (d, IH, J= 10.2 Hz), 8.01 (t, IH, J= 8.5 Hz).
Example A(12): 6-Cyclopentyl-6-{2-[3-f luoro-4-(5-methyl-thiophen-2-yl)-phenyl]-ethyl}- dihydro-pyran-2,4-dione
Figure imgf000045_0002
The title compound was prepared analogously to Example A(64), where 2-(4-Bromo-2- fluoro-phenyl)-5-methyl-thiophene (described below ) was substituted in place of 4-bromo-2- fluoro-1-isopropylbenzene of that example.
Η NMR (CDCI3): δ 1.55-1.80 (br m, 8H), 1.97 (m, 2H), 2.28 (m, 1 H), 2.51 (s, 3H), 2.68 (m, 2H), 2.78 (s, 2H), 3.44 (s, 2H), 6.75 (d, 1 H, = 4.5 Hz), 6.90 (d, IH, J= 2.6 Hz), 6.93 (s, IH), 7.22 (d, IH, J = 2.5 Hz), 7.48 (t, IH, J= 8.3 Hz). Anal. Calcd. For C23H2503SF: C, 68.97; H, 6.29. Found: C, 69.29; H, 6.24. Step 1: 2-(4-Bromo-2-fluoro-phenyl)-5-methyl-thiophene
Figure imgf000046_0001
A mixture of 5-methyl-2-thiophene-boronic acid (1g, 7.0mmol), 1-bromo-3-fluoro-4- iodobenzene (1.77g, 5.9mmol), tetrakis(triphenylphosphine)palladium(0) (0.34g, 0.3mmol), 2M Na2CO3 (10 mL) in DME (10mL) was heated to 75°C under N2for 15h. The reaction mixture was partitioned between 1 N HCl and EtOAc. The organic layer was washed with saturated NaHC03, brine, dried over Na2S04and concentrated. The residue was purified by silica gel chromatography (hexanes) to give the title compound (1 ,2g, 75%).
'HNMR CCDCls): δ 2.52 (s, 3H), 6.76 (S, 1H), 7.25 - 7.32 (m, 3H), 7.43 (t, 1H, J= 8.5 Hz).
Example A(13): 6-(2-Cyclohex-1-enyl-ethyl)-6-cyclopentyl-dihydro-pyran-2,4-dione
Figure imgf000046_0002
Methyl acetoacetate (0.66g, 5.7mmol) was added to a cooled 0 °C suspension of NaH (0.23 g, 5.7 mmol, 60% dispersion in mineral oil) in THF (10ml). After 30 min n-BuLi (2.3mL,
5.7mmol, 2.5M in hexanes) was added. The resulting dianion was stirred for an additional 30 min and then treated with a solution 3-Cyclohex-1-enyl-1-cyclopentyl-propan-1-one (0.39g, 1.9mmol, Step 4 below ) in THF (3ml). After stirring for 4h at 0 °C, the reaction mixture was quenched with 1N HCl and extracted with EtOAc. The organic layers were washed with brine, dried over Na2S04 and concentrated to an orange oil that was used without further purification. The oil was dissolved in methanol (8mL), treated with potassium carbonate (0.79g, 5.7 mmol), and refluxed under N2for 90min. The reaction mixture was partitioned between 1N HCl and EtOAc. The organic layers were washed with brine, dried over Na2S04 and concentrated to an orange oil that was purified by silica gel chromatography (0% to 20% EtOAc in hexanes). to give the title compound as a white solid. (0.22 g, 40% yield).
1H NMR (CDCI3): δ 1.42-1.98 (br m, 20H), 2.22 (m, 1H), 2.71 (s, 2H), 3.40 (s, 2H), 5.40 (s, 1H). Anal. Calcd. For C18H26θ3 «0.2 H20: C, 75.53; H, 9.05. Found: C, 73.74; H, 9.01.
Step 1: 3-Cyclohex-1-enyl-propionic acid ethyl ester.
Figure imgf000047_0001
The title compound was prepared as described in the following reference: JOC, 1998, 63, 2755-57.
Step 2: 3-Cyclohex-1-enyl-propionic acid:
Figure imgf000047_0002
2N LiOH (3.5mL) was added to a solution of 3-Cyclohex-1-enyl-propionic acid ethyl ester (0.6g, 3.4mmol, from Step 1 ) dissolved in THF (12mL) and MeOH (3mL). The mixture was stirred for 2 h under N2 and then partitioned between 1 N HCl and EtOAc. The organic layer was washed with brine, dried over Na2S04 and concentrated to a clear oil.
1H NMR (CDCI3): δ 1.54 (m, 2H), 1.62 (m, 2H), 1.92 (m, 2H), 1.97 (m, 2H), 2.26 (m, 2H), 2.46 (t, 2H, J = 8.3 Hz), 5.44 (s, 1H).
Step 3: 3-Cyclohex-1-enyl-thiopropionic acid S-pyridin-2-yl ester.
Figure imgf000048_0001
A solution of 3-Cyclohex-1-enyl-propionic acid (0.47g, 3.04mmol, from Step 2), triphenylphosphine (1.04 g, 3.95 mmol) and 2,2'-dipyridyl disulfide (0.87 g, 3.95 mmol) dissolved in CH2CI2 (12 mL) was stirred under N2 for 3 h. The reaction mixture was concentrated to a yellow oil and purified by silica gel chromatography (5% to 20% EtOAc in hexanes) to give the title compound as a yellow oil (0.7g, 93%).
1H NMR (CDCI3): δ 1.55 (m, 2H), 1.63 (m, 2H), 1.94 (m, 2H), 1.99 (m, 2H), 2.35 (t, 2H, J = 7.3 Hz), 2.81 (t, 2H, J = 8.0 Hz), 5.47 (s, 1H), 7.28 (dd, 1H, J = 7.8, 4.8 Hz), 7.61 (d, 1H, J = 7.8 Hz), 7.74 (td, 1 H, J = 7.8 Hz), 8.61 (d, 1 H, J = 4.8 Hz).
Step 4: 3-Cyclohex-1-enyl-1-cyclopentyl-propan-1-one. {TB-4059-095}
Figure imgf000048_0002
Cyclopentylmagnesium bromide (1.6mL, 3.15mmol, 2M soln in ether) was added to a cooled -78 °C solution of 3-Cyclohex-1-enyl-thiopropionic acid S-pyridin-2-yl ester (0.65g, 2.63mmol, from Step 3) dissolved in THF (10mL). The reaction mixture was stirred for 45 min at -78°C and then warmed up to rt. The reaction was quenched with 1 N HCl and extracted with EtOAc. The organic layer was washed with saturated NaHC03, brine, dried over Na2S0 and concentrated. The residue was purified by silica gel chromatography (0% to 5% EtOAc in hexanes) to give the title compound as a clear oil (0.39g, 72%).
1H NMR (CDCI3): δ 1.51-1.83 (br m, 12H), 1.91 (m, 2H), 1.97 (m, 2H), 2.20 (t, 2H, J = 7.6 Hz), 2.54 (t, 2H, J = 7.8 Hz), 2.87 (m, 1H), 5.39 (s, 1H).
Example A(14): 6-Cyclopentyl-6-[2-(2-oxo-pyrrolidin-1-yl)-ethyl]-dihydro-pyran-2,4-dione.
Figure imgf000049_0001
The title compound was prepared as described in Example A(13), where 1-(3-Cyclopentyl-3-oxo- propyl)-pyrrolidin-2-one (described in Step 2 below) was substituted in place of 3-Cyclohex-1- enyl-1 -cyclopentyl-propan-1 -one.
1H NMR (CDCI3): δ 1.41-1.84 (br m, 9H), 1.98 - 2.21 (m, 4H), 2.37 (m, 2H), 2.67 (d, 1H, J= 15.8 Hz), 3.08 (d, 1H, J = 15.8 Hz), 3.28 - 3.51 (m, 5H), 3.61 (m, 1H). Anal. Calcd. For C16H23N04: C, 63.55; H, 8.00; N, 4.63. Found: C, 63.41; H, 8.04; N, 4.52.
Step 1: 3-(2-Oxo-pyrrolidin-1-yl)-propionic acid
Figure imgf000049_0002
A solution of 2-oxo-1-pyrrolidinepropionitrile (22.4g, 16.2mmol), 15% NaOH solution
(40mL) and dioxane (40mL) was heated under reflux for 5 h under N2. The reaction mixture was extracted with EtOAc. The aqueous layer was made acidic with 6N HCl amd extracted with CH2CI2 (5 x50mL). The organic layers were dried over Na2S04and concentrated to give the title compound as a cream solid (12.4g, 49%).
1H NMR (CDCI3): δ 2.04 (m, 2H), 2.42 (t, 2H, J = 7.9 Hz), 2.60 (t, 2H, J = 6.8 Hz), 3.48 (t, 2H, J = 7.2 Hz), 3.59 (t, 2H, J = 6.8 Hz), 10.29 (br s, 1H).
Step 2: 1-(3-Cyclopentyl-3-oxo-propyl)-pyrrolidin-2-one.
Figure imgf000049_0003
2-Chloro-4-6-dimethoxy-1,3,5-triazine (2.68g, 15.2mmol) and N-methylmorpholine ( 4.2mL, 38.1 mmol) were added to a solution of 3-(2-Oxo-pyrrolidin-1-yl)-propionic acid ( 2g, 12.7mmol, from Step 1) in THF (35mL). After 1h the reaction mixture was filtered through a glass frit to remove a white precipitate. The filtrate was treated with copper iodide (2.4g, 12.7mmol), cooled to 0 °C and then cyclopentyl magnesium bromide (6.35mL, 12.7mmol, 2M in ether) was added. After 4h the resulting black mixture was quenched with saturated NH CI and extracted with CH2CI2. The organic layers were washed with 1 N HCl, saturated NaHC03, brine, dried over Na2S04and concentrated. The residue was purifed by silica gel chromatography (75% EtOAc in hexanes then 5% MeOH in CH2CI2) to give the title compound as a yellow oil. (0.4g, 15% yield).
1H NMR (CDCI3): δ 1.55-1.83 (br m, 8H), 1.99 (m, 3H), 2.35 (t, 2H, J = 8.3 Hz), 2.74 (t, 2H, J = 6.8 Hz), 3.41 (d, 2H, J = 7.2 Hz), 3.53 (t, 2H, J = 6.6 Hz).
Example A(15): 6-Cyclopentyl-6-{2-[3-fluoro-4-(5-methyl-[1,2,4]oxadiazol-3-yl)-phenyl]- ethyl}~dihydro-pyran-2,4-dione
Figure imgf000050_0001
The title compound was prepared analogously to Example A(64), where 3-(4-Bromo-2- fluoro-phenyl)-5-methyl-[1,2,4]oxadiazole (described below), was substituted in place of 4-bromo- 2-fluoro-1-isopropylbenzene of that example.
1H NMR (CDCI3): δ 1.55-1.82 (br m, 8H), 1.99 (m, 2H), 2.29 (m, 1H), 2.68 (s, 3H), 2.73 -2.79 (m, 4H), 3.45 (s, 2H), 7.06 (m, 2H), 7.96 (t, 1 H, J = 7.5 Hz). ESIMS: MH+ 387.20, MK 385.20.
Step 1: 3-(4-Bromo-2-fluoro-phenyl)-5-methyl-[1,2,4]oxadiazole
Figure imgf000050_0002
A mixture of 4-bromo-2-fluorobenzonitrile (3g, 15mmol), hydroxylamine hydrochloride (5.21 g, 75mmol), potassium carbonate (10.4g, 75mmol) in EtOH (50mL) was refluxed under N2. After 24 hrs the reaction mixture was filtered through a glass frit washing with hot EtOH. The filtrate was concentrated to give a white solid.
The solid was suspended in pyridine (20mL) and treated with acetic anhydride (4.24mL, 45mmol). The mixture was refluxed for 2 h and then stirred at rt for 15h. The reaction mixture was partitioned between 2N HCl and EtOAc. The organic layer was washed with 1 N HCl, saturated NaHC03, brine, dried over Na2S04and concentrated. The residue was purifed by silica gel chromatography (5% hexanes in EtOAc), to give the title compound as a white solid, (1.1g, 29% yield).
1H NMR (CDCI3): δ 2.68 (s, 3H), 7.43 (m, 2H), 7.92 (t, 1H, J = 7.7 Hz).
Example A(16): 4-[2-(2-Cyclopentyl-4,6-dioxo-tetrahydro-pyran-2-yl)-ethyl]-2-f luoro-N,N- dimethyl-benzamide
Figure imgf000051_0001
The title compound was prepared analogously to Example A(64), where 4-Bromo-2-fluoro-Λ/,Λ/- dimethyl-benzamide (described below), was substituted in place of 4-bromo-2-fluoro-1- isopropylbenzene.
1H NMR (CDCI3): δ 1.42-1.79 (br m, 8H), 1.95 (m, 2H), 2.28 (m, 1H), 2.71 (m, 2H), 2.79 (m, 2H), 2.94 (s, 3H), 3.12 (s, 3H), 3.44 (s, 2H), 6.88 (d, 1 H, J = 10.5 Hz), 6.99 (d, 1H, J = 7.7 Hz), 7.32 (t, 1H, J = 7.3 Hz). Anal. Calcd. For C21H26NO4F«0.4 H20: C, 65.91; H, 7.06; N, 3.66. Found: C, 65.84; H, 6.79; N, 3.59.
Stepl : 4-Bromo-2-fluoro-/V,Λ/-dimethyl-benzamide
Figure imgf000052_0001
The title compound was prepared as described in Step 1 of Example A(11), where dimethylamine hydrochloride was substituted in place of methylamine.
1H NMR (CDCIs): δ 2.93 (s, 3H), 3.12 (s, 3H), 7.28 (m, 2H), 7.36 (d, 1H, J = 6.4 Hz).
Example A(17): 4-[2-(2-Cyclopentyl-4,6-dioxo-tetrahydro-pyran-2-yl)-ethyl]-N-ethyl-2-fluoro- benzamide.
Figure imgf000052_0002
The title compound was prepared analogously to Example A(64), where 4-Bromo-Λ/- ethyl-2-fluoro-benzamide (described below), was substituted in place of 4-bromo-2-fluoro-1- isopropylbenzene of that example.
1H NMR (CDCI3): δ 1.25 (t, 3H, J = 7.1 Hz), 1.45-1.80 (br m, 8H), 1.96 (m, 2H), 2.27 (m, 1H), 2.70 - 2.82 (m, 4H), 3.44 (s, 2H), 3.51 (m, 2H), 6.70 (br s, 1H), 6.90 (d, 1H, J = 14.1 Hz), 7.05 (d, 1H, J = 9.6 Hz), 8.03 (t, 1H, J = 8.1 Hz). Anal. Calcd. For C21H26NO4F«0.5 H20: C, 65.61; H, 7.08; N, 3.64. Found: C, 65.76; H, 6.89; N, 3.58.
Stepl : 4-Bromo-W-ethyl-2-fluoro-benzamide.
Figure imgf000052_0003
The title compound was prepared as described in Step 1 of Example A(11), where ethylamine hydrochloride was substituted in place of methylamine.
1H NMR (CDCIs): δ 1.26 (t, 3H, J = 7.4 Hz), 3.65 (m, 2H), 6.63 (br s 1H), 7.32 (d, 1H, J = 11.3 Hz), 7.42 (d, 1 H, J = 10.2 Hz), 8.48 (t, 1 H, J = 8.5 Hz).
Example A(18): 6-Cyclopentyl-6-{2-[4-(3,5-dimethyl-isoxazol-4-yl)-phenyl]-ethyl}-dihydro- pyran-2,4-dione.
Figure imgf000053_0001
The title compound was prepared analogously to Example A(64), where 4-(4-Bromo- phenyl)-3,5-dimethyl-isoxazole (described below) was substituted in place of 4-bromo-2-fluoro-1- isopropylbenzene of that example.
1H NMR (CDCI3): δ 1.48-1.82 (br m, 8H), 2.02 (m, 2H), 2.26 (s, 3H), 2.32 (m, 1H), 2.40 (s, 3H), 2.73 (m, 2H), 2.80 (s, 2H), 3.44 (s, 2H), 7.18 (d, 2H, J = 8.3 Hz), 7.05 (d, 2H, J = 8.3 Hz) Anal. Calcd. For C23H27N04O.2 H20: C, 71.74; H, 7.17; N, 3.64. Found: C, 71.77; H, 7.14; N, 3.47.
Step 1 : 4-(4-Bromo-phenyl)-3,5-dimethyl-isoxazole
Figure imgf000053_0002
A mixture of 4-bromophenylboronic acid (1g, 5mmol), 3,5-dimethyl-4-iodoisoxazole (0.93g, 4.2 mmol), bis(triphenylphospine)palladium(ll) chloride (59mg, 2mol%), NaHCO3(1.06g, 12.6mmol) in DME (5mL) and H20 (5mL) was heated to 80°C under N2for 18h. The reaction mixture was partitioned between 1 N HCl and EtOAc. The organic layer was washed with saturated NaHC03, brine, dried over Na2S0 and concentrated. The residue was purified by silica gel chromatography (5% EtOAc in hexanes) to give the title compound as a white solid (0.9g, 86%).
1H NMR (CDCI3): δ 2.26 (s, 3H), 2.40 (s, 3H), 7.13 (d, 2H, J = 8.3 Hz), 7.58 (d, 2H, J = 8.3 Hz).
Example A(19): 6-[2-(1-Acetyl-3,5-dimethyl-1H-pyrazol-4-yl)-ethyl]-6-cyclopentyl-dihydro- pyran-2,4-dione
Figure imgf000054_0001
The title compound was prepared analogously to Example A(64), where 1-(4-lodo-3,5- dimethyl-pyrazol-1-yl)-ethanone (described below) was substituted in place of 4-bromo-2-fluoro- 1-isopropylbenzene of that example.
1H NMR (CDCI3): δ 1.46-1.83 (br m, 9H), 2.18 (s, 3H), 2.28 - 2.44 (m, 4H), 2.45 (s, 3H), 2.63 (s, 3H), 2.75 (d, 1 H, J = 16.0 Hz), 2.83 (d, 1H, J = 16.0 Hz), 3.37 (d, 1H, J = 21.3 Hz), 3.47 (d, 1H, J = 21.3 Hz) Anal. Calcd. For C19H26N204O.5 H20: C, 64.20; H, 7.66; N, 7.88. Found: C, 64.35; H,7.61; N,7.56.
Step 1: 1-(4-lodo-3,5-dimethyl-pyrazol-1-yl)-ethanone
Figure imgf000054_0002
Acetic anhydride (0.51 mL, 5.4mmol) and triethylamine (0.75mL, 5.4mmol) were added to a solution of 3,5-dimethyl-4-iodopyrazole (1g, 4.5mmol) in CH2CI2. After 1 h the reaction mixture was partitioned between 1 N HCl and EtOAc. The organic layer was washed with 1 N HCl, saturated NaHC03, brine, dried over Na2S04, and concentrated to give the title compound as a white solid (1g, 85%).
1H NMR (CDCI3): δ 2.27 (s, 3H), 2.60 (s, 3H), 2.66 (s, 3H).
Example A(20): 6-Cyclopentyl-6-(5-methoxy-indan-1 -ylmethyl)-dihydro-pyran-2,4-dione
Figure imgf000055_0001
The title compound was prepared as described in Example A(13), where 1-Cyclopentyl-2-
(5-methoxy-indan-1-yl)-ethanone (described in Step 4 below), was substituted in place of 3- Cyclohex-1 -enyl-1 -cyclopentyl-propan-1 -one.
1H NMR (CDCI3): δ 1.24-1.87 (br m, 10H), 2.24 - 2.56 (m 3H), 2.75 - 2.93 (m, 4H), 3.15 - 3.31 (m, 1H), 3.42 (s, 2H), 3.78 (s, 3H), 6.73 (d, 1H, J = 8.3 Hz), 6.78 (s, 1H), 7.02 (d, 1H, J - 8.3 Hz). ESIMS: MH+ 343.10, MK 341.10.
Step 1 : [3(1 "R),4R]-3-[2'-(5"-Methoxy-1 "-indanyl)acetyl]-4-(phenylmethyl)-2-oxazolidinone (A) and [3(1 "S),4R]-3-[2'-(5"-Methoxy-1 "-indanyl)acetyl]-4-(phenylmethy l)-2-oxazolidinone (B):
Figure imgf000055_0002
The diastereomers were prepared and separated as described in the following reference: J. Med Chem. 1995, 38, 1386-1396. Step 2: (5- ethoxy-indan-1-yl)-acetic acid
Figure imgf000056_0001
2N LiOH (0.82mL) was added to a solution of [3(1"S),4R]-3-[2'-(5"-Methoxy-1"- indanyl)acetyl]-4-(phenylmethyl)-2-oxazolidinone (0.3g, 1.64mmol, from Step 1 ) dissolved in THF (3mL). The mixture was stirred for 2 h under N2 and then partitioned between 1 N HCl and EtOAc. The organic layer was extracted with 1N NaOH (x2). The aqueous layers were made acidic with 2N HCl and extracted with EtOAc (x3). The organic layers were washed with brine, dried over Na2S0 and concentrated to an clear oil (0.14g, 83%).
1H NMR (CDCI3): δ 1.78 (m, 1 H), 2.38 - 2.50 (m, 2H), 2.77 - 2.95 (m, 3H), 3.54 (m, 1 H), 3.79 (s, 3H), 6.72 (d, 1H, J = 10.6 Hz), 6.78 (s, 1H), 7.10 (d, 1 H, J = 10.6 Hz).
Step 3: (5-Methoxy-indan-1-yl)-thioacetic acid S-pyridin-2-yl ester.
Figure imgf000056_0002
The title compound was prepared as described in Step 3 of Example A(13), where (5-
Methoxy-indan-1-yl)-acetic acid (from Step 2 below) was substituted in place of 3-Cyclohex-1- enyl-propionic acid.
1H NMR (CDCI3): δ 1.85 (m, 1H), 2.41 (m, 1H), 2.78 - 2.95 (m, 3H), 3.13 (dd, 1H, J = 15.6, 5.7 Hz), 3.64 (m, 1H), 3.79 (s, 3H), 6.72 (d, 1H, J = 8.3 Hz), 6.78 (s, 1H), 7.10 (d, 1H, J = 8.3 Hz), 7.31 (m, 1H), 7.65 (m, 1H), 7.76 (t, 1H, J = 7.8 Hz), 8.63 (d, 1H, J = 5.05 Hz).
Step 4: 1-Cyclopentyl-2-(5-methoxy-indan-1-yl)-ethanone.
Figure imgf000057_0001
The title compound was prepared as described in Step 4 of Example A(13), where (5- Methoxy-indan-1-yl)-thioacetic acid S-pyridin-2-yl ester (from Step 3) was substituted in place of 3-Cyclohex-1-enyl-thiopropionic acid S-pyridin-2-yl ester.
Η NMR (CDCI3): δ 1.55 - 1.85 (br m, 9H), 2.39 (m, IH), 2.60 (dd, IH, = 17.2, 8.6 Hz), 2.80 - 2.92 (m, 4H), 3.59 (m, IH), 3.78 (s, 3H), 6.70 (d, IH, = 8.3 Hz), 6.77 (s, IH), 7.02 (d, IH, J= 8.3 Hz).
Example A(21): 6-Cyclopentyl-6-(5-methoxy-indan-1-ylmethyl)-dihydro-pyran-2,4-dione
Figure imgf000057_0002
The title compound was prepared analogously to Example A(20), where [3(1"R),4R]-3-[2'-
(5"-Methoxy-1"-indanyl)acetyl]-4-(phenylmethyl)-2-oxazolidinone (A) (from Step 1 of that example) was substituted in place of [3(1"S),4R]-3-[2'-(5"-Methoxy-1"-indanyl)acetyl]-4- (phenylmethyl)-2-oxazolidinone (B) in Step 2 of that Example.
Η NMR (CDCI3): δ 1.24-1.87 (br m, 10H), 2.24 - 2.41 (m, 2H), 2.51 (m 1 H), 2.73 - 2.93 (m, 4H), 3.15 - 3.31 (m, 1H), 3.42 (s, 2H), 3.78 (s, 3H), 6.73 (d, 1H, = 8.3 Hz), 6.78 (s, IH), 7.02 (d, IH, J= 8.3 Hz). ESIMS: MH+ 343.10, MH" 341.10.
Example A(22): 6-Cyclopentyl-6-[2-(3-ethyl-4-hydroxy-phenyl)-ethyl]-dihydro-pyran-2,4- dione.
Figure imgf000058_0001
A mixture of acetic acid 4-[2-(2-cyclopentyl-4,6-dioxo-tetrahydro-pyran-2-yl)-ethyl]-2- ethyl-phenyl ester (0.92g, 2.47mmol, from Step 3 ), potassium carbonate (0.68g, 4.9mmol) in MeOH (1 OmL) was stirred at rt for 1 h. The reaction mixture was partitioned between 1 N HCl and EtOAc. The organic layer was washed with brine, dried over Na2S04and concentrated to a yellow oil. The oil was purified by silica gel chromatography (20% to 40% EtOAc in hexanes) to give the title compound (2.44g, 59%).
'HNMR tCDClj): δ 1.22 (t, 3H, J= 7.6 Hz), 1.43-1.78 (br m, 8H), 1.87 -2.01 (m, 2H), 2.28 (m, IH), 2.57 - 2.63 (m, 4H), 2.76 (s, 2H), 3.42 (s, 2H), 4.63 (s, IH), 6.68 (d, IH, J= 8.1 Hz), 6.84 (d, IH, J= 8.1 Hz), 6.90 (s, IH). Anal. Calcd. For C20H26CV0.25 H20: C, 71.72; H, 7.98. Found: C, 71.10; H, 7.99.
Step 1: 4-Bromo-2-ethyl-phenol
Figure imgf000058_0002
Sodium hydroxide (1.4g, 35mmol) and hydrazine monohydrate (2.04mL, 42mmol) were added to a solution of 5'-bromo-2'-hydroxyacetophenone (3g, 14mmol) dissolved in triethylene glycol (17mL). The reaction mixture was heated to 170°C for 24 h and then partitioned between 1 N HCl and EtOAc. The organic layer was washed with saturated NaHC03, brine, dried over Na2S0 and concentrated. The residue was purified by flash silica gel chromatography (0% to 10% EtOAc in hexanes) to give the title compound (2.52 g, 90%).
Η NMR (CDC13): δ 1.22 (t, 3H, J= 7.5 Hz), 2.60 (q, 2H, J= 7.5 Hz), 6.64 (d, IH, J= 8.5 Hz), 7.17 (dd, IH, J= 8.5, 2.5 Hz), 7.24 (d, IH, J= 2.5 Hz). Step 2: Acetic acid 4-bromo-2-ethyl-phenyl ester.
Figure imgf000059_0001
Acetyl chloride (1.06mL, 14.9mmol) followed by triethylamine (2.08mL, 14.9mmol) were added to a cooled 0°C solution of 4-Bromo-2-ethyl-phenol (2.5g, 12.4mmol, from Step 1) dissolved in CH2CI2. The reaction was stirred for 2 hrs and then partitioned between 1N HCl and EtOAc. The organic layer was washed with saturated NaHC03, brine, dried over Na2S0 and concentrated to a brown oil. The oil was purified by silica gel chromatography (0% to 10% EtOAc in hexanes) to give the title compound as a clear oil (2.44g, 81%).
Η NMR (CDC13): δ 1.19 (t, 3H, J= 7.7 Hz), 2.32 (s, 3H), 2.52 (q, 2H, = 7.7 Hz), 6.89 (d, IH, J= 8.5 Hz), 7.32 (dd, IH, J= 8.5, 2.2 Hz), 7.38 (d, IH, J= 2.2 Hz).
Step 3: Acetic acid 4-[2-(2-cyclopentyl-4,6-dioxo-tetrahydro-pyran-2-yl)-ethyl]-2-ethyl- phenyl ester.
Figure imgf000059_0002
The title compound was prepared analogously to Example A(64), where Acetic acid bromo-2-ethyl-phenyl ester (from Step 2) was substituted in place of 4-bromo-2-fluoro-1- isopropylbenzene of that example.
ESIMS: Mrf" 373.20, MET 371.20
Example A(23): 6-Ethyl-6-[2-(4-methoxy-phenyl)-ethyl]-dihydro-pyran-2,4-dione
Figure imgf000060_0001
The title compound was prepared as described in Example A(13), where 1-(4-Methoxy- phenyl)-pentan-3-one (described Step 2 below ) was substituted in place of 3-Cyclohex-1-enyl-1- cyclopentyl-propan-1-one.
'HNMRζCDCla): δ 1.01 (t, 3H, J= 7.5 Hz), 1.80 ( , 2H), 1.95 (m, 2H), 2.66 (m, 2H), 2.72 (s, 2H), 3.42 (s, 2H), 3.79 (s, 3H), 6.83 (d, 2H, J= 8.5 Hz), 7.08 (d, 2H, J= 8.5 Hz) Anal. Calcd. For C16H20O4: C, 69.70; H, 7.52. Found: C, 69.54; H, 7.30.
Step 1: N-Methoxy~3-(4~methoxy-phenyl)-N-methyl-propionamide.
Figure imgf000060_0002
N.O-dimethylhydroxylamine hydrochloride (5.41g, 55.5mmol), EDC (12.77g, 66.6mmol), followed by triethylamine (17mL, 122mmol) were added to a cooled 0°C solution of 3-(4- methoxyphenyl)propionic acid (10g, 55.5mmol). The reaction mixture was stirred for 15h under N2 and then concentrated. The residue was partitioned between 1 N HCl and EtOAc. The organic layers were washed with saturated NaHC03, brine, dried over Na2S04and concentrated to an oil. The oil was purified by silica gel chromatography (40% EtOAc in hexanes) to give a clear oil (10.6g, 85%).
ΗNMR (CDC13): δ 2.70 (t, 2H, J= 7.5 Hz), 2.91 (t, 2H, J= 7.5 Hz), 3.18 (s, 3H), 3.61 (s, 3H); 3.79 (s, 3H), 6.83 (d, 2H, J= 8.7 Hz), 7.15 (d, 2H, J= 8.7 Hz).
Step 2: 1-(4-Methoxy-phenyl)-pentan-3-one.
Figure imgf000061_0001
Ethylmagnesium bromide (10.8mL, 10.8mmol, 1M soln in THF) was added to a cooled - 78 °C solution of N-Methoxy-3-(4-methoxy-phenyl)-N-methyl-propionamide (2g, 8.96mmol, from Step 1) dissolved in THF (20mL). The reaction mixture was stirred for 60 min. The reaction was quenched with saturated NH4CI and extracted with EtOAc. The organic layer was washed brine, dried over Na2S04and concentrated to a clear oil. The residue was purified by silica gel chromatography (5% EtOAc in hexanes) to give the title compound as a clear oil (0.87g, 50%).
Η NMR (CDC13): δ 1.04 (t, 3H, J= 1.4 Hz), 2.39 (q, 2H, = 7.4 Hz), 7.54 (m, 2H), 2.84 (m, 2H), 3.78 (s, 3H), 6.82 (d, 2H, J= 8.7 Hz), 7.09 (d, 2H, J= 8.7 Hz).
Example A(24): 6-lsobutyl-6-[2-(4-methoxy-phenyl)-ethyl]-dihydro-pyran-2,4-dione
Figure imgf000061_0002
The title compound was prepared as described in Example A(13), where 1-(4-Methoxy- phenyl)-5-methyl-hexan-3-one (described in Step 2 below ) was substituted in place of 3- Cyclohex-1 -enyl-1 -cyclopentyl-propan-1 -one.
'HNMR (CDC13): δ 0.99 (d, 3H, J= 6.6 Hz), 1.02 (d, 3H, J= 6.6 Hz), 1.65 (m 2H), 1.88 (m, IH), 2.01 (m, 2H), 2.64 (m, 2H), 2.74 (s, 2H), 3.24 (s, 2H), 3.79 (s, 3H), 6.85 (d, 2H, J= 8.5 Hz), 7.08 (d, 2H, = 8.5 Hz). ESIMS: MH4305.20, MH_ 303.20
Step 1 : 3-(4-Methoxy-phenyl)-thiopropionic acid S-pyridin-2-yl ester.
Figure imgf000062_0001
The title compound was prepared as described in Step 3 of Example A(13), where 3-(4- methoxyphenyl)propionic acid was substituted in place of 3-Cyclohex-1-enyl-propionic acid.
Η NMR (CDC13): δ 2.98 (s, 4H), 3.76 (s, 3H), 6.83 (d, 2H, J= 8.7 Hz), 7.13 (d, 2H, J= 8.7 Hz), 7.28 (dd, IH, J= 7.5, 5.8 Hz), 7.60 (m, IH), 7.74 (td, IH, J= 7.7, 1.9 Hz), 8.63 (d, IH, J= 5.8 Hz).
Step 2: 1-(4-Methoxy-phenyl)-5-methyl-hexan-3-one.
Figure imgf000062_0002
Isobutylmagnesium bromide (0.88mL, 1.75mmol, 2M soln in THF) was added to a cooled -78°C solution of 3-(4-Methoxy-phenyl)-thiopropionic acid S-pyridin-2-yl ester (0.4g, 1.46mmol, from Step 1) dissolved in THF (6mL). The reaction mixture was stirred for 60 min. The reaction was quenched with saturated NH4CI and extracted with EtOAc. The organic layer was washed with brine, dried over Na2S04and concentrated to a yellow oil. The residue was purified by silica gel chromatography (5% EtOAc in hexanes) to give the title compound as a clear oil (0.24g, 75%).
Η NMR (CDCI3): δ 0.89 (d, 6H, J= 6.6 Hz), 2.12 (m, IH), 2.26 (d, 2H, J= 7.0 Hz), 2.60 - 2.69 (m, 2H), 2.81 -2.90 (m, 2H), 3.78 (s, 3H), 6.82 (d, 2H, J= 8.7 Hz), 7.09 (d, 2H, J= 8.7Hz).
Example A(25): 6-[2-(4-Methoxy-phenyl)-ethyl]-6-propyl-dihydro-pyran-2,4-dione
Figure imgf000062_0003
The title compound was prepared analogously to Example A(13), where propylmagnesium chloride was substituted in place of Cyclopentylmagnesium bromide in Step 4 of that Example.
'HNMR (CDC13): δ 0.96 (t, 3H, J= 7.2 Hz), 1.44 (m, 2H), 1.70 (m, 2H), 1.95 (m, 2H), 2.66 (m, 2H), 2.72 (s, 2H), 3.42 (s, 2H), 3.79 (s, 3H), 6.83 (d, 2H, J= 8.5 Hz), 7.08 (d, 2H, J= 8.5 Hz) Anal. Calcd. For CI7H2204O.2 H20: C, 69.46; H, 7.68. Found: C, 69.40; H, 7.75.
Example A(26): 6-Allyl-6-[2-(4-methoxy-phenyl)-ethyl]-dihydro-pyran-2,4-dione
Figure imgf000063_0001
The title compound was prepared analogously to Example A(23), where allyl magnesium chloride was substituted in place of ethylmagnesium bromide in Step 2 of that Example.
'H NMR CDCU: δ 1.95 (m, 2H), 2.53 (d, 2H, J= 7.2 Hz), 2.66 -2.74 (m, 4H), 3.43 (s, 2H), 3.79 (s, 3H), 5.23 (d, IH, J= 18.5 Hz), 5.27 (d, IH, J= 10.2 Hz), 5.79 (m, IH), 6.83 (d, 2H, J= 8.5 Hz), 7.08 (d,
2H, J= 8.5 Hz) Anal. Calcd. For Cι7H20O4: C, 70.56; H, 7.07. Found: C, 70.81; H, 6.99.
Example A(27): 6-[2-(3-Chloro-4-(6-Met yl-dihydro-pyran-2,4-dione)-phenyl)-ethyl]-6- cyclopentyl-dihydro-pyran-2,4-dione
Figure imgf000063_0002
NaH (60% in mineral oil, 0.14 g, 3.42 mmol) was suspended in THF (5mL) and cooled to 0 °C. Methylacetoacetate (0.19 mL, 1.72 mmol) was slowly added via syringe and the reaction mixture stirred 20 min. A solution of n-BuLi in hexanes (1.6 M, 2.13 mL, 3.42 mmol) was added dropwise and the resulting mixture was stirred an additional 20 min. A solution of 3-(4-Acetyl-3- chloro-phenyl)-1-cyclopentyl-propan-1-one (0.16 g, 0.57 mmol) from Step 3 below in THF (2 mL) was added dropwise. After stirring 1 h, the reaction mixture was quenched with 1N HCl (10 mL) and extracted with EtOAc (10 mL). The organic phase was dried over Na2S04 and evaporated. The crude organic product was then dissolved in 5 mL of MeOH, and 0.47 grams of finely powdered K2C03 (anhydrous) was added. The slurry was s,tirred at 60 °C for 1.5 h, and then concentrated by rotary evaporation. The residue was dissolved in 10 mL of water and 10 mL of EtOAc, and acidified with 2N HCl. The aqueous solution was extracted 3 times with 5 mL of EtOAc. The organics were combined, and dried with Na2S04. After filtering the residue was purified by flash column chromatography (40% EtOAc in hexanes) to give the product (0.035 g, 45%) as a white foam.
'HNMR CDCl : δ 1.44-1.69 (m, 8H), 1.85 (s, 3H), 1.86-1.90 (m, 2H), 2.17-2.22 (m, IH), 2.57-2.63 (m, 2H), 2.69 (d, = 8.1 Hz, 2H), 2.88 (d, J= 17.3 Hz, IH), 3.06 (dd, J= 20.5, 3.4 Hz, IH), 3.29 (d, J= 20.5 Hz, IH), 3.36 (s, 2H), 3.86 (dd, J= 17.3, 1.7 Hz, IH), 7.02 (dd, J= 8.3, 1.7 Hz, IH), 7.15 (d, J= 1.7 Hz, IH), 7.86 (d, = 8.1 Hz, IH). Anal. Calcd. For C24H27ClO6-0.5H2O: C, 63.22; H, 6.19. Found: C, 63.45; H, 6.3. ESIMS (MH+): 447.1
Step 1: 4-Bromo-2-chloro-thiobenzoic acid S-pyridin-2-yl ester.
Figure imgf000064_0001
4-Bromo-2-chlorobenzoic acid (15 g, 63.70 mmol), triphenylphosphine (21.72 g, 82.81 mmol) and 2,2'-dipyridyl disulfide (18.24 g, 82.81 mmol) were combined successively in CH2CI2 (200 mL). The reaction mixture was stirred 1 h and then loaded directly onto a column for purification by flash chromatography (10% EtOAc in hexanes) to give the product (13.34 g, 67%) as a white solid. *H NMR (CDC13) δ 7.34-7.38 (m, IH), 7.53 (dd, / = 8.3, 1.7 Hz, IH), 7.67-7.85 (m, 4H), 8.68 (d, J= 5. Hz, IH). ESIMS (MH+): 329.
Step 2: 1-(4-Bromo-2-chloro-phenyl)-ethanone.
Figure imgf000065_0001
4-Bromo-2-chloro-thiobenzoic acid S-pyridin-2-yl ester (1.86 g, 5.66 mmol) from Step 1 above was dissolved in dry THF (30 mL) and cooled to -78 °C. A solution of methyl magnesium bromide in 75:25 toluene/THF (1.4 M, 4.45 mL, 6.23 mmol) was added dropwise. After stirring 35 min, the cooling bath was removed. The reaction mixture was quenched with saturated 1N HCl and extracted with EtOAc (30 mL). The organic phase was washed with brine (50 mL), dried over Na2S04 and evaporated. The residue was purified by flash column chromatography (10% EtOAc in hexanes) to give the product (1.05 g, 80%) as a colorless oil. lH NMR (CDCI3) δ 2.64 (s, 3H), 7.46-7.48 (m, 2H), 7.61 (s, IH).
Step 3: 3-(4-Acetyl-3-chloro-phenyl)-1-cyclopentyl-propan-1-one.
Figure imgf000065_0002
To a magnetically stirring solution of 1-(4-Bromo-2-chloro-phenyl)-ethanone (0.92 g, 3.96 mmol) from Step 2 above and 1-Cyclopentyl-2-propen-1-ol (0.60 g, 4.75 mmol) in anhydrous N- methylpyrrolidinone (3.0 mL), under argon at room temperature, was added sodium bicarbonate (0.40 g, 4.75 mmol) followed by dichlorobis (triphenylphosphine) palladium (II) (84 mg, 0.12 mmol). The resulting mixture was heated to 140 °C in an oil bath and maintained for 4 hours. The resulting dark reaction mixture was cooled to room temperature and poured into water (50 mL) and extracted with EtOAc (2 X 25 mL). The organics were washed with water (50 mL) and brine (50 mL) then dried over Na2S04, filtered and concentrated. The crude residue was purified by flash chromatography (1% through 10% EtOAc in Hexanes) to yield the intermediate ketone as a yellow oil (0.16 g, 16%). Η NMR (CDCI3): δ 71.55-1.8 (m, 8H), 2.64 (s, 3H), 2.78-2.93 (m, 5H), 7.14 (dd, /= 8.0, 1.7 Hz, IH), 7.25 (d, J= 1.7 Hz, IH), 7.51 (d, /= 8.0 Hz, IH).
Example A(28): 6-Cyclopentyl-6-[2-(3-(6-Methyl-dihydro-pyran-2,4-dione)-phenyl)-ethyl]- dihydro-pyran-2,4-dione
Figure imgf000066_0001
The title compound was prepared analogously to Example A(27), where 3-Bromo acetophenone was substituted in place of 1-(4-Bromo-2-chloro-phenyl)-ethanone in Step 3 of that example.
Η NMR (CDC13): δ 1.17-1.70 (m, 11H), 1.86-1.89 (m, 2H), 2.35-2.45 (m, IH), 2.53-3.35 (m, 10H), 7 .05- 7.256 (m, 4H). ESIMS (MH+) ^ 6: 413.
Example A(29): 6-Cyclopentyl-6-{2-[4-(2-methyl-5-oxo-tetrahydro-furan-2-yl)-phenyl]-ethyl}- dihydro-pyran-2,4-dione
Figure imgf000066_0002
The title compound was prepared analogously to Example A(27), where 5-(3-Bromo- phenyl)-5-methyl-dihydro-furan-2-one (described in Step 1 below) was substituted in place of 1- (4-Bromo-2-chloro-phenyl)-ethanone in Step 3 of that example. "H NMR (CDC13): δ 1.58-1.83 (m, 11H), 1.90-2.0 (m, 2H), 2.26-2.33 (m, IH), 2.26-2.27 (m, 6H), 2.78 (s, 2H), 3.42 (s, 2H), 7.14 (d, = 8.2 Hz, 2H), 7.29 (d, / = 8.2 Hz, 2H). ESIMS (MH+) C23H2s05: 385
Step 1 : 5-(3-Bromo-phenyl)-5-methyl-dihydro-furan-2-one
Figure imgf000067_0001
To a magnetically stirring solution of 3-(4-Bromobenzoyl)propionic acid (1.0g, 3.89 mmol) in anhydrous THF (20 mL), under argon at room temperature, was added a solution of methyl magnesium bromide in 75:25 toluene/THF (1.4 M, 5.8 mL, 8.17 mmol) over a period of 1 h. The resulting solution was stirred at room temperature for 18 hours. Ice and cone HCl (2 mL) were carefully added and the resulting reaction mixture was stirred at 80 °C for 8 h. The resultant reaction was cooled to room temperature and extracted with EtOAc (2 X 25 mL). The organics were washed with water (50 mL) and brine (50 mL) then dried over Na2S0 , filtered and concentrated. The crude residue was purified by flash chromatography (40% EtOAc in Hexanes) to yield the intermediate bromide as a clear oil (0.49 g, 50%).
Η NMR (CDC13): δ 71.70 (m, 3H), 2.39-2.71 (m, 4H), 7.23-7.28 (m, 2H), 7.48-7.53 (m, 2H).
Example A(30): 6-[2-(3-Chloro-4-(6-Ethyl-dihydro-pyran-2,4-dione)-phenyl)-ethyl]-6- cyclopentyl-dihydro-pyran-2,4-dione.
Figure imgf000067_0002
The title compound was prepared analogously to Example A(27), where 1-(4-Bromo-2- chloro-phenyl)-propan-1-one (described in Step 1 below) was substituted in place of 1-(4-Bromo- 2-chloro-phenyl)-ethanone in Step 3 of that example. 'H NMR (CDC13): δ 0.87 (t, / = 7.3 Hz, 3H), 1.4-1.7 (m, 8H), 1.92-1.98 (m, 2H), 2.09-2.17 (m, IH), 2.18 (s, 2H), 2.22-2.33 (m, IH), 2.37-2.47 (m, IH), 2.62-2.78 (m, 2H), 2.95 (d, J = 17 Hz, IH), 3.09 (dd, / = 20, 4.7 Hz, IH), 3.33 (d, / = 20 Hz, IH), 3.43 (s, 2H), 3.93 (ά, J = 17 Hz, IH), 7.09(d, J = 8.1, IH), 7.22 (s, IH), 7.88 (d, J= 8.1 Hz, IH). ESIMS (MH-) C25H29C106: 459.
Step 1: 1-(4-Bromo-2-chloro-phenyl)-propan-1-one
Figure imgf000068_0001
The title compound was prepared as described in Step 2 of Example A(27), where ethyl magnesium bromide was substituted for methyl magnesium bromide. Yield 84%.
lU NMR (CDC13) δ 1.2 ( t, / = 7.3 Hz, 3H), 2.93 (q, / = 7.3 Hz, 2H), 7.44-7.64 (m, 3H).
Example A(31): 6-[2-(3-Chloro-4-(6-Cyclopropyl-dihydro-pyran-2,4-dione)-phenyl)-ethyl]-6- cyclopentyl-dihydro-pyran-2,4-dione
Figure imgf000068_0002
The title compound was prepared analogously to Example A(27), where (4-Bromo- phenyl)-cyclopropyl-methanone was substituted in place of 1-(4-Bromo-2-chloro-phenyl)- ethanone in Step 3 of that example.
!H NMR (CDC13): δ 0.46-0.61 (m, 2H), 0.83-1.01 (m, 2H), 1.20-1.79 (m, 8H), 1.88-2.10 (m, 2H), 2.23- 2.42 (m, 2H), 2.62-3.43 (m, 10H), 7.17-7.24 (m, 4H). ES S (MH-) C26H30O6: 437.
Example A(32): 6-Cyclopentyl-6-[2-(4-cyclopropanecarbonyl-phenyl)-ethyl]-dihydro-pyran- 2,4-dione
Figure imgf000069_0001
The title compound was prepared analogously to Example A(27), where (4-Bromo- phenyl)-cyclopropyI-methanone was substituted in place of 1-(4-Bromo-2-chloro-phenyl)- ethanone in Step 3 of that example. The title compound was obtained side product previously described Example A(31).
!H NMR (CDC13): δ 1.02-1.06 (m, 2H), 1.21-1.25 (m, 2H), 1.28-1.75 (m, 9H), 1.97-2.05 (m, 2H), 2.24- 2.30 (m, IH), 2.64-2.73 (m, 2H), 2.79 (s, 2H), 3.44 (s, 2H), 7.25 (d, /= 8.3 Hz, 2H), 7.95 (d, J= 8.3 Hz, 2H). Anal. Calcd. For C22H26O4-0.5 H20: C, 72.70; H, 7.49. Found: C, 72.87; H, 7.38. ESIMS (MH-):
353.
Example A(33): 2-{4-[2-(2-Cyclopentyl-4,6-dioxo-tetrahydro-pyran-2-yl)-ethyl]-phenyl}-2- methyl-propionic acid methyl ester
Figure imgf000069_0002
The title compound was prepared analogously to Example A(64), where 2-(4-Bromo- phenyl)-2-methyI-propionic acid methyl ester was substituted in place of 4-bromo-2-fluoro-1- isopropylbenzene in Step 3 of that example.
Η NMR (CDC13): 1.53-1.68 (m, 14H), 1.93-1.98 (m, 2H), 2.25-2.38 (m, IH), 2.63-2.68 (m, 2H) 2.77 (s, 2H), 3.42 (s, 2H), 3.65 (s, 3H), 7.09-7.12 (m, 2H), 7.22-7.24 (m, 2H) Anal. Calcd. For C23H30O5-0.25 H20: C, 70.65, H, 7.86. Found: C, 70.88, H, 7.82. ESIMS (MH+): 345.2 Example A(34): 6-{2-[4-(2-tert-Butyl-[1 ,3]dioxolan-2-yl)-phenyl]-ethyl}-6-cyclopentyl- dihydro-pyran-2,4-dione
Figure imgf000070_0001
The title compound was prepared analogously to Example A(64), where 2-(4-Bromo- phenyl)-2-fe/t-butyl-[1,3]dioxolane was substituted in place of 4-bromo-2-fluoro-1- isopropylbenzene in Step 3 of that example.
'H NMR (CDC13): δ 0.94 (s, 9H), 1.5-1.8 (m, 8H), 1.91-2.05 (m, 2H), 2.27-2.32 (m, IH), 2.64-2.70 (m, 2H) 2.77 (s, 2H), 3.42 (s, 2H), 3.64-3.68 (m, 2H), 3.92-3.95 (m, 2H), 7.07 (d, J = 8.3 Hz, 2H), 7.35 (d, / = 8.3 Hz, 2H). Anal. Calcd. For C25H3405: C, 72.44; H, 8.27. Found: C, 72.65; H, 8.43. ESIMS (MH+): 415
Example A(35): 6-Cyclopentyl-6-{2-[4-(1-hydroxy-ethyl)-phenyl]-ethyl}-dihydro-pyran-2,4- dione
Figure imgf000070_0002
ΩH The title compound was prepared analogously to Example A(27), where (R)1-(4-Bromo-phenyl)-ethanol (described in Step 1 below) was substituted in place of 1- (4-Bromo-2-chloro-phenyl)-ethanone in Step 3 of that example.
'H NMR (CDC13): δ 1.48 (d, = 6.4 Hz, 3H), 1.52-1.79 (m, 8H), 1.95 (q, J= 17, 8.5Hz, 2H), 2.26-2.32 (m, IH), 2.68 (t, / = 8.5 Hz, 2H), 2.78 (s, 2H), 3.42 (s, 2H), 4.88 (q, /= 13, 6.4Hz, IH), 7.13 (d, /= 8.1 Hz, 2H), 7.31 (d, = 8.1 Hz, 2H). Anal. Calcd. For C20H26O4-0.5H2O: C, 70.77; H, 8.02. Found: C, 70.37; H, 7.95. ESIMS (MH-): 329.
Step 1: (R)1-(4-Bromo-phenyl)-ethanol
Figure imgf000071_0001
OH
This compound was prepared as described in the following reference: Tetrahedron 2001 , 57, 5027-5038.
Example A(36): 6-Cyclopentyl-6-{2-[4-(1 -hydroxy-ethyl)-phenyl]-ethyl}-dihydro-pyran-2,4- dione
Figure imgf000071_0002
The title compound was prepared analogously to Example A(27), where (S)1-(4-Bromo- phenyl)-ethanoI (described below) was substituted in place of 1-(4-Bromo-2-chloro-phenyl)- ethanone in Step 3 of that example.
'H NMR (CDC13): δ 1.48 (d, J = 6.4 Hz, 3H), 1.55-1.80 (m, 8H), 1.95 (q, J = 17, 8.5Hz, 2H), 2.23-2.35 (m, IH), 2.68 (t, J = 8.5 Hz, 2H), 2.78 (s, 2H), 3.42 (s, 2H), 4.88 (q, J = 13, 6.4Hz, IH), 7.13 (d, J = 8.1 Hz, 2H), 7.31 (d, / = 8.1 Hz, 2H). Anal. Calcd. For C20H26O4-0.25H2O: C, 71.72; H, 7.97. Found: C, 71.4; H, 7.95. ESIMS (MH-): 329.
Step 1: (S)1-(4-Bromo-phenyl)-ethanol
Figure imgf000071_0003
This compound was prepared as described in the following reference: Tetrahedron 2001 , 57, 5027-5038.
Example A(37): 6-Cyclopentyl-6-{2-[4-(2,2-dimethyl-propionyl)-pheηyl]-ethyl}-dihydro- pyran-2,4-dione.
Figure imgf000072_0001
To a solution of 6-{2-[4-(2-tert-Butyl-[1 ,3]dioxolan-2-yl)-phenyl]-ethyl}-6-cyclopentyl- dihydro-pyran-2,4-dione from Example A(34), . (0.173 g) in acetone (1 mL) was added Amberlyst 15 (0.05g). The reaction mixture was stirred at room temperature overnight, and then filtrated. The solvent was removed under reduced pressure. The residue was purified by flash chromatography (40% EtOAc in Hexanes) to yield the product as a white foam (0.04 g, 95%). .
'H NMR (CDC13): δ 1.35 (s, 9H), 1.47-1.84 (m, 8H), 1.91-2.03 (m, 2H), 2.25-2.34 (m, IH), 2.72 (t, 7 = 8.0 Hz, 2H), 2.78 (s, 2H), 3.44 (s, 2H), 7.18 (d, 7 = 8.2 Hz, 2H), 7.67 (d, 7 = 8.2 Hz, 2H). Anal. Calcd. For C23H30O4: C, 74.56; H, 8.16. Found: C, 74.86; H, 8.43. ESIMS (MH+): 371
Example A(38): N-(1-{4-[2-(2-Cyclopentyl-4,6-dioxo-tetrahydro-pyran-2-yl)-ethyl]-phenyl}- ethyl)-acetamide.
Figure imgf000072_0002
The title compound was prepared analogously to Example A(64), where (R) Λ/-[1-(4- Bromo-phenyl)-ethyl]-acetamide (described in Step 1 below) was substituted in place of 4-bromo- 2-fluoro-1-isopropylbenzene in Step 3 of that example.
Η NMR (CDC13): δ 1.47 (d, 7 = 6.8 Hz, 3H), 1.53-1.82 (m, 8H), 1.91-1.96 (m, 2H), 1.98 (s, 3H), 2.24- 2.33 (m, IH), 2.62-2.70 (m, 2H), 2.77 (s, 2H), 3.41 (d, 7 = 2.0 Hz, 2H), 5.05-5.13 (m, IH), 5.66 (d, 7 = 7.5 Hz, IH), 7.11 (d, 7 = 8.1 Hz, 2H), 7.24 (d, 7 = 8.1 Hz, 2H). Anal. Calcd. For C22H29NO4-0.25AcOH: C, 69.92; H, 7.82, N, 3.62; Found: C, 69.66; H, 7.66, N, 3.75. ESIMS (MH+): 372. Step 1 : (R) W-[1-(4-Bromo-phenyl)-ethyl]-acetamide.
Figure imgf000073_0001
HN
0
To a stirred solution of (R)-(+)-1-(4-bromophenyl)ethylamine (0.52g, 2.59 mmol) in anhydrous CH2CI2 (5mL) under argon were added acetic anhydride (0.37 mL, 3.89 mmol) and Pyridine (0.31 mL, 3.89 mmol). The resulting solution was stirred at 25 °C for 3 hrs. The reaction mixture was quenched with saturated 1 N HCl and extracted with EtOAc (30 mL). The organic phase was washed with brine (50 mL), dried over Na2S04 and evaporated. The residue was purified by flash column chromatography (80% EtOAc in hexanes) to give the product (0.62 g, 100%) as a white solid.
Η NMR (CDC13) δ: 1.46 (d, 7= 7.0 Hz, 3H), 1.99 (s, 3H), 5.03-5.12 (m, IH), 5.68 (brs, IH), 7.18 (d, 7 = 8.4 Hz, 2H), 7.47 (d, 7= 8.4 Hz, 2H). ESIMS (MNa+): 264.
Example A(39): N-(1 -{4-[2-(2-Cyclopentyl-4,6-dioxo-tetrahydro-pyran-2-yl)-ethyl]-phenyl}- ethy l)-malonamic acid ethyl ester.
Figure imgf000073_0002
The title compound was prepared analogously to Example A(64), where (R) Λ/-[1-(4- Bromo-phenyl)-ethyl]-malonamic acid ethyl ester (described in Step 1 below) was substituted in place of 4-bromo-2-fluoro-1-isopropylbenzene in Step 3 of that example.
Η NMR (CDC13): δ 1.29 (t, 7 = 7.7 Hz, 3H), 1.48 (d, 7= 7.1 Hz, 3H), 1.59-1.78 (m, 8H), 1.89-2.05 (m, 2H), 2.25-2.30 (m, IH), 2.64-2.68 (m, 2H), 2.77 (s, 2H), 3.31 (d, 7= 3.4 Hz, 2H), 3.42 (s, 2H), 4.19 (q, 7 = 7.1 Hz, 2H), 5.09-5.14 (m, IH), 7.11 (d, 7 = 8.1 Hz, 2H), 7.25 (d, 7 = 8.1 Hz, 2H), 7.49 (d, 7= 7.3 Hz, IH). Anal. Calcd. For C25H33NO6-1.0AcOH-0.5H2O: C, 63.27; H, 7.47, N, 2.73; Found: C, 63.30; H, 7.19, N, 2.91. ESIMS (MH+): 444..
Step 1: (R) W-[1-(4-Bromo-phenyl)-ethyl]-malonamic acid ethyl ester.
Figure imgf000074_0001
To a magnetically stirred solution of (R)-(+)-1-(4-bromophenyl)ethylamine (0.51 g, 2.55 mmol) in anhydrous CH2CI2 under argon and cooled to 0 °C, were added ethyl hydrogen malonate (0.4 g, 3.06 mmol) EDC.HCI (0.58 g, 3.06 mmol) and HOBt (0.41 g, 3.06 mmol). The resulting solution was stirred at 25 °C overnight. CH2CI2 was evaporate and residue partitioned between EtOAC and 1N HCl. The organic layer was washed with H20, brine and dried over Na2S04. The solvent was removed in vacuo and the residue was purified by flash column chromatography (40% EtOAc in hexanes) to provide the desired product (0.57 g, 71%) as a white solid.
*H NMR (CDC13): δ 1.29 (t, 7 = 7.2 Hz, 3H), 1.48 (d, 7= 7.0 Hz, 3H), 3.31 (d, 7 = 1.9 Hz, 2H), 4.2 (q, 7 = 7.2 Hz, 2H), 5.06-5.14 (m, IH), 7.20 (d, 7 = 8.3 Hz, 2H), 7.45 (d, 7= 8.3 Hz, 2H), 7.48 (brs, IH). ESIMS (MH+): 315
Example A(40): 1-{4-[2-(2-Cyclopentyl-4,6-dioxo-tetrahydro-pyran-2-yl)-ethyl]-phenyl}- cyclopropanecarbonitrile.
Figure imgf000074_0002
The title compound was prepared analogously to Example A(64), where 1-(4- Bromophenyl)cyclopropane carbonitrile was substituted in place of 4-bromo-2-fluoro-1- isopropylbenzene in Step 3 of that example. Η NMR (CDC13): δ 1.35-1.39 (m, 2H), 1.5-1.87 (m, 10H), 1.87-2.00 (m, 2H), 2.22-2.33 (m, IH), 2.67 (t, 7= 8.4 Hz, 2H), 2.77 (s, 2H), 3.42 (d, 7= 1.5 Hz, 2H), 7.12 (d, 7= 8.3 Hz, 2H), 7.22 (d, 7= 8.3 Hz, 2H). Anal. Calcd. For C22H25N03: C, 75.19; H, 7.17, N, 3.99. Found: C, 75.38; H, 7.40, N, 4.04. ESIMS (MH-): 352.
Example A(41 ): 1 -(1 -{4-[2-(2-Cyclopentyl-4,6-dioxo-tetrahydro-pyran-2-yl)-ethyl]-phenyl}- ethyl)-3-methyl-urea.
Figure imgf000075_0001
The title compound was prepared analogously to Example A(64), where (R) 1-[1-(4- Bromo-phenyl)-ethyl]-3-methyl-urea (described in Step 1 below) was substituted in place of 4- bromo-2-fluoro-1-isopropylbenzene in Step 3 of that example.
Η NMR (DMSO-d6): δ 1.09 (d, 7 = 6.8 Hz, 3H), 1.32-1.47 (m, 8H), 1.69-1.73 (m, 2H), 1.91 (s, 3H), 2.12- 2.18 (m, IH), 2.33-2.42 (m, 2H), 3.16 (s, 2H), 4.45-4.57 (m, IH), 4.80 (s, IH), 5.4 (q, 7 = 4.3 Hz, IH), 6.10 (d, 7= 8.3 Hz, IH), 6.93 (d, 7= 8.1 Hz, 2H), 7.00 (d, 7= 8.1 Hz, 2H), 11.17 (s, IH). ESFMS (MH-) C22H30N2O4: 385.
Step 1: (R) 1-[1-(4-Bromo-phenyl)-ethyl]-3-methyl-urea
Figure imgf000075_0002
To a stirred solution of (R)-(+)-1-(4-bromophenyl)ethylamine (0.5 g, 2.49 mmol) in anhydrous CH2CI2 was added methyl isocyanate (0.15 mL, 2.49 mmol). The resulting solution was stirred at 25 °C overnight. CH2CI2 was evaporate and residue partitioned between EtOAC and 1 N HCl. The organic layer was washed with H20, brine and dried over Na2S04. The solvent was removed in vacuo and the residue was purified by flash column chromatography (80% EtOAc in hexanes) to provide the desired product (0.60 g, 94%) as a white solid. Η NMR (CDC13) δ: 1.42 (d, 7= 7.0 Hz, 3H), 2.72 (d, 7= 4.9 Hz, 3H), 4.25 (brs, IH), 4.73 (brs, IH), 4.74- 4.81 (m, IH), 7.20 (d, 7= 8.3 Hz, 2H), 7.45 (d, 7= 8.3 Hz, 2H). ESIMS (MNa+): 258.
Example A(42): W-(1 -{4-[2-(2-Cyclopentyl-4,6-dioxo-tetrahydro-pyran-2-yl)-ethyl]-phenyl}- ethyl)-methanesulfonamide
Figure imgf000076_0001
The title compound was prepared analogously to Example A(64), where (R) Λ/-[1-(4- Bromo-phenyl)-ethyl]-methanesulfonamide (described in Step 1 below) was substituted in place of 4-bromo-2-fluoro-1-isopropylbenzene in Step 3 of that example .
Η NMR (CDC13): δ 1.52 (d, 7 = 7.2 Hz, 3H), 1.58-1.72 (m, 8H), 1.93-2.05 (m, 2H), 2.27-2.30 (m, 2H), 2.66 (s, 3H), 2.45-2.46 (m, IH), 2.78 (s, 2H), 3.42 (d, 7= 2.7 Hz, 2H), 4.54 (d, 7 = 3.0 Hz, IH), 4.60-4.65 (m, IH), 7.15 (d, 7 = 8.3 Hz, 2H), 7.26 (d, 7= 8.3 Hz, 2H). Anal. Calcd. For C2iH29N05S: C, 61.89; H, 7.17, N, 3.44; Found: C, 61.94; H, 7.40, N, 3.59. ESIMS (MH-): 406.
Step 1: (R) W-[1-(4-Bromo-phenyl)-ethyl]-methanesulfonamide.
Figure imgf000076_0002
To a stirred solution of (R)-(+)-1-(4-bromophenyl)ethylamine (0.5g, 2.49 mmol), in anhydrous CH2CI2 (5mL) under argon were added methane sulfonyl chloride (0.23 mL, 2.99 mmol) and Pyridine (0.30 mL, 3.73 mmol). The resulting solution was stirred at 25 °C for 3 hrs. The reaction mixture was quenched with 1N HCl and extracted with EtOAc (30 mL). The organic phase was washed with brine (50 mL), dried over Na2S04 and evaporated. The residue was purified by flash column chromatography (80% EtOAc in hexanes) to give the product (0.40 g, 58%) as a white solid.
Η NMR (CDC13) δ: 1.52 (d, 7= 6.8 Hz, 3H), 2.67 (s, 3H), 4.61-4.72 (m, 2H), 7.24 (d, 7= 8.3 Hz, 2H), 7.51 (d, 7= 8.3 Hz, 2H). ESIMS (MNa+): 279.
Example A(43): 5-Methyl-isoxazole-3-carboxylic acid (1-{4-[2-(2-cyclopentyl-4,6-dioxo- tetrahydro-pyran-2-yl)-ethyl]-phenyl}-ethyl)-amide
Figure imgf000077_0001
The title compound was prepared analogously to Example A(64), where (R)-δ-Methyl- isoxazole-3-carboxylic acid [1-(4-bromo-phenyl)-ethyl]-amide (described in Step 1 below) was substituted in place of 4-bromo-2-fluoro-1-isopropylbenzene in Step 3 of that example.
Η NMR (CDC13): δ 1.56 (d, 7= 6.0 Hz, 3H), 1.58-1.89 (m, 8H), 1.91-2.05 (m, 2H), 2.25-2.29 (m, IH), 2.47 (s, 3H), 2.64-2.67 (m, 2H), 2.77 (s, 2H), 3.42 (s, 2H), 5.19-5.25 (m, IH), 6.42 (s, IH), 6.99 (d, 7= 3.0 Hz, IH), 7.13 (d, 7 = 6.0 Hz, 2H), 7.29 (d, 7 = 6.0 Hz, 2H). Anal. Calcd. For C25H3oN205: C, 68.47; H, 6.90, N, 6.39; Found: C, 68.70; H, 7.10, N, 6.65. ESIMS (MH+): 439.
Step 1: (R)-5-Methyl-isoxazole-3-carboxylic acid [1-(4-bromo-phenyl)-ethyl]-amide.
Figure imgf000077_0002
The title compound was prepared as described in Step 1 of Example A(39), where 5- methylisoxazole-3-carboxyIic acid was substituted for ethyl hydrogen malonate. Yield 84%.
Example A(44): 6-(2-Cyclohexyl-ethyl)-6-cyclopentyl-dihydro-pyran-2,4-dione
Figure imgf000078_0001
The title compound was prepared analogously to Example A(27), where 3-Cyclohexyl-1- cyclopentyl-propan-1-one (from Step 2 below), was substituted in place of 3-(4-Acetyl-3-chloro- phenyl)-1-cyclopentyl-propan-1-one of that example.
Η NMR (CDC13): δ 1.17-2.17 (m, 24H), 2.69 (s, 2H), 3.39 (s, 2H) Anal. Calcd. For C18H2803: C, 73.93; H, 9.65. Found: C, 74.01; H, 9.80. ESIMS (MH+): 293
Step 1: 3-Cyclohexyl-thiopropionic acid S-pyridin-2-yl ester
Figure imgf000078_0002
3-Cyclohexylpropionic acid (1 g, 6.40 mmol), triphenylphosphine (2.18 g, 8.32 mmol) and 2,2'-dipyridyl disulfide (1.83 g, 8.32 mmol) were combined successively in CH2CI2 (20 mL). The reaction mixture was stirred 1 h and then loaded directly onto a column for purification by flash chromatography (20% EtOAc in hexanes) to give a residue. This residue was washed with hexanes (20 mL) and the solid, partially crystalline material was collected by filtration and air dried to give the product (1.43 g, 90%) as a white solid.
Η NMR (CDC13): δ: 0.91-1.52 (m, 13 H), 2.1 (t, 7 = 7.5 Hz, 2 H), 7.21-7.26 (m, 1 H), 7.53-7.56 (m, 1 H), 7.65-7.70 (m, 1 H), 8.54-8.56 (m, 1 H).
Step 2: 3-Cyclohexyl-1-cyclopentyl-propan-1-one
Figure imgf000079_0001
3-Cyclohexyl-thiopropionic acid S-pyridin-2-yl ester (1.43 g, 5.74 mmol) from Step 1 above was dissolved in dry THF (28 mL) and cooled to -78 °C. A solution of cyclopentylmagnesium bromide in Et20 (2.0 M, 3.01 mL, 6.02 mmol) was added dropwise. After stirring 1 h, the cooling bath was removed. The reaction mixture was quenched with 1N HCl and extracted with EtOAc (100 mL). The organic phase was washed with brine (50 mL), dried over Na2S04 and evaporated. The residue was purified by flash column chromatography (1% EtOAc in hexanes) to give the product (0.99 g, 83%) as clear oil.
Η NMR (CDC13) δ : 0.82-1.84 (m, 21 H), 2.42-2.47 (m, 2H), 2.82-2.92 (m, 1 H).
Example A(45): 4'-[2-(2-Cyclopentyl-4,6-dioxo-tetrahydro-pyran-2-yl)-ethyl]-biphenyl-3-
carbonitrile
Figure imgf000080_0001
The title compound was prepared analogously to Example A(27), where 4'-Bromo- biphenyl-3-carbonitrile (described in Step 1 below), was substituted in place of 1-(4-Bromo-2- chloro-phenyl)-ethanone in Step 3 of that example.
Η NMR (CDC13): δ 1.59-1.81 (m, 8H), 1.99-2.05 (m, 2H), 2.30-2.33 (m, IH), 2.72-2.79 (m, 2H), 2.8 (s, 2H), 3.45 (s, 2H), 7.26 (d, 7 = 7.4 Hz, 2H), 7.46-7.56 (s, 3H), 7.61-7.64 (m, IH), 7.77-7.8 (m, IH), 7.83- 7.85 (m, IH). Anal. Calcd. For C25H2503: C, 77.49; H, 6.50, N, 3.61. Found: C, 77.63; H, 6.75, N, 3.80. ESIMS (MH+): 388. IR (cm"'): 3397, 2955, 2229, 1659, 1227.
Step 1 : 4'-Bromo-biphenyl-3-carbonitrile.
Figure imgf000080_0002
To a magnetically stirring solution of 3-cyanophenyl boronic acid (0.62 g, 4.24 mmol) and 1-bromo-4-iodobenzene (1.0 g, 3.53 mmol) in anhydrous DMF (7.0 mL), under argon at room temperature, was added 2M sodium carbonate solution (7.0 mL) followed by Pd(PPh3)4 (0.21 g, 0.18 mmol). The resulting mixture was heated to 75 °C overnight. The resulting dark reaction mixture was cooled to room temperature filtered to remove the solids and the resultant filtrate was poured into water (50 mL) and extracted with EtOAc (2 X 25 mL). The organics were washed with water (50 mL) and brine (50 mL) then dried over Na2S04, filtered and concentrated. The BU
crude residue was purified by flash chromatography (5% EtOAc in Hexanes) to yield the intermediate bromide as a white solid (0.36 g, 33%).
Η NMR (CDC13): δ Η NMR (CDC13) δ : 7.43 ( d, 7 = 7.4 Hz, 2 H), 7.53-7.67 (m, 4H), 7.76-7.84 (m, 2 H).
Example A(46): 2-[2-(2-Cyclopentyl-4,6-dioxo-tetrahydro-pyran-2-yl)-ethyl]-benzonitrile.
Figure imgf000081_0001
The title compound was prepared analogously to Example A(27), where 2- bromobenzonitrile was substituted in place of 1-(4-Bromo-2-chloro-phenyl)-ethanone in Step 3 of that example.
Η NMR (CDC13): δ 1.59-1.81 (m, 8H), 1.99-2.05 (m, 2H), 2.30-2.33 (m, IH), 2.72-2.77 (m, 2H), 2.81 (s, 2H), 3.48 (s, 2H), 7.26-7.85 (m, 4H)Anal. Calcd. For C19H21N03: C, 73.29; H, 6.80; N, 4.50. Found: C, 73.17; H, 6.84; N, 4.42. ESIMS (MH-): 310
Example A(47): 6-Cyclopentyl-6-(2-naphthalen-2-yl-ethyl)-dihydro-pyran-2,4-dione.
Figure imgf000081_0002
The title compound was prepared analogously to Example A(64), where 2- bromonaphatalene was substituted in place of 4-bromo-2-fluoro-1-isopropylbenzene in Step 3 of that example.
Η NMR (CDC13): δ 1.5-1.9 (m, 8H), 1.93 (m, 2H), 2.24 (m, IH), 2.9 (s, 2H), 2.90 (t, 7= 8.4 Hz, 2H), 3.5 (s, 2H), 7.2 (m, IH), 7.4 (m, 2H), 7.6 (s, IH), 7.8 (m 3H). Anal. Calcd. For C22H2403: C, 78.54; H, 7.19. Found: C, 78.70; H, 7.25. ESIMS (MH+): 337 Example A(48): 6-Cyclopentyl-6-{2-[4-(tetrahydro-pyran-2-yloxy)-phenyl]-ethyl}-dihydro- pyran-2,4-dione.
Figure imgf000082_0001
The title compound was prepared analogously to Example A(64), where 2-(4- bromophenoxyl) tetrahydro 2/-/-pyran was substituted in place of 4-bromo-2-fluoro-1- isopropylbenzene in Step 3 of that example.
Η NMR (CDC13): δ 1.28-1.98 (m, 16H), 2.2-2.31 (m, IH), 2.62 (t, 7= 8.6, 2H), 2.76 (s, 2H), 3.42 (s, 2H), 3.55-3.61 (m, IH), 3.86-3.94 (m, IH), 5.38 (t, 7 = 3.1, IH), 6.97 (d, 7= 8.7, 2H), 7.05 (d, 7= 8.7, 2H). Anal. Calcd. For C23H3oθ5-0.5 H20: C, 69.85; H, 7.90. Found: C, 70.19; H, 8.01. ESIMS (MNa+): 409
Example A(49): 2-{4-[2-(2-Cyclopentyl-4,6-dioxo-tetrahydro-pyran-2-yl)-ethyl]-phenyl}-N- methyl-isobutyramide.
Figure imgf000082_0002
The title compound was prepared analogously to Example A(64), where 2-(4-Bromo- phenyl)-Λ/-methyl-isobutyramide (described in Step 1 below), was substituted in place of 4-bromo- 2-fluoro-1-isopropylbenzene in Step 3 of that example.
Η NMR (CDC13): δ 1.55 (s, 6H); 1.59-1.73 (m, 8H), 1.94-2.05 (m, 2H), 2.28-2.35 (m, IH), 2.67-2.69 (m, 2H), 2.76 (s, 3H), 2.76 (s, 2H), 3.40 (s, 2H), 5.2 (brs, IH), 7.14 (d, 7= 8.3, 2H), 7.30 (d, 7= 8.3, 2H). Anal. Calcd. For C23H3ιN04: C, 71.66; H, 8.10, N, 3.63. Found: C, 71.80; H, 8.35, N, 3.77. ESIMS (MH+): 386.
Step 1: 2-(4-Bromo-phenyl)-W-methyl-isobutyramide.
Figure imgf000083_0001
The title compound was prepared as described in Step 1 of Example A(39), where 2-(4- bromophenyl)-2-methyl propionic acid was substituted for ethyl hydrogen malonate and methyl amine was substituted instead of (R)-(+)-1-(4-bromophenyl)ethylamine on that example. Yield 84%.
Η NMR (CDC13) δ: 1.55 (s, 6H), 2.72 (d, 7 = 4.6 Hz, 3H), 5.15 (brs, IH), 7.22-7.26 (m, 2H), 7.46-7.50 (m, 2H).
Example A(50): 6-Cyclopentyl-6-{2-[4-(5-phenyl-[1 ,3,4]oxadiazol-2-yl)-phenyl]-ethyl}- dihydro-pyran-2,4-dione.
Figure imgf000083_0002
The title compound was prepared analogously to Example A(64), where 2-(4- bromophenyl)-5-phenyl-1,2,3-oxadiazole was substituted in place of 4-bromo-2-fluoro-1- isopropylbenzene in Step 3 of that example.
'H NMR (CDC13): δ 1.44-1.82 (m, 8H), 1.99-2.05 (m, 2H), 2.30-2.34 (m, IH), 2.76-2.79 (m, 2H), 2.81 (s, 2H), 3.46 (s, 2H), 7.32 (d, 7= 8.3, 2H), 7.51-7.58 (m, 3H), 8.07 (d, 7= 8.3, 2H), 8.13-8.16 (m, 2H). Anal. Calcd. For C2l5H26N2O4-0.5 H20: C, 71.05; H, 6.19, N, 6.37. Found: C, 71.32; H, 6.06, N, 6.45. ESIMS (MH+): 431.
Example A(51 ): 2-{4-[2-(2-CycIopentyl-4,6-dioxo-tetrahydro-pyran-2-yl)-ethyl]-phenyl}-N- ethyl-isobutyramide.
Figure imgf000084_0001
The title compound was prepared analogously to Example A(64), where 2-(4-Bromo- phenyl)-Λ/-ethyl-isobutyramide (described in Step 1 below) was substituted in place of 4-bromo-2- fluoro-1-isopropylbenzene in Step 3 of that example.
'H NMR (CDC13): δ 1.01 (t, 7 = 7.2, 3H), 1.54 (s, 6H); 1.63-1.7 (m, 8H), 1.92-1.99 (m, 2H), 2.29-2.32 (m, IH), 2.69 (t, 7= 8.3, 2H), 2.76 (s, 2H), 3.21 (q, 7 = 7.2, 5.28, 2H), 3.40 (s, 2H), 5.4 (brs, IH), 7.12 (d, 7 = 8.3, 2H), 7.28 (d, 7= 8.3, 2H). Anal. Calcd. For C24H33N04: C, 72.15; H, 8.32, N, 3.51. Found: C, 72.40; H, 8.60, N, 3.77. ESIMS (MH+): 400.
Step 1 : 2-(4-Bromo-phenyl)-W-ethyl-isobutyramide
Figure imgf000084_0002
The title compound was prepared as described in Step 1 of Example A(39), where 2-(4- bromophenyl)-2-methyl propionic acid was substituted for ethyl hydrogen malonate and ethyl amine was substituted for (R)-(+)-1-(4-bromophenyl)ethylamine on that example. Yield 82%.
Η NMR (CDC13) δ: 1.01 (t, 7= 5.3 Hz, 3H), 1.55 (s, 6H),), 3.2 (q, 7 = 7.0, 5.3, 2H), 5.15 (brs, IH), 7.22- 7.26 (m, 2H), 7.46-7.50 (m, 2H).
Example A(52): 6-{4-[2-(2-Cyclopentyl-4,6-dioxo-tetrahydro-pyran-2-yl)-ethyl]-2-fluoro- phenoxy}-6-methyl-3,5-dioxo-heptanoic acid methyl ester.
Figure imgf000085_0001
The title compound was prepared analogously to Example A(27), where 2-(4-Bromo-2- fluoro-phenoxy)-2-methyl-propionic acid methyl ester (described in Step 1 below) was substituted in place of 1-(4-Bromo-2-chloro-phenyl)-ethanone in Step 3 of that example
Η NMR (CDC13): δ 1.48 (s, 3H); 1.55 (s, 3H), 1.58-1.77 (m, 8H), 1.90-1.97 (m, 2H), 2.22-2.30 (m, IH), 2.60-2.88 (m, 6H), 3.39 (s,2H), 3.43 (s, IH), 3.72 (s, IH), 3.75 (s, 3H), 6.76-7.01 (m, 3H). ESIMS (MH+): 505.
Step 1: 2-(4-Bromo-2-fluoro-phenoxy)-2-rnethyl-propionic acid methyl ester.
Figure imgf000085_0002
To a solution of 4-Bromo-2-fluorophenol (1 g, 5.24 mmol) and methyl D-bromobutyrate (1.89 g, 10.47 mmol) in DMF (20 mL) was added K2C03 (3.6 g, 26 mmol). The resultant slurry was heated to 100°C under argon for 12h. DMF was evaporate and residue partitioned between EtOAC and 1N HCl. The organic layer was washed with H20, and brine then dried over Na2S04. The solvent was removed in vacuo and the residue was purified by flash column chromatography (10% EtOAc in hexanes) to provide the desired product (1.17 g, 77%) as a white solid. Η NMR (CDC13) δ: 1.57 (s,6H), 3.79 (s, 3H),), 6.86 (t, 7 = 8.7, IH), 7.12-7.16 (m, IH), 7.23-7.27 (m, IH).
Example A(53): 2-{2-Chloro-4-[2-(2-cyclopentyl-4,6-dioxo-tetrahydro-pyran-2-yl)-ethyl]- phenoxy}-2-methyl-propionic acid methyl ester.
Figure imgf000086_0001
REVERSE ADDITION MODIFICATION: NaH (60% in mineral oil, 0.13 g, 3.13 mmol) was suspended in THF (10mL) and cooled to 0 °C. Methylacetoacetate (0.19 mL, 1.72 mmol) was slowly added via syringe and the reaction mixture stirred 20 min. A solution of n-BuLi in hexanes (1.6 M, 1.95 mL, 3.13 mmol) was added dropwise and the resulting mixture was stirred an additional 20 min. The resultant slurry was added via canula to a solution of 2-[2-Chloro-4-(3- cyclopentyl-3-oxo-propyl)-phenoxy]-2-methyl-propionic acid methyl ester (0.85 g, 2.41 mmol) from Step 1 below in THF (2 mL) pre-cooled to 0 °C. After stirring 1 h, the reaction mixture was quenched with 1N HCl (10 mL) and extracted with EtOAc (10 mL). The organic phase was dried over Na2S0 and evaporated. The crude organic product was then dissolved in 5 mL of MeOH, and 0.67 grams of finely powdered K2C03 (anhydrous) was added. The slurry was stirred at 60 °C for 1.5 h, and then concentrated by rotary evaporation. The residue was dissolved in 10 mL of water and 10 mL of EtOAc, and acidified with 2N HCl. The aqueous solution was extracted 3 times with 5 mL of EtOAc. The organics were combined, and dried with Na2S0 . After filtering the residue was purified by flash column chromatography (50% EtOAc in hexanes) to give the product (0.22 g, 25%) as a white foam
'H NMR (CDC13): δ 1.60 (s, 6H); 1.55-1.81 (m, 8H), 1.88-1.96 (m, 2H), 2.23-2.26 (m, IH), 2.60 (t, 7 = 7.9, 2H), 2.75 (d, 7 = 2.6, 2H), 3.43 (s, 2H), 3.80 (s, 3H), 6.79 (d, 7= 8.3, IH), 6.90 (d, 7 = 2, IH), 7.15 (d, 7 = 2, IH). Anal. Calcd. For C23H29C106: C, 63.23; H, 6.69. Found: C, 63.20; H, 6.95. ESIMS (MH+): 437.
Step 1 : 2-[2-Chloro-4-(3-cyclopentyl-3-oxo-propyl)-phenoxy]-2-methyl-propionic acid methyl ester.
Figure imgf000087_0001
The title compound was prepared analogously to Step 1 from example A(52), where 3-(3- Chloro-4-hydroxy-phenyl)-1-cyclopentyl-propan-1-one was substituted for 4-Bromo-2- fluorophenol in Step 1 of that example. Yield 74%.
'H NMR (CDC13) δ: 1.59 (s, 6H), 1.61-1.80 (m, 9H), 2.70-2.84 (m, 4H), 3.79 (s, 3H),), 6.78 (d, 7 = 8.4, IH), 6.93 (dd, 7 = 8.4, 2.3, IH), 7.18 (d, 7 = 2.3, IH).
Example A(54): 2-Chloro-4-[2-(2-cyclopentyl-4,6-dioxo-tetrahydro-pyran-2-yl)-ethyl]-
Figure imgf000087_0002
phenoxy}-acetic acid.
The title compound was prepared analogously to Example A(53), where [2-Chloro-4-(3- cyclopentyl-3-oxo-propyl)-phenoxy]-acetic acid methyl ester (described in Step 1 below) was substituted in place of 2-[2-Chloro-4-(3-cyclopentyl-3-oxo-propyl)-phenoxy]-2-methyl-propionic acid methyl ester) of that example.
'H NMR (CDC13): δ 1.47-1.74 (s, 8H); 1.89-1.96 (m, 2H), 2.23-2.29 (m, IH), 2.62 (t, 1 7 = 8.3, 2H), 2.76 (s, 2H),3.43 (s, 2H), 4.72 (s, 2H), 6.81 (d, 7 = 8.3, IH), 6.98 (dd, 7= 8.3, 2.3, IH), 7.18 (d, 7 = 2.3, IH). ESIMS (MH+): 395.
Step 1 : [2-Chloro-4-(3-cyclopentyl-3-oxo-propyl)-phenoxy]-acetic acid methyl ester.
Figure imgf000087_0003
The title compound was prepared analogously to Step 1 from Example A(52), where 3- (3-Chloro-4-hydroxy-phenyl)-1-cyclopentyl-propan-1-one was substituted for 4-Bromo-2- fluorophenol and methyl bromo acetate was substituted for methyl D-bromobutyrate in Step 1 of that example. Yield 78%.
Η NMR (CDC13) δ: 1.55-1.77 (m, 9H), 2.70-2.85 (m, 4H), 3.80 (s, 3H),), 4.68 (sm 2H), 6.75 (d, 7= 8.5, IH), 7.0 (dd, 7= 8.5, 2.2, IH), 7.21 (d, 7= 2.2, IH).
Example A(55): 2-{4-[2-(2-Cyclopentyl-4,6-dioxo-tetrahydro-pyran-2-yl)-ethyl]-2-fluoro- phenoxy}-2-methyl-propionic acid methyl ester.
Figure imgf000088_0001
The title compound was prepared analogously to Example A(27), where 2-(4-Bromo-2- fluoro-phenoxy)-2-methyl-propionic acid methyl ester (described in Step 1 of Example A(52), was substituted in place of 1-(4-Bromo-2-chloro-phenyl)-ethanone in Step 3 of that example. Η NMR (CDC13): δ 1.56 (s, 6H); 1.58-1.73 (m, 8H), 1.90-1.97 (m, 2H), 2.20-2.23 (m, IH), 2.62 (t, 7 = 8.1, 2H), 2.75 (s, 2H), 3.43 (s, 2H), 3.79 (s, 3H), 6.80-6.92 (m, 2H), 7.32-7.38 (m, IH). Anal. Calcd. For C23H29FO6-0.5 H20: C, 65.00; H, 7.00. Found: C, 65.30; H, 7.32. ESIMS (MH+): 421.
Example A(56): 6-Cyclopentyl-6-(2-{4-[1-methyl-1-(5-methyl-[1,2,4]oxadiazol-3-yl)-ethyl]- phenyl}-ethyl)-dihydro-pyran-2,4-dione.
Figure imgf000088_0002
The title compound was prepared analogously to Example A(27), where 3-[1-(4-Bromo- phenyl)-1-methyl-ethyl]-5-methyl-[1,2,4]oxadiazole (described in Step 1 below) was substituted in place of 1-(4-Bromo-2-chloro-phenyl)-ethanone in Step 3 of that example. Η NMR (CDC13): δ 1.59-1.78 (m 9H); 1.85-1.98 (m, 2H), 2.18 (s, 6H), 2.20-2.31 (m, IH), 2.52 (s, 3H), 2.61-2.67 (m, IH), 2.77 (s, 2H), 3.42 (s, 2H), 7.09 (d, 7= 8.3, 2H), 7.24 (d, 7= 8.3, 2H). ESIMS (MH+): 411.
Step 1 : 3-[1 -(4-Bromo-phenyl)-1 -methyl-ethyl]-5-methyl-[1 ,2,4]oxadiazole
Figure imgf000089_0001
To a solution of 2-(4-bromophenyl)-2-methylpropionitrile (3 g, 13.38 mmol)) in EtOH (40 mb) was added hydroxylamine HCl (4.65 g, 66.93 mmol) and K2C03 (9.25 g, 66.93 mmol). The reaction mixture was stirred at room temperature overnight. The resultant white precipitate was eliminated by filtration and the filtrate was concentrated to a yellow oil which was dissolved in pyridine (16 mL). Acetic anhydride (3.79 mL, 40.14 mol) was added and the reaction was stirred to reflux for 2 hours. The solution was quenched with 2N HCl (50 mL) and extracted 3 times with EtOAc (20 mL). The organics were combined, and dried with Na2S04. The solvent was removed under reduced pressure and the residue was purified by flash chromatography (40% EtOAc in Hexanes) to yield the product as a white foam (0.88 g, 30%). Η NMR (CDC13): δ 1.71 (s, 6H); 2.53 (s, 3H), 7.18-7.54 (m, 4H).
Example A(57): 6-(4-Cyclohexyl-butyl)-6-cyclopentyl-dihydro-pyran-2,4-dione.
Figure imgf000089_0002
The title compound was prepared analogously to Example A(44), where 4-Cyclohexyl- butyric acid was substituted in place of 3-Cyclohexylpropionic acid in Step 1 of that example. Η NMR (CDC13): δ 0.75-1.9 (m, 26H), 2-2.25 (m, 2H), 2.69 (s, 2H), 3.40 (s, 2H). Anal. Calcd. For C20H32O3: C, 74.96; H, 10.06. Found: C, 75.04; H, 10.34. ESIMS (MH+): 321
Example A(58): 6-Cyclopentyl-6-[2-(4-difluoromethoxy-phenyl)-ethyl]-dihydro-pyran-2,4- dione.
Figure imgf000090_0001
The title compound was prepared analogously to Example A(64), where 4- (difluoromethoxy) bromobenzene was substituted in place of 4-bromo-2-fluoro-1- isopropylbenzene in Step 3 of that example.
Η NMR (CDC13): δ 1.5-1.9 (m, 8H), 1.93 (m, 2H), 2.24 (m, 2H), 2.9 (s, 2H), 2.93 (t, 7 = 8.4 Hz, 2H), 3.2 (s, 2H), 7.2 (d, 7= 8.3, 2H), 7.4 (d, 7= 8.3, 2H). ESIMS (MH+): 353
Example A(59): 6-Cyclopentyl-6-[2-(2,2,3,3-tetraf luoro-2,3-dihydro-benzo[1 ,4]dioxin-6-yl)- ethyl]-dihydro-pyran-2,4-dione
Figure imgf000090_0002
The title compound was prepared analogously to Example A(64), where 6-bromo-2, 2,3,3- tetrafluoro-1 ,4-benzodioxene was substituted in place of 4-bromo-2-fluoro-1 -isopropylbenzene in Step 3 of that example.
Η NMR (CDC13): δ 1.63-1.75 (m, 8H), 1.90-1.97 (m, 2H), 2.24-2.29 (m, IH), 2.64-2.71 (m, 2H), 2.77 (d, 7 = 4.9, 2H), 3.43 (d, 7 = 2.4, 2H), 6.90-6.97 (m, 2H), 7.07 (d, 7 = 7.5, IH). Anal. Calcd. For C20H20 F405: C, 57.69; H, 4.84. Found: C, 57.76; H, 4.90. ESIMS (MH+): 417
Example A(60): 6-Cyclopentyl-6-[2-(4-propoxy-phenyl)-ethyl]-dihydro-pyran-2,4-dione
Figure imgf000091_0001
The title compound was prepared analogously to Example A(44), where 3-(4-Propoxy- phenyl)-propionic acid (described in Step 1 below) was substituted in place of 3- Cyclohexylpropionic acid in Step 3 of that example of that example.
Η NMR (dmso-d6): δ 0.96 (t, 7 = 7.4, 3H), 1.34-1.73 (m, 10H), 1.87-1.90 (m, 2H), 2.25-2.35 (m, IH), 2.46-2.55 (m, 2H), 3.33 (s, 2H), 3.87 (t, 7= 6.5, 2H), 4.98 (s, 2H), 6.82 (d, 7 = 8.4, 2H), 7.07 (d, 7 = 8.4, 2H). Anal. Calcd. For C21H2804: C, 73.23; H, 8.19. Found: C, 73.24; H, 8.30. ESIMS (MH+): 345
Step l: 3-(4-Propoxy-phenyl)-propionic acid.
Figure imgf000091_0002
To a solution of methyl 3-(hydroxyphenyl)propionate (15 g, 83.24 mmol) and iodopropane (12.14 mL, 124.5 mmol) in DMF (80 mL) was added K2C03 (34 g, 249.7 mmol). The resultant slurry was stirred vigorously and heated to 60°C under argon for 12h. DMF was evaporated and residue partitioned between EtOAC and 1 N HCl. The organic layer was washed with H20, and brine then dried over Na2S0 . The solvent was removed in vacuo and the residue was purified by flash column chromatography (10% EtOAc in hexanes) to provide the desired product (17 g, 98%) as a clear oil. The resultat oil was dissolved in THF (150 mL), and 2M NaOH (68 mL) was added. The reaction was stirred overnight at room temperature. THF was evaporated and residue acidified with concentrated HCl and extracted 3 times with EtOAC (100 mL). The organic layer was washed with H20, dried over Na2S04 and concentrated to a white solid which was recrystalized from hexanes to provide the desired product (14.06 g 82%). 'HNMR (CDC13) δ: 1.04 (t, 7 = 7.2, 3H), 1.76-1.85 (m, 2H), 2.64 (t, 7= 8.1, 2H), 2.90 (t, 7= 8.1, 2H), 3.89 (t, 7 = 6.6, 2H), 6.82 (d, 7 = 8.6, 2H), 7.10 (d, 7 = 8.6, 2H).
Example A(61 ): 6-[2-(2-acetyl-4-methoxyphenyl)ethyl]-6-cyclopentyldihydro-2H-pyran- 2,4(3H)-dione.
Figure imgf000092_0001
The title compound was prepared analogously to Example A(64), where 1-(2-bromo-5- methoxyphenyl)ethanone was substituted in place of 4-bromo-2-fluoro-1 -isopropylbenzene. 'H MR (300 MHz, CDCL3) δ ppm 1.41 (m, 1 H), 1.61 (m, 5 H), 1.78 (m, 2 H), 1.88 (ddd, 7=14.0, 12.2, 5.0 Hz, 1 H), 2.02 (td, 7=12.25 4.5 Hz, 1 H), 2.36 (m, 1 H), 2.56 (s, 3 H), 2.72 (td, 7=122, 4.7 Hz, 1 H), 2.76 (d, 7=16.4 Hz, 1 H), 2.84 (d, 7=16.4 Hz, 1 H), 2.92 (td, 7=12.2, 4.6 Hz, 1 H), 3.42 (d, 7=21.2 Hz, 1 H), 3.62 (d, 7=21.2 Hz, 1 H), 3.83 (s, 3 H), 6.97 (dd, 7=8.5, 2.8 Hz, 1 H), 7.13 (d, 7=8.5 Hz, 1 H), 7.24 (d, 7=2.8 Hz, 1 H). HRMS calcd. For C21H2605Na (M+Na): 381.1672. Found: 381.1666.
Example A(62): 6-cyclopentyl-6-[2-(4-methoxy-2-propionylphenyl)ethyl]dihydro-2H-pyran- 2,4(3H)-dione
Figure imgf000092_0002
The title compound was prepared analogously to Example A(64), where 1-(2-bromo-5- ethoxyphenyl)ethanone was substituted in place of 4-bromo-2-fluoro-1 -isopropylbenzene. 'HNMR (300 MHz, CDC13) δ ppm 1.17 (t, 7=7.2 Hz, 3 H), 1.40 (m, 1 H), 1.73 (m, 8 H), 2.03 (m, 1 H), 2.35 (m, 1 H), 2.68 (td, 7=12.3, 4.8 Hz, 1 H), 2.79 (m, 2 H), 2.89 (m, 3 H), 3.42 (d, 7=21.1 Hz, 1 H), 3.63 (d, 7=21.1 Hz, 1 H), 3.82 (s, 3 H), 6.95 (dd, 7=8.4, 2.7 Hz, 1 H), 7.13 (d, 7=8.4 Hz, 1 H), 7.16 (d, 7=2.7 Hz, 1 H). Anal. Calcd. For C22H2805: C, 70.94; H, 7.58; 0, 21.48. Found: C, 70.72; H, 7.60; O, 21.33.
Example A(63): 6-[2-(3-chloro-4-isopropylphenyl)ethyl]-6-cyclopentyldihydro-2H-pyran- 2,4(3H)-dione
Figure imgf000093_0001
The title compound was prepared analogously to Example A(82), where 4-bromo-2- chloro-1 -isopropylbenzene was substituted in place of 2-Bromopyridine. 'H NMR (300 MHz, CDC13) δ: 1.22 (d, 7=6.78 Hz, 6 H), 1.60-1.80 (m, 8 H), 1.91-1.98 (m, 2 H), 2.22-2.30 (m, 1 H), 2.59-2.66 (m, 2 H), 2,76 (s, 2 H), 3.31-3.38 (m, 1 H), 3.43 (s, 2 H), 7.01 (dd, 7=8.01, 1.79 Hz, 1 H), 7.12 (d, 7=1.88 Hz, 1 H), 7.20 (d, 7=7.91 Hz, 1 H). HRMS calcd for C21H27C103Na: 385.1541. Found: 385.1543.
Example A(64): 6-cyclopentyl-6-[2-(3-fluoro-4-isopropylphenyl)ethyl]dihydro-2H-pyran- 2,4(3H)-dione
Figure imgf000093_0002
6-[2-cyclopentyl-4-(3-fluoro-4-isopropylphenyl)-2-hydroxybut-3-ynyl]-2,2-dimethyl-4H-1 ,3- dioxin-4-one (3.83 g, 9.6 mmol, described in Step 3 below) dissolved in anhydrous MeOH (45 mL) was added Pd(OH)2 (1.26 g). The reaction was stirred under H2 (1 atm) for 12 hours. The mixture was filtered through a pad of celite. The solvent was removed in vacuo and the residue was taken directly into next step without further purification. The crude mixture from previous Step was dissolved in anhydrous MeOH (70 mL) and treated with K2C03 (3.97 g, 28.8 mmol) at 45 °C for 1 hour before it was cooled down to 25 °C. The mixture was diluted with EtOAc (200 mL) and the combined organic extracts were washed with aqueous NH4C1, brine, and dried over Na2S04. The solvent was removed in vacuo and the residue was purified by flash column chromatography (0-40% EtOAc in hexanes) to give the desired product (2.2 g, 65% yield).
'HNMR (CDC13, 300 MHz) δ: 1.23 (d, 7=6.97 Hz, 4 H), 1.64-1.80 (m, 8 H), 1.91-1.98 (m, 2 H), 2.22-2.30 (m, 1 H), 2.61-2.67 (m, 2 H), 2.77 (s, 2 H), 3.14-3.23 (m, 1 H), 3.42 (s, 2 H), 6.79 (dd, 7=11.21, 1.60 Hz, 1 H), 6.87 (dd, 7=7.82, 1.60 Hz, 1 H), 7.15 (t, 7=7.91 Hz, 1 H). HRMS calcd for C21H28F03 (M+H+): 347.2017. Found: 347.2021.
Step 1 : 2-(4-bromo-2-fluorophenyl)propan-2-ol
Figure imgf000094_0001
A solution of methyl 4-bromo-2-fluorobenzoate (8.0 g, 34.3 mmol) in anhydrous Et20 (85 mL) was treated with MeMgBr (3.0 M in THF, 30 mL). The resulting solution was stirred at 25 °C for 3 hours before it was quenched by the addition of H20 (10 mL). The mixture was extracted with EtOAc (50 mL) three times and the combined organic extracts were washed with aqueous NH CI, brine, and dried over Na2S0 . The solvent was removed in vacuo and the residue was purified by flash column chromatography (0-25% EtOAc in hexanes) to give the desired product (7.2 g, 91% yield).
1H NMR (CDCI3, 300 MHz) δ: 1.62 (s, 6 H), 7.19-7.22 (m, 1 H), 7.27-7.29 (m, 1 H), 7.45-7.49 (m, 1 H).
Step 2: 4-bromo-2-fluoro-1 -isopropylbenzene
Figure imgf000095_0001
To a solution of 2-(4-bromo-2-fluorophenyl)propan-2-ol (7.6 g, 32.8 mmol) dissolved in anhydrous CH2CI2 (300 mL) at 25 °C was added triethylsilane (7.8 mL, 49.1 mmol), followed by trifluoroacetic acid (25 mL, 328 mmol). The resulting solution was stirred at that temperature for 45 min. The solvent was removed in vacuo and the residue was purified by flash column chromatography (0-10% EtOAc in hexanes) to give the desired product (5.7 g, 80% yield). 'HNMR(CDC13, 400 MHz) δ: 1.23 (d, 7=6.82 Hz, 3 H), 3.15-3.22 (m, 1 H), 7.11 (t, 7=8.08 Hz, 1 H), 7.17 (dd, 7=9.85, 1.77 Hz, 1 H), 7.22 (d, 7=8.34 Hz, 1 H).
Step 3: 6-[2-cyclopentyl-4-(3-fluoro-4-isopropylphenyl)-2-hydroxybut-3-ynyl]-2,2-dimethyl- 4H-1 ,3~dioxin-4-one.
Figure imgf000095_0002
4-Bromo-2-fluoro-1 -isopropylbenzene (5.0g, 23.2 mmol), 6-(2-cyclopentyl-2-hydroxybut- 3-ynyl)-2,2-dimethyl-4H-1,3-dioxin-4-one (5.56 g, 21.0 mmol) were dissolved in anhydrous DMF (30 mL). To this solution, Cui (120 mg, 0.63 mmol), Pd(PPh3)2CI2 (0.59 g, 0.84 mmol), and diisopropylamine (60 mL), were added sequentially. The mixture was then heated at 90 °C for 20 min before it was cooled down to 25 °C. The reaction was diluted with EtOAc (150 mL) and washed with aqueous NH4CI, brine, and dried over Na2S04. The solvent was removed in vacuo and the residue was purified by flash column chromatography (0-40% EtOAc in hexanes) to give the desired product (7.5 g, 81% yield).
'H NMR (CDClj, 300 MHz) δ: 1.22-1.28 (m, 8 H), 1.69-1.74 (m, 10 H), 1.80-1.86 (m, 2 H), 2.19-2.26 (m, 1 H), 2.62-2.70 (m, 2 H), 3.18-3.25 (m, 1 H), 5.46 (s, 1 H), 7.00 (dd, 7=10.61, 1.52 Hz, 1 H), 7.09-7.11 (m, 1 H), 7.18 (t, 7=7.71 Hz, 1 H).
Example A(65): 6-cyclopentyl-6-[2-(3-ethyl-4-fluorophenyl)ethyl]dihydro-2H-pyran-2,4(3H)- dione
Figure imgf000096_0001
The title compound was prepared analogously to Example A(82), where 4-bromo-2-ethyl- 1-fluorobenzene was substituted in place of 2- bromopyridine in Step 1 of that example.
LCMS : 331 -ve APCI. Anal. Calcd. For C20H25O3F: C, 72.76; H, 7.58. Found: C, 72.87, H, 8.03.
Step 1 : 4-bromo-2-ethyl-1 -f luorobenzene
Figure imgf000096_0002
Ethyl iodide (0.14ml, 1.8mmol) was added to a solution of (5-bromo-2- fluorophenyl)(iodo)zinc (0.5M in tetrahydrofuran) (5.4ml, 2.7mmol) in HMPA (10ml). The reaction mixture was heated to 100°C for 48 hrs. After which time the reaction mixture was cooled to room temperature and partitioned between ethyl acetate (100ml) and water (100ml). The organic layer was separated and dried over anhydrous sodium sulfate, filtered and the solvent was removed in vacuo. The crude oil was purified by column chromatography on silica gel eluting with 80:20 hexanes: ethyl acetate, to afford the title compound as a yellow oil (0.4g). Η NMR (CDCI3): δ 1.19 (t, J= 7.06Hz, 3H), 3.45 (q, 7= 7.03Hz, 2H), 7.10 (m, IH), 7.25 (m, 2H).
Figure imgf000097_0001
Example A(66): 6-Cyclopentyl-6-[2-(3-ethyl-phenyl)-ethyl]-dihydro-pyran-2,4-dione.
The title compound was prepared analogously to Example A(86), where 3-Bromo- ethylbenzene was substituted in place of 1-(4-Bromo-phenyl)-cyclopropanecarboxylic acid methyl ester in Step 3 of that example.
'H NMR (CDClj): δ 1.81 (t, 7= 8.4 Hz, IH), 1.30 to 1.80 (bm, 8H), 1.94 (m, 2H), 2.26 (m, IH), 2.59 (m, 4H), 2.72 (s, 2H), 3.39 (s, 2H), 6.95 (m, 2H), 7.04 (d, 7= 5.2 Hz, IH), 7.17 (m, IH). ESIMS (M+H+): 315.19
Example A(67): {3-[2-(2-Cyclopentyl-4,6-dioxo-tetrahydro-pyran-2-yl)-ethyl]-phenyl}-acetic acid methyl ester
Figure imgf000097_0002
The title compound was prepared analogously to Example A(86), where (3-Bromo- phenyl)-acetic acid methyl ester was substituted in place of 1-(4-Bromo-phenyl)- cyclopropanecarboxylic acid methyl ester in Step 3 of that example.
'H NMR (CDCI3): δ 1.30 to 1.80 (bm, 8H), 1.90 (m, 2H), 2.23 (m, IH), 2.64 (m, 2H), 2.70 (s, 2H), 3.36 (s, 2H), 3.65 (s, 2H), 6.95 (m, 2H), 7.00 (m, 2H), 7.09 (d, 7= 4.6 Hz, IH) 7.22 (m, IH). ESIMS (M+H+): 359.18
Example A(68): 6-Cyclopentyl-6-[2-(3,3-dimethyl-2-oxo-2,3-dihydro-benzofuran-5-yl)-ethyl]- dihydro-pyran-2,4-dione
Figure imgf000098_0001
The title compound was prepared analogously to example A(86), where 5-Bromo-3,3- dimethyl-3H-benzofuran-2-one was substituted in place of 1-(4-Bromo-phenyl)- cyclopropanecarboxylic acid methyl ester in Step 3 of that example.
'HNMR(CDCl3): δ 1.55 (s, 6H), 1.59 to 1.89 (bm, 8H), 2.01 (m, 2H), 2.33 (m, IH), 2.74 (m, 2H), 2.83 (m, 2H), 3.48 (m, 2H), 7.05 (s, IH), 7.10 (s, 2H). ESIMS (M+ϊ ): 371.18
Step l: 3,3-Dimethyl-3H-benzofuran-2-one
Figure imgf000098_0002
A solution of 3H-Benzofuran-2-one (4.02g, 30 mmol) dissolved in THF (15 mL) was added cautiously to a suspension of NaH (95% dry, 1.58g, 66 mmol) in DMF (60 mL) and THF (30 mL) under a nitrogen atmosphere, at 0 °C. The mixture was stirred until gas evolution ceased, then Mel (5.6 mL, 90 mmol) was added slowly to avoid boiling over. After Mel addition was complete the reaction further stirred 1h at room temperature then quenched by carefully pouring onto a mixture of HCl (1 N) and ice. The resulting solution was extracted with ether, washed with brine, dried over MgS04, and chromatographed on silica eluted with a gradient of 5- 50%) ethyl acetate/hexanes, yielding 3.16g (65% yield) of the product.
Step 2: 5-Bromo-3,3-dimethyl-3H-benzofuran-2-one
Figure imgf000098_0003
3,3-Dimethyl-3H-benzofuran-2-one (2.81 g, 17.3 mmol) was added to a solution of
Bromine (1.51 mL, 29.5 mmoL) and Acetic acid (35 mL) at room temperature, then stirred overnight. The resulting mixture was stripped of solvent, then distilled under high vacuum. The product fraction (2.08 g, 50%) was collected between 65 °C and 79 °C.
Example A(69): 1-{3-[2-(2-Cyclopentyl-4,6-dioxo-tetrahydro-pyran-2-yl)-ethyl]-phenyl}- cyclopropanecarboxylic acid methyl ester
Figure imgf000099_0001
The title compound was prepared analogously to example A(86), where 1-(3-Bromo- phenyl)-cyclopropanecarboxylic acid methyl ester was substituted in place of 1-(4-Bromo-phenyl)- cyclopropanecarboxylic acid methyl ester in Step 3 of that example.
Η NMR (CDC13): δ 1.19 (s, 2H), 1.39 to 1.86 (bm, 10H), 1.98 (m, 2H), 2.68 (m, IH), 2.77 (s, 2H), 3.42 (s, 2H), 3.14 (s, 3H), 7.05 (d, 7= 2.7 Hz, IH), 7.14 (s, IH), 7.24 (m, 2H). ESIMS (M+H+): 385.19
Step 1: 1-(3-Bromo-phenyl)-cyclopropanecarboxylic acid methyl ester.
Figure imgf000099_0002
A solution of (3-Bromo-phenyl)-acetic acid methyl ester (4.54g, 20 mmol) dissolved in dry THF (10 mL) was added dropwise to suspension of NaH (95% dry, 1.05g, 44 mmol) in DMF (40 mL) and THF (10 mL), under a nitrogen atmosphere, at 0 °C. After 30 min, gas evolution ceased, and 1,2-dibromoethane (3.79 mL, 44 mmol) was added dropwise over 20 min. The resulting mixture was stirred for 1h, then quenched with 1N HCl, extracted with ether, washed with brine, dried over MgS04, and stripped of solvent. The resulting oil was distilled under high vacuum. The product was collected between 95 °C and 105 °C. Yield 2g, 39%.
Example A(70): {3-[2-(2-Cyclopentyl-4,6-dioxo-tetrahydro-pyran-2-yl)-ethyl]-phenyl}- acetonitrile
Figure imgf000100_0001
The title compound was prepared analogously to example A(86), where (3-Bromo- phenyl)-acetonitrile was substituted in place of 1-(4-Bromo-phenyl)-cyclopropanecarboxylic acid methyl ester in Step 3 of that example.
Η NMR (CDC13): δ 1.40 to 1.85 (bm, 8H), 1.97 (m, 2H), 2.28 (m, IH), 2.70 (t, 7= 7.1 Hz, 2H), 2.78 (s, 2H), 3.74 (s, 2H), 7.12 (m, 2H), 7.18 (m, IH), 7.30 (m, IH). ESIMS (M+H1"): 326.17
Example A(71): 1 H-Pyrazole-3-carboxylic acid (2-{3-[2-(2-cyclopentyl-4,6-dioxo-tetrahydro- pyran-2-yl)-ethyl]-phenyl}-2-methyl-propyl)-amide
Figure imgf000100_0002
HATU (169.6 mg, 0.4464 mmol) was added to a solution of 6-{2-[3-(2-Amino-1,1- dimethyl-ethyl)-phenyl]-ethyl}-6-cyclopentyl-dihydro-pyran-2,4-dione trifluoroacetic acid salt (175 mg, 0.372 mmol), Et3N (207 μL, 1.488 mmol), 1H-Pyrazole-3-carboxylic acid (50.0 mg, 0.4464 mmol), dissolved in DMF (2 mL). The reaction was stirred overnight, then purified directly by
RPHPLC. Yield 55 mg, 33%.
'H NMR (CDCI3): δ 1.38 (s, 6H), 1.40 to 2.00 (bm, 10H), 2.36 (m, IH), 2.64 (m, 2H), 2.81 (m, 2H), 3.46 (m, 2H), 3.63 (m, 2H), 6.63 to 6.79 (bm, 3H), 6.84 (s, IH), 7.03 (s, IH), 7.19 (s, IH), 7.45 to 7.60 (bm, 3H). ESIMS (M+Na+): 474.25
Step 1 : [2-(3-Bromo-phenyl)-2-methyl-propyl]-carbamic acid tert-butyl ester
Figure imgf000100_0003
2-(3-Bromo-phenyl)-2-methyl-propionitrile was added to a solution of Lithium aluminum hydride (1M in THF, 37.4 ml, 37.4 mmol), in dry THF (70 mL), under a nitrogen atmosphere. The reaction was stirred for 5h then quenched by cautiously adding water (1.51 ml), followed by 15% NaOH/water (1.51 mL), followed by water (4.53 ml). A white precipitate formed which was removed by filtration. The resulting solution was treated with di-tert butyl dicarbonate (1 M in THF, 37.4 mL, 37.4 mmol), and stirred for an additional 30 minutes. The reaction was stripped of solvent and purified by column chromatography (5% to 25% ethyl acetate/hexanes). Yield 8.64 g, 87%.
Step 2: (2-{3-[2-(2-Cyclopentyl-4,6-dioxo-tetrahydro-pyran-2-yl)-ethyl]-phenyl}-2-methyl- propyl)-carbamic acid tert-butyl ester
Figure imgf000101_0001
The above compound was prepared analogously to example A(86), where [2-(3-Bromo- phenyl)-2-methyl-propyl]-carbamic acid tert-butyl ester (from Step 1 above) was substituted in place of 1-(4-Bromo-phenyl)-cyclopropanecarboxylic acid methyl ester in Step 3 of that example.
Step 3: 6-{2-[3-(2-Amino-1,1-dimethyl-ethyl)-phenyl]-ethyl}-6-cyclopentyl-dihydro-pyran- 2,4-dione trifluoroacetic acid salt
Figure imgf000101_0002
(2-{3-[2-(2-Cyclopentyl-4,6-dioxo-tetrahydro-pyran-2-yl)-ethyl]-phenyl}-2-methyl-propyl)- carbamic acid tert-butyl ester (1.80g, 3.94 mmol), was stirred with 30% TFA/CH2CI2 (30 mL), for 2h. The reaction was diluted with Toluene (30 mL) and stripped of all solvents. The crude product was used without further purification. Yield 3.22g.
Example A(72): Λ/-(2-{3-[2-(2-Cyclopentyl-4,6-dioxo-tetrahydro-pyran-2-yl)-ethyl]-phenyl}-2- methyl-propyl)-3-furan-2-yl-propionamide
Figure imgf000102_0001
The title compound was prepared analogously to example A(71), where 3-Furan-2-yl- propionic acid was substituted in place of 1 -Pyrazole-3-carboxylic acid methyl ester in the final Step of that example. Yield 34 mg, 19%.
Η NMR (CDC13): δ 1.34 (s, 6H), 1.40 to 2.05 (bm, 9H), 2.08 to3.13 (bm, 12H), 3.44 (bs, 2H), 6.93 to 7.58 (bm, 8H). ESIMS (M+Na+): 502.27
Example A(73): 4,5-Dimethyl-furan-2-carboxylic acid (2-{3-[2-(2-cyclopentyl-4,6-dioxo- tetrahydro-pyran-2-yl)-ethyl]-phenyl}-2-methyl-propyl)-amide
Figure imgf000102_0002
The title compound was prepared analogously to example A(71), where 4,5-Dimethyl- furan-2-carboxylic acid was substituted in place of IH-Pyrazole-3-carboxylic acid methyl ester in the final Step of that example. Yield 23 mg, 13%.
Η NMR (CDCI3): δ 1.39 (bs, 6H), 1.43 tol.84 (bm, 8H), 1.95 (s, 3H), 2.10 (s, 3H), 2.17 (s, 2H), 2.33 (m, IH), 2.65 (m, 4H), 3.44 (m, 2H), 3.57 (m, 2H), 6.00 (bs, IH), 6.83 (m, IH), 7.19 (bm, 4H). ESIMS (M+Na+): 502.27
Example A(74): 5-Hydroxy-pyrazine-2-carboxylic acid (2-{3-[2-(2-cyclopentyl-4,6-dioxo- tetrahydro-pyran-2-yl)-ethyl]-phenyl}-2-methyl-propyl)-amide
Figure imgf000102_0003
The title compound was prepared analogously to example A(71), where 5-Hydroxy- pyrazine-2-carboxylic acid was substituted in place of 1 H-Pyrazole-3-carboxylic acid methyl ester in the final Step of that example. Yield 6.4 mg, 4%.
Η NMR (CDC13): δ 1.35 (bs, 6H), 1.49 tol.89 (bm, 8H), 2.00 (m, 2H), 2.23 (s, IH), 2.66 (m, 2H), 2.78 (s, 2H), 3.45 (m, 2H), 3.59 (m, 2H), 7.00 (m, IH), 7.03 to 7.58 (bm, 5H), 7.99 (m, IH), 8.11 (m, IH). ESIMS (M+Na+): 502.24
Example A(75): 3-{4-[2-(2-Cyclopentyl-4,6-dioxo-tetrahydro-pyran-2-yl)-ethyl]-phenyl}-3- oxo-propionitrile
Figure imgf000103_0001
The title compound was prepared analogously to example A(86), where 5-(4-lodo- phenyl)-isoxazole was substituted in place of 1-(4-Bromo-phenyl)-cyclopropanecarboxylic acid methyl ester in Step 3 of that example (Note that the isoxazole opens to the cyanomethyl ketone during the Sonogashira coupling Step). Yield 30 mg, 14%.
Η NMR (CDCI3): δ 1.18 to 1.70 (bm, 8H), 1.85 (m, 2H), 2.15 (m, IH), 2.67 (m, 4H), 3.31 (m, 2H), 3.94 (s, 2H), 7.18 (d, 7= 8.1 Hz, 2H), 7.72 (d, 7= 8.3 Hz, 2H). ESIMS (M+Na+): 376.16
Example A(76): 6-Cyclopentyl-6-[2-(3,3-dimethyl-2,3-dihydro-benzofuran-5-yl)-ethyl]- dihydro-pyran-2,4-dione
Figure imgf000103_0002
The title compound was prepared analogously to example A(86), where 5-Bromo-3,3- dimethyl-2,3-dihydro-benzofuran was substituted in place of 1-(4-Bromo-phenyl)- cyclopropanecarboxylic acid methyl ester in Step 3 of that example. Η NMR (CDC13): δ 1.34 (s, 6H), 1.971.4 to 1.88 (bm, 8H), 1.96 (m, 2H), 2.30 (s, IH), 2.63 (t, 7= 8.2 Hz, 2H), 2.79 (s, 2H), 3.46 (s, 2H), 4.24 (s, 2H), 6.73 (d, 7= 6.5 Hz, IH), 6.90 (m, 2H). ESIMS (M+H+): 357.20
Step 1: 5-Bromo-3,3-dimethyl-2,3-dihydro-benzofuran-2-ol:
Figure imgf000104_0001
To a solution of 5-Bromo-3,3-dimethyl-3H-benzofuran-2-one (1.199g, 5.0 mmol) (described in Step 2 of Example A(68), ), dissolved in anhydrous CH2CI2 (20 ml), and cooled to - 78 °C, was added DIBAL (3.67 mL, 5.5 mmol, 1.5M in Toluene). The reaction was stirred for 1h at this temperature then quenched with 1N HCl until acidic. The resulting mixture was extracted with ether, which was washed with brine, dried with MgS04, concentrated and purified by silica gel chromatography (gradient elution 5-15% Ethylacetate/Hexanes). Yield 0.95 g, 79%.
Step 2: 5-Bromo-3,3-dimethyl-2,3-dihydro-benzofuran:
Figure imgf000104_0002
A solution of 5-Bromo-3,3-dimethyl-2,3-dihydro-benzofuran-2-ol (813 mg, 3.36 mmol), Triethylsilane (805 DL, 5.04 mmol), and 30% TFA/CH2CI2 (15 mL), were stirred at room temperature for 1h. The solution was then diluted with Toluene (15 mL), stripped of all solvents, and chromatographed on silica eluted with a gradient 5-25% Ethyl acetate/Hexanes. Yield 549 mg, 72%.
Example A(77): 6-Cyclopentyl-6-[2-(3-fluoro-4-thiazol-2-ylmethyl-phenyl)-ethyl]-dihydro- pyran-2,4-dione.
Figure imgf000105_0001
The title compound was prepared analogously to example A(86), where 2-(4-Bromo-3- fluoro-benzyl)-thiazole (prepared below), was substituted in place of 1-(4-Bromo-phenyl)- cyclopropanecarboxylic acid methyl ester in Step 3 of that example.
Η NMR (CDC13): δ 1.40 to 1.85 (bm, 8H), 1.99 (m, 2H), 2.33 (m, IH), 2.75 (m, 2H), 2.86 (s, 2H), 3.50 (s, 2H), 4.44 (s, 2H), 6.94 (m, 2H), 7.29 (m, 2H), 7.75 (d, J= 3.5 Hz, IH). ESIMS (M+H÷): 402.15
Step l: (4-Bromo-3-fluoro-phenyl)-thiazol-2-yl-methanol
Figure imgf000105_0002
To a solution of Butyl lithium (9.6 mL, 24 mmol, 2.5 M in Hexane), in anhydrous Ether (80ml), at -78 °C, was added 2-Bromothiazole (2.0 mL, 22 mmol). After stirring for 20 min at this temperature, 4-Bromo-2-fluoro-benzaldehyde (20 mmol) was added, and stirring was continued an additional 30 min, then quenched with MeOH and Citric acid. The resulting mixture was extracted into ether, which was then washed with NaHC03 (sat. aq.), brine, dried over MgS04, and purified by silica gel chromatography (gradient elution 15-50% Ethyl acetate/Hexanes). Yield 4.55g, 79%.
Step 2: 2-(4-Bromo-3-fluoro-benzyl)-thiazole
Figure imgf000105_0003
A solution of (4-Bromo-3-fluoro-phenyl)-thiazol-2-yl-methanol (3.4g, 12.6 mmol), TFA (25 mL), and Triethylsilane (10 mL, 63 mmol), were refluxed overnight. The reaction was then concentrated under vacuum, and purified by silica gel chromatography (gradient elution 10-40% Ethylacetate/Hexanes). Yield 1.96g, 61%.
Example A(78): 6-Cyclopentyl-6-[2-(3-thiazol-2-ylmethyl-phenyl)-ethyl]-dihydro-pyran-2,4- dione
Figure imgf000106_0001
The title compound was prepared analogously to example A(77), where 3- Bromobenzaldehyde was substituted in place of 4-Bromo-2-fluoro-benzaldehyde in Step 1 of that example.
Η NMR (CDC13): δ 1.40 to 1.85 (bm, 8H), 1.86 (m, 2H), 2.18 (m, IH), 2.58 (m, 2H), 2.67 (s, 2H), 3.33 (s, 2H), 4.27 (s, 2H), 6.96 to 7.20 (m, 5H), 7.64 (d, 7= 3.3 Hz, IH). ESIMS (M+ET): 384.16
Example A(79): 6-Cyclopentyl-6-{2-[4-(2-hydroxy-ethyl)-phenyl]-ethyl}-dihydro-pyran-2,4- dione
Figure imgf000106_0002
The title compound was prepared analogously to example A(86), where 2-(4-Bromo- phenyl)-ethanol was substituted in place of 1-(4-Bromo-phenyl)-cyclopropanecarboxylic acid methyl ester in Step 3 of that example.
Η NMR (CDCI3): δ 1.40 to 1.82 (bm, 8H), 1.96 (m, 2H), 2.29 (m, IH), 2.66 (d, 7= 8.2 Hz, 2H), 2.76 (s, 2H), 2.84 (d, J= 6.2 Hz, IH), 3.41 (s, 2H), 3.84 (d, 7= 6.6 Hz, IH), 7.10 (d, 7= 8.2 Hz, 2H), 7.16 (d, 7= 8.2 Hz, 2H). ESIMS (M+H*): 331.18
Example A(80): 6-Cyclopentyl-6-{2-[3-(2-hydroxy-ethyl)-phenyl]-ethyl}-dihydro-pyran-2,4- dione
Figure imgf000107_0001
The title compound was prepared analogously to example A(86), where 2-(3-Bromo- phenyI)-ethanol was substituted in place of 1-(4-Bromo-phenyl)-cyclopropanecarboxylic acid methyl ester in Step 3 of that example.
'H NMR (CDCI3): δ 1.39 to 1.84 (bm, 8H), 1.99 (m, 2H , 2.30 (m, IH), 2.68 (d, 7= 8.6 Hz, 2H), 2.76 (s, 2H), 2.84 (d, 7= 6.6 Hz, IH), 3.40 (s, 2H), 3.86 (d, 7= 6.6 Hz, IH), 7.02 (m, 2H), 7.08 (m,lH), 7.23 (m, IH). ESIMS (M+H+): 331.18
Example A(81 ): 2-{4-[2-(2-Cyclopentyl-4,6-dioxo-tetrahydro-pyran-2-yl)-ethyl]-2-f luoro- phenyl}-2-methyl-propionitrile
Figure imgf000107_0002
The desired product was prepared analogously to Step 5 of Example A(86), substituting 2-{4-[3-Cyclopentyl-4-(2,2-dimethyl-6-oxo-6H-t1,3]dioxin-4-yl)-3-hydroxy-butyl]-2-fluoro-phenyl}-2- methyl-propionitrile (1.23 g, 2.9 mmol) from Step 3 below in place of 1-{4-[3-Cyclopentyl-4-(2,2- dimethyl-6-oxo-6H-[1,3]dioxin-4-yl)-3-hydroxy-butyl]-2-fluoro-phenyl}-cyclopropanecarbonitrile. Yield: 0.614 g, 56 %.
1H NMR (CDCI3) δ: 1.24 - 1.66 (m, 14H), 1.75 - 1.80 (m, 2H), 2.10 (p, J = 9.35 Hz, 1H), 2.47 - 2.56 (m, 2H), 2.60 (d, J = 5.56 Hz, 2H), 3.26 (d, J = 3.28 Hz, 2H), 6.71 - 6.79 (m, 2H), 7.23 (t, J = 8.24 Hz, 1H). MS (ESI): 370 (M-H). Step 1 : 2-(4-Bromo-2-fluoro-phenyl)-2-methyl-propionitrile
Figure imgf000108_0001
The desired product was prepared analogously to Example A(86), Step 2, substituting iodomethane (1.3 mL, 20.6 mmol) in place of 1,2-dibromoethane. Yield: 2.25 g, 99%,
1H NMR (CDCI3) δ: 2.81 (s, 3H), 2.88 (s, 3H), 7.20 - 7.25 (m, 3H).
Step 2: 2-{4-[3-Cyclopenty!-4-(2,2-dimethyl-6-oxo-6H-[1 ,3]dioxin-4-yl)-3-hydroxy-but-1- ynyl]-2-fluoro-phenyl}-2-methyl-propionitrile
Figure imgf000108_0002
The desired product was prepared analogously to Example A(86), Step 5, substituting 2- (4-bromo-2-fluoro-phenyl)-2-methyl-propionitrile (1.1 g, 4.5 mmol) from Step 1 above in place of 1-(4-bromo-2-fluoro-phenyl)-cyclopropanecarbonitrile. Yield: 1.415 g, 74 %. MS (ESI): 424 (M-H).
Step 3: 2-{4-[3-Cyclopentyl-4-(2,2-dimethyl-6-oxo-6H-[1 ,3]dioxin-4-yl)-3-hydroxy-butyl]-2- fluoro-phenyl}-2-methyl-propionitrile
Figure imgf000109_0001
The desired product was prepared analogously to example A(86), Step 6, substituting 2- {4-[3-Cyclopentyl-4-(2,2-dimethyi-6-oxo-6H-[1,3]dioxin-4-yl)-3-hydroxy-but-1-ynyl]-2-fluoro- phenyl}-2-methyl-propionitrile (1.25 g, 2.9 mmol) from Step 2 above in place of 1-{4-[3- Cyclopentyl-4-(2,2-dimethyl-6-oxo-6H-[1,3]dioxin-4-yl)-3-hydroxy-but-1-ynyl]-2-fluoro-phenyl}- cyclopropanecarbonitrile. Yield: 1.23 g, 99%.
MS (ESI): 428 (M-H).
Example A(82): 6-Cyclopentyl-6-(2-pyridin-2-yl-ethyl)-dihydro-pyran-2,4-dione
Figure imgf000109_0002
Sodium hydride (60%) (0.24 g, 5.90 mmol) was magnetically stirred in dry THF (12 mL) and cooled to 0 °C. The mixture was then treated with Methyl acetoacetate (0.64 mL, 5.90 mmol) dropwise over 15 min. The reaction was allowed to stir for 30 min at 0 °C. To the resulting clear solution was added nBuLi (1.6M in Hexanes) (3.68 mL, 5.90 mmol). The reaction was then allowed to stir for 30 min at 0 °C. To the yellow solution was added the ketone from Step 1 below (0.4 g, 1.96 mmol) as a solution in dry THF (6 mL). The result was stirred at 0 °C for 15 min and then at room temperature for 90 min. The solution was next poured into 0.5N HCl (50 mL) and extracted with EtOAc (2X 50 mL). The organics were concentrated and the residue dissolved in MeOH (12 mL) and treated with K2C03 (0.6 g). The mixture was heated to 65 °C and maintained for 1 hr. The reaction was cooled and poured into 0.5N HCl (50 mL) and extracted with EtOAc (2X 50 mL). The organics were dried over Na2S04, filtered and concentrated. The residue was purified by flash chromatography (silica gel) eluting with CH2CI2 through 1% MeOH in CH2CI2 to yield the title compound as a white solid. (0.41 g, 73%).
Η NMR (CDC13): δ 1.41-1.85 (brm, 8H), 1.95 (m, 2H), 2.29 (t, 7= 7.6 Hz, IH), 2.65 (t, 7= 8.6 Hz, 2H), 2.80 (s, 2H), 3.40 (s, 2H), 7.10 (d, 7= 6.6 Hz, IH), 7.24 (brs, IH), 7.32 (m, 2H). ESIMS (MH+): 288.3
Step 1: 1-Cyclopentyl-3-pyridin-2-yl-propan-1-one
Figure imgf000110_0001
To a magnetically stirring solution of 2-Bromopyridine (0.4 g, 2.61 mmol) and 1- Cyclopentyl-2-propen-1 -ol (1.5 eq, 0.49 g, 3.88 mmol) in anhydrous N-Methylpyrrolidinone (3.0 mL), under argon at room temperature, was added Sodium Bicarbonate (1.2 eq, 0.26 g, 3.10 mmol) followed by Dichlorobis (triphenylphosphine) palladium (II) (0.02 eq, 36.7 mg, 0.05 mmol). The resulting mixture was heated to 140 °C in an oil bath and maintained for 4 hours. The dark reaction mixture was cooled to room temperature and poured into water (50 mL) and extracted with EtOAc (2 X 25 mL). The organics were washed with water (50 mL) and brine (50 mL) then dried over Na S0 , filtered and concentrated. The crude residue was purified by flash chromatography (1% through 10% EtOAc in Hexanes) to yield the intermediate ketone as a yellow oil (0.43 g, 81%).
'H NMR (CDCI3): δ?1.45-1.87 (m, 8H), 2.70-2.95 (m, 5H), 7.10 (d, J= 6.6 Hz, IH), 7.24 (brs, IH), 7.32 (m, 2H). Example A(83): 6-{2-[3-Chloro-4-(1-ethyl-propoxy)-phenyl]-ethyl}-6-cyclopentyl-dihydro- pyran-2,4-dione
Figure imgf000111_0001
The title compound was prepared analogously to Example A(82), where 4-Bromo-2- chloro-1-(1-ethyl-propoxy)-benzene was substituted in place of 2-Bromopyridine in Step 1 of that example.
Η NMR (CDC13): δ 1.04 (t, 7= 7.5 Hz, 6H), 1.52-1.86 (brm, 12H), 1.92 (m, 2H), 2.27 (m, IH), 2.65 (t, 7 = 7.9 Hz, 2H), 2.76 (s, 2H), 3.43 (s, 2H), 4.48 (m, IH), 6.81-6.92 (m, 3H). Anal. Calcd. For C23H31C104: C, 67.88; H, 7.68. Found: C, 67.63; H, 7.43.
Example A(84): 6-[2-(5-Acetyl-thiophen-2-yl)-ethyl]-6-cyclopentyl-dihydro-pyran-2,4-
Figure imgf000111_0002
The title compound was prepared analogously to Example A(82), where 1-(5-Bromo- thiophen-2-yl)-ethanone was substituted in place of 2-Bromopyridine in Step 1 of that example. Η NMR (CDC13): δ 1.49-1.79 (brm, 8H), 2.05-2.25 (m, 2H), 2.27 (m, IH), 2.55 (s, 3H), 2.71 (d, 7= 15.8 Hz, IH), 2.79 (d, 7= 15.8 Hz, 1H),2.96 (m, 2H), 3.45 (s, 2H), 6.83 (d, 7= 3.5 Hz, IH), 7.52 (d, 7= 3.5 Hz, IH). Anal. Calcd. For C18H2204S: C, 64.64; H, 6.63. Found: C, 64.34; H, 6.73.
Example A(85): 4-[2-(2-Cyclopentyl-4,6-dioxo-tetrahydro-pyran-2-yl)-ethyl]-2-fluoro-methyl- benzenesulfonamide
Figure imgf000111_0003
The title compound was prepared analogously to Example A(82), where 4-Bromo-2- fluoro-N-methyl-benzenesulfonamide was substituted in place of 2-Bromopyridine in Step 1 of that example. Η NMR (CDC13): δ 1.50-1.82 (brm, 8H), 1.92 (m, 2H), 2.27 (m, IH), 2.63 (s, 3H), 2.79 (m, 4H), 3.38 (s, 2H), 7.02-7.41 (m, 2H), 7.70 (s, IH). Anal. Calcd. For C19H24FN05S: C, 57.42; H, 6.09; N, 3.52. Found: C, 57.60; H, 6.22; N, 3.25.
Example A(86): 1 -{4-[2-(2-Cyclopentyl-4,6-dioxo-tetrahydro-pyran-2-yl)-ethyl]-2-f luoro- phenyl}-cyclopropanecarbonitrile
Figure imgf000112_0001
A solution of 1-{4-[3-Cyclopentyl-4-(2,2-dimethyl-6-oxo-6H-[1,3]dioxin-4-yl)-3-hydroxy- butyl]-2-fluoro-phenyl}-cyclopropanecarbonitrile (0.9 g, 2.1 mmol) from Step 6 below in NaOH (0.3 M in MeOH, 21 mL, 6.3 mmol) was stirred at room temperature for 3 hours. The reaction was then quenched with 100 mL saturated NH4CI and 5 mL 1 N HCl. To this solution was added 100 mL CH2CI2 and the layers were separated. The aqueous layer was extracted with 2 x 100 mL CH2CI2 and the organic layers were combined. After drying the organic with MgS04l and filtering to remove the solids, the solvent was removed by rotary evaporation. The remaining oil was purified by flash chromatography to yield the desired product (0.367 g, 47%).
1H NMR (CDCI3) δ: 1.27 - 1.30 (m, 2H), 1.51 - 1.73 (m, 10H), 1.84 - 1.89 (m, 2H), 2.19 (p, J = 8.08 Hz, 1 H), 2.58 - 2.71 (m, 4H), 3.36 (d, J = 4.04 Hz, 2H), 6.81 - 6.86 (m, 2H), 7.16 - 7.18 (m, 1H). MS (ESI): 368 (M-H).
Step 1: (4-Bromo-2-fluoro-phenyl)-acetonitrile 112
Figure imgf000113_0001
To a solution of 4-bromo-1-bromomethyl-2-fluoro-benzene (8.15 g, 30.4 mmol) dissolved in DMF (16 mL) were added sodium cyanide (2.24 g, 45.6 mmol) and water (2 mL). The reaction was stirred for one hour at 70 °C. To the reaction was added 130 mL water; 120 mL saturated NaHC03, and 100 mL EtOAc. The layers were separated, and the aqueous layer was extracted with 3 x 100 mL EtOAc. The combined organics were washed with 100 mL water, and then dried over Na2S0 . After filtering off the solids, the mother liquor was concentrated to the desired product by rotary evaporation (6.5 g, 99% yield).
MS (APCI): 240 (M+H), 242 (M+2+H).
Step 2: 1-(4-Bromo-2-fluoro-phenyl)-cyclopropanecarbonitrile
Figure imgf000113_0002
To a slurry of sodium hydride (60% dispersion in mineral oil, 0.82 g, 20.6 mmol) in DMF (20 mL) cooled to 0 °C was added a solution of (4-bromo-2-fluoro-phenyl)-acetonitrile (2.0 g, 9.35 mmol) from Step 1 above dissolved in THF (10 mL). The reaction was stirred till gas evolution ceased, and then 1,2-dibromoethane (1.8 mL, 20.6 mmol) was added slowly. The reaction was stirred for 30 minutes, and then diluted with 100 mL EtOAc. The solids were removed by filtration, and the organic layer was washed with 100 mL water. The organic layer was dried over MgS04, and then filtered. The mother liquor was concentrated by rotary evaporation, and the product was distilled under high vacuum (0.3 torr, 45 °C). Yield: 0.98 g, 44 %.
1H NMR (CDCI3) δ: 1.15 (dd, J1 = 5.31 Hz, 72 = 2.27 Hz, 2H), 1.48 (dd, Jl = 5.05 Hz, J2 = 2.53 Hz, 2H), 6.97 - 7.12 (m, 3H).
Step 3: 1-Cyclopentyl-3-trimethylsilanyl-propynone
Figure imgf000114_0001
The title compound was prepared as described in the following reference: Journal of Organic Chemistry 1984, 106, 4786-4800. 1H NMR (CDCI3): δ 0.24 (s, 9H), 1.63 (m, 4H), 1.90 (m, 4H), 2.92 (pentet, 1 H, J = 8.2 Hz).
Step 4: 6-(2-Cyclopentyl-2-hydroxy-4-trimethylsilanyl-but-3-ynyl)-2,2-dimethyl-[1,3]dioxin- 4-one
A solution of diisopropylamine (3.85 mL, 27.5 mmol) dissolved in THF (100 mL; dry), was cooled to -78 GC, where BuLi (11 mL, 27.5 mmol; 2.5 M in hexanes) was added dropwise over 10 minutes. After stirring at this temperature for 5 minutes the mixture was warmed to room temperature for 5 minutes, then cooled back to -78 °C, where commercially available 2,2,6- trimethyl-[1,3]dioxin-4-one (3.60 mL, 27.5 mmol) was added dropwise over 5 minutes, then stirred an additional 30 minutes at -78 °C. To this solution was added 1-Cyclopentyl-3-trimethylsilanyl- propynone (4.85 g, 25 mmol; prepared as described in Step 3 above over 5 minutes. The resulting mixture was stirred at -78 °C fo\1 hr, then slowly warmed to -30 °C and quenched with 0.5 N citric acid. The mixture was diluted wth ether, extracted with 1N NaHC03, brine, and then dried with MgS04. This material (9.38 g), whitih contained a unreacted 2,2 6-trimethyl-[1 ,3]dioxin- 4-one, was used without further purification.
'H NMR CDCy δ: 0.15 (s, 9H), 1.60 (m, 4H), 1.72 (s,3H), 1.75 (s, 3H), 2.01 (s, 1H)\2.14 (pentet, IH), 2.47 (s, IH), 2.55 (s, 2H), 5.40 (s, IH). ESIMS (M+Na+): 359.1
Step 5: 1-{4-[3-Cyclopentyl-4-(2,2-dimethyl-e-oxo-6H-[1,3]dioxin-4-yl)-3 hydroxy-but-1- ynyl]-2-fluoro-phenyl}-cyclopropanecarbonitrile
Figure imgf000115_0001
The desired product was prepared analogously to example F(7), Step 5, substituting 1-(4- bromo-2-fluoro-phenyl)-cyclopropanecarbonitrile (0.96 g, 4.0 mmol), from Step 2 above in place of 3-iodophenol, and 6-(2-cyclopentyl-2-hydroxy-but-3-ynyl)-2,2-dimethyl-[1,3]dioxin-4-one (1.06 g, 4.0 mmol; from Step 4 above) in place of 6-but-3-ynyl-3-chloro-6-cyclopentyl-dihydro-pyran-
2,4-dione. Yield: 1.241g, 73 %.
MS (ESI): 422 (M-H).
Step 6: 1-{4-[3-Cyclopentyl-4-(2,2-dimethyl-6-oxo-6H-[1,3]dioxin-4-yl)-3-hydroxy-butyl]-2- fluoro-phenyl}-cyclopropanecarbonitrile
Figure imgf000116_0001
To a solution of 1-{4-[3-Cyclopentyl-4-(2,2-dimethyl-6-oxo-6H-[1,3]dioxin-4-yl)-3-hydroxy- but-1-ynyl]-2-fluoro-phenyl}-cyclopropanecarbonitrile (1.0 g, 2.4 mmol) from Step 5 above dissolved in EtOH (20 mL) was added Pd(OH)2/C (20 % wt dry basis, 100 mg) and the reaction was stirred under a hydrogen atmosphere for 6 hours. The palladium catalyst was removed by filtration, and the solvent removed by rotary evaporation. The resulting oil was used without further purification (1.02 g, 99% yield).
MS (ESI): 426 (M-H).
Example A(87): W-{4-[2-(2-cyclopentyl-4,6-dioxotetrahydro-2W-pyran-2-yl)ethyl]-2- ethylphenyl}-Λ/-methylmethanesulfonamide
Figure imgf000116_0002
The title compound was prepared analogously to Example A(64)where Λ/-(4-bromo-2- ethylphenyl)-Λ/-methylmethanesulfonamide was substituted in place of 4-bromo-2-fluoro-1- isopropylbenzene in step 2 of that example. lH NMR(CDCl3): δ 1.12 (t, J- 7.54 Hz, 3H), 1.4-2.2 (brm, 1 IH), 2.60-2.80 (brm, 6H), 2.94s, 3), 3.02(s, 3H), 6.56 (d, 7= 4.90 Hz, IH), 7.00, (d, J= 4.90 Hz, IH), 7.07 (s, IH). Anal. Calcd. For C22H31N05S: C, 62.68; H, 7.41; N, 3.32. Found: C, 62.49; H, 6.98; N, 3.20. Step 1: W-(4-bromo-2-ethylphenyl)methanesuιτonamide
Figure imgf000117_0001
Methane sulfonyl chloride (1.93ml, 0.025M) was added to a solution of 4-bromo-2-ethylaniline (5.0g, 0.025M) and pyridine (2.02ml, 0.025M) ^dichloromethane (100ml) at 0°C. The reaction mixture was stirred for lhr, after which time it was partitioned between dichloromethane (100ml) and IN hydrochloric acid (100ml). The organics were separated and dried over magnesium sulfate, filtered and concentrated in vacuuo to afford the title compound as a clear oil (4.77g).
'H NMR (CDC13): δ 1.12 (t, J = 8.60 Hz, 3H), 2.91 (q, 2H), 3.06 (s, 3H), 6.81 (d, J= 7.54 Hz, IH), 7.05 (d, J = 7.54 Hz, IH), 7.26 (s, IH).
Step 2: Λ/-(4-bromo-2-ethylphenyl)-Λ/-methylmethanesulfonamide
Figure imgf000117_0002
Methyl iodide (1.6g, 0.0256M) was added to a mixture ofN-(4-bromo-2- ethylphenyl)methanesulfonamide (4.77g, 0.0171M) and potassium carbonate (3.5g, 0.0256M) in dimethylformamide (50ml) at room temperature under an atmosphere of nitrogen. The reaction mixture was stirred for a further 24hrs after which time it was partitioned between diethylether (100ml) and water (100ml). The aqueous was extracted further with diethyl ether (2x100ml). The combined organics were dried over magnesium sulfate, filtered and the solvent concentrated in vacuuo to afford the title compound as a brown oil (3.6g).
'HΝMR (CDCl3): δ 1.12 (t, J = 8.60 Hz, 3H), 2.94 (m, 5H), 3.02 (s, 3H), 6.71 (d, 7= 8.5 Hz, IH), 7.05 (d, J = 8.5 Hz, IH), 7.28 (s, IH).
Example A(88): Λ/-{4-[2-(2-cyclopentyl-4,6-dioxotetrahydro-2H-pyran-2-yl)ethyl]phenyl}-W- rnethylmethanesulfonamide
Figure imgf000118_0001
The title compound was prepared analogously to Example A(64)where /V-(4-bromophenyl)-Λ/- methylmethanesulfonamide was substituted in place of 4-bromo-2-fluoro-1 -isopropylbenzene in step 2 of that example.
Η NMR (CDC13): δ 1.4-2.24 (brm, 1 IH), 2.60-2.89 (brm, 4H), 2.94 (s, 3H), 3.04 (m, 5H), 6.96 (dd, 7= 4,96 Hz, 2H), 7.23 (dd, J= 4.96 Hz, 2H). Anal. Calcd. For C20H27NO5S: C, 61.04; H, 6.91; N, 3 56. Found: C, 61.35; H, 6.94; N, 3.20.
Step 1: N-(4-bromophenyl)methanesulfonamide
Figure imgf000118_0002
H
Methane sulfonyl chloride (2.4ml, 0.031 M) was added to a solution of 4-bromo-aniline (5.28g, 0.031 M) and pyridine (2.5ml, 0.031 M) in dichloromethane (100ml) at 0°C. The reaction mixture was stirred for 1 hr, after which time it was partitioned between dichloromethane (100ml) and 1N hydrochloric acid (100ml). The organics were separated and dried over magnesium sulfate, filtered and concentrated in vacuuo to afford the title compound as a white solid (6.37g). Η NMR (CDC13): 2.97 (s, 3H), 6.81 (d),7= 2.56 Hz, 2H), 7.25 (d, J = 2.56 Hz, 2H),).
Step 2: /-(4-bromophenyl)-N-methylmethanesulfonamide
Figure imgf000118_0003
Methyl iodide (2.38g, 0.0382yi) was added to a mixture of Λ/-(4- bromophenyl)methanesulfonamide 6.37g, 0.0255M) and potassium carbonate (5.21 g, 0.0382M in dimethylformamide (50ml) at room temperature under an atmosphere of nitrogen. The reaction mixture was stirred for a further 24(jrs after which time it was partitioned between diethylether (100ml) and water (100ml). The aqueous was extracted further with diethyl e her (2x100ml). The combined organics were dried over magnesium sulfate, filtered and the solvent" concentrated in vacuuo to afford the title compound as a white solid (5.6g).
1 \
HNMR (CDCI3): 2.94 (s, 3H), 3.04 (s, 3Η)),6.89 (d, 7= 2.56 Hz, 2H), 7.30 (d, J = 2.56 Hz, 2H),).
Example A(89): 6-cyclopentyl-6-[2-(3-cyclopentyl-4-hydroxyphenyl)ethyl]dihydι-p-2W-pyran- 2,4(3W)-dione
Figure imgf000119_0001
The title compound was prepared analogously to Example A(22): where 4-bromo-2- cyclopentylphenol, from step 1 , was used in place of 4-Bromo-2-ethyl-phenol in step 2 of that example.
'HNMR (CDC13): δ 1.43-1.85 (br m, 16H), 1.87 - 2.21, (m, 3H), 2.70-3.18 (brm, 7H), 4.95 (s, 1H), 6.60 (d, 7= 8.1 Hz IH)), 6.84 (d, J= 8.1 Hz, IH), 7.12 (s, IH). LCMS = 369 -ve APCI.
Step 1. 4-bromo-2-cyclopentylphenol
Figure imgf000119_0002
2-cyclopentyl phenol (3.0g, 0.0185 mol) was dissolved in CHCI3 (100 mL) and magnetically stirred at room temperature. To this solution was added a solution of Tetrabutyl ammonium tribromide (8.92g, 0.0185 mol) in CHCI3 (100mL). The resulting yellow solution was allowed to stir at room temperature for 1 hour. The reaction was quenched with a 5% solution of sodium thiosulfate (200 mL). The biphasic mixture was stirred for 15 min. The organics were separated and concentrated. The residue was dissolved in EtOAc (100 mL) and washed with water (2 x 100 mL) and brine (1 x 100mL). The organics were dried over Na2S04, filtered and concentrated. The residue was purified by flash chromatography (silica gel) eluting with 3% EtOAc in Hexanes. The result was a yellow oil (3.70g)
Η NMR (CDC13): δ 1.39 -1.73 (brm, 8H), 2.83 (m, 1H), 4.81 (s, 1H), 6.68 (d, 7= 7.10 Hz IH), 7.19 (d, 7= 7.10 Hz, IH), 7.26 (s, IH).
Example A(90): 6-cyclopentyl-6-[2-(4-hydroxy-3-propylphenyl)ethyl]dihydro-2W-pyran- 2,4(3W)-dione
Figure imgf000120_0001
The title compound was prepared analogously to Example A(22): where 4-bromo-2- propylphenol, from step 1 , was used in place of 4-Bromo-2-ethyl-phenol in step 2 of that example. 'HNMR (CDCl3): δ 1.00 (t, J = 8.1Hz 3H,), 1.33-1.85 (brm, 8H), 1.87-2.01 (m, 2H), 2.22 (m, 3H),2.30 (m, 2H), 2.60 -3.10 (brm, 6H), 5.78 (s, IH), 6.70 (d, 7= 2.07 Hz IH)), 6.80 (s, IH), 6.85 (d, 7= 2.07 Hz, IH). LCMS = 343 -ve APCI.
Step 1. 4-bromo-2-propylphenol
Figure imgf000120_0002
2-propylphenol (3.0g, 0.022 mol) was dissolved in CHCI3 (100 mL) and magnetically stirred at room temperature. To this solution was added a solution of Tetrabutyl ammonium tribromide (10.68g, 0.022 mol) in CHCI3 (100mL). The resulting yellow solution was allowed to stir at room temperature for 1 hour. The reaction was quenched with a 5% solution of sodium thiosulfate (200 mL). The biphasic mixture was stirred for 15 min. The organics were separated and concentrated. The residue was dissolved in EtOAc (100 mL) and washed with water (2 x 100 mL) and brine (1 x 100mL). The organics were dried over Na2S0 , filtered and concentrated. The residue was purified by flash chromatography (silica gel) eluting with 3% EtOAc in "Hexanes. The result was a yellow oil (4.54g)
'HNMR (CDCi3): δ 1.00 (t, J = 8.10 Hz, 3H),' 1.52 (m, 2H), 2.50 (t, J = 4.56 Hz, 2H), 4.95 (s, 1 H), 6.72 (d, 7= 2.07 Hz IH)), 6.80 (s, IH), 6.85 (d, 7= 2.07 Hz, IH).
Example A(91 ): 2-{4-[2-(2-Cyclopentyl-4,6-di xo-tetrahydro-pyran-2-yl)-efhyl]-2-f luoro- phenyl}-2jjethyl-butyronitrile
Figure imgf000121_0001
The desired 'product was prepared analogously to Example A(86) step 5, substring 2- {4-[3-Cyclopentyl-4-(2,2-c imethyl-6-oxo-6H-[1,3]dioxin-4-yl)-3-hydrpxy-butyl]-2-fluoro-phenyl}v?.. ethyl-butyronitrile (0.84 g,γl.8 mmol) from step 3 below in place of 1-{4-[3-Cyclopentyl-4-(2^. dimethyl-6-oxo-6H-[1,3]dioxln-4-yl)-3-hydroxy-butyl]-2-fluoro-phenyl}-cyclopropanecarbonitrile. Yield: 0.393 g, 54 %.
Figure imgf000121_0002
1H), 7.57 (t, 7 = 8.21 Hz, 1H).
Step 1: 2-(4-Bromo-2-f!uoro-pheriyl)-2-ethyl-butyronitrile
Figure imgf000122_0001
The desired product was prepared analogously to Example A(86) step 2, substituting bromoethane (1.94 mL, 20.6 mmol) in place of 1 ,2-dibromoethane. Yield: 2.1 g, 84%.
MS (APCI) 270 (M+H), 272 (M+2+H).
Step 2: 2-{4-[3-Cyclopentyl-4-(2,2-dimethyl-6-oxo-6H-[1,3]dioxin-4-yl)-3-hydroxy-but-1- ynyl]-2-fluoro-phenyl}-2-ethyl-butyronitrile
Figure imgf000122_0002
The desired product was prepared analogously to Example A(86) step 5, substituting 2- (4-Bromo-2-fluoro-phenyl)-2-ethyl-butyronitrile (1.01 g, 4.0 mmol) from step 1 above in place of 1- (4-bromo-2-fluoro-phenyl)-cyclopropanecarbonitrile. Yield: 0.953 g, 53 %.
MS (ESI): 436 (M-H). Step 3: 2-{4-[3-Cyclopentyl-4-(2,2-dimethyl-6-oxo-6H-[1 ,3]dioxin-4-yl)-3-hydroxy-butyl]-2- fluoro-phenyl}-2-ethyl-butyronitrile
Figure imgf000123_0001
The desired product was prepared analogously to example A(86) step 6, substituting 1- {4-[3-Cyclopentyl-4-(2,2-dimethyl-6-oxo-6H-[1,3]dioxin-4-yl)-3-hydroxy-but-1-ynyl]-2-fluoro- phenyl}-2-ethyl-butyronitrile (0.900 g, 2.0 mmol) from step 2 above in place of 1-{4-[3- Cyclopentyl-4-(2,2-dimethyl-6-oxo-6H-[1,3]dioxin-4-yl)-3-hydroxy-but-1-ynyl]-2-fluoro-phenyl}- cyclopropanecarbonitrile. Yield: 0.841 g, 92%.
MS (ESI): 456 (M-H).
Example A(92): 1 -{4-[2-(2-Cyclopentyl-4,6-dioxo-tetrahydro-pyran-2-yl)-ethyl]-2-fluoro- phenyl}-cyclobutanecarbonitrile
Figure imgf000123_0002
The desired product was prepared analogously to Example A(86) step 5 substituting 1-{4- [3-Cyclopentyl-4-(2,2-dimethyl-6-oxo-6H-[1,3]dioxin-4-yl)-3-hydroxy-butyl]-2-fluoro-phenyl}- cyclobutanecarbonitrile (1.00 g, 2.2 mmol) from step 3 below in place of 1-{4-[3-Cyclopentyl-4- (2,2-dimethyl-6-oxo-6H-[1,3]dioxin-4-yl)-3-hydroxy-butyl]-2-fluoro-phenyl}- cyclopropanecarbonitrile. Yield: 0.477 g, 57 %.
1H NMR (CDCI3) δ: 1.79 - 2.05 (br, 8H), 2.14 - 2.19 (m, 2H), 2.21 - 2.29 (m, 1H), 2.49 (p, 7 = 9.35 Hz, 1H), 2.65 - 2.76 (m , 1H), 2.83 - 2.95 (m, 4H), 3.00 (d, 7 = 5.05 Hz, 2H), 3.02 - 3.10 (m, 2H), 3.66 (d, J = 3.28 Hz, 2H), 7.12 (dd, J1 = 11.24 Hz, 72 = 1.64 Hz, 1H), 7.17 (dd, 71 = 7.96 Hz, J2 = 1.64 Hz, 1H), 7.38 (t, J = 7.96 Hz, 1H).
Step 1: 1-(4-Bromo-2-fluoro-phenyl)-cyclobutanecarbonitrile
Figure imgf000124_0001
To a slurry of NaH (1.64 g, 60 % suspension in mineral oil, 41.1 mmol) in DMSO (19 mL) stirred at room temperature, was added a solution of 1, 3-dibromopropane (2.1 mL, 20.6 mmol) and (4-Bromo-2-fluoro-phenyl)-acetonitrile (4.0 g, 18.7 mmol) in diethyl ether (10 mL) slowly keeping the temprature of the reaction between 25 degrees Celsius and 35 degrees Celsius. Stir for two hours after the addition is complete, and pour into saturated ammonium chloride (150 mL). Add 100 ml of CH2CI2 and separate the layers. Extract the aqueous phase with 2 x 50 mL CH2CI2 and combine the organics. After drying the organic liquid over MgS0 , the solids were removed by filtration, and the liquid was concentrated to an oil. The oil was purified by flash chromatography to yield the desired product. Yield: 1.43 g, 30%.
MS (APCI) 254 (M+H), 256 (M+2+H). Step 2: 1-{4-[3-Cyclopentyl-4-(2,2-dimethyl-6-oxo-6H-[1 ,3]dioxin-4-yl)-3-hydroxy-but-1- ynyl]-2-fluoro-phenyl}-cyclobutanecarbonitrile
Figure imgf000125_0001
The desired product was prepared analogously to Example A(86) step 5, substituting 1- (4-Bromo-2-fluoro-phenyl)-cyclobutanecarbonitriie (1.06 g, 4.0 mmol) from step 1 above in place of 1-(4-bromo-2-fluoro-phenyl)-cyclopropanecarbonitrile. Yield: 1.226 g, 70 %.
MS (ESI): 436 (M-H).
Step 3: 1-{4-[3-Cyclopentyl-4-(2,2-dimethyl-6-oxo-6H-[1 ,3]dioxin-4-yl)-3-hydroxy-butyl]-2- fluoro-phenylj-cyclobutanecarbonitrile
Figure imgf000125_0002
The desired product was prepared analogously to Example A(86) step 6, substituting 1- {4-[3-Cyclopentyl-4-(2,2-diιfιethyl-6-oxo-6H-[1,3]dioxin-4-yl)-3-hydroxy-but-1-ynyl]-2-fluoro- phenyl}-cyclobutanecarborjjtrile (1.200 g, 2.7 mmol) from' step 2 above in place of 1-{4-[3- Cyclopentyl-4-(2,2-dimethyJ-6-oxo-6H-[1,3]dioxin-4-yl)-3-hydroxy-but-1-ynyl]-2-fluoro-phenyl}- cyclopropanecarbonitrile. Yield: 1.00 g, 84%.
MS (ESI): 440 (M-H).
Example A(93): 6-Cyclo(jentyl-6-[2-(4-hydroxy-3-isopropyl-phenyl)-ethyi]-dihydro-py n- 2,4-dione
Figure imgf000126_0001
The title compotlήd was prepared analogously to Example A(22)where Acetic acid 4-[2- (2-cyclopentyl-4,6-dioxθιtetrahydro-pyran-2-yl)-ethyl]-2-isopropyl-phenyl ester (Example A(94) ) was substituted in place Jjδf acetic acid 4-[2-(2-cyclopentyl-4,6-dioxo-tetrahydro-pyran-2-yl)-ethyl]- 2-ethyl-phenyl ester.
Η NMR (CDC13): δ 1.2-jW, 6H, J= 6.8 Hz), 1.47-1.81 (br m, 8H), 1.87 -2.01 (m, 2H), 2.27 (m, IH), 2.60 (m, 2H), 2.77 (s, 3H)|.18 (m, IH), 3.42 (s, IH), 4.80 (s, IH), 6.67 (d, IH, J= 8.1 Hz), 6.83 (dd, IH, 7= 8.1, 2.3 Hz), 6.94 (d, ψf 7= 2.3 Hz). Anal. Calcd. For C2ιH28O4 «0.3 H20: C, 72.09; H, 8.24. Found: C, 72.12; H, 8.23.
Example A(94): Aceti cid 4-[2-(2-cyclopentyl-4,6-dioxo-tetrahydro-pyran-2-yl)-ethyl]-2- isopropyl-phenyl este
Figure imgf000126_0002
The title compound was prepared analogously to Example A(64)where Acetic acid 4- bromo-2-isopropyl-phenyl ester (from step 2) was substituted in place of 4-bromo-2-fiuoro-1- isopropylbenzene.
Step 1 : 4-Bromo-2-isopropyl-phenol
Figure imgf000127_0001
The title compound was prepared as described in Step 1 of Example A(2) where 2- isopropyl-phenol was substituted in place of 2-ethyl-phenol.
'H NMR (CDC13): δ 1.23 (d, 6H, 7= 7.1 Hz), 3.17 (m, IH), 4.87 (br s, IH), 6.63 (d, IH, J= 8.5 Hz), 7.16 (dd, IH, 7= 8.5, 2.3 Hz), 7.28 (d, IH, 7= 2.5 Hz).
Step 2: Acetic acid 4-bromo-2-isopropyl-phenyl ester
Figure imgf000127_0002
The title compound was prepared as described in Step 2 of Example A(22) where 4- Bromo-2-isopropyl-phenol from step 1 , was substituted in place of 4-Bromo-2-ethyl-phenol. Η NMR (CDCI3): δ 1.20 (d, 6H, 7= 7.1 Hz), 2.32 (s, 3H), 2.98 (m, IH), 6.88 (d, IH, 7= 8.6 Hz), 7.31 (dd, IH, 7= 8.6, 2.3 Hz), 7.41 (d, IH, 7= 2.5 Hz).
Example A(95): 6-[2-(3-Chloro-4-hydroxy-phenyl)-ethyl]-6-cyclopentyl-dihydro-pyran-2,4- dione
Figure imgf000127_0003
The title compound was prepared analogously to Example A(13)where 3-(3-Chloro-4- hydroxy-phenyl)-1-cyclopentyl-propan-1-one was substituted in place of 3-Cyclohex-1-enyl-1- cyclopentyl-propan-1-one.
'H NMR (CDC13): δ 1.44-1.80 (br m, 8H), 1.93 (m, 2H), 2.26 (m, 1 H), 2.60 (m, 2H), 2.73 (d, 1H, J = 15.9 Hz), 2.78 (d, IH, J= 15.9 Hz), 3.43 (s, 2H), 5.44 (s, IH), 6.94 (m, 2H), 7.10 (s, IH). Anal. Calcd. For Cι8H2ι04Cl: C, 64.19; H, 6.28. Found: C, 64.33; H, 6.39.
Example A(96): 6-Cyclopentyl-6-[2-(3-ethyl-4-methoxy-phenyl)-ethyl]-dihydro-pyran-2,4- dione
Figure imgf000128_0001
The title compound was prepared analogously to Example A(13)where 1-Cyclopentyl-3- (3-ethyl-4-methoxy-phenyl)-propan-1-one (from step 2) was substituted in place of 3-Cyclohex-1- enyl-1 -cyclopentyl-propan-1 -one. 'H NMR (CDCl3): δ 1.17 (t, 3H, J= 7.3 Hz),1.44-1.80 (brm, 8H), 1.95 (m, 2H), 2.28 (m, IH), 2.57- 2.63 (m, 4H), 2.77 (s, 2H), 3.42 (s, 2H), 3.80 (s, 3H), 6.75 (d, IH, 7= 8.1 Hz), 6.91 - 6.94 (m, 2H). Anal. Calcd. For C21H28O4 «0.2 H20: C, 72.47; H, 8.23. Found: C, 72.52; H, 8.25.
Step 1: 4-Bromo-2-ethyl-1-methoxy-benzene
Figure imgf000128_0002
'HNMR (CDC13): δ 1.17 (t, 3H, 7= 7.4 Hz), 2.59 (q, 2H, J= 1A Hz), 3.80 (s, 3H), 6.70 (d, IH, 7= 8.8 Hz), 7.26 (m, 2H).
Potassium carbonate (3.9g, 28.3mmol) and methyl iodide (0.59mL, 9.43mmol) were added to a solution of 4-Bromo-2-ethyl-phenol (1.9g, 9.43mmoI, from step 1 of Example A(22) ) dissolved in DMF (10mL). The mixture was stirred for 16 h under N2 and then partitioned between 1 N HCl and EtOAc. The organic layer was washed with saturated NaHC03, brine, dried over Na2S04 and concentrated to a yellow oil. The oil was purifed by silica gel chromatography to give the title compound as a clear oil (1.37g, 68%).
Step 2: 1-Cyclopentyl-3-(3-ethyl-4-methoxy-phenyl)-propan-1-one
Figure imgf000129_0001
A mixture of bromide (1.3g, 6.02mmol, from step 1), 1-Cyclopentyl-2-propen-1-ol (1.14g, 9.07mmol), dichlorobis (triphenylphosphine) palladium (II) (85 mg, 0.12- omol), sodium bicarbonate (0.61 g, 7.25 mmol) in N-methylpyrrolidinone (12mL) was heated to 140 °C under N2 for 5h. The reaction mixture was partitioned between 1N HCl and EtOAc. The organic layer was washed with saturated NaHC03, brine, dried over Na2S04 and concentrated* to a brown oil. The oil was purifed by silica gel chromatography to give the title compound as a yellow oil (0.74g, 47%). 'HNMR (CDC13): δ 71.17 (t, 3H, 7= 7.6 Hz), 1.54-1.80 (m, 9H), 1.17 (q, 2H, 7= 7.6 Hz), -2.73 (m, 2H), 2.84 (m, 2H), 3.80 (s, 3H), 6.75 (d, IH, 7= 8.0Hz), 6.97 (m, 2H).
Example A(97): 2-[4-(2-{2-cyclopentyl-5-[(2-ethyl-4-methyl-1 W-imidazol-5-yl)methyl]-4- hydroxy-6-oxo-3,6-dihydro-2H-pyran-2-yl}ethyl)-2-fluorophenyl]-2-methylpropanenitrile
Figure imgf000129_0002
A solution of 2-{4-[2-(2-cyclopentyl-4-hydroxy-6-oxo-3,6-dihydro-2W-pyran-2-yl)ethyl]-2- fluorophenyl}-2-methylpropanenitrile (300 mg, 0.81 mmol) in anhydrous MeOH (8.0 mL) was treated with 2-ethyl-4-methyl-1H-imidazole-5-carbaldehyde (167 mg, 1.21 mmol), followed by borane-dimethylamine complex (62 mg, 1.05 mmol) at room temperature. The reaction was stirred for 12 hours before it was quenched by the addition of 1 N HCl. The mixture was extracted with 10% MeOH in CH2CI2 (3 x 10 mL) and the combined organic layers were washed with brine, dried over Na2S04. The solvent was removed and the residue was purified by HPLC to give product as a white powder (150 mg, 38% yield). 1H NMR (300 MHz, DMSO-cfe) δ: 1.15-1.20 (m, 3 H), 1.30-1.65 (m, 8 H), 1.71 (s, 6 H), 1.85-1.93 (m, 2 H), 2.10 (s, 3 H), 2.25-2.40 (m, 2 H), 2.56- 2.68 (m, 4 H), 3.32-3.44 (m, 2 H), 7.02-7.13 (m, 2 H), 7.35 (t, 7=8.38 Hz, 1 H). Anal. Calcd. For C29H36FN3O3.0.1H2O: C, 70.30; H, 7.37; N, 8.48. Found: C, 70.09; H, 7.37; N, 8.47.
Step 4: Preparation of compound 2-{4-[2-(2-cyclopentyl-4,6-dioxotetrahydro-2W-pyran-2- yl)ethyl]-2-fluorophenyl}-2-methylpropanenitrile.
Figure imgf000130_0001
To a solution of 2-{4-[3-cyclopentyl-4-(2,2-dimethyl-4-oxo-4/-/-1,3-dioxin-6-yl)-3- hydroxybut-1-ynyl]-2-fluorophenyl}-2-methylpropanenitrile (4.25 g, 10.0 mmol) in MeOH (100 mL) was added Pd(OH)2 (1.0 g, 20 wt%). The mixture was stirred under H2 for 12 hours before it was filtered through a pad of celite. The solvent was removed and the residue was taken directly into next step without further purification.
The crude mixture was dissolved in anhydrous MeOH (100 mL) and treated with K2C03 (2.8 g, 10 mmol). The reaction was heated at 45 °C for 40 min before it was cooled down to room temperature. The crude mixture was diluted with aqueous NH CI and extracted with EtOAc (3 x 100 mL). The combined organic layers were washed with brine, dried over Na2S04. The solvent was removed and the mixture was purified by flash column chromatography (EtOAc in hexanes, 10-40 % gradient) to give the desired product (1.4 g, 35% for two steps). Η NMR (CDC13) δ: 1.60- 1.73(m, 6 H), 1.92-1.98 (m, 2 H), 2.22-2.30 (m, 1 H), 2.65-2.71 (m, 2 H), 2.75-2.80 (m, 2 H), 6.88-6.96 (m, 2 H), 7.37-7.43 (m, 1 H).
Step 3: Preparation of compound 2-{4-[3-cyclopentyl-4-(2,2-dimethyl-4-oxo-4H-1,3-dioxin-6- yl)-3-hydroxybut-1-ynyl]-2-fluorophenyl}-2-methylpropanenitrile
Figure imgf000130_0002
To a solution of 2-(4-bromo-2-fluorophenyl)-2-methylpropanenitrile (3.0g, 12.4 mmol) in diisopropylamine (32 mL) and DMF (16 mL) was added 6-(2-cyclopentyl-2-hydroxybut-3-ynyl)- 2,2-dimethyl-4H-1,3-dioxin-4-one (3.2 g, 12.4 mmol), PdCI2(PPh3)2 (350 mg, 4 mol%), Cui (71 mg, 3 mol%). The mixture was heated to 90 °C for 30 min before it was cooled down to room temperature. The reaction was diluted with aqueous NH CI, extracted with EtOAc (3 x 50 mL). The combined organic extracts were washed with brine, dried with Na2S04 and evaporated to dryness. The mixture was purified by flash column chromatography (10-50 % EtOAc in hexanes) to give the product (4.2 g, 79% yield). 'HNMR (300 MHz, CDC13) δ: 1.65-1.76 (m, 14 H), 1.79 (s, 6 H), 1.82-1.85 ( , 1 H), 2.24 (s, 1 H), 2.59 (s, 1 H), 2.67 (m, 2 H), 5.46 (m, 1 H), 7.11 (dd, 7=12.15, 1.60 Hz, 1 H), 7.18 (dd, 7=8.10, 1.70 Hz, 1 H), 7.45 (t, 7=8.10 Hz, 1 H).
Step 2: Preparation of compound 2-(4-bromo-2-fluorophenyl)-2-methylpropanenitrile
Figure imgf000131_0001
To a solution of Mel (3.2 mL, 49.3 mmol) in anhydrous DMF (82 mL) at 0 °C was added NaH (60%, 2.0 g), followed by (4-bromo-2-fluorophenyl)acetonitrile (3.5 g, 16.4 mmol). The mixture was slowly warmed up to room temperature and stirred for 3 hours. The reaction was quenched by the addition of saturated NH4CI and extracted with EtOAc (3 x 150 mL). The combined organic extracts were washed with brine, dried with Na2S04 and evaporated to dryness. The mixture was purified by flash column chromatography (0-20 % EtOAc in hexanes) to give the product (3.0 g, 77% yield). 'HNMR (300 MHz, CDC13) δ: 1.78 (s, 6 H), 7.26-7.42 (m, 3 H).
Step 1: Preparation of compound (4-bromo-2-fluorophenyl)acetonitrile
Figure imgf000131_0002
To a solution of 4-bromo-1-(bromomethyl)-2-fluorobenzene (5.0 g, 18.7 mmol) in DMF (80 mL) and H20 (8 mL) was added KCN (1.21 g, 18.7 mmol). The mixture was heated to 40 °C for 3 hours before it was cooled down to room temperature. The reaction was diluted with H20 (40 mL) and extracted with Et20 (3 x 100 mL). The combined organic layers were washed with brine and dried over Na2S04. The solvent was removed and the residue was purified by flash column chromatography (0-15% EtOAc in hexanes) to give the product (3.5 g, 87% yield). Η NMR (300 MHz, CDC13) δ: 3.72 (s, 2 H), 7.26-7.35 (m, 3 H).
Example A(98): 2-[4-(2-{5-[(5"Chloro-1-methyl-1H-benzimidazol-2-yl)methyl]-2-cyclopentyl- 4-hydroxy-6-oxo-3,6-dihydro-2H-pyran-2-yl}ethyl)-2-fluorophenyl]-2-methylpropanenitrile
Figure imgf000132_0001
The title compound was prepared analogously to Example A(97), where 5-chloro-1-methyl-1 H- benzimidazole-2-carbaldehyde was substituted in place of 2-ethyl-4-methyl-1 H-imidazole-5- carbaldehyde.'H NMR (300 MHz, DMSO-dø δ: 1.14-1.49 (m, 8 H), 1.52 (s, 6 H), 1.87-2.07 (m, 2 H), 2.15-2.25 (m, 2 H), 2.38-2.46 (m, 2 H), 2.56-2.62 (m, 1 H), 3.49-3.65 (m, 2 H), 3.58 (s, 3 H), 6.86 (dd, 7=8.01, 1.22 Hz, 1 H), 6.98 (m, 2 H), 7.14 (m, 2 H), 7.30 (d, 7=8.67 Hz, 1 H). HRMS: calcd for C3ιH34ClFN303 (M+H+) 550.2267, found 550.2273. Step 3: 5-chloro-1-methyl- H-benzimidazole-2-carbaldehyde
Figure imgf000132_0002
A solution of (5-chloro-1-methyl-1H-benzimidazol-2-yl)methanol (1.5 g, 7.7 mmol) dissolved in CH2CI2 at room temperature was treated with Dess-Martin periodinane (4.9 g, 11.5 mmol). The reaction was stirred for 15 hours before the solvent was removed. The residue was purified by flash column chromatography (0-3% MeOH in CH2CI2) to give the product (1.0 g, 66% yield). 1H NMR (300 MHz, CDCI3) δ: 4.16 (s, 3 H), 7.40-7.47 (m, 2 H), 7.90-7.93 (m, 1 H), 10.11 (s, 1 H).
Step 2: (5-chloro-1-methyl-1H-benzimidazoI-2-yl)methanol
Figure imgf000132_0003
4-chloro-Λ/1-methylbenzene-1,2-diamine (15.0 g, 96 mmol) and glycolic acid (8.1 g, 106 mmol) were mixed together in a sealed tube. The mixture was heated at 150 °C for 5 hours before it was cooled down to room temperature. The residue was purified by flash column chromatography (0-5% MeOH in CH2CI2) to give the product (8.5 g, 45% yield). 1H NMR (300 MHz, CDCI3) δ: 3.80 (s, 3 H), 4.86 (s, 2 H), 7.13-7.22 (m, 2 H), 7.62-7.64 (m, 1 H).
Step 1: 4-chloro-/V1-methylbenzene-1,2-diamine
Figure imgf000132_0004
A solution of 1 ,4-dichloro-2-nitrobenzene (5 g, 26 mmol) dissolved in 33% MeNH2 in EtOH (20 mL) was heated to 80 °C for 15 hours. The reaction was cooled to room temperature and the solvent was removed. The crude product was taken directly into next step without further purification.
The mixture dissolved in EtOH (250 mL) was treated with Zn dust (15 g), followed by dropwise addition of aqueous HCl (6 N, 40 mL). The reaction was stirred at room temperature for 3 hours. The solution was made basic by slow addition of saturated NaOH. The aqueous was extracted with CH2CI2 (3 x 100 mL). The combined organic layers were washed with brine and dried over Na2S04. The solvent was removed to afford product (1.7 g, 42% yield for two steps). 1H NMR (300 MHz, CDCI3) δ: 2.84 (s, 3 H), 6.54 (d, 7 = 6.0 Hz, 1 H), 6.70 (d, J = 3.0 Hz, 1 H), 6.79 (dd, 7 = 3.0, 6.0 Hz, 1 H).
Example A(99): 2-[4-(2-{2-cyclopentyl-4-hydroxy-6-oxo-5-[(2-oxo-1 ,2-dihydropyridin-4- yl)methyl]-3,6-dihydro-2r -pyran-2-yl}ethyl)-2-fluorophenyl]-2-methylpropanenitrile
Figure imgf000133_0001
The title compound was prepared analogously to Example A(97), where 2-oxo-1 ,2- dihydropyridine-4-carbaldehyde was substituted in place of 2-ethyl-4-methyl-1/-/-imidazole-5- carbaldehyde. 'HNMR (300 MHz, DMSO-</6) δ: 1.25-1.78 (m, 8 H), 1.71 (s, 6 H), 1.87-1.93 (m, 2 H), 2.56-2.64 (m, 2 H), 2.71-2.76 (m, 1 H), 3.25-2.26 (m, 4 H), 7.00-7.03 (m, 1 H), 7.09-7.20 (m, 3 H), 7.23- 7.28 (m, 1 H), 7.32-7.38 (m, 1 H). HRMS: calcd for C28H32FN204 (M+H1) 479.2341, found 479.2331.
Step 1 : 2-oxo-1,2-dihydropyridine-4-carbaldehyde
Figure imgf000133_0002
The title compound was prepared as described in the following reference: J. Am. Chem. Soc, 1997, 3619-3620.
Example A(100): 2-(4-{2-[2-cyclopentyl-4-hydroxy-5-(3-methoxybenzyl)-6-oxo-3,6-dihydro- 2H-pyran-2-yl]ethyl}-2-fluorophenyl)-2-methylpropanenitrile
Figure imgf000134_0001
The title compound was prepared analogously to Example A(97), where 3- methoxybenzaldehyde was substituted in place of 2-ethyl-4-methyl-1W-imidazole-5-carbaldehyde. 'H NMR (300 MHz, DMSO-c?6) δ: 1.24-1.66 (m, 8 H), 1.71 (s, 6 H), 1.83-1.93 (m, 2 H), 2.27-2.36 (m, 2 H), 2.54-2.59 (m, 2 H), 2.73-2.79 (m, 1 H), 3.42-3.56 (m, 2 H), 3.65 (s, 3 H), 6.69-6.77 (m, 3 H), 6.93-7.19 (m, 3 H), 7.30-7.36 (m, 1 H). Anal. Calcd. For C30H34FNO4.0.3H2O: C, 72.50; H, 7.02; N, 2.82. Found: C, 72.13; H, 6.97; N, 2.88.
Step 1 : 3-methoxybenzaldehyde
Figure imgf000134_0002
A solution of 3-hydroxybenzaldehyde (1.22 g, 10 mmol) in anhydrous acetone (50 mL) was treated with K2C03 (2.76 g, 20 mmol) and Mel (0.9 mL, 15 mmol) at room temperature for 12 hours. The mixture was poured into water and extracted with EtOAc (3 x 30 mL). The combined organic layers were washed with brine and dried over Na2S0 . The solvent was removed and the product was purified by flash column chromatography (0-15% EtOAc in hexanes, 1.2 g, 88% yield). 1H NMR (300 MHz, CDCI3) δ: 3.88 (s, 3 H), 7.17-7.21 (m, 1 H), 7.38-7.42 (m, 1 H), 7.45- 7.47 (m, 2 H), 9.99 (s, 1 H).
Example A(101): 2-[4-(2-{2-cyclopentyl-4-hydroxy-5-[3-(methylsulfonyl)benzyl]-6-oxo-3,6- dihydro-2W-pyran-2-yl}ethyl)-2-fluorophenyl]-2-methylpropanenitrile
Figure imgf000134_0003
The title compound was prepared analogously to Example A(97), where 3- (methylsulfonyl)benzaldehyde was substituted in place of 2-ethyl-4-methyl-1 /-Mmidazole-5- carbaldehyde. Η NMR (300 MHz, OMSO-d6) δ: 1.23-1.64 (m, 8 H), 1.70 (s, 6 H), 1.84-1.91 (m, 2 H),
2.26-2.34 (m, 1 H), 2.54-2.59 (m, 2 H), 2.68-2.74 (m, 1 H), 3.10 (s, 3 H), 3.17 (s, 1 H), 3.55-3.66 (m, 2 H),
6.92-6.95 (m, 1 H), 7.04-7.09 (m, 1 H), 7.30-7.35 (m, 1 H), 7.46-7.54 (m, 2 H), 7.69-7.74 (m, 2 H). HRMS: calcd for C30H35FSNO5 (M+H ) 540.2215, found 540.2228.
Step 2: 3-(methylsulfonyl)benzaldehyde
Figure imgf000135_0001
A solution of [3-(methylsulfonyl)phenyl]methanol (680 mg, 3.66 mmol) in anhydrous CH2CI2 (20 mL) was treated with PCC (1.03 g, 4.75 mmol) at room temperature for 2 hours. The solvent was removed and the residue was purified by flash column chromatography (20-60% EtOAc in hexanes) to give the product (500 mg, 74% yield). Η NMR (300 MHz, CDC13) δ: 3.13 (s, 3 H), 7.77-7.82 (m, 1 H), 8.18-8.24 (m, 2 H), 8.46-8.48 (m, 1 H), 10.12 (s, 1 H).
Step l: [3-(methylsulfonyl)phenyl]methanol
Figure imgf000135_0002
A solution of 3-(methylsulfonyl) benzoic acid (1.0 g, 5.0 mmol) in anhydrous THF (25 mL) was treated with BH3.THF (1 M solution, 7.5 mL) at room temperature. The reaction was stirred for 12 hours before it was quenched by slow addition of MeOH. The solvent was removed and the residue was purified by flash column chromatography (0-5 % MeOH in CH2CI2) to give the product (0.84 g, 90% yield). 1H NMR (300 MHz, CDCI3) δ: 3.06 (s, 3 H), 4.81 (d, 7 = 6.0 Hz, 2 H), 7.54-7.59 (m, 1 H), 7.65-7.68 (m, 1 H), 7.85-7.88 (m, 1 H), 7.96 (s, 1 H).
Example A(102): 2-[4-(2-{5-[(4-chloro-1-methyl-1H-pyrazol-3-yl)methyl]-2-cyclopentyl-4- hydroxy-6-oxo-3,6-dihydro-2H-pyran-2-yl}ethyl)-2-fluorophenyl]-2-methylpropanenitrile
Figure imgf000135_0003
The title compound was prepared analogously to Example A(97), where 4-chloro-1- methyl-1 W-pyrazole-3-carbaldehyde was substituted in place of 2-ethyl-4-methyl-1H-imidazole-5- carbaldehyde. Η NMR (300 MHz, OMSO-d6) δ: 1.46-1.78 (m, 8 H), 1.88 (s, 6 H), 2.21-2.26 (m, 2 H), 2.52-2.60 (m, 1 H), 2.78-2.94 (m, 4 H), 3.57-3.60 (m, 2 H), 3.72 (s, 3 H), 7.24-7.31 (m, 2 H), 7.51-7.56 (m, 1 H), 7.92 (s, 1 H). Anal. Calcd. For C27H3iFClN3O3.1.0H2O: C, 62.60; H, 6.42; N, 8.11. Found: C, 62.36; H, 6.44; N, 8.47.
Example A(103): 2-(4-{2-[2-cyclopentyl-4-hydroxy-5-(imidazo[1 ,2-a]pyridin-2-ylmethyl)-6-
Figure imgf000136_0001
The title compound was prepared analogously to Example A(97), where imidazo[1,2- a]pyridine-2-carbaldehyde was substituted in place of 2-ethyl-4-methyl-1/-/-imidazole-5- carbaldehyde. Η NMR (300 MHz, OMSO-d6) δ: 1.23-1.58 (m, 8 H), 1.60 (s, 6 H), 1.82-1.90 (m, 2 H), 2.19-2.29 (m, 2 H) 2.46-2.66 (m, 3 H), 3.50-3.63 (m, 2 H), 6.76 (t, 7=6.31 Hz, 1 H), 6.87 (d, 7=8.29 Hz, 1 H), 7.12 (m, 3 H), 7.32 (d, 7=9.04 Hz, 1 H), 7.51 (s, 1 H), 8.34 (d, 7=6.22 Hz, 1 H). Anal. Calcd. For C3oH32FN3θ3.0.5H20: C, 70.57; H, 6.51; N, 8.23. Found: C, 70.73; H, 6.55; N, 7.85.
Step 1 : lmidazo[1 ,2-a]pyridine-2-carbaldehyde
Figure imgf000136_0002
The title compound was prepared as described in the following reference: J.Heterocycl.Chem.; 1992; 691-697.
Example A(104): 2-{4-[2-(2-Cyclopentyl-4,6-dioxo-5-[1,2,4]triazolo[1,5-a]pyrimidin-2- ylmethyl-tetrahydro-pyran-2-yl)-ethyl]-2-fluoro-phenyl}-2-methyl-propionitrile
Figure imgf000136_0003
The title compound was prepared analogously to Example A(97), where [1 ,2,4]triazolo[1 ,5-a]pyrimidine-2-carbaldehyde was substituted in place of 2-ethyl-4-methyl-1H- imidazole-5-carbaldehyde in final step of that example. 1H NMR (400 MHz, CDCI3) δ: 1.47 - 1.71 (m, 8H), 1.75 (s, 6H), 2.00 (m, 2H), 2.39 (m, 1H), 2.66 (dd, 7 = 103, 18 Hz, 2H), 2.69 (m, 2H), 4.12 (s, 2H), 6.88 (d, J = 12.9 Hz, 1H), 6.93 (d, 7 = 8.1 Hz, 1H), 7.20 (m, 1H), 7.84 (t, 7 = 8.1Hz, 1H), 8.85 (m, 2H). MS (ESI): 504.1(M+H+)
Example A(105): (+)-2-{4-[2-(2-Cyclopentyl-4,6-dioxo-5-[1 ,2,4]triazolo[1 ,5-a]py rimidin-2- ylmethyl-tetrahydro-pyran-2-yl)-ethyl]-2-fluoro-phenyl}-2-methyl-propionitrile
Figure imgf000137_0001
The title compound was isolated by chiral chromatography of racemic material described in Example A(104). Conditions: Chiralpak OJ-RH, 150 x 4.6 mm, 0.6 mL/min, 30 °C; 35% acetonitrile, 65% water, 0.1% formic acid; retention time 17.6 min.
Example A(106): (-)-2-{4-[2-(2-Cyclopentyl-4,6-dioxo-5-[1 ,2,4]triazolo[1 ,5-a]pyrimidin-2- ylmethyl-tetrahydro-pyran-2-yl)-ethyl]-2-fluoro-phenyl}-2-methyl-propionitrile
Figure imgf000137_0002
The title compound was isolated by chiral chromatography of racemic material described in Example A(104). Conditions: Chiralpak OJ-RH, 150 x 4.6 mm, 0.6 mL/min, 30 °C; 35% acetonitrile, 65% water, 0.1% formic acid; retention time 21.7 min. Example A(107): 2-(4-{2-[2-Cyclopentyl-5-(5-methyl-3H-imidazol-4-ylmethyl)-4,6-dioxo- tetrahydro-pyran-2-yl]-ethyl}-2-fluoro-phenyI)-2-methyl-propionitrile
Figure imgf000138_0001
The title compound was prepared analogously to Example A(97), where 5-Methyl-3H- imidazole-4-carbaldehyde was substituted in place of 2-ethyl-4-methyl-1H-imidazole-5- carbaldehyde in the final step of that example. 1H NMR (400 MHz, CDCI3) δ: 1.47 - 1.71 (m, 8H), 1.70 (s, 6H), 1.88 (m, 2H), 2.12 (s, 3H), 2.28 (m, 1H), 2.43 (d, 7 = 103, 17.4 Hz, 1 H), 2.50 (m, 2H), 2.58 (m, 3H), 7.02 (d, 7 = 6.57 Hz, 1H), 7.11 (d, 7 = 13.1 Hz, 1H), 7.34 (t, 7 = 8.6Hz, 1H), 7.78 (s, 1 H). MS (ESI): 467.1 (M+H+).
Example A(108): 2-(4-{2-[2-Cyclopentyl-5-(6-methyl-[1 ,2,4]triazolo[1 ,5-a]pyrimidin-2- ylmethyl)-4,6-dioxo-tetrahydro-pyran-2-yl]-ethyl}-2-fluoro-phenyl)-2-methyl-propionitrile
Figure imgf000138_0002
The title compound was prepared analogously to Example A(97), where 6-Methyl- [1,2,4]triazolo[1,5-a]pyrimidine-2-carbaldehyde was substituted in place of 2-ethyl-4-methyl-1 H- imidazole-5-carbaldehyde in the final step of that example. 1H NMR (400 MHz, CDCI3) δ: 1.48 - 1.71 (m, 8H), 1.76 (s, 6H), 2.00 (m, 2H), 2.06 (s, 1H), 2.10 (s, 1H), 2.38 (m, 1H), 2.39 (s, 3H), 2.68 (m, 2H), 2.81(m, 1H), 4.09 (s, 2H), 6.86 (d, 7 = 12.9 Hz, 1H), 6.92 (d, 7 = 8.1 Hz, 1H), 7.84 (t, 7 = 8.1Hz, 1H), 8.63 (s, 1H), 8.70 (s, 1H). MS (ESI): 518.6(M+H+).
Step 2: Preparation of 6-methyl [1,2,4]triazolo[1,5-a]pyrimidine-2-carbaldehyde
Figure imgf000139_0001
A mixture of (6-methyl[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methanol(15.7 g, 95.6 mmol), TEMPO (1.12 mg, 7.2 mmol), iodobenzene diacetate (33.9 g, 105.2 mmol) in CH2CI2 (100 mL) was stirred at room temperature for 2 hours. Once the reaction was deemed complete, methyl- tert-butyl ether (50 mL) was added slowly to precipitate the product. The concentrated mother liquor was introduced into a silica gel column and eluted with 2% MeOH/CH2CI2 to give additional amount of the aldehyde product as a while solid (12 g, 80%). 1H NMR (300 MHz, CDCI3) δ: 2.54 (m, 3 H), 8.73 (m, 1 H), 8.85 (m, 1 H), 10.23 (m, 1 H). MS (APCI, M+H+): 163.1.
Step 1: Preparation of (6-methyl[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methanol
Figure imgf000139_0002
To a solution of (3-amino-1/-M,2,4-triazol-5-yl)methanol (16.6 g, 87.6 mmol) in acetic cid was added 3-ethoxymethacrolein (10.0 g, 87.6 mmol), and the mixture was heated to 80 °C for 4 hours. Upon cooling of the reaction, the product crystallized out of solution. The collected product was a white solid (14.0 g, 92%). H NMR (300 MHz, DMSO-D6) δ: 2.38 (m, 3 H) 4.63 (m, 2 H) 5.52 (m, 1 H) 8.75 (m, 1 H) 9.21 (m, 1 H). MS (APCI, M+H+): 163.1, 165.1.
Example A(109): (+)-2-(4-{2-[2-Cyclopentyl-5-(6-methyl-[1,2,4]triazolo[1,5-a]pyrimidin-2- ylmethyl)-4,6-dioxo-tetrahydro-pyran-2-yl]-ethyl}-2-fluoro-phenyl)-2-methyl-propionitrile
Figure imgf000139_0003
The title compound was isolated by chiral chromatography of racemic material described in Example A(108). Conditions: Chiralpak AS-RH, 150 x 4.6 mm, 0.6 mL/min, 30 °C; 40% acetonitrile, 60% water, 0.1 %> formic acid; retention time 24.5 min.
Example A(110): (-)-2-(4-{2-[2-Cyclopentyl-5-(6-methyl-[1 ,2,4]triazolo[1 ,5-a]pyrimidin-2- ylmethyl)-4,6-dioxo-tetrahydro-pyran-2-yl]-ethyl}-2-fluoro-phenyl)-2-methyl-propionitrile
Figure imgf000140_0001
The title compound was isolated by chiral chromatography of racemic material described in Example A(108). Conditions: Chiralpak AS-RH, 150 x 4.6 mm, 0.6 mL/min, 30 °C; 40% acetonitrile, 60% water, 0.1% formic acid; retention time 17.99 min.
Example A(111 ): 2-(4-{2-[5-(6-Chloro-[1 ,2,4]triazolo[1 ,5-a]pyrimidin-2-ylmethyl)-2- cyclopentyl-4,6-dioxo-tetrahydro-pyran-2-yl]-ethyl}-2-fluoro-phenyl)-2-methyl-propionitrile
Figure imgf000140_0002
The title compound was prepared analogously to Example A(97), where 6-Chloro- [1,2,4]triazolo[1,5-a]pyrimidine-2-carbaldehyde was substituted in place of 2-ethyl-4-methyl-1 H- imidazole-5-carbaldehyde in the final step of that example. 1H NMR (400 MHz, CDCI3) δ: 1.47 -
1.71 (m, 8H), 1.75 (s, 6H), 2.00 (m, 2H), 2.39 (m, 1H), 2.65 (dd, 7 = 101, 17.9 Hz, 2H), 2.68 (m, 2H), 4.11 (m, 2H), 6.87 (d, 7 = 11.6 Hz, 1H), 6.93 (d, 7 = 6.6 Hz, 1H), 7.35 (t,7= 8.3 Hz, 1H), 8.79 (s, 1H), 8.88 (s, 1H). MS (ESI): 539.1(M+H+).
Step 2: Preparation of Compound 6-chloro[1,2,4]triazolo[1,5-a]pyrimidine-2-carbaldehyde
Figure imgf000141_0001
A mixture of (6-chloro[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methanol (9.86 g, 53.4 mmol), TEMPO (626 mg, 4.01 mmol), iodobenzene diacetate (18.9 g, 58.76 mmol) in CH2CI2 (75 mL) was stirred at room temperature for 2 hours. Once the reaction was deemed complete, methyl- tert-butyl ether (50 mL) was added slowly to precipitate the product, as a while solid (8.72 g,
90%). 'H NMR (300 MHz, CDC13) δ: 8.93 (d, 7=2.45 Hz, 1 H), 8.99 (d, 7=2.64 Hz, 1 H), 10.25 (s, 1 H). MS (APCI): 183.0, 185.0 (M+H÷).
Step 1: Preparation of compound (6-chloro[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methanol
Figure imgf000141_0002
To a slurry of (3-amino-1/-/-1,2,4-triazol-5-yl)methanol (28.5 g, 150 mmol) in acetic acid was added chloromalonaldehyde (16 g, 150 mmol). The mixture was heated to 80 °C for 4 hours. Upon cooling of the reaction to room temperature, the product crystallized out as a white solid (25.5 g, 92%>). 'HNMR (300 MHz, DMSO-D6) δ: 4.67 (s, 2 H), 5.62 (s, 1 H), 8.94 (d, 7=2.45 Hz, 1 H), 9.81 (d, 7=2.45 Hz, 1 H). MS (APCI): 185.0 (M+H÷).
Example A(112): 2-(4-{2-[2-Cyclopentyl-5-(5,7-dimethyl-[1 ,2,4]triazolo[1 ,5-a]pyrimidin-2- ylmethyl)-4,6-dioxo-tetrahydro-pyran-2-yl]-ethyl}-2-fluoro-phenyl)-2-ethyl-butyronitrile
Figure imgf000142_0001
A solution of 2-{4-[2-(2-cyclopentyl-4,6-dioxo-tetrahydro-pyran-2-yl)-ethyl]-2-fluoro- phenyl}-2-ethyl-butyronitrile (300 mg, 0.75 mmol) in anhydrous MeOH (3.0 mL) was treated with 5,7-dimethyI-[1,2,4]triazolo[1,5-a]pyrimidine-2-carbaldehyde (198 mg, 1.1 mmol), followed by borane-dimethylamine complex (62 mg, 1.05 mmol) at room temperature. The reaction was stirred for 12 hours before it was quenched by the addition of CH2CI2 (30 mL) and Amberlite IR 120(plus) (3 g). The reaction was stirred for 30 minutes, and then filtered. The filtrate was concentrated to an oil, dissolved in CH2CI2 (25 mL, and then washed with 10 mL 1 N HCl. The aqueous layer was extracted with 2 x 25 mL CH2CI2. The organic layers were combined and dried over Na2S0 . After removing the solids by filtration, the liquid was concentrated to an oil. The desired product was isolated by preparatory HPLC (76 mg, 18%). 'HNMR (400 MHz, CDC13) δ: 0.74 (t, J=7.45 Hz, 6 H), 1.37-1.59 (m, 8 H), 1.79-1.88 (m, 4 H), 1.94-2.03 (m, 2 H), 2.21 (t, J=8.84 Hz, 3 H), 2.36 (d, 7=17.94 Hz, 1 H), 2.47-2.55 (m, 5 H), 2.59-2.63 (m, 4 H), 3.95 (d, J = 3.54 Hz, 2 H), 6.66 (dd, 77=13.26 Hz, 72=1.64 Hz, 1 H), 6.72-6.75 (m, 2 H), 7.23 (t, 7=8.21 Hz, 1 H).
Step 2: Preparation of compound 2-{4-[2-(2-Cyclopentyl-4,6-dioxo-tetrahydro-pyran-2-yl)- ethyl]-2-fluoro-phenyl}-2-ethyl-butyronitrile.
Figure imgf000142_0002
The desired product was prepared analogously to step 4 of Example A(97), substituting 2-{4-[3-cyclopentyl-4-(2,2-dimethyl-6-oxo-6H-[1,3]dioxin-4-yl)-3-hydroxy-butyl]-2-fluoro-phenyl}-2- ethyl-butyronitriie from step 1 below in place of 1-{4-[3-Cyclopentyl-4-(2,2-dimethyl-6-oxo-6H- [1 ,3]dioxin-4-yl)-3-hydroxy-butyl]-2-fluoro-phenyl}-cyclopropanecarbonitrile. 'HNMR (CDC13) δ: 1.01 (t, 7= 7.45 Hz, 6H), 1.62-1.90 (br, 8H), 2.03 -2.17 (br, 4H), 2.20-2.29 (br, 2H), 2.37 (p, 7= 9.35 Hz, IH), 2.75 -2.82 (m, 2H), 2.86 (d, 7= 7.58 Hz, 2H), 3.53 (d, 7= 2.02 Hz, 2H), 6.94 (dd, J= 13.01, 1.64 Hz, IH), 7.04 (dd, 7= 7.83, 1.77 Hz, IH), 7.57 (t, 7= 8.21 Hz, IH). Step 1: Preparation of compound 2-(4-bromo-2-fluoro-phenyl)-2-ethyl-butryonitrile
Figure imgf000143_0001
The desired product was prepared analogously to step 2 of Example A(97) , substituting bromoethane in place of Mel. MS (APCI): 270 (M+H+).
Example A(113): 1-(4-{2-[2-Cyclopentyl-5-(6-methyl-[1,2,4]triazolo[1,5-a]pyrimidin-2- ylmethyl)-4,6-dioxo-tetrahydro-pyran-2-yl]-ethyl}-2-fluoro-phenyl)-cyclopropanecarbonitrile
Figure imgf000143_0002
A solution of 1-{4-[2-(2-cyclopentyl-4,6-dioxo-tetrahydro-pyran-2-yl)-ethyl]-2-fluoro- phenylj-cyclopropanecarbonitrile (568 mg, 1.54 mmol) in anhydrous MeOH (6.0 mL) was treated with 6-methyl-[1 ,2,4]triazolo[1 ,5-a]pyrimidine-2-carbaldehyde (324 mg, 2.0 mmol), followed by borane-dimethylamine complex (118 mg, 2.0 mmol) at room temperature. The reaction was stirred for 1 hour before it was cooled to -10 °C for 2 hours. The precipitate was removed by filtration, and the filtrate was concentrated to an oil. The oil was purified by flash chromatography (50g Si02, 1:3 -> 1:0 (93.5%> ethyl acetate, 6% methanol, 0.5% acetic acid) : (81.5% hexanes, 12% ethyl acetate, 6% methanol, 0.5% acetic acid)) to give the desired product as an oil. It was further purified by crystallization from ethyl acetate / hexanes to give a white powder (146 mg,
18%). 'HNMR (400 MHz, CDC13) δ: 1.41-1.64 (m, 8 H), 1.84-1.88 (m, 2 H), 2.22-2.28 (m, 2 H), 2.42 (s, 3 H), 2.49-2.59 (m, 4 H), 2.65-2.74 (m, 3 H), 3.97-4.05 (m, 2 H), 6.72-6.82 (m, 2 H), 7.05-7.10 (m, 1 H), 8.55 (s, 1 H), 8.67 (s, 1 H).
Step 2: Preparation of compound 1-{4-[2-(2-Cyclopentyl-4,6-dioxo-tetrahydro-pyran-2-yl)- ethyl]-2-fluoro-phenyl}-cyclopropanecarbonitrile.
Figure imgf000143_0003
The desired product was prepared analogously to step 4 of Example A(97), substituting 1-{4-[3-Cyclopentyl-4-(2,2-dimethyl-6-oxo-6H-[1,3]dioxin-4-yl)-3-hydroxy-but-1-ynyl]-2-fluoro- phenyl}-cyclopropanecarbonitrile [prepared analogously to step 3 of Example A(97) substituting 1-(4-bromo-2-fluoro-phenyl)-cyclopropanecarbonitrile in place of 2-(4-bromo-2-fluorophenyl)-2- methylpropanenitrile)] in place of 2-{4-[2-(2-cyclopentyl-4,6-dioxotetrahydro-2/- -pyran-2-yl)ethyl]- 2-fluorophenyl}-2-methylpropanenitrile. Η NMR (CDC13) δ: 1.27- 1.30 (m, 2H), 1.51 - 1.73 (m, 10H), 1.84 - 1.89 (m, 2H), 2.19 (p, 7= 8.08 Hz, IH), 2.58 - 2.71 (m, 4H), 3.36 (d, 7= 4.04 Hz, 2H), 6.81 - 6.86 (m, 2H), 7.16 - 7.18 (m, IH). MS (ESI): 368 (M-H).
Step 1: Preparation of compound 1-(4-Bromo-2-fluoro-phenyl)-cyclopropanecarbonitrile
Figure imgf000144_0001
The desired product was prepared analogously to step 2 of Example A(97), substituting 1,2-bromoethane in place of Mel. Η NMR (400 MHz, CDC13) δ: 1.15 (dd, 7= 5.31, 2.27 Hz, 2H), 1.48 (dd, 7= 5.05, 2.53 Hz, 2H), 6.97 - 7.12 (m, 3H).
Example A(114): 1-{4-[2-(2-Cyclopentyl-4,6-dioxo-5-[1,2,4]triazolo[1,5-a]pyrimidin-2- ylmethyl-tetrahydro-pyran-2-yl)-ethyl]-2-fluoro-phenyl}-cyclopropanecarbonitrile
Figure imgf000144_0002
A solution of 1-{4-[2-(2-cyclopentyl-4,6-dioxo-tetrahydro-pyran-2-yl)-ethyl]-2-fluoro- phenylj-cyclopropanecarbonitrile (568 mg, 1.54 mmol) in anhydrous MeOH (6.0 mL) was treated with [1 ,2,4]triazolo[1 ,5-a]pyrimidine-2-carbaldehyde (296 mg, 2.0 mmol), followed by borane- dimethylamine complex (118 mg, 2.0 mmol) at room temperature. The reaction was stirred for 1 hour and then was concentrated to an oil. The oil was purified by flash chromatography (50g Si02, 70%) ethyl acetate, 6%> methanol, 0.5% acetic acid, 23.5% hexanes) to give the desired product as an oil. It was further purified by crystallization from ethyl acetate / hexanes to give a white powder (142 mg, 18%). 'H NMR (400 MHz, CDC13) δ: 1.11-1.18 (m, 2 H), 1.31-1.52 (m, 10 H), 1.75-1.80 (m, 2 H), 2.16 (t, 7=8.84 Hz, 1 H), 2.34 (d, 7=17.68 Hz, 1 H), 2.46 (t, 7=7.83 Hz, 2 H), 2.59 (d, 7=17.94 Hz, 1 H), 3.94 (d, 7=3.79 Hz, 2 H), 6.62-6.70 (m, 2 H), 6.97 (t, 7=7.83 Hz, 1 H), 7.02-7.04 (m, 1 H), 6.82-6.85 (m, 2 H).
Example A(115): 1-(4-{2-[5-(6-Chloro-[1,2,4]triazolo[1,5-a]pyrimidin-2-ylmethyl)-2- cyclopentyl-4,6-dioxo-tetrahydro-pyran-2-yl]-ethyl}-2-fluoro-phenyl)- cyclopropanecarbonitrile
Figure imgf000145_0001
A solution of 1 -{4-[2-(2-cyclopentyl-4,6-dioxo-tetrahydro-pyran-2-yl)-ethyl]-2-fluoro- phenyl}-cyclopropanecarbonitrile (568 mg, 1.54 mmol) in anhydrous MeOH (6.0 mL) was treated with 6-chloro-[1,2,4]triazolo[1,5-a]pyrimidine-2-carbaldehyde (365 mg, 2.0 mmol), followed by borane-dimethylamine complex (118 mg, 2.0 mmol) at room temperature. The reaction was stirred for 1 hour and then was concentrated to an oil. The oil was purified by flash chromatography (50g Si02, 70% ethyl acetate, 6% methanol, 0.5% acetic acid, 23.5% hexanes). The resultant oil was further purified by flash 50g Si02, 1:3 -> 1:0 (93.5% ethyl acetate, 6% methanol, 0.5% acetic acid): (81.5% hexanes, 12% ethyl acetate, 6% methanol, 0.5% acetic acid) to give the desired product as an oil. It was further purified by crystallization from ethyl acetate / hexanes to give a white powder (48.6 mg, 6%). Η NMR (400 MHz, CDC13) δ: 1.19-1.24 (m, 2 H), 1.39-1.61 (m, 10 H), 1.83-1.87 (m, 2 H), 2.25 (t, 7=8.59 Hz, 1 H), 2.38 (d, 7=17.94 Hz, 1 H), 2.54 (t,
7=7.71 Hz, 2 H), 2.64 (d, 7=17.94 Hz, 1 H), 3.98 (d, 7=5.56 Hz, 2 H), 6.71-6.77 (m, 2 H), 7.06 (t, 7=7.83 Hz, 1 H), 8.66 (s, 1 H), 8.73 (s, 1 H).
Example A(116): (+)-2-(4-{2-[2-Cyclopentyl-5-(5,7-dimethyl-[1 ,2,4]triazolo[1 ,5-a]pyrimidin-2- ylmethyl)-4-hydroxy-6-oxo-3,6-dihydro-2H-pyran-2-yl]-ethyl}-2-fluoro-phenyl)-2-methyl- propionitrile
Figure imgf000145_0002
The desired compound was separated from racemic 2-(4-{2-[2-Cyclopentyl-5-(5,7- dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-ylmethyl)-4-hydroxy-6-oxo-3,6-dihydro-2H-pyran-2-yl]- ethyl}-2-fluoro-phenyl)-2-methyl-propionitrile (100 mg) using chiral HPLC (Chiralpak AS-RH, 150 x 4.6 mm, 0.6 mL/min, 50% CAN, 50% H20, 30 °C). (40 mg, 80 % recovery, 14.743 min retention time).
Step 1 : Preparation of (+/-) 2-(4-{2-[2-Cyclopentyl-5-(5,7-dimethyl-[1 ,2,4]triazolo[1 ,5- a]pyrimidin-2-ylmethyl)-4-hydroxy-6-oxo-3,6-dihydro-2H-pyran-2-yl]-ethyl}-2-fluoro- phenyl)-2-methyl-propionitrile
Figure imgf000146_0001
To a solution of 2-{4-[2-(2-cyclopentyl-4,6-dioxo-tetrahydro-pyran-2-yl)-ethyl]-2-fluoro- phenyl}-2-methyl-propionitrile (0.40 g, 1.1 mmol) in MeOH (7 mL) was added 5,7-dimethyl-
[1,2,4]triazolo[1,5-a]pyrimidine-2-carbaldehyde (0.19 g, 1.08 mmol) and borane-dimethylamine complex (76 mg, 1.3 mmol) and stirred at room temperature for 3 hours. The reaction was quenched with 10 mL saturated NH4CI and 5 mL water. To this was added 20 mL CH2CI2 and the pH of the aqueous phase was adjusted to 3. The layers were separated, and the aqueous layer was extracted with 3 x 30 mL 10% MeOH in CH2CI2. The organic layers were combined, and dried over Na2S0 . After filtering off the solids, the liquid was concentrated by rotary evaporation to an oil. The oil was flash chromatographed, and the resulting product was further purified by preparatory HPLC. Yield: 28 mg, 5%. MS (ESI): 530 (M-H).
Example A(117): (-)-2-(4-{2-[2-Cyclopentyl-5-(5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2- ylmethyl)-4-hydroxy-6-oxo-3,6-dihydro-2H-pyran-2-yl]-ethyl}-2-fluoro-phenyl)-2-methyl- propionitrile
Figure imgf000146_0002
The desired compound was separated from racemic 2-(4-{2-[2-Cyclopentyl-5-(5,7- dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-ylmethyl)-4-hydroxy-6-oxo-3,6-dihydro-2H-pyran-2-yl]- ethyl}-2-fluoro-phenyl)-2-methyI-propionitrile (100 mg) using chiral HPLC (Chiralpak AS-RH, 150 x 4.6 mm, 0.6 mL/min, 50% CAN, 50% H20, 30 °C). (38 mg, 76 % recovery, 7.536 min retention time).
Example A(118): 2-{4-[2-(2-cyclopentyl-4,6-dioxotetrahydro-2H-pyran-2-yl) ethyl]-2- fluorophenyl}-2-methylpropanenitrile.
Figure imgf000147_0001
The desired product was prepared analogously to step 4 of Example A(97), substituting 2-{4-[3-Cyclopentyl-4-(2,2-dimethyl-6-oxo-6H-[1,3]dioxin-4-yl)-3-hydroxy-but-1-ynyl]-2-fluoro- phenyl}-2-methyl-propionic acid methyl ester in place of 2-{4-[3-cyclopentyl-4-(2,2-dimethyl-4-oxo- 4/-/-1,3-dioxin-6-yl)-3-hydroxybut-1-ynyl]-2-fluorophenyl}-2-methylpropanenitrile. 1H NMR (300 MHz, CDCI3) δ: 1.30-1.74 (m, 16H), 1.82-1.84 (m, 1H), 2.50-2.65 (m, 4H), 3.31 (s, 2H), 3.56 (s, 3H), 6.71 (t, 7=10.0 Hz, 1H), 7.08 -7.21 (m, 2H). MS(ESI): 403(M-H).
Step 3: 2-{4-[3-cyclopentyl-4-(2,2-dimethyl-6-oxo-4r -1,3-dioxin-4-yl)-3-hydroxybut-1-2- fluoro-phenyl]-2-methyl-propionic acid methyl ester
Figure imgf000147_0002
The desired product was prepared analogously to step 3 of Example A(97), substituting
2-(4-Bromo-2-fluoro-phenyl)-2-methyl-propionic acid methyl ester in place of 2-(4-bromo-2- fluorophenyl)-2-methylpropanenitrile . Η NMR (CDC13) δ: 1.48 (s, 6 H), 1.48 - 1.76 ( , 14 H), 2.16- 2.18 (m, IH), 2.54 (s, IH), 2.58 (d, 7=2.8 Hz, 2H), 3.60 (s, 3H), 5.39 (s, IH), 6.97 -7.21 (m, 3H). MS(ESI): 457 (M-H). Step 2: 2-(4-Bromo-2-fluoro-phenyl)-2-methyl-propionic acid methyl ester
Figure imgf000148_0001
The desired product was prepared analogously to step 2 of Example A(97). 1H NMR (300 MHz, CDCI3) δ: 1.47 (s, 6 H), 3.65 (s, 3H), 7.11- 7.23 (m, 3H).
Step 1: Preparation of compound (4-Bromo-2-fluoro-phenyl)-acetic acid methyl ester
Figure imgf000148_0002
MeOH (16mmol, 0.81 ml), TMSCI (20mmol, 2.13g) and (4-bromo-2-fluorophenyl) acetonitrile (10mmol, 2.13g) were sequentially added to a dry flask under a nitrogen atmosphere at room temperature. The reaction mixture was heated at 50 °C for 4 hours. After being cooled to room temperature, water (20mmol, 0.36ml) was added to the mixture, followed by the addition of Na2C03 (10mmol, 1.06g) and CH2CI2 (10ml). Drying over MgS04 and concentrating at low pressure afforded product (0.85 g, 35% yield). 1H NMR (300 MHz, CDCI3) δ: 3.57 (s, 2 H), 3.65 (s, 3H), 7.08 (t, 7=8.3 Hz, 1H), 7.16 -7.21 (m, 2H).
Example A(119) 6-Cyclopentyl-3- (5,7-dimethyl- [1,2,4] triazolo[1,5-a]pyrimidin-2- ylmethyl)-6-{2-[3-fluoro-4-(2-hydroxy-ethyl)-phenyl]-ethyl}-4-hydroxy-5,6-dihydro-pyran-2- one
Figure imgf000149_0001
A solution of 6-CycIopentyl-6-{2-[3-fluoro-4-(2-hydroxy-ethyl)-phenyl]-ethyl}-dihydro- pyran-2, 4-dione (270 mg, 0.73 mmol) in anhydrous MeOH (7.0 mL) was treated with 1A7- pyrazole-4-carbaldehyde (122 mg, 1.46 mmol), followed by addition of borane-dimethylamine complex (62 mg, 1.05 mmol) at room temperature. The reaction was stirred for 12 hours before it was quenched by the addition of 1 N HCl. The mixture was extracted with 10% MeOH in CH2CI2 (3 x 10 mL), and the combined organic layers were washed with brine, then dried over MgS0 . The solvent was removed, and the residue was purified by chromatography (80:14:6:0.5 of EtOAc:Hexane:MeOH:Acetic acid) to give the product (23 mg, 6.5% yield). 1H NMR (CDCI3) δ: 1.19-1.69 (m, 10 H), 2.61 (s, 3H), 2.79 (s, 3H), 3.40-3.43 (m, 1H), 3.6-3.64 (m, 2H), 3.80-3.84 (m, 2H), 4.19-4.24 (m, 2H), 5.03 (m, 2H), 6.88 (s, 1H), 7.15-7.18 (m, 1H), 7.50-7.55 (m, 1H), 7.70 - 7.73 (m, 1H). MS(ESI): 507 (M-H).
Example A(120): 6-Cyclopentyl-6- 2-[3-f luoro-4- (2-hydroxy-ethyl)-phenyl]-ethyl}-dihydro- pyran-2, 4-dione
Figure imgf000149_0002
The desired product was prepared analogously to step 4 of Example A(97), substituting
6-{2-Cyclopentyl-4-[3-fluoro-4-(2-hydroxy-ethyl)-phenyl]-2-hydroxy-butyl}-2,2-dimethyI-[1,3]dioxin- 4-one in place of 2-{4-[3-cyclopentyl-4-(2,2-dimethyl-4-oxo-4H-1,3-dioxin-6-yl)-3-hydroxybut-1- ynyl]-2-fluorophenyl}-2-methylpropanenitrile. 1H NMR (CDCI3) δ: 1.20 (t, 7=6.95 Hz, 1 H), 1.41 - 1.79 (m, 7 H), 1.87 - 2.00 (m, 2 H), 2.26 (m, 1 H), 2.65 (t, 7=8.34 Hz, 2 H), 2.75 (d, 7=2.53 Hz, 2 H), 2.87 (t, 7=6.44 Hz, 2 H), 3.41 (d, 7=2.27 Hz, 2 H), 3.47 (q, 7=7.07 Hz, 1 H), 3.84 (t, 7=6.57 Hz, 1 H), 6.82 (d, 7=10.86 Hz, 1 H), 6.86 (d, 7=7.58 Hz, 1 H), 7.15 (t, 7=7.71 Hz, 1 H). MS (ESI): 347 (M-H).
Step 3: 6-{2-Cyclopentyl-4-[3-fluoro-4-(2-hydroxy-ethyl)-phenyl]-2-hydroxy-but-3-ynyl}-2,2- dimethyl-[1 ,3]dioxin-4-one
Figure imgf000150_0001
The desired product was prepared analogously to step 3 of Example A(97), substituting 2-(4-Bromo-2-2-fluoro-phenyl)-ethanol in place of 2-(4-bromo-2-fluorophenyl)-2- methylpropanenitrile. 1H NMR (CDCI3) δ: 1.25 (t, 7=7.20 Hz, 1 H), 1.36 - 1.41 (m, 2 H), 1.55 - 1.60 (m, 3 H), 1.65 - 1.70 (m, 3 H), 1.71 (s, 3 H), 1.72 (s, 3 H), 1.78 - 1.83 (m, 2 H), 2.90 (t, 7=6.44 Hz, 2 H), 3.47 (q, 7=6.99 Hz, 1 H), 3.85 (t, 7=6.57 Hz, 2 H), 5.45 (s, 1 H), 7.04 (d, 7=10.11 Hz, 1 H), 7.09 (d, 7=7.83 Hz, 1 H), 7.19 (t, 7=7.58 Hz, 1 H). MS (ESI): 401 (M-H).
Step 2: 2-(4-Bromo-2-2-fluoro-phenyl)-ethanol
Figure imgf000150_0002
In a dried flask equipped with a reflux condenser and an argon line, 2-(4-Bromo-2-fluoro- phenyl)-acetic acid (1.35 g, 5.78 mmol) was dissolved in THF. To this solution, a solution of IMBH3THF (11.57 ml, 11.57 mmol) was added at 0 °C for 4 hours. The reaction mixture was diluted with cold water (15 ml), washed with a saturated solution of NaHC03 (15 ml), and extracted with ether (3x20 ml). The combined organic layers were washed with brine and dried over MgS04. The solvent was removed, and the residue was purified by flash column chromatography (1-50% EtOAc in Hexane) to give the product (0.52 g, 41.0% yield). 1H NMR (CDCI3) δ: 2.80(t, J=6.0 Hz, 2H), 3.78 (t, J=6.5 Hz, 2H), 7.06 (t, J=8.4 Hz, 1H), 7.14 -7.18 (m, 2H).
Step 1 : 2-(4-Bromo-2-2-fluoro-phenyl)-acetic acid
Figure imgf000151_0001
A mixture of (4-bromo-2-fluorophenyl)acetonitrile (8.55 g, 40 mmol) from step 1 in Example A (97); Potassium hydroxide (11.52 g, 320 mmol); Ethanol (80 ml) and water (16 ml) was heated at 70 °C for 24 hours. The mixture was then diluted with water (50 ml), and subsequently extracted with ether (3x 75 ml). The pH of the aqueous layer was adjusted to approximately 3 with dropwise addition of 1N H2S0 . After the aqueous layer was extracted with ether (3X125 ml), the combined organic layers were washed with brine and dried over MgS04. The solvent was removed to give product (4.50 g, 48% yield). 1H NMR (CDCI3) δ: 3.60 (s, 2H), 7.07-7.22 (m, 3H).
Example A(121): 6-Cyclopentyl-6- {2-[3-fluoro-4-(2-hydroxy-1,1-dimethyl-ethyl)-phenyl]- ethyl}-dihydro-pyran-2,4-dione
Figure imgf000151_0002
The desired product was prepared analogously to step 4 of Example A(97), substituting
6-{2-Cyclopentyl-4-[3-fluoro-4-(2-hydroxy-1,1-dimethyl-ethyI)-phenyl]-2-hydroxy-butyl}-2,2- dimethyl-[1 ,3]dioxin-4-one (1.70 g, 3.91 mmol) in place of 2-{4-[3-cyclopentyl-4-(2,2-dimethyl-4- oxo-4H-1 ,3-dioxin-6-yl)-3-hydroxybut-1-ynyl]-2-fluorophenyl}-2-methylpropanenitrile. 1H NMR (CDCI3) δ: 1.35 (s, 6 H), 1.52 - 1.78 (m, 8 H), 1.90 - 1.99 (m, 2 H), 2.27 (m, 1 H), 2.65 (t, 7=8.34 Hz, 2 H), 2.74 (d, 7=2.27 Hz, 2 H), 3.40 (d, 7=1.77 Hz, 2 H), 3.75 (s, 2 H), 6.80 (dd, 7=13.64, 1.77 Hz, 1 H), 6.88 (dd, 7=8.08, 1.77 Hz, 1 H), 7.22 (d, 7=8.59 Hz, 1 H). MS (ESI): 375 (M-H). Step 3: 6-{2-Cyclopentyl-4- [3-fluoro-4- (2-hydroxy-1,1-dimethyl-ethyl)-phenyl]-2-hydroxy- but-3-ynyl}-2,2-dimethyl-[1 ,3]dioxin-4-one )
Figure imgf000152_0001
The desired product was prepared analogously to step 3 of Example A(97), substituting 2-(4-Bromo-2-fluoro-phenyl)-2-methyl-propan-1-ol in place of 2-(4-bromo-2-fluorophenyl)-2- methylpropanenitrile. 1H NMR (CDCI3) δ: 1.35 (s, 6 H), 1.48 - 1.62 (m, 5 H), 1.71 (s, 3 H), 1.72 (s, 3 H), 1.77 - 1.87 (m, 2 H), 2.20 (m, 1 H), 2.61 (s, 1 H), 2.64 (d, 7=3.03 Hz, 2 H), 3.76 (d, 7=5.56 Hz, 2 H), 5.44 (s, 1 H), 7.01 (d, 7=12.88 Hz, 1 H), 7.10 (d, 7=8.08 Hz, 1 H), 7.26 (m, 1 H). MS (ESI): 429(M-H).
Step 2: 2-(4-Bromo-2-fluoro-phenyl)-2-methyl-propan-1-ol
Figure imgf000152_0002
To a solution of 2-(4-Bromo-2-fluoro-phenyl)-2-methyl-propionaldehyde (1.37 g, 5.58 mmol) in MeOH (18 ml) at 0 °C was added NaBH4 (0.21 g, 5.58 mmol). After being stirred for 2 hours at 0 °C, the mixture was allowed to warm to room temperature. The reaction mixture was diluted with water (20 ml) and extracted with ether (3 x 75 ml). The combined organic layers were dried over MgS04. The solvent was removed, and the residue was purified by flash column chromatography (15-35% EtOAc in Hexane) to give the product (1.10 g, 80.0% yield). 1H NMR (CDCI3) δ: 1.23 (s, 1 H) 1.35 (s, 3 H) 1.35 (s, 3 H) 3.75 (d, 7=1.26 Hz, 2 H) 7.17 (d, 7=2.27 Hz, 1 H) 7.20 (d, 7=3.03 Hz, 1 H) 7.22 (m, 1 H).
Step 1: 2-(4-Bromo-2-fluoro-phenyl)-2-methyl-propionaldehyde
Figure imgf000153_0001
DIBAL-H (14ml, 14.0 mmol) was added slowly to a solution of 2-(4-Bromo-2-fluoro- phenyl)-2-methyl-propionitrile (2.42 g, 10 mmol) in CH2CI2 (10 ml) at 0 °C, and the reaction mixture was stirred for 4 hours. To the reaction was added 10 ml of 1N HCl (10 ml). The layers were separated, and the aqueous layer was extracted with 3X50 ml ether. The combined organics were washed with 10 ml H20, and then dried over MgS0 . After filtering off the solids, the mother liquor was concentrated to the desired product by rotary evaporation (1.56 g, 64% yield). 1H NMR (CDCI3) δ: 1.29 (s, 6H), 7.05-7.26 (m, 3H), 9.53 (s, 1H).
Example A(122): 6-Cyclopentyl-6- [2-(3,5-difluoro-phenyl)-ethyl]-dihydro-pyran-2,4-dione
Figure imgf000153_0002
The desired product was prepared analogously to Example A(97), substituting 1-Bromo- 3, 5-difluoro-benzene in place of 2-(4-bromo-2-fluorophenyl)-2-methylpropanenitrile in step 2 of that example. 1H NMR (CDCI3, 300 MHz) δ: 1.40-1.75 (m, 8 H), 1.82-2.12 (m, 2H), 2.25-2.74 (m, 1H), 2.67-2.81 (m, 4H), 3.45-3.59 (m, 2H), 6.82-6.94 (m, 1 H), 6.95-7.06 (m, 1H), 7.25 (dd, 7=8.40, 1.70 Hz).
Example A(123): 6-Cyclopentyl-3-(5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-ylmethyl)-6- [2-(3-ethyl-5-fluoro-4-hydroxy-phenyl)-ethyl]-4-hydroxy-5,6-dihydro-pyran-2-one.
Figure imgf000153_0003
5,7-Dimethyl-[1 ,2,4]triazolo[1,5-a]pyrimidine-2-carbaldehyde (0.2g, 0.57mmol) was added to a solution of 6-Cyclopentyl-6-[2-(3-ethyl-5-fluoro-4-hydroxy-phenyl)-ethyl]-dihydro-pyran-2,4- dione (0.2g, 0.53 mmol) in MeOH (6 mL). The reaction mixture was stirred for 15 mins and then treated with borane-dimethylamine complex (50mg, O.δδmmoL). After 15 hours the reaction mixture was quenched with 1 N HCl and extracted with 10% MeOH in CH2CI2. The combined organic layers were concentrated and recrystallized from EtOAc to give the product as a white soild (0.15g, 52%). :H NMR (400 MHz, OMSO-d6): δ 1.09 (t, 7=7.3 Hz, 3 H), 1.43-1.72 (br m, 8 H), 2.05-2.17 (m, 2 H), 2.43 (m, 1 H), 2.48-2.58 (m, 10 H), 2.66 (d, 7=17.4 Hz, 1 H), 2.81 (d, 7=17.4 Hz, 1 H), 3.74 (d, 7=16.2 Hz, 1 H), 3.85 (d, 7=16.2 Hz, 1 H), 6.76 (s, 1 H), 6.84 (d, 7=11.6 Hz, 1 H) 7.07 (s, 1 H), 9.08 (s, 1 H), 11.01 (s, 1 H). MS: C28H32N404F (M + H+) 509.10.
Example A(124): 6-Cyclopentyl-6-[2-(3-ethyl-5-fluoro-4-hydroxy-phenyl)-ethyl]-dihydro- pyran-2,4-dione.
Figure imgf000154_0001
The title compound was prepared analogously to Example A(97) where acetic acid 4- bromo-2-ethyl-6-fluoro-phenyl ester (from step 4 below) was substituted in place of 2-(4-bromo-2- fluorophenyl)-2-methylpropanenitrile in that example. 'H NMR (400 MHz, CDC13) δ: 1.21 (t, 7=7.6 Hz, 3 H), 1.44-1.75 (m, 8 H), 1.92 (m, 2 H), 2.27 (m, 1 H), 2.58 (m, 2 H), 2.64 (q, 7=7.6 Hz, 2 H), 2.76 (m, 2 H), 3.43 (s, 2 H), 5.04 (s, 1 H), 6.68 (s, 1 H), 6.71 (d, 7=10.6 Hz, 1 H). Anal. Calcd. For C20H25O4F: C, 68.95; H, 7.23. Found: C, 68.71; H, 7.28.
Step 4: Preparation of compound Acetic acid 4-bromo-2-ethyl-6-f luoro-phenyl ester.
Figure imgf000154_0002
Acetyl chloride (0.39mL, 5.5mmol) followed by triethylamine (0.76mL, 5.5mmol) were added to a cooled 0°C solution of 2-ethyl-6-fluoro-phenol (1g, 4.5mmol, from step 3) dissolved in CH2CI2 (10mL). The reaction was stirred for 2 hrs and then partitioned between 1 N HCl and EtOAc. The organic layer was washed with saturated NaHC03, brine, dried over Na2S04and concentrated to a yellow oil. The oil was purified by silica gel chromatography (0% to 5% EtOAc in hexanes) to give the title compound as a clear oil (1g, 84%). :H NMR (400 MHz, CDC13): δ 1.18 (t, 7=7.6 Hz, 3 H), 2.35 (s, 3 H), 2.54 (q, 7=7.6 Hz, 2 H), 7.18 (m, 2 H).
Step 3: Preparation of compound 4-Bromo-2-ethyl-6-fluoro-phenol.
Figure imgf000155_0001
A solution of tetrabutyl ammonium tribromide (4.2g, 8.6mmol) in CHCI3(25mL) was added to a stirred solution of 2-ethyl-6-fluoro-phenol (1.1g, 7.9mmol) dissolved in CHCI3 (25 mL). The reaction mixture was stirred for 24 hrs and then quenched with 5% solution of sodium thiosulfate (30 mL). The biphasic mixture was stirred for 30 mins and then the layers were separated. The organic layer was washed with 1 N HCl, saturated NaHC03, brine, dried over Na2S04 and concentrated. The crude residue was purified by flash column chromatography (0 - 10% EtOAc in hexanes) to give the desired product (1g, 60%). 'HNMR (400 MHz, CDC13): δ 1.21 (t, 7=7.6 Hz, 3 H), 2.65 (q, 7=7.6 Hz, 2 H), 5.09 (d, 7=4.8 Hz, 1 H), 7.06 (s, 1 H), 7.09 (d, 7=11.9 Hz, 1 H).
Step 2: Preparation of compound 2-Ethyl-6-fluoro-phenol.
Figure imgf000155_0002
A mixture of 2-fluoro-6-(1-hydroxy-ethyl)-phenol (1.7g, 10.9mmol) and 10 wt % Pd/C (0.85g, Degussa type) in MeOH (30mL) was stirred under a balloon of H2 for 6 hours. The reaction mixture was filtered through a pad of celite washing with EtOAc. The filtrate was concentrated to a yellow oil (1.35g, 87%). *H NMR (400 MHz, CDC13): δ 1.22 (t, 7=7.6 Hz, 3 H), 2.68 (q, 7=7.3 Hz, 2 H), 5.12 (s, 1 H), 6.76 (m, 1 H), 6.92 (m, 2 H).
Step 1: Preparation of compound 2-Fluoro-6-(1-hydroxy-ethyl)-phenol.
Figure imgf000155_0003
Methyl lithium (25.5mL, 35.7mmol, 1.4M in ether) was added to a cooled -78°C solution of 3-fluorosalicylaldehyde (2g, 14.3mmol) dissolved in THF (50mL). The reaction mixture was stirred for 3 hours and then warmed up to room temperature. After 3 hours the reaction was quenched with saturated NH4CI and extracted with EtOAc. The organic extracts were washed with 1N HCl, brine, dried over Na2S04and concentrated to an oil. The oil was purified by flash column chromatography (0% to 20%> EtOAc in hexanes) to give the title compound as a clear oil (2.2g, 99%). Η NMR (400 MHz, CDC13): δ 1.58 (d, 7=6.6 Hz, 3 H), 2.68 (s, 1 H), 5.13 (m, 1 H), 6.78 (td, 7=7.8, 4.8 Hz, 1 H), 6.87 (d, 7=7.6, 1 H), 6.99 (m, 1 H), 7.33 (s, 1 H).
Example A(125): 6-CycIopentyl-6-[2-(3-ethyl-5-fluoro-4-hydroxy-phenyl)-ethyl]-4-hydroxy-3- (6-methyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-ylmethyl)-5,6-dihydro-pyran-2-one.
Figure imgf000156_0001
The title compound was prepared analogously to Example A(123), where 6-Methyl- [1,2,4]triazolo[1,5-a]pyrimidine-2-carbaldehyde was substituted in place of 5,7-Dimethyl- [1,2,4]triazolo[1,5-a]pyrimidine-2-carbaldehyde. 'H NMR (400 MHz, OMSO-d6) δ: 1.14 (t, 7=7.6 Hz, 3 H), 1.41-1.75 (m, 8 H), 2.13 (m, 2H), 2.41 (s, 3 H), 2.44 (m, 1 H), 2.47-2.62 (m, 4 H), 2.72 (d, 7=17.7 Hz, 1 H), 2.82 (d, 7=17.7 Hz, 1 H), 3.78 (d, 7=16.2 Hz, 1 H), 3.86 (d, 7=16.2 Hz, 1 H), 6.80 (s, 1 H), 6.86 (d, 7=11.6 Hz, 1 H), 8.74 (s, 1 H), 8.90 (s, 1 H), 9.13 (s, 1 H), 10.93 (s, 1 H). MS:
Figure imgf000156_0002
(M - H) 493.20.
Example A(126): 6-Cyclopentyl-6-[2-(3-ethyl-4-hydroxy-phenyl)-ethyl]-4-hydroxy-3-(6- methyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-ylmethyl)-5,6-dihydro-pyran-2-one
Figure imgf000156_0003
A solution of 6-Cyclopentyl-6-[2-(3-ethyl-4-hydroxy-phenyl)-ethyl]-dihydro-pyran-2,4-dione (150 mg, 0.45 mmol) in anhydrous MeOH (3.0 mL) was treated with 6-Methyl-[1,2,4]triazolo[1,5- a]pyrimidine-2-carbaldehyde (120 mg, 0.73 mmol), followed by borane-dimethylamine complex (40 mg, 0.68 mmol) at room temperature. The reaction was stirred for 5 hours before it was quenched by the addition of 0.5N HCl (25 mL). The mixture was extracted with 10%> MeOH in CH2CI2 (3 x 10 mL) and the combined organic layers were washed with brine, dried over Na2S0 , filtered and concentrated. The residue was purified by crystallization from EtOAc/Hexanes to give the product as a white solid (75 mg, 35% yield). JH NMR (300 MHz, OMSO-d6) δ: 1.08 (t, 7= 7.3 Hz, 3 H), 1.67 (m, 8 H), 2.07 (m, 2 H), 2.36 (s, 3 H), 2.47 (m, 7 H), 2.76 (m, 1 H), 3.81 (q, 7= 7.3 Hz, 2 H), 6.70 (m, 3 H), 8.66 (s, 1 H), 8.94 (s, 1 H), 10.78 (s, 1 H).
Step 1: Preparation of compound 6-Cyclopentyl-6-[2-(3-ethyl-4-hydroxy-phenyl)-ethyl]- dihydro-pyran-2,4-dione
Figure imgf000157_0001
This compound was prepared analogously to example A(124), using 2-ethylphenol in place of 2-Ethyl-5-fluorophenol. The result was an off white solid. XH NMR (300 MHz, CDC13): δ 1.22 (t, 3H, 7= 7.6 Hz), 1.43-1.78 (m, 8H), 1.8 -2.01 (m, 2H), 2.28 (m, IH), 2.57-2.63 (m, 4H), 2.76 (s, 2H), 3.42 (s, 2H), 4.63 (s, IH), 6.68 (d, IH, 7= 8.1 Hz), 6.84 (d, IH, 7= 8.1 Hz), 6.90 (s, IH). Anal. Calcd. For C20H26θ4O.25 H20: C, 71.72; H, 7.98. Found: C, 71.10; H, 7.99.
Example A(127): 3-(6-Chloro-[1 ,2,4]triazolo[1 ,5-a]pyrimidin-2-ylmethyl)-6-cyclopentyl-6-[2- (3-ethyl-4-hydroxy-phenyl)-ethyl]-4-hydroxy-5,6-dihydro-pyran-2-one
Figure imgf000157_0002
This compound was prepared analogously to example A(126), except that 6-Chloro- [1 ,2,4]triazolo[1 ,5-a]pyrimidine-2-carbaldehyde was used in place of 6-Methyl-[1 ,2,4]triazolo[1 ,5- a]pyrimidine-2-carbaldehyde. The result was a white solid. Η NMR (300 MHz, OMSO-d6) δ: 1.10 (t, 7= 7.3 Hz, 3 H), 1.65 (m, 8 H), 2.04 (m, 2 H), 2.47 (m, 7 H), 2.75 (m, 1 H), 3.81 (q, 7= 7.3 Hz, 2 H), 6.68 (m, 3 H), 8.82 (s, 1 H), 9.43 (s 1 H), 10.83 (brs, 1 H).
Example A(128): 6-Cyclopentyl-6-{2-[3-ethyl-4-(2-hydroxy-ethoxy)-phenyl]-ethyl}-dihydro- pyran-2,4-dione
Figure imgf000158_0001
This compound was prepared analogously to example A(124), using 2-(4-Bromo-2-ethyl- phenoxy)-ethanol in place of 2-Ethyl-4-bromo-6-fluorophenol. The result was an off white solid. 'HNMR (300 MHz, CDC13): δ 1.19 (t, 3H, 7= 7.6 Hz), 1.43-1.98 (m, 11H), 2.28 (m, IH), 2.63 (m, 4H), 2.77 (s, 2H), 3.42 (s, 2H), 4.05 (m, 4H), 6.77 (d, 7= 9.1 Hz, 1 H), 6.93 (m, 2 H).
Step 1 : Preparation of compound 2-(4-Bromo-2-ethyl-phenoxy)-ethanol
Figure imgf000158_0002
To a solution of 2-ethyl-4-bromophenol (3.5 g, 17.4 mmol) and ethylene carbonate (3.22 g, 37 mmol) in NMP (60 mL) was added potassium carbonate (5.17 g, 37.4 mmol). The resulting mixture was heated to 125 °C and maintained for 3h. The reaction was cooled and poured into water (250 mL) and extracted with EtOAc (2X 100 mL). The combined organics were washed with brine, dried over Na2S04, filtered and concentrated. The residue was purified by flash column chromatography (10-20 % EtOAc in hexanes) to give the product (3.5 g, 82% yield) as a clear oil. Η NMR (300 MHz, CDC13) δ: 1.19 (t, 7= 7.6 Hz, 3 H), 1.89 (brs, 1 H), 2.61 (q, 7= 7.6 Hz, 2 H), 4.05 (m, 4 H), 6.70 (d, 7= 8.7 Hz, 1 H), 7.24 (m, 2 H).
Example A(129): 6-Cyclopentyl-6-[2-(3-fluoro-4-hydroxy-phenyl)-ethyl]-dihydro-pyran-2,4- dione
Figure imgf000159_0001
This compound was prepared analogously to example A(124), using 4-Bromo-2-fluoro- phenol in place of 2-Ethyl-4-bromo-6-fIuorophenol. The result was an off white solid. 'HNMR (300 MHz, CDC13): δ: 1.42-1.78 (m, 8 H), 2.01 (m, 2 H), 2.28 (m, 1 H), 2.63 (m, 2 H), 2.76 (s, 2 H), 3.42 (s, 2 H), 4.63 (s, 1 H), 6.74 (d, 7= 8.1 Hz, 1 H), 6.86 (d, 7= 8.1 Hz, 1 H), 7.13 (s, IH).
Example A(130): 6-Cyclopentyl-6-[2-(3-cyclopropyl-4-methoxy-phenyl)-ethyl]-dihydro- pyran-2,4-dione
Figure imgf000159_0002
This compound was prepared analogously to example A(124), using 4-Bromo-2- cyclopropyl-1-methoxy-benzene in place of 2-Ethyl-4-bromo-6-fluorophenol. The result was an off white solid. Η NMR (300 MHz, CDC13): δ: 0.64 (m, 2 H), 0.91 (m, 2 H), 1.69 (m, 10 H), 2.13 (m, 1 H), 2.26 (m, 1 H), 2.57 (t, 7= 8.5 Hz, 2 H), 2.76 (s, 2 H), 3.41 (s, 2 H), 3.84 (s, 3 H), 6.60 (s, 1 H), 6.77 (d, 7= 8.1 Hz, 1 H), 6.89 (d, 7= 8.1 Hz, 1 H).
Example A(131 ): 6-cyclopentyl-3-[(5,7-dimethyl[1 ,2,4]triazolo[1 ,5-a]pyrimidin-2-yl)methyl]- 6-[2-(3-fluoro-4-{methyl[methyl(dimethylene)-l6-sulfanyl]amino}phenyl)ethyl]-4-hydroxy-5,6- dihydro-2H-pyran-2-one
Figure imgf000159_0003
5,7-Dimethyl-[1,2,4]triazolo[1,5-a]pyrimidine-2-carbaldehyde (0.072g, 0.41 mmol) was added to a solution of 6-cyclopentyl-6-[2-(3-fluoro-4-{methyl[methyl(dimethylene)-6- sulfanyl]amino} phenyl) ethyl] dihydro-2H-pyran-2,4(3H)-dione (0.14g, 0.34 mmol ) in MeOH (10 mL). The reaction mixture was stirred for 15mins and then treated with borane-dimethylamine complex (30mg, 0.51 mmoL). After 15 hours the reaction mixture was quenched with concentrated HCl, and concentrated to a residual oil. Purification by flash column chromatography (EtOAc then 0%-5% MeOH in CH2CI2) gave the product as a white solid (100mg, 51%). Η NMR (CDC13): δ 1.40-2.24 (brm, 11H), 2.60 (s, 3H), 2.73 (m,5H); 2.94 (s, 3H), 3.10 (m, 5H), 3.50(m, 2H), 3.74 (m, IH), 6.77 (t, 7= 15.07 Hz, IH), 6.95 (m, 2H), 7.05 (m, IH). Anal. Calcd. For Q^OsNsSF: C, 58.83; H, 5.99, N, 12.25. Found: C, 58.94; H, 6.07, N, 12.13.
Example A(132): 6-cyclopentyl-6-[2-(3-f luoro-4-{methyl[methyl(dimethylene)-6- sulfanyl]amino} phenyl)ethyl]dihydro-2H-pyran-2,4(3H)-dione
Figure imgf000160_0001
The title compound was prepared analogously to Example A(97), where Λ/-(4- bromophenyl)-Λ/-methylmethanesulfonamide (from step 1 below) was substituted in place of 2-(4- bromo-2-fluorophenyl)-2-methylpropanenitrile in step 3 of that example. Η NMR (CDC13): δ 1.40- 1.80 (brm, 8H), 2.01-2.69 (m, 3H), 2.78-2.83 (m, 3H), 2.94 (m, 4H), 3.10 (m, 5H), 6.77 (t, 7= 12.07 Hz, IH), 6.95 (d, 7= 2.09 Hz, IH), 7.05 (m, IH). Anal. Calcd. For C20H26O5NSF: C, 58.38; H, 6.37, N, 3.40. Found: C, 58.64; H, 6.46, N, 3.13.
Step 1: Preparation of compound N-(4-bromo-2-fluorophenyl)-W- methylmethanesulfonamide
Figure imgf000160_0002
Methane sulfonyl chloride (2.03ml, 26mmol) was added to a solution of 4-bromo-2- fluoroaniline (5.0g, 26mmol) and pyridine (2.12ml, 26mmol) in dichloromethane (100ml) at 0°C. The reaction mixture was stirred for 1 hr, after which time it was partitioned between dichloromethane (100ml) and 1N hydrochloric acid (100ml). The organics were separated and dried over magnesium sulfate, filtered and concentrated in vacuo to afford a yellow oil. The crude oil was dissolved in dimethylformamide (50mL) and treated with potassium carbonate (5.1g, 37.5mmol) followed by methyl iodide (2.33ml, 37.4mmol). The reaction mixture was stirred for 24hrs after which time it was partitioned between diethylether (100ml) and water (100ml). The aqueous was extracted further with diethyl ether (2x100ml). The combined organics were dried over magnesium sulfate, filtered and the solvent concentrated in vacuuo to afford the title compound as a brown oil (6.9g). *H NMR (CDC13): δ 2.94 (s, 3H), 3.10 (s, 3H), 6.77 (t, 7= 4,96 Hz, IH), 6.95 (d, 7= 4.96 Hz, IH), 7.05 (m, IH).
Example A(133): 6-cyclopenty l-3-[(5,7-dimethyl[1 ,2,4]triazolo[1 ,5-a]pyrimidin-2-yl)methyl]-
4 4--hhyyddrrooxxyy--66--[[22--((<4-{methyl[methyl(dimethylene)-l6-sulfanyl]amino}phenyl)ethyl]-5,6-dihydro-
2W-pyran-2-one
Figure imgf000161_0001
The title compound was prepared analogously to Example A(131), where Λ/-{4-[2-(2- cyclopentyl-4,6-dioxotetrahydro-2H-pyran-2-yl) ethyl] phenyl}-/V-methylmethanesulfonamide (from step 1 below) was substituted in place of 6-cyclopentyl-6-[2-(3-fluoro-4-
{methyI[methyl(dimethylene)-6-sulfanyl]amino} phenyl) ethyl] dihydro-2H-pyran-2,4(3H)-dione. Η NMR (CDC13): δ 1.40-1.80 (brm, 8H), 2.05-2.20 (m, 4H), 2.62 (s, 3H), 2.67 (m, 5H), 2.94 (s, 3H), 3.04 (m,
5H), 4.02 (s, 2H), 6.95 (m, 3H), 7.24 (s, 2H). Anal. Calcd. For C28H35θ5N5S: C, 60.74; H, 6.37, N, 12.65.
Found: C, 61.04; H, 6.46, N, 12.33.
Step 1: Preparation of compound W-{4-[2-(2-cyclopentyl-4,6-dioxotetrahydro-2H-pyran-2- yl)ethyl]phenyl}-Λ -methylmethanesulfonamide
Figure imgf000161_0002
The title compound was prepared analogously to Example A(132), (where 4-bromo- aniline was used in place of 4-bromo-2-fluoroaniline in that example. 'HNMR CDClj): δ 1.4-2.24 (brm, 1 IH), 2.60-2.89 (brm, 4H), 2.94 (s, 3H), 3.04 (m, 5H), 6.96 (dd, 7= 4,96 Hz, 2H), 7.23 (dd, 7= 4.96 Hz, 2H). Anal. Calcd. For C20H27NO5S: C, 61.04; H, 6.91; N, 3.56. Found: C, 61.35; H, 6.94; N, 3.20.
Example A(134): Preparation of compound 6-cyclopentyl-6-{2-[4-(1,1-dioxidoisothiazolidin- 2-yl)-3-fluorophenyl]ethyl}dihydro-2H-pyran-2,4(3H)-dione
Figure imgf000162_0001
The title compound was prepared analogously to Example A(97),where 2-(4-bromo-2- fluorophenyl)isothiazolidine 1,1 -dioxide (from step 2 below) was substituted in place of 2-(4- bromo-2-fluorophenyl)-2-methylpropanenitrile of that example. *H NMR (CDC13): δl.4-2.54 (brm, 12H), 2.80-2.99 (brm, 3H), 3.06 (m, 3H), 3.50 (m, 2H), 4.00 (m, 2H), 6.86 (m, 2H), 7.03 (d, 7= 2.96 Hz, IH). Anal. Calcd. For C2ιH26N05SF: C, 59.56; H, 6.19; N, 3.31. Found: C, 59.57; H, 6.24; N, 3.20.
Step 2: Preparation of compound 2-(4-bromo-2-fluorophenyl)isothiazolidine 1,1 -dioxide
Figure imgf000162_0002
Λ/-(4-bromo-2-fluorophenyl)-3-chloropropane-1-sulfonamide (8.27g, 0.025M) and potassium carbonate (5.1 Og, 0.0375M) was dissolved in dimethylformamide (50ml) at room temperature under an atmosphere of nitrogen. The reaction mixture was stirred for a further 24hrs after which time it was partitioned between diethylether (500ml) and water (500ml). The organics were washed with 1N HCl (300mi) and then water (100ml) The organics were then dried over magnesium sulfate, filtered and the solvent concentrated in vacuuo to afford the title compound as a brown oil (9.0g). Η NMR (CDC13): δ 2.40-2.50 (m, 2H), 3.25-3.40 (m, 2H), 4.00 (m, 2H); 6.78 (m, 2H), 7.10 (d, 7= 2.56 Hz, IH),).
Step 1: Preparation of compound Λ/-(4-bromo-2-fluorophenyl)-3-chloropropane-1- sulfonamide
Figure imgf000163_0001
3-chIoropropane-1-sulfonyl chloride (3.16ml, 0.026M) was added to a solution of 4- bromo-2-fluoroaniline (5.00g, 0.026M) and pyridine (2.12ml, 0.026M) in dichloromethane (100ml) at 0°C. The reaction mixture was stirred for 1hr, after which time it was partitioned between dichloromethane (100ml) and 1N hydrochloric acid (100ml). The organics were separated and dried over magnesium sulfate, filtered and concentrated in vacuuo to afford the title compound as a yellow oil (8.3g). Η NMR (CDC13): δ 2.54 (m, 2H), 2.90 (m, 2H), 3.64 (d, 7= 2.56 Hz, 2H), 6.91 (d, 7 = 3.56 Hz, IH), 7.07 (m, 2H).
Example A(135): 6-cyclopentyl-6-[2-(3-cyclopentyl-4-hydroxyphenyl)ethyl]-3-[(5,7- dimethyl[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-4-hydroxy-5,6-dihydro-2H-pyran-2-one
Figure imgf000163_0002
The title compound was prepared analogously to Example A(131 ) where 6-cyclopentyl-6-
[2-(3-cyclopentyl-4-hydroxyphenyl)ethyl]dihydro-2W-pyran-2,4(3/-/)-dione (from step 1 below) was substituted in place of 6-cyclopentyl-6-[2-(3-fluoro-4-{methyl[methyl(dimethylene)-6- sulfanyl]amino} phenyl) ethyl] dihydro-2tf-pyran-2,4(3H)-dione Η NMR (CDC13): δ 1.40-1.80 (brm, 16H), 2.20 (m, 3H), 2.58 (s, 3H), 2.73 (m, 5H), 3.00 (m, 3H), 4.00 (s, 2H), 6.60 (d, 7= 2.07 Hz, IH), 6.85 (d, 7= 2.07 Hz, IH), 6.99 (s, IH), 7.13 (s, IH). Anal. Calcd. For C31H38θ4N4: C, 70.16; H, 7.22, N, 10.56. Found: C, 70.54; H, 7.46, N, 10.13.
Step 1 : Preparation of compound 6-cyclopentyl-6-[2-(3-cyclopentyl-4-hydroxyphenyl) ethyl] dihydro-2H-pyran-2,4(3H)-dione
Figure imgf000164_0001
The title compound was prepared analogously to Example A(124) where 2-cyclopentyl phenol was used in place of 2-ethyl-5-fluorophenol in that example. 1H NMR (CDCI3): δ 1.43-1.85 (br m, 16H), 1.87 - 2.21, (m, 3H), 2.70-3.18 (brm, 7H), 4.95 (s, 1H), 6.60 (d, 7 = 8.1 Hz 1H), 6.84 (d, 7 = 8.1 Hz, 1H), 7.12 (s, 1H). MS(APCI): 369 (M-H).
Example A(136): 6-cyclopentyl-3-[(5,7-dimethyl[1 ,2,4]triazolo[1 ,5-a]pyrimidin-2-yl)methyl]- 4-hydroxy-6-[2-(4-hydroxy-3-propylphenyl)ethyl]-5,6-dihydro-2W-pyran-2-one
Figure imgf000164_0002
The title compound was prepared analogously to Example A(131), where 6-cyclopentyl- 6-[2-(4-hydroxy-3-propylphenyl)ethyl]dihydro-2H-pyran-2,4(3H)-dione (from step 1 below) was substituted in place of 6-cyclopentyl-6-[2-(3-fluoro-4-{methyl[methyl(dimethylene)-6- sulfanyl]amino} phenyl) ethyl] dihydro-2tf-pyran-2,4(3/-/)-dione. Η NMR (CDC13): δ 1.00 (t, 7= 7.54 Hz, 3H), 1.40-1.80 (brm, 10H), 2.00-2.18(m, 5H)52.59 (s, 3H), 2.73 (m, 5H), 2.95 (m, 2H), 4.00 (s, 2H), 6.67 (d, 7= 5.78 Hz, IH), 6.95 (m, 2H), 7.21 (s, IH). Anal. Calcd. For C29H36θ4N4: C, 69.02, H, 7.19, N, 11.10. Found: C, 69.23; H, 7.43, N, 11.31.
Step 1: 6-cyclopentyl-6-[2-(4-hydroxy-3-propylphenyl)ethyl]dihydro-2H-pyran-2,4 (ZH) - dione
Figure imgf000165_0001
The title compound was prepared analogously to Example A(124), where 2-propylphenol was used in place of 2-ethyl-5-fluorophenol in that example. Η NMR (CDC13): δ 1.00 (t, 7= 8.1Hz 3H,), 1.33-1.85 (brm, 8H), 1.87-2.01 (m, 2H), 2.22 (m, 3H), 2.30 (m, 2H), 2.60-3.10 (brm, 6H), 5.78 (s, IH), 6.70 (d, 7= 2.07 Hz IH), 6.80 (s, IH), 6.85 (d, 7= 2.07 Hz, IH). MS (APCI): 343 (M-H).
Example A(137): 6-cyclopentyl-3-[(5,7-diethyl[1 ,2,4]triazolo[1 ,5-a]pyrimidin-2-yl)methyl]-4- hydroxy-6-[2-(4-hydroxy-3-propylphenyl)ethyl]-5,6-dihydro-2H-pyran-2-one
Figure imgf000165_0002
The title compound was prepared analogously to Example A(131), where 6-cycIopentyl- 6-[2-(4-hydroxy-3-propylphenyI)ethyl]dihydro-2/-/-pyran-2,4(3H)-dione was substituted in place of 6-cyclopentyl-6-[2-(3-fluoro-4-{methyl[methyl(dimethylene)-6-sulfanyl]amino} phenyi) ethyl] dihydro-2/-/-pyran-2,4(3H)-dione and 5,7-diethyl[1 ,2,4]triazoIo[1 ,5-a]pyrimidine-2-carbaldehyde was substituted in place of 5,7-Dimethyl-[1,2,4]triazolo[1,5-a]pyrimidine-2-carbaldehyde. 'HNMR (CDC13): δ 1.00 (t, 7= 7.54 Hz, 3H), 1.40-1.80 (brm, 16H), 2.00-2.18(m, 5H), 2.59 (m, 2H), 2.73 (m, 4H), 2.95 (m, 2H), 4.00 (s, 2H), 6.67 (d, 7= 5.78 Hz, IH), 6.95 (m, 2H), 7.21 (s, IH). Anal. Calcd. For C32H40O4N4: C, 70.56; H, 7.40; N, 10.29. Found: C, 70.23; H, 7.69; N, 10.31.
Example A(138): 6-cyclopentyl-3-[(5,7-diethyl[1 ,2,4]triazolo[1 ,5-a]pyrimidin-2-y l)methyl]-6- [2-(3-ethyl-4-hydroxyphenyl)ethyl]-4-hydroxy-5,6-dihydro-2W-pyran-2-one
Figure imgf000166_0001
The title compound was prepared analogously to Example A(126), where 5,7- diethyl[1 ,2,4]triazolo[1 ,5-a]pyrimidine-2-carbaldehyde was substituted in place of 6-methyl- [1,2,4]triazolo[1,5-a]pyrimidine-2-carbaldehyde. 'HNMR^DC ): δ 1.40-1.90 (brm, 17H), 2.09-2.40 (m, 5H), 2.60-2.80 (m, 6H), 3.00 (m, 2H), 3.25 (m, 2H), 3.95 (m, IH), 6.64 (d, J = 5.21 Hz, IH), 6.78 (d, J = 5.21 Hz, IH), 7.00 (s, IH), 7.22 (s, IH). Anal. Calcd. For
Figure imgf000166_0002
C, 69.47; H, 7.38; N, 10.80. Found: C, 69.54; H, 7.40; N, 10.89.
Example A(139): Λ/-{2-[4-(2-{2-cyclopentyl-5-[(5,7-dimethyl[1,2,4]triazolo[1,5-alpyrimidin-2- yl)methyl]-4-hydroxy-6-oxo-3,6-dihydro-2H-pyran-2-yl}ethyl)-2- ethylphenoxy]ethyl}acetamide
Figure imgf000166_0003
The title compound was prepared analogously to Example A(131), where Λ/-(2-{4-[2-(2- cyclopentyl-4,6-dioxotetrahydro-2/-/-pyran-2-yl)ethyl]-2-ethyl phenoxy}ethyl)acetamide (from step 3 below) was substituted in place of 6-cyclopentyl-6-[2-(3-fluoro-4-{methyl[methyl(dimethylene)-6- sulfanyl]amino} phenyl) ethyl] dihydro-2H-pyran-2,4(3H)-dione. 'HNMR(CDCl3):δ 1.20 (t, 7= 9.54 Hz, 3H), 1.40-1.80 (brm, 10H), 2.00-2.40 (m, 3H), 2.60 (m, 5H), 2.87 (m, 5H), 2.99 (m, 2H), 3.35 (t, 7= 6.24 Hz, 2H), 3.80 (t; 7= 6.24 Hz, 2H), 4.02 (s, 2H), 6.65 (m, 2H), 6.95 (s, IH), 6.99 (s, IH). Step 3: Preparation of compound W-(2-{4-[2-(2-cyclopentyl-4,6-dioxotetrahydro-2H-pyran-2- yl)ethyl]-2-ethylphenoxy}ethyl)acetamide.
Figure imgf000167_0001
To a solution of {4-[3-cyclopentyl-4-(2,2-dimethyl-4-oxo-4/-M ,3-dioxin-6-yl)but-1 -ynyl]-2- ethylphenoxy}acetonitrile (1.90 g, 4.4 mmol) in EtOH (100 mL) was added Pd(OH)2 (500mg, 20 wt%). The mixture was stirred under H2 for 3 hours before it was filtered through a pad of celite. The solvent was removed and the residue was taken directly into next step without further purification. The crude mixture was dissolved in dichloromethane (10ml) and acetyl chloride (0.041ml,
0.579mmol) followed by pyridine (0.046ml, 0.579mmol) were added. The reaction mixture was stirred at room temperature for 12hours, after which time the mixture was partitioned between dichloromethane (100ml) and 1N HCl (100ml). The organics were separated, dried over sodium sulfate, filtered and concentrated in vacuuo. The crude mixture was taken on directly to the next step without further purification
The crude mixture was dissolved in anhydrous MeOH (20 mL) and treated with K2C03 (500mg). The reaction was heated at 45°C for 40 min before it was cooled down to room temperature. The crude mixture was diluted with aqueous NH CI and extracted with EtOAc (3 x 100 mL). The combined organic layers were washed with brine, dried over Na2S04. The solvent was removed and the mixture was purified by flash column chromatography (EtOAc in hexanes, 10-40 % gradient) to give the desired product (200 mg). 'HNMR(CDC13) δ: 1.23 (t, 7= 12.07 Hz, 3H) 1.60- 1.83(m, 11 H), 2.00-2.38 (m, 3 H), 2.60 (m, 2H), 2.82-3.20 (m, 6H), 3.35 (m, 2H), 3.90 (m, 2 H), 6.66(m, 2 H), 6.99 (s, IH).
Step 2: Preparation of compound {4-[3-cyclopentyl-4-(2,2-dimethyl-4-oxo-4W-1 ,3-dioxin-6- yl)but-1-ynyl]-2-ethylphenoxy}acetonitrile
Figure imgf000167_0002
To a solution (4-bromo-2-ethylphenoxy)acetonitrile (1.99g, 8.33 mmol) in diisopropylamine (9 mL) and DMF (3 mL) was added 6-(2-cyclopentyl-2-hydroxybut-3-ynyl)-2,2- dimethyl-4W-1,3-dioxin-4-one (2.00 g, 7.57 mmol), PdCI2(PPh3)2 (211 mg, 4 mol%), Cui (115 mg, 8 mol%). The mixture was heated to 90 °C for 30 min before it was cooled down to room temperature. The reaction was diluted with aqueous NH4CI, extracted with EtOAc (3 x 50 mL). The combined organic extracts were washed with brine, dried with Na2S04 and evaporated to dryness. The mixture was purified by flash column chromatography (10-50 % EtOAc in hexanes) to give the product (1.9 g). Η NMR (300 MHz, CDC13) δ: 1.23 (t, 7= 12.07 Hz, 3H) 1.35-1.80 (m, 14 H), 2.30 (m, IH), 3.50 (m, 5 H), 4.62 (s, 2 H), 4.87 (s, 1 H), 6.90 (d, 7= 2.54Hz, 1 H), 7.14 (m, 1 H), 7.38 (m, 1 H).
Step 1 : Preparation of compound (4-bromo-2-ethylphenoxy)acetonitrile
Figure imgf000168_0001
Bromoacetonitrile (1.19ml, 9.94mmol) was added to a solution of 4-bromo-2-ethylphenol (2.0g, 9.94mmol) and potassium carbonate (1.35g, 9.94mmol) in DMF (50ml). The reaction was stirred for 12hours and then partitioned between diethyl ether (200ml) and water (200ml). The organics were separated, dried over magnesium sulfate, filtered and concentrated in vacuuo to afford the title compound as a yellow oil (2.0g). 1H NMR (CDCI3): δ 1.13 (t, 7 = 12.07 Hz, 3 H), 2.45 (m, 2H), 4.84 (s, 2H), 7.03-7.10 (m, 2H), 7.21 (m, 1H).
Example A(140) 2-(4-{2-[2-Cyclopentyl-5- (5,7-dimethyl- 1,2,4 )triazolo[1 ,5-a]pyrimidin-2- ylmethyl]-4-hydroxy-6-oxo-3,6-dihydro-2H-pyran-2-yl]-ethyl]-2,6-difluoro-phenyl]-2-methyl- propionitrile
Figure imgf000168_0002
A solution of 2-{4-[2-(2-Cyclopentyl-4, 6-dioxo-tetrahydro-pyran-2-yl)-ethyl]-2,6-difluoro- phenyl}-2-methyl-propionitrile (389 mg, 1.0 mmol) in anhydrous MeOH (4.0 mL) was treated with 5,7-dimethyl[1,2,4]triazolo[1,5-a]pyrimidine-2-carbaldehyde (76.6 mg, 1.30 mmol), followed by borane-dimethylamine complex at room temperature. The reaction was stirred for 12 hours before it was quenched by the addition of 1 N HCl. The mixture was extracted with 10% MeOH in CH2CI2 (3 x 10 mL) and the combined organic layers were washed with brine, dried over MgS04. The solvent was removed and the residue was purified by flash column chromatography (80% EtOAc, 14% Hexane, 6% MeOH and 0.5% Acitic acid) to give the product (192 mg, 35% yield). 1H NMR (CDCIs) δ: 1.52 - 1.75 (m, 6 H), 1.83 (s, 3 H), 1.93 - 1.99 (m, 3 H), 2.09 (s, 3 H), 2.36 (m, 1 H), 2.45 (d, 7=17.94 Hz, 2 H), 2.60 - 2.64 (m, 2 H), 2.66 (s, 3 H), 2.72 (d, 7=6.06 Hz, 1 H), 2.78 (d, 7=7.33 Hz, 1 H), 2.79 (s, 3 H), 4.08 (s, 2 H), 6.68 (d, 7=10.86 Hz, 2 H), 6.85 (s, 1 H). MS (ESI): 548 (M-H).
Example A(141 ): 2-{4-[2-(2-Cyclopentyl-4,6-dioxo-tetrahydro-pyran-2-yl)-ethyl]-2,6-difluoro- phenyl}-2-methyl-propionitrile
Figure imgf000169_0001
The desired product was prepared analogously to step 4 in Example A(97), substituting 2-{4-[3-Cyclopentyl-4-(2,2-dimethyl-6-oxo-6H-[1,3]dioxin-4-yl)-3-hydroxy-but-1-ynyl]-2,6-difluoro- phenyl}-2-methyl-propionitrile in place of 2-{4-[3-cyclopentyl-4-(2,2-dimethyl-4-oxo-4/- ,3-dioxin- 6-yl)-3-hydroxybut-1-ynyl]-2-fluorophenyl}-2-methylpropanenitrile. 1H NMR (CDCI3) δ: 1.38 - 1.48 (m, 4 H), 1.57 - 1.77 (m, 5 H), 1.85 (s, 6 H), 1.92 (t, 7=8.59 Hz, 2 H), 2.25 (m, 1 H), 2.65 (dd, 7=15.92, 7.58 Hz, 2 H), 2.75 (dd, 7=28.80, 15.66 Hz, 2 H), 3.43 (d, 7=4.55 Hz, 2 H), 6.71 (d, 7=10.86 Hz, 1 H). MS (ESI): 388 (M-H).
Step 4: Preparation of compound 2-{4-[3-Cyclopentyl-4-(2,2-dimethyl-6-oxo-6H-
[1,3]dioxin-4-yl)-3-hydroxy-but-1-ynyl]-2,6-difluoro-phenyl}-2-methyl-propionitrile
Figure imgf000170_0001
The desired product was prepared analogously to step 3 in Example A(97), substituting
2-(4-Bromo-2,6-difluoro-phenyl)-2-methyl-propionitrile in place of 2-(4-Bromo-2-fluoro-phenyl)-2- methyl-propionitrile. 1H NMR (CDCI3) δ: 1.38 - 1.48 (m, 4 H), 1.57 - 1.77 (m, 5 H), 1.85 (s, 6 H),
1.92 (t, 7=8.6 Hz, 2 H), 2.25 (m, 1 H), 2.65 (dd, 7=15.9, 7.6 Hz, 2 H), 2.75 (dd, 7=28.8, 15.7 Hz, 2
H), 3.43 (d, 7=4.6 Hz, 2 H), 6.71 (d, 7=10.9 Hz, 1 H). MS (ESI): 442 (M-H).
Step 3: Preparation of compound 2-(4-Bromo-2, 6-difluoro-phenyl)-2-methyl- propionitrile
Figure imgf000170_0002
The desired product was prepared analogously to step 2 in Example A(97), substituting (4-Bromo-2,6-difluoro-phenyl)-acetonitrile in place of 1-(4-bromo-2-fluoro-phenyl)- acetonitrile. 1H NMR (CDCI3) δ: 1.87 (s, 6H), 7.13 (d, 7=9.3 Hz, 2 H).
Step 2: Preparation of compound (4-Bromo-2, 6-difluoro-phenyl)-acetonitrile
Figure imgf000170_0003
The desired product was prepared analogously to step 1 in Example A(97), substituting
(4-Bromo-2,6-difluoro-phenyl)-acetonitrile from step 1 below in place of 1-(4- bromo-2-fluoro- phenyl)-c acetonitrile. 1H NMR (CDCI3) δ: 3.59 (s, 2H), 7.18 (d, 7=6.6 Hz, 2 H). Step 1: Preparation of compound 5-Bromo-2-bromomethyl-1 , 3-difluoro-benzene
Figure imgf000171_0001
A solution of 5-Bromo-2-hydroxymethyl-1 , 3-difluoro-benzene (0.89g, 4.0 mmol) and 30 wt% of hydrogen bromide in acetic acid was stirred at room temperature for 90 minutes before it was poured into 80 ml of water. The mixture was extracted with pentane (3 X 50 ml) and the combined organic layers were washed with water (3 X 20 ml), dried over MgS0 and concentrated at low pressure to afford the desired product (10.0 g, 98% yield). 1H NMR (CDCI3) δ: 4.47 (s, 2H), 7.09-7.10 (m, 1H), 7.12- 7.13 (m, 1H).
Example A (142) 2-(4-{2-[2-Cyclopentyl-5- 5,7-dimethyl- [1,2,4] triazolo[1,5-a]pyrimidin-2- ylmethyl]-4-hydroxy-6-oxo-3,6-dihydro-2H-pyran-2-yl}-ethyl)-2,6-difluoro-phenyl)-2-methyl- propionitrile
Figure imgf000171_0002
The desired product was prepared analogously to Example A (140), substituting 6- Chloro-[1 ,2,4]triazolo[1 ,5-a]pyrimidine-2-carbaldehyde in place of 5,7-Dimethyl-[1,2,4]triazolo[1,5- a]pyrimidine-2-carbaidehyde. 1H NMR (CDCI3) δ: 1.57 - 1.71 (m, 4 H), 1.83 (s, 6 H), 1.94 - 2.00 (m, 3 H), 2.33 - 2.40 (m, 2 H), 2.46 (d, 7=17.68 Hz, 1 H), 2.65 (t, 7=9.09 Hz, 2 H), 2.75 (d, 7=18.19 Hz, 2 H), 3.42 (d, 7=2.02 Hz, 1 H), 3.75 (t, 7=9.35 Hz, 1 H), 4.11 (s, 2 H), 6.68 (d, 7=10.86 Hz, 2 H), 8.78 (d, 7=2.53 Hz, 1 H), 8.87 (d, 7=2.53 Hz, 1 H). MS (ESI): 555 (M-H). Example A (143) 2-(4-{2-[2-Cyclopentyl-4-hydroxy-5-(6-methyl-[1,2,4]triazolo[1,5- a]pyrimidin-2-ylmethyl)-6-oxo-3,6-dihydro-2H-pyran-2-yl]-ethyl}-2,6-difluoro-phenyl)-2- methyl-propionitrile
Figure imgf000172_0001
The desired product was prepared analogously to Example A (140), substituting 6- Methyl-[1,2,4]triazolo[1,5-a]pyrimidine-2-carbaldehyde in place of 5,7-Dimethyl-[1,2,4]triazolo[1,5- a]pyrimidine-2-carbaldehyde. 1H NMR (CDCI3) δ: 1.34 - 1.40 (m, 2 H), 1.60 - 1.73 (m, 4 H), 1.83 (s, 6 H), 1.83 - 1.86 (m, 3 H), 1.93 - 1.99 (m, 2 H), 2.37 (m, 1 H), 2.42 (d, 7=5.56 Hz, 1 H), 2.48 (s, 3 H), 2.64 (t, 7=8.34 Hz, 2 H), 2.75 (d, 7=17.94 Hz, 1 H), 4.09 (s, 2 H), 6.67 (d, 7=11.12 Hz, 2 H), 8.61 (d, 7=1.26 Hz, 1 H), 8.69 (d, 7=2.27 Hz, 1 H). MS (ESI): 534 (M-H).
Example A (144) 2-{4-[2-(2-Cyclopentyl-4-hydroxy-6-oxo-5- [1,2,4]triazolo[1,5-a]pyrimidin-2- ylmethyl-3,6-dihydro-2H-pyran-2-yl)-ethyl]-2,6-difluoro-phenyl}-2-methyl-propionitrile
Figure imgf000172_0002
The desired product was prepared analogously to Example A (140), substituting [1,2,4] Triazolo[1,5-a]pyrimidine-2-carbaldehyde in place of 5,7-Dimethyl-[1,2,4]triazolo[1,5-a]pyrimidine- 2-carbaldehyde. 1H NMR (CDCI3) δ: 1.11 (t, 7=7.1 Hz, 2H), 1.49-1.61 (m, 6H), 1.84 (s, 6H), 1.86- 1.88 (m, 1H), 1.95-1.99 (m, 1H), 2.40-2.26 (m, 1H), 2.49 (d, 7=17.94 Hz, 1H), 2.66 (t, 7=8.85 Hz, 2H), 2.77 (d, 7=17.69 Hz, 1H), 4.13 (s, 2H), 6.89 (d, 7=10.87 Hz, 2H), 7.20 (t, 7=6.06 Hz, 1 H), 8.85-8.87 (m, 2H). MS (ESI): 520 (M-H). ■\ IΔ
Example A(145): 2-{4-[2-(2-Cyclopentyl-4-methoxy-6-oxo-3,6-dihydro-2W-pyran-2-yl)-ethyl]- 2-fluoro-phenyl}-2-methyl-propionitrile.
Figure imgf000173_0001
A magnetically stirring solution of 2-{4-[2-(2-cyclopentyl-4,6-dioxotetrahydro-2H-pyran-2- yl)ethyl]-2-fluorophenyl}-2-methylpropanenitrile (- rotation, 0.15g, 0.40 mmol) was cooled to 0 °C. DBU (0.18 mL, 1.21 mmol) was added followed by Mel (0.076 mL, 1.21 mmol) and reaction was stirred at 0 °C for 1 hour. The reaction mixture was partitioned between 1N HCl and EtOAc. The layers of the resulting reaction mixture were separated and the organic layer was washed with brine (1 x 10 mL), then dried over Na2S04, filtered and concentrated in vacuo. The crude residue was purified by flash column chromatography (20% EtOAc in Hexanes) to give the desired product as a yellow oil (0.062 g, 41%). 1H NMR (400MHz, CDCI3): δ 1.18 (d, 7 = 6.5 Hz, 3H), 1.40 (d, 7 = 6.5 Hz, 3H), 1.50-1.78 (m, 8 H), 1.94-2.05 (m, 2 H), 2.18 (s, 3H), 2.64-2.73 (m, 3 H), 3.75 (s, 2 H), 5.17 (s, 1 H), 6.89-6.97 (m, 2 H), 7.35-7.40 (m, 1 H). MS (ESI): 386 (M+H).
Example A(146): 2-(2-Chloro-4-{2-[2-cyclopentyl-5-(5,7-dimethyl-[1,2,4]triazolo[1,5- a]pyrimidin-2-ylmethyl)-4-hydroxy-6-oxo-3,6-dihydro-2W-pyran-2-yl]-ethyl}-phenyl)-2- methyl-propionitrile.
Figure imgf000174_0001
The title compound was prepared analogously to Example B(97), where 2-{2-Chloro-4-[2- (2-cyclopentyl-4,6-dioxo-tetrahydro-pyran-2-yl)-ethyl]-phenyl}-2-methyl-propionitrile was substituted in place of 6-[2-(3-Chloro-5-ethyl-4-methoxy-phenyl)-ethyl]-6-cyclopentyl-dihydro- pyran-2,4-dione in that example. 1H NMR (400MHz, DMSO-d6): δ 1.39-1.64 (m, 8H), 1.67 (s, 6H), 2.01-2.05 (m, 2H), 2.36-2.46 (m, 7H), 2.51-2.57 (m, 2H), 2.69(d, 7 = 17 Hz, 2H), 3.61(d, 7 = 16 Hz, 1H), 3.72 (d, 7 = 16 Hz, 1 H), 6.94 (s, 1 H), 7.25 (s, 1H), 7.28 (s, 1 H), 7.35 (d, 7 = 8 Hz, 1H), 10.75 (s, 1H). IR (neat): 2243, 2355 (CN), 1666, 1625, 1543, 1390. Anal. Calcd. For C30H34CIN5O3-1.0 H20: C, 63.65; H, 6.41; N, 12.37. Found: C, 63.60; H, 6.30; N, 12.21. MS(ESI): 549 (M+H)+.
Example A(147): 2-{2-Chloro-4-[2-(2-cyclopentyl-4,6-dioxo-tetrahydro~pyran-2-yl)~ethyl]- phenyl}-2-methyl-propionitrile.
Figure imgf000174_0002
The title compound was prepared analogously to step 4 from Example A(97), where 2-(4- Bromo-2-chloro-phenyl)-2-methyl-propionitrile (described in step 4 below) was substituted in place of 2-(4-Bromo-2-fluoro-phenyl)-2-methyl-propionitrile in step 3 of that example. 1H NMR (400MHz, CDCI3): δ 1.39-1.71 (m, 8H), 1.81-1.87 (m, 8H), 2.10-2.15 (m, 1H), 2.59-2.68 (m, 2H), 3.51 (s, 2H), 3.75 (s, 2H), 7.11 (dd, 7 = 8.1 Hz, 1.8), 7.27 (d, 7 = 1.8 Hz, 1 H), 7.37 (d, 7 = 8.1 Hz, 1H). MS (ESI): 388 (M+H)+.
Step 4: 2-(4-Bromo-2-chloro-phenyl)-2-methyl-propionitrile
Figure imgf000175_0001
NaH (95%, 1.18 g, 49.35 mmol) was suspended in DMF (25mL) and cooled to 0 °C. 4- Bromo-2-chloro-phenyl)-acetonitrile (2.27 g, 9.87 mmol) from step 3 below, was dissolved in THF (10 mL) and slowly added via cannula and the reaction mixture stirred 20 min. Mel (6.10 mL, 98 mmol) was added and the resulting mixture was stirred overnight at room temperature. Reaction was quenched with H20 (50 mL). Solvents were removed in vacuo and residue partitioned between EtOAc and 1N HCl (50 mL). The organic phase was dried over Na2S04 and evaporated. The crude organic product was purified by flash column chromatography (5% EtOAc in hexanes) to give the product (2.23 g, 87%) as a clear oil. 1H NMR (400MHz, CDCI3): δ 7.34 (d, 7 = 8.4 Hz, 1 H), 7.43 (dd, 7 = 8.4, 2.0 Hz, 1 H), 7.61 (d, "7 = 1.8 Hz, 1 H).
Step 3: (4-Bromo-2-chloro-phenyl)-acetonitrile
Figure imgf000175_0002
To a magnetically stirring solution of 4-Bromo-1-bromomethyl-2-chloro-benzene (3.59g, 12.67 mmol) from step 2 below and tetrabutylammonium bromide (0.41 g, 1.27 mmol) in CH2CI2/H20 1:1 (60.0 mL), was added a solution of KCN (2.48g, 38.01 mmol) in H20 (30 mL). The resulting orange mixture was stirred at room temperature for 3 hours. The layers of the resulting reaction mixture were separated and the organic layer was washed with NaHC03 sat solution (3 x 50 mL), then dried over Na S04, filtered and concentrated in vacuo. The crude residue was purified by flash chromatography (30% EtOAc in Hexanes) to yield the intermediate as a clear oil (3.59 g, 100%). 1H NMR (400MHz, CDCI3): δ 3.79 (s, 2H), 7.37-7.60 (m, 3H).
Step 2: 4-Bromo-1-bromomethyl-2-chloro-benzene
Figure imgf000176_0001
To a magnetically stirring solution of 4-Bromo-2-chloro-phenyl)-methanol (2.80g, 12.67 mmol) from step 1 below in CH2CI2 (60.0 mL) under argon at 0 °C, was added carbon tetrabromide (4.41 g, 13.30 mmol) followed by triphenylphosphine (3.48 g, 13.30 mmol). The resulting mixture was stirred for 4 hours at room temperature. The resulting reaction mixture was concentrated in vacuo and the crude residue was purified by flash column chromatography (10% EtOAc in Hexanes) to yield the intermediate bromide as a clear oil (3.59 g, 100%). 1H NMR (400MHz, CDCI3): δ 4.53 (s, 2H), 7.29 (d, 7 = 8.2 Hz, 1H), 7.39 (dd, 7 = 8.2, 1.9 Hz, 1 H), 7.56 (d, 7 = 1.9 Hz, 1H).
Step 1: (4-Bromo-2-chloro-phenyl)-methanol
Figure imgf000176_0002
4-Bromo-2-chlorobenzoic acid (5 g, 21.23 mmol) was dissolved in dry THF (100 mL) and cooled to 0 °C. A 1M solution of BH3.THF in THF(31.85 mL, 31.85 mmol) was slowly added. The reaction was stirred overnight, allowing it to gradually reach room temperature. K2C03 solid (1g) and H20 (100 mL) were added and the reaction was stirred for 30 minutes. THF was evaporated and residue extracted with EtOAc (30 mL). The organic phase was washed with 1N HCl (3 x 50 mL), brine (3 x 50 mL), dried over Na2S04 and evaporated. The residue was purified by flash column chromatography (30% EtOAc in hexanes) to give the product (2.80 g, 50%) as a color less oil. 1H NMR (400MHz, CDCI3): δ 4.73 (d, 7 = 5.8 Hz, 2H), 7.37 (d, 7 = 8.1 Hz, 1 H), 7.42 (dd, 7 = 8.1 Hz, 1.7), 7.52 (d, 7 = 1.7 Hz, 1H).
Example A(148): 1-(2-Chloro-4-{2-[2-cyclopentyl-5-(5,7-dimethyl-[1,2,4]triazolo[1,5- a]pyrimidin-2-ylmethyl)-4-hydroxy-6-oxo-3,6-dihydro-2H-pyran-2-yl]-ethyl}-phenyl)- cyclopropanecarbonitrile
Figure imgf000177_0001
The title compound was prepared analogously to Example B(97), where 1-{2-Chloro-4-[2- (2-cyclopentyl-4,6-dioxo-tetrahydro-pyran-2-yl)-ethyl]-phenyl}-cyclopropanecarbonitrile (from step 2 below) was substituted in place of 6-[2-(3-Chloro-5-ethyl-4-methoxy-phenyl)-ethyl]-6- cyclopentyl-dihydro-pyran-2,4-dione in that example. 1H NMR (400MHz, DMSO-d6): δ 1.50-1.53 (m, 4H), 1.65-1.75 (m, 8H), 1.87-1.99 (m, 2H), 2.26-2.29 (m, 1H), 2.62 (s, 3H), 2.72 (s, 3H), 2.62- 2.78 (m, 3H), 2.95 (d, 7 = 17 Hz, 1H), 3.87(d, 7 = 16 Hz, 1H), 3.98 (d, 7 = 16 Hz, 1H), 7.20(s, 1H), 7.45 (dd, 7 = 7.8, 1.3 Hz, 1H), 7.55-7.59 (m, 2H), 11 (brs, 1H). Anal. Calcd. For C30H32CIN5O3-0.4 H20: C, 65.13; H, 5.98; N, 12.66. Found: C, 65.52; H, 6.02; N, 12.29. MS(ESI): 547(M+H)+. i / /
Example A(149): 1-{2-Chloro-4-[2-(2-cyclopentyl-4,6-dioxo-tetrahydro-pyran-2-yl)-ethyl]- phenyl}-cyclopropanecarbonitrile.
Figure imgf000178_0001
The title compound was prepared analogously to step 4 from Example A(97), where 1-(4- Bromo-2-chloro-phenyl)-cyclopropanecarbonitriIe (from step 1 below) was substituted in place of 2-(4-Bromo-2-fluoro-phenyl)-2-methyI-propionitrile in step 3 of that example. 1H NMR (400MHz, CDCI3): δ 1.26-1.33 (m, 4H),1.53-1.75 (m, 8H), 1.90-1.95 (m, 2H), 2.24-2.29 (m, 1H), 2.64-2.69 (m, 2H), 2.77 (d, 7 = 6.5 Hz, 2H), 3.43 (d, 7 = 3.5 Hz, 2H), 7.03 (dd, 7 = 7.8, 1.7 Hz, 1H), 7.23 (d, 7 = 1.7 Hz, 1 H), 7.26 (d, 7 = 7.8 Hz, 1H).' IR (neat): 3084, 2931 (CN), 1584, 1561, 1466. Anal. Calcd. For C22H24CINO3-0.25H2O: C, 67.69; H, 6.33; N, 3.59. Found: C, 67.55; H, 6.34; N, 3.58. MS(ESI): 384(M+H)+.
Step 1 : 2-(4-Bromo-2-chloro-phenyl)-2-methyl-propionitrile
Figure imgf000178_0002
The title compound was prepared analogously to step 4 from Example A(147), where 1- Bromo-2-chloroethane was substituted in place of methyl iodide of that example. 1H NMR (400MHz, CDCI3): δ 7.22 (d, 7 = 8.2 Hz, 1H), 7.39 (dd, 7 = 8.2 Hz, 1.9, 1H), 7.61 (d, 7 = 1.9 Hz, 1H). Example A(150): 6-Cyclopentyl-3-(5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-ylmethyl)-6- [2-(5-ethyl-4-hydroxy-2-methoxy-phenyl)-ethyl]-4-hydroxy-5,6-dihydro-pyran-2-one
Figure imgf000179_0001
The title compound was prepared analogously to Example B(97), where 6-Cyclopentyl-6- [2-(5-ethyl-4-hydroxy-2-methoxy-phenyl)-ethyl]-dihydro-pyran-2,4-dione (from step 2 below) was substituted in place of 6-[2-(3-Chloro-5-ethyl-4-methoxy-phenyl)-ethyl]-6-cyclopentyl-dihydro- pyran-2,4-dione in that example. 1H NMR (400MHz, DMSO-d6): δ 1.01 (t, 7 = 7.4 Hz, 3H), 1.41- 1.76 (m, 8H), 1.87-2.12 (m, 2H), 2.37-2.53 (m, 11H), 2.58 (d, 7 = 17 Hz, 1H), 2.73 (d, 7 = 17 Hz, 1H), 3.59 (s, 3H), 3.70 (d, 7 = 17 Hz, 1H), 3.80 (d, 7 = 17 Hz, 1H), 6.34 (s, 1H), 6.73 (s, 1H), 7.0 (s, 1H), 9.0 (s, 1H), 10.62 (s, 1H). Anal. Calcd. For C29H36N4O5-0.5CH2CI2 0.5 H20: C, 61.93; H, 6.69; N, 9.79. Found: C, 62.02; H, 7.08; N, 9.48. MS(ESI): 521 (M+H)+.
Example A(151): 6-Cyclopentyl-6-[2-(5-ethyl-4-hydroxy-2-methoxy-phenyl)-ethyl]-dihydro- pyran-2,4-dione.
Figure imgf000179_0002
The title compound was prepared analogously to step 4 from Example A(97), where 4- bromo-2-ethyl-5-methoxypheny! acetate (described in step 1 below) was substituted in place of 2- (4-Bromo-2-fluoro-phenyl)-2-methyl-propionitrile in step 3 of that example. 1H NMR (400MHz, CDCI3): δ 1.19 (t, 7 = 7.4 Hz, 3H) 1.53-1.54 (m, 8H), 1.81-1.95 (m, 2H), 2.31-2.36 (m, 1H), 2.52 (q, 7 = 7.4 Hz, 2H), 2.59-2.65 (m, 2H), 2.75 (d, 7 = 7.3 Hz, 2H ), 3.41 (s, 2H), 3.74 (s, 3H), 4.71 (s, 1H), 6.35 (s, 1H), 6.80 (s, 1H). Anal. Calcd. For C21H28O5-0.25 H20: C, 69.11, H, 7.87. Found: C, 69.13, H, 8.00. MS(ESI): 359 (M+H)+.
Step 1: Preparation of compound 4-bromo-2-ethyl-5-methoxyphenyl acetate.
Figure imgf000180_0001
The title compound was prepared analogously to step 4 from Example A(124), where 2'- hydroxy-4'-methoxy acetophenone was substituted in place of 2-fluoro-6-(1-hydroxy-ethyl)-phenol in step 2 of that example. 1H NMR (400MHz, CDCI3): δ 1.16 (t, 7 = 7.4 Hz, 3H), 2.32 (s, 3H), 2.45 (q, 7 = 7.4 Hz, 2H) , 3.85 (s, 3H), 6.59 (s, 1H), 7.42 (s, 1H).
Example A(152): (+)-2-(2-Chloro-4-{2-[2-cyclopentyl-5-(5,7-dimethyl-[1,2,4]triazolo[1,5- a]pyrimidin-2-ylmethyl)-4-hydroxy-6-oxo-3,6-dihydro-2W-pyran-2-yl]-ethyl}-phenyl)-2- methyl-propionitrile
Figure imgf000181_0001
The title compound was prepared analogously to Example B(97), where (+)-2-{4-[2-(2- cyclopentyl-4,6-dioxotetrahydro-2H-pyran-2yl)ethyl]2-fluorophenyl}-2-methylpropanenitrile was substituted in place of 6-[2-(3-Chloro-5-ethyl-4-methoxy-phenyl)-ethyl]-6-cyclopentyl-dihydro- pyran-2,4-dione in that example. 1H NMR (400MHz, DMSO-d6): δ 1.25-1.57 (m, 8H), 1.72 (s, 6H), 2.11-2.17 (m, 2H), 2.50-2.56 (m, 8H), 2.63-2.65 (m, 2H), 2.78(d, 7 = 16 Hz, 1H), 3.71(d, 7 = 16 Hz, 1H), 3.84 (d, 7 = 16 Hz, 1H), 7.06 (s, 1H), 7.17-7.23 (m, 2H), 7.36-7.42 (m, 1H), 10.88 (s, 1 H). Anal. Calcd. For C3oH36FN503-1.0 H20: C, 65.56; H, 6.60; N, 12.74. Found: C, 65.50; H, 6.41; N, 12.61. MS(ESI): 532 (M+H)+.
Step 4: (+)-2-{4-[2-(2-cyclopentyl-4,6-dioxotetrahydro-2H-pyran-2-yl)ethyl]-2-fluorophenyl}- 2-methylpropanenitrile.
Figure imgf000181_0002
The title compound was prepared analogously to from Example A(97), where (+)-6-(2- cyclopentyl-2-hydroxybut-3-ynyl)-2,2-dimethyl-4H-1 ,3-dioxin-4-one was substituted in place of the racemic material. 1H NMR (CDCI3) δ: 1.60-1.73(m, 6 H), 1.92-1.98 (m, 2 H), 2.22-2.30 (m, 1 H), 2.65-2.71 (m, 2 H), 2.75-2.80 (m, 2 H), 6.88-6.96 (m, 2 H), 7.37-7.43 (m, 1 H). MS(ESI):372 (M+H)+.
Step 3: Preparation of compound (+)-6-(2-cyclopentyl-2-hydroxybut-3-ynyl)-2,2-dimethyl- 4W-1 ,3-dioxin-4-one
Figure imgf000182_0001
To the optically pure (+)-1-cyclopentyl-1-[(2,2-dimethyl-4-oxo-4/-/-1,3-dioxin-6- yl)methyl]prop-2-ynyl ethyl oxalate (2.5 g, 15.1 mmol) in 50 ml of MeOH was added K2C03 (2.0 g). The mixture was stirred at 23 °C for 8h. After complete conversion, the mixture was neutralized with 1N HCl at cold temperature. The aqueous solution was extracted with MTBE (x3) and the organic layer was washed with brine and dry over MgS0 . After removal of MTBE, 1.75 g of the desired product (+ enantiomer) was produced with 95.5%> ee and 96%> yield.
Step 2: Preparation of compound (-)-6-(2-cyclopentyl-2-hydroxybut-3-ynyl)-2,2-dimethyl- 4W-1 ,3-dioxin-4-one
Figure imgf000182_0002
To a 250 ml three-necked flask equipped with a pH electrode was added 72 ml of phosphate buffer (pH 4.0, 0.5M) and Candida rugosa lipase (5 g, Amano AY). The mixture was stirred vigorously and then the racemic oxalate (from step 1 below, 6 g) in 18 ml of acetonitrile was added. The reaction mixture was allowed to stir at 23 °C and the pH was kept at 4.0 using a pH titrator. The reaction was monitored with HPLC and stopped after 50% conversion (<20 hrs). The mixture was extracted by MTBE (x3) and the combined organic layer was dried over MgS04. After removal of the solvent, the crude product was separated carefully by silica-gel chromatography, using heptane/EtOAC, which afforded 2.6 g of the oxalate (+ enantiomer, 43% yield, 96% ee) and 2.0 g of product (- enantiomer, 46% yield, 92% ee). 1H NMR (300 MHz, CDCI3) : δ 1.45-1.80 (m, 8 H), 1,72 (s, 3 H), 1.74 (s, 3 H), 2.13-2.18 (m, 1 H), 2.49 (s, 1 H), 2.56 (s, 1H), 2.58 (s, 2 H), 5.43 (s, 1 H).
Step 1: Preparation of compound 1-cyclopentyl-1-[(2,2-dimethyl-4-oxo-4W-1,3-dioxin-6- yl)methyl]prop-2-ynyl ethyl oxalate
Figure imgf000183_0001
• To a solution of racemic 6-(2-cyclopentyl-2-hydroxybut-3-ynyl)-2,2-dimethyl-4H-1,3- dioxin-4-one (10 g, 37.9 mmol) in CH2CI2 (200 ml) was added triethylamine (3.0 eq, 113.7 mmol) at 0 °C. Then ethyl chlorooxoacetate (3.0 eq, 113.7 mmol) in CH2CI2 (10 ml) was added dropwise over a 30-minute period under argon. The solution was allowed to stir overnight at room temperature. After removal of solvent, the crude product was purified using a flash column (heptane: EtOAc, 3:1) to afford the desired oxalate (13.5 g, >95%). API-MS: [M+Na+]: 387; Example A(153): Preparation of compound (-)-2-(2-Chloro-4-{2-[2-cyclopentyl-5-(5,7- dimethyl-Il^^ltriazoloIljS-alpyrimidin^-ylmethy ^-hydroxy-β-oxo-S.β-dihydro^H-pyran-
2-yl]-ethyl}-phenyl)-2-methyl-propionitrile
Figure imgf000184_0001
The title compound was prepared analogously to Example B(97), where (-)-2-{4-[2-(2- cyclopentyl-4,6-dioxotetrahydro-2H-pyran-2yl)ethyl]2-fluorophenyl}-2-methylpropanenitrile (from step 1 below) was substituted in place of 6-[2-(3-Chloro-5-ethyl-4-methoxy-phenyl)-ethyl]-6- cyclopentyl-dihydro-pyran-2,4-dione in that example. 1H NMR (400MHz, DMSO-ds): δ 1.25-1.57 (m, 8H), 1.72 (s, 6H), 2.11-2.17 (m, 2H), 2.50-2.56 (m, 8H), 2.63-2.65 (m, 2H), 2.78(d, 7 = 16 Hz, 1H), 3.71(d, 7 = 16 Hz, 1H), 3.84 (d, 7 = 16 Hz, 1H), 7.06 (s, 1H), 7.17-7.23 (m, 2H), 7.36-7.42 (m, 1H), 10.88 (s, 1H). Anal. Calcd. For C30H34FN5O30.3 EtOAc: C, 65.15; H, 6.57; N, 12.55. Found: C, 66.86; H, 6.59; N, 12.21. MS(ESI): 532 (M+H)+.
Step 1: Preparation of compound (-)-2-{4-[2-(2-cyclopentyl-4,6-dioxotetrahydro-2H- pyran-2-yl)ethyl]-2-fluorophenyl}-2-methylpropanenitrile.
Figure imgf000184_0002
The title compound was prepared analogously to from Example A(97), where (-)-6-(2- cyclopentyl-2-hydroxybut-3-ynyl)-2,2-dimethyl-4H-1,3-dioxin-4-one was substituted in place of the racemic material. 1H NMR (400MHz, CDCI3): δ 1.60-1.73(m, 6 H), 1.92-1.98 (m, 2 H), 2.22-2.30 (m, 1 H), 2.65-2.71 (m, 2 H), 2.75-2.80 (m, 2 H), 6.88-6.96 (m, 2 H), 7.37-7.43 (m, 1 H).
Example A(154): 6-Cyclopentyl-3-(5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-ylmethyl)-6- [2-(5-ethyl-4-hydroxy-2-methoxy-phenyl)-ethyl]-4-hydroxy-5,6-dihydro-pyran-2-one
Figure imgf000185_0001
The title compound was prepared via chiral separation of Example A(150), 6-Cyclopentyl- 3-(5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-ylmethyl)-6-[2-(5-ethyl-4-hydroxy-2-methoxy- phenyl)-ethyl]-4-hydroxy-5,6-dihydro-pyran-2-one. The method used involved a Chiralpak AS-RH, 150 x4.6 mm column, 0.6 mL/min, 50% CAN; 50% H20, 30 min. 1H NMR (400MHz, DMSO-d6): δ 1.01 (t, 7 = 7.4 Hz, 3H), 1.41-1.76 (m, 8H), 1.87-2.12 (m, 2H), 2.37-2.53 (m, 11H), 2.58 (d, 7 = 17 Hz, 1H), 2.73 (d, 7 = 17 Hz, 1H), 3.59 (s, 3H), 3.70 (d, 7 = 17 Hz, 1H), 3.80 (d, 7 = 17 Hz, 1H), 6.34 (s, 1H), 6.73 (s, 1H), 7.0 (s, 1H), 9.0 (s, 1H), 10.62 (s, 1H). MS(ESI): 521 (M+H)+. Retention time using the conditions above was 8.64 min. 100%> ee, (+) rotation.
Example A(155): Preparation of compound (-)-6-Cyclopentyl-3-(5,7-dimethyl-
[1,2,4]triazolo[1,5-a]pyrimidin-2-ylmethyl)-6-[2-(5-ethyl-4-hydroxy-2-methoxy-phenyl)-ethyl]- 4-hydroxy-5,6-dihydro-pyran-2-one
Figure imgf000186_0001
The title compound was prepared via chiral separation of Example A(150), 6-Cyclopentyl- 3-(5,7-dimethyl-[1,2,4]triazolo[1 ,5-a]pyrimidin-2-ylmethyl)-6-[2-(5-ethyl-4-hydroxy-2-methoxy- phenyl)-ethyl]-4-hydroxy-5,6-dihydro-pyran-2-one. The method used involved a Chiralpak AS- RH, 150 x4.6 mm column, 0.6 mL/min, 50% CAN; 50% H20, 30 min. 1H NMR (400MHz, DMSO- dβ): δ 1.01 (t, 7 = 7.4 Hz, 3H), 1.41-1.76 (m, 8H), 1.87-2.12 (m, 2H), 2.37-2.53 (m, 11 H), 2.58 (d, 7 = 17 Hz, 1H), 2.73 (d, 7 = 17 Hz, 1 H), 3.59 (s, 3H), 3.70 (d, 7 = 17 Hz, 1H), 3.80 (d, 7 = 17 Hz, 1H), 6.34 (s, 1H), 6.73 (s, 1H), 7.0 (s, 1H), 9.0 (s, 1H), 10.62 (s, 1H). MS(ESI): 521 (M+H)+. Retention time using the conditions above was 6.13 min. 100% ee, (-) rotation.
Example A(156): 6-Cyclopentyl-6-[2-(5-ethyl-4-hydroxy-2-methoxy-phenyl)-ethyl]-4- hydroxy-3-(5-methyl-1/7-imidazol-4-ylmethyl)-5,6-dihydro-pyran-2-one.
Figure imgf000186_0002
The title compound was prepared analogously to Example A(126),where 6-Cyclopentyl-6- [2-(5-ethyl-4-hydroxy-2-metho'xy-phenyl)-ethyl]-dihydro-pyran-2,4-dione was substituted in place of 6-Cyclopentyl-6-[2-(3-ethyl-4-hydroxy-phenyl)-ethyl-dihydro-pyran-2,4-dione and 4- -methyl-5- imidazol carboxaldehyde was substituted in place of 6-Methyl-[1,2,4]triazolo[1,5-a]pyrimidine-2- carbaldehyde of that example. 1H NMR (400MHz, DMSO-d6): δ 0.86 (t, 7 = 7.5 Hz, 3H), 1.10-1.56 (m, 10H), 1.73-1.68 (m, 1H), 1.92 (s, 3H), 2.21-2.5 (m, 6H), 3.20-3.22 (m, 2H), 3.44 (s, 3H), 6.17 (s, 1H), 6.50 (s, 1 H), 7.53 (s, 1H). Anal. Calcd. For C26H34N205-1 H20: C, 66.08; H, 7.68; N, 5.93. Found: C, 65.93; H, 7.66; N, 5.89. MS(ESI): 455.2 (M+H)+.
Example A(157): 6-Cyclopentyl-6-[2-(5-ethyl-4-hydroxy-2-methoxy-phenyl)-ethyl]-3-(2-ethyl- 5-methyl-1W-imidazol-4-ylmethyl)-4-hydroxy-5,6-dihydro-pyran-2-one.
Figure imgf000187_0001
The title compound was prepared analogously to Example A(126),where 6-Cyclopentyl-6- [2-(5-ethyl-4-hydroxy-2-methoxy-phenyl)-ethyl]-dihydro-pyran-2,4-dione was substituted in place of 6-Cyclopentyl-6-[2-(3-ethyl-4-hydroxy-phenyl)-ethyl-dihydro-pyran-2,4-dione and 2-ethyl-5- formyl-4-methylimidazole was substituted in place of 6-Methyl-[1,2,4]triazoIo[1 ,5-a]pyrimidine-2- carbaldehyde of that example. 1H NMR (400MHz, DMSO-d6): δ 1.07-1.34 (m, 6H), 1.49-1.81 (m, 10H), 2.13 (s, 3H), 2.28-2.35 (m, 1H), 2.39-2.68 (m, 8H), 3.40 (d, 7 = 6.9 Hz, 2H), 3.68 (s, 3H), 6.41 (s, 1H), 6.74 (s, 1H). Anal. Calcd. For C28H38N205-1 H20: C, 67.18; H, 8.05; N, 5.60. Found: C, 67.50; H, 8.09; N, 5.60. MS(ESI): 483.2 (M+H)+.
Example A(158) 3-[(6-chloro[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-6-cyclopentyl-6-[2- (5-ethyl-4-hydroxy-2-methoxyphenyl)ethyl]-4-hydroxy-5,6-dihydro-2H-pyran-2-one
Figure imgf000188_0001
The title compound was prepared analogously to Example A(150), where 6- chloro[1,2,4]triazolo[1,5-a]pyrimidine-2-carbaldehyde was substituted in place of 5,7- dimethylll^^jtriazolofl.δ-ajpyrimidine^-carbaldehyde. H NMR (300 MHz, DMSO-d6) δ: 1.02 (t, 7=7.44 Hz, 3 H), 1.30-1.69 (m, 8 H), 1.85-1.92 (m, 2 H), 2.25-2.44 (m, 7 H), 3.62 (s, 3 H), 3.71 (s, 2 H), 6.36 (s, 1 H), 6.72 (s, 1 H), 8.81 (d, 7=2.64 Hz, 1 H), 9.47 (d, 7=2.45 Hz, 1 H). Anal. Calcd. For C27H31CIN4O5.0.5H2O: C, 60.50; H, 6.02; N, 10.45. Found: C, 60.43; H, 6.22; N, 10.20.
Example A(159) 6-cyclopentyl-6-[2-(5-ethyl-4-hydroxy-2-methoxyphenyl)ethyl]-4-hydroxy-3- [(6-methyl[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-5,6-dihydro-2H-pyran-2-one
Figure imgf000188_0002
The title compound was prepared analogously to Example A(150), where 6- methyl[1,2,4]triazolo[1,5-a]pyrimidine-2-carbaldehyde was substituted in place of 5,7- dimethyl[1,2,4]triazolo[1,5-a]pyrimidine-2-carbaldehyde. 1H NMR (300 MHz, DMSO-d6) δ: 0.95 (t, 7=7.44 Hz, 3 H), 1.30-1.64 (m, 8 H), 1.84-1.92 (m, 2 H), 2.27-2.38 (m, 7 H), 3.55 (s, 3 H), 3.68- 3.70 (m, 2 H), 6.30 (s, 1 H), 6.68 (s, 1 H), 8.61 (d, 7=3.0 Hz, 1 H), 8.74 (s, 1 H), 8.95 (s, 1 H). HRMS calcd for C28H35N405 (M+H)+: 507.2602, found 507.2616.
Example A(160): 3-(6-Chloro-[1,2,4]triazolo[1,5-a]pyrimidin-2-ylmethyl)-6-cyclopentyl-6-[2- (5-ethyl-4-hydroxy-2-methyl-phenyl)-ethyl]-4-hydroxy-5,6-dihydro-pyran-2-one
Figure imgf000189_0001
6-Chloro-[1,2,4]triazolo[1,5-a]pyrimidine-2-carbaldehyde (0.16g, 0.85mmol) was added to a solution of 6-cyclopentyl-6-[2-(5-ethyl-4-hydroxy-2-methyl-phenyl)-ethyl]-dihydro-pyran-2,4- dione (0.2g, 0.53 mmol, from step 1 below) in MeOH (7 mL). The reaction mixture was stirred for 20 mins and then treated with borane-dimethylamine complex (63mg, HmmoL). After 15 hours the reaction mixture was quenched with cone HCl and concentrated to a brown oil. Purification by flash silica gel chromatography (50% EtOAc in hexanes then 0% to 5%> MeOH in CH2CI2) gave the product as a white solid (50 mg, 14%). 1H NMR (400 MHz, DMSO-d6) δ: 1.06 (t, 7=7.6 Hz, 3 H), 1.36-1.68 (br m, 8 H), 1.88 (m, 2 H), 2.04 (m, 3 H), 2.43-2.56 (m, 4 H), 2.75 (d, 7=16.9 Hz, 1 H), 3.29-3.44 (m, 2H), 4.64 (s, 2 H), 6.51 (s, 1 H), 6.72 (m, 2 H), 8.84 (s, 1 H), 9.59 (d, 7=4.0 Hz, 1 H), 10.77 (s, 1 H). MS (ESI): 513.30 (M+H+)
Step 1 : 6-Cyclopentyl-6-[2-(5-ethyl-4-hydroxy-2-methyl-phenyl)-ethyl]-dihydro-pyran-2,4- dione
Figure imgf000189_0002
The title compound was prepared analogously to Example A(124) where 1-(2-hydroxy-4- methyl-phenyl)-ethanone was substituted in place of 2-fluoro-6-(1-hydroxy-ethyl)-phenol in step 2 of that example. 1H NMR (400 MHz, CDCI3): δ 1.20 (t, 7=7.6 Hz, 3 H), 1.55- 1.94 (br m, 10 H),
2.19 (s, 3 H), 2.32 (m, 1 H), 2.58 (m, 4 H), 2.79 (s, 2 H), 3.42 (s, 2 H), 4.53 (s, 1 H), 6.56 (s, 1 H),
6.81 (s, 1 H).
Example A(161): 3-(6-Chloro-[1,2,4]triazolo[1,5-a]pyrimidin-2-ylmethyl)-6-cyclopentyl-6-[2- (5-ethyl-2-fluoro-4-hydroxy-phenyl)-ethyl]-4-hydroxy-5,6-dihydro-pyran-2-one
Figure imgf000190_0001
The title compound was prepared analogously to Example A(160) where 1-(4-fluoro-2- hydroxy-phenyl)-ethanone was substituted in place of 1-(2-hydroxy-4-methyl-phenyl)-ethanone in step 1 of that example. 1H NMR (400 MHz, DMSO-d6) δ: 1.00 (t, 7=7.6 Hz, 3 H), 1.24-1.58 (br m, 8 H), 1.90 (m, 2 H), 2.29-2.49 (m, 4 H), 2.64 (d, 7=17.2 Hz, 1 H), 3.32-3.37 (m, 2H), 4.58 (s, 2 H), 6.43 (d, 7=11.7 Hz, 1 H), 6.61 (d, 7=5.1 Hz, 1 H), 6.80 (d, 7=9.4 Hz, 1 H), 9.43 (s, 1 H), 9.53 (d, 7=5.1 Hz, 1 H), 10.7 (s, 1 H).
Example A(162): 6-Cyclopentyl-3-(5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-ylmethyl)-6- [2-(2-ethyl-pyridin-4-yl)-ethyl]-4-hydroxy-5,6-dihydro-pyran-2-one
Figure imgf000190_0002
The title compound was prepared analogously to Example A(123) where 6-cyclopentyl-6- [2-(2-ethyl-pyridin-4-yl)-ethyl]-dihydro-pyran-2, 4-dione (Example A(163) was substituted in place of 6-cyclopentyl-6-[2-(3-ethyl-5-fluoro-4-hydroxy-phenyl)-ethyl]-dihydro-pyran-2,4-dione. 1H NMR (400 MHz, DMSO-ce) δ: 1.24 (t, 7=7.6 Hz, 3 H), 1.44-1.75 (br m, 8 H), 2.2 (m, 2 H), 2.50-2.86 (m, 13 H), 3.76 (d, 7=16.0 Hz, 1 H), 3.89 (d, 7=16.0 Hz, 1 H), 7.11 (s, 1 H), 7.18 (s, 2 H), 8.39 (s, 1 H), 11.12 (s, 1 H). MS (ESI): 476.25 (M+H+)
Example A(163): 6-Cyclopenty din-4-yl)-ethyl]-dihydro-pyran-2,4-dione
Figure imgf000190_0003
The title compound was prepared analogously to Example A(97) where 4-bromo-2-ethyl- pyridine (from step 3 below) was substituted in place of 2-(4-bromo-2-fluorophenyl)-2- methylpropanenitrile in step 3 of that example. 1H NMR (400 MHz, CDCI3): δ 1.30 (t, 7=7.6 Hz, 3 H), 1.37- 1.76 (br m, 8 H), 1.96 (m, 2 H), 2.28 (s, 1 H), 2.68 (m, 2 H), 2.79 (m, 4 H), 3.44 (s, 2 H),
6.91 (s, 1 H), 6.95 (s, 1 H), 8.42 (s, 1 H). Anal. Calcd. For C19H25N03O.5H20: C, 70.34; H, 8.08; N, 4.32. Found: C, 70.37; H, 7.96; N, 4.34.
Step 3: 4-Bromo-2-ethyl-pyridine
Figure imgf000191_0001
A mixture of 2-ethy l-4-n itro-py rid ine (2.3g, 15.1 mmol) and acetyl bromide (9 mL) were heated together at 75°C for 16 hours. More acetyl bromide (10 mL) was added and the reaction was heated to 100°C for 5 hrs. The reaction mixture was poured into ice, made basic with 20% NaOH and extracted with EtOAc. The organic extracts were washed with brine, dried over Na2S04 and concentrated to a black oil. Purification by flash silica gel chromatography (0% to 25% EtOAc) gave the product as an oil (1.72g, 62%). 1H NMR (400 MHz, CDCI3): δ 1.30 (t, 7=7.6 Hz, 3 H), 2.81 (d, 7=7.6 Hz, 2 H), 7.28 (dd, 7=5.3, 1.8 Hz, 1 H), 7.35 (d, 7=1.8 Hz, 1 H), 8.34 (d, 7=5.3 Hz, 1 H).
Step 2: 2-Ethyl-4-nitro-pyridine
Figure imgf000191_0002
A solution of phosphorous trichloride (7.2 mL, 82 mmol) in CH2CI2 was added to a cooled 0°C solution of 2-ethyI-4-nitro-pyridine 1-oxide (3g, 17.8 mmol) in CH2CI2. The reaction was stirred for 2 hours and then warmed up to rt. After 3 hours the mixture was poured into ice, made basic with 15% NaOH and extracted with EtOAc. The organic extracts were dried over Na2S04 and concentrated to a yellow oil that solidified on standing (2.56g, 95%). 1H NMR (400 MHz, CDCI3): δ 1.40 (t, 7=7.6 Hz, 3 H), 3.14 (d, 7=7.6 Hz, 2 H), 8.04 (d, 7=5.6 Hz, 1 H), 8.06 (s, 1 H),
8.92 (d, 7=5.6 Hz, 1 H).
Step 1: 2-Ethyl-4-nitro-pyridine 1-oxide
Figure imgf000191_0003
Hydrogen peroxide (4.8 mL, 47 mmol, 30% wt in H20) was added to a solution of 2- ethylpyridine (5g, 47 mmol) in AcOH (30 L). The reaction was refluxed for 24 hours and then concentrated to a dark oil.
The oil was dissolved in H2S04 (11.4mL) and cooled to 0°C. HN03 (9.2 mL) was added slowly and after the addition was complete the reaction mixture was heated to 100°C for 16 hours. The mixture was poured into ice, made basic with 15% NaOH and extracted with CH2CI2. The organic layers were washed with brine, dried over Na2S04 and concentrated. Purification by by flash column chromatography (40%> to 60% EtOAc in hexanes) gave the title compound as a yellow solid (3.13g, 53%). 1H NMR (400 MHz, CDCI3): δ 1.37 (t, 7=7.3 Hz, 3 H), 2.96 (d, 7=7.3 Hz, 2 H), 7.99 (dd, 7=7.1 , 3.1 Hz, 1 H), 8.10 (d, 7=3.1 Hz, 1 H), 8.31 (d, 7=7.1 Hz, 1 H).
Example A(164): 3-(6-Chloro-[1,2,4]triazolo[1,5-a]pyrimidin-2-ylmethyl)-6-cyclopentyl-6-[2- (2-ethyl-pyridin-4-yl)-ethyl]-4-hydroxy-5,6-dihydro-pyran-2-one
Figure imgf000192_0001
The title compound was prepared analogously to Example A(160) where 6-cyclopentyl-6- [2-(2-ethyl-pyridin-4-yl)-ethyl]-dihydro-pyran-2,4-dione (Example A(163)) was substituted in place of 6-cyclopentyl-6-t2-(5-ethyl-4-hydroxy-2-methyl-phenyl)-ethyl]-dihydro-pyran-2,4-dione. 1H NMR (400 MHz, DMSO-d6) δ: 1.18 (t, 7=6.1 Hz, 3 H), 1.34-1.66 (br m, 8 H), 1.99 (m, 1 H), 2.12 (m, 1 H), 2.33 (m, 2 H), 2.50-2.62 (m, 3 H), 2.70 (d, 7=6.1 Hz, 2 H), 3.69 (d, 7=16.0 Hz, 1 H), 3.80 (d, 7=16.0 Hz, 1 H), 5.77 (s, 1 H), 7.10 (m, 2 H), 8.33 (d, 7=4.8, 1 H), 8.86 (d, 7=2.5, 1 H), 9.53 (d, 7=6.1 Hz, 1 H).
Example A(165): 3-(6-Chloro-[1,2,4]triazolo[1,5-a]pyrimidin-2-ylmethyl)-6-cyclopentyl-6-[2-
(2-ethyl-pyridin-4-yl)-ethyl]-4-hydroxy-5,6-dihydro-pyran-2-one
Figure imgf000192_0002
The title compound was prepared analogously to Example A(160) where 1-(2-hydroxy-4- trifluoromethyl-phenyl)-ethanone (from step 1 below) was substituted in place of 1-(2-hydroxy-4- methyl-phenyl)-ethanone in step 1 of that example. 1H NMR (400 MHz, DMSO-d6) δ: 1.07 (t,
7=7.3 Hz, 3 H), 1.34-1.66 (br m, 8 H), 1.91-2.11 (m, 2 H), 2.37-2.70 (m, 7 H), 3.75 (s, 2 H), 5.77 (s, 1 H), 7.00 (s, 1 H), 7.07 (s, 1 H), 8.84 (s, 1 H), 9.52 (s, 1 H), 9.75 (s, 1 H).
Step 1: 1-(2-Hydroxy-4-trifluoromethyl-phenyl)-ethanone
Figure imgf000193_0001
4-Ethoxy-1,1,1-trifluoro-3-buten-2-one (5g, 29.7 mmol) followed by 2,4-pentadione
(3.05ml, 29.7mmol) were added to a cooled 0°C suspension of NaH (2.38g, 59.4 mmol) in THF (120 mL). The reaction mixture was refluxed for 4 hrs and then partitioned between 1N HCl and EtOAc. The organic layers were washed with brine, dried over Na2S0 and concentrated to a red oil. Purification by flash column chromatography (0% to 10% EtOAc in hexanes) gave the title compound as a yellow oil (1.73g, 29%). 1H NMR (400 MHz, CDCI3): δ 2.69 (s, 3 H), 7.15 (d, 7=9.9 Hz, 1 H), 7.25 (s, 1 H), 7.86 (d, 7=8.3 Hz, 1 H), 12.29 (s, 1 H).
Example A(166): 6-Cyclopentyl-3-(5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-ylmethyl)-6- [2-(5-ethyl-2-hydroxy-phenyl)-ethyl]-4-hydroxy-5,6-dihydro-pyran-2-one
Figure imgf000193_0002
5,7-Dimethyl-[1,2,4]triazolo[1,5-a]pyrimidine-2-carbaIdehyde (0.19g, 1.1 mmol) was added to a solution of 6-cyclopentyl-6-[2-(5-ethyl-2-hydroxy-phenyl)-ethyl]-dihydro-pyran-2,4-dione (0.3g, 0.91 mmol Example A(169)) in MeOH (8 mL). The reaction mixture was stirred for 15mins and then treated with borane-dimethylamine complex (47mg, O.δOmmoL). After 24 hours the reaction mixture was filtered through a glass frit to remove a fine white ppt. The filtrate was concentrated and purified by prep HPLC to give the product (175mg, 40%). 1H NMR (400 MHz, DMSO-d6) δ: 1.07 (t, 7=7.6 Hz, 3 H), 1.41-1.72 (br m, 8 H), 1.97 (m, 1 H), 2.10 (m, 1 H), 2.41-2.73 (m, 13 H), 3.70 (d, 7=16.2 Hz, 1 H), 3.79 (d, 7=16.2 Hz, 1 H), 6.66 (d, 7=8.1 Hz, 1 H), 6.81 (d, 7=8.1 Hz, 1 H), 6.84 (s, 1 H), 7.02 (s, 1 H), 9.02 (s, 1 H), 10.88 (s, 1 H). MS (ESI): 491.20 (M+H+).
Example A(167): Enantiomer 1 of 6-Cyclopentyl-3-(5,7-dimethyl-[1,2,4]triazolo[1,5- a]pyrimidin-2-ylmethyl)-6-[2-(5-ethyl-2-hydroxy-phenyl)-ethyl]-4-hydroxy-5,6-dihydro- pyran-2-one
Figure imgf000194_0001
The title compound was separated from racemic 6-cyclopentyl-3-(5,7-dimethyl- [1,2,4]triazolo[1,5-a]pyrimidin-2-ylmethyl)-6-[2-(5-ethyl-2-hydroxy-phenyl)-ethyl]-4-hydroxy-5,6- dihydro-pyran-2-one (118mg, Example A(166)) using chiral HPLC (Chiralpak AS-H, 120 bar,
2.5mL/min, 30% MeOH). (42.4mg, 4.695 min retention time)
Example A(168): Enantiomer 2 of 6-Cyclopentyl-3-(5,7-dimethyl-[1 ,2,4]triazolo[1 ,5- a]pyrimidin-2-ylmethyl)-6-[2-(5-ethyl-2-hydroxy-phenyl)-ethyl]-4-hydroxy-5,6-dihydro- pyran-2-one
Figure imgf000194_0002
The title compound was separated from racemic 6-Cyclopentyl-3-(5,7-dimethyl- [1,2,4]triazoio[1,5-a]pyrimidin-2-ylmethyl)-6-[2-(5-ethyl-2-hydroxy-phenyl)-ethyl]-4-hydroxy-5,6- dihydro-pyran-2-one (118mg, Example A(166)) using chiral HPLC (Chiralpak AS-H, 120 bar, 2.5mL/min, 30% MeOH). (41.3mg, 7.341 min retention time)
Example A(169): 6-Cyclopentyl-6-[2-(5-ethyl-2-hydroxy-phenyl)-ethyl]-dihydro-pyran-2,4- dione
Figure imgf000194_0003
The title compound was prepared analogously to Example A(124) where 1-benzyloxy-2- bromo-4-ethyl-benzene (from step 1 of Example D(8)was substituted in place of acetic acid 4- bromo-2-ethyl-6-fluoro-phenyl ester. 1H NMR (400 MHz, CDCI3): δ 1.19 (t, 7=7.6 Hz, 3 H), 1.41- 2.07 (br m, 10 H), 2.35 (m, 1 H), 2.54 (q, 7=7.6 Hz, 2 H), 2.57-2.82 (br m, 4 H), 3.45 (d, 7=21.2 Hz, 1 H), 3.47 (d, 7=21.2 Hz, 1 H), 4.84 (s, 1 H), 6.64 (d, 7=7.8 Hz, 1 H), 6.91 (m, 2 H). ). Anal. Calcd. For C20H26O4'0.2H2O: C, 71.91; H, 7.97. Found: C, 71.96; H, 7.96.
Example A(170): 3-(6-Chloro-[1 ,2,4]triazolo[1 ,5-a]pyrimidin-2-ylmethyl)-6-cyclopentyl-6-[2- (5-ethyl-2-hydroxy-phenyl)-ethyl]-4-hydroxy-5,6-dihydro-pyran-2-one
Figure imgf000195_0001
The title compound was prepared analogously to Example A(166) where 6-chloro- [1,2,4]triazolo[1,5-a]pyrimidine-2-carbaldehyde was substituted in place of 5,7-dimethyl- [1,2,4]triazolo[1,5-a]pyrimidine-2-carbaldehyde. 1H NMR (400 MHz, DMSO-d6) δ: 1.09 (t, 7=7.6 Hz, 3 H), 1.37-1.71 (br m, 8 H), 2.01 (m, 2 H), 2.39-2.54 (m, 5 H), 2.61 (d, 7=17.7 Hz, 1 H), 2.77 (d, 7=17.7 Hz, 1 H), 3.80 (s, 2 H), 6.67 (d, 7=8.1 Hz, 1 H), 6.82 (d, 7=8.1 Hz, 1 H), 6.86 (s, 1 H), 8.86 (s, 1 H), 9.05 (s, 1 H), 9.45 (s, 1 H), 10.9 (s, 1 H). Anal. Calcd. For C26H29N404CIO.5H20: C, 61.71; H, 5.98; N, 11.07. Found: C, 61.73; H, 5.98; N, 10.99.
Example A(171): Enantiomer 1 of 3-(6-Chloro-[1,2,4]triazolo[1,5-a]pyrimidin-2-ylmethyl)-6- cyclopentyl-6-[2-(5-ethyl-2-hydroxy-phenyl)-ethyl]-4-hydroxy-5,6-dihydro-pyran-2-one
Figure imgf000195_0002
The title compound was separated from racemic 3-(6-chloro-[1,2,4]triazolo[1 ,5- a]pyrimidin-2-ylmethyl)-6-cyclopentyl-6-[2-(5-ethyl-2-hydroxy-phenyl)-ethyl]-4-hydroxy-5,6- dihydro-pyran-2-one (98mg, Example A(170)) using chiral HPLC (Chiralpak AS-H, 140 bar, 2.5mL/min, 20% MeOH). (26mg, 12.409 min retention time) Example A(172): Enantiomer 2 of 3-(6-Chloro-[1,2,4]triazolo[1,5-a]pyrimidin-2-ylmethyl)-6- cyclopentyl-6-[2-(5-ethyl-2-hydroxy-phenyl)-ethyl]-4-hydroxy-5,6-dihydro-pyran-2-one
Figure imgf000196_0001
The title compound was separated from racemic 3-(6-chloro-[1 ,2,4]triazolo[1 ,5- a]pyrimidin-2-ylmethyl)-6-cyclopentyl-6-[2-(5-ethyl-2-hydroxy-phenyl)-ethyl]-4-hydroxy-5,6- dihydro-pyran-2-one (98mg, Example A(170)) using chiral HPLC (Chiralpak AS-H, 140 bar, 2.5mL/min, 20% MeOH). (26mg, 16.775 min retention time)
Example A(173): 6-Cyclopentyl-6-[2-(5-ethyl-2-hydroxy-phenyl)-ethyI]-4-hydroxy-3-(6- methyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-ylmethyl)-5,6-dihydro-pyran-2-one
Figure imgf000196_0002
The title compound was prepared analogously to Example A(166) where 6-methyl-
[1,2,4]triazolo[1,5-a]pyrimidine-2-carbaldehyde was substituted in place of 5,7-dimethyl- [1,2,4]triazolo[1,5-a]pyrimidine-2-carbaldehyde. 1H NMR (400 MHz, DMSO-d6) δ: 0.99 (t, 7=7.6 Hz, 3 H), 1.29-1.62 (br m, 8 H), 1.92 (m, 2 H), 2.24 (s, 3 H), 2.32-2.50 (m, 6 H), 2.63 (d, 7=11.6 Hz, 1 H), 3.66 (s, 2 H), 6.58 (d, 7=8.1 Hz, 1 H), 6.74 (m, 2 H), 8.57 (s, 1 H), 8.74 (s, 1 H), 8.95 (s, 1 H), 10.85 (s, 1 H). MS (ESI): 477.10 (M+H+).
Example A(174): Enantiomer 1 of 6-Cyclopentyl-6-[2-(5-ethyl-2-hydroxy-phenyl)-ethyl]-4- hydroxy-3-(6-methyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-ylmethyl)-5,6-dihydro-pyran-2-one
Figure imgf000196_0003
The title compound was separated from racemic 6-cyclopentyl-6-[2-(5-ethyl-2-hydroxy- phenyl)-ethyl]-4-hydroxy-3-(6-methyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-ylmethyl)-5,6-dihydro-pyran- 2-one (97mg, Example A(173)) using chiral HPLC (Chiralpak AS-H, 120 bar, 2.5mL/min, 25% MeOH). (42mg, 7.534 min retention time)
Example A(175): Enantiomer 2 of 6-Cyclopentyl-6-[2-(5-ethyl-2-hydroxy-phenyl)-ethyl]-4- hydroxy-3-(6-methyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-ylmethyl)-5,6-dihydro-pyran-2-one
Figure imgf000197_0001
The title compound was separated from racemic 6-cyclopentyl-6-[2-(5-ethyl-2-hydroxy- phenyl)-ethyl]-4-hydroxy-3-(6-methyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-ylmethyl)-5,6-dihydro-pyran- 2-one (97mg, Example A(173)) using chiral HPLC (Chiralpak AS-H, 120 bar, 2.5mL/min, 25% MeOH). (37mg, 10.983 min retention time)
Example A(176): 6-CycIopentyl-6-[2-(5-ethyl-2-hydroxy-phenyl)-ethyl]-4-hydroxy-3- [1,2,4]triazolo[1,5-a]pyrimidin-2-ylmethyl-5,6-dihydro-pyran-2-one
Figure imgf000197_0002
The title compound was prepared analogously to Example A(166) where [1,2,4]triazolo[1,5-a]pyrimidine-2-carbaldehyde was substituted in place of 5,7-dimethyl- [1,2,4]triazolo[1,5-a]pyrimidine-2-carbaldehyde. 1H NMR (400 MHz, DMSO-d6) δ: 1.21 (t, 7=7.6 Hz, 3 H), 1.50-1.82 (br m, 8 H), 2.12 (m, 2 H), 2.54-2.67 (m, 5 H), 2.71 (d, 7=17.7 Hz, 1 H), 2.87 (d, 7=17.7 Hz, 1 H), 3.90 (s, 2 H), 6.79 (d, 7=8.1 Hz, 1 H), 6.94 (dd, 7=8.1, 2.0 Hz, 1 H), 6.98 (s, 1 H), 7.37 (dd, 7= 6.8, 4.3 Hz, 1 H), 8.90 (dd, 7= 4.3, 2.0 Hz, 1 H), 9.17 (s, 1 H), 9.22 (dd, 7= 6.6, 1.8 Hz, 1 H), 11.06 (s, 1 H). Anal. Calcd. For C26H30N4O4O.6H2O: C, 65.97; H, 6.64; N, 11.84. Found: C, 66.02; H, 6.53; N, 11.71. Example A(177): 6-Cyclopentyl-3-(5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-ylmethyl)-6-
{2-[5-ethyl-2-(2-methoxy-eth ihydro-pyran-2-one
Figure imgf000198_0001
The title compound was prepared analogously to Example A(123) where 6-cyclopentyl- 6-{2-[5-ethyl-2-(2-methoxy-ethoxy)-phenyl]-ethyl}-dihydro-pyran-2,4-dione (Example A(178)) was substituted in place of 6-cyclopentyl-6-[2-(3-ethyl-5-fluoro-4-hydroxy-phenyl)-ethyl]-dihydro-pyran- 2,4-dione. 1H NMR (400 MHz, DMSO-d6) δ: 1.07 (t, 7=7.6 Hz, 3 H), 1.39-1.73 (br m, 8 H), 2.05 (m, 1 H), 2.40-2.61 (m, 13 H), 2.77 (d, 7=17.4 Hz, 1 H), 3.27 (s, 3 H), 3.58 (m, 2 H), 3.71 (d, 7=16.2 Hz, 1 H), 3.80 (d, 7=16.2 Hz, 1 H), 3.99 (m, 2 H), 6.82 (d, 7=8.3 Hz, 1 H), 6.91 (dd, 7= 2.0 Hz, 1 H), 6.96 (dd, 7= 8.3, 2.0 Hz, 1 H), 7.02 (s, 1 H), 10.8 (s, 1 H). Anal. Calcd. For C31H40N4O5O.3H2O: C, 67.20; H, 7.39; N, 10.11. Found: C, 67.21; H, 7.35; N, 10.11.
Example A(178): 6-Cyclopentyl-6-{2-[5-ethyl-2-(2-methoxy-ethoxy)-phenyl]-ethyl}-dihydro- pyran-2,4-dione
Figure imgf000198_0002
The title compound was prepared analogously to Example A(124) where 2-bromo-4- ethyl-1-(2-methoxy-ethoxy)-benzene (from step 1 below)was substituted in place of acetic acid 4- bromo-2-ethyl-6-fluoro-phenyl ester. 1H NMR (400 MHz, CDCI3): δ 1.19 (t, 7=7.6 Hz, 3 H), 1.39- 2.06 (br m, 10 H), 2.35 (m, 1 H), 2.59-2.64 (m, 3 H), 2.69-2.81 (m, 3 H), 3.38 (d, 7=21.2 Hz, 1 H), 3.41 (s, 3 H), 3.58 (d, 7=21.2 Hz, 1 H), 3.71 (m, 2 H), 4.08 (m, 2 H), 6.74 (d, 7=8.3 Hz, 1 H), 6.91 (s, 1 H), 6.99 (d, 7=8.3 Hz, 1 H). MS (ESI): 387.10 (M-H+)
Step 1: 2-Bromo-4-ethyl-1-(2-methoxy-ethoxy)-benzene
Figure imgf000198_0003
Potassium carbonate (8.25g, 60 mol) followed by 2-bromoethyl methyl ether (1.87 mL, 20 mmol) were added to a solution of 2-bromo-4-ethyl-phenol (4g, 20 mmol, from step 1 of Example B(98)) in DMF (25mL). The mixture was stirred for 20 hours and then partitioned between 1N HCl and EtOAc. The organic layers were washed with brine, dried over Na2S0 and concentrated. The crude yellow oil was purified by flash column chromatography (0% to 10% EtOAc in hexanes) to give the desired product (4.63 g, 90%). H NMR (400 MHz, CDCI3): δ 1.20 (t, 7=7.6 Hz, 3 H), 2.57 (q, 7=7.6 Hz, 2 H), 3.48 (s, 3 H), 3.79 (t, 7=5.1 Hz, 2 H), 4.15 (t, 7=4.8 Hz, 2 H), .6.85 (d, 7=8.3 Hz, 1 H), 7.06 (dd, 7=8.3, 2.3 Hz, 1 H), 7.37 (d, 7=2.3 Hz, 1 H).
Example A(179): 6-Cyclopentyl-6-{2-[5-ethyl-2-(2-methoxy-ethoxy)-phenyl]-ethyl}-4- hydroxy-3-(6-methyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-ylmethyl)-5,6-dihydro-pyran-2-one
Figure imgf000199_0001
The title compound was prepared analogously to Example A(126) where 6-cyclopentyl-6-
{2-[5-ethyl-2-(2-methoxy-ethoxy)-phenyl]-ethyl}-dihydro-pyran-2,4-dione (Example A(178)) was substituted in place of 6-Cyclopentyl-6-[2-(3-ethyl-4-hydroxy-phenyl)-ethyl]-dihydro-pyran-2,4- dione. 1H NMR (400 MHz, DMSO-d6) δ: 1.24 (t, 7=7.6 Hz, 3 H), 1.51-1.87 (br m, 8 H), 2.24 (m, 2 H), 2.48 (s, 3 H), 2.55 (m, 1 H), 2.60-2.73 (m, 5 H), 2.90 (d, 7=18.0 Hz, 1 H), 3.43 (s, 3 H), 3.75 (t, 7=6.1 Hz, 2 H), 3.88 (d, 7=17.7 Hz, 1 H), 3.93 (d, 7=17.7 Hz, 1 H), 4.16 (d, 7=5.1 Hz, 2 H), 6.98 (d, 7=8.3 Hz, 1 H), 7.08 (s, 1 H), 7.12 (d, 7= 8.3 Hz, 1 H), 8.81 (s, 1 H), 9.0 (s, 1 H), 11.03 (s, 1 H). MS (ESI): 535.15 (M+H+).
Example A(180): 6-Cyclopentyl-3-(5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-ylmethyl)-6- [2-(5-ethyl-4-hydroxy-2,3-dihydro-benzofuran-7-yl)-ethyl]-4-hydroxy-5,6-dihydro-pyran-2- one
Figure imgf000199_0002
The title compound was prepared analogously to Example A(123) where 6-Cyclopentyl- 6-[2-(5-ethyl-4-hydroxy-2,3-dihydro-benzofuran-7-yl)-ethyl]-dihydro-pyran-2,4-dione (Example A(181)) was substituted in place of 6-cyclopentyl-6-[2-(3-ethyl-5-fluoro-4-hydroxy-phenyl)-ethyl]- dihydro-pyran-2,4-dione. 1H NMR (400 MHz, DMSO-d6) δ: 1.08 (t, 7=7.3 Hz, 3 H), 1.45-1.75 (br m, 8 H), 2.01 (m, 1 H), 2.15 (m, 1 H), 2.39-2.65 (m, 12 H), 2.80 (d, 7=17.4 Hz, 1 H), 3.09 (t, 7=8.8 Hz, 2 H), 3.77 (d, 7=15.9 Hz, 1 H), 3.85 (d, 7=15.9 Hz, 1 H), 4.47 (t, 7= 11.4 Hz, 2 H), 6.64 (s, 1 H), 7.09 (s, 1 H), 8.58 (s, 1 H), 10.89 (s, 1 H). Anal. Calcd. For C30H36N4O5O.4H2O: C, 66.74; H, 6.87; N, 10.38. Found: C, 66.71; H, 6.65; N, 10.21.
Example A(181): 6-Cyclopentyl-6-[2-(5-ethyl-4-hydroxy-2,3-dihydro-benzofuran-7-yl)-ethyl]- dihydro-pyran-2,4-dione
Figure imgf000200_0001
The title compound was prepared analogously to Example A(124) where 5-ethyI-2,3- dihydro-benzofuran-4-ol (from step 2 below)was substituted in place of 2-ethyl-6-fluoro-phenol in step 3 of that example. 1H NMR (400 MHz, CDCI3): δ 1.19 (t, 7=7.6 Hz, 3 H), 1.42-2.05 (br m, 10
H), 2.30 (m, 1 H), 2.47-2.60 (m, 4 H), 2.72 (d, 7=16.2 Hz, 1 H), 2.76 (d, 7=16.2 Hz, 1 H), 3.12 (t,
7=8.6 Hz, 2 H), 3.43 (m, 2 H), 4.56 (t, 7=8.6 Hz, 2 H), 6.64 (s, 1 H). MS (ESI): 373.10 (M-H+)
Step 2: 5-Ethyl-2,3-dihydro-benzofuran-4-ol
Figure imgf000200_0002
A mixture of 1-(4-Hydroxy-benzofuran-5-yl)-ethanone (1.37g, 7.8 mmol) and 10 wt % Pd/C (0.7g, Degussa type) in MeOH (20 mL) was stirred under a balloon of H2 for 24 hours. The reaction mixture was filtered through a pad of celite washing with EtOAc. The filtrate was concentrated to an oil (0.9g, 70%). 1H NMR (400 MHz, CDCI3): δ 1.21 (t, 7=7.6 Hz, 3 H), 2.56 (q, 7=7.6 Hz, 2 H), 3.14 (t, 7=8.6 Hz, 2 H), 4.59 (t, 7=8.6 Hz, 2 H), 4.68 (s, 1 H), 6.37 (d, 7=8.1 Hz, 1 H), 6.37 (d, 7=8.1 Hz, 1 H).
Step 1: 1-(4-Hydroxy-benzofuran-5-yl)-ethanone
Figure imgf000201_0001
The title compound was prepared as described in the following reference: Tetrahedron 1995, 51, 4909-4922. 1H NMR (400 MHz, CDCI3): δ 1.58 (s, 3 H), 7.00 (dd, 7=2.0, 1.0 Hz, 1 H), 7.05 (dd, 7=8.8, 1.0 Hz, 1 H), 7.57 (d, 7=2.0 Hz, 1 H), 7.66 (d, 7=8.8 Hz, 1 H), 13.3 (s, 1 H).
Example A(182): 6-Cyclopentyl-6-[2-(5-ethyl-4-hydroxy-2,3-dihydro-benzofuran-7-yl)-ethyl]-
4-hydroxy-3-(6-methyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-ylmethyl)-5,6-dihydro-pyran-2-one
Figure imgf000201_0002
The title compound was prepared analogously to Example A(126) where 6-cyclopentyl- 6-[2-(5-ethyl-4-hydroxy-2,3-dihydro-benzofuran-7-yl)-ethyl]-dihydro-pyran-2, 4-dione (Example A(181)) was substituted in place of 6-cyclopentyl-6-[2-(3-ethyl-4-hydroxy-phenyl)-ethyl]-dihydro- pyran-2,4-dione. 1H NMR (400 MHz, DMSO-d6) δ: 1.09 (t, 7=7.3 Hz, 3 H), 1.39-1.75 (br m, 8 H), 2.06 (m, 2 H), 2.40-2.62 (m, 9 H), 2.80 (d, 7=17.7 Hz, 1 H), 3.11 (t, 7=8.3 Hz, 2 H), 3.78 (d, 7=15.9 Hz, 1 H), 3.84 (d, 7=15.9 Hz, 1 H), 4.48 (t, 7= 8.6 Hz, 2 H), 6.66 (s, 1 H), 8.61 (s, 1 H), 8.73 (s, 1 H), 8.87 (s, 1 H), 10.97 (s, 1 H). MS (ESI): 519.10 (M+H+).
Example A(183): 6-Cyclopentyl-3-(5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-ylmethyl)-6- {2-[3-ethyl-4-(2-methoxy-ethoxy)-phenyl]-ethyl}-4-hydroxy-5,6-dihydro-pyran-2-one
Figure imgf000201_0003
The title compound was prepared analogously to Example A(123) where 6-cyclopentyl-6-
{2-[3-ethyl-4-(2-methoxy-ethoxy)-phenyl]-ethyl}-dihydro-pyran-2,4-dione (Example A(184)) was substituted in place of 6-cyclopentyl-6-[2-(3-ethyl-5-fluoro-4-hydroxy-phenyl)-ethyl]-dihydro-pyran- 2,4-dione. 1H NMR (400 MHz, DMSO-d6) δ: 1.13 (t, 7=7.6 Hz, 3 H), 1.46-1.76 (br m, 8 H), 2.15 (m, 2 H), 2.45-2.64 (m, 12 H), 2.85 (d, 7=17.4 Hz, 1 H), 3.40 (s, 3 H), 3.71 (t, 7=4.6 Hz, 2 H), 3.79 (d, 7=16.2 Hz, 1 H), 3.89 (d, 7=16.2 Hz, 1 H), 4.12 (d, 7=4.8 Hz, 2 H), 6.89 (d, 7=8.3 Hz, 1 H), 7.01 (s, 1 H), 7.06 (dd, 7= 8.3, 2.3 Hz, 1 H), 7.10 (s, 1 H), 10.95 (s, 1 H). Anal. Calcd. For C31H40N4O5O.75H2O: C, 66.23; H, 7.44; N, 9.97. Found: C, 66.23; H, 7.36; N, 9.81.
Example A(184): 6-Cyclopentyl-6-{2-[3-ethyl-4-(2-methoxy-ethoxy)-phenyl]-ethyl}-dihydro- pyran-2,4-dione
Figure imgf000202_0001
The title compound was prepared analogously to Example A(178) where 4-bromo-2- ethyl-phenol (from step 1) was substituted in place of 2-bromo-4-ethyl-phenol in step 1 of that example. 1H NMR (400 MHz, CDCI3): δ 1.18 (t, 7=7.3 Hz, 3 H), 1.46-1.78 (br m, 8 H), 1.89-2.02 (m, 2 H), 2.27 (s, 1 H), 2.62 (m, 4 H), 2.76 (s, 2 H), 3.42 (s, 2 H), 3.45 (s, 3 H), 3.76 (t, 7=4.8 Hz, 2 H), 4.09 (t, 7=5.0 Hz, 2 H), 6.75 (d, 7=9.1 Hz, 1 H), 6.91 (m, 2 H). Anal. Calcd. For C23H3205: C, 71.11; H, 8.31. Found: C, 71.07; H, 8.27.
Step 1: 4-Bromo-2-ethyl-phenol
Figure imgf000202_0002
A solution of tetrabutyl ammonium tribromide (41.4g, 86 mmol) in CHCI3 (100 mL) was added to a stirred solution of 2-ethyl phenol (10 g, 81.8 mmol) dissolved in CHCI3 (100 mL). The reaction mixture was stirred for 1 hr and then quenched with 5% solution of sodium thiosulfate (100 mL). The biphasic mixture was stirred for 30 mins and then the layers were separated. The organic layer was washed with 1N HCl, saturated NaHC03, brine, dried over Na2S04 and concentrated. The crude residue was purified by flash column chromatography (0 - 10% EtOAc in hexanes) to give the desired product (14.3 g, 87%). 1H NMR (400 MHz, CDCI3): δ 1.22 (t, 7=7.5 Hz, 3 H), 2.60 (q, 7=7.5 Hz, 2 H), 6.64 (d, 7=8.5 Hz, 1 H), 7.17 (dd, 7=8.5, 2.5 Hz, 1 H), 7.24 (d, 7=2.5 Hz, 1 H). Example A(185): 6-Cyclopentyl-6-{2-[3-ethyl-4-(2-methoxy-ethoxy)-phenyl]-ethyl}-4- hydroxy-3-(6-methyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-ylmethyl)-5,6-dihydro-pyran-2-one
Figure imgf000203_0001
The title compound was prepared analogously to Example A(126) where 6-cyclopentyl-6- {2-[3-ethyl-4-(2-methoxy-ethoxy)-phenyl]-ethyl}-dihydro-pyran-2,4-dione (Example A(184)) was substituted in place of 6-Cyclopentyl-6-[2-(3-ethyl-4-hydroxy-phenyl)-ethyl]-dihydro-pyran-2,4- dione. 1H NMR (400 MHz, DMSO-d6) δ: 1.09 (t, 7=7.6 Hz, 3 H), 1.40-1.76 (br m, 8 H), 2.08 (m, 2 H), 2.35 (s, 3 H), 2.40 (m, 1 H), 2.52 (m, 5 H), 2.79 (d, 7=14.9 Hz, 1 H), 3.33 (s, 3 H), 3.67 (t, 7=3.0 Hz, 2 H), 3.74 (d, 7=15.9 Hz, 1 H), 3.82 (d, 7=15.9 Hz, 1 H), 4.06 (d, 7=3.0 Hz, 2 H), 6.83 (d, 7=8.1 Hz, 1 H), 6.97 (s, 1 H), 6.98 (d, 7= 8.1 Hz, 1 H), 8.70 (s, 1 H), 8.85 (s, 1 H), 10.85 (s, 1 H). MS (ESI): 535.20 (M+H+).
Example A(186): 6-Cyclopentyl-3-(5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-ylmethyl)-6- [2-(3-ethyI-5-hydroxy-phenyl)-ethyl]-4-hydroxy-5,6-dihydro-pyran-2-one
Figure imgf000203_0002
The title compound was prepared analogously to Example A(123) where 6-cyclopentyl-6- [2-(3-ethyl-5-hydroxy-phenyl)-ethyl]-dihydro-pyran-2, 4-dione (from step 2 below) was substituted in place of 6-cyclopentyl-6-[2-(3-ethyl-5-fluoro-4-hydroxy-phenyl)-ethyl]-dihydro-pyran-2,4-dione. 1H NMR (400 MHz, DMSO-d6) δ: 1.29 (t, 7=7.6 Hz, 3 H), 1.59-1.87 (br m, 8 H), 2.28 (m, 2 H), 2.60-2.73 (m, 12 H), 2.96 (d, 7=17.9 Hz, 1 H), 3.90 (d, 7=16.4 Hz, 1 H), 4.01 (d, 7=16.2 Hz, 1 H), 6.60 (s, 1 H), 6.65 (s, 1 H), 6.66 (s, 1 H), 7.24 (s, 1 H), 9.34 (s, 1 H), 11.10 (s, 1 H). Anal. Calcd. For C28H34N404O.4AcOH: C, 67.21; H, 6.97; N, 10.89. Found: C, 67.48; H, 7.05; N, 10.53.
Step 2: 6-Cyclopentyl-6-[2-(3-ethyl-5-hydroxy-phenyl)-ethyl]-dihydro-pyran-2,4-dione 203
Figure imgf000204_0001
The title compound was prepared analogously to Example A(124) where 3-bromo-5- ethyl-phenolwas substituted in place of 4-bromo-2-ethyl-6-fluoro-phenol in step 4 of that example. 1H NMR (400 MHz, CDCI3): δ 1.20 (t, 7=7.6 Hz, 3 H), 1.45-1.76 (br m, 8 H), 1.96 (m, 2 H), 2.27 (m, 1 H), 2.58 (m, 4 H), 2.76 (s, 2 H), 3.42 (s, 2 H), 4.75 (s, 1 H), 6.44 (s, 1 H), 6.53 (s, 1 H), 6.55 (s, 1 H). MS (ESI): 329.00 (M-H+).
Step 2: 3-Bromo-5-ethyl-phenol
Figure imgf000204_0002
The title compound was prepared as described in the following reference: J. Chem Soc Perkin Trans 1, 1984, 1621-1626.
Example A(187): 6-Cyclopentyl-3-(5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-ylmethyl)-6- [2-(5-ethyl-2-hydroxy-4-methoxy-phenyl)-ethyl]-4-hydroxy-5,6-dihydro-pyran-2-one
Figure imgf000204_0003
The title compound was prepared analogously to Example A(124) where 6-cyclopentyl-6-
[2-(5-ethyl-2-hydroxy-4-methoxy-phenyl)-ethyl]-dihydro-pyran-2,4-dione was substituted in place of 6-cyclopentyl-6-[2-(3-ethyl-5-fluoro-4-hydroxy-phenyl)-ethyl]-dihydro-pyran-2,4-dione. 1H NMR (400 MHz, DMSO-d6) δ: 1.06 (t, 7=7.3 Hz, 3 H), 1.47-1.78 (br m, 8 H), 1.97 (m, 1 H), 2.15 (m, 2 H), 2.42-2.69 (m, 11 H), 2.80 (d, 7= 17.6 Hz, 1 H), 3.74 (s, 3 H), 3.78 (d, 7= 16.4 Hz, 1 H), 3.85 (d, 7= 16.4 Hz, 1 H), 6.44 (s, 1 H), 6.79 (s, 1 H), 7.10 (s, 1 H), 9.13 (s, 1 H), 10.90 (s, 1 H). MS (ESI): 521.20 (M+H+). Step 4: 6-Cyclopentyl-6-[2-(5-ethyl-2-hydroχy-4-methoxy-phenyl)-ethyl]-dihydro-pyran-2,4- dione
Figure imgf000205_0001
The title compound was prepared analogously to Example A(124) where 1-benzyioxy-2- bromo-4-ethyl-5-methoxy-benzene (from step 3 below) was substituted in place of acetic acid 4- bromo-2-ethyl-6-fluoro-phenyl ester. MS (ESI): 361.10 (M+H+).
Step 3: 1-Benzyloxy-2-bromo-4-ethyl-5 zene
Figure imgf000205_0002
Sodium hydroxide (0.39g, 9.7mmol) and hydrazine monohydrate (0.57mL, 11.7 mmol) were added to a solution of 1-(4-benzyloxy-5-bromo-2-methoxy-phenyl)-ethanone (1.3g, 3.9 mmol) dissolved in triethylene glycol (5mL). The reaction mixture was heated to 170°C for 24 hours and then partitioned between 1N HCl and EtOAc. The organic layer was washed with brine, dried over Na2S04and concentrated. The residue was purified by flash silica gel chromatography (0% to 5% EtOAc in hexanes) to give the title compound (0.52 g, 40%). 1H NMR (400 MHz, CDCI3): δ 1.14 (t, 7=7.3 Hz, 3 H), 2.53 (q, 7=7.3 Hz, 2 H), 3.75 (s, 3 H), 5.14 (s, 2 H), 6.48 (s, 1 H), 7.26 (s, 1 H), 7.32 (m, 1 H), 7.39 (m, 2 H), 7.49 (d, 7=8.3 Hz, 2 H).
Step 2: 1-(4-Benzyloxy-5-bromo-2-methoxy-phenyl)-ethanone
Figure imgf000205_0003
A solution of tetrabutyl ammonium tribromide (12.1g, 25 mmol) in CHCI3 (75 mL) was added to a stirred solution of 1-(4-benzyloxy-2-hydroxy-phenyl)-ethanone (6.07 g, 25.1 mmol) dissolved in CHCI3 (75 mL). The reaction mixture was stirred for 18 hrs and then quenched with
5% solution of sodium thiosulfate (100 mL). The biphasic mixture was stirred for 30 mins and then the layers were separated. The organic layer was washed with 1 N HCl, saturated NaHC03, brine, dried over Na2S04 and concentrated to a brown oil.
The oil was dissolved in DMF (30mL) and treated with potassium carbonate (10.4g, 75.3 mmol) followed by methyl iodide (1.9 mL, 30 mmol). The mixture was stirred for 20 hours and then partitioned between 1 N HCl and EtOAc. The organic layers were washed with brine, dried over Na2S04and concentrated. The oil was purified by flash column chromatography (0% to 15% EtOAc in hexanes) to give the desired product (2.39 g, 28%). 1H NMR (400 MHz, CDCI3): δ 2.55 (s, 3 H), 3.85 (s, 3 H), 5.23 (s, 2 H), 6.48 (s, 1 H), 7.32-7.43 (m, 3 H), 7.47 (d, 7=8.3 Hz, 2 H), 8.06 (s, 1 H).
Step 1: 1-(4-Benzyloxy-2-hydroxy-phenyl)-ethanone
Figure imgf000206_0001
Potassium carbonate (27.2g, 0.2 mol) followed by benzyl bromide (7.04 mL, 59.2 mmol) were added to a solution of 1-(2,4-dihydroxy-phenyl)-ethanone (10g, 66 mmol) in DMF (90mL). The mixture was stirred for 2 hours and then partitioned between 1 N HCl and EtOAc. The organic layers were washed with brine, dried over Na2S04and concentrated. Purification by flash column chromatography (0%> to 20%> EtOAc in hexanes) followed by recrystallization gave the title compound as a white solid (8.7 g, 55%). 1H NMR (400 MHz, CDCI3): δ 2.55 (s, 3 H), 5.09 (s, 2 H), 6.50 (s, 1 H), 6.51 (dd, 7=9.1, 3.9 Hz, 1 H), 7.34-7.43 (m, 5 H), 7.64 (d, 7=9.1 Hz, 1 H), 12.73 (s, 1 H).
Example A(188): 1 -(4-{2-[2-Cyclopentyl-5-(5,7-dimethyl-[1 ,2,4]triazolo[1 ,5-a]pyrimidin-2- ylmethyl)-4-hydroxy-6-oxo-3,6-dihydro-2r -pyran-2-yl]-ethyl}-2-fluoro-phenyl)- cyclopentanecarbonitrile
Figure imgf000206_0002
The title compound was prepared analogously to Example A(97) 2-[4-(2-{2-cyclopentyl- 5-[(2-ethyl-4-methyl-1H-imidazol-5-yl)methyl]-4-hydroxy-6-oxo-3,6-dihydro-2/-/-pyran-2-yl}ethyI)-2- fluorophenyl]-2-methylpropanenitrile where 1-{4-[2-(2-Cyclopentyl-4,6-dioxo-tetrahydro-pyran-2- yl)-ethyl]-2-fluoro-phenyl}-cyclopentanecarbonitrile Example A(189) was substituted in place of 2- {4-[2-(2-cyclopentyl-4-hydroxy-6-oxo-3,6-dihydro-2H-pyran-2-yl)ethyl]-2-fluorophenyl}-2- methylpropanenitrile and 5,7-Dimethyl-[1,2,4]triazolo[1,5-a]pyrimidine-2-carbaldehyde was substituted in place of 2-ethyl-4-methyl-1H-imidazole-5-carbaldehyde. 1H NMR (400 MHz, CDCI3) δ: 1.44-1.96 (m, 17 H), 2.14-2.22 (m, 2 H), 2.56-2.62 (m, 8 H), 2.70-2.74 (m, 2 H), 3.79 (d, 7=16 Hz, 1 H), 3.92 (d, J = 16 Hz, 1 H), 7.12 (s, 1 H), 7.24 (s, 1 H), 7.26 (d, 7=5 Hz, 1 H), 7.42- 7.47 (m, 1 H), 10.9 (s, 1 H). Anal. Calcd. For C32H36FN503: C, 68.92; H, 6.51; N, 12.56. Found: C, 68.74; H, 6.60; N, 12.47. MS (ESI): 558 (M+H)+.
Example A(189): 1-{4-[2-(2-Cyclopentyl-4,6-dioxo-tetrahydro-pyran-2-yl)-ethyl]-2-fluoro- phenylj-cyclopentanecarbonitrile (
Figure imgf000207_0001
The title compound was prepared analogously to step 4 from Example A(97) where 1-{4- [3-Cyclopentyl-4- (2,2-dimethyl-6-oxo-6AV-[1,3]dioxin-4-yl)-3-hydroxy-but-1-ynyl]-2-fluoro-phenyl}- cyclopentanecarbonitrile (from step 2 below) was substituted in place of 2-{4-[3-cyclopentyl-4- (2,2-dimethyl-4-oxo-4H-1,3-dioxin-6-yl)-3-hydroxybut-1-ynyl]-2-fluorophenyl}-2- methylpropanenitrile. 1H NMR (CDCI3) δ: 1.18-1.74 (m, 16 H), 1.92-2.17 (m, 2 H), 2.5-2.52 (m, 1H), 2.66-2.68 (m, 2 H), 2.77 (s, 2 H), 3.43 (s, 2 H), 6.89-6.94 (m, 2 H), 7.33 - 7.37 (m, 1 H). MS (ESI): 398 (M+H)+.
Step 2: 1-{4-[3-Cyclopentyl-4-(2,2-dimethyl-6-oxo-6W-[1,3]dioxin-4-yl)-3-hydroxy-but-1- ynyl]-2-fluoro-phenyl}-cyclopentanecarbonitrile
Figure imgf000208_0001
The title compound was prepared analogously to step 3 from Example A(97) where 1-(4- Bromo-2-fluoro-phenyl)-cyclopentanecarbonitrile (described in step 1 below) was substituted in place of 2-(4-Bromo-2-fluoro-phenyl)-2-methyl-propionitrile in step 3 of that example . MS (ESI): 452 (M+H)+.
Step 1: 2-(4-Bromo-2-chloro-phenyl)-2-methyl-propionitrile
Figure imgf000208_0002
(4-bromo-2-fluorophenyl)acetonitrile (1 g, 4.67 mmol) described in step 1 from Example A(97) , benzyltriethylammonium chloride (0.02 g, 0.09 mmol) and 1 ,4-Dibromobutane (1.43 g, 0.79 mmol) were dissolved 50% aqueous NaOH (3 mL) and the resulting mixture was stirred for 3 hours at 50 °C. Reaction was quenched with 4N HCl (50 mL extracted with EtOAc. The organic phase was dried over Na2S0 and evaporated. The crude organic product was purified by flash column chromatography (5% EtOAc in hexanes) to give the product (1.25 g, 100%>) as a clear oil). 1H NMR (CDCI3) δ: 1.93-2.17 (m, 4 H), 2.50-2.55 (m, 2 H), 3.42-3.46 (m, 2H), 7.26-7.34 (m, 3 H).
Example A(190): 1-(4-{2-[2-Cyclopentyl-4-hydroxy-5-(6-methyl-[1,2,4]triazolo[1,5- a]pyrimidin-2-ylmethyl)-6-oxo-3,6-dihydro-2H-pyran-2-yl]-ethyl}-2-fluoro-phenyl)- cyclopentanecarbonitrile
Figure imgf000209_0001
The title compound was prepared analogously to Example A(97) where 6-Methyl- [1,2,4]triazolo[1,5-a]pyrimidine-2-carbaldehyde was substituted in place of 2-ethyl-4-methyl-1H- imidazole-5-carbaIdehyde and 1-{4-[2-(2-Cyclopentyl-4,6-dioxo-tetrahydro-pyran-2-yl)-ethyl]-2- fluoro-phenyl}-cyclopentanecarbonitrile (Example A(189) ( was substituted in place of 2-{4-[2-(2- cyclopentyl-4-hydroxy-6-oxo-3,6-dihydro-2H-pyran-2-yi)ethyI]-2-fluorophenyl}-2- methylpropanenitrile. 1H NMR (400 MHz, CDCI3) δ: 1.35-2.16 (m, 16 H), 2.42-2.82 (m, 7 H), 3.33 (s, 3 H), 3.74 (d, 7=16 Hz, 1 H), 3.84 (d, 7=16 Hz, 1 H), 7.14-7.19 (m, 2 H), 7.36-7.41 (m, 1 H), 8.71 (s, 1 H), 9 (s, 1 H), 10.9 (s, 1 H). Anal. Calcd. For C31H34FN5O30.75H2O: C, 66.83; H, 6.42; N, 12.57. Found: C, 66.93; H, 6.18; N, 12.45. MS (ESI): 544 (M+H)+.
Example A(191): 1-(4-{2-[5-(6-Chloro-[1,2,4]triazolo[1,5-a]pyrimidin-2-ylmethyl)-2- cyclopentyl-4-hydroxy-6-oxo-3,6-dihydro-2H-pyran-2-yl]-ethyl}-2-fluoro-phenyl)- cyclopentanecarbonitrile
Figure imgf000209_0002
The title compound was prepared analogously to Example A(97) where 6-Chloro- [1,2,4]triazolo[1,5-a]pyrimidine-2-carbaldehyde was substituted in place of 2-ethyl-4-methyl-1 H- imidazole-5-carbaldehyde and 1-{4-[2-(2-Cyclopentyl-4,6-dioxo-tetrahydro-pyran-2-yl)-ethyl]-2- fluoro-phenyl}-cyciopentanecarbonitrile (Example A(189) ( was substituted in place of 2-{4-[2-(2- cyclopentyl-4-hydroxy-6-oxo-3,6-dihydro-2H-pyran-2-yl)ethyl]-2-fluorophenyl}-2- methylpropanenitrile. 1H NMR (400 MHz, CDCI3) δ: 1.41-1.98 (m, 17 H), 2.30-2.68 (m, 6 H), 3.62 (d, 7=16 Hz, 1 H), 3.71 (d, 7=16 Hz, 1 H), 6.99-7.03 (m, 2 H), 7.21-7.25 (m, 1 H), 8.74 (s, 1 H), 9.45 (s, 1 H), 10.8 (s, 1 H). Anal. Calcd. For C30H31CIFN5O3: C, 63.88; H, 5.54; N, 12.42. Found: C, 63.73; H, 5.71; N, 12.17. MS (ESI): 564 (M+H)+.
Example A(192): 6-Cyclopentyl-3-(5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-ylmethyl)-4- hydroxy-6-[2-(4-hydroxy-3-methoxymethyl-phenyl)-ethyl]-5,6-dihydro-pyran-2-one 209
Figure imgf000210_0001
The title compound was prepared analogously to Example A(97) where 6-Cyclopentyl-6- [2-(4-hydroxy-3-methoxymethyl-phenyl)-ethyl]-dihydro-pyran-2,4-dione (Example A(194)) was substituted in place of 2-{4-[2-(2-cyclopentyl-4-hydroxy-6-oxo-3,6-dihydro-2H-pyran-2-yl)ethyl]-2- fluorophenyl}-2-methylpropanenitrile and 5,7-Dimethyl-[1 ,2,4]triazolo[1 ,5-a]pyrimidine-2- carbaldehyde was substituted in place of 2-ethyl-4-methyl-1 V-imidazole-5-carbaldehyde in that example. 1H NMR (400MHz, DMSO-d6): δ 1.5-2.0 (m, 11H) 2.46-2.75 (m, 11H), 3.25 (s, 3H), 3.73 (d, 7 = 16 Hz, 1H), 3.80 (d, 7= 16 Hz, 1H), 4.32 (s, 2H), 6.70 (d, 7= 8 Hz, 1H), 6.94-7.04 (m, 3 H), 9.20 (s, 1H). Anal. Calcd. For C28H34N405.1.5H20: C, 63.02; H, 6.99; N, 10.50. Found: C, 63.92; H, 6.74; N, 10.42. MS (ESI): 507.2 (M+H)+.
Example A(193): 6-Cyclopentyl-3-(5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-ylmethyl)-4- hydroxy-6-[2-(4-hydroxy-3-hydroxymethyl-phenyl)-ethyl]-5,6-dihydro-pyran-2-one
Figure imgf000210_0002
The title compound was prepared analogously to Example A(97) where 6-Cyclopentyl-6- [2-(4-hydroxy-3-hydroxymethyl-phenyl)-ethyl]-dihydro-pyran-2,4-dione (Example A(195)) was substituted in place of 2-{4-[2-(2-cyclopentyl-4-hydroxy-6-oxo-3,6-dihydro-2/V-pyran-2-yl)ethyl]-2- fluorophenyl}-2-methylpropanenitrile and 5,7-Dimethyl-[1 ,2,4]triazolo[1 ,5-a]pyrimidine-2- carbaldehyde was substituted in place of 2-ethyl-4-methyl-1 V-imidazole-5-carbaldehyde from that example. 1H NMR (400MHz, DMSO-d6): δ 1.34-2.09 (m, 11H) 2.0-2.21 (m, 2H), 2.47-2.74 (m, 10H), 3.74 (d, 7 = 16 Hz, 1H), 3.80 (d, 7 = 16 Hz, 1H), 4.44 (s, 2H), 6.65 (d, 7 = 8 Hz, 1H), 6.88 (d, 7 = 8 Hz, 1H), 7.04 (s, 1H), 7.09 (s, 1H), 9.06 (s, 1H). Anal. Calcd. For C27H32N405.H20: C, 62.96; H, 6.75; N, 10.88. Found: C, 62.97; H, 6.57; N, 10.83. MS (ESI): 493.2 (M+H)+. Example A(194): 6-Cyclopentyl-6-[2-(4-hydroxy-3-methoxymethyl-phenyl)-ethyl]-dihydro- pyran-2,4-dione
Figure imgf000211_0001
The title compound was prepared analogously to step 4 from Example A(97) where Acetic acid 2-acetoxy-5-[3-cyclopentyl-4-(2,2-dimethyl-6-oxo-6H-[1 ,3]dioxin-4-yl)-3-hydroxy-but-1 - ynyl]-benzyl ester (from step 2 below ) was substituted in place of 2-{4-[3-cyclopentyl-4-(2,2- dimethyl-4-oxo-4/-/-1,3-dioxin-6-yl)-3-hydroxybut-1-ynyl]-2-fluorophenyl}-2-methylpropanenitrile. The product was obtained together with Example A(195) 6-Cyclopentyl-6-[2-(4-hydroxy-3- hydroxymethyl-phenyl)-ethyl]-dihydro-pyran-2,4-dione below. 1H NMR (400MHz, CDCl3): δ 1.48- 1.82 (m, 8H), 1.87-2.09 (m, 3H), 2.22-2.28 (m, 1H), 2.55-2.61 (m, 2H), 2.76 (s, 2H), 3.41 (s, 2H), 3.45 (2, 3H), 4.62 (2, 2H), 6.78-6.82 (m, 1H), 6.96-6.99 (m, 1H), 7.38 (s, 1H). ESIMS (MH-): 345.
Example A(195): 6-Cyclopentyl-6-[2-(4-hydroxy-3-hydroxymethyl-phenyl)-ethyl]-dihydro- pyran-2,4-dione
Figure imgf000211_0002
The title compound was prepared analogously to step 4 from Example A(97) where Acetic acid 2-acetoxy-5-[3-cyclopentyl-4-(2,2-dimethyl-6-oxo-6H-[1 ,3]dioxin-4-yl)-3-hydroxy-but-1 - ynyl]-benzyl ester (from step 2 below ) was substituted in place of 2-{4-[3-cyclopentyl-4-(2,2- dimethyl-4-oxo-4/-/-1 ,3-dioxin-6-yl)-3-hydroxybut-1-ynyl]-2-fluorophenyl}-2-methylpropanenitrile. The product was obtained together with compound from Example A(194) . 6-Cyclopentyl-6-[2-(4- hydroxy-3-methoxymethyl-phenyl)-ethyl]-dihydro-pyran-2,4-dione above H NMR (400MHz, CDCI3): δ 1.30-1.80 (m, 9H), 1.83-1.86 (m, 2H), 2.15-2.18 (m, 1H), 2.49-2.54 (m, 2H), 2.67 (s, 2H), 3.33 (s, 2H), 4.76 (s, 2H), 6.71-6.91 (m, 3H). ESIMS (MH-): 331. Step 2: Acetic acid 2-acetoxy-5-[3-cyclopentyl-4-(2,2-dimethyl-6-oxo-6W-[1,3]dioxin-4-yl)-3- hydroxy-but-1-ynyl]-benzyl ester.
Figure imgf000212_0001
The title compound was prepared analogously to step 3 from Example A(97) where
Acetic acid 2-acetoxy-5-bromo-benzyl ester (described in step 1 below) was substituted in place of 2-(4-Bromo-2-fluoro-phenyl)-2-methyl-propionitrile in step 3 of that example. MS (ESI): 471 (M+H)+.
Step 1 : 2-(4-Bromo-2-chloro-phenyl)-2-methyl-[1 ,3]dioxolane.
Figure imgf000212_0002
Acetyl chloride (4.38 mL g, 61.56 mmol followed by TEA (8.58 mL, 61.56 mmol were added to a solution of 5-bromo-2-hydroxyphenol (5 g, 24.63 mmol in CH2CL2 (120 mL). The resulting mixture was stirred overnight at room temperature. The CH2Cl2 was then evaporated and residue was partitioned between EtOAc and 1N HCl. The organic phase was dried over Na2S04 and evaporated. The crude organic product was purified by flash column chromatography (30% EtOAc in hexanes) to give the product (7.07 g, 100%o) as a pale yellow oil).
1H NMR (CDCIs) $ 2.09 (s, 3H), 2.32 (s, 3H), 5.03 (s, 2H), 6.99 (d, 7 = 8.6 Hz, 1H), 7.47 (dd, 7 = 8, 2.3 Hz, 1H), 7.58 (d, 7 = 2.3 Hz, 1H). ESIMS (MH+): 286.2. Example A(196): 6-Cyclopentyl-3-(5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-ylmethyl)-6- {2-[3-fluoro-4-(1-hydroxy-ethyl)-phenyl]-ethyl}-4-hydroxy-5,6-dihydro-pyran-2-one
Figure imgf000213_0001
enantiomer 1
The title compound was separated from racemic Example A(146) ( 2-(2-Chloro-4-{2-[2- cyclopentyl-5-(5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-ylmethyl)-4-hydroxy-6-oxo-3,6- dihydro-2H-pyran-2-yl]-ethyl}-phenyl)-2-methyl-propionitrile. using chiral HPLC: Chiralpak AS-H, 140 Bar, 2.5 mL/min, 35% MeOH. 70% recovery. (3.61 min retention time).
Example A(197): 6-Cyclopentyl-3-(5,7-dimethyl-[1 ,2,4]triazolo[1 ,5-a]pyrimidin-2-ylmethyl)-6- {2-[3-fluoro-4-(1-hydroxy-ethyl)-phenyl]-ethyl}-4-hydroxy-5,6-dihydro-pyran-2-one
Figure imgf000213_0002
enantiomer 2
The title compound was separated from racemic Example A(146) ( 2-(2-Chloro-4-{2-[2- cyclopentyl-5-(5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-ylmethyl)-4-hydroxy-6-oxo-3,6- dihydro-2H-pyran-2-yl]-ethyl}-phenyl)-2-methyl-propionitrile. using chiral HPL (Chiralpak AS-H, 140 Bar, 2.5 mL/min, 35% MeOH. 70% recovery. (12 min retention time).
Example A(198): 2-(2-Chloro-4-{2-[5-(6-chloro-[1 ,2,4]triazolo[1 ,5-a]pyrimidin-2-ylmethyl)-2- cyclopentyl-4-hydroxy-6-oxo-3,6-dihydro-2W-pyran-2-yl]-ethyl}-phenyl)-2-methyl- propionitrile
Figure imgf000213_0003
The title compound was prepared analogously to Example A(97) where 6-Chloro- [1,2,4]triazolo[1,5-a]pyrimidine-2-carba!dehyde was substituted in place of 2-ethyl-4-methyl-1 H- imidazole-5-carbaldehyde and 2-{2-Chloro-4-[2-(2-cyclopentyl-4,6-dioxo-tetrahydro-pyran-2-yl)- ethyl]-phenyl}-2-methyl-propionitrile from Example A(147) ( was substituted in place of 2-{4-[2-(2- cyclopentyl-4-hydroxy-6-oxo-3,6-dihydro-2/-/-pyran-2-yl)ethyl]-2-fluorophenyl}-2- methylpropanenitrile. 1H NMR (400 MHz, CDCI3) δ: 1.17 - 1.59 (m, 8H), 1.56-1.6 (m, 2H)), 1.82 (s, 6H), 1.88-2.01 (m, 2H), 2.31-2.79 (m, 3H), 3.79 (d, 7 = 16 Hz, 1H), 3.89 (d, 7 = 16 Hz, 1 H), 7.34-7.52 (m. 3H), 8.91 (d, 7 = 2.5 Hz, 1H), 9.63 (d, 7 = 2.5 Hz, 1H), 10.9 (s, 1H). C28H29CI2N503: C, 60.65; H, 5.27; N, 12.63. Found: C, 60.45; H, 5.19; N, 12.40. MS (ESI): 555.2(M+H+).
Example A(199): 2-(2-Chloro-4-{2-[2-cyclopentyl-4-hydroxy-5-(6-methyl-[1,2,4]triazolo[1 ,5- a]pyrimidin-2-ylmethyl)-6-oxo-3,6-dihydro-2H-pyran-2-yl]-ethyl}-phenyl)-2-methyl- propionitrile
Figure imgf000214_0001
The title compound was prepared analogously to Example A(97) where 6-Methyl- [1,2,4]triazolo[1,5-a]pyrimidine-2-carbaldehyde was substituted in place of 2-ethyl-4-methyl-1H- imidazole-5-carbaldehyde and 2-{2-Chloro-4-[2-(2-cyclopentyl-4,6-dioxo-tetrahydro-pyran-2-yl)- ethyl]-phenyl}-2-methyl-propionitril from Example A(147) ( was substituted in place of 2-{4-[2-(2- cyclopentyl-4-hydroxy-6-oxo-3,6-dihydro-2H-pyran-2-yl)ethyl]-2-fluorophenyl}-2- methylpropanenitrile. 1H NMR (400 MHz, CDCI3) δ: 1.17 - 1.59 (m, 8H), 1.59-1.62 (m, 2H)), 1.62 (s, 6H), 1.82-2.01 (m, 2H), 2.19 (s, 3H), 2.38-2.65 (m, 3H), 3.55 (d, 7 = 16 Hz, 1H), 3.65 (d, 7 = 16 Hz, 1H), 7.15-7.32 (m. 3H), 8.53 (d, 7 = 2.3Hz, 1H), 8.82 (s, 1H), 10.7 (s, 1H). C29H32CIN503: C, 65.22; H, 6.04; N, 13.11. Found: C, 65.15; H, 5.99; N, 13.10. MS (ESI): 535.2(M+H+).
Example A(200): 1 -(2-Chloro-4-{2-[2-cyclopentyl-5-(5,7-dimethyl-[1 ,2,4]triazolo[1 ,5- a]pyrimidin-2-ylmethyl)-4-hydroxy-6-oxo-3,6-dihydro-2r -pyran-2-yl]-ethyl}-phenyl)- cyclopropanecarbonitrile
Figure imgf000215_0001
enantiomer 1
The title compound was separated from racemic Example A(148) ( 1-(2-Chloro-4-{2-[2- cyclopentyl-5-(5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-ylmethyl)-4-hydroxy-6-oxo-3,6- dihydro-2AV-pyran-2-yl]-ethyl}-phenyl)-cyclopropanecarbonitrile. using chiral HPLC (Chiralpak AS- H, 120 Bar, 2.5 mL/min, 35% MeOH). 70% recovery. (2.31 min retention time).
Example A(201): 1-(2-Chloro-4-{2-[2-cyclopentyI-5-(5,7-dimethyl- [1 ,2,4]triazolo[1 ,5a]pyrimidin 2-ylmethyl)-4-hydroxy-6-oxo-3,6-dihydro-2H-pyran-2-yl]-ethyl}-phenyl)- cyclopropanecarbonitrile
Figure imgf000215_0002
The title compound was separated from racemic Example A(148) ( 1-(2-Chloro-4-{2-[2- cyclopentyl-5-(5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-ylmethyl)-4-hydroxy-6-oxo-3,6- dihydro-2/-/-pyran-2-yl]-ethyl}-phenyl)-cyclopropanecarbonitrile. using chiral HPLC (Chiralpak AS- H, 120 Bar, 2.5 mL/min, 50% MeOH). 70% recovery. (10.26 min retention time).
Example A(202): 2-(2-Chloro-4-{2-[2-cyclopentyl-4-hydroxy-5-(6-methyl-[1,2,4]triazolo[1,5- a]pyrimidin-2-ylmethyl)-6-oxo-3,6-dihydro-2W-pyran-2-yl]-ethyl}-phenyl)-2-methyl- propionitrile
Figure imgf000215_0003
The title compound was separated from racemic Example A(199) ( using chiral HPLC (Chiralpak AS-H, 130 Bar, 2.5 mL/min, 25% MeOH. 70% recovery. (7.16 min retention time).
Example A(203): 2-(2-Chloro-4-{2-[2-cyclopentyl-4-hydroxy-5-(6-methyl-[1,2,4]trϊazolo[1 ,5- a]pyrimidin-2-ylmethyl)-6-oxo-3,6-dihydro-2r-pyran-2-yl]-ethyl}-phenyl)-2-methyl- propionitrile
Figure imgf000216_0001
The title compound was separated from racemic Example A(199) using chiral HPL (Chiralpak AS-H, 130 Bar, 2.5 mL/min, 25% MeOH. 70% recovery. (14.71 min retention time).
Example A(204): 2-(2-Chloro-4-{2-[5-(6-chloro-[1,2,4]triazolo[1,5-a]pyrimidin-2-ylmethyl)-2- cyclopentyl-4-hydroxy-6-oxo-3,6-dihydro-2H-pyran-2-yl]-ethyl}-phenyl)-2-methyl- propionitrile
Figure imgf000216_0002
The title compound was separated from racemic Example A(198) using chiral HPLC (Chiralpak AS-H, 140 Bar, 2.5 mL/min, 20% MeOH. 70% recovery. (17.33 min retention time).
Example A(205): 2-(2-Chloro-4-{2-[5-(6-chloro-[1 ,2,4]triazolo[1 ,5-a]py rimidin-2-y lmethyl)-2- cyclopentyl-4-hydroxy-6-oxo-3,6-dihydro-2H-pyran-2-yl]-ethyl}-phenyl)-2-methyl- propionitrile
Figure imgf000216_0003
The title compound was separated from racemic Example A(198) using chiral HPLC (Chiralpak AS-H column, 140 Bar, 2.5 mL/min, 20% MeOH. 70% recovery. (28.93 min retention time).
Example A(206): 3-[(6-ethyl[1 ,2,4]triazolo[1 ,5-a]pyrimidin-2-yl)methyl]-6-cyclopentyl-6-[2-(5- ethyl-4-hydroxy-2-methoxyphenyl)ethyl]-4-hydroxy-5,6-dihydro-2H-pyran-2-one
Figure imgf000217_0001
The title compound was prepared analogously to Example A (150), where 6- ethyl[1 ,2,4]triazolo[1,5-a]pyrimidine-2-carbaldehyde was substituted in place of 5,7- dimethyl[1 ,2,4]triazolo[1,5-a]pyrimidine-2-carbaldehyde. 1H NMR (300 MHz, DMSO-d6) δ: 1.03 (t, 7=7.44 Hz, 3 H), 1.23 (t, 7=7.44 Hz, 3 H), 1.36-1.74 (m, 8 H), 1.89-2.01 (m, 2 H), 2.33-2.45 (m, 4 H), 2.55-2.60 (m, 1 H), 2.64-2.79 (m, 4 H), 3.62 (s, 3 H), 3.72-3.78 (m, 2 H), 6.37 (s, 1 H), 6.75 (s, 1 H), 8.73 (d, 7=1.88 Hz, 1 H), 8.86 (s, 1 H), 9.02 (s, 1 H). Anal, calcd for C29H36N4θ5 0.8H2O: C, 65.10; H, 7.08; N, 10.47. Found C, 65.03; H, 6.77; N, 10.34.
Example A(207): 6-cyclopentyl-6-[2-(5-ethyl-4-hydroxy-2-methoxyphenyl)ethyl]-4-hydroxy- 3-([1,2,4]triazolo[1,5-a]pyrimidin-2-ylmethyl)-5,6-dihydro-2W-pyran-2-one
Figure imgf000217_0002
The title compound was prepared analogously to Example A(150), where [1,2,4]triazolo[1 ,5-a]pyrimidine-2-carbaldehyde was substituted in place of 5,7- dimethyl[1,2,4]triazolo[1,5-a]pyrimidine-2-carbaldehyde. 1H NMR (300 MHz, DMSO-d6) δ: 0.96 (t, 7=7.44 Hz, 3 H), 1.30-1.69 (m, 8 H), 1.81-1.90 (m, 2 H), 2.28-2.38 (m, 4 H), 2.49-2.52 (m, 1 H), 2.65-2.70 (m, 1 H), 3.55 (s, 3 H), 3.70 (s, 2 H), 6.29 (s, 1 H), 6.68 (s, 1 H), 8.70-8.73 (m, 1 H), 8.94 (s, 1 H), 9.03-9.06 (m, 1 H). Anal. Calcd for C27H32N4O5.0.3H2O: C, 65.12; H, 6.60; N, 11.25. Found: C, 65.33; H, 6.32; N, 10.93. Example A(208): 6-cyclopentyl-6-[2-(5-ethyl-4-hydroxy-2-methoxyphenyl)ethyl]-4-hydroxy- 3-([1,2,4]triazolo[1,5-a]pyrimidin-2-ylmethyl)-5,6-dihydro-2H-pyran-2-one
Figure imgf000218_0001
The title compound was isolated by chiral SFC of racemic material described in example A(207) Condition: ChiralPac AD-H column, 140 bar, 25% MeOH, 2.5 mL/min, retention time 13.20 min.
Example A(209): 6-cyclopentyl-6-[2-(5-ethyl-4-hydroxy-2-methoxyphenyl)ethyl]-4-hydroxy- 3-([1,2,4]triazolo[1,5-a]pyrimidin-2-ylmethyl)-5,6-dihydro-2r-pyran-2-one
Figure imgf000218_0002
The title compound was isolated by chiral SFC of racemic material described in example A(207) Condition: ChiralPac AD-H column, 140 bar, 25% MeOH, 2.5 mL/min, retention time 20.11 min.
Example A(210): 3-[(6-chloro[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-6-cyclopentyl-6-[2- (5-ethyl-4-hydroxy-2-met n-2-one
Figure imgf000218_0003
The title compound was isolated by chiral SFC of racemic material described in example A (158) . Condition: ChiralPac AS-H column, 140 bar, 40% MeOH, 2.5 mL/min, retention time 7.77 min. Example A(211 ): l-6- [2-(5-ethyl-4-hyd
Figure imgf000219_0001
The title compound was isolated by chiral SFC of racemic material described in example
A (158). Condition: ChiralPac AS-H column, 140 bar, 40% MeOH, 2.5 mL/min, retention time 15.0 min.
Example A(21 methyl]-6-cyclopentyl-6-[2- (5-ethyl-4-hyd ro-2H-pyran~2-one
Figure imgf000219_0002
The title compound was isolated by chiral SFC of racemic material described in example A (159). Condition: ChiralPac AS-H column, 140 bar, 40% MeOH, 2.5 mL/min, retention time 5.65 min.
Figure imgf000219_0003
The title compound was isolated by chiral SFC of racemic material described in example A (159). Condition: ChiralPac AS-H column, 140 bar, 40% MeOH, 2.5 mL/min, retention time 8.77 min.
Example A(214): 3-[(6-chloro[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-6-cyclopentyl-6-{2- [3-fluoro-4-(1-hydroxy-1-methylethyl)phenyl]ethyl}-4-hydroxy-5,6-dihydro-2H-pyran-2-one
Figure imgf000220_0001
The title compound was prepared analogously to Example A(97), where 6- chloro[1 ,2,4]triazolo[1,5-a]pyrimidine-2-carbaldehyde was substituted in place of 2-ethyl-4-methyl- 1tf-imidazole-5-carbaldehyde.1H NMR (300 MHz, DMSO-d6) δ: 1.44 (s, 6 H), 1.52-1.70 (m, 8 H), 1.96-2.10 (m, 2 H), 2.37-2.42 (m, 1 H), 2.55-2.64 (m, 3 H), 2.74-2.80 (m, 1 H), 3.73-3.86 (m, 2 H), 5.17 (s, 1 H), 6.88-6.93 (m, 1 H), 6.99-7.02 (m, 1 H), 7.47-7.52 (m, 1 H), 8.86 (d, 7=3.0 Hz, 1 H), 9.58 (d, 7=3.0 Hz, 1 H). Anal: calcd for C27H30CIFN4O4.0.9H2O: C, 59.48; H, 5.88; N, 10.28. Found: C, 59.52; H, 5.86; N, 9.90.
Example A(215): 6-cyclopentyl-6-{2-[3-fluoro-4-(1-hydroxy-1-methylethyl) phenyl]ethyl} dihydro-2tf-pyran-2,4(3/-/)-dione
Figure imgf000220_0002
To a solution of methyl acetoacetate (3.9 mL, 36.0 mmol) in anhydrous THF (90 mL) at 0°C was added NaH (60%, 1.44 g, 36.0 mmol) portionwise. After 10 min, the solution was cooled further to -40 °C. n-BuLi (1.6 M, 22.5 mL) was added dropwise and the resulting solution was stirred at that temperature for 30 min. A solution of 1-cyclopentyl-3-[3-fluoro-4-(1-hydroxy-1- methylethyl)phenyl]propan-1-one (2.5 g, 9.0 mmol) in THF (4 mL) was added and the mixture was slowly warmed up to 25 °C and stirred for 4 hours. The reaction was quenched by the addition of NH4CI and the mixture was extracted with EtOAc (3 x 50 mL). The combined organic layers were washed with brine, dried over Na2S0 . The solvent was removed and the crude product was taken directly into next step without futher purification.
The crude product from previous step was dissolved in THF (40 mL) and the solution was treated with 2.0 N NaOH (18 mL). The resulting mixture was stirred at 25 °C for 4 hours before it was quenched by the addition of 1 N HCl. The mixture was extracted with EtOAc (3 x 30 mL) and the combined organic layers were washed with brine, dried over Na2S04. The solvent was removed and the crude product was purified by column chromatography to give the desired product in 58% yield (two steps). 1H NMR (CDCI3) δ: 1.43-1.77 (m, 8 H), 1.62 (s, 6 H), 1.92-1.99 (m, 2 H), 2.23-2.32 (m, 1 H), 2.64-2.71 (m, 2 H), 2.75-2.78 (m, 2 H), 3.41-3.45 (m, 2 H), 6.81-6.84 (m, 1 H), 6.90-6.92 (m, 1 H), 7.44-7.48 (m, 1 H).
Step 2: Preparation of compound 1-cyclopentyl-3-[3-fluoro-4-(1-hydroxy-1 -methylethyl) phenyl]propan-1 -one
Figure imgf000221_0001
To a solution of 2-(4-bromo-2-fluorophenyl)propan-2-ol (5.8 g, 25.0 mmol) in anhydrous NMP (63 mL) was added 1-CyclopentyI-2-propen-1-ol (3.15 g, 25.0 mmol), NaHC03 (4.2 g, 50 mmol) and PdCI2(PPh3)2 (350 mg, 2 mol%). The mixture was heated to 140 °C for 4 hours before it was cooled down to room temperature. The reaction was diluted with aqueous NH4CI, extracted with EtOAc (3 x 50 mL). The combined organic extracts were washed with brine, dried with Na2S0 and evaporated to dryness. The mixture was purified by flash column chromatography (10-50 % EtOAc in hexanes) to give the product (2.5 g, 36% yield). 1H NMR (300 MHz, CDCI3) δ: 1.56-1.82 (m, 8 H), 1.62 (s, 6 H), 2.74-2.78 (m, 2 H), 2.82-2.89 (m, 2 H), 6.84-6.88 (m, 1 H), 6.93- 6.95 (m, 1 H), 7.40-7.44 (m, 1 H).
Step 1: Preparation of compound 2-(4-bromo-2-fluorophenyl)propan-2-ol
Figure imgf000221_0002
A solution of 4-bromo-2-fluorobenzoic acid (10 g) in anhydrous MeOH (200 mL) was added cone, sulfuric acid (0.5 mL). The mixture was heated to reflux for 15 hours before it was cooled down to room temperature. The solvent was removed and the residue was taken up in EtOAc (100 mL) and washed with sat. NaHC03, brine and dried over Na2S04. The crude product was taken into next step without further purification.
To a solution of methyl 4-bromo-2-fluorobenzoate (12 g, 51.5 mmol) in anhydrous ether (140 mL) at 0 °C was added MeMgBr (3.0 M, 70 g) dropwise. The mixture was slowly warmed up to room temperature and stirred for 3 hours. The reaction was quenched by the addition of saturated NH CI and extracted with EtOAc (3 x 150 mL). The combined organic extracts were washed with brine, dried with Na2S04 and evaporated to dryness. The mixture was purified by flash column chromatography (0-20 % EtOAc in hexanes) to give the product (12 g, 95% yield). 1H NMR (300 MHz, CDCI3) δ: 1.62 (s, 6 H), 7.18-7.23 (m, 1 H), 7.25-7.28 (m, 1 H), 7.44-7.49 (m, 1 H).
Example A(216): 3-[(6-chloro[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-6-cyclopentyl-6-{2- [3-fluoro-4-(1-hydroxy-1-methylethyl)phenyl]ethyl}-4-hydroxy-5,6-dihydro-2H-pyran-2-one
Figure imgf000222_0001
The title compound was prepared analogously to Example A(214), where 6- methyl[1,2,4]triazolo[1,5-a]pyrimidine-2-carbaldehyde was substituted in place of 6- chloro[1,2,4]triazolo[1 ,5-a]pyrimidine-2-carbaldehyde.1H NMR (400 MHz, DMSO-d6) δ: 1.25-1.32 (m, 1 H), 1.39 (s, 6 H), 1.43-1.64 (m, 7 H), 1.90-2.07 (m, 2 H), 2.29 (s, 3 H), 2.32-2.36 (m, 2 H), 2.46-2.54 (m, 2 H), 2.67-2.71 (m, 1 H), 3.64-3.76 (m, 2 H), 6.85 (dd, 7=13.14, 1.52 Hz, 1 H), 6.92 (dd, 7=8.08, 1.52 Hz, 1 H), 7.43 (m, 1 H), 8.62 (d, 7=2.27 Hz, 1 H), 8.88 (dd, 7=2.27, 1.01 Hz, 1 H). Anal, calcd for C28H33FN404.1.2H20: C, 63.43; H, 6.73; N, 10.57. Found: C, 63.19; H, 6.51; N, 10.41.
Example A(217): 6-cyclopentyl-3-[(5,7-dimethyl[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]- 6-{2-[3-fluoro-4-(1-hydroxy-1-methylethyl)phenyl]ethyl}-4-hydroxy-5,6-dihydro-2W-pyran-2- one
Figure imgf000222_0002
The title compound was prepared analogously to Example A(214), where 5,7- dimethyl[1,2,4]triazolo[1,5-a]pyrimidine-2-carbaldehyde was substituted in place of 6- chloro[1,2,4]triazolo[1,5-a]pyrimidine-2-carbaldehyde.1H NMR (400 MHz, DMSO-d6) δ: 1.29-1.34 (m, 1 H), 1.39 (s, 6 H), 1.44-1.64 (m, 7 H), 2.02-2.07 (m, 2 H), 2.31-2.37 (m, 1 H), 2.40 (s, 3 H), 2.48 (s, 3 H), 2.50-2.55 (m, 3 H), 2.70-2.74 (m, 1 H), 3.63-3.78 (m, 2 H), 6.84-6.87 (m, 1 H), 6.96- 6.98 (m, 2 H), 7.43-7.47 (m, 1 H). Anal, calcd for C29H35FN4O40.8H2O: C, 64.86; H, 6.87. Found: C, 64.96; H, 6.61.
Example A(218): 6-cyclopentyl-3-[(5,7-dimethyl[1 ,2,4]triazolo[1 ,5-a]pyrimidin-2-yl)methyl]- 6-{2-[3-fluoro-4-(1-hydroxy-1-methylethyl)phenyl]ethyl}-4-hydroxy-5,6-dihydro-2H-pyran-2- one (enantiomer A)
Figure imgf000223_0001
The title compound was isolated by chiral SFC of racemic material described in example A(217) . Condition: ChiralPac AD-H column, 140 bar, 40% MeOH, 2.5 mL/min, retention time 6.16 min.
Example A(219): 6-cyclopentyl-3-[(5,7-dimethyl[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]- 6-{2-[3-fluoro-4-(1-hydroxy-1-methylethyl)phenyl]ethyl}-4-hydroxy-5,6-dihydro-2W-pyran-2- one (enantiomer B)
Figure imgf000223_0002
The title compound was isolated by chiral SFC of racemic material described in example A(120) . Condition: ChiralPac AD-H column, 140 bar, 40% MeOH, 2.5 mL/min, retention time 9.13 min.
Example A(220): 6-cyclopentyl-6-{2-[3-fluoro-4-(1-hydroxy-1-methylethyl)phenyl]ethyl}-4- hydroxy-3-([1,2,4]triazolo[1,5-a]pyrimidin-2-ylmethyl)-5,6-dihydro-2tf-pyran-2-one 223
Figure imgf000224_0001
The title compound was prepared analogously to Example A(214), where l[1,2,4]triazolo[1,5-a]pyrimidine-2-carbaldehyde was substituted in place of 6- chloro[1,2,4]triazolo[1,5-a]pyrimidine-2-carbaldehyde.1H NMR (400 MHz, DMSO-d6) δ: 1.25-1.32 (m, 1 H), 1.39 (s, 6 H), 1.43-1.64 (m, 7 H), 1.91-2.08 (m, 2 H), 2.30-2.36 (m, 1 H), 2.46-2.55 (m, 3 H), 2.68-2.73 (m, 1 H), 3.67-3.79 (m, 2 H), 6.86 (dd, 7=13.01, 1.39 Hz, 1 H), 6.94 (dd, 7=8.08, 1.52 Hz, 1 H), 7.19 (dd, 7=6.82, 4.29 Hz, 1 H), 7.44 (m, 1 H), 8.73 (dd, 7=4.29, 1.77 Hz, 1 H), 9.03 (dd, 7=6.82, 2.02 Hz, 1 H). Anal, calcd for C27H31FN4O40.4H2O: C, 64.63; H, 6.39; N, 11.17. Found: C, 64.63; H, 6.15; N, 10.71.
Example A(221): 2-(4-{2-[2-cyclopentyl-4-hydroxy-5-(imidazo[1,2-a]pyrimidin-2-ylmethyl)-6- oxo-3,6-dihydro-2#-pyran-2-yl]ethyl}-2-fluorophenyl)-2-methylpropanenitrile
Figure imgf000224_0002
The title compound was prepared analogously to Example A(97), where imidazo[1,2- a]pyrimidine-2-carbaldehyde was substituted in place of 2-ethyl-4-methy!-1H-imidazole-5- carbaldehyde.1H NMR (400 MHz, DMSO-d6) δ: 1.16-1.45 (m, 8 H), 1.56 (s, 6 H), 1.78-1.85 (m, 2 H), 1.93-1.96 (m, 2 H), 2.19-2.27 (m, 1 H), 2.46-2.51 (m, 3 H), 2.62-2.67 (m, 1 H), 6.92 (d, 7=9.60 Hz, 1 H), 7.00 (d, 7=11.62 Hz, 1 H), 7.19 (t, 7=8.46 Hz, 1 H), 7.29 (s, 1 H), 7.69 (s, 1 H), 8.66 (s, 1 H), 8.94 (d, 7=5.81 Hz, 1 H). HRMS calcd for C29H32FN403(M+H)+. 503.2453. Found: 503.2455.
Example A(222): 2-(4-{2-[2-cyclopentyl-4-hydroxy-5-(imidazo[1 ,2-a]pyrimidin-3-ylmethyl)-6- oxo-3,6-dihydro-2r -pyran-2-yl]ethyl}-2-fluorophenyl)-2-methylpropanenitrile
Figure imgf000225_0001
The title compound was prepared analogously to Example A(97), where imidazo[1,2- a]pyrimidine-3-carbaldehyde was substituted in place of 2-ethyl-4-methyl-1H-imidazole-5- carbaldehyde.1H NMR (400 MHz, DMSO-d6) δ: 1.24-1.58 (m, 8 H), 1.64 (s, 6 H), 1.79-1.85 (m, 2 H), 2.21-2.31 (m, 1 H), 2.47-2.60 (m, 3 H), 2.71-2.75 (m, 1 H), 3.10 (s, 2 H), 6.91 (dd, 7=8.08, 1.52 Hz, 1 H), 7.02 (dd, 7=13.01, 1.39 Hz, 1 H), 7.26 (t, 7=8.46 Hz, 1 H), 7.55 (dd, 7=6.95, 4.42 Hz, 1 H), 7.87 (s, 1 H), 8.87 (dd, 7=4.17, 1.39 Hz, 1 H), 9.15 (dd, 7=6.95, 1.64 Hz, 1 H). HRMS calcd for C29H32FN403(M+H)+. 503.2453. Found: 503.2458.
Example A(223): 3-[(6-chloro[l,2,4]triazolo[l,5- ]pyrimidin-2-yl)methyl]-6- cycIopentyl-4-hydroxy-6-{2-[4-hydroxy-3-(2,2,2-trifluoroethyl)phenyl]ethyI}-5,6- dihydro-2H-pyran-2-one
Figure imgf000225_0002
6-chloro-[1,2,4]triazolo[1,5-a]pyrimidine-2-carbaldehyde (0.131g, 0.72mmol) was added to a solution of example A(228) 6-cyclopentyl-6-{2-[4-hydroxy-3-(2,2,2- trifluoroethyl)phenyl]ethyl}dihydro-2H-pyran-2,4(3W)-dione (0.230g, 0.60mmol) in MeOH (10 mL). The reaction mixture was stirred for 15mins and then treated with borane-dimethylamine complex (53mg, 0.9mmoL). After 15 hours the reaction mixture was quenched with concentrated HCl, and concentrated to a residual oil. Purification by flash column chromatography (EtOAc then 0%-5% MeOH in CH2CI2) gave the product as a white solid (17mg). 1H NMR (DMSO): δ 1.30-1.80 (brm, 8H), 2.08-2.18 (brm, 3H), 2.74 (s, 2H), 2.99(m, 2H); 3.15 (m, 2H), 3.47 (m, 3H), 6.81 (m, 2H), 7.00(s, 1H), 8.76 (s, 1 H), 8.82 (s, 1 H). Anal. Calcd. For C26H26θ4N4CIF3: C, 56.68; H, 4.75, N, 10.17. Found: C, 56.50; H, 4.69, N, 10.20.
Example A(224): 6-cyclopentyI-4-hydroxy-6-{2-[4-hydroxy-3-(2,2,2- trifluoroethyl)phenyI]ethyl}-3-[(6-methyl[l,2,4]triazolo[l,5- ]pyrimidin-2- yl)methyI]-5,6-dihydro-2H~pyran-2-one
Figure imgf000226_0001
6-methyl-[1 ,2,4]triazolo[1 ,5-a]pyrimidine-2-carbaldehyde (0.88g, 0.546mmol) was added to a solution of example A(228) 6-cyclopentyl-6-{2-[4-hydroxy-3-(2,2,2- trifIuoroethyl)phenyl]ethyl}dihydro-2H-pyran-2,4(3H)-dione (0.175g, 0.455mmol) and borane- dimethylamine complex (53mg, 0.9mmoL) in MeOH (10 mL). The reaction was stirred at room temperature for 15 hours, after which time the mixture was concentrated to a residual oil, and purified by preparatory HPLC to afford the title compound as a white solid (50mg). 1H NMR (DMSO): δ 1.35-1.85 (brm, 8H), 2.00-2.20 (brm, 3H), 2.50 (s, 3H), 2.74 (s, 2H), 2.99(m, 2H); 3.04 (m, 2H), 3.54 (m, 3H), 6.81 (m, 2H), 7.00(s, 1 H), 8.55 (s, 1 H), 8.72 (s, 1 H). Anal. Calcd. For C27H2904N4F3: C, 61.14; H, 5.51 , N, 9.06. Found: C, 61.21 ; H, 5.60, N, 9.14.
Example A(225): 6-cyclopentyI-3-[(5,7-dimethyI[l,2,4]triazolo[l,5- ]pyrimidin-2- yI)methyl]-4-hydroxy-6-{2-[4-hydroxy-3-(2,2,2-trifluoroethyl)phenyl]ethyl}-5,6- dihydro-2H~pyran-2-one
Figure imgf000227_0001
The title compound was prepared analogously to Example A(224) where 5,7-dimethyl- [1 ,2,4]triazolo[1 ,5-a]pyrimidine-2-carbaldehyde was used in place of 6-methyI-[1,2,4]triazolo[1 ,5- a]pyrimidine-2-carbaldehyde in that example. 1H NMR (DMSO): δ 1.40-1.90 (brm, 8H), 1.99-2.28 (brm, 3H), 2.58 (s, 3H), 2.73 (m, 5H), 3.00(m, 2H); 3.10 (m, 2H), 3.47 (m, 3H), 6.79 (m, 2H), 7.05(m, 2H), 8.83 (bs, 1 H), 10.0 (bs, 1 H). Anal. Calcd. For C28H3104N4F3: C, 61.76; H, 5.74, N, 10.29. Found: C, 61.50; H, 5.50, N, 10.14.
Example A(226): 3-[(6-chIoro[l,2,4]triazolo[l,5- ]pyrimidin-2-yl)methyI]-6- cyclopentyl-4-hydroxy-6-{2-[4-hydroxy-3-(2,2,2-trifluoroethyl)phenyI]ethyI}-5,6-
Figure imgf000227_0002
dihydro-2H-pyran-2-one
The title compound was separated from racemic Example A(223), 3-[(6- chloro[1 ,2,4]triazolo[1 ,5-a]pyrimidin-2-yl)methyl]-6-cyclopentyl-4-hydroxy-6-{2-[4-hydroxy-3-(2,2,2- trifluoroethyl)phenyl]ethyI}-5,6-dihydro-2H-pyran-2-one using chiral HPLC (AS-H, 120 Bar, 2.5 mL/min, 30%> MeOH). (4.76 min retention time).
Example A(227): 3-[(6-chloro[l,2,4]triazoIo[l,5-α]pyrimidin-2-yl)methyl]-6- cyclopentyl-4-hydroxy-6-{2-[4-hydroxy-3-(2,2,2-trifluoroethyI)phenyl]ethyl}-5,6- , dihydro-2H-pyran-2-one
Figure imgf000228_0001
The title compound was separated from racemic Example A(223), 3-[(6- chloro[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-6-cyclopentyl-4-hydroxy-6-{2-[4-hydroxy-3-(2,2,2- trifluoroethyl)phenyl]ethyl}-5,6-dihydro-2H-pyran-2-one using chiral HPLC (AS-H, 120 Bar, 2.5 mL/min, 30%> MeOH). (9.617 min retention time).
Example A(228): 6-cycIopentyl-6-{2-[4-hydroxy-3-(2,2,2- trifluoroethyl)phenyl]ethyl}dihydro-2H-pyran-2,4(3ij )-dione
Figure imgf000228_0002
The title compound was prepared analogously to Example A(124) where 4-bromo-2- (2,2,2-trifluoroethyl)phenol from step 6 below was used in place of 2-ethyl-5-fluorophenol in that example. 1H NMR (CDCI3): δ 1.35-1.70 (brm, 6H), 1.93, (brm, 2H), 2.04-2.21 (brm, 3H), 2.83-3.12 (brm, 8H), 6.78 (dd, 7 = 2.81 Hz 2H), 6.99 (s, 1 H). MS(APCI): 385 (M-H).
Step 6: Preparation of compound 4-bromo-2-(2,2,2-trifluoroethyI)phenol.
Figure imgf000228_0003
Tetrabutylammonium tribromide (6.56g) was dissolved in chloroform (50ml) and added dropwise to a solution of 2-(2,2,2-trifluoroethyl)phenol (2.4g) in chloroform (50ml). The reaction mixture was stirred at room temperature for 2hrs, after which time 5% sodium thiosulfate solution (100ml) was added and the resultant stirred for 30mins.The mixture was then partitioned between dichloromethane (100ml) and 1N HCl (200ml). The organics were separated and dried over magnesium sulfate. The solvent was then removed in vacuuo, the crude residue was then purified by column chromatography on silica gel eluting with 90:10 hexanes : ethl acetate to afford the title compound as a yellow oil (3.24g). 1H NMR (CDCI3): δ 3.50 (q, 7 = 21.48Hz 2H), 6.70 (d, 7 = 2.54Hz, 1 H), 7.32 (d, 7 = 2.54Hz, 1 H), 7.45 (s, 1 H).
Step 5: Preparation of compound 2-(2,2,2-trifluoroethyl)phenol.
Figure imgf000229_0001
Sodium Borohydride (.930g) was added to a solution of 2-(1-chloro-2,2,2- trifluoroethyI)phenol (2.6g) in THF (30ml). The reaction mixture was then stirred for 14hrs at room temperature under an atmosphere of nitrogen, after which time the reaction was quenched with 1N HCl (50ml) and partitioned between 1NHCI (100) and ethyl acetate (200ml), the organics were separated and dried over magnesium sulfate, filtered and solvent evaporated in vacuuo to afford title compound as a semi solid (2.4g). 1H NMR (CDCI3): δ 3.50 (q, 7 = 21.06Hz 2H), 6.80 (m, 1H), 7.00 (m, 1H), 7.25 (m, 2H).
Step 4: Preparation of compound 2-(l-chIoro-2,2,2-trifluoroethyl)phenol.
Figure imgf000229_0002
Thionyl chloride (2.28ml) was added to a solution of 2-(2,2,2-trifiuoro-1- hydroxyethyl)phenol (3.0g) and pyridine (1.23ml) in toluene (50ml). The reaction was stirred at room temperature for 1hr, after which time the toluene was removed in vacuuo and the residue partitioned between ethyl acetate (100ml) and 1n HCl (100ml). The organics were separated and dried over magnesium sulfate, filtered and solvent removed in vacuuo to afford the title compound as a clear oil (3.0g). 1H NMR (CDCI3): δ 5.93 (m, 1H), 6.90 (d, 7 = 4.52Hz, 1H), 7.10 (m, 1H), 7.35 (m, 1H), 7.69 (m, 1H). Step 3: Preparation of compound 2-(2,2,2-trifluoro-l-hydroxyethyI)phenol.
Figure imgf000230_0001
Boron Tribromide (10ml) (1M soln in DCM) was added to a solution of 2,2,2-trifluoro-1-(2- methoxyphenyl)ethanol (1.5g) in dichloromethane (20ml). The reaction mixture was stirres at room temperature under a atmosphere of nitrogen for 56hrs. The mixture was then partitioned between DCM (100ml) and 1N HCl (100ml), organics washed with water (100ml), dried over magnesium sulfate, filtered and solvent removed in vacuuo to afford the title compound as a clear yellow oil (1.5g). 1H NMR (CDCI3): δ 3.50 (bs, 1H), 5.25 (m, 1H), 6.73 (bs, 1 H), 7.00 (m, 2H), 7.32 (d, 7 = 2.56Hz, 1H), 7.45 (m, 1H). Step 2: Preparation of compound 2,2,2-trifluoro-l-(2-methoxyphenyl)ethanoI.
Figure imgf000230_0002
10% palladium on carbon (1.5g) was added to a solution of 2,2,2-trifluoro-1-(2- methoxyphenyl)ethanone (3.0g) in methanol (50ml). The resultant was hydrogenated at room temperature for 12hrs. After which time the catalyst was filtered off through a plug of celiteand the solvent concentrated in vacuuo. The crude was purified by column chromatography on silica gel eluting with 100% hexanes the 80:20 hexanes:ethylacetate to afford the title compound as a yellow oil (3.0g). 1H NMR (CDCI3): δ 3.75 (d, 7 = 2.56Hz, 1H), 3.96 (s, 3H), 5.35 (m,1H), 7.05 (m, 2H), 7.50 (m,2H).
Step 1: Preparation of compound 2,2,2-trifluoro-l-(2-methoxyphenyl)ethanone.
Figure imgf000230_0003
2 Methoxy Phenyl magnesium bromide (35ml) was added slowly to a solution of methyl trifluoroacetate (5.0g) in diethyl ether (100ml) @ -78°C. The reaction mixture was warmed to room temperature over 12hrs and the quenched with saturated ammonium chloride solution (100ml). The mixture was then partitioned between ethyl acetate (500ml) and water (250ml) The organics were separated and dried over magnesium sulfate filtered and concentrated in vacuuo. The crude residue was purified by column chromatography on silica gel eluting with 100 %> hexanes, 90:10 and 80:20, hexanes:ethyl acetate, to afford title compound as a yellow oil. (4.0g). 1H NMR (CDCI3): δ 3.57 (s, 3H), 7.00 (m, 2H), 7.35 (m,1H), 7.63, (d, 7 = 2.54 Hz 2H).
Example A(229): 6-cycIopentyI-6-[2-(3-ethyI-4-hydroxyphenyI)ethyl]-4-hydroxy-3-[(5- methyl[l,2,4]triazolo[l,5-α]pyrimidin-2-yI)methyl]-5,6-dihydro-2H-pyran-2-one
Figure imgf000231_0001
The title compound was prepared analogously to Example A(224) where 5-methyl- [1,2,4]triazolo[1,5-a]pyrimidine-2-carbaldehyde was used in place of 6-methyl-[1 ,2,4]triazolo[1,5- a]pyrimidine-2-carbaldehyde and 6-cyclopentyl-6-[2-(3-ethyl-4-hydroxyphenyl)ethyl]dihydro-2H- pyran-2,4(3H)-dione was used in place of 6-cyclopentyl-6-{2-[4-hydroxy-3-(2,2,2- trifluoroethyl)phenyl]ethyl}dihydro-2/-/-pyran-2,4(3f/)-dione in that example. 1H NMR (DMSO): δ 1.15 (t, 7 = 7.54Hz, 3H), 1.30-1.80 (brm, 8H), 2.00-2.40 (brm, 3H), 2.50 (q, 7 = 10.74Hz 2H), 2.68 (s, 1H), 2.70(8, 2H); 2.92 (m, 2H), 3.69 (m, 3H), 6.64 (d, 7 = 3.56Hz, 1H), 6.66 (d, 7 = 3.56Hz, 1H), 7.00 (m, 2H), 8.55 (d, 7 = 6.97Hz, 1H). Anal. Calcd. For C27H3204N4: C, 68.05; H, 6.77, N, 11.76. Found: C, 68.24; H, 6.80, N, 11.77.
Example A(230): 3-[(6-bromo[l,2,4]triazolo[l,5-α]pyrimidin-2-yl)methyl]-6- cyclopentyl-6-[2-(3-ethyl-4-hydroxyphenyl)ethyl]-4-hydroxy-5,6-dihydro-2H-pyran-
2-one
Figure imgf000232_0001
The title compound was prepared analogously to Example A(224) where 6-bromo- [1,2,4]triazolo[1 ,5-a]pyrimidine-2-carbaldehyde was used in place of 6-methyl-[1,2,4]triazolo[1,5- a]pyrimidine-2-carbaldehyde and 6-cyclopentyl-6-[2-(3-ethyl-4-hydroxyphenyl)ethyl]dihydro-2/-/- pyran-2,4(3H)-dione was used in place of 6-cyclopentyl-6-{2-[4-hydroxy-3-(2,2,2- trifluoroethyl)phenyl]ethyl}dihydro-2H-pyran-2,4(3H)-dione in that example. 1H NMR (DMSO): δ 1.15 (t, 7 = 7.54Hz, 3H), 1.30-1.90 (brm, 8H), 2.00-2.40 (brm, 3H), 2.50 (q, 7 = 10.74Hz 2H), 2.75 (m, 2H); 2.90 (m, 2H), 3.50 (m, 3H), 6.64 (d, 7 = 5.26Hz, 1H), 6.70 (d, 7 = 5.26Hz, 1H), 7.00 (s, 1H), 8.75 (s, 1 H), 9.19 (s, 1 H). Anal. Calcd. For C26H2904N4Br C, 57.68; H, 5.40, N, 10.35. Found: C, 57.50; H, 5.50, N, 10.30.
Step 2. 6-bromo-[1,2,4]triazolo[1,5-a]pyrimidine-2-carbaldehyde
Figure imgf000232_0002
A slurry of (6-bromo-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)-methanol (6.5 g, 28.51 mmol) from step 1 above in dichloromethane (60 mL) was added Phl(OAc)2 (10.1 mg, 31.4 mmol) and with catalytic TEMPO (334 mg, 2.14 mmol). After reaction at room temperature for 3 hours, the reaction is complete. MTBE is added slowly(50 mL) to crystallize the product, filtration followed by drying the product by vacuum oven overnight. The filtrate was concentrated and purified by flash chromatography (2% MeOH in CH2CI2) to give the desired product as light white solid ( combine total 4.8g, 75% yield). 1H NMR (300 MHz, CDCI3) D ppm 8.96 (d, J=2.45 Hz, 1H) 9.09 (d, J=2.45 Hz, 1H) 10.22 (s, 1H). MS: (APCI) 228 (M+H)
Step 1. (6-Bromo-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)-methanol
Figure imgf000233_0001
To a slurry of (5-amino-1H-[1,2,4]triazol-3-yl)-methanol (6.29 g, 33.12 mmol)in acetic acid (25 ml) was added bromomalonaldehyde (5 g, 33.12 mmol). The mixture was heated at 60°C for 5 hours, and then cooled to room temperature. The light yellow solid was formed. After the solid were removed by filtration followed by drying in vacuum oven provides the light yellow solid as desired product, the filtrate was concentrate by rotary evaporation to give yellow oil. The crude oil was purified by flash chromatography (2% MeOH in CH2CI2) to give the desired product as light yellow solid ( combine total 6.5g, 86% yield). 1H NMR (300 MHz, DMSO-D6) δ ppm 4.65 (d, 7=5.46 Hz, 2 H) 5.50 - 5.67 (m, 1 H) 8.94 (d, 7=2.45 Hz, 1 H) 9.83 (d, 7=2.26 Hz, 1 H). MS: (APCI) 230 (M+H)
Example A(231): 3-[(6-chloro[l,2,4]triazolo[l,5-α]pyrimidin-2-yl)methyI]-6- cyclopentyl-6-[2-(3,5-diethyl-4-hydroxyphenyI)ethyl]-4-hydroxy-5,6-dihydro-2H- pyran-2-one
Figure imgf000233_0002
The title compound was prepared analogously to Example A(224) where 6-chloro- [1,2,4]triazolo[1,5-a]pyrimidine-2-carbaldehyde was used in place of 6-methyl-[1,2,4]triazolo[1,5- a]pyrimidine-2-carbaldehyde and 6-cyclopentyl-6-[2-(3,5-diethyl-4-hydroxyphenyl)ethyl]dihydro- 2H-pyran-2,4(3H)-dione (Example A(235)) was used in place of 6-cyclopentyl-6-{2-[4-hydroxy-3- (2,2,2-trifluoroethyl)phenyl]ethyl}dihydro-2H-pyran-2,4(3/-/)-dione in that example. 1H NMR (DMSO): δ 1.15 (t, 7 = 3.89Hz, 6H), 1.30-1.80 (brm, 8H), 2.00-2.20 (brm, 5H), 2.43 (q, 7 = 20.06Hz 4H), 2.85 (m, 4H), 3.55 (m, 3H), 6.70 (s, 2H), 8.76 (s, 1H), 8.82 (s, 1H). Anal. Calcd. For C28H3304N4CI, C, 64.05; H, 6.34, N, 10.67. Found: C, 64.35; H, 6.50, N, 10.75. Example A(232): 6-cyclopentyl-6-[2-(3,5-diethyl-4-hydroxyphenyl)ethyl]-3-[(5,7- dimethyl[l,2,4]triazolo[l,5-a]pyrimidin-2-yl)methyI]-4-hydroxy-5,6-dihydro-2H- pyran-2-one
Figure imgf000234_0001
The title compound was prepared analogously to Example A(224) where 5,7- dimethyl[1,2,4]triazolo[1,5-a]pyrimidine-2-carbaldehyde was used in place of 6-methyl- [1 ,2,4]triazoIo[1 ,5-a]pyrimidine-2-carbaldehyde and 6-cyclopentyl-6-[2-(3,5-diethyl-4- hydroxyphenyl)ethyl]dihydro-2H-pyran-2,4(3H)-dione (Example A(235)) was used in place of 6- cyclopentyl-6-{2-[4-hydroxy-3-(2,2,2-trifluoroethyl)phenyl]ethyl}dihydro-2H-pyran-2,4(3H)-dione in that example. 1H NMR (DMSO): δ 1.15 (t, 7 = 7.54Hz, 6H), 1.30-1.80 (brm, 8H), 2.00-2.20 (brm, 5H), 2.43 (q, 7 = 19.06Hz 4H), 2.60 (s, 3H), 2.80 (brm, 7H), 3.34 (m, 3H), 6.70 (s, 2H), 6.99 (s, 1H). Anal. Calcd. For C3oH38θ4N4, C, 69.47; H, 7.38, N, 10.80. Found: C, 69.45; H, 7.35, N, 10.75.
Example A(233): 6-cyclopentyl-6-[2-(3,5-diethyl-4-hydroxyphenyl)ethyl]-4-hydroxy-3- [(6-methyl[l,2,4]triazolo[l,5-α]pyrimidin-2-yl)methyI]-5,6-dihydro-2H-pyran-2-one
Figure imgf000234_0002
The title compound was prepared analogously to Example A(224) where 6-cyclopentyl-6- [2-(3,5-diethyl-4-hydroxyphenyl)ethyl]dihydro-2H-pyran-2,4(3H)-dione (Example A(235)) was used in place of 6-cyclopentyl-6-{2-[4-hydroxy-3-(2,2,2-trifluoroethyl)phenyl]ethyl}dihydro-2H- pyran-2,4(3H)-dione in that example. 1H NMR (DMSO): δ 1.17 (t, 7 = 2.56Hz, 6H), 1.30-1.80 (brm, 6H), 1.99-2.21 (brm, 5H), 2.45 (q, 7 = 19.06Hz 4H), 2.50 (s, 3H), 2.80 (m, 4H), 3.34 (m, 3H), 6.70 (s, 2H), 8.55 (s, 1H), 8.72 (s, 1H), 9.30 (s, 1 H). Anal. Calcd. For C29H3604N4, C, 69.03; H, 7.19, N, 11.10. Found: C, 69.00; H, 7.05, N, 11.20.
Example A(234): 6-cycIopentyl-6-[2-(3,5-diethyl-4-hydroxyphenyI)ethyl]-4-hydroxy-3- ([l,2,4]triazolo[l,5-α]pyrimidin-2-ylmethyl)-5,6-dihydro-2H-pyran-2-one
Figure imgf000235_0001
The title compound was prepared analogously to Example A(224) where
[1,2,4]triazolo[1 ,5-a]pyrimidine-2-carbaldehyde was used in place of 6-methyl[1 ,2,4]triazolo[1,5- a]pyrimidine-2-carbaldehyde and 6-cyclopentyl-6-[2-(3,5-diethyl-4-hydroxyphenyl)ethyl]dihydro- 2H-pyran-2,4(3H)-dione (Example A(235)) was used in place of 6-cycIopentyl-6-{2-[4-hydroxy-3- (2,2,2-trifluoroethyl)phenyl]ethyl}dihydro-2W-pyran-2,4(3 -/)-dione in that example. 1H NMR (DMSO): δ 1.20 (t, 7 = 2.56Hz, 6H), 1.30-1.80 (brm, 6H), 2.00-2.18 (brm, 5H), 2.40 (q, 7 = 20.06Hz 4H), 2.80 (m, 4H), 3.45 (m, 3H), 6.70 (s, 2H), 7.17 (d, 7 = 2.54Hz, 1H), 8.80 (m, 2H), 9.29 (s, 1 H). Anal. Calcd. For C28H3404N4, C, 68.55; H, 6.99, N, 11.42. Found: C, 68.80; H, 7.31, N, 11.45.
Example A(235): 6-cyclopentyl-6-[2-(3,5-diethyl-4-hydroxyphenyl)ethyl]dihydro-2H- pyran-2,4(3H)-dione
Figure imgf000235_0002
The title compound was prepared analogously to Example A(124) where 2,6- diethylphenol (Selassie.Cynthia et al. J.Chem.Soc, Perkin Trans 2. EN; 2002; 1112-1117) was used in place of 2-ethyl-5-fluorophenol in that example. 1H NMR (CDCI3): δ 1.17 (t, 7 = 9.57Hz, 6H) 1.30-2.21 (br m, 11H), 2.45, (m, 4H), 2.70-3.10 (brm, 6H), 6.69 (s, 2H). MS(APCI): 357 (M- H).
Example A(236): 1-(4-{2-[2-Cyclopentyl-5-(5,7-dimethyl-[1 ,2,4]triazolo[1 ,5-a]pyrimidin-2- ylmethyl)-4-hydroxy-6-oxo-3,6-dihydro-2H-pyran-2-yl]~ethyl}-2-fluoro-phenyl)- cyclobutanecarbonitrile
Figure imgf000236_0001
A solution of example A(237) in anhydrous MeOH (6 mL) was treated with 5,7-dimethyl-
[1 ,2,4]triazolo[1 ,5-a]pyrimidine-2-carbaldehyde (0.352 g, 2.0 mmol), followed by borane- dimethylamine complex (118 mg, 2.0 mmol) at room temperature. The reaction was stirred for 2 hours, and the solids were filtered away. The organic liquid was concentrated to a thick oil, and then purified by flash chromatography (50g Si02, 3:10 -> 3:5 (93.5% ethyl acetate, 6% methanol, 0.5%) acetic acid) : (81.5% hexanes, 12% ethyl acetate, 6% methanol, 0.5% acetic acid)) to give the desired product as an oil. It was further purified by crystallization from ethyl acetate / hexanes to give a white powder (89 mg, 11%). 1H NMR (400 MHz, CDCI3) δ: 1.31-1.65 (m, 8H), 1.89- 2.00 (m, 4H), 2.28-2.34 (m, 1H), 2.36-2.44 (m, 1H), 2.50 (d, 7 = 3.54 Hz, 1H), 2.54-2.65 (m, 6H), 2.67-2.78 (m, 7H), 4.08 (d, 7 = 4.80 Hz, 2H), 6.79 (dd, 7 = 11.49 Hz, H), 6.84-6.81 (m, 2H), 7.04 (t, 7 = 7.96 Hz, H).
Example A(237): 1-{4-[2-(2-Cyclopentyl-4,6-dioxo-tetrahydro-pyran-2-yl)-ethyl]-2-fluoro- phenyl}-cyclobutanecarbonitrile
Figure imgf000236_0002
To a solution of 1-{4-[3-cyclopentyl-4-(2,2-dimethyl-6-oxo-6H-[1,3]dioxin-4-yl)-3-hydroxy- but-1-ynyl]-2-fluoro-phenyl}-cyclobutanecarbonitrile (6.0g, 13.7 mmol) from step 3 below was added Pd(OH)2/C (2.0g) and ethanol (100 mL). The reaction was placed under a nitrogen atmosphere using a balloon filled with hydrogen. The slurry was stirred vigorously for 18 hours. The reaction was filtered to remove all of the solids, and the liquid was concentrated to an oil. The oil was dissolved in methanol (100 mL), and solution of NaOH (1.64g, 41 mmol) dissolved in water (30 mL). The reaction was stirred for 18 hours, and then acetic acid (1 mL) was added. The liquid was concentrated to an oil, then redissolved in CH2CI2, and washed with 1 N HCl. The organic layer was dried over MgS0 , filtered, and then concentrated to give the desired product (4.338g, 83%). MS (ESI): 382 (M-H+).
Step 3: 1-{4-[3-Cyclopentyl-4-(2,2-dimethyl-6-oxo-6H-[1,3]dioxin-4-yl)-3-hydroxy-but-1- ynyl]-2-fluoro-phenyl}-cyclobutanecarbonitrile
Figure imgf000237_0001
The title compound was prepared analogously to step 3 from Example A(97) where 1-(4- bromo-2-fluoro-phenyl)-cyclobutanecarbonitrile from step 2 below, was substituted in place of 2- (4-Bromo-2-fluoro-phenyl)-2-methyl-propionitrile in step 3 of that example. MS (ESI): 438.0 (M+H+).
Step 2: 1-(4-Bromo-2-fluoro-phenyl)-cyclobutanecarbonitrile
Figure imgf000237_0002
A solution of (4-bromo-2-fluoro-phenyl)-acetonitrile (4.0g, 18.7 mmol) from step 1 and
1, 3-dibromopropane (2.1 mL, 20.6 mmol) in Et20 (5 mL) was slowly added to a slurry of NaH (1.64g, 41.1 mmol, 60% in mineral oil) in DMSO (19 mL) at room temperature, being careful to keep the temperature below 35 degrees Celsius. The reaction was stirred for 2.5 hours, and then poured into 150 mL of saturated ammonium chloride. To this mixture was added CH22CI2, and the layers were separated. The aqueous layer was extracted with 2 x 50 mL of CH2CI2, and the organic layers were combined. After drying the liquid over MgS04, the solids were filtered away, and the organic was concentrated to an oil. It was further purified by flash chromatography (90g Si02, 1:99 -> 1:20 (EtOAc / Hexanes) to give the desired product (2.81g, 59%). 1H NMR (400 MHz, CDCI3) δ: 2.06-2.16 (m, H), 2.51-2.63 (m, H), 2.66-2.76 (qd, 7 = 9347 Hz, 2H), 2.86-2.94 (m, 2H), 7.16-7.22 (t, 7 = 8.21 Hz, H), 7.30-7.41 (m, 2H).
Step 1 : (4-Bromo-2-fluoro-phenyl)-acetonitrile
Figure imgf000238_0001
To a solution of 4-bromo-1-bromomethyl-2-fluoro-benzene (100g, 373 mmol) in DMF (190 mL) and water (10 mL) was added sodium cyanide (22g, 448 mmol). The reaction was heated to 70 degrees Celsius for 3 hours, concentrated to a volume of 100 mL, and then the solution was diluted with 100 mL of ethyl acetate. After the solids were removed by filtration, water (250 mL) was added and the layers were separated. The organic layer was further washed with 3 x 100 mL of water. The organic layer was dried over MgS0 , filtered to remove solids, and then concentrated. Purification by distillation gave the desired product (37.124g, 46%). B.P. = 72-75 degrees Celsius.
Example A(238): 1-{4-[2-(2-Cyclopentyl-4-hydroxy-6-oxo-5-[1 ,2,4]triazolo[1 ,5-a]pyrimidin-2- ylmethyl-3,6-dihydro-2H-pyran-2-yl)-ethyl]-2-fluoro-phenyl}-cyclobutanecarbonitrile
Figure imgf000238_0002
The title compound was prepared analogously to example A(236) substituting [1,2,4]triazolo[1,5-a]pyrimidine-2-carbaldehyde in place of 5,7-dimethyl-[1 ,2,4]triazolo[1,5- a]pyrimidine-2-carbaldehyde . H NMR (400 MHz, CDCI3) δ: 1.35-1.56 (m, 8H), 1.79-1.89 (m, 3H), 2.19-2.25 (m, 1H), 2.27-2.33 (m, 1H), 2.43-2.54 (m, 5H), 2.59-2.69 (m, 4H), 3.98-4.06 (m, 2H), 6.69 (dd, 71= 1.52Hz, 72 = 11.62 Hz, 1H), 6.76 (dd, 71 = 7.83 Hz, 72 = 1.52 Hz, 1H), 6.94 (t, 7 = 7.96 Hz, 1H), 7.11 (dd, 71 = 6.82 Hz, 72 = 4.29 Hz, 1H), 8.66 (dd, 71 = 6.69 Hz, 72 = 1.89 Hz, 1H), 8.71 (dd, 71 = 4.42 Hz, 72 = 1.89 Hz, 1H). Example A(239): 1-(4-{2-[2-Cyclopentyl-4-hydroxy-5-(6-methyl-[1 ,2,4]triazolo[1 ,5- a]pyrimidin-2-ylmethyl)-6-oxo-3,6-dihydro-2H-pyran-2-yl]-ethyl}-2-fluoro-phenyl)- cyclobutanecarbonitrile
Figure imgf000239_0001
The title compound was prepared analogously to example A(236) substituting 6-methyl- [1,2,4]triazolo[1 ,5-a]pyrimidine-2-carbaldehyde in place of 5,7-dimethyl-[1 ,2,4]triazoIo[1,5- a]pyrimidine-2-carbaldehyde. 1H NMR (400 MHz, CDCI3) δ: 1.54-1.82 (m, 8H), 2.01-2.13 (m, 3H), 2.38-2.48 (m, 2H), 2.48-2.57 (m, 4H), 2.67-2.77 (m, 4H), 2.82-2.85 (m, 1H), 2.88 (d, 7 = 6.06 Hz, 2H), 4.19 (s, 2H), 6.92 (dd, 71 = 11.62 Hz, 72 = 1.26 Hz, 1 H), 6.99 (d, 7 = 8.08 Hz, 1H), 7.17 (t, 7 = 7.96 Hz, 1H), 8.69 (s, 1H), 8.78 (d, 7 = 1.52 Hz, 1H).
Example A(240): 2-(4-{2-[2-Cyclopentyl-4-hydroxy-5-(6-methyl-[1 ,2,4]triazolo[1 ,5- a]pyrimidin-2-ylmethyl)-6-oxo-3,6-dihydro-2H-pyran-2-yl]-ethyl}-2-fluoro-phenyl)- propionitrile
Figure imgf000239_0002
The title compound was prepared analogously to example A(236) substituting 2-{4-[2-(2- cyclopentyl-4,6-dioxo-tetrahydro-pyran-2-yl)-ethyl]-2-fluoro-phenyl}-propionitrile from example A(241) in place of 1-(4-{2-[2-cyclopentyI-5-(5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2- ylmethyl)-4-hydroxy-6-oxo-3,6-dihydro-2H-pyran-2-yl]-ethyl}-2-fluoro-phenyl)- , cyclobutanecarbonitrile and 6-methyl-[1,2,4]triazolo[1,5-a]pyrimidine-2-carbaldehyde in place of 5J-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidine-2-carbaldehyde. 1H NMR (400 MHz, CDCI3) δ: 1.66- 2.00 (m, 8H), 2.30 (s, 2H), 2.36 (s, 2H), 2.49-2.62 (m, 4H), 2.69-2.85 (m, 3H), 3.49-3.59 (m, 1H), 3.89-3.94 (m, 1H), 4.01-4.08 (m, 2H), 4.18 (s, 1H).
Example A(241): 2-{4-[2-(2-Cyclopentyl-4,6-dioxo-tetrahydro-pyran-2-yl)-ethyl]-2-fluoro- phenyl}-propionitrile
Figure imgf000240_0001
The title compound was prepared analogously to example A(237) substituting 2-{4-[3- cyclopentyl-4-(2,2-dimethyl-6-oxo-6H-[1,3]dioxin-4-yl)-3-hydroxy-but-1-ynyl]-2-fluoro-phenyl}- propionitriie from step 2 below in place of 1-{4-[3-cyclopentyl-4-(2,2-dimethyl-6-oxo-6H- [1,3]dioxin-4-yl)-3-hydroxy-but-1-ynyl]-2-fluoro-phenyl}-cyclobutanecarbonitrile. 1H NMR (400 MHz, CDCI3) δ: 1.33-1.50 (m, 3H), 1.56 (d, 7 = 7.33 Hz, 3H), 1.62-1.75 (m, 5H), 1.85-1.93 (m, 2H), 2.15-2.26 (m, 1H), 2.58-2.68 (m, 3H), 2.72 (d, 7 = 6.57 Hz, 2H), 3.38 (d, 7 = 3.54 Hz, 2H), 4.09 (q, 7 = 7.33 Hz, 1H), 6.84 (d, 7 = 11.12 Hz, 1H), 6.93 (d, 7 = 7.83 Hz, 1H), 7.34 (t, 7 = 7.83 Hz, 1H).
Step 2: 2-{4-[3-Cyclopentyl-4-(2,2-dimethyl-6-oxo-6H-[1 ,3]dioxin-4-yl)-3-hydroxy-but-1 - ynyl]-2-fluoro-phenyl}-propionitrile
Figure imgf000240_0002
The title compound was prepared analogously to 1-{4-[3-Cyclopentyl-4-(2,2-dimethyl-6- oxo-6H-[1,3]dioxin-4-yl)-3-hydroxy-but-1-ynyl]-2-fluoro-phenyl}-cyclobutanecarbonitrile in step 3 of example A(236) substituting 2-(4-bromo-2-fluoro-phenyl)-propionitrile from step 1 below in place of 1-(4-bromo-2-fluoro-phenyl)-cyclobutanecarbonitrile. MS (ESI): 437.0 (M+H+).
Step 1 : 2-(4-Bromo-2-fluoro-phenyl)-propionitrile
Figure imgf000240_0003
The title compound was prepared analogously to 1-(4-Bromo-2-fluoro-phenyl)- cyclobutanecarbonitrile in step 2 of example A(236) substituting iodomethane in place of 1 ,3- dibromopropane. MS (APCI): 253 (M+H+), 255 (M+2+H+).
Example A(242): (+)-1-(4-{2-[2-Cyclopentyl-5-(6-methyl-[1,2,4]triazolo[1,5-a]pyrimidin-2- ylmethyl)-4,6-dioxo-tetrahydro-pyran-2-yl]-ethyl}-2-fluoro-phenyl)-cyclopropanecarbonitrile
Figure imgf000241_0001
The title compound was prepared by using chiral SFC to separate the racemic example
A(113) . Optical rotation determined to be (+).
Example A(243): (-)-1-(4-{2-[2-Cyclopentyl-5-(6-methyl-[1 ,2,4]triazolo[1 ,5-a]pyrimidin-2- ylmethyl)-4,6-dioxo-tetrahydro-pyran-2-yi]-ethyl}-2-fluoro-phenyl)-cyclopropanecarbonitrile
Figure imgf000241_0002
The title compound was prepared by using chiral SFC to separate the racemic example A(113) . Optical rotation determined to be (-).
Example A(244): (+)-1 -{4-[2-(2-Cyclopentyl-4,6-dioxo-5-[1 ,2,4]triazolo[1 ,5-a]pyrimidin-2- ylmethyl-tetrahydro-pyran-2-yl)-ethyl]-2-fluoro-phenyl}-cyclopropanecarbonitrile
Figure imgf000242_0001
The title compound was prepared by using chiral SFC to separate the racemic example A(114). Optical rotation determined to be (+).
Example A(245): (-)-1-{4-[2-(2-Cyclopentyl-4,6-dioxo-5-[1,2,4]triazolo[1,5-a]pyrimidin-2- ylmethyl-tetrahydro-pyran-2-yl)-ethyl]-2-fluoro-phenyl}-cyclopropanecarbonitrile
Figure imgf000242_0002
The title compound was prepared by using chiral SFC to separate the racemic example A(1 4) . Optical rotation determined to be (-).
Example A(246): (+)-1-(4-{2-[5-(6-Chloro-[1,2,4]triazolo[1,5-a]pyrimidin-2-ylmethyl)-2- cyclopentyl-4,6-dioxo-tetrahydro-pyran-2-yl]-ethyl}-2-fluoro-phenyl)- cyclopropanecarbonitrile
Figure imgf000242_0003
The title compound was prepared by using chiral SFC to separate the racemic example
A(115). Optical rotation determined to be (+). Example A(247): (-)-1-(4-{2-[5-(6-Chloro-[1 ,2,4]triazolo[1 ,5-a]pyrimidin-2-ylmethyl)-2- cyclopentyl-4,6-dioxo-tetrahydro-pyran-2-yl]-ethyl}-2-fluoro-phenyl)- cyclopropanecarbonitrile
Figure imgf000243_0001
The title compound was prepared by using chiral SFC to separate the racemic example A(115) . Optical rotation determined to be (-).
Example A(248): (+)-2-(4-{2-[5-(6-Chloro-[1,2,4]triazolo[1J5-a]pyrimidin-2-ylmethyl)-2- cyclopentyl-4,6-dioxo-tetrahydro-pyran-2-yl]-ethyl}-2-fluoro-phenyl)-2-methyl-propionitrile
Figure imgf000243_0002
The title compound was prepared by using chiral SFC to separate the racemic example A(111) Optical rotation determined to be (+).
Example A(249): (-)-2-(4-{2-[5-(6-Chloro-[1 ,2,4]triazolo[1 ,5-a]pyrimidin-2-ylmethyl)-2-
Figure imgf000243_0003
The title compound was prepared by using chiral SFC to separate the racemic A(15).
Optical rotation determined to be (-).
Step 2: Preparation of Compound 6-chloro[1,2,4]triazolo[1,5-a]pyrimidine-2-carbaldehyde
Figure imgf000244_0001
A mixture of (6-chloro[1 ,2,4]triazolo[1,5-a]pyrimidin-2-yl)methanol (9.86 g, 53.4 mmol), TEMPO (626 mg, 4.01 mmol), iodobenzene diacetate (18.9 g, 58.76 mmol) in CH2CI2 (75 mL) was stirred at room temperature for 2 hours. Once the reaction was deemed complete, methyl-tert-butyl ether (50 mL) was added slowly to precipitate the product, as a while solid (8.72 g, 90%>). 1H NMR (300 MHz, CDCI3) δ: 8.93 (d, 7=2.45 Hz, 1 H), 8.99 (d, 7=2.64 Hz, 1 H), 10.25 (s, 1 H). MS (APCI): 183.0, 185.0 (M+H+).
Step 1 : Preparation of compound (6-chloro[1 ,2,4]triazolo[1 ,5-a]pyrimidin-2-yl)methanol
Figure imgf000244_0002
To a slurry of (3-amino-1/-M,2,4-triazol-5-yl)methanol (28.5 g, 150 mmol) in acetic acid was added chloromalonaldehyde (16 g, 150 mmol). The mixture was heated to 80 °C for 4 hours. Upon cooling of the reaction to room temperature, the product crystallized out as a white solid (25.5 g, 92%). 1H NMR (300 MHz, DMSO-D6) δ: 4.67 (s, 2 H), 5.62 (s, 1 H), 8.94 (d, 7=2.45 Hz, 1 H), 9.81 (d, 7=2.45 Hz, 1 H). MS (APCI): 185.0 (M+H+).
Example A(250): (-)-1-(4-{2-[2-Cyclopentyl-5-(5,7-dimethyI-[1,2,4]triazolo[1,5-a]pyrimidin-2- ylmethyl)-4-hydroxy-6-oxo-3,6-dihydro-2H-pyran-2-yl]-ethyl}-2-fluoro-phenyl)- cyclopropanecarbonitrile
Figure imgf000244_0003
The title compound was prepared by using chiral SFC to separate the racemic 1-(4-{2-[5- (6-Chloro-[1,2,4]triazolot1,5-a]pyrimidin-2-ylmethyl)-2-cyclopentyl-4,6-dioxo-tetrahydro-pyran-2- yl]-ethyl}-2-fluoro-phenyl)-cyclopropanecarbonitriIe. Optical rotation determined to be (-). Example A(251): (+)-1-(4-{2-[2-Cyclopentyl-5-(5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2- ylmethyl)-4-hydroxy-6-oxo-3,6-dihydro-2H-pyran-2-yl]-ethyl}-2-fluoro-phenyl)- cyclopropanecarbonitrile
Figure imgf000245_0001
The title compound was prepared by using chiral SFC to separate the racemic 1-(4-{2-[5- (6-Chloro-[1,2,4]triazolo[1,5-a]pyrimidin-2-ylmethyl)-2-cyclopentyl-4,6-dioxo-tetrahydro-pyran-2- yl]-ethyl}-2-fluoro-phenyl)-cyclopropanecarbonitrile. Optical rotation determined to be (+).
Example A(252): 2-(4-{2-[2-Cyclopentyl-5- (6-ethyl- [1,2,4]triazolo[1,5-a]pyrimidin-2- ylmethyl)-4-hydroxy-6-oxo-3,6-dihydro-2H-pyran-2-yl]-ethyl}-2,6-difluoro-phenyl)-2-methyl- propionitrile (3428-187 PF-00389530)
Figure imgf000245_0002
A solution of 2-{4-[2-(2-Cyclopentyl-4-hydroxy-6-oxo-3,6-dihydro-2H-pyran-2-yl)-ethyl]- 2,6-difluoro-phenyl}-2-methyl-propionitriie (272 mg, 0.7 mmol) in anhydrous MeOH (1.5 mL) was treated with 6-ethyl-[1,2,4]triazolo[1,5-a]pyrimidine-2-carbaldehyde (324 mg, 2.0 mmol), followed by borane-dimethylamine complex (191.7 mg, 1.05 mmol) at room temperature. The reaction was stirred for 12 hours. The precipitate was removed by filtration, and the filtrate was concentrated to a crude oil. The crude oil was purified by flash chromatography (25g Si02, 1:3 :1:0 (93.5% ethyl acetate, 6% methanol, 0.5% acetic acid) : (81.5% hexanes, 12% ethyl acetate, 6% methanol, 0.5% acetic acid)) to give product as an oil. It was further purified by preparatory HPLC. Yield: 19.0 mg, 8.0 %. H NMR (CDCI3) δ: 1.37 (t, 7=3.75 Hz, 3H)), 1.48-1.75 (m, 8H), 1.84 (s, 6H), 1.91-2.02 (m, 2H), 2.32-2.49 (m, 3H), 2.61-2.70 (m, 2H), 2.79-2.86 (m, 2H), 4.10 (s, 2H), 6.69 (d, 7=10.86 Hz, 2H), 8.62 (s, 1 H), 8.73 (s, 1 H). MS (ESI): 548 (M-H).
Example A(253): 2-(4-{2-[2-Cyclopentyl-4-hydroxy-5-(5-methyl-[1 ,2,4]triazolo[1 ,5- a]pyrimidin-2-ylmethyl)-6-oxo-3,6-dihydro-2H-pyran-2-yl]-ethyl}-2,6-difluoro-phenyl)-2- methyl-propionitrile (3428-020 PF-00460708)
Figure imgf000246_0001
The desired product was prepared analogously to Example A (112), substituting 5- Methyl- [1,2,4 ]triazolo[1 ,5-a]pyrimidine-2-carbaldehyde (86.0 mg, 0.53 mmol) in place of 5,7- dimethyl[1 ,2,4]triazolo[1,5-a]pyrimidine-2-carbaldehyde. Yield: 66.0 mg, 14 %. 1H NMR (CDCI3) δ: 0.88 (t, 7=3.4 Hz, 2H), 1.20 -1.41 (m, 6H), 1.84 (s, 6H), 1.94-2.03 (m, 2H), 2.31-2.48 (m, 2H), 2.64 (t, 7=3.18 Hz, 2H), 2.74 (s, 3H), 4.09 (s, 2H), 6.70 (d, 7=11.1 Hz, 2H), 7.03 (d, 7=9.8 Hz, 1 H), 8.67 (d, 7=7.0 Hz, 1 H). MS (ESI): 534 (M-1).
Example A(254): 2-(4-{2-[2-Cyclopentyl-5- (5,7-dimethyl- 1,2,4 ]triazolo[1,5-a]pyrimidin-2- ylmethyl)-4-hydroxy-6-oxo-3,6-dihydro-2H-pyran-2-yl]-ethyl}-2,6-difluoro-phenyl)-2-methyl- propionitrile (3428-192 PF-00398981)
Figure imgf000246_0002
The desired product was prepared analogously to Example A (112), substituting 1-{4-[2- (2-Cyclopentyl-4,6-dioxo-tetrahydro-pyran-2-yl)-ethyl]-2,6-difluoro-phenyl} cyclopropanecarbonitrile in place of 2-{4-[2-(2-CycIopentyl-4,6-dioxo-tetrahydro-pyran-2-yl)-ethyl]- 2-fluoro-phenyl}-2-ethyl-butyronitrile. Yield: 18.0 mg, 5.0 %. 1H NMR (CDCI3) δ: 1.34 (t, 7=2.50 Hz, 2H), 1.63-1.74 (m, 9H), 1.81-1.91 (m, 2H), 2.36-2.44 (m, 4H), 2.49 (s, 3H), 2.64-2.74 (m, 4H), 4.10 (s, 2H), 6.70 (d, 7=7.4 Hz, 2H), 8.62 (d, 7=2.3 Hz, 1H), 8.70 (d, 7=2.2 Hz, 1H). MS (ESI): 532 (M-1).
Example A(255): 1-{4-[2-(2-Cyclopentyl-4, 6-dioxo-tetrahydro-pyran-2-yl)-ethyl]-2,6-difluoro- phenyl}-cyclopropanecarbonitrile
Figure imgf000247_0001
The desired product was prepared analogously to step of example A (97), substituting 1-{4-[3- Cyclopentyl-4-(2,2-dimethyl-6-oxo-6H-[1,3]dioxin-4-yl)-3-hydroxy-but-1-ynyl]-2,6-difluorophenyl}- cyclopropanecarbonitrile (1.0 g, 2.66 mmol) from Step 2 below in place of 2-{4-[3-cycIopentyl-4- (2,2-dimethyl-4-oxo-4H-1,3-dioxin-6-yl)-3-hydroxybut-1-ynyl]-2-fluorophenyl}-2- methylpropanenitrile. Yield: 0.43 g, 42 %. δ: 1H NMR (CDCI3) δ: 1.35 (t, 7=2.8 Hz, 2H), 1.56- 1.73 (m, 10H), 1.92 (t, 7=4.45 Hz, 2H), 2.21-2.30 (m, 1H), 2.65-2.79 (m, 4H), 3.44 (d, 7=5.6 Hz, 2H), 6.71(d, 7=8.6 Hz, 2H). MS (ESI): 386 (M-1).
Step 2: 1-{4-[3-Cyclopentyl-4- (2,2-dimethyl-6-oxo-6H- [1,3]dioxin-4-yl)-3-hydroxy-but-1- ynyl]-2,6-difluoro-phenyl}-cyclopropanecarbonitrile
Figure imgf000247_0002
The desired product was prepared analogously to Example A (97) step 3, substituting 1-
(4-Bromo-2,6-difluoro-phenyl)-cyclopropanecarbonitrile (1.07g, 4.16 mmol) from step 1 below in place of 1-(4- bromo-2-fluoro-phenyl)-cyclopropanecarbonitrile. Yield: 1.20g, 80.0%. 1H NMR (CDCI3) δ: 1.37 (t, 7=2.8 Hz, 2H), 1.62-1.70 (m, 6H), 1.72 (s, 3H), 1.73 (s, 3H), 1.74-1.83 (m, 4H), 2.22-2.27 (m, 1H), 2.66 (s, 2H), 5.44 (s, 1H), 6.92 (d, 7=8.0 Hz, 2H). MS (ESI): 440 (M-1). Step 1: 1-(4-Bromo-2, 6-difluoro-phenyl)-cycloρropanecarbonitrile
Figure imgf000248_0001
The desired product was prepared analogously to Example A (141) step 3, substituting 1,2-bromoethane in place of Mel. Yield: 1.07g, 74.4%. 1H NMR (CDCI3) δ: 1.36 (t, 2.8 Hz, 2H), 1.77 (t, 7=2.7 Hz, 2H), 7.13 (d, 7=6.8 Hz, 2H).
Example A(256): 1-(4-{2-[5-(6-Chloro- [1,2,4]triazolo[1,5-a]pyrimidin-2-ylmethyl)-2- cyclopentyl-4-hydroxy-6-oxo-3,6-dihydro-2H-pyran-2-yl]-ethyl}-2,6-difluoro-phenyl)- cyclopropanecarbonitrile
Figure imgf000248_0002
The desired product was prepared analogously to Example A (112), substituting 6-
Chloro- [1,2,4]triazolo[1,5-a]pyrimidine-2-carbaIdehyde (180.9 mg, 1.0 mmol) in place of 5,7- Dimethyl-[1 ,2,4]triazolo[1,5-a]pyrimidine-2-carbaldehyde. Yield: 85.0 mg, 23 %. 1H NMR (CDCI3) δ: 1.34 (t, 7=2.70 Hz, 2H), 1.69-1.71 (m, 4H), 1.94-1.99 (m, 3H), 2.35-2.49 (m, 4H), 2.65-2.78 (m, 4H), 3.42 (d, 7=3.8 Hz, 2H), 4.11 (d, 7=4.0 Hz, 2H), 6.70 (d, 7=4.6 Hz), 8.80 (s, 1H), 8.87 (s, 1H). MS (ESI): 552 (M-1).
Example A(257): (+)-2-(4-{2-[2-Cyclopentyl-4-hydroxy-5-(6-methyl-[1 ,2,4]triazolo[1 ,5 a]pyrimidin-2-ylmethyl)-6-oxo-3,6-dihydro-2H-pyran-2-yl]-ethyl}-2,6-difluoro-phenyl)-2- methyl-propionitrile
Figure imgf000249_0001
(+) enantiomer
The title compound was isolated by chiral SFC of racemic material described in example A (143) Condition: ChiralPac AS-H column, 250x4.6 mm, 120 bar, 30% MeOH, 50 mL/min, retention time 4.84 min.
Example A(258): (-)-2-(4-{2-[2-Cyclopentyl-4-hydroxy-5-(6-methyl-[1 ,2,4]triazolo[1 ,5- a]pyrimidin-2-ylmethyl)-6-oxo-3,6-dihydro-2H-pyran-2-yl]-ethyl}-2,6-difluoro-phenyl)-2- methyl-propionitrile (3428-175 PF-00419774)
Figure imgf000249_0002
(-) enantiomer
The title compound was isolated by chiral SFC of racemic material described in example A (143) Condition: ChiralPac AS-H column, 250x4.6 mm, 120 bar, 30% MeOH, 50 mL/min, retention time 2.85 min.
Example A(259): (+)-2-(4-{2-[5-(6-Chloro-[1,2,4]triazolo[1,5-a]pyrimidin-2-ylmethyl)-2- cyclopentyl-4-hydroxy-6-oxo-3,6-dihydro-2H-pyran-2-yl]-ethyl}-2,6-difluoro-phenyl)-2- methyl-propionitrile
Figure imgf000250_0001
(+) enantiomer
The title compound was isolated by chiral SFC of racemic material described in example A (142) Condition: ChiralPac AS-H column, 250x20 mm, 110 bar, 30% MeOH, 2.5 mL/min, retention time 4.86 min.
Example A(260): (-)-2-(4-{2-t5-(6-Chloro-[1,2,4]triazolo[1,5-a]pyrimidin-2-ylmethyl)-2- cyclopentyl-4-hydroxy-6-oxo-3,6-dihydro-2H-pyran-2-yl]-ethyl}-2,6-difluoro-phenyl)-2- methyl-propionitrile
Figure imgf000250_0002
The title compound was isolated by chiral SFC of racemic material described in example A (142) Condition: ChiralPac AS-H column, 250x20 mm, 110 bar, 30% MeOH, 2.5 mL/min, retention time 3.31 min.
Example A(261): 2-(4-{2-[2-Cyclopentyl-4-hydroxy-5- (6-methyl- [1,2,4]triazolo[1,5- a]pyrimidin-2-ylmethyl)-6-oxo-3,6-dihydro-2H-pyran-2-yl]-ethyl}-2-fluoro-5-methoxy- phenyl)-2-methyl-propionitrile
Figure imgf000251_0001
The desired product was prepared analogously to Example A (112), substituting 2-{4-[2- (2-Cyclopentyl-4-hydroxy-6-oxo-3, -dihydro-2H-pyran-2-y!)-ethyl]-2-fluoro-5-methoxy-phenyl}-2- methyl-propionitrile from Step 4 below in place of 2-{4-[2-(2-Cyclopentyl-4,6-dioxo-tetrahydro- pyran-2-yl)-ethyl]-2-fluoro-phenyl}-2-ethyl-butyronitrile. Yield: 0.071 g, 16%. 1H NMR (CDCI3) δ: 1.54-1.63 (m, 4H), 1.77 (s, 6H), 1.91-1.97 (s, 4H), 2.37-2.45 (m, 1H), 2.48 (s, 3H), 2.57-2.80 (m, 4H), 3.75-3.85 (m, 5H), 4.10 (d, 7=5.5 HZ, 2H), 6.84 (d, 7=2.1 Hz, 1H), 6.89 (d, 6.6 Hz, 1H), 8.62 (d, 7=2.3 Hz, 1H), 8.69 (d, 7=2.2 Hz, 1H). MS (ESI): 546 (M-1).
Step 4: 2-{4-[2-(2-Cyclopentyl-4-hydroxy-6-oxo-3,6-dihydro-2H-pyran-2-yl)-ethyl]-2-fluoro-5- methoxy-phenyl}-2-methyl-propionitrile
Figure imgf000251_0002
The desired product was prepared analogously to Example A (97), step 4, substituting 2- {4-[3-Cyclopentyl-4-(2,2-dimethyl-6-oxo-6H-[1,3]dioxin-4-yl)-3-hydroxy-but-1-ynyl]-2-fluoro-5- methoxy-phenyl}-2-methyl-propionitrile (2.0 g, 4.39 mmol) from Step 6 below in place of 2-{4-[3- cyclopentyl-4-(2,2-dimethyl-4-oxo-4H-1,3-dioxin-6-yl)-3-hydroxybut-1-ynyl]-2-fluorophenyl}-2- methylpropanenitrile. Yield: 0.87 g, 49 %. 1H NMR (CDCI3) δ: 1.39-1.48 (m, 2H), 1.59-1.68 (m, 5H), 1.79 (s, 6H), 1.83-1.95 (m, 3H), 2.30-2.37 (m, 1H), 2.54-2.69 (m, 4H), 3.83 (s, 3H), 5.30 (s, 1H), 6.86 (d, 7=11.9 Hz, 1H), 6.95 (d, 7=6.6 Hz, 1H). MS (ESI): 400 (M-1).
Step 6: 2-{4-[3-Cyclopentyl-4-(2,2-dimethyl-6-oxo-6H-[1 ,3]dioxin-4-yl)-3-hydroxy-but-1 - ynyl]-2-fluoro-5-methoxy-phenyl}-2-methyl-propionitrile
Figure imgf000252_0001
The desired product was prepared analogously to Example A (97) step 3, substituting 2- (4-Bromo-2, 6-difluoro-phenyl)-2-methyl-propionitrile (5.28g, 20.32 mmol) from step 5 below in place of 1-(4- bromo-2-fluoro-phenyl)-cyclopropanecarbonitrile. Yield: 8.72g, 96.0%>. 1H NMR (CDCI3) δ: 1.50-1.61 (m, 8H), 1.72 (s, 3H), 1.75 (s, 3H), 1.80 (s, 6H), 2.20-2.29 (m, 1H), 2.61 (s, 1 H), 2.65 (d, 7=9.1 Hz, 2H), 3.87 (s, 3H), 5.53 (s, 1H), 7.00 (d, 7=6.5 Hz, 1H, 7.03 (d, 7=11.6 Hz, 1H). MS (ESI): 454 (M-1).
Step 5: 2-(4-Bromo-2-fluoro-5-methoxy-phenyl)-2-methyl-propionitrile
Figure imgf000252_0002
The desired product was prepared analogously to Example A (97) step 2, substituting (4- Bromo-2-fluoro-5-methoxy-phenyl)-acetonitrile (1.95g, 8.0 mmol) from step 4 below in place of 1- (4- bromo-2-fluoro-phenyl)-cyclopropanecarbonitrile. Yield: 8.72g, 96.0%>. 1H NMR (CDCI3) δ: 1.34 (s, 6H), 3.92 (s, 3H), 7.06 (d, 7=6.8 Hz, 1H), 7.33 (d, 7=10.6 Hz, 1H).
Step 4: (4-Bromo-2-fluoro-5-methoxy-phenyl)-acetonitrile
Figure imgf000252_0003
The desired product was prepared analogously to Example A (97) step 1, substituting (4- Bromo-2-fluoro-5-methoxy-phenyl)-acetonitrile (1.95g, 8.0 mmol) from step 3 below in place of 1- (4- bromo-2-fluoro-phenyl)-cyclopropanecarbonitrile. Yield: 2.26 g, 99.9%. 1H NMR (CDCI3) δ: 3.74 (s, 2H), 3.91 (s, 3H), 6.95 (d, 7=6.4 Hz, 1H), 7.35 (d, 7=4.6 Hz, 1H).
Step 3: 1-Bromo-4-bromomethyl-5-fluoro-2-methoxy-benzene
Figure imgf000253_0001
The desired product was prepared analogously to Example A (141) step 1, substituting (4-Bromo-2-fluoro-5-methoxy-phenyl)-acetonitrile (1.95g, 8.0 mmol) from step 3 below in place of 1-(4- bromo-2-fluoro-phenyl)-cyclopropanecarbonitriie. Yield: 2.45 g, 82.2 %. 1H NMR (CDCI3) δ: 3.82 (s, 3H), 4.40 (s, 2H), 6.82 (d, 7=5.8 Hz, 1H), 7.24 (d, 7=10.58 Hz, 1H).
Step 2: (4-Bromo-2-fluoro-5-methoxy-phenyl)-methanol
Figure imgf000253_0002
To a solution of 4-Bromo-2-fluoro-5-methoxy-benzaldehyde (4.03 g, 17.33 mmol) from step (1) below in Methanol at 0°C was added NaBH4 (0.65 g, 17.33 mmol). After the reaction mixture was stirred at 0°C for 2 hours, it was allowed to warm to room temperature. The organic layer was taken up in ethyl ether, washed with water and dried over MgS0 , filtered and concentrated. The residue was purified by flash chromatography (25-45% EtOAc in hexanes) to give the product. Yield: 3.90 g, 99.0 %. 1H NMR (CDCI3) δ: 3.90 (s, 3H), 4.74 (d, J=6.02 Hz, 2H), 6.82 (d, 7=6.1 Hz, 1H), 7.29 (d, 7=10.58 Hz, 1H).
Step 1: 4-Bromo-2~fluoro~5-methoxy-benzaldehyde
Figure imgf000253_0003
Bromine (15 ml, 300 mmol) was added slowly to a solution of 2-Fluoro-5-methoxy-benzaldehyde (23.12 g, 150 mmol) in chloroform (500 ml), and the mixture was stirred at room temperature for 5 days. The mixture was poured into water (200 ml) and extracted with chloroform (2X 200 mL). The organics were washed with water (200 mL) and brine (200 mL), dried over MgS04, filtered and concentrated. The residue was purified by flash column chromatography (2-16 % EtOAc in hexanes) to give the product. Yield: 20.7 g, 60 %. 1H NMR (CDCI3) δ: 3.93 (s, 3H), 7.08-7.13 (m, 1H), 7.29 (d, 7=12.4 Hz, 1H).
Example A(262): 2-(4-{2-[2-Cyclopentyl-4-hydroxy-5- (6-methyl- [1,2,4]triazolo[1,5- alpyrimidin^-ylmethy -β-oxo-S.β-dihydro^H-pyran^-ylJ-ethy^^.β-difluoro-phenyl)^- ethyl-butyronitrile
Figure imgf000254_0001
The desired product was prepared analogously to Example A (112), substituting 6- Methyl- [1,2,4] triazolo [1,5-a]pyrimidine-2-carbaldehyde (243.2 mg, 1.5 mmol) in place of 5,7- Dimethyl-[1,2,4]triazolo[1,5-a]pyrimidine-2-carbaldehyde. Yield: 178.0 mg, 32 %. 1H NMR (CDCI3) δ: 1.01 (tt, 7=3.75, 3.70Hz, 6H), 1.32-1.58 (m, 6H), 1.99-2.09 (m, 5H), 2.19-2.43 (m, 4H), 2.49 (s, 3H), 2.63-2.79 (m, 4H), 4.10 (s, 2H), 6.68 (d, 7=11.1 Hz, 2H), 8.63 (s, 1 H), 8.70 (s, 1H). MS (ESI): 562 (M-1).
Step 3: 2-{4-[2-(2-Cyclopentyl-4, 6-dioxo-tetrahydro-pyran-2-yl)-ethyl]-2,6-difluoro-phenyl}- 2-ethyl-butyronitrile
Figure imgf000254_0002
The desired product was prepared analogously to Example A (97), step 4, substituting 2- {4-[3-CycIopentyl-4-(2,2-dimethyl-6-oxo-6H-[1,3]dioxin-4-yl)-3-hydroxy-but-1-ynyl]-2,6- difluorophenyl}-2-ethyl-butyronitrile (3.11 g, 6.55 mmol) from Step 2 below in place of 2-{4-[3- cyclopentyl-4-(2,2-dimethyl-4-oxo-4H-1,3-dioxin-6-yl)-3-hydroxybut-1-ynyl]-2-fluorophenyl}-2- methylpropanenitrile. Yield: 1.52 g, 56 %. 1H NMR (CDCI3) δ: 1.03 (t, 7=3.65 Hz, 6H), 1.18-1.29 (m, 2H), 1.38-1 42 (m, 1 H), 1.60-1.82 (m, 4H), 1.92-2.09 (m, 5H), 2.23-2.29 (m, 3H), 2.63-2.80 (m, 4H), 3.45 (d, 7=3.6 Hz, 2H) 6.73 (d, 7=10.8 Hz, 2H). MS (ESI): 416 (M-1).
Step 2: 2-{4-[3-Cyclopentyl-4- (2,2-dimethyl-6-oxo-6H-[1,3]dioxin-4-yl)-3-hydroxy-but-1- ynyl]-2,6-difluoro-phenyl}-2-ethyl-butyronitrile
Figure imgf000255_0001
The desired product was prepared analogously to Example A (97) step 3, substituting 2- (4-Bromo-2, 6-difluoro-phenyl)-2-methyl-propionitrile (5.28g, 20.32 mmol) from step 1 below in place of 1-(4- bromo-2-fluoro-phenyl)-cyclopropanecarbonitrile. Yield: 3.0g, 58.0%. 1H NMR (CDCI3) δ: 1.04 (t, 7=3.65 Hz, 6H), 1.17-1.39 (m, 3H), 1.57-1.67 (m, 1H), 1.73 (s, 3H), 1.74 (s, 3H), 1.82-1.87 (m, 1 H), 2.02-2.07 (m, 4H), 2.22-2.29 (m, 4H), 2.57 (s, 1 H), 2.66 (s, 2H), 5.45 (s, 1 H), 6.93 (d, 7=10.3 Hz, 2H). MS (ESI): 470 (M-1).
Step 1: 2-(4-Bromo-2, 6-difluoro-phenyl)-2-ethyl-butyronitrile
FYΥBr
The desired product was prepared analogously to Example A (141) step 3, substituting bromoethane in place of Mel. Yield: 3.16g, 91.4%. 1H NMR (CDCI3) δ: 1.04 (t, 7=3.65 Hz, 6H), 2.01-2.07 (m, 2H), 2.20-2.27 (m, 2H), 7.13 (d, 7=9.3 Hz, 2H).
Example A(263): (+)-2-(4-{2-[2-Cyclopentyl-4-hydroxy-5- (6-methyl- [1 ,2,4]triazolo[1 ,5- a]pyrimidin-2-ylmethyl)-6-oxo-3,6-dihydro-2H-pyran-2-yl]-ethyl}-2,6-difluoro-phenyl)-2- ethyl-butyronitrile 255
Figure imgf000256_0001
(+) enantiomer
The title compound was isolated by chiral SFC of racemic material described in example A (262) (4649-011 PF-00433966) Condition: ChiralPac AS-H column, 250x4.6 mm, 120 bar, 30% MeOH, 2.5 mL/min, retention time 4.62 min.
Example A(254): (-)-2-(4-{2-[2-Cyclopentyl-4-hydroxy-5- (6-methyl- [1,2,4]triazolo[1,5- a]pyrimidin-2-ylmethyl)-6-oxo-3,6-dihydro-2H-pyran-2-yl]-ethyl}-2,6-difluoro-phenyl)-2- ethyl-butyronitrile
Figure imgf000256_0002
(-) enantiomer
The title compound was isolated by chiral SFC of racemic material described in example A (262) Condition: ChiralPac AS-H column, 250x4.6 mm, 120 bar, 30% MeOH, 2.5 mL/min, retention time 2.54 min.
Example A(265): 2-(4-{2-[5-(6-Chloro-[1,2,4]triazolo[1,5-a]pyrimidin-2-ylmethyl)-2- cyclopentyl-4-hydroxy-6-oxo-3,6-dihydro-2H-pyran-2-yl]-ethyl}-2-fluoro-phenyl)-2-ethyl- butyronitrile
Figure imgf000257_0001
The desired product was prepared analogously to Example A (112), substituting 6-Chloro- [1,2,4]triazolo[1,5-a]pyrimidine-2-carbaldehyde (273.9 mg, 1.5 mmol) in place of 5,7-Dimethyl- [1,2,4]triazolo[1,5-a]pyrimidine-2-carbaldehyde. Yield: 70.0 mg, 12 %. 1H NMR (CDCI3) δ: 1.01 (tt, 7=3.7, 3.7 Hz, 6H), 1.49-1.72 (m, 8H), 1.97-2.06 (m, 4H), 2.21-2.27 (m, 2H), 2.20-2.34 (m, 1H), 2.49 (d, 7=14.71 Hz, 1H), 2.66 (t, 7=4.15 Hz, 2H), 2.84 (d, 7=17.1 Hz, 1H), 4.10 (s, 2H), 6.70 (d, 7=11.1 Hz, 2H), 8.80 (s (1H), 8.90 (s, 1H). MS (ESI): 583 (M-1).
Example A(266): (+)-2-(4-{2-[5-(6-Chloro-[1 ,2,4]triazolo[1 ,5-a]pyrimidin-2-ylmethyl)-2- cyclopentyl-4-hydroxy-6-oxo-3,6-dihydro-2H-pyran-2-yl]-ethyl}-2-fluoro-phenyl)-2-ethyl- butyronitrile
Figure imgf000257_0002
(+) enantiomer
The title compound was isolated by chiral SFC of racemic material described in example A (265) Condition: ChiralPac AS-H column, 250x4.6 mm, 120 bar, 30% MeOH, 2.5 mL/min, retention time 4.69 min.
Example A(267): (-)-2-(4-{2-[5-(6-Chloro-[1 ,2,4]triazolo[1 ,5-a]pyrimidin-2-ylmethyl)-2- cycIopentyl-4-hydroxy-6-oxo-3,6-dihydro-2H-pyran-2-yl]-ethyl}-2-fluoro-phenyl)-2-ethyl- butyronitrile )
Figure imgf000258_0001
(-) enantiomer
The title compound was isolated by chiral SFC of racemic material described in example A (265) Condition: ChiralPac AS-H column, 250x4.6 mm, 120 bar, 30% MeOH, 2.5 mL/min, retention time 2.90 min.
Example A(268) 2-(4-{2-[2-Cyclopentyl-4-hydroxy-5-(6-methyl-[1 ,2,4]triazolo[1 ,5- a]pyrimidin-2-ylmethyl)-6-oxo-3,6-dihydro-2H-pyran-2-yl]-ethyl}-2-fluoro-phenyl)-N-ethyl- isobutyramide
Figure imgf000258_0002
The desired product was prepared analogously to Example A (112), substituting 6- Methyl-[1 ,2,4]triazolo[1,5-a]pyrimidine-2-carbaldehyde (243.2 mg, 1.5 mmol) in place of 5,7- Dimethyl-[1 ,2,4]triazolo[1,5-a]pyrimidine-2-carbaldehyde. Yield: 66.0 mg, 14.0 %. 1H NMR (CDCI3) δ: 1.05 (t, 7=3.7 Hz, 2H), 1.52 (s, 6H), 1.60-1.76 (m, 2H), 2.02-2.09 (m, 4H), 2.36-2.44 (m, 2H), 2.48 (s, 3H), 2.62-2.79 (m, 4H), 3.15-3.27 (m, 3H), 4.05 (S, 2H), 6.81 (d, 7=11.4 Hz, 1H), 6.94 (d, 7=6.8 Hz, 1H), 7.20-7.22 (m, 1H), 8.61 (d, 7=2.1 Hz, 1 H), 8.69 (d, 7=2.3 Hz, 1H). MS (ESI): 562 (M-1). Example A(269): 6-Cyclopentyl-6-{2-[3-fluoro-4-(2-hydroxy-1,1-dimethyl-ethyl)-phenyl]- ethyl}-4-hydroxy-3-(6-methyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-ylmethyl)-5,6-dihydro-pyran-
2-one
Figure imgf000259_0001
The desired product was prepared analogously to Example A (112), substituting 6- Methyl-[1,2,4]triazolo[1,5-a]pyrimidine-2-carbaldehyde (243.2 mg, 1.5 mmol) in place of 5,7- Dimethyl-[1 ,2,4]triazolo[1,5-a]pyrimidine-2-carbaldehyde. Yield: 35.0 mg, 10.0 %. 1H NMR (CDCI3) δ: 1.35 (s, 6H), 1.53-1.77 (m, 6H), 1.99-2.05 (m, 4H), 2.32-2.44 (m, 2H), 2.48 (s, 3H), 3.75 (s, 2H), 4.08 (s, 2H), 6.80 (dd, 7=13.19, 1.6 Hz, 1H), 7.00 (dd, 7=10.5, 1.8 Hz, 1H), 7.20 - 7.24 (m, 1H), 8.62 (d, 7=2.5 Hz, 1H), 8.69 (d, 7=2.3 Hz, 1H). MS (ESI): 521 (M-1).
Example A(271): 2-(4-{2-[2-Cyclopentyl-4-hydroxy-5- (6-methyl- [1,2,4]triazolot1,5- a]pyrimidin-2-ylmethyl)-6-oxo-3,6-dihydro-2H-pyran-2-yl]-ethyl}-2-fluoro-phenyl)-2-methyl- propionic acid methyl ester
Figure imgf000259_0002
The desired product was prepared analogously to Example A (112), substituting 6- Methyl- [1,2,4]triazolo[1,5-a]pyrimidine-2-carbaldehyde (176.0 mg, 0.967 mmol) in place of 5,7- Dimethyl-[1 ,2,4]triazolo[1,5-a]pyrimidine-2-carbaldehyde. Yield: 29.0 mg, 4.0 %. 1H NMR (CDCI3) δ: 1.35-1.44 (m, 2H), 1.53 (s, 6H), 1.55-1.74 (m, 8H), 2.41-2.46 (m, 2H), 2.49 (s, 3H), 2.63-2.79 (m, 3H), 3.66 (s, 3H), 4.10 (s, 2H), 6.80 (dd, 7=10.4, 1.8 Hz, 1H), 6.93 (dd, 7=9.6, 1.5 Hz, 1H), 7.19-7.24 (m, 1H), 8.62 (d, 7=1.3 Hz, 1H), 8.70 (d, 7=2.3 Hz, 1H). MS (ESI): 549 (M-1). 259
Example A(271): 3-(6-Chloro-[1,2,4]triazolo[1,5-a]pyrimidin-2-ylmethyl)-6-cyclopentyl-6-[2- (3-ethyl-4-hydroxy-phenyl)-ethyl]-4-hydroxy-5,6-dihydro-pyran-2-one
Figure imgf000260_0001
The title compound was isolated by chiral SFC of racemic material described in example A(127) Condition: ChiralPac AD-H column, 140 bar, 25%> MeOH, 2.5 mL/min.
Example A(272): 3-(6-Chloro-[1,2,4]triazolo[1,5-a]pyrimidin-2-ylmethyl)-6-cyclopentyl-6-[2- (3-ethyl-4-hydroxy-phenyl)-ethyl]-4-hydroxy-5,6-dihydro-pyran-2-one
Figure imgf000260_0002
The title compound was isolated by chiral SFC of racemic material described in example A(127) Condition: ChiralPac AD-H column, 140 bar, 25% MeOH, 2.5 mL/min.
Example A(273): Enantiomer 1 of 6-Cyclopentyl-3-(5,7-dimethyl-[1,2,4]triazolo[1,5- a]pyrimidin-2-ylmethyl)-6-[2-(5-ethyl-4-hydroxy-2,3-dihydro-benzofuran-7-yl)-ethyl]-4- hydroxy-5,6-dihydro-pyran-2-one
Figure imgf000260_0003
260
The title compound was separated from racemic 6-cyclopentyl-3-(5,7-dimethyl- [1,2,4]triazolo[1,5-a]pyrimidin-2-ylmethyl)-6-[2-(5-ethyl-4-hydroxy-2,3-dihydro-benzofuran-7-yl)- ethyl]-4-hydroxy-5,6-dihydro-pyran-2-one, (280mg) using chiral HPLC (Chiralpak AS-H, 140 bar, 2.5mL/min, 40% MeOH) (113mg, 5.140 min retention time).
Example A(274): Enantiomer 2 of 6-Cyclopentyl-3-(5,7-dimethyl-[1,2,4]triazolo[1 ,5- a]pyrimidin-2-ylmethyl)-6-[2-(5-ethyl-4-hydroxy-2,3-dihydro-benzofuran-7-yl)-ethyl]-4- hydroxy-5,6-dihydro-pyran-2-one
Figure imgf000261_0001
The title compound was separated from racemic 6-cyclopentyl-3-(5,7-dimethyl- [1,2,4]triazolo[1,5-a]pyrimidin-2-ylmethyl)-6-[2-(5-ethyl-4-hydroxy-2,3-dihydro-benzofuran-7-yl)- ethyl]-4-hydroxy-5,6-dihydro-pyran-2-one (280mg) using chiral HPLC (Chiralpak AS-H, 140 bar, 2.5mL/min, 40%> MeOH) (106mg, 8.992 min retention time).
Example A(275): 6-Cyclopentyl-3-(5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-ylmethyl)-6- [2-(5-ethyl-pyridin-3-yl)-ethyl]-4-hydroxy-5,6-dihydro-pyran-2-one
Figure imgf000261_0002
The title compound was prepared analogously to Example A(27) where 6-Cyclopentyl-6- [2-(5-ethyl-pyridin-3-yl)-ethyl]-dihydro-pyran-2, 4-dione from step 2 below was substituted in place of 6-cyclopentyl-6-[2-(3-ethyl-5-fluoro-4-hydroxy-phenyl)-ethyl]-dihydro-pyran-2,4-dione. 1H NMR (400 MHz, DMSO-d6) δ: 1.14 (t, 7=7.6 Hz, 3 H), 1.40-1.73 (br m, 8 H), 2.14 (m, 2 H), 2.44-2.67 (m, 12 H), 2.78 (d, 7=17.7 Hz, 1 H), 3.72 (d, 7=16.4 Hz, 1 H), 3.83 (d, 7=16.2 Hz, 1 H), 7.04 (s, 1 H), 7.50 (s, 1 H), 8.25 (s, 2 H), 10.90 (s, 1 H). Step 2: 6-Cyclopentyl-6-[2-(5- hyl]-dihydro-pyran-2,4-dione
Figure imgf000262_0001
The title compound was prepared analogously to Example A(1) where 3-bromo-5-ethyl- pyridine (from step 1 below) was substituted in place of 2-(4-bromo-2-fluorophenyl)-2- methylpropanenitrile in step 3 of that example. MS (ESI): 316.10 (M+H)+
Step 1: 3-Bromo-5-ethyl-pyridine
Figure imgf000262_0002
Sodium hydroxide (10g, 0.25 mol) and hydrazine monohydrate (10mL) were added to a solution of 3-acetyl-5-bromopyridine (5g, 25 mmol) dissolved in diethylene glycol (18mL). The reaction mixture was heated to 140°C for 6 hours and then partitioned between H20 and Ether.
The organic layers were washed with brine, dried over MgS0 and concentrated. The residue was purified by flash silica gel chromatography (0%> to 40%> EtOAc in hexanes) to give the title compound (3 g, 65%). 1H NMR (400 MHz, CDCI3): δ 1.26 (t, 7=7.6 Hz, 3 H), 2.65 (q, 7=7.6 Hz, 2
H), 7.67 (s, 1H), 8.37 (s, 1 H), 8.51 (s, 1 H).
Section B: Pyrone prepared by Heck route.
Scheme 2
Figure imgf000263_0001
Example B(1): 6-Cyclopentyl-3-(5,7-dimethyl-[1,2,4]triazolo[1,5-a-pyrimidin-2-ylmethyl)-6- [2-(3-fluoro-4-methoxy-phenyl)-ethyl]-4-hydroxy-5,6-dihydro-pyran-2-one
Figure imgf000263_0002
The title compound was prepared by coupling the 6-Cyclopentyl-6-[2-(3-fluoro-4- methoxy-phenyl)-ethyl]-dihydro-pyran-2,4-dione from Step 1 below, to 5,7-Dimethyl- [1,2,4]triazolo[1,5-D]pyrimidine-2-carbaldehyde using the Me2NHBH3 method described in the synthesis of Example B(31). 1HNMR(DMSO- 6): δ 1.39-1.71 (br m, 8H), 2.11 (m, 2H), 2.40 (m, 10H), 2.76 (d, 1H, 7= 17.5 Hz), 3.71 (d, IH, 7= 16.2 Hz), 3.80 (s, 3H), 3.85 (d, IH, 7= 16.2 Hz), 7.05 (m, 4H), 10.83 (s, IH). Anal. Calcd. For C27H3IN4O4F'0.5 H20: C, 64.40; H, 6.41; N, 11.13. Found: C, 64.33; H, 6.34, N, 11.12.
Step 1 : 6-Cyclopentyl-6-[2-(3-fluoro-4-methoxy-phenyl)-ethyl]-dihydro-pyran-2,4-dione
Figure imgf000264_0001
The title compound was prepared analogously to Example A(64), where 4-Bromo-2- fluoroanisole was substituted in place of 4-bromo-2-fluoro-1 -isopropylbenzene of that example. 'HNMR CDCla): δ 1.43-1.82 (brm, 8H), 1.92 (m, 2H), 2.27 (m, IH), 2.62 (t, J= 8.5 Hz, 2H), 2.76 (s, 2H), 3.43 (s, 2H), 3.86 (s, 3H), 6.85 (m, 3H). Anal. Calcd. For Cι9H23F04: C, 68.24; H, 6.93. Found: C, 68.46; H, 6.84.
Figure imgf000264_0002
Example B(2): 6-Cyclopentyl-3-(5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-ylmethyl)-6- [2-(4-ethoxy-3-fluoro-phenyl)-ethyl]-4-hydroxy-5,6-dihydro-pyran-2-one
The title compound was prepared by coupling 6-Cyclopentyl-6-[2-(4-ethoxy-3-fluoro- phenyl)-ethyl]-dihydro-pyran-2,4-dione from Stepl to 5,7-Dimethyl-[1 ,2,4]triazolo[1 ,5- α]pyrimidine-2-carbaldehyde using the Me2NHBH3 method described in the synthesis of Example B(31).
'H NMR (DMSO-^s): d 1.33 (t, 3H, 7 = 7.0 Hz), 1.39-1.71 (br m, 8H), 2.11 (m, 2H), 2.40 - 2.58 (m, 10H), 2.78 (d, IH, 7= 17.5 Hz), 3.72 (d, IH, 7= 16.1 Hz), 3.84 (d, IH, 7= 16.1 Hz), 4.06 (q, 2H, 7= 7.0 Hz), 7.05 (m, 4H), 10.90 (s, IH). Anal. Calcd. For C28H33N4O4F«0.4 AcOH: C, 64.94; H, 6.55; N, 10.52. Found: C, 65.05; H, 6.53, N, 10.55.
Step 1 : 6-Cyclopentyl-6-[2-(4-ethoxy-3-fluoro-phenyl)-ethyl]-dihydro-pyran-2,4-dione.
Figure imgf000265_0001
The title compound was prepared analogously to Example A(64), where 4-Bromo-1-ethoxy-2- fluoro-benzene was substituted in place of 4-bromo-2-fluoro-1 -isopropylbenzene of that example.
Example B(3): 6-[2-(3-tert-Butyl-phenyl)-ethyl]-6-cyclopentyl-3-(5,7-dimethyl- [1,2,4]triazolo[1,5-a]pyrimidin-2-ylmethyl)-4-hydroxy-5,6-dihydro-pyran-2-one
Figure imgf000265_0002
The title compound was prepared by coupling the 6-[2-(3-tert-Butyl-phenyl)-ethyl]-6- cyclopentyl-dihydro-pyran-2,4-dione from Step 1 to 5,7-Dimethyl-[1,2,4]triazolo[1,5-α]pyrimidine- 2-carbaldehyde using the Me2NHBH3 method described in the synthesis of Example B(31). lH NMR DMSO-d6): d 1.29 (s, 9H), 1.46-1.76 (br m, 8H), 2.19 (m, 2H), 2.47 (s, 3Hz), 2.56 - 2.70 (m, 7H), 2.87 (d, IH, 7= 17.5 Hz), 3.80 (d, IH, 7= 16.2 Hz), 3.90 (d, IH, 7= 16.2 Hz), 7.12 (m, 2H), 7.28 (m, 3H), 10.92 (s, IH). Anal. Calcd. For Q^tW OΛ AcOH: C, 70.24; H, 7.58; N, 10.64. Found: C, 70.27; H, 7.42, N, 10.59.
Figure imgf000265_0003
Step 1 : 6-[2-(3-tert-Butyl-phenyl)-ethyl]-6-cyclopentyl-dihydro-pyran-2,4-dione The title compound was prepared analogously to Example A(64), where trifluoro- methanesulfonic acid 3-tert-butyl-phenyl ester was substituted in place of 4-bromo-2-fluoro-1- isopropylbenzene of that example.
'H NMR (CDCI3): δ 1.31 (s, 9H), 1.35-1.81 (m, 4H), 1.97 (m, 2H), 2.29 (m, IH), 2.68 (t, 2H, 7= 8.7 Hz), 2.78 (s, 2H), 2.86 (s, 2H), 3.42 (s, 2H), 4.08 (s, 2H), 6.96 (m, IH), 7.15 (s, IH), 7.23 (m, 2H). Anal. Calcd. For C22H30O3 .10 H20: C, 76.75; H, 8.84. Found: C, 76.89; H, 9.03. ESIMS (M-H"): 341.2
Example B(4): 6-Cyclopentyl-6-{2-[4-(3,5-dimethyl-isoxazol-4-yl)-phenyl]-ethyl}-3-(5,7- dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-ylmethyl)-4-hydroxy-5,6-dihydro-pyran-2-one
Figure imgf000266_0001
The title compound was prepared by coupling 6-Cyclopentyl-6-{2-[4-(3,5-dimethyl- isoxazol-4-yl)-phenyl]-ethyl}-dihydro-pyran-2,4-dione (Example A(18)) to 5,7-Dimethyl- [1,2,4]triazolo[1,5-α]pyrimidine-2-carbaldehyde using the Me2NHBH3 method described in the synthesis of Example B(31).
Η NMR (DMSO- ): d 1.39-1.72 (br m, 8H), 2.19 (m, 2H), 2.21 (s, 3H), 2.39 (s, 3Hz), 2.47 - 2.70 (m, 10H), 2.81 (d, IH, 7 = 17.5 Hz), 3.71 (d, IH, 7 = 16.1 Hz), 3.85 (d, IH, 7 = 16.2 Hz), 7.04 (s, IH), 7.27 (d, 2H, 7= 8.1 Hz), 7.36 (d, 2H, 7= 8.1 Hz), 10.98 (s, IH). Anal. Calcd. For C31H35N5O4O.6 H20: C, 67.39; H, 6.61; N, 12.68. Found: C, 67.39; H, 6.52, N, 12.45.
Figure imgf000266_0002
Example B(5): 6-[2-(3-Chloro-4-methoxy-phenyI)-ethyl]-6-cyclopentyl-4-hydroxy-3-(4- [1,2,3]thiadiazol-4-yl-benzyl)-5,6-dihydro-pyran-2-one The title compound was prepared by coupling the 6-[2-(3-Chloro-4-methoxy-phenyl)- ethyl]-6-cyclopentyl-dihydro-pyran-2,4-dione to 4-[1,2,3]thiadiazol-4-yl-benzaldehyde using the Me2NHBH3 method described in the synthesis of Example B(31).
Η NMR (DMSO-ds): d 1.36-1.71 (br m, 8H), 1.92 (m, 2H), 2.37 (m, IH), 2.56 (m, 3H), 2.84 (d, IH, 7 = 17.5 Hz), 3.60 (d, IH, 7= 14.3 Hz), 3.71 (d, IH, 7= 14.3 Hz), 3.79 (s, 3H), 6.96 (s, 2H), 7.19 (s, IH), 7.41 (d, 2H, 7= 8.1 Hz), 8.08 (d, 2H, 7= 8.3 Hz), 9.59 (s, IH), 11.01 (s, IH) Anal. Calcd. For C28H29N2O4ClS»0.75 H20: C, 62.44; H, 5.71; N, 5.20. Found: C, 62.43; H, 5.58; N, 5.30.
Figure imgf000267_0001
Example B(6): 6-[2-(3-Chloro-4-methoxy-phenyl)-ethyl]-6-cyclopentyl-3-[4-(2,5-dimethyl- pyrrol-1-yl)-benzyl]-4-hydroxy-5,6-dihydro-pyran-2-one
The title compound was prepared by coupling 6-[2-(3-Chloro-4-methoxy-phenyl)-ethyl]-6- cyclopentyl-dihydro-pyran-2,4-dione to 4-(2,5-Dimethyl-pyrrol-1-yl)-benzaldehyde using the Me2NHBH3 method described in the synthesis of Example B(31).
1HNMR (DMSO- 6): δ 1.32-1.66 (br m, 8H), 1.89 (m, 2H), 1.90 (s,6H), 2.30 (m, IH), 2.52 (m, 2H), 2.61 (d, IH, 7= 17.7 Hz), 2.79 (d, IH, 7= 17.7 Hz), 3.57 (d, IH, 7= 14.4 Hz), 3.65 (d, IH, 7= 14.4 Hz), 3.80 (s, 3H), 5.77 (s, 2H), 7.01 (t, IH, J= 8.6 Hz), 7.10 (t, IH, J= 8.4 Hz), 7.10 (d, 2H, 7= 8.3 Hz), 7.21 (s, IH), 7.31 (d, 2H, 7= 8.1 Hz), 10.91 (s, IH) Anal. Calcd. For
Figure imgf000267_0002
H20: C, 70.77; H, 6.887; N, 2.58. Found: C, 70.92; H, 6.79; N, 2.54.
Example B(7): 6-Cyclopentyl-3-(5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-ylmethyl)-6- [2-(3-ethyl-4-hydroxy-phenyl)-ethyl]-4-hydroxy-5,6-dihydro-pyran-2-one
Figure imgf000267_0003
The title compound was prepared by coupling 6-Cyclopentyl-6-[2-(3-ethyl-4-hydroxy- phenyl)-ethyl]-dihydro-pyran-2,4-dione (from Example A(22)) to 5,7-Dimethyl-[1 ,2,4]triazolo[1 ,5- α]pyrimidine-2-carbaldehyde using the Me2NHBH3 method described in the synthesis of Example B(31). Η NMR DMSO-d6): d 0.96 (t, 3H, 7= 7.4 Hz), 1.30-1.58 (br m, 8H), 1.95 (m, 2H), 2.41 (m, 12H), 2.63 (d, IH, 7= 17.5 Hz), 3.61 (d, IH, 7= 15.8 Hz), 3.72 (d, IH, 7= 15.8 Hz), 6.52 (d, IH, 7= 8.1 Hz), 6.74 (m, 2H), 6.93 (s, IH), 8.84 (s, IH). Anal. Calcd. For C28H34N4O4 «0.5 AcOH: C, 66.90; H, 6.97; N, 10.76. Found: C, 66.89; H, 6.97, N, 10.83.
Example B(8): 6-[2-(3-tert-Butyl-4-hydroxy-phenyl)-ethyl]-6-cyclopentyl-3-(5,7-dimethyl- [1,2,4]triazolo[1,5-a]pyrimidin-2-ylmethyl)-4-hydroxy-5,6-dihydro-pyran-2-one
Figure imgf000268_0001
The title compound was prepared by coupling 6-[2-(3-tert-Butyl-4-hydroxy-phenyl)-ethyl]- 6-cyclopentyl-dihydro-pyran-2, 4-dione from Example A(2), to 5,7-Dimethyl-[1 ,2,4]triazolo[1 ,5- α]pyrimidine-2-carbaldehyde (described in Step 3 of example B(75)) using the Me2NHBH3 method described in the synthesis of Example B(31)1H NMR (CDC13): δ 1.37 (s, 9H), 1.43-1.86 (br m, 8H), 1.93 - 2.05 (m, 2H), 2.37 (m, 1H), 2.53-2.79 (m, 10), 3.49 (s, 2H), 4.06 (d, 7= 15.4 Hz, IH), 4.11 (d, 7= 15.4 Hz, IH), 6.58 (d, 7= 8.1 Hz IH)), 6.81-6.84 (m, 2H), 7.00 (s, IH). Example B(9): 6-Cyclopentyl-3-(5,7-dimethyl-[1,2,4]triazolo[1,5]pyrimidin-2-ylmethyl)-4- hydroxy-6-[2-(4-methoxy-3-methyl-phenyl)-ethyl]-5,6-dihydro-pyran-2-one
Figure imgf000269_0001
The title compound was prepared by coupling 6-Cyclopentyl-6-[2-(4-methoxy-3-methyl- phenyl)-ethyl]-dihydro-pyran-2,4-dionefromStep 1 below to 5,7-Dimethyl-[1,2,4]triazolo[1,5- α]pyrimidine-2-carbaldehyde (described in Step 3 of example B(75)) using the Me2NHBH3 method described in Example B(31).1HNMR(CDC13): δ 1.52-1.92 (brm, 8H), 2.05 (m, 2H), 2.16 (s, 3H), 2.35 (m, IH), 2.51-2.71 (m, 8H), 2.79 (s, 3H), 3.78 (s, 3H), 4.05 (d, 7= 15.6 Hz, IH), 4.12 (d, 7= 15.6 Hz, IH), 6.71 (d, 7= 8.5 Hz, IH), 6.84 (s, IH), 6.94 (m, 2H). Anal. Calcd. For C28H34N404: C, 68.55; H, 6.99; N, 11.43. Found: C, 68.42; H, 6.76; N, 11.57.
Figure imgf000269_0002
Step 1 : 6-Cyclopentyl-6-[2-(4-methoxy-3-methyl-phenyl)-ethyl]-dihydro-pyran-2,4-dione
6-CyclopentyI-6-[2-(4-methoxy-3-methyl-phenyl)-ethyl]-dihydro-pyran-2,4-dione was prepared analogously to Example A(82), where 4-Bromo-1 -methoxy-2-methyI-benzene was substituted in place of 2-Bromopyridine in Step 1 of that example.
Example B(10): 6-Cyclopentyl-3-(5,7-dimethyl-[1,2,4]triazolo[1,5]pyrimidin-2-ylmethyl)-6-[2- (4-ethoxy-3-methyl-phenyl)-ethyl]-4-hydroxy-5,6-dihydro-pyran-2-one
Figure imgf000270_0001
The title compound was prepared by coupling 6-Cyclopentyl-6-[2-(4-ethoxy-3-methyl- phenyl)-ethyl]-dihydro-pyran-2,4-dione from Example A(3), to 5,7-Dimethyl-[1 ,2,4]triazolo[1 ,5- α]pyrimidine-2-carbaldehyde (described in Step 3 of example B(75)) using the Me2NHBH3 method described in the synthesis of Example B(31).
*H NMR (CDC13): δ 1.39 (t, 7= 7 Hz, 3H), 1.52-1.81 (brm, 8H), 2.05 (m, 2H), 2.16 (s, 3H), 2.35 (m, IH), 2.50-2.71 (m, 8H), 2.79 (s, 3H), 3.98 (q, 7= 7Hz, 2H), 4.05 (d, 7= 15.5 Hz, IH), 4.12 (d, 7= 15.5 Hz, IH), 6.69 (d, 7= 8.8 Hz, IH), 6.84 (s, IH), 6.91 (m, 2H). Anal. Calcd. For C29H36N404: C, 69.02; H, 7.19; N, 11.10. Found: C, 69.42; H, 7.34; N, 11.22.
Example B(11 ): 6-Cyclopentyl-3-(5,7-dimethyl-[1 ,2,4]triazolo[1 ,5]pyrimidin-2-ylmethyl)-4- hydroxy-6-[2-(4-isopropoxy-3-methyl-phenyl)-ethyl]-5,6-dihydro-pyran-2-one
Figure imgf000270_0002
The title compound was prepared by coupling 6-Cyclopentyl-6-[2-(4-isopropoxy-3-methyl- phenyl)-ethyl]-dihydro-pyran-2,4-dione from Example A(4), to 5,7-Dimethyl-[1,2,4]triazolo[1,5- α]pyrimidine-2-carba!dehyde (described in Step 3 of example B(75)) using the Me2NHBH3 method described in the synthesis of Example B(31). 'H NMR (CDCI3): δ 1.30 (d, 7= 6.2 Hz, 6H), 1.52-1.81 (brm, 8H), 1.99 (m, 2H), 2.15 (s, 3H), 2.38 (m, IH), 2.50-2.71 (m, 8H), 2.79 (s, 3H), 4.05 (d, 7= 15.5 Hz, IH), 4.12 (d, 7= 15.5 Hz, IH), 4.43 (m, IH), 6.71 (d, 7= 8.1 Hz, IH), 6.84 (s, IH), 6.88 (m, 2H). Anal. Calcd. For C3oH38N404: C, 69.47; H, 7.38; N, 10.80. Found: C, 69.18; H, 7.54; N, 10.66.
Example B(12): 6-Cyclopentyl-3-(5,7-dimethyl-[1 ,2,4]triazolo[1 ,5]pyrimidin-2-ylmethyl)-6-[2- (3-ethyl-phenyl)-ethyl]-4-hydroxy-5,6-dihydro-pyran-2-one
Figure imgf000271_0001
The title compound was prepared by coupling 6-Cyclopentyl-6-[2-(3-ethyl-phenyl)-ethyl]- dihydro-pyran-2,4-dione from Step 1 below to 5,7-Dimethyl-[1,2,4]triazolo[1,5- ]pyrimidine-2- carbaldehyde (described in Step 3 of example B(75)) using the Me2NHBH3 method described in the synthesis of Example B(31). 'H NMR (CDCI3): δ 1.20 (t, 7= 7.5 Hz, 3H), 1.52-1.81 (brm, 8H), 2.04 (m, 2H), 2.39 (m, IH), 2.50-2.73 (m, 10H), 2.79 (s, 3H), 4.05 (d, 7= 15.5 Hz, IH), 4.12 (d, 7= 15.5 Hz, IH), 6.84 (s, IH), 6.98 (m, 3H), 7.17 (t, J = 7.6 Hz, IH). Anal. Calcd. For C28H34N403: C, 70.86; H, 7.22; N, 11.81. Found: C, 70.68; H, 7.06; N, 11.64.
Figure imgf000271_0002
Step 1: 6-Cyclopentyl-6-[2-(3-ethyl-phenyl)-ethyl]-dihydro-pyran-2,4-dione 6-Cyclopentyl-6-[2-(3-ethyl-phenyl)-ethyl]-dihydro-pyran-2,4-dione was prepared analogously to Example A(82), where 3-ethyl-bromobenzene was substituted in place of 2-Bromopyridine in Step 1 of that example.
Example B(13): 6-[2-(3-Chloro-4-methoxy-phenyl)-ethyl]-6-cyclopentyl-3-(5,7-dimethyl- [1,2,4]triazolo[1,5-a]pyrimidin-2-ylmethyl)-dihydro-pyran-2,4-dione
Figure imgf000272_0001
6-[2-(3-Chloro-4-methoxy-phenyl)-ethyl]-6-cyclopentyl-dihydro-pyran-2,4-dionefrom Step 1 below (1 g, 2.90 mmol) was combined with 5,7-Dimethyl-[1,2,4]triazolo[1,5-α]pyrimidine-2- carbaldehyde (0.5 g, 2.90 mmol) (described in Step 3 of example B(75)) in dry THF (15 mL) with magnetic stirring. To this solution was added AICI3 (0.76 g, 5.81 mmol) as a soln in THF (6 mL) dropwise over 1 min. The resulting yellow solution was stirred at room temperature for 3 hours. The reaction was quenched with solid Na2CO3'10H2O (1.63 g, 5.81 mmol) and stirred at room temperature for 10 min. Next, the mixture was treated with MgS0 (2.5 g) and the slurry allowed to stand for 1.5 hours. The yellow mixture was filtered through celite and the filtrate was concentrated. The crude residue was dissolved in EtOAc (50 mL) and treated with Pt02 and stirred with H2 (one balloon pressure). This was maintained for 1 hour then filtered through celite. The filtrate was concentrated and the residue chromatographed on silica gel eluting with CH2CI2 through 0.75% MeOH in CH2CI2 to yield the title compound as a white solid. Η NMR (CDC13): δ 1.37-1.85 (brm, 8H), 1.98 (m, 2H), 2.37 (m, IH), 2.49-2.80 (m, 11H), 3.86 (s, 3H), 4.05 (d, 7= 15.6 Hz, IH), 4.12 (d, 7= 15.6 Hz, IH), 6.81 (d, = 8.6 Hz, IH), 6.85 (s, IH), 7.00 (d, 7= 8.6 Hz, IH), 7.12 (s, IH). Anal. Calcd. For C27H31C1N404: C, 63.46; H, 6.11; N, 10.96. Found: C, 63.23; H, 6.27; N, 10.74.
Figure imgf000273_0001
Step 1 : 6-[2-(3-Chloro-4-methoxy-phenyl)-ethyl]-6-cyclopentyl-dihydro-pyran-2,4-dione
6-[2-(3-Chloro-4-methoxy-phenyl)-ethyl]-6-cyclopentyl-dihydro-pyran-2,4-dione was prepared analogously to Example A(82), where 4-Bromo-2-chloro-1-methoxy-benzene was substituted in place of 2-Bromopyridine in Step 1 of that example.
Example B(14): 3-(5-Chloro-1-isopropyl-1H-benzoimidazol-2-ylmethyl)-6-cyclopentyl-6-[2- (3-fluoro-4-isopropoxy-phenyl)-ethyl]-4-hydroxy-5,6-dihydro-pyran-2-one
Figure imgf000273_0002
The title compound was prepared by coupling 6-Cyclopentyl-6-[2-(3-fluoro-4-isopropoxy- phenyl)-ethyl]-dihydro-pyran-2,4-dionefrom Step 1 below to 5-Chloro-1-isopropyl-1H- benzoimidazole-2-carbaldehyde using the AICI3/reduction procedure described in Example B(13). ESIMS (MH+): 570.3
Figure imgf000273_0003
Step 1 : 6-Cyclopentyl-6-[2-(3-fluoro-4-isopropoxy-phenyl)-ethyl]-dihydro-pyran-2,4-dione 6-Cyclopentyl-6-[2-(3-fluoro-4-isopropoxy-phenyl)-ethyl]-dihydro-pyran-2,4-dione was prepared analogously to Example A(82), where 4-Bromo-2-fluoro-1-isopropoxy-benzene was substituted in place of 2-Bromopyridine in Step 1 of that example.
Example B(15): 6-Cyclopentyl-6-[2-(3-fluoro-4-isopropoxy-phenyl)-ethyl]-4-hydroxy-3-(5- methyl-isoxazol-3-ylmethyl)-5,6-dihydro-pyran-2-one
Figure imgf000274_0001
The title compound was prepared by coupling 6-Cyclopentyl-6-[2-(3-fluoro-4-isopropoxy- phenyl)-ethyl]-dihydro-pyran-2,4-dionefrom Step 1 of Example B(14), to 5-Methyl-isoxazole-3- carbaldehyde using the AICI3/reduction procedure described for Example B(13). 'H NMR (CDCls): δ 1.32 (d, 7= 6 Hz, 6H), 1.44-1.92 (brm, 8H), 2.05 (m, 2H), 2.44-2.88 (m, 8H), 2.95 (s, 3H), 4.47 (m, IH), 6.72-6.92 ( , 2H), 7.66 (m, 2H). ESIMS (MH+): 458.3
Example B(16): 6-CyclopentyI-6-[2-(3-fluoro-4-isopropoxy-phenyl)-ethyl]-4-hydroxy-3-(1- methyl-1H-benzoimidazol-2-ylmethyl)-5,6-dihydro-pyran-2-one
Figure imgf000274_0002
The title compound was prepared by coupling 6-Cyclopentyl-6-[2-(3-fluoro-4-isopropoxy- phenyl)-ethyl]-dihydro-pyran-2,4-dionefrom Step 1 of Example B(14), to 1-Methyl-1H- benzoimidazole-2-carbaldehyde using the AICI3/reduction procedure described for Example
B(13).
Η NMR (CDClj): δ 1.32 (d, 7= 6 Hz, 6H), 1.45-1.91 (brm, 8H), 2.05 (m, 2H), 2.44-2.88 (m, 8H), 2.91
(s, 3H), 4.48 (m, IH), 6.75-6.92 (m, 3H) 7.22-7.45 (m, 3H) 7.66 (s, IH). ESIMS (MH+): 507.2
Example B(17): 6-[2-(3-Chloro-4-methoxy-phenyl)-ethyl]-6-cyclopentyl-4-hydroxy-3-(4- methoxy-benzyl)-5,6-dihydro-pyran-2-one
Figure imgf000275_0001
The title compound was prepared by coupling 6-[2-(3-Chloro-4-methoxy-phenyl)-ethyl]-6- cyclopentyl-dihydro-pyran-2,4-dionefrom Step 1 of Example B(13), to 4-Methoxy-benzaldehyde using the AICI3/reduction procedure described for Example B(13).IHNMR (CDC13): δ 1.45-1.85 (brm, 8H), 1.98 (m, 2H), 2.29 (t, 7= 7.6 Hz, IH) 2.44-3.02 (m, 7H), 3.88 (s, 3H), 3.94 (s, 3H), 6.73-7.85 (m, 7H). ESIMS (MH+): 471.7
Example B(18): 6-Cyclopentyl-3-(5,7-dimethyl-[1 ,2,4]triazolo[1 ,5-pyrimidin-2-ylmethyl)-6-[2- (3-fluoro-4-isopropoxy-phenyl)-ethyl]-4-hydroxy-5,6-dihydro-pyran-2-one
Figure imgf000275_0002
The title compound was prepared by coupling 6-Cyclopentyl-6-[2-(3-fluoro-4-isopropoxy- phenyl)-ethyl]-dihydro-pyran-2,4-dionefrom Step 1 of Example B(14), to 5,7-Dimethyl- [1,2,4]triazolo[1,5-D]pyrimidine-2-carbaldehyde (described in Step 3 of example B(75)) using the Me2NHBH3 method described in the synthesis of Example B(31).'HNMR (CDC13): δ 1.30 (d, 7= 6.2 Hz, 6H), 1.52-1.81 (brm, 8H), 1.99 (m, 2H), 2.38 (m, IH), 2.50-2.72 (m, 8H), 2.78 (s, 3H), 4.05 (d, 7= 15.5 Hz, IH), 4.12 (d, 7= 15.5 Hz, IH), 4.45 (m, IH), 6.84 (s, IH), 6.86-6.93 (m, 3H).' Anal. Calcd. For C29H35FN404: C, 66.65; H, 6.75; N, 10.72. Found: C, 66.28; H, 6.87; N, 10.52.
Example B(19): 6-[2-(3-Chloro-4-fluoro-phenyl)-ethyl]-6-cyclopentyl-3-(5,7-dimethyl- [1 ,2,4]triazolo[1 ,5]pyrimidin-2-ylmethyl)-4-hydroxy-5,6-dihydro-pyran-2-one
Figure imgf000276_0001
The title compound was prepared by coupling 6-[2-(3-Chloro-4-fluoro-phenyl)-ethyl]-6- cyclopentyl-dihydro-pyran-2,4-dione from Step 1 below to 5,7-Dimethyl-[1,2,4]triazolo[1 ,5- α]pyrimidine-2-carbaldehyde (described in Step 3 of example B(75), using the Me2NHBH3 method described in the synthesis of Example B(31).IHNMR (CDC13): δ 1.44-1.92 (brm, 8H), 2.05 (m, 2H), 2.35 (m, IH) 2.44-2.88 (m, 1 IH), 4.05 (s, 2H), 6.85 (s, IH), 6.99 (m, 2H) 7.15 (d, J = 7.5 Hz, IH). Anal. Calcd. For C26H28C1FN403: C, 62.58; H, 5.66; N, 11.23. Found: C, 62.42; H, 5.46; N, 11.55.
Figure imgf000276_0002
Step 1 : 6-[2-(3-Chloro-4-fluoro-phenyl)-ethyl]-6-cyclopentyl-dihydro-pyran-2,4-dione 6-[2-(3-Chloro-4-fluoro-phenyl)-ethyl]-6-cyclopentyl-dihydro-pyran-2,4-dione was prepared analogously to Example A(82), where 4-Bromo-2-chloro-1-fluoro-benzene was substituted in place of 2-Bromopyridine in Step 1 of that example.
Example B(20): 6-[2-(3-Chloro-4-ethoxy-phenyl)-ethyl]-6-cyclopentyl-3-(5,7-dimethyl- [1,2,4]triazolo[1,5]pyrimidin-2-ylmethyl)-4-hydroxy-5,6-dihydro-pyran-2-one
Figure imgf000277_0001
The title compound was prepared by coupling 6-[2-(3-Chloro-4-ethoxy-phenyl)-ethyl]-6- cyclopentyl-dihydro-pyran-2,4-dionefrom Step 1 below to 5,7-Dimethyl-[1 ,2,4]triazolo[1 ,5- α]pyrimidine-2-carbaldehyde (described in Step 3 of example B(75), using the Me2NHBH3 method described in the synthesis of Example B(31).1HNMR(CDC13): δ 1.39 (t, 7= 7.2 Hz, 3H), 1.52-1.82 (brm, 8H), 2.05 (m, 2H), 2.35 (m, IH), 2.50-2.71 (m, 8H), 2.79 (s, 3H), 3.96 (q, 7= 7.2 Hz, 2H), 4.05 (d, 7= 15.5 Hz, IH), 4.12 (d, 7= 15.5 Hz, lH), 6.67 (d, J= 8.4 Hz, IH), 6.84 (s, IH), 6.91 (m, 2H). Anal. Calcd. For C2SH33C1N404: C, 64.05; H, 6.34; N, 10.67. Found: C, 64.40; H, 6.26; N, 10.88.
Figure imgf000277_0002
Step 1: 6-[2-(3-Chloro-4-ethoxy-phenyl)-ethyl]-6-cyclopentyl-dihydro-pyran-2,4-dione
6-[2-(3-Chloro-4-ethoxy-phenyl)-ethyl]-6-cyclopentyl-dihydro-pyran-2,4-dione was prepared analogously to Example A(82), where 4-Bromo-2-chloro-1-ethoxy-benzene was substituted in place of 2-Bromopyridine in Step 1 of that example. Example B(21): 6-[2-(3-Chloro-4-methoxy-phenyl)-ethyl]-6-cyclopentyl-4-hydroxy-3-(4- methanesulfonyl-benzyl)-5,6-dihydro-pyran-2-one
Figure imgf000278_0001
The title compound was prepared by coupling 6-[2-(3-Chloro-4-methoxy-phenyl)-ethyl]-6- cyclopentyl-dihydro-pyran-2,4-dionefrom Step 1 of Example B(13), to 4-Methanesulfonyl- benzaldehyde using the Me2NHBH3 method described in the synthesis of Example 6(31).^ NMR (CDC13): δ 1.45-1.86 (brm, 8H), 1.96 (m, 2H), 2.29 (t, 7= 7.6 Hz, IH) 2.44-3.02 (m, 7H), 3.91 (s, 3H), 3.94 (s, 3H), 6.88-7.85 (m, 7H).
Example B(22): 4-{6-[2-(3-Chloro-4-methoxy-phenyl)-ethyl]-6-cyclopentyl-4-hydroxy-2-oxo- 5,6-dihydro-2-pyran-3-ylmethyl}-benzonitrile
Figure imgf000278_0002
The title compound was prepared by coupling 6-[2-(3-Chloro-4-methoxy-phenyl)-ethyl]-6- cyclopentyl-dihydro-pyran-2,4-dionefrom Step 1 of Example B(13), to 4-Formyl-benzonitrile using the Me2NHBH3 method described in the synthesis of Example B(31).Η NMR (CDC13): δ 1.45-1.86 (brm, 8H), 2.02 (m, 2H), 2.29 (m, IH) 2.44-3.02 (m, 7H), 3.94 (s, 3H), 6.88-7.85 (m, 7H). Anal. Calcd. For C27H28C1N04: C, 69.59; H, 6.06; N, 3.01. Found: C, 69.40; H, 6.22; N, 3.07. Example B(23): 3-{6-[2-(3-Chloro-4-methoxy-phenyl)-ethyl]-6-cyclopentyl-4-hydroxy-2-oxo- 5,6-dihydro-2-pyran-3-ylmethyl}-benzonitrile
Figure imgf000279_0001
The title compound was prepared by coupling 6-[2-(3-Chloro-4-methoxy-phenyl)-ethyl]-6- cyclopentyl-dihydro-pyran-2,4-dionefrom Step 1 of Example B(13), to 3-Formyl-benzonitrile using the Me2NHBH3 method described in the synthesis of Example B(31).1HNMR(CDC13): δ 1.43-1.86 (brm, 8H), 2.02 (m, 2H), 2.29 (m, IH) 2.44-3.02 (m, 7H), 3.95 (s, 3H), 6.88-7.91 (m, 7H). Anal. Calcd. For C27H28C1N04: C, 69.59; H, 6.06; N, 3.01. Found: C, 69.67; H, 6.14; N, 3.13.
Example B(24): 6-[2-(3-Chloro-4-methoxy-phenyl)-ethyl]-6-cyclopentyl-4-hydroxy-3-(4- pyrazol-1-yl-benzyl)-5,6-dihydro-pyran-2-one
Figure imgf000279_0002
The title compound was prepared by coupling 6-[2-(3-Chloro-4-methoxy-phenyl)-ethyl]-6- cyclopentyl-dihydro-pyran-2,4-dionefrom Step 1 of Example B(13), to 4-Pyrazol-1-yl- benzaldehyde using the Me2NHBH3 method described in the synthesis of Example B(31).ESIMS (MH+): 508.1 Example B(25): 6-[2-(3-Chloro-4-methoxy-phenyl)-ethyl]-6-cyclopentyl-4-hydroxy-3-(4- [1,2,4]triazol-1-yl-benzyl)-5,6-dihydro-pyran-2-one
Figure imgf000280_0001
The title compound was prepared by coupling 6-[2-(3-Chloro-4-methoxy-phenyl)-ethyl]-6- cyclopentyl-dihydro-pyran-2,4-dionefrom Step 1 of Example B(13), to 4-[1,2,4]Triazol-1-yl- benzaldehyde using the Me2NHBH3 method described in the synthesis of Example B(31).ESIMS (MH+): 509.1
Example B(26): 6-[2-(3-Chloro-4-cyclopropylmethoxy-phenyl)-ethyl]-6-cyclopentyl-4- hydroxy-3-(1-methyl-1W-benzoimidazol-2-ylmethyl)-5,6-dihydro-pyran-2-one
Figure imgf000280_0002
The title compound was prepared analogously to Example B(31), carbaldehydewhere 6- [2-(3-Chloro-4-cyclopropylmethoxy-phenyl)-ethyl]-6-cyclopentyl-dihydro-pyran-2,4-dione was substituted in place of 6-[2-(3-Chloro-4-isopropoxy-phenyl)-ethyl]-6-cyclopentyl-dihydro-pyran- 2,4-dione and 1-methyl-2-formylbenzimidazole was substituted in place of 5,7-Dimethyl- [1,2,4]triazolo[1,5-a]pyrimidine-2-carbaldehyde of that example.
Η NMR (DMSO-d6): δ 0.10 (d, 7= 4.7, 2H), 0.33-0.36 (m, 2H), 0.98-2.04 (m, 14H), 2.17-2.26 (m, 2H), 2.29 (d, 7= 17, IH), 2.54 (d, 7= 17 Hz, IH), 3.56 (s, 3H), 3.60-3.65 (m, 2H), 3.85 (brs, IH), 6.71-7.26 (m, 7H). Anal. Calcd. For C31H3SClN2θ4-0.5 H20: C, 68.43, H, 6.67, N, 5.15. Found: C, 68.36, H, 6.58, N, 4.81. ESIMS (MH+): 536.
Example B(27): 6-[2-(3-Chloro-4-isopropoxy-phenyl)-ethyl]-6-cyclopentyl-4-hydroxy-3-(1 - methyl-1W-benzoimidazol-2-ylmethyl)-5,6-dihydro-pyran-2-one
Figure imgf000281_0001
The title compound was prepared analogously to Example B(31), where 1-methyl-2- formylbenzimidazole was substituted in place of 5,7-Dimethyl-[1,2,4]triazolo[1,5-a]pyrimidine-2- carbaldehydeof that example. Η NMR (DMSO-d6): δ 0.90-1.36 (m, 14H), 1.54-1.61 (m, 2H), 2.20-2.39 (m, 3H), 2.57-2.73 (m, 4H), 4.10 (s, 3H), 4.44-4.49 (m, IH), 6.49-6.48 (m, 7H), 13.5 (brs, IH); Anal. Calcd. For C30H35CIR : C, 68.89, H, 6.74, N, 5.36. Found: C, 69.11, H, 6.73, N, 5.36. ESIMS (MH+): 524
Example B(28): 6-[2-(3-Chloro-4-cyclopropylmethoxy-phenyl)-ethyl]-6-cyclopentyl-3-(5,7- dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-ylmethyl)-4-hydroxy-5,6-dihydro-pyran-2-one
Figure imgf000281_0002
The title compound was prepared analogously to Example B(31), where 6-[2-(3-Chloro-4- cyclopropylmethoxy-phenyl)-ethyl]-6-cyclopentyl-dihydro-pyran-2,4-dione was substituted in place of 6-[2-(3-Chloro-4-isopropoxy-phenyl)-ethyl]-6-cyclopentyl-dihydro-pyran-2,4-dione of that example. Η NMR (DMSO-d6): δ 0.35-0.38 (m, 2H), 0.61-0.64 (m, 2H), 1.26-1.85 (m, 8H), 1.94-2.05 (m, IH), 2.18 (s, 2H), 2.37-2.79 (m, 12H), 3.83 (d, 7 = 6.8 Hz, 2H), 4.09 (s, IH), 6.79 (d, 7 = 8.1 Hz, IH), 6.95 (dd, 7 = 8.1, 2.2 Hz, IH), 7.11 (d, 7 = 2.2 Hz, IH), 7.26 (s, IH), 14.1 (brs, IH). Anal. Calcd. For C30H35ClN4O4-0.2 AcOH: C, 64.84, H, 6.41, N, 9.95. Found: C, 64.82, H, 6.42, N, 9.69. ESIMS (MH+): 552.
Example B(29): 6-[2-(3-Chloro-4-methoxy-phenyl)-ethyl]-3-(4-chloro-1-methyl-1H-pyrazol-3- ylmethyl)-6-cyclopentyl-4-hydroxy-5,6-dihydro-pyran-2-one
Figure imgf000282_0001
The title compound was prepared analogously to Example B(31), where 6-[2-(3-Chloro-4- methoxy-phenyl)-ethyl]-6-cyclopentyl-dihydro-pyran-2,4-dione was substituted in place of 6-[2-(3- Chloro-4-isopropoxy-phenyl)-ethyl]-6-cyclopentyl-dihydro-pyran-2,4-dione and 4-chloro-1-methyl- 1 H-pyrazoIe-3-carbalehyde was substituted in place of 5,7-Dimethyl-[1 ,2,4]triazolo[1 ,5- a]pyrimidine-2-carbaldehydeof that example. Η NMR (DMSO-d6): δ 1.50-1.71 (m, 8H), 2.01-2.05 (m, 2H), 2.39-2.41 (m, IH), 2.49-2.57 (m, 2H), 2.74 (d, 7= 16 Hz, IH), 3.18 (d, 7 = 5.3 Hz, IH), 3.39 (d, 7= 16.0 Hz, IH), 3.47 (d, 7= 16 Hz, IH), 3.60 (s, 3H), 3.83 (s, 3H), 7.05 (d, 7= 8.3 Hz, IH), 7.11 (dd, 7= 8.3. 2.0 Hz, IH), 7.23 (d, 7 = 2.0 Hz,lH), 7.76 (s, IH), 10.64 (s, IH). Anal. Calcd. For C24H28C12N204: C, 60.13, H, 5.89, N, 5.84. Found: C, 59.94, H, 5.95, N, 5.69. ESIMS (MH+): 480.
Example B(30): 6-[2-(3-Chloro-4-methoxy-phenyl)-ethyi]-6-cyclopentyl-4-hydroxy-3-(1 H- imidazol-2-ylmethyl)-5,6-dihydro-pyran-2-one
Figure imgf000283_0001
The title compound was prepared analogously to Example B(31), where 6-[2-(3-Chloro-4- methoxy-phenyl)-ethyl]-6-cyclopentyl-dihydro-pyran-2,4-dione was substituted in place of 6-[2-(3- Chloro-4-isopropoxy-phenyl)-ethyl]-6-cyclopentyl-dihydro-pyran-2,4-dione and imidazole-2- carboxaldehyde was substituted in place of 5,7-Dimethyl-[1,2,4]triazolo[1,5-a]pyrimidine-2- carbaldehydeof that example.
Η NMR (DMSO-ds): δ 1.05-1.55 (m, 8H), 1.79-1.83 (m, 2H), 2.21-2.29 (m, 2H), 2.42-2.45 (m, 2H), 2.62- 2.76 (m, 3H), 3.70 (s, 3H), 4.64 (s, IH), 6.93 (d, 7 = 8.3 Hz, IH), 6.99-7.02 (m, IH), 7.15 (d, 7= 2.0 Hz, IH), 7.39 (s,lH), 7.48 (s, IH), 11.76 (brs, IH). ESIMS (MH+): 431.
Example B(31): 6-[2-(3-Chloro-4-isopropoxy-phenyl)-ethyl]-6-cyclopentyl-3-(5,7-dimethyl- [1,2,4]triazolo[1,5-a]pyrimidin-2-ylmethyl)-4-hydroxy-5,6-dihydro-pyran-2-one
Figure imgf000283_0002
6-[2-(3-Chloro-4-isopropoxy-phenyl)-ethyl]-6-cyclopentyl-dihydro-pyran-2,4-dione (0.3 g, 0.79 mmol) and 5,7-Dimethyl-[1,2,4]triazolo[1,5-a]pyrimidine-2-carbaldehyde (0.17 g, 0.95 mmol, described in Step 3 of example B(75)) were dissolved in 3:1 MeOH/CH2CI2 (4 mL). To this suspension, Me2NH.BH3(0.07 g, 1.19 mmol) was added as a solid from top. After stirring 1 h at room temperature, the reaction mixture became clear and it was stirred for an additional 5 hours. After this time, 1 M HCl (1 mL) was added and the reaction stirred for 30 minutes at room temperature, the solvent was the evaporated to half the volumen and extracted 3 times with 10% MeOH/ CH2CI2 (10 mL). The organic phase was dried over MgS04 and evaporated. The residue purified by flash column chromatography (80% EtOAc in hexanes)to eliminate unreacted pyrone and reduced 5,7-Dimethyl-[1 ,2,4]triazolo[1 ,5-a]pyrimidine-2-carbaldehyde, then 3% MeOH/ CH2CI2 to give the product (0.1 g, 24%) as a white solid..
'HNMR (DMSO-d6): δ 1.14 (d, 7= 6.3, 6H), 1.4-1.53 (m, 8H), 1.7-1.75 (m, 2H), 1.95-1.98 ( , IH), 2.35- 2.44 (m, 8H), 3.19 (s, 2H), 3.57 (d, 7= 16 Hz, IH), 3.69 (d, 7= 16 Hz, IH), 4.41-4.47 (m, IH), 6.91-6.93 (s, IH), 7-7.07 (m, 2H), 7.10 (d, 7= 2.0, IH), 10.7 (brs, IH). Anal. Calcd. For C29H35 N404: C, 64.61, H, 6.54, N, 10.39. Found: C, 64.30, H, 6.81, N, 10.35. ESIMS (MH+): 540
Example B(32): 6-[2-(5-Chloro-2,4-dimethoxy-phenyl)-ethyl]-3-(4-chloro-1 -methyl-1 H- pyrazol-3-ylmethyl)-6-cyclopentyl-4-hydroxy-5,6-dihydro-pyran-2-one
Figure imgf000284_0001
The title compound was prepared analogously to Example B(31), where 6-[2-(5-Chloro- 2,4-dimethoxy-phenyl)-ethyl]-6-cyclopentyl-dihydro-pyran-2,4-dione (described in Step 1 of example B(35)) was substituted in place of 6-[2-(3-Chloro-4-isopropoxy-phenyl)-ethyl]-6- cyclopentyl-dihydro-pyran-2,4-dione and 4-chloro-1 -methyl-1 H-pyrazole-3-carbalehyde was substituted in place of 5,7-Dimethyl-[1,2,4]triazolo[1,5-a]pyrimidine-2-carbaldehydeof that example.
*H NMR (DMSO-d6): δ 1.35-1.70 (m, 8H), 1.90-1.99 (m, 2H), 2.33-2.38 (m, IH), 2.39-2.53 (m, 3H), 2.72 (d, 7= 17 Hz, IH), 3.34-3.47 (m, 2H), 3.57 (s, 3H), 3.78 (s, 3H), 3.85 (s, 3H), 6.73 (s, IH), 7.07 (s, IH), 7.73 (s, IH), 10.61 (s, IH). Anal. Calcd. For C25H3oCl2N205: C, 58.94, H, 5.94, N, 5.50. Found: C, 58.78, H, 6.02, N, 5.39. ESIMS (MH+): 510.
Example B(33): 6-Cyclopentyl-6-[2-(4-cyclopropylmethoxy-3-fluoro-phenyl)-ethyl]-3-(5,7- dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-ylmethyl)-4-hydroxy-5,6-dihydro-pyran-2-one
Figure imgf000285_0001
The title compound was prepared analogously to Example B(31), where 6-Cyclopentyl-6- [2-(4-cyclopropylmethoxy-3-fluoro-phenyl)-ethyl]-dihydro-pyran-2,4-dione (prepared in Step 2 below) was substituted in place of 6-[2-(3-Chloro-4-isopropoxy-phenyl)-ethyl]-6-cyclopentyl-dihydro- pyran-2,4-dione of that example.
'H NMR (DMSO-d6): δ 0.09-0.11 (m, 2H), 0.32-0.39 (m, 2H), 0.98-1.48 (m, 8H), 1.84-1.90 (m, 2H), 2.16- 2.22 (m, IH), 2.28-2.33 (m, 10H), 2.56 (d, 7= 16 Hz, IH), 3.47-3.63 (m, 4H), 6.76-6.86 (m, 4H), 10.65
(brs, IH). Anal. Calcd. For C3oH35FN404-0.25 H20: C, 66.84, H, 6.64, N, 10.39. Found: C, 67.07, H, 6.74, N, 10.05. ESIMS (MH+): 535.
Step 1: 4-Bromo-1-cyclopropylmethoxy-2-fluoro-benzene
Figure imgf000285_0002
The title compound was prepared analogously to Step 1 in Example A(52), where (bromomethyl)-cyclopropane was substituted instead of methyl α-bromobutyrate of that example.
*H NMR (CDC13) δ 0.32-0.42 (m, 2H), 0.62-0.68 (m, 2H), 1.23-1.33 (m, IH), 3.85 (d, /= 6.9 Hz, 2H), 6.82 (t, 7= 8.8 Hz, IH), 7.14-7.18 (m, IH), 7.23 (dd, 7= 10.5, 2.3 Hz, IH). ESIMS (MH+): 246.1.
Step 2 6-Cyclopentyl-6-[2-(4-cyclopropylmethoxy-3-fluoro-phenyl)-ethyl]-dihydro-pyran- 2,4-dione
Figure imgf000286_0001
The title compound was prepared analogously to Example A(27), , where 4-Bromo-1- cyclopropylmethoxy-2-fluoro-benzene from Step 1 below was substituted in place of 1-(4-Bromo- 2-chloro-phenyl)-ethanone in Step 3 of that example
'HNMR (CDCl3-d6): δ 0.32-0.37 (m, 2H), 0.61-0.67 (m, 2H), 1.26-1.30 (m, IH), 1.57-1.84 (m, 8H), 1.89- 1.96 (m, 2H), 2.26 (t, 7= 8.4 Hz, IH), 2.61 (t, 7= 8.4 Hz, 2H), 2.75 (s, 2H), 3.42 (s, 2H), 3.84 (d, 7= 6.9 Hz, 2H), 6.78-6.89 (m, 3H). Anal. Calcd. For C22H27F04: C, 70.57; H, 7.27. Found: C, 70.63; H, 7.40. ESIMS (MNa+): 397.1
Example B(34): 6-Cyclopentyl-3-(5,7-dimethyl-[1,2,4]triazolo[1,5-a!pyrimidin-2-ylmethyl)-4- hydroxy-6-[2-(4-isopropoxy-phenyl)-ethyl]-5,6-dihydro-pyran-2-one
Figure imgf000286_0002
The title compound was prepared analogously to Example B(31), where 6-Cyclopentyl-6- [2-(4-isopropoxy-phenyl)-ethyl]-dihydro-pyran-2, 4-dione was substituted in place of 6-[2-(3- Chloro-4-isopropoxy-phenyl)-ethyl]-6-cyclopentyl-dihydro-pyran-2,4-dione of that example. Η NMR (DMSO-d6): δ 1.39 (d, 7= 6.1, 6H), 1.43-1.86 (m, 8H), 2.22-2.28 (m, 2H), 2.54-2.57 (m, IH), 2.57-2.70 (m, 9H), 2.94 (d, 7= 17 Hz, IH), 3.86 (d, 7= 16 Hz, IH), 3.97 (d, 7= 16 Hz, IH), 4.65-4.71 (m, IH), 6.93 (d, 7= 8.6 Hz, 2H), 7.20 (s, IH), 7.27 (d, 7= 8.6, 2H), 10.99 (s, IH). Anal. Calcd. For C29H36 N4O4-0.25 H20: C, 68.41, H, 7.23, N, 11.00 Found: C, 68.40, H, 7.23, N, 10.99. ESIMS (MH+): 505 Stepl: 6-Cyclopentyl-6-[2-(4-isopropoxy-phenyl)-ethyl]-dihydro-pyran-2,4-dione
Figure imgf000287_0001
The title compound was prepared analogously to Example A(27), , where 1-Bromo-4- isopropoxy-benzene was substituted in place of 1-(4-Bromo-2-chloro-phenyl)-ethanone in Step 3 of that example
Η NMR (CDCl3-d6): δ 1.32 (d, 7= 6.2 Hz, 6H),1.58-1.7 (m, 8H), 1.89-1.99 (m, IH), 2.2-2.31 (m, 2H), 2.61 (t, 7= 8.6 Hz, 2H), 2.77 (s, 2H), 3.43 (s, 2H), 4.52 (septet, 7= 12, 6 Hz, IH), 6.82 (d, 7= 8.5 Hz, 2H), 7.03 (d, 7= 8.5 Hz, 2H). Anal. Calcd. For C21H2804: C, 73.23; H, 8.19. Found: C, 73.43; H, 8.44. ESIMS (MH+): 345.2
Example B(35): 6-[2-(5-Chloro-2,4-dimethoxy-phenyl)-ethyl]-6-cyclopentyl-4-hydroxy-3-(2- methyl-1H-imidazol-4-ylmethyl)-5,6-dihydro-pyran-2-one
Figure imgf000287_0002
The title compound was prepared analogously to Example B(31), where 6-[2-(5-Chloro- 2,4-dimethoxy-phenyl)-ethyl]-6-cyclopentyl-dihydro-pyran-2,4-dione (described below), as substituted in place of 6-[2-(3-Chloro-4-isopropoxy-phenyl)-ethyl]-6-cyclopentyl-dihydro-pyran-
2, 4-dione and 2-methyl-1H-imidazole-4-carbaldehyde was substituted in place of 5,7-Dimethyl-
[1 ,2,4]triazolo[1 ,5-a]pyrimidine-2-carbaIdehydeof that example.
Η NMR (DMSO-d6): δ 1.08-1.58 (m, 10H), 2.02-2.42 (m, 9H), 3.20-3.22 (m, 2H), 3.53 (s, 3H), 3.61 (s, 3H), 6.47 (s, IH), 6.53 (s, IH), 6.86 (s, IH), 10.9 (s, IH). Anal. Calcd. For C25H3ιClN205-1.5 H20: C,
59.82, H, 6.83, N, 5.58. Found: C, 59.87, H, 6.58, N, 5.46. ESIMS (MH+): 475.
Step 1. 6-[2-(5-chloro-2,4-dimethoxyphenyl)ethyl]-6-cyclopentyldihydro-2H-pyran-2,4(3/7)- dione
Figure imgf000288_0001
A solution of 6-[2-(2,4-dimethoxyphenyl)ethyl]-6-cyclopentyldihydro-2/- -pyran-2,4(3H)- dione (from example A(39); 4.50 g, 13 mmol) in CH2CI2 (20 mL) was cooled to -5 °C and treated with a solution of S02CI2 (1.94 g, 14.3 mmol) in CH2CI2 (10 mL) dropwise under nitrogen. The reaction mixture was stirred for an additional 15 minutes at -5 °C, then allowed to warm gradually to room temperature. After a total reaction time of 2h, an aqueous solution of NaHC03 (5 wt%) was added to achieve a pH of 8 in the aqueous phase. The volatiles were removed in vacuo. The residue was treated with water and extracted with ethyl acetate (3 x 25 mL). The combined ethyl acetate extract was acidified to a pH 2 using 2 N HCl, then washed with water. The organic phase was dried over Na2S0 , filtered, and concentrated to a yellowish solid. Recrystallization from ether afforded the title product as a white solid (2.18 g, 44%).
Η NMR (CDC13) δ 1.74 (m, 8H), 2.32 (m, 1 H), 2.58 (m, 2H), 2.78 (s, 2H), 3.43 (s, 2H), 3.82 (s, 3H), 3.92 (s, 3H), 6.44 (s, 1 H), 7.07 (s, 1 H). HRMS calcd for C20H25O5Cl (M+H+): 381.1469, found 381.1475.
Example B(36): 6-Cyclopentyl-6-[2-(2,3-dihydro-benzo[1,4]dioxin-6-yl)-ethyl]-3-(5,7- dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-ylmethyl)-4-hydroxy-5,6-dihydro-pyran-2-one
Figure imgf000288_0002
The title compound was prepared analogously to Example B(31), where 6-CycIopentyl-6- [2-(2,3-dihydro-benzo[1 ,4]dioxin-6-yl)-ethyl]-dihydro-pyran-2,4-dione (from Step 1 below) was substituted in place of 6-[2-(3-Chloro-4-isopropoxy-phenyl)-ethyl]-6-cyclopentyl-dihydro-pyran- 2,4-dione of that example.
Η NMR (DMSO-dfi): δ 1.31-1.55 (m, 8H), 1.82-1.91 (m, 2H), 2.20-2.22 (m, IH), 2.33-2.63 (m, 10H), 3.54 (d, 7 = 16 Hz, IH), 3.65 (d, 7 = 16 Hz, IH), 4.01 (s, 4H), 6.47-6.57 (m, 3H), 6.88 (s, IH), 10.65 (s, IH). Anal. Calcd. For C28H32N405: C, 66.65, H, 6.39, N, 11.10 Found: C, 66.80, H, 6.75, N, 11.38. ESIMS (MH+): 505
Step l 6-Cyclopentyl-6-[2-(2,3-dihydro-benzo[1,4]dioxin-6-yl)-ethyl]-dihydro-pyran-2,4- dione
Figure imgf000289_0001
The title compound was prepared analogously to Example A(27), where 1-Bromo-1,2- (ethylene-dioxy)benzene was substituted in place of 1-(4-Bromo-2-chloro-phenyl)-ethanone in Step 3 of that example 'H NMR (CDCl3-d6): δ 1.5-1.6 (m, 8H), 1.71-1.97 (m, 2H), 2.2-2.3 (m, IH), 2.57 (t, 7= 8.5 Hz, 2H), 2.76 (s, 2H), 3.42 (s, 2H), 4.24 (s, 4H), 6.59-6.85 (m, 2H), 6.78 (d, 7= 8.3 Hz, IH). Anal. Calcd. For C^H^ϋs: C, 69.75; H, 7.02. Found: C, 69.83; H, 7.31. ESIMS (MH+): 345.2
Example B(37): 6-Cyclopentyl-6-[2-(3,5-dichloro-4-ethoxy-phenyl)-ethyl]-3-(5,7-dimethyl- [1,2,4]triazolo[1,5-a]pyrimidin-2-ylmethyl)-4-hydroxy-5,6-dihydro-pyran-2-one
Figure imgf000289_0002
The title compound was prepared analogously to Example B(31), where 6-Cyclopentyl-6- [2-(3,5-dichloro-4-ethoxy-phenyl)-ethyl]-dihydro-pyran-2, 4-dione (from Step 2 below) was substituted in place of 6-[2-(3-Chloro-4-isopropoxy-phenyl)-ethyl]-6-cyclopentyl-dihydro-pyran- 2,4-dione of that example.
'H NMR (DMSO-d6): δ 1.53 (t, 7 = 6.9, 3H), 1.59-1.9 (m, 8H), 2.26-2.32 (m, 2H), 2.67-2.98 (m, 11H), 3.89 (d, 7= 16 Hz, IH), 4.0 (d, 7 = 16 Hz, IH), 4.17 (q, 7 = 6.9 Hz, 2H), 7.23 (s, IH), 7.51 (s, 2H), 11.01 (s, IH). Anal. Calcd. For C28H32Cl2N4O4-0.75 H20: C, 58.60, H, 5.64, N, 9.59 Found: C, 58.60, H, 5.64, N, 9.59. ESIMS (MH+): 560
Step 1: 4-Bromo-1-cyclopropylmethoxy-2-fluoro-benzene
Figure imgf000290_0001
The title compound was prepared analogously to Step 1 in Example A(52), where iodoethane was substituted instead of methyl α-bromobutyrate and 4-Bromo-2,6-dichloro-phenol was substituted instead of 4-Bromo-2-fluorophenol of that example. lU NMR (CDC13) δ 0.32-0.42 (m, 2H), 0.62-0.68 (m, 2H), 1.23-1.33 (m, IH), 3.85 (d, 7= 6.9 Hz, 2H), 6.82 (t, 7= 8.8 Hz, IH), 7.14-7.18 (m, IH), 7.23 (dd, 7= 10.5, 2.3 Hz, IH). ESIMS (MH+): 246.1.
Step 2: 6-Cyclopentyl-6-[2-(3,5-dichloro-4-ethoxy-phenyl)-ethyl]-dihydro-pyran-2,4-dione
Figure imgf000290_0002
The title compound was prepared analogously to Example A(27), where 5-Bromo-1,3- dichloro-2-ethoxy-benzene (from Step 1 above) was substituted in place of 1-(4-Bromo-2-chloro- phenyl)-ethanone in Step 3 of that example.
Example B(38): 6-Cyclopentyl-6-[2-(3,4-dichloro-phenyl)-ethyl]-3-(5,7-dimethyl- [1,2,4]triazolo[1,5-a]pyrimidin-2-ylmethyl)-4-hydroxy-5,6-dihydro-pyran-2-one
Figure imgf000291_0001
The title compound was prepared analogously to Example B(31), where 6-Cyclopentyl-6- [2-(3,4-dichloro-phenyl)-ethyl]-dihydro-pyran-2,4-dione was substituted in place of 6-[2-(3-Chloro- 4-isopropoxy-phenyl)-ethyl]-6-cyclopentyl-dihydro-pyran-2,4-dione of that example. Η NMR (DMSO-d6): δ 1.5-2.0 (m, 8H), 2.18-2.24 (m, 2H), 2.45-2.54 (m, IH), 2.60-2.93 (m, 10H), 3.81 (d, 7= 16 Hz, IH), 3.93 (d, 7= 16 Hz, IH), 7.15 (s, IH), 7.42 (dd, 7= 8.2, 2.0 Hz, IH), 7.58 (d, 7= 2.0 Hz, IH), 7.62 (d, 7= 8.2 Hz,lH), 10.94 (s, IH). Anal. Calcd. For C26H28C12N403: C, 60.59, H, 5.48, N, 10.87; Found: C, 60.71, H, 5.79, N, 10.98. ESIMS (MH+): 516
Step 1: 6-Cyclopentyl-6-[2-(3,4-dichloro-phenyl)-ethyl]-dihydro-pyran-2,4-dione
Figure imgf000291_0002
The title compound was prepared analogously to Example A(27), where 4-Bromo-1 ,2- dichloro-benzene was substituted in place of 1-(4-Bromo-2-chloro-phenyl)-ethanone in Step 3 of that example.
Example B(39): 6-(4-CyclohexyI-butyl)-6-cyclopentyl-3-(5,7-dimethyI-[l,2,4]triazoIo[l,5-α]pyrimidin- 2-yImethyl)-4-hydroxy-5,6-dihydro-pyran-2-one.
Figure imgf000292_0001
The title compound was prepared analogously to Example B(31), where 6-(4-Cyclohexyl- butyl)-6-cyclopentyl-dihydro-pyran-2,4-dione was substituted in place of 6-[2-(3-Chloro-4- isopropoxy-phenyl)-ethyl]-6-cyclopentyI-dihydro-pyran-2,4-dione of that example,
Η NMR (DMSO-d6): δ 0.76-1.93 (m, 25H), 2.27-2.32 (m, IH), 2.50-2.75 (m, 10H), 3.69 (d, = 16 Hz, IH), 3.80 (d, 7= 16 Hz, IH), 7.08 (s, IH), 10.77 (s, IH). Anal. Calcd. For C28H40N4O3'0.5 CH30H: C, 68.92, H, 8.39, N, 11.28; Found: C, 69.24, H, 8.34, N, 11.00. ESIMS (MH+): 481
Example B(40): 6-Cyclopentyl-3-(5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-ylmethyl)-4- hydroxy-6-[2-(2,2,3,3-tetrafluoro-2,3-dihydro-benzo[1,4]dioxin-6-yl)-ethyl]-5,6-dihydro- pyran-2-one
Figure imgf000292_0002
The title compound was prepared analogously to Example B(31), where 6-Cyclopentyl-6-
[2-(2,2,3,3-tetrafluoro-2,3-dihydro-benzo[1,4]dioxin-6-yl)-ethyl]-dihydro-pyran-2,4-dione (prepared in Step 1 below) was substituted in place of 6-[2-(3-Chloro-4-isopropoxy-phenyl)-ethyl]-6- cyclopentyl-dihydro-pyran-2,4-dione of that example. Η NMR (DMSO-d6): δ 0.98-1.68 (m, 8H), 1.93-2.02 (m, 2H), 2.27-2.68 (m, 11H), 3.56 (d, 7= 16 Hz, IH), 3.68 (d, 7= 16 Hz, IH), 6.90 (s, IH), 7.12 (dd, 7 = 8.5, 1.8 Hz, IH), 7.19 (s, IH), 7.22 (d, 7= 1.8 Hz, IH), 10.69 (s, IH). Anal. Calcd. For C28H28F4N4O5-0.5 H20: C, 57.43, H, 4.99, N, 9.57; Found: C, 57.42, H, 4.89, N, 9.65. ESIMS (MH+): 577
Step 1 : 6-Cyclopentyl-6-[2-(2,2,3,3-tetrafluoro-2,3-dihydro-benzo[1 ,4]dioxin-6-yl)-ethyl]- dihydro-pyran-2,4-dione
Figure imgf000293_0001
The title compound was prepared analogously to Example A(27), where 6-Bromo-2,2,3,3- tetrafluoro-2,3-dihydro-benzo[1,4]dioxinewas substituted in place of 1-(4-Bromo-2-chloro-phenyl)- ethanone in Step 3 of that example
Example B(41): 6-Cyclopentyl-3-(5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-ylmethyl)-4- hydroxy-6-[2-(4-propoxy-phenyl)-ethyl]-5,6-dihydro-pyran-2-one
Figure imgf000293_0002
The title compound was prepared analogously to Example B(31), where 6-Cyclopentyl-6- [2-(4-propoxy-phenyl)-ethyl]-dihydro-pyran-2,4-dione was substituted in place of 6-[2-(3-Chloro-4- isopropoxy-phenyl)-ethyl]-6-cyclopentyl-dihydro-pyran-2,4-dione of that example Η NMR (DMSO-d6): δ 0.79 (t, 7= 7.4, 3H), 1.20-1.57 (m, 10H), 1.85-1.96 (m, 2H), 2.20-2.44 (m, 10H), 2.61 (d, 7= 16 Hz, IH), 3.53 (d, 7= 16 Hz, IH), 3.63-3.72 (m, 3H), 6.62 (d, 7= 8.4 Hz, 2H), 6.87 (s, IH), 6.95 (d, 7= 8.4, 2H), 10.65 (s, IH). Anal. Calcd. For C29H36N404: C, 69.02, H, 7.19, N, 11.10 Found: C, 69.25, H, 7.40, N, 10.92. ESIMS (MH+): 505 Example B(42): 6-Cyclopentyl-6-{2-[4-(3,5-dimethyl-isoxazol-4-ylmethoxy)-phenyl]-ethyl}-3- (5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-ylmethyl)-4-hydroxy-5,6-dihydro-pyran-2-one
Figure imgf000294_0001
The title compound was prepared analogously to Example B(31), where 6-Cyclopentyl-6- {2-[4-(3, 5-dimethyl-isoxazol-4-ylmethoxy)-phenyl]-ethyl}-dihydro-pyran-2, 4-dione 6-Cyclopentyl-6- (2-{4-[(3,5-dimethylisoxazol-4-yl)methoxy]phenyl}ethyl)-4-hydroxy-5,6-dihydro-2H-pyran-2-one was substituted in place of 6-[2-(3-Chloro-4-isopropoxy-phenyl)-ethyl]-6-cyclopentyl-dihydro- pyran-2,4-dione of that example
Η NMR (DMSO-d6): 1.36-1.71 (m, 8H), 2.08-2.09 (m, 2H), 2.22 (s, 3H), 2.40 (s, 3H), 2.48-2.56 (m, 10H), 2.77 (d, 7 = 16 Hz, IH), 3.70 (d, 7 = 16 Hz, IH), 3.82 (d, 7 = 16 Hz, IH), 4.88 (s, 2H), 6.90 (d, 7 = 8.2 Hz, 2H), 7.04 (s, IH), 7.17 (d, 7 = 8.2, 2H), 10.69 (s, IH). Anal. Calcd. For C32H37N5θ5: C, 67.23, H, 6.52, N, 12.25 Found: C, 67.36, H, 6.80, N, 12.45. ESIMS (MH+): 572
Example B(43): 6-[2-(3-chloro-4-methoxyphenyl)ethyl]-3-[(5-chloro-1 -methyl-1 H- benzimidazol-2-yl)methyl]-6-cyclopentyl-4-hydroxy-5,6-dihydro-2H-pyran-2-one
Figure imgf000294_0002
The title compound was prepared analogously to Example B(31), where 6-cyclopentyl-6-
[2-(3-fluoro-4-methoxyphenyl)ethyl]dihydro-2H-pyran-2,4(3H)-dione was substituted in place of 6- [2-(3-chloro-4-isopropoxyphenyl)ethyl]-6-cyclopentyldihydro-2/-/-pyran-2,4(3H)-dione and 5- chloro-1 -methyl-1 /-/-benzimidazole-2-carbaldehyde was substituted in place of 5,7-Dimethyl-
[1 ,2,4]triazolo[1 ,5-α]pyrimidine-2-carbaldehyde.
Η NMR (300 MHz, CDC13) 5:1.51-1.75 (m, 8 H), 1.96-2.02 (m, 2 H), 2.51-2.58 (m, 2 H), 2.70-2.82 (m, 3
H), 3.86 (s, 3 H), 3.87 (s, 2 H), 3.89 (s, 3 H), 6.82 (t, 7=8.01 Hz, 1 H), 6.96-7.05 (m, 1 H), 7.14-7.19 (m, 1
H), 7.25-7.28 (m, 2 H), 7.64 (s, 1 H). HRMS calcd for C28H3ιCl2N204 (M+H+): 529.1656. Found:
529.1637.
Example B(44): 6-[2-(3-chloro-4-isopropylphenyl)ethyl]-6-cyclopentyl-3-[(5,7- dimethyl[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-4-hydroxy-5,6-dihydro-2H-pyran-2-one
Figure imgf000295_0001
The title compound was prepared analogously to Example B(31), where 6-cyclopentyl-6- [2-(3-chloro-4-isopropylphenyl)ethyl]dihydro-2H-pyran-2,4(3H)-dione was substituted in place of 6-[2-(3-chloro-4-isopropoxyphenyl)ethyl]-6-cyclopentyldihydro-2H-pyran-2,4(3H)-dione. Η NMR (300 MHz, CDC13) δ: 1.20 (d, 7=6.78 Hz, 6 H), 1.47-1.74 (m, 8 H), 1.96-2.02 (m, 2 H), 2.32-2.40 (m, 1 H), 2.50-2.61 (in, 3 H), 2.66 (s, 3 H), 2.71-2.73 (m, 1 H), 2.79 (s, 3 H), 3.29-3.38 (m, 1 H), 4.09 (s, 2 H), 6.84 (s, 1 H), 7.00 (dd, 7=7.91, 1.51 Hz, 1 H), 7.10 (s, 1 H), 7.16 (d, 7=7.91 Hz, 1 H). HRMS calcd for C29H36C1N403 (M+H+): 523.2471. Found: 523.2465.
Example B(45): 6-cyclopentyl-3-[(5,7-dimethyl[1 ,2,4]triazolo[1 ,5-a]pyrimidin-2-yl)methyl]-6- [2-(3-fluoro-4-isopropylphenyl)ethyl]-4-hydroxy-5,6-dihydro-2H-pyran-2-one
Figure imgf000295_0002
The title compound was prepared analogously to Example B(31), where 6-cyclopentyl-6- [2-(3-fluoro-4-isopropylphenyl)ethyl]dihydro-2H-pyran-2,4(3H)-dione was substituted in place of 6- [2-(3-chloro-4-isopropoxyphenyl)ethyl]-6-cyclopentyldihydro-2H-pyran-2,4(3H)-dione. 'HNMR (CDCI3. 300 MHz) δ: 1.21 (d, 7=6.97 Hz, 6 H), 1.24-1.26 (m, 2 H), 1.46-1.76 (m, 6 H), 1.97-2.03 (m, 2 H), 2.35-2.41 (m, 1 H), 2.48-2.54 (m, 1 H), 2.61-2.65 (m, 2 H), 2.67 (s, 3 H), 2.70-2.73 (m, 1 H), 2.79 (s, 3 H), 3.12-3.20 (m, 1 H), 4.03-4.15 (m, 2 H), 6.76 (dd, 7=11.49, 1.51 Hz, 1 H), 6.85 (s, 1 H), 6.88 (d, 7=1.51 Hz, 1 H), 7.11 (t, 7=7.91 Hz, 1 H). HRMS calcd for C29H36FN4θ3 (M+tf): 507.2766. Found: 507.2751.
Example B(46): 6-cyclopentyl-3-[(5,7-dimethyl[1 ,2,4]triazolo[1 ,5-a]pyrimidin-2-yl)methyl]-6- [2-(3-ethyl-4-fluorophenyl)ethyl]dihydro-2H-pyran-2,4(3H)-dione
Figure imgf000296_0001
The title compound was prepared analogously to Example B(31), where 6-cyclopentyl-6-[2-(3- ethyl-4-fluorophenyl)ethyl]dihydro-2H-pyran-2,4(3 -/)-dione was substituted in place of 6-[2-(3- chloro-4-isopropoxyphenyl)ethyl]-6-cyclopentyldihydro-2H-pyran-2,4(3H)-dione in the final Step of that example. 'H NMR (CDC13): δ 0.80 (m, 2H), 1.06 (m, 2H), 1.19 (t, J = 7.63 Hz, 3H), 1.45-1.80 (brm, 8H), 2.06 (m, 2H), 2.45 (m, 2H), 2.65 (m, 2H), 2.70 (s, 3H), 2.80 (s, 3H), 4.13 (d, J = 5.09 Hz, 2H), 6.74 (m, IH), 6.80 ( , 2H), 7.15 (m, IH). Anal. Calcd. For C2SH33θ3 4F: C, 68.27; H, 6.75, N, 11.37. Found: C, 68.14; H, 6.46, N, 11.53.
Example B(47): 6-[2-(3-chloro-4-methoxyphenyl)ethyl]-6-cyclopentyl-3-(1 ,3-thiazol-2- ylmethyl)dihydro-2H-pyran-2,4(3H)-dione
Figure imgf000297_0001
The title compound was prepared analogously to Example B(31), where 1,3-thiazole-2- carbaldehyde was substituted in place of 5,7-dimethyl[1,2,4]triazolo[1,5-a]pyrimidine-2- carbaldehyde and 6-[2-(3-chloro-4-methoxyphenyl)ethyl]-6-cyclopentyldihydro-2H-pyran-2,4(3/-/)- dione was substituted in place of 6-[2-(3-chloro-4-isopropoxyphenyl)ethyl]-6-cyclopentyldihydro-
2 /-pyran-2,4(3H)-dione in final Step of that example.
'H MR (CDC13): δ 1.44-1.70 (bm, 8H), 2.0 (m, 2H), 2.40 (m, IH), 2.60 (m, 3H), 2.76 (d, 7= 17.90 Hz, IH), 3.88 (s. 3H), 4.56 (d, 7= 15.07 Hz, IH), 4.76 (d, 7= 15.07 Hz, IH), 6.70 (d, 7= 2.07Hz, IH), 6.98, (d, 7 = 2.07 Hz, IH), 7.11 ( s, IH), 7.63, (d, 7= 3.96 Hz, IH), 7.87 (d, 7= 3.96 Hz, IH). Anal. Calcd. For C24H2803SNC1: C, 64.63; H, 6.33, N, 3.14. Found: C, 64.55; H, 6.64, N, 3.10.
Example B(48): 6-[2-(3-chloro-4-methoxyphenyl)ethyl]-6-cyclopentyl-3-[(1-methyl-1H- imidazol-2-yl)methyl]dihydro-2H-pyran-2,4(3H)-dione
Figure imgf000297_0002
The title compound was prepared analogously to Example B(31), where 1 -methyl-1 H- imidazole-2-carbaldehyde was substituted in place of 5,7-dimethyl[1 ,2,4]triazolo[1 ,5-a]pyrimidine-
2-carbaldehyde and 6-[2-(3-chloro-4-methoxyphenyl)ethyl]-6-cyclopentyldihydro-2/-/-pyran- 2,4(3/-/)-dione was substituted in place of 6-[2-(3-chloro-4-isopropoxyphenyl)ethyl]-6- cyclopentyldihydro-2H-pyran-2,4(3H)-dione in that example. 'H NMR (CDCI3): δ 1.44-1.70 (bm, 8H), 2.0 (m, 2H), 2.20 (m, 3H), 2.30 (m, 2H), 2.99 (m, 2H), 3.01 (M. 2H), 3.46 (s, 3H) 3.78 (m, IH), 3.89 (s, 3H), 6.72 (d, 7= 2.15Hz, IH), 6.83, (d, 7 = 2.15 Hz, IH), 6,90 (s, IH), 7.14, (d, 7= 3.07 Hz, IH), 7.24 (d, 7= 3.06 Hz, IH). Anal. Calcd. For C25H3103N2C1: C, 67.78; H, 7.05, N, 6.32. Found: C, 67.48; H, 7.25, N, 6.37.
Example B(49): 6-cyclopentyl-3-[(5,7-dimethyl [1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-6- [2-(3-isopropylphenyl)ethyl]dihydro~2H-pyran-2,4(3H)-dione.
Figure imgf000298_0001
The title compound was prepared analogously to Example B(31), where 6-cyclopentyl-6-
[2-(3-isopropylphenyl)ethyl]dihydro-2H-pyran-2,4(3/-/)-dione (described below) was substituted in place of 6-[2-(3-chloro-4-isopropoxyphenyl)ethyl]-6-cyclopentyldihydro-2/-/-pyran-2,4(3/-/)-dione in that example.
Η NMR (CDC13): δ 0.88 (m, IH), 1.21 (d, 7= 6.78 Hz, 6H), 1.26 (s, 2H), 1.48-1.77 (brm, 8H), 2.04 (m, 2H), 2.41 (m, IH), 2.52-2.58 (m, 2H), 2.67 (s, 3H), 2.79 (s, 3H), 2.87 (m, 2H) 4.09 (s, 2H), 6.84 (s, IH), 6.98 (d, 7= 7.54Hz, IH), 7.00 (m, 2H), 7.18 (t, 7 = 7.54 Hz IH). Anal. Calcd. For C29H36θ3N4: C, 71.28; H, 7.43, N, 11.47. Found: C, 71.51; H, 7.25, N, 11.37.
Step 1: 6-Cyclopentyl-6-[2-(3-isopropyl-phenyl)-ethyl]-dihydro-pyran-2,4-dione
Figure imgf000298_0002
The title compound was prepared analogously to Example A(64), where 3-bromo- isopropyl-benzene was substituted in place of 4-Bromo-2-fluoro-1 -isopropyl benzene in Step 3 of that example.
'H NMR (CDC13): ? 1.24 (d, 6H, 7= 8.5 Hz)1.40-1.75 (m, 4H), 1.99 (m, 2H), 2.29 (pentet, IH, 7= 8.1 Hz), 2.66 (t, 2H, 7= 8.5 Hz), 2.78 (s, 2H), 2.87 (m, IH), 3.42 (s, 3H), 6.97 (m, 2H), 7.10 (m, IH), 7.22 (m, IH). Anal. Calcd. For C21H28O3-0.25 H2O: C, 75.75; H, 8.63. Found: C, 75.68; H, 8.48. ESIMS (M-H"): 327.2
Example B(50): 6-cyclopentyl-3-[(5,7-dimethyl[1,2,4]triazolo [1,5-a] pyrimidin-2-yl)methyl]- 6-[2-(4-isopropylphenyl)ethyl]dihydro-2H-pyran-2,4(3W)-dione
Figure imgf000299_0001
The title compound was prepared analogously to Example B(31), where 6-cyclopentyl-6- [2-(4-isopropylphenyl)ethyl]dihydro-2H-pyran-2,4(3/-/)-dione was substituted in place of 6-[2-(3- chloro-4-isopropoxyphenyl)ethyl]-6-cyclopentyldihydro-2/--pyran-2,4(3 -/)-dione in that example.
Η NMR (CDCI3): δ 0.98 (m, IH), 1.24 (d, J = 6.78 Hz, 6H), 1.31 (s, 2H), 1.40-1.77 (brm, 8H), 2.06 (m, 2H), 2.41 (m, IH), 2.50-2.59 (m, 2H), 2.68 (s, 3H), 2.79 (s, 3H), 2.95 (m, 2H) 4.25 (s, 2H), 6.90 (s, IH), 7.15 (d, J = 8.10Hz, IH), 7.30 (d, 7 = 8.10 Hz IH), Anal. Calcd. For C29H3603N4: C, 71.28; H, 7.43, N, 11.47. Found: C, 71.35; H, 7.55, N, 11.47.
Example B(51 ): 6-[2-(3-chlorophenyl)ethyl]-6-cyclopentyl-3-[(5,7-dimethyl[1 ,2,4]triazolo[1 ,5- a]pyrimidin-2-yl)methyl]dihydro-2W-pyran-2,4(3r/)-dione
Figure imgf000300_0001
The title compound was prepared analogously to Example B(31), where 6-[2-(3- chlorophenyl)ethyl]-6-cyclopentyldihydro-2/-/-pyran-2,4(3H)-dione was substituted in place of 6-[2- (3-chloro-4-isopropoxyphenyl)ethyl]-6-cyclopentyldihydro-2/-/-pyran-2,4(3/-/)-dione in that example.
'H NMR (CDCl3): δ 1.30 (m, IH), 1.40-1.80 (brm, 8H), 2.10 (m, 2H), 2.41 (m, IH), 2.52-2.58 (m, 2H), 2.67 (s, 3H), 2.80 (s, 3H), 2.87 (m, 2H) 4.09 (s, 2H), 6.84 (s, IH), 6.98 (d, J = 6.25Hz, IH), 7.20 (t, 7 = 8.35 Hz 2H), 7.30 (m, IH) Anal. Calcd. For C26H2903N4C1: C, 64.92; H, 6.08, N, 11.65. Found: C, 65.14; H, 6.25, N, 11.73.
Example B(52): 6-[2-(5-chloro-2,4-dimethoxyphenyl)ethyl]-6-cyclopentyl-3-[(5,7- dimethyl[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]dihydro-2W-pyran-2,4(3H)-dione
Figure imgf000300_0002
The title compound was prepared by treating a suspension of 6-[2-(5-chloro-2,4- dimethoxyphenyl)ethyl]-6-cyclopentyldihydro-2H-pyran-2,4(3/-/)-dione (350 mg, 0.917 mmol) and 5,7-dimethyl[1 ,2,4]triazolo[1,5-a]pyrimidine-2-carboxaldehyde (described in Step 3 of example B(75))(242 mg, 1.375 mmol, 1.5 equiv, from Step 3 of Example B(75)) in MeOH (10 mL) with dimethylamine borane (65 mg, 1.1 mmol, 1.2 equiv). The resulting mixture was stirred at room temperature for 18 h. A 1 M solution of HCl (3 mL) was added to the reaction mixture to acidify to a pH of 3. The mixture diluted with water and extracted with dichloromethane containing 10% methanol (3 x 10 mL). The organic layers were combined, dried over Na2S0 , filtered and concentrated to a white amorphous foam. The foam was chromatographed on silica gel, eluting with 2% methanol in dichloromethane affording a white solid. This solid was recrystallized from ethyl acetate/hexanes to give 100 mg (19%) of the product as a fine white powder. Isolated as a monohydrate.
Η NMR d (300 MHz, CDC13) 1.58-1.76 (m, 8H), 1.94-1.99 (m, 2H), 2.38-2.43 (m, IH), 2.57-2.77 (m, 2H), 2.69 (s, 3H), 2.81 (s, 3H), 3.82, (s, 3H), 3.85-3.92 (m, 2H), 3.80 (s, 3H), 4.08 (ABQ pattern, 2H, 7 = 15 Hz), 6.45 (s, IH), 6.89 (s, IH), 7.04 (s, IH). MS calcd for C28H33C1N405: 540.05, found (M+H÷): 541.04. Anal. Calcd for C28H33C1N405 H20: C, 60.19; H, 6.32; N, 10.03. Found C, 60.76; H, 5.98; N, 9.54.
Step 1: (5-Amino-1W-1,2,4-triazoI-3-yI)methanol glycolate
Figure imgf000301_0001
The title compound was prepared by a slight modification of a reported procedure (Allen, C. F. H. J. Org. Chem, 1959, 24, 793): A 5-L 3-necked flask was charged with aminoguanidine bicarbonate (275.6 g, 2.025 mol) and octyl alcohol (5.5 mL, to control foaming). To the mixture was added 70% aqueous glycolic acid (440 g, 4.05 mol, 2 equiv) gradually, during which time evolution of C02 was observed. When foaming and gas evolution had ceased, concentrated nitric acid (2.2 mL) was added so that it wet the sides of the flask above the liquid. The reaction mixture was refluxed for 40 h, then cooled to 5 °C and maintained at this temperature for 40 min. The resulting slurry was filtered, and the solid washed with EtOH and dried in vacuo at 30 °C to give the crude product as a white solid (313 g). The mother liquor was stirred at 0 °C (ice bath) for 1 h and filtered, affording a second batch of material (51 g). These two batches were combined and recrystallized from hot EtOH, affording 271.5 g, (70.5 %). Η NMR (300 MHz, DMSO-d6) δ 3.89 (2H), 4.24 (2H), 5.58 (2H). LC-MS (APCI) calcd for C3H6N40: 114.05; found (M+H): 115.1 m/z
Step 2: (5,7-Dimethyl[1 ,2,4]triazolo[1 ,5-a]pyrimidin-2-yl)methanol
Figure imgf000301_0002
The title compound was prepared by a slight modification of a reported procedure (Lippman, E.; Becker, V., Z Chem., 1974, 14, 405): A solution of (5-amino-1H-1,2,4-triazol-3- yl)methano! glycolate (30.7 g, 0.161 mol, from Step 1, above) and 2,4-pentadione (32.3 g, 0.323 mol, 2 equiv) in a mixture of EtOH (750 mL) and AcOH (250 mL) was refluxed 20 h. At the beginning the reaction mixture was clear solution, then gradually turned yellow towards the end of the heating period. The solvent was removed under reduced pressure, and the resulting yellow paste triturated with EtOH (100 mL) and stirred for 15 min. The slurry was chilled to 5 °C (ice bath) with stirring for 30 min, filtered, and washed with cold (0-5 °C) EtOH. The product was dried in vacuo at 25-30 °C to give 24 g (83.7%). 'HNMR (300 MHz, DMSO-d6) δ 2.57 (3H), 2.71 (3H), 4.63 (2H), 5.5 (IH, OH), 7.13 (IH). LC-MS (APCI) calcd for C8Hι0N4O: 178.19; found (M+H+): 179.1 m/z
Example B(53): 6-[2-(Chloro-4-methoxyphenyl)ethyl]-6-cyclopentyl-3-[(1,3-dimethyl-1H- 1,2,4-triazol-5-yl)methyl]-4-hydroxy-5,6-dihydro-2W-pyran-2-one
Figure imgf000302_0001
A suspension of 6-[2-(3-chloro-4-methoxyphenyl)ethyl]-6-cyclopentyldihydro-2H-pyran- 2,4(3H)-dione (140 mg, 0.4 mmol) in 1:1 H20/DME (4 mL) was treated sequentially with a 0.5 M aqueous solution of Na2C03 (0.88 mL, 1.1 equiv), a 0.5 M aqueous solution of Nal (0.88 mL, 1.1 equiv), and a 0.1 M solution of 5-(chloromethyl)-1,3-dimethyl-1H-1,2,4-triazole in 1:1 H20/DME (4.4 mL, 1.1 equiv, from Step 1, below). The reaction mixture was stirred and heated at 80 °C for 18 h. The mixture was then cooled and treated with 0.4 mL (1 equiv) each of a 1 M HCl solution and a 1 M acetic acid solution in water. The volatiles were removed in vacuo, and the residue was dissolved in DMSO to a concentration of 0.01 M. The product was purified by HPLC in multiple injections using a Pecke Hi-Q 5 μm, 20 x 100 mm column with a 5-90% CH3CN/0.05% TFA gradient. A run time of 8.1 min, a flow rate of 30.0 mL/min, and a monitoring wavelength of 260 nm were used. The product-containing fractions were combined and lyophilized, affording the product as a powder. Yield: 11%. Η NMR (300 MHz, DMSO-d6) δ 1.2-1.68 (m, 8H), 2.13 (s, 3H), 2.29 (m, IH), 2.4-2.53 (m, 5H, overlap with DMSO-dj), 2.70 (d, 7= 18 Hz, IH), 3.62 (m, 2H, overlap with H20), 3.72 (s, 3H), 3.74 (s, 3H), 6.96 (d, 7 = 8.4 Hz, IH), 7.04 (dd, 7 = 8.4, 1.8 Hz, IH), 7.18 (d, 7= 1.8 Hz, IH). LC-MS calcd for C24H30ClN3O4: 459.19, found (M+H ): 460.1 m/z.
Step 1. 5-(Chloromethyl)-1,3-dimethyl-1H-1,2,4-triazole
Figure imgf000303_0001
The title compound was prepared by a modification of a reported method (Kuebel, B. DE 3118258, Dec 2, 1982): A 2 L-round bottomed flask equipped with a magnetic stirrer was charged with acetamidine hydrochloride (94.5 g, 1.0 mol) and methanol (500 mL). Methylhydrazine (50.0 g, 1.1 mol) was added slowly via a dropping funnel over 30 min at room temperature under nitrogen blanket. After 2 d, the solvent was removed in vacuo, and the resulting residue triturated with ethyl acetate, filtered, and washed with ethyl acetate (3 x 400 mL). After drying the residue in a vacuum oven at 50 °C, the crude intermediate amidrazone, N- methylethanehydrazonamide hydrochloride (109.8 g) was used directly in the next step. This intermediate (109.8 g) was suspended in dichloromethane (400 mL), cooled to 0-5 °C, and treated slowly with triethylamine (100.2 g) at this temperature. Chloroacetyl chloride (103.7 g, 1.02 mol) was added slowly over 30 min at 0-5 °C via a dropping funnel. The reaction mixture was allowed to warm to room temperature and stirred for 18 h under nitrogen blanket. The solvent was then removed under reduced pressure, affording a residue (432.6 g) containing the Λ/-chloroacetyl amidrazone intermediate. Polyphosphoric acid, PPA (400 g) was added to this material in a 2 L-3 necked flask, which was equipped with an overhead stirrer, a water condenser and a thermometer. The reaction mixture was stirred and heated at 120 -130 °C for 4 h. Upon cooling to 80 °C, water (400 mL) was added slowly and stirring continued for an additional 2 h. Aqueous NaOH (100 g/150 mL) was used to adjust the pH from 3 to 9. The organic material was extracted with chloroform (4 x 1 L), and the resulting solution treated with activated charcoal, dried with Na2S0 , filtered, and evaporated carefully. The dark oily residue thus obtained was extracted with a mixture of ether (700 mL) and pentane (300 mL) to separate the product from insoluble impurities. The yellow supernatant was decanted and the solvent removed carefully in vacuo (30 °C and ~10 Torr), affording 60.0 g (46 % overall) of the title product as an oil (95% pure by NMR).
Η NMR (300 MHz, CDC13) δ 2.35 (s, 3H, C-CH3), 3.87 (s, 3H, N-CH3), and 4.62 (s, 2H, CH2). I3C NMR (300 MHz, CDC13) δ 14.05 (C-CH3), 34.37 (CH2), 35.81 (N-CH3), 151.20 (q-C) and 60.22 (q-C). An NOE between CH2 and the N-CH was observed, consistent with the reported regioisomer. LC-MS (APCI) calcd for C5H8C1N3: 145.04; found (M+H1) 146.1 m/z (with chorine isotope pattern).
Example B(54): 2-({6-[-(3-chloro-4-methoxyphenyl)ethyl]-6-cyclopentyl-4-hydroxy-2-oxo- 5,6-dihydro-2H-pyran-3-yl}methyl)-6-methylpyrimidin-4(3H)-one
Figure imgf000304_0001
The title compound was prepared as described in Example B(53) employing 2- (chloromethyl)-6-methylpyrimidin-4(3)-one in place of 5-(chloromethyl)-1 ,3-dimethyl-1 H-1 ,2,4- triazole . Yield: 26%.
Η NMR (300 MHz, DMSO-d6) δ 1.25-1.65 (m, 8H), 1.88 (s, 3H), 1.9-2.1 (m, 2H), 2.35 (m, IH), 2.4-2.54 (m, 3H, overlap with DMSO-d5), 2.66 (d, 7 = 18 Hz, IH), 3.45 (ABQ, 7= 15 Hz, 2H), 3.74 (s, 3H), 5.98 (s, IH), 6.96 (d, 7= 8 Hz, IH), 7.04 (d, 7= 8, Hz, IH), 7.17 (S, IH). LC-MS calcd for C25H29C1N205: 472.18, found (M+H+): 473.1 m/z.
Step 1: 2-(Chloromethyl)-6-methyIpyrimidin-4(3H)-one
Figure imgf000304_0002
Prepared according to a reported procedure: Okabe, T.; Hirano, M.; Mukai, K. US 4,326,058 (April 20, 1982). Yield: 12%.
'H NMR (300 MHz, DMSO-d6) δ 2.18 (s, 3 H), 4.42 (s, 2H), 6.16 (s, IH), 12.61 (br s, IH). LC-MS (APCI) calcd for C6H7C1N20: 158.02; found (M+H+): 159.0 m/z
Example B(55): 2-({6-[2-(3-Chloro-4-methoxyphenyl)ethyl]-6-cyclopentyl-4-hydroxy-2-oxo- 5,6-dihydro-2H-pyran-3-yl}methyl)quinazolin-4(3H)-one
Figure imgf000305_0001
The title compound was prepared as described in Example B(53), employing 2- (bromomethyl)quinazolin-4(3 -/)-one in place of 5-(chloromethyl)-1,3-dimethyl-1H-1,2,4-triazole. Yield: 16%.
Η NMR (300 MHz, DMSO-d6) δ 1.25-1.70 (m, 8H), 2.20-2.25 (m, 2H), 2.35 (m, IH), 2.45-2.60 (m, 3H, overlap with DMSO-d5), 2.73 (d, 7= 18 Hz, IH), 3.52 (m, 2H, overlap with H20 peak), 3.76 (s, 3H), 6.92 (d, 7 = 8 Hz, IH), 6.96 (d, 7= 8 Hz, IH), 7.06 (d, 7= 8 Hz, IH), 7.21 (s, IH), 7.36 (t, 7 = 8 Hz, 1 H), 7.50 (t, 7= 8 Hz, IH), 7.97 (d, 7= 8 Hz, IH). LC-MS calcd for C2SH29C1N205: 508.18, found (M+H+): 509.1 m z.
Step 1. 2-(Bromomethyl)quinazolin-4(3H)-one
Figure imgf000305_0002
The title compound was made by a slight modification of a reported procedure (Bergman,
J.; Brynolf, A. Tetrahedron 1990, 46, 1295). A 3-necked 500-mL round bottomed flask was charged with 2-(methyl)quinazolin-4(3/-/)-one (50.09 g, 0.303 mol), 200 mL of dry DMF, and N- bromosuccinimide (54.53 g, 0.303 mol, 1 equiv). The reaction mixture was warmed to 40 °C and maintained at this temperature for 2 h. The mixture was cooled to room temperature and allowed to stand for 4 d. The resulting tan slurry was filtered, and the filter cake washed with ether (3 x 50 mL), and dried in vacuo. The crude solid was suspended in mixture of 95% ethanol (600 mL) and water (6 mL) and the mixture heated to boiling. The hot slurry was cooled to room temperature, chilled in an ice bath, and filtered. The cake was washed with chilled 95% ethanol (50 mL), followed by ether (2 x 50 mL), then dried in vacuo, affording 52.90 g of material containing 11% starting material. This was recrystallized from hot (95 °C) DMF (750 mL). Upon cooling to room temperature, the slurry was filtered, and the cake washed with DMF (80 mL), and methanol (3 x 50 mL), then dried in vacuo at 50 °C, affording 39.40 g (54%). The product was found to be 98% pure by both HPLC and 1H NMR.
'H NMR (300 MHz, DMSO-d6) δ 4.40 (s, 2H), 7.55 (t, 7 = 8 Hz, IH), 7.67 (d, 7 = 8 Hz, IH), 7.84 (t, 7 = 8 Hz, IH), 8.12 (d, 7= 8 Hz, IH), 12.57 (br s, IH). LC-MS (APCI) calcd for C9H7BrN20: 238.0; found (M+H÷) 239.1, 241.1 (1:1) m/z.
Example B(56): 2-({6-[2-(3-Chloro-4-methoxyphenyl)ethyl]-6-cyclopentyl-4-hydroxy-2-oxo- 5,6-dihydro-2W-pyran-3-yl}methyl)thieno[3,2-d]pyrimidin-4(3H)-one.
Figure imgf000306_0001
The title compound was prepared as described in Example B(53), using 2-
(chloromethyl)thieno[3,2- ]-pyrimidine-4(3H)-one (Step 1) in place of 5-(chloromethyl)-1 ,3- dimethyl-1H-1,2,4-triazole. Yield: 22%.
Η NMR (300 MHz, DMSO-d6) δ 1.5-1.7 (m, 8H), 1.90-2.18 (m, 2H), 2.35 (m, IH), 2.52 (m, 3H,), 2.70 (d, 7 = 18 Hz, IH), 3.53 (ABQ, 7 = 15 Hz, 2H), 3.72 (s, 3H, overlap with H20 peak), 6.72 (d, 7 = 5.1 Hz,
IH), 6.96 (d, 7= 8.6 Hz, IH), 7.04 (dd, 7= 8.6, 2.1 Hz, IH), 7.18 (d, 7 = 2.1 Hz, IH), 7.97 (t, 7= 5.1 Hz, 1
H). LC-MS (APCI) calcd for C26H27C1N205S: 514.13; found (M+H+) 515.0 m/z
Step 1: 2-(Chloromethyl)thieno[3,2-d]-pyrimidine-4(3H)-one.
Figure imgf000306_0002
This compound was prepared by a modification of a method reported for related fused pyrimidine-4(3H)-ones: (1) Shishoo, C. J.; Devani, M. B.; Pathak, U. S.; Ananthan, S.; Bhadti, V. S.; Ullas, G. V.; Jain, K. S.; Rathod, I. S.; Talati, D. S.; Doshi, N. H. J. Heterocyclic Chem. 1984, 21, 375, and (2) Gerecke, M.; Kyburz, E.; Borer, R.; Gassner, W. Heterocycles 1994, 39, 693). An oven-dried 1-L round bottomed flask was charged with chloroacetonitrile (21.86 g, 0.29 mol, 1.3 equiv), methyl 3-aminothiophene-2-carboxylate (35 g, 0.223 mol), and 4 M HCl in 1,4-dioxane (350 mL). The reaction mixture was stirred at room temperature for 1 d. The mixture was evaporated to dryness. The residue was dissolved in water (600 mL) and treated with aqueous 10% sodium bicarbonate to a pH of 8. The resulting slurry was filtered, and the cake washed with water and dried, affording 38.2 g (85%) of the title product.
Η NMR (DMSO-d6) δ 4.58 (s, 2H), 7.42 (d, 7 = 5.3 Hz, IH), 8.22 (d, 7 = 5.3 Hz, IH), 12.84 (br s, IH). LC-MS (APCI) calcd for C7H5ClN2OS: 200.0; Found (M+H+): 201.0 m/z.
Example B(57): 2-({6-[2-(3-chloro-4-methoxyphenyl)ethyI]-6-cyclopentyl-4-hydroxy-2-oxo- 5,6-dihydro-2W-pyran-3-yl}methyl)-6,7-dimethoxyquinazolin-4(3H)-one.
Figure imgf000307_0001
The title compound was prepared as described in Example B(53), using 2-(chloromethyl)- 6,7-dimethoxyquinazolin-4(3H)-one (Step 1) in place of 5-(chloromethyl)-1,3-dimethyl-1/-M,2,4- triazole. Yield: 18%.
Η NMR (300 MHz, DMSO-d6) δ 1.55-1.67 (m, 8H), 1.85-2.1 (m, 2H), 2.36 (m, IH), 2.5-2.6 (m, 3H), 2.71 (d, 7 = 18 Hz, IH), 3.59 (s, m overlap, 5H), 3.73 (s, 3H, overlap with H20 peak), 3.79 (s, 3H, overlap with H20 peak), 6.64 (s, IH), 6.90 (d, 7= 8.7 Hz, IH), 7.03 (dd, 7 = 8.7, 1.6 Hz, IH), 7.20 (d, 7 = 1.6 Hz, IH), 7.34 (s, 1 H). LC-MS (APCI) calcd for C3oH33ClN207: 568.20; found (M+H+) 569.1 m/z.
Step l: 2-(Chloromethyl)-6,7-dimethoxyquinazolin-4(3H)-one.
Figure imgf000307_0002
The title compound was prepared as described in Step 1 of Example B(56), except using methyl 2-amino-4,5-dimethoxy benzoate in place of methyl 3-aminothiophene-2-carboxylate. The crude product (20 g) obtained from 22.8 g (0.108 mol) of 2-amino-4,5-dimethoxy benzoate was recrystallized from a hot (70 °C) mixture of ethyl acetate (600 mL) and methanol (200 mL), to give 13.3 g (50%) of the title product. Η NMR (DMSO-d6) δ 3.87 (s, 3H), 3.90 (s, 3H), 4.52 (s, 2H), 7.15 (s, IH), 7.43 (s, IH), 12.4 (v br s, IH). LC-MS (APCI, Neg) calcd for CuHnCWV 254.05; found (M-H*) 253.0 m/z.
Example B(58): 7-[(6-{2-[3-Chloro-4-(cyclopropylmethoxy)phenyl]ethyl}-6-cyclopentyl-4- hydroxy-2-oxo-5,6-dihydro-2H-pyran-3-yl)methyl]-3-methyl-5W-[1,3]thiazolo[3,2- a]pyrimidin-5-one.
Figure imgf000308_0001
The title compound was prepared as described in Example B(53), using 7-(chloromethyl)- 3-methyl-5H-[1,3]thiazolo[3,2-a]pyrimidin-5-one (prepared according to a reported procedure: Doria, G.; Passarotti, C; Sala, R.; Magrini, R.; Sberze, P.; Tibolla, M.; Cesarani, R.; Arcari, G.; Castello, R.; Toti, D. Farmaco Ed. Sci. 1985, 40, 885) in place of 5-(chloromethyl)-1,3-dimethyl- 1H-1,2,4-triazole , and using 6-{-[3-chloro-4-(cyclopropylmethoxy)phenyl]ethyl}-6- cydopentyldihydro-2H-pyran-2,4(3H)-dione (from Step 4, below) in place of 6-[2-(3-chloro-4- methoxyphenyl)ethyl]-6-cyclopentyldihydro-2H-pyran-2,4(3H)-dione . Yield: 1%.
1H NMR (300 MHz, DMSO-d6) Q 0.31 (m, 2H), 0.56 (m, 2H), 1.22 (m, 1H), 1.23-1.65 (m, 8H), 1.92 (m, 2H), 2.33 (m, 1H), 2.48-2.75 (s, m, 7H, overlap with DMSO-d5), 3.45 (m, 2H, overlap with H20 peak), 3.84 (d, 7 = 7.8 Hz, 2H), 4.87 (s, 2H), 5.20 (s, 1H), 6.16 (s, 1H), 6.93 (d, 7 = 9 Hz, 1H), 7.01 (dd, 7 = 9, 1.5 Hz, 1H), 7.18 (d, 7 = 1.5 Hz, 1H). LC-MS (APCI) calcd for C3oH33CIN205S: 568.18; found (M+H+) 569.0 m/z.
Step ! 3-[4-(Benzyloxy)-3-chlorophenyl]-1-cyclopentylpropan-1-one.
Figure imgf000308_0002
A solution of 3-[4-(benzyloxy)-3-chlorophenyl]propanoic acid (80 g, 0.28 mol, obtained as described: Kuchar, M.; Brunova, B.; Rejholec, V.; Roubal, Z.; Nemecek, O. Collect. Czech. Chem. Commun 1981, 46, 1173) in DCE (500 mL) was treated with oxalyl chloride (26.5 mL, 0.30 mol, 1.05 equiv). After stirring for 2 min, DMF (0.2 mL) was added, and stirring continued for an additional 3 h. The volatiles were removed in vacuo, affording a quantitative yield of the acid chloride, a green oil, which was used directly in the next step. The crude acid chloride thus obtained was dissolved in CH2CI2 (1 L), and added dropwise via an addition funnel to 2- mercaptopyridine (30.5 g, 0.28 mol, 1 equiv) in CH2CI2 (3 L). The reaction mixture was stirred for an additional 3 h at 23 °C. The mixture was treated with 1.0 N NaOH (320 mL), and extracted with ethyl acetate (3 x 200 mL). The combined extracts were washed with aqueous NaHC03 and brine, dried over MgS0 , filtered, and evaporated. The resulting crude S-pyridin-2-yl 3-[4- (benzyloxy)-3-chlorophenyl]propanethioate, an amber oil, was used directly in the next step. This thioester intermediate was dissolved in THF (450 mL), the solution chilled in a dry ice bath to -70 °C, and treated dropwise at this temperature with a 2M solution of cyclopentylmagnesium bromide in diethyl ether (145 mL, 0.28 mol, 1 equiv). When the addition was complete, a sample taken from the resulting peach-colored slurry was treated with 5% HCl, and subjected to TLC analysis on silica gel using 20% ethyl acetate in hexanes. A UV-active spot at Rf = 0.5 stained orange with 2,4-DNP. The reaction mixture was warmed to room temperature, then treated with 5% aqueous HCl (350 mL) and diethyl ether (20 mL). The layers were separated and the organic phase washed with aqueous NaHC03 and brine, dried over MgS04, filtered, and evaporated, affording an amber oil (93 g). This was chromatographed on silica gel using 10% ethyl acetate in hexanes, affording 48 g (51% overall) of the cyclopentyl ketone as a pale yellow oil. Η NMR (DMSO-d6) d 1.45-1.8 (m, 8H), 2.7-2.9 (m, 5H), 5.15 (s, 2H), 7.10 (s, 2H), 7.3-7.5 (m, 6H). LC- MS (neg) calcd for C2ιH23C102, 342.14; found [M-1]: 341.1.
Step 2. 3-(3-Chloro-4-hydroxyphenyl)-1-cyclopentylpropan-1-one.
Figure imgf000309_0001
A mixture of 3-[4-(benzyloxy)-3-chlorophenyl]-1-cyclopentylpropan-1-one (48 g, 0.140 mole), from Step 1 , and 10% palladium-on-carbon (11.52 g of 50 wt% wet, 0.005 mol, 3.5 mole%) in ethyl acetate (500 mL) was degassed and purged with hydrogen three times. The reaction was stirred with 1 atm H2 for 4 h, resulting in complete conversion. The mixture was filtered through a fine fritted glass funnel and the filtrate concentrated in vacuo, affording a yellow oil which crystallized on cooling. This material was recrystallized from two parts of isopropyl ether, affording 22 g (62%) of the title product, mp 88-90 °C.
'H NMR (DMSO-d6) δ 1.4-1.75 (m, 8H), 2.5-2.7 (m, 4H), 2.9 (m, 1 H), 6.83 (d, 7= 8.3 Hz, IH), 6.94 (dd, 7= 8.3, 1.9 Hz, IH), 7.15 (d, 7= 1.9 Hz, IH), 9.86 (br s, IH). MS calcd for C14HπC102) 252.09, found [M+l)]: 253.10
Step 3: 3-[3-Chloro-4-(cyclopropylmethoxy)phenyl]-1-cyclopentylpropan-1-one.
Figure imgf000310_0001
A solution of 3-(3-chloro-4-hydroxyphenyl)-1-cyclopentylpropan-1-one ( (25 g, 0.099 mol, from Step 2) in 1:1 DMF/CH3CN (200 mL) was treated with K2C03 (15 g, 0.109 mol, 1.1 equiv), and the mixture stirred for 15 min. A solution of (bromomethyl)cyclopropane (17.4 g, 0.129 mol, 1.3 equiv) in DMF (50 mL) was added dropwise, and the reaction mixture heated to 100 °C for 1 h. The volatiles were removed in vacuo. The residue was dissolved in a minimal amount of ethyl acetate, and this solution washed with water, dried over Na2S0 , filtered, and evaporated. Chromatographic purification of the residue on silica gel using hexanes/ethyl acetate afforded 29.12 g (96%) of the title compound. Η NMR (CDC13) δ 0.32 (m, 2H), 0.58 (m, 2H), 1.23 (m, 1 H), 1.64 (m, 8H), 2.70 (m, 5H), 3.8 (d, 7= 6 Hz, 2H), 6.78 (d, 7= 9 Hz, IH), 6.93 (d, 7= 9 Hz, IH), 7.13 (s, IH). MS calcd for CI8H23C102, 306.83, found [M+l)]: 307.0
Step 4. 6-{-[3-Chloro-4-(cyclopropylmethoxy)phenyl]ethyl}-6-cyclopentyldihydro-2H-pyran- 2,4(3H)-dione.
Figure imgf000310_0002
An oven-dried, 500-mL 3-necked round-bottomed flask, cooled under a blanket of N2, was charged with NaH (1.48 g, 61.74 mmol) and 25 mL dry THF. The slurry was cooled to -40 °C in a dry ice/CH3CN bath and treated slowly with a cold solution of methyl acetoacetate (6.83 g, 58.8 mmol) in THF (30 mL), delivered via syringe at such a rate that the internal temperature stays within a 5 °C interval. The mixture was stirred for 30 min, then cooled to -70 °C with a dry ice/acetone bath. The mixture was treated with n-BuLi (23.5 mL, 61.74 mmol) at -70 °C, and stirred at this temperature for an additional 45 min. To the resulting solution of acetoacetate dianion was added a solution of 3-[3-chloro-4-(cyclopropylmethoxy)phenyl]-1-cyclopentylpropan- 1-one (15.03 g, 49 mmol, from Step 3) in THF (50 mL) via an addition funnel, at such a rate that a reaction temperature of -70 °C is maintained. After stirring at this temperature for an additional 1 h, the reaction mixture was allowed to warm to room temperature over 3 h, then quenched with 4 M NH4CI (aq) (30.87 mL). After stirring at room temperature for 10 min, the mixture is concentrated in vacuo. To the oily residue was added water, then the mixture extracted with ethyl acetate (3 x 100 mL). The ethyl acetate solution was dried over Na2S04, filtered, and concentrated to a viscous resin, which was chromatographed on silica gel with 5:1 hexanes/ethyl acetate, affording 14.82 g (71 %) of the hydroxy ester intermediate. This intermediate was dissolved in THF (100 mL) added to 1 M NaOH (aq) (3 L), and the resulting mixture stirred at room temperature for 3 h. The mixture was acidified with 1 M aqueous HCl (1.5 L) to a pH 2. The product was extracted into dichloromethane (3 x 400 mL), and the extract dried over Na2S04, filtered, and concentrated to a resin. The resin was chromatographed on silica gel using 3:1 hexanes/ethyl acetate, and the resulting foam crystallized from ethyl acetate/hexanes to obtain 4.45 g, (23% overall) of the product as an off-white solid.
Η NMR (300 MHz, CDC13) d 0.38 (d, 7= 5 Hz, 2H), 0.65 (d, 7 = 7.5 Hz, 2H), 1.32 (m, IH), 1.40-1.85 (m, 8H), 1.95 (m, 2H), 2.27 (m, IH), 2.61 (t, 7 = 8.2 Hz, 2H), 2.77 (s, 2H), 3.43 (s, 2H), 3.86 (d, 7= 6.7 Hz, 2H), 6.84 (d, IH, 7 = 8.1 Hz, IH), 6.96 (d, 7 = 8.1 Hz, IH), 7.16 (s, IH). MS calcd for C22H27C104: 390.90, MS found, [M+l]: 391.
Example B(59): 7-({6-[2-(5-Chloro-2,4-dimethoxyphenyl)ethyl]-6-cyclopentyl-4-hydroxy-2- oxo-5,6-dihydro-2W-pyran-3-yl}methyl)-3-methyl-5H-[1,3]thiazolo[3,2-a]pyrimidin-5-one.
Figure imgf000311_0001
The title compound was prepared as described in Example B(53), using 7-(chloromethyl)- 3-methyl-5H-[1,3]thiazolo[3,2-a]pyrimidin-5-one (prepared according to a reported procedure: Doria, G.; Passarotti, C; Sala, R.; Magrini, R.; Sberze, P.; Tibolla, M.; Cesarani, R.; Arcari, G.; Castello, R.; Toti, D. Farmaco Ed. Sci. 1985, 40, 885) in place of 5-(chloromethyl)-1,3-dimethyl- 1H-1 ,2,4-triazole, and using 6-[2-(5-chloro-2,4-dimethoxyphenyl)ethyl]-6-cyclopentyldihydro-2H- pyran-2,4(3H)-dione in place of 6-[2-(3-chloro-4-methoxyphenyl)ethyl]-6-cyclopentyldihydro-2H- pyran-2,4(3H)-dione . Yield: 18%.
Η NMR (300 MHz, DMSO-d6) δ 1.23-1.73 (m, 8H), 1.78-2.0 (m, 2H), 2.35 (m, IH), 2.48-2.58 (m, 2H, overlap with DMSO-d5), 2.64 (s, m, overlap, 4H), 2.78 (d, 7= 18 Hz, IH), 3.44 (s, 2H), 3.78 (s, 3H, overlap with HzO peak), 3.85 (s, 3H), 5.80 (s, IH), 6.70 (s, IH), 6.97 (s, IH), 7.11 (s, IH), 10.96 (br s, IH). LC-MS (APCI) calcd for C28H31C1N206S: 558.16; found (M+H+) 559.0 m z.
Example B(60): Methyl 5-({6-cyclopentyl-4-hydroxy-6-[2-(4-methoxyphenyl)ethyl]-2-oxo-5,6- dihydro-2H-pyran-3-yl}methyl)isoxazol-3-ylcarbamate
Figure imgf000312_0001
The title compound was prepared as described in Example B(53), using methyl 5- (bromomethyl)isoxazol-3-ylcarbamate (prepared as described: Sircar, J. C; Capiris, T. US4,489,077, Dec 18, 1984) in place of 5-(chloromethyl)-1 ,3-dimethyl-l H-1 ,2,4-triazole, and using 6-cyclopentyl-6-[2-(4-methoxyphenyl)ethyl]dihydro-2H-pyran-2,4(3H)-dione in place of 6- [2-(3-chloro-4-methoxyphenyl)ethyl]-6-cyclopentyldihydro-2H-pyran-2,4(3H)-dione. Yield: 13%. Η NMR (300 MHz, DMSO-d6) δ 1.15-1.65 (m, 8H), 1.80 (m, 2H), 2.25 (m, IH), 2.39-2.51 (m, 3H, overlap with DMSO-d5), 2.68 (d, 7= 17.4 Hz, IH), 3.51 (s, 2H), 3.56 (s, 3H), 3.61 (s, 3H), 6.24 (s, IH), 6.72 (d, 7 = 8.4 Hz, 2H), 6.95 (d, 7 = 8.4 Hz, 2H), 10.47 (s, IH), 11.15 (br s, IH). LC-MS (APCI) calcd for C25H3oN207: 470.21; found (M+H4) 471.1 m/z. Example B(61): 7-({6-Cyclopentyl-4-hydroxy-6-[2-(4-methoxyphenyl)ethyl]-2-oxo-5,6- dihydro-2H-pyran-3-yl}methyl)-3-methyl-5H-[1,3]thiazolo[3,2-a]pyrimidin-5-one.
Figure imgf000313_0001
The title compound was prepared as described in Example B(53), using 7-(chloromethyl)-
3-methyl-5fV-[1,3]thiazolo[3,2-a]pyrimidin-5-one (prepared according to a reported procedure: Doria, G.; Passarotti, C; Sala, R.; Magrini, R.; Sberze, P.; Tibolla, M.; Cesarani, R.; Arcari, G.; Castello, R.; Toti, D. Farmaco Ed. Sci. 1985, 40, 885) in place of 5-(chloromethyl)-1,3-dimethyl- 1 H-1 ,2,4-triazole, and using 6-cyclopentyl-6-[2-(4-methoxyphenyl)ethyl]dihydro-2H-pyran-2,4(3/-/)- dione in place of 6-[2-(3-chloro-4-methoxyphenyl)ethyl]-6-cyclopentyldihydro-2H-pyran-2,4(3H)- dione . Yield: 17%.
'HNMR (300 MHz, DMSO-d6) δ 1.2-1.65 (m, 8H), 1.87 (m, 2H), 2.31 (m, IH), 2.48-2.53 (d, m, 3H, overlap with DMSO-d5), 2.59 (s, 3H), 2.71 (d, 7= 17.1 Hz, IH), 3.38 (ABQ pattern, 7= 15.8 Hz, 2H), 3.64 (s, 3H), 5.77 (s, IH), 6.73 (d, 7 = 8.7 Hz, 2H), 6.91 (s, IH), 6.98 (d, 7= 8.7 Hz, 2H), 10.9 (br s, IH). LC- MS (APCI) calcd for C27H3oN205S: 494.19; found (M+ET) 495.0 m z.
Example B(62): 6-[2-(5-Chloro-2,4-dimethoxyphenyl)ethyl]-6-cyclopentyl-3-[(3-ethyl-1 ,2,4- oxadiazol-5-yl)methyl]-4-hydroxy-5,6-dihydro-2H-pyran-2-one.
Figure imgf000313_0002
The title compound was prepared as described in Example B(53), using 5-(chloromethyl)- 3-ethyl-1 ,2,4-oxadiazole (Stepl, below) in place of 5-(chloromethyl)-1,3-dimethyl-1/-/-1 ,2,4- triazole, and using 6-[2-(5-chloro-2,4-dimethoxyphenyl)ethyl]-6-cyclopentyldihydro-2H-pyran- 2,4(3H)-dione in place of 6-[2-(3-chloro-4-methoxyphenyl)ethyl]-6-cyclopentyldihydro-2H-pyran- 2,4(3H)-dione. Yield: 7 %. Η NMR (300 MHz, DMSO-d6) δ 1.10 (t, 7 = 7.8 Hz, 3H), 1.25-1.73 (m, 8H), 1.89 (m, 2H), 2.33 (m, IH), 2.43-2.53 (m, 2H, overlap with DMSO-d5), 2.58 (q, m, overlap, 3H), 2.76 (d, 7= 18 Hz, IH), 3.75 (ABQ pattern, 7= 16 Hz, 2H), 3.77 (s, 3H), 3.84 (s, 3H), 6.71 (s, IH), 7.10 (s, IH), 11.31 (br s, IH). LC-MS (APCI) calcd for C25H31C1N206: 490.19; found (M+ET) 491.0 m/z.
Step 1: 5-(Chloromethyl)-3-ethyl-1,2,4-oxadiazole
Figure imgf000314_0001
To crude Λ/-hydroxypropanimidamide (80 g, 0.91 mol), obtained from propionitrile and hydroxylamine (Moloney, G. P.; Martin, G. R.; Mathews, N.; Maclennan, S.; Dodsworth, S.; Sang, P. Y.; Knight, C; Maxwell, M.; Glen, R. C. 7. Chem. Soc Perkin I 1999, 19, 2725), was added chloroacetyl chloride (411 g, 3.64 mol, 4 equiv). After the initial exothermic reaction subsided, the mixture was refluxed for 70 min. The reaction mixture was cooled to room temperature, and the excess chloroacetyl chloride evaporated. The residue was dissolved in ethyl acetate, diluted with hexanes, and filtered to remove dark solid impurities. The filtrate was evaporated, treated with ice-cold aqueous NaHC03, and extracted with ethyl acetate (2 x 150 mL). The extract was dried over Na2S04, filtered, and the solvent evaporated, affording 76.25 g of an oil. This was subjected to fractional distillation, affording 16.5 g (14%) of the title product (bp 36 °C/0.05 Torr; lit bp 88 °C/35 Torr: Hagerty, J. D. US 3,956,498, May 11, 1976). Η NMR (CDC13) d 1.31 (t, 7 = 7 Hz, 3H), 2.75 (q, 7 = 7 Hz, 2H), 4.64 (s, 2H). LC-MS (APCI) calcd for C5H7C1N20: 146.02; found (M+H÷): 147.0 m/z
Example B(63): 2-({6-[2-(5-Chloro-2,4-dimethoxyphenyl)ethyl]-6-cyclopentyl-4-hydroxy-2- oxo-5,6-dihydro-2H-pyran-3-yl}methyl)-6,7-dimethoxyquinazolin-4(3H)-one.
Figure imgf000314_0002
The title compound was prepared as described in Example B(53), using 2-(chloromethyl)- 6,7-dimethoxyquinazolin-4(3/-/)-one (Example B(57), Step 1) in place of 5-(chloromethyl)-1,3- dimethyl-1/-/-1 ,2,4-triazole, and using 6-[2-(5-chloro-2,4-dimethoxyphenyl)ethyl]-6- cyclopentyldihydro-2H-pyran-2,4(3H)-dione in place of 6-[2-(3-chloro-4-methoxyphenyl)ethyl]-6- cyclopentyldihydro-2H-pyran-2,4(3H)-dione. Yield: 20%.
Η NMR (300 MHz, DMSO-d6) δ 1.27-1.75 (m, 8H), 1.85 (m, IH), 2.05 (m, IH), 2.37 (m, IH), 2.50 (m, 2H, overlap with DMSO-d5), 2.53 (d, 7 = 18 Hz, IH), 2.69 (d, 7 = 18 Hz, IH), 3.59 (m, 2H, overlap with H20), 3.62 (s, 3H, overlap with H20), 3.67 (s, 3H, overlap with H20), 3.81 (s, 3H, overlap with H20), 3.84 (s, 3H, overlap with H20), 6.61 (s, IH), 6.63 (s, IH), 7.13 (s, IH), 7.39 (s, IH). LC-MS (APCI) calcd for C31H35C1N208: 598.21; found (M+H+) 599.1 m/z.
Example B(64): 2-({6-[2-(5-Chloro-2,4-dimethoxyphenyl)ethyl]-6-cyclopentyl-4-hydroxy-2- oxo-5,6-dihydro-2H-pyran-3-yl}methyl)thieno[3,2-d pyrimidin-4(3H)-one.
Figure imgf000315_0001
The title compound was prepared as described in Example B(53), using 2- (chloromethyl)thieno[3,2-d]-pyrimidine-4(3H)-one (Example B(56), Step 1) in place of 5- (chloromethyl)-l ,3-dimethyl-1 HA ,2,4-triazole, and using 6-[2-(5-chloro-2,4- dimethoxyphenyi)ethyl]-6-cyclopentyldihydro-2H-pyran-2,4(3H)-dione in place of 6-[2-(3-chloro-4- methoxyphenyl)ethyl]-6-cyclopentyldihydro-2H-pyran-2,4(3H)-dione. Yield: 20%. Η NMR (300 MHz, DMSO-d6) δ 1.24-1.67 (m, 8H), 1.90 (m, IH), 2.04 (m, IH), 2.32 (m, IH), 2.40-2.54 (m, 3H, overlap with DMSO-d5), 2.71 (d, 7 = 18 Hz, IH), 3.52 (ABQ pattern, 7 = 15 Hz, 2H, overlap with H20), 3.69 (s, 3H), 3.80 (s, 3H), 6.65 (s, IH), 6.71 (d, 7 = 5.4 Hz, IH), 7.05 (s, IH), 7.96 (d, 7 = 5.4 Hz,
IH), 10.88 (br s, IH), 12.26 (br s, IH). LC-MS (APCI) calcd for C27H29C1N206S: 544.14; found (M+H+) 544.9 m/z.
Example B(65): 2-({6-[2-(5-Chloro-2,4-dimethoxyphenyl)ethyl]-6-cyclopentyl-4-hydroxy-2- oxo-5,6-dihydro-2W-pyran-3-yl}methyl)quinazolin-4(3H)-one.
Figure imgf000316_0001
The title compound was prepared as described in Example B(53), using 2- (bromomethyl)-quinazolin-4(3/-/)-one (Example B(55), Step 1) in place of 5-(chloromethyl)-1,3- dimethyl-1H-1 ,2,4-triazole, and using 6-[2-(5-chloro-2,4-dimethoxyphenyI)ethyl]-6- cyclopentyldihydro-2H-pyran-2,4(3H)-dione in place of 6-[2-(3-chloro-4-methoxyphenyl)ethyl]-6- cyclopentyldihydro-2H-pyran-2,4(3H)-dione. Yield: 19%.
Η NMR (300 MHz, DMSO-d6) δ 1.33-1.74 (m, 8H), 1.99 (m, IH), 2.23 (m, IH), 2.37 (m, IH), 2.45-2.53 (m, 2H, overlap with DMSO-d5), 2.58 (d, 7= 17.5 Hz, IH), 2.78 (d, 7 = 17.5 Hz, IH), 3.59 (ABQ pattern, 7 = 16.6 Hz, 2H), 3.73 (s, 3H), 3.84 (s, 3H), 6.69 (s, IH), 7.01 (d, 7= 8 Hz, IH), 7.13 (s, IH), 7.42 (t, 7= 8 Hz, IH), 7.57 (t, 7 = 8 Hz, IH), 8.03 (d, 7 = 8 Hz, IH). LC-MS (APCI) calcd for C29H31C1N206: 538.19; found (M+H4) 539.0 m/z.
Example B(66): 6-({6-Cyclopentyl-4-hydroxy-6-[2-(4-methoxyphenyl)ethyl]-2-oxo-5,6- dihydro-2H-pyran-3-yl}methyl)-2-pyridin-2-ylpyrimidin-4(3H)-one.
Figure imgf000316_0002
The title compound was prepared as described in Example B(53), using 6-(chloromethyl)- 2-pyridin-2-ylpyrimidin-4(3/-/)-one in place of 5-(chloromethyl)-1 ,3-dimethyl-1 H-1 ,2,4-triazole, and using 6-cyclopentyl-6-[2-(4-methoxyphenyl)ethyl]dihydro-2H-pyran-2,4(3H)-dione in place of 6-[2- (3-chloro-4-methoxyphenyl)ethyl]-6-cyclopentyldihydro-2H-pyran-2,4(3H)-dione . Yield: 11%. Η NMR (300 MHz, DMSO-d6) δ 1.32-1.67 (m, 8H), 1.92 (m, 2H), 2.38 (m, IH), 2.45-2.52 (m, 2H, overlap with DMSO-d5), 2.60 (d, 7= 17.7 Hz, IH), 2.80 (d, 7= 17.7 Hz, IH), 3.52 (m, 2H, overlap with H20), 3.66 (s, 3H, overlap with H20), 6.07 (s, 3H), 6.68 (d, 7= 8.4 Hz, 2H), 6.95 (d, 7= 8.4 Hz, 2H), 7.60 (dd, 7 = 7.5, 4.8 Hz, IH), 7.93 (td, 7= 8 Hz, 1.5 Hz, IH), 8.18 (d, 7= 8 Hz, IH), 8.70 (d, 7= 4.8 Hz, IH), 10.98 (br s, IH). LC-MS (APCI) calcd for C29H3ιN3θ5: 501.23; found (M+H4) 502.1 m/z.
Example B(67): 6-[(6-{2-[4-(Benzyloxy)phenyl]ethyl}-6-cyclopentyl-4-hydroxy-2-oxo-5,6- dihydro-2W-pyran-3-yl)methyl]-2-cyclopropylpyrimidin-4(3f/)-one.
Figure imgf000317_0001
The title compound was prepared as described in Example B(53), using 6-(chloromethyl)- 2-cyclopropylpyrimidin-4(3f/)-one in place of 5-(chIoromethyl)-1,3-dimethyl-1H-1,2,4-triazole , and using 6-{2-[4-(benzyloxy)phenyl]ethyl}-6-cyclopentyldihydro-2H-pyran-2,4-(3H)-dione (Step 6, below) in place of 6-[2-(3-chloro-4-methoxyphenyl)ethyl]-6-cyclopentyIdihydro-2H-pyran-2,4(3H)- dione . Yield: 12%.
Η NMR (300 MHz, DMSO-d6) δ 0.91 (m, 4H), 1.15-1.65 (m, 8H), 1.82-1.92 (m, 3H), 2.34 (m, IH), 2.38- 2.58 (m, 3H, overlap with DMSO-d5), 2.75 (d, 7= 18 Hz, IH), 3.29 (ABQ pattern, 7 = 16.7 Hz, 2H), 5.05 (s, 2H), 5.72 (s, IH), 6.90 (d, 7 = 8.4 Hz, 2H), 7.05 (d, 7 = 8.4 Hz, 2H), 7.43-7.28 (m, 5H). LC-MS (APCI) calcd for C33H36N205: 540.26; found (M+H+) 541.1 m z.
Step 1: 3-(4-Hydroxyphenyl)propionic acid methyl ester.
Figure imgf000317_0002
A solution of HCl in dioxane (4.0 M, 7.4 mL) was added to a solution of 4- hydroxyphenylpropionic acid (15.0 g, 90.3 mmol) in MeOH (500 mL). The reaction mixture was stirred overnight and then evaporated. The residue was evaporated from benzene (2 x 50 mL) to provide the product as an oil, which was used without further purification.
Step 2: 3-(4-Benzyloxyphenyl)propionic acid methyl ester.
Figure imgf000318_0001
Benzyl bromide (12.9 mL, 108 mmol), K2C03 (15.0 g, 109 mmol) and the 3-(4- hydroxyphenyl)propionic acid methyl ester from Step 1 above were combined in acetone (300 mL) and refluxed 40 h. The crude reaction mixture was filtered and the cake washed with acetone (2 x 100 mL). The filtrate was evaporated and the residue was triturated with MeOH (50 mL, 6 mL, 4 mL) to provide the product as a solid which was used without further purification.
Step 3: 3-(4-Benzyloxyphenyl)propionic acid:
Figure imgf000318_0002
An aqueous solution of NaOH (1 M, 270 mL) was added to a mixture of the 3-(4- benzyloxyphenyl)propionic acid methyl ester from Step 2 above in MeOH (600 mL) and the reaction was stirred overnight. The crystalline ppt was collected by filtration, air dried and then partitioned between EtOAc/Et20/1 M HCl (500 mL, 250 mL, 150 mL). The organic phases were dried over MgS04 and evaporated to give the product as a white solid (16.2 g, 70%, 3 Steps).
!H NMR (CDC13) δ 2.61-2.68 (m, 2H), 2.86-2.93 (m, 2H), 5.03 (s, 2H), 6.88-6.93 (m, 2H), 7.10-7.15 (m, 2H), 7.28-7.45 (m, 5H).
Step 4: 3-(4-Benzyloxyphenyl)thiopropionic acid S-pyridin-2-yl ester.
Figure imgf000318_0003
3-(4-BenzyloxyphenyI)propionic acid (5.40 g, 21.1 mmol) from Step 3 above, triphenylphosphine (7.18 g, 27.4 mmol) and 2,2'-dipyridyl disulfide (5.80 g, 26.3 mmol) were combined successively in CH2CI2 (24 mL). The reaction mixture was stirred 1 h and then loaded directly onto a column for purification by flash chromatography (33% EtOAc in hexanes) to give a residue. This residue was washed with hexanes (20 mL) and the solid, partially crystalline material was collected by filtration and air dried to give the product (7.11 g, 97%). lU NMR (CDC13) δ 2.98 (s, 4H), 5.04 (s, 2H), 6.88-6.94 (m, 2H), 7.10-7.16 (m, 2H), 7.25-7.45 (m, 6H), 7.57-7.60 (m, IH), 7.70-7.77 (m, IH), 8.60-8.64 (m, IH).
Step 5: 3-(4-Benzyloxyphenyl)-1-cyclopentylpropan-1-one.
Figure imgf000319_0001
3-(4-Benzyloxyphenyl)thiopropionic acid S-pyridin-2-yl ester (3.00 g, 8.58 mmol) from Step 4 above was dissolved in dry THF (45 mL) and cooled to -78 °C. A solution of cyclopentylmagnesium bromide in Et20 (2.0 M, 4.51 mL, 9.02 mmol) was added dropwise along the sides of the reaction vessel. After stirring 35 min, the cooling bath was removed. The reaction mixture was quenched with saturated aq. NH CI upon reaching ambient temperature and extracted with Et20 (500 mL). The organic phase was washed with brine (50 mL), dried over MgS0 and evaporated. The residue was purified by flash column chromatography (10% EtOAc in hexanes) to give the product (2.22 g, 84%) as a white semi-crystalline material. lR NMR (CDCI3) δ 1.48-1.83 (m, 8H), 2.69-2.77 (m, 2H), 2.79-2.88 (m, 3H), 5.03 (s, 2H), 6.86-6.92 (m, 2H), 7.07-7.12 (m, 2H), 7.28-7.45 (m, 5H).
Step 6: 6-[2-(4-Benzyloxyphenyl)ethyl]-6-cyclopentyldihydropyran-2,4-dione.
Figure imgf000319_0002
Methylacetoacetate (1.63 mL, 15.1 mmol) was dissolved in dry THF (42 mL) and cooled to 0 °C. NaH (60% in mineral oil, 0.604 g, 15.1 mmol) were carefully added and the reaction mixture was stirred for 20 min. A solution of BuLi in hexanes (1.6 M, 9.44 mL, 15.1 mmol) was added dropwise and the resulting mixture was stirred an additional 20 min. A solution of 3-(4- benzyloxyphenyl)-1-cyclopentylpropan-1-one (2.33 g, 7.55 mmol) from Step 5 above in THF (37 mL) was added dropwise. After stirring 1 h, the reaction mixture was quenched with saturated aq NH CI (100 mL) and extracted with Et20 (600 mL). The organic phase was dried over MgS0 and evaporated. The residue was then stirred overnight in a mixture of 0.1 M NaOH (370 mL) and THF (37 mL). After the addition of an aq solution of 10% aq KHS04 (50 mL) the resulting mixture was stirred 30 min and then extracted with Et20 (600 mL). The organic phase was washed with brine, dried over MgS04 and evaporated. The residue was purified by flash column chromatography (50% EtOAc in hexanes) to give the product (1.54 g, 52%) as a white foam. H NMR (CDC13) δ 1.39-2.04 (m, 10H), 2.21-2.33 (m, IH), 2.56-2.67 (m, 2H), 2.76 (s, 2H), 3.41 (s, 2H), 5.03 (s, 2H), 6.87-6.93 (m, 2H), 7.02-7.08 (m, 2H), 7.28-7.44 (m, 5H).
Example B(68): 2-({6-[2-(5-Chloro-2,4-dimethoxyphenyl)ethyl]-6-cyclopentyl-4-hydroxy-2- oxo-5,6-dihydro-2W-pyran-3-yl}methyl)-6-methylpyrimidin-4(3H)-one.
Figure imgf000320_0001
The title compound was prepared as described in Example B(53), using 2-(chIoromethyl)- 6-methylpyrimidin-4(3/-/)-one (Example B(54), Step 1) in place of 5-(chloromethyl)-1,3-dimethyl- 1 H-1 ,2,4-triazole, and using 6-[2-(5-chloro-2,4-dimethoxyphenyl)ethyl]-6-cyclopentyldihydro-2H- pyran-2,4(3H)-dione in place of 6-[2-(3-chloro-4-methoxyphenyl)ethyl]-6-cyclopentyldihydro-2H- pyran-2,4(3H)-dione. Yield: 19%.
Η NMR (300 MHz, DMSO-dβ) δ 1.25-1.75 (m, 8H), 1.87 (s, m overlap, 4H), 2.05 (m, IH), 2.36 (m, IH), 2.43-2.50 (m, 2H, overlap with DMSO-d5), 2.56 (d, 7 = 17.5 Hz, IH), 2.67 (d, 7 = 17.5 Hz, IH), 3.48 (m, 2H, overlap with H20), 3.77 (s, 3H), 3.84 (s, 3H), 5.98 (s, IH), 6.71 (s, IH), 7.09 (s, IH). LC-MS (APCI) calcd for C26H31C1N206: 502.19; found (M+H+) 503.0 m/z.
Example B(69): 6-Cyclopentyl-6-{2-[4-(difluoromethyl)-3-fluorophenyl]ethyl}-3-[(1,3- dimethyl-1H-1,2,4-triazol-5-yl)methyl]-4-hydroxy-5,6-dihydro-2H-pyran-2-one.
Figure imgf000321_0001
The title compound was prepared as described in Example B(53), using 6-cyclopentyl-6- {2-[4-(difluoromethyl)-3-fluorophenyl]ethyl}-dihydro-2H-pyran-2,4(3H)-dione (Step 3, below) in place of 6-[2-(3-chloro-4-methoxyphenyl)ethyl]-6-cyclopentyldihydro-2H-pyran-2,4(3H)-dione. Yield: 12%.
Η NMR (300 MHz, DMSO-dδ) δ 1.18-1.68 (m, 8H), 2.04 (m, 2H), 2.13 (s, 3H), 2.34 (m, IH), 2.40-2.63 (m, 3H, overlap with DMSO-d5), 2.71 (d, 7 = 17.4 Hz, IH), 3.48 (m, 2H, overlap with H20), 3.76 (s, 3H), 7.15 (t, 7= 55 Hz, IH), 7.18 (m, 2H), 7.52 (t, 7 = 7.8 Hz, IH). LC-MS (APCI) calcd for C24H28F3N3θ3: 463.21; found (M+H+): 464.1 m/z.
Step 1. 4-Bromo-1-(difluoromethyl)-2-fluorobenzene
Figure imgf000321_0002
A solution of 2-fluoro-4-bromobenzaldehyde (50 g, 0.245 mol) in CH2CI2 (500 mL) was treated with a solution of DAST (44 g, 0.271 mol, 1.1 equiv) in CH2CI2 (200 mL) dropwise at such a rate that the internal temperature was maintained below 35 °C. The reaction temperature was also controlled using an ice/water bath. Once the addition was completed, the reaction was stirred at room temperature for 14 h. The reaction mixture was poured over crushed ice and neutralized with NaHC03. The organic layer was separated, the aqueous layer extracted with CH2CI2, and the combined extracts dried over Na2S0 and concentrated. The residue was purified by fractional distillation to give 44g (80%) of desired product (bp 43 °C7 1 Torr). Η NMR (DMSO-dd) d 7.10 (t, IH, 7 = 54 Hz), 7.46 (m, 3H). MS(APCI) calcd for CvHftBr, 225.06; found [M-19(-F)]: 206 m/z.
Step 2. 1-Cyclopentyl-3-[4-(difluoromethyl)-3-fluorophenyl]propan-1-one..
Figure imgf000322_0001
A mixture of 1-cyclopentyl-2-propen-1-ol (34 g, 0.266 mol), 2-fluoro-4-bromo- difluoromethyl benzene,(40 g, 0.177 mol, 1.5 equiv), and NaHC03 (17.8 g, 0.212 mol, 1.2 equiv) in anhydrous NMP (200 mL) was heated to 140 °C for 1 h, resulting in complete conversion by TLC. The reaction mixture was poured into water and extracted with CH2CI2. The organic layer was separated, washed with brine and dried over anhydrous Na2S04. After the removal of the solvent, the residue was purified by column chromatography using hexanes/ethyl acetate, and the product-containing fractions combined and concentrated. The residue was fractionally distilled through a Vigreux column to give 16 g (33%) of the desired product (bp 100 °C/0.2 Torr). 1H NMR (CDCI3) d 1.57 (m, 8H), 2.81 (m, 4H), 3.09 (m, 1 H), 6.86 (t, 1H, 7 = 57 Hz), 6.95 (m, 2H), 7.51 (t, 1H, 7= 7.5 Hz). MS (APCI) calcd for C15H17F30, 270.29; found [M-19(-F)]: 251.02 m/z.
Step 3. 6-Cyclopentyl-6-{2-[4-(difluoromethyl)-3-fluorophenyl]ethyl}-dihydro-2 -pyran- 2,4(3W)-dione.
Figure imgf000322_0002
The title compound was prepared as described in Step 4 of Example B(58), using 1- cyclopentyl-3-[4-(difluoromethyl)-3-fluorophenyl]propan-1-one (Step 2, above) in place of 3-[3- chioro-4-(cyclopropylmethoxy)phenyl]-1-cyclopentylpropan-1-one, with the exception that the intermediate hydroxyester was not purified. The crude product, a viscous yellow oil, was dissolved in a minimal amount of ethyl ether, diluted with hexanes and cooled, affording 4 g (16%) of the product as a white solid. Η NMR (CDC13) d 1.66 (m, 8H), 1.94 (t, 2H), 2.26 (m, IH), 2.75 (m, 4H), 3.42 (s, 2H), 6.67-7.04 (m, 3H,), 7.5 (t, IH, 7 = 7.5). MS calcd for Cι9H2ιF303: 354.363; found [M-19(-F)]: 335.2 m/z. Example B(70): 6-{2-[3-Chloro-4-(cyclopropylmethoxy)phenyl]ethyl}-6-cyclopentyl-3-[(1.3- dimethyl-1W-1,2,4-triazol-5-yl)methyl]-4-hydroxy-5,6-dihydro-2W-pyran-2-one.
Figure imgf000323_0001
The title compound was prepared as described in Example B(53), using 6-{-[3-chloro-4- (cyclopropylmethoxy)phenyl]ethyl}-6-cyclopentyldihydro-2H-pyran-2,4(3H)-dione (Example B(58), Step 4) in place of 6-[2-(3-chloro-4-methoxyphenyl)ethyl]-6-cyclopentyldihydro-2H-pyran-2,4(3H)- dione . Yield: 9%.
Η NMR (300 MHz, DMSO-d6) δ 0.26 (m, 2H), 0.50 (m, 2H), 1.13-1.65 (m, 9H), 1.92 (m, 2H), 2.08 (s, 3H), 2.29 (m, IH), 2.35-2.50 (m, 3H, overlap with DMSO-d5), 2.69 (d, 7= 17.7 Hz, IH), 3.57 (ABQ pattern, 7= 15.6 Hz, 2H, overlap with H20 peak), 3.69 (s, 3H, overlap with H20 peak), 3.80 (d, 7= 6.9 Hz, 2H), 6.93 (d, 7= 8.4 Hz, IH), 7.00 (dd, 7= 8.4 Hz, 1.9 Hz, IH), 7.16 (d, 7= 1.9 Hz, IH). LC-MS (APCI) calcd for C27H34C1N304: 499.22; found (M+H ): 500.1 m/z.
Example B(71): 6-[2-(5-Chloro-2,4-dimethoxyphenyl)ethyl]-6-cyclopentyl-3-[(1,3-dimethyl- 1W-1,2,4-triazol-5-yl)methyl]-4-hydroxy-5,6-dihydro-2tø-pyran-2-one.
Figure imgf000323_0002
The title compound was prepared as described in Example B(53), using 6-[2-(5-chloro- 2,4-dimethoxyphenyl)ethyl]-6-cyclopentyldihydro-2H-pyran-2,4(3H)-dione in place of 6-[2-(3- chloro-4-methoxyphenyl)ethyl]-6-cyclopentyldihydro-2H-pyran-2,4(3H)-dione . Yield: 14%. Η NMR (300 MHz, DMSO-d6) δ 1.2-1.7 (m, 8H), 1.87 (m, 2H), 2.19 (s, 3H), 2.32 (m, IH), 2.35-2.52 (m, 2H, overlap with DMSO-d5), 2.56 (d, 7= 17.7 Hz, IH), 2.76 (d, 7= 17.7 Hz, IH), 3.68 (s, 2H), 3.78 (s, 6H), 3.85 (s, 3H), 6.71 (s, IH), 7.11 (s, IH). LC-MS (APCI) calcd for CAClNaOj: 489.20; found (M+H ): 490.1 m/z. Example B(72): Methyl 5-[(6-cyclopentyl-6-{2-[4-(difluoromethyl)-3-fluorophenyl]ethyl}-4- hydroxy-2-oxo-5,6-dihydro-2H-pyran-3-yl)methyl]isoxazol-3-ylcarbamate
Figure imgf000324_0001
The title compound was prepared as described in Example B(53), using methyl 5- (bromomethyl)isoxazol-3-ylcarbamate (prepared as described: Sircar, J. C; Capiris, T. US 4,489,077, Dec 18, 1984) in place of 5-(chloromethyl)-1,3-dimethyl-1/-/-1 ,2,4-triazole, and using 6- cyclopentyl-6-{2-[4-(difluoromethyl)-3-fluorophenyl]ethyl}-dihydro-2/-/-pyran-2,4(3/-/)- dione(Example B(69), Step 3) in place of 6-[2-(3-chloro-4-methoxyphenyi)ethyl]-6- cyclopentyldihydro-2H-pyran-2,4(3H)-dione . Yield: 6%.
Η NMR (300 MHz, DMSO-d6) δ 1.18-1.75 (m, 8H), 1.94 (m, 2H), 2.35 (m, IH), 2.40-2.70 (m, 3H, overlap with DMSO-d5), 2.76 (d, 7= 18.3 Hz, IH), 3.59 (m, 2H, overlap with H20), 3.63 (s, 3H), 6.31 (s, IH), 7.08 (t, 7 = 55 Hz, overlap with m, combined: 3H), 7.50 (t, 7 = 7.5 Hz, IH), 10.55 (s, IH), 11.26 (s, IH). LC-MS (APCI) calcd for C25H27F3N206: 508.18; found (M+H+): 509.1 m z.
Example B(73): 6-[2-(5-Chloro-2,4-dimethoxyphenyl)ethyl]-6-cyclopentyl-4-hydroxy-3-[(3- pyridin-2-yl-1,2,4-oxadiazol-5-yl)methyl]-5,6-dihydro-2H-pyran-2-one.
Figure imgf000324_0002
The title compound was prepared as described in Example B(53), using 2-[5- (chloromethyl)-1,2,4-oxadiazol-3-yl]pyridine (from Step 1, below) in place of 5-(chloromethyl)-1, 3- dimethyl-1 H-1 ,2,4-triazole, and using 6-[2-(5-chloro-2,4-dimethoxyphenyl)ethyl]-6- cyclopentyldihydro-2H-pyran-2,4(3H)-dione in place of 6-[2-(3-chloro-4-methoxyphenyl)ethyl]-6- cyclopentyldihydro-2H-pyran-2,4(3H)-dione. Yield: 9%. Η NMR (300 MHz, DMSO-d6) δ 1.25-1.75 (m, 8H), 1.76-2.03 (m, 2H), 2.34 (m, IH), 2.4-2.55 (m, 2H, overlap with DMSO-d5), 2.62 (d, 7 = 17.7 Hz, IH), 2.81 (d, 7 = 17.7 Hz, IH), 3.74 (s, 3H, overlap with H20), 3.80 (s, 3H), 3.90 (ABQ pattern, 7= 16.8 Hz, 2H), 6.66 (s, IH), 7.13 (s, IH), 7.55 (m, IH), 7.81 (m, 2H), 8.70 (d, 7 = 4.8 Hz, IH), 11.43 (br s, IH). LC-MS (APCI) calcd for C^oClNaOc: 539.18; found (M+H+): 540.1 m/z.
Step 1: 2-[5-(Chloromethyl)-1,2,4-oxadiazol-3-yl]pyridine
Figure imgf000325_0001
The title compound was prepared by a modification of a reported method: a) Mylari, B. L;
Beyer, T. A.; Scott, P. J.; Aldinger, C. E.; Dee, M. F.; Siegel, T. W.; Zembrowski, W. J. J. Med. Chem. 1992, 35, 457, and b) Palazzo, G.; Tavella, M.; Strani, G.; Silvestrini, B.; J. Med. Pharm. Chem. 1961, 4, 351. To a suspension of /V-hydroxypyridine-2-carboximidamide (25.0 g, 0.182 mol) in chloroform (350 mL) was added chloroacetyl chloride (20.5 g, 0.182 mol, 1 equiv) and triethylamine (20.23 g, 0.2 mol, 1.1 equiv). When most of the triethylamine had been added, the suspension turned to a clear light-yellow solution. The solution was allowed to stand at room temperature for 1 d. The mixture was extracted with water (3 x 75 mL), resulting in the precipitation of a crystalline solid. The resulting slurry was filtered, and filter cake triturated with ethanol, re-filtered, and dried, affording 29.62 g (73%) of the O-chloracetyl amidoxime intermediate. This intermediate was refluxed in xylenes (300 mL) for 3 h, and the volatiles removed completely in vacuo, affording 25.55 g (72% overall) of the pure 1,2,4-oxadiazole. 1H NMR (DMSO-d6) D 5.20 (s, 2H), 7.62 (m, 1H), 8.06 (m, 2H), 8.76 (m, 1H). LC-MS (APCI) calcd for C8H6CIN30: 195.02; found (M+H+): 196.0 m/z.
Example B(74): 6-{2-[3-Chloro-4-(difluoromethoxy)phenyl]ethyl}-6-cyclopentyl-3-[(1,3- dimethyl-1H-1,2,4-triazol-5-yl)methyl]-4-hydroxy-5,6-dihydro-2W-pyran-2-one.
Figure imgf000325_0002
The title compound was prepared as described in Example B(53), using 6-{2-[3-chIoro-4- (difluoromethoxy)phenyl]ethyl}-6-cyclopentadihydro-2H-pyran-2,4(3H)-dione (from Step 2, below) in place of 6-[2-(3-chloro-4-methoxyphenyl)ethyl]-6-cyclopentyldihydro-2H-pyran-2,4(3H)-dione. Yield: 1%. Η NMR (300 MHz, DMSO-d6) δ 1.22-1.75 (m, 8H), 2.03 (m, 2H), 2.11 (s, 3H), 2.35 (m, IH), 2.45-2.60 (m, 3H, overlap with DMSO-d5), 2.75 (d, 7= 18.3 Hz, IH), 3.61 (m, 2H, overlap with H20), 3.74 (s, 3H), 7.24 (t, 7 = 73 Hz, overlap with m, combined: 3H), 7.42 (m, IH). LC-MS (APCI) calcd for CAClFzNaO^ 495.17; found (M+H÷): 496.1 m/z.
Step 1: 3-[3-Chloro-4-(difluoromethoxy)phenyl]-1-cyclopentylpropan-1-one.
Figure imgf000326_0001
A mixture of 3-(3-chloro-4-hydroxyphenyl)-1-cyclopentylpropan-1-one (15 g, 59.35 mmol, Example B(58), Step 2)), methyl 2-chloro-2,2-difluoroacetate (17.15 g, 118.7 mmol, 2 equiv) and K2C03 (12.4 g, 124.6 mmol, 2.1 equiv) in dry DMF (150 mL) was stirred at 75-80 °C for 2 h. The mixture was poured into water and extracted with ethyl acetate. The organic layer was washed with aqueous 1 M NaOH and brine. The organic phase was dried over Na2S04, filtered, and concentrated in vacuo. The residue was subjected to fractional distillation affording 15.3 g (72 %) of material that was about 80% pure by 1H NMR (bp 70 °C/2 Torr). 'HNMR (CDC13) δ 1.63 (m, 9H), 2.84 (m, 5H), 6.49 (t, 1 H, 7=72), 7.11 (m, 2H), 7.27 (s,lH). MS calcd for Cι5H17F202Cl, 302.744; found [M-19(-F)]: 283.7 m z.
Step 2: 6-{2-[3-Chloro-4-(difluoromethoxy)phenyl]ethyl}-6-cyclopentadihydro-2H-pyran- 2,4(3H)-dione.
Figure imgf000326_0002
The title compound was prepared as described in Example B(58), Step 4, using 3-[3- Chloro-4-(difluoromethoxy)phenyl]-1-cyclopentylpropan-1-one in place of 3-[3-chloro-4- (cyclopropylmethoxy)phenyI]-1-cyclopentylpropan-1-one, with the exception that the intermediate hydroxy ester was not purified. The residue obtained from the cyclization Step was purified by reverse phase column chromatography (C18 stationary phase using acetonitrile/water/methanol mixture in a polarity gradient). After concentration in vacuo, the residual oil was dissolved in a minimal amount of ethyl ether, and diluted with hexanes. Upon cooling, a white solid was obtained. Yield 891 mg (5% overall).
'H MR (CDC13) δ 1.62(m, 8H), 1.95 (m, 2H), 2.26 (m, 1 H), 2.75 (m, 4H), 3.42 (s, 2H), 6.84 (m, 3H,), 7.5 (t, 1 H, 7= 7.5). MS calcd for Cι9H2ιClF204: 386.0; found (M-1): 385.0 m/z
Example B(75): 2-(4-{2-[2-Cyclopentyl-5-(5,7-dimethyl-[1 ,2,4]triazolo[1 ,5-a]pyrimidin-2- ylmethyl)-4-hydroxy-6-oxo-3,6-dihydro-2H-pyran-2-yl]-ethyl}-2-fluoro-phenyl)-2-methyl- propionitrile
Figure imgf000327_0001
To a solution of 2-{4-[2-(2-cyclopentyl-4,6-dioxo-tetrahydro-pyran-2-yl)-ethyl]-2-fluoro- phenyl}-2-methyl-propionitrile (0.40 g, 1.1 mmol) from example A(81), in MeOH (7 mL) was added 5,7-dimethyl-[1,2,4]triazolo[1 ,5-a]pyrimidine-2-carbaldehyde (0.19 g, 1.08 mmol, described in Step 3 of example B(75)) from Step 3 below and borane-dimethylamine complex (76 mg, 1.3 mmol) and stirred at room temperature for 3 hours. The reaction was quenched with 10 mL saturated NH CI and 5 mL water. To this was added 20 mL CH2CI2 and the pH of the aqueous phase was adjusted to 3. The layers were separated, and the aqueous layer was extracted with 3 x 30 mL 10% MeOH in CH2CI2. The organic layers were combined, and dried over Na2S04. After filtering off the solids, the liquid was concentrated by rotary evaporation to an oil. The oil was flash chromatographed, and the resulting product was further purified by preparatory HPLC. Yield: 28 mg, 5%.
MS (ESI): 530 (M-H).
Step 1 : (5-Amino-1 H-[1 ,2,4]triazol-3-yl)-methanol
Figure imgf000328_0001
A solution of glycolic acid (70 % in water, 70 mL, 805 mmol) was added to aminoguanidine bicarbonate (55.12 g, 405 mmol) carefully. After foaming subsided, concentrated nitric acid (0.5 mL) was added and the entire reaction was refluxed for 40 hours. The reaction was cooled to 5 °C for 30 minutes, and the solids were filtered. The solids were then triturated with EtOH for 1 hour. The product was then filtered and dried under nitrogen (40.36 g, 52% yield).
MS (ESI): 115 (M+H).
Step 2: (5,7-Dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)-methanol
Figure imgf000328_0002
To a slurry of (5-amino-1H-[1,2,4]triazol-3-yl)-methanol (9.5 g, 50 mmol) from Step 1 above in acetic acid (200 mL) was added 2,4-pentanedione (5.13 mL, 50 mmol). The mixture was heated to reflux for 4 hours, and then cooled to room temperature. The product was isolated by removing the solvent by rotary evaporation (8.5 g, 95% yield).
MS (ESI): 179 (M+H).
Step 3: 5,7-Dimethyl-[1 ,2,4]triazolo[1 ,5-a]pyrimidine-2-carbaldehyde
Figure imgf000329_0001
A slurry of 5,7-Dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)-methanol (0.3 g, 1.7 mmol) from Step 2 above and IBX (1.4 g, 5.0 mmol) in 1 ,2-dichloroethane (22 mL) was stirred at 80 °C for 18 hours. The reaction was cooled to room temperature, and diluted with 100 mL CH2CI2. After the solids were removed by filtration, the solvent was removed by rotary evaporation to give a yellow solid. The solid was purified by flash chromatography to give the desired product (229 mg, 77% yield).
1H NMR (CDCI3) δ: 2.72 (s, 3H), 2.86 (s, 3H), 6.96 (s, 1H), 10.24 (s, 1 H).
Example B(76): l^^-p-Cyclopentyl-δ^δ -dimethyl-π^^ltriazoloIljS-alpyrimidin^- ylmethyl)-4-hydroxy-6-oxo-3,6-dihydro-2H-pyran-2-yl]-ethyl}-2-fluoro-phenyl)- cyclopropanecarbonitrile
Figure imgf000330_0001
The desired product was prepared analogously to example B(75), substituting 1-{4-[2-(2- Cyclopentyl-4,6-dioxo-tetrahydro-pyran-2-yl)-ethyl]-2-fluoro-phenyl}-cyclopropanecarbonitrile (0.24 g, 0.65 mmol) from Example A(86), in place of 2-{4-[2-(2-cyclopentyl-4,6-dioxo-tetrahydro- pyran-2-yl)-ethyl]-2-fluoro-phenyl}-2-methyl-propionitrile. Yield: 64 mg, 19%.
1H NMR (CDCI3) δ: 1.25 - 1.30 (m, 2H), 1.42 - 1.68 (m, 10H), 1.88 - 1.93 (m, 2H), 2.30 (p, 7 = 8.59 Hz, 1H), 2.44 - 2.73 (m, 10H), 4.05 (d, 7 = 3.03 Hz, 2H), 6.76 - 6.84 (m, 3H), 7.09 - 7.22 (m, 1H).
Example B(77): 3-benzyl-6-cyclopentyl-6-[2-(4-methoxyphenyl)ethyI]dihydro-2H-pyran- 2,4(3H)-dione.
Figure imgf000330_0002
DBU (28.6ul, 0.191mmol) was added to a solution of 6-cyclopentyl-6-[2-(4- methoxyphenyl)ethyl]dihydro-2H-pyran-2,4(3H)-dione (55mg, 0.174mmol, described below) in benzene (1.9ml), under an atmosphere of argon. Benzyl bromide (21 ul, 0.174mmol) was then added. The reaction mixture was stirred at room temperature for 20 minutes, followed by the addition of 5 crystals of sodium iodide. The reaction mixture was stirred for a further 24hrs, after which time the mixture was filtered through a plug of Celite. The filtrate was concentrated in vacuo and the residue purified by prep HPLC to afford the title compound as a white solid
(9.0mg).
'HNMR (CDC13): δ 1.43-1.80 (bm, 8H), 2.20 (m, 2H), 2.24 (m, IH), 2.72 (m, 2H), 3.06 (m, 3H), 3.30 (m,
IH), 3.76 (m, 4H), 6.72 (d, 7= 8.64 Hz, 2H), 6.78 (d, 7= 8.64 Hz, 2H), 6.94 (m, 3H), 7.23 (m, 2H). Exact
Mass: Calcd, 406.51; Found, 406.21.
Step 1: 6-cyclopentyl-6-[2-(4-methoxyphenyl)ethyl]dihydro-2r/-pyran-2,4(3H)-dione.
Figure imgf000331_0001
This compound was prepared analogously to Example A(82), where 4-Bromo-1-methoxy- benzene was substituted in place of 2-Bromopyridine in Step 1 of that example.
Example B(78): 3-benzyl-6-[2-(3-chloro-4-methoxyphenyl) ethyl] -6-cyclopentyldihydro-2H- pyran-2,4(3H)-dione.
Figure imgf000331_0002
DBU (28.6ul, 0.191 mmol) was added to a solution of 6-[2-(3-chloro-4- methoxyphenyl)ethyl]-6-cyclopentyldihydro-2H-pyran-2,4(3H)-dione (60.6mg, 0.172mmol) in benzene (2.0 ml), under an atmosphere of argon. Benzyl bromide (20.5ul, 0.172mmol) was then added. The reaction mixture was stirred at room temperature for 20 minutes, followed by the addition of 5 crystals of sodium iodide. The reaction mixture was stirred for a further 24hrs, after which time the mixture was filtered through a plug of Celite. The filtrate was concentrated in vacuo and the residue purified by prep HPLC to afford the title compound as a white solid
(11.1mg).
Η NMR (CDC13): δ 1.40-1.90 (bm, 8H), 2.21 (m, 3H), 2.74 (m, 2H), 3.01 (t37= 3.10Hz, IH), 3.10 (t, 7=
3.10Hz, IH), 3.72 (d, 7= 2.07 Hz, IH), 3.89 (s, 3H), 6.91 (d, 7= 2.24 Hz, IH), 7.17 (m, 3H), 7.30 (m, 4H).
Exact Mass: Calcd, 440.96; Found, 440.18.
Step 1 : {6-[2-(3-Chloro-4-methoxy-phenyl)-ethyl]-6-cyclopentyl-dihydro-pyran-2,4-dione.
Figure imgf000332_0001
This compound was prepared analogously to Example A(82), where 4-Bromo-2-chloro-1- methoxy-benzene was substituted in place of 2-Bromopyridine in Step 1 of that example.
Η NMR (CDC13): δ 1.41-1.86 (brm, 8H), 1.96 (m, 2H), 2.29 (t, 7= 7.6 Hz, IH), 2.61 (t, 7= 8.6 Hz, 2H), 2.81 (s, 2H), 3.40 (s, 2H), 3.89, (s, 3H), 6.45 (d, 7= 8.5 Hz, IH), 7.0 (d, 7= 8.5 Hz, IH), 7.15 (brs, IH). ESIMS (MH+): 351.8
Example B(79): 3-allyl-6-[2-(3-chloro-4-methoxyphenyl)ethyl]-6-cyclopentyIdihydro-2H- pyran-2,4(3H)-dione.
Figure imgf000332_0002
The title compound was prepared analogously to Example B(78), where allyl bromide was substituted in place of benzyl bromide in that example.
'H NMR (CDC13): δ 1.44-1.95 (bm, 8H), 2.19 (m, 3H), 2.45 (m, IH), 2.65 (m, 3H), 3.01 (t, J= 3.10Hz, IH), 3.10 (t, 7= 2.56Hz, 2H), 3.14 (m, IH), 3.89 (s, 3H), 5.35 (m, 2H), 6.01 (m, IH), 6.85 (d, 7= 1.92 Hz, IH), 7.17 (m, 2H). Exact Mass: Calcd, 390.90; Found, 390.16.
Example B(80): 6-[2-(3-chloro-4-methoxyphenyl)ethyl]-6-cyclopentyl-3-(pyridin-3- ylmethyl)dihydro-2H-pyran-2,4(3H)-dione.
Figure imgf000333_0001
DBU (55ul, 0.367mmol) was added to a solution of 6-[2-(3-chloro-4- methoxyphenyl)ethyl]-6-cyclopentyldihydro-2H-pyran-2,4(3 )-dione (58.6mg, 0.167mmol) in benzene (16.0 ml) and acetonitrile (3ml), under an atmosphere of argon. 3-(chloromethyl)pyridine hydrochloride (27.4mg, 0.167mmol) was then added. The reaction mixture was stirred at room temperature for 24hrs, after which time the mixture was filtered through a plug of Celite. The filtrate was concentrated in vacuo and the residue purified by prep HPLC to afford the title compound as a white solid (8.60mg).
Η NMR (CDC13): δ 1.40-1.80 (bm, 8H), 1.90 (m, 2H), 2.30 (m, IH), 2.51 (m, 3H), 2.74 (d, 7= 17.27 Hz, IH), 3.74 (m, 3H), 3.85 (s, 3H), 6.73 (d, 7= 8.32 Hz, IH), 6.89 (m, IH), 7.02 (s, IH), 7.30 (m, IH), 7.92 (m, IH), 8.26 (s, IH), 8.55 (s, IH).
Example B(81): 6-[2-(3-chloro-4-methoxyphenyl)ethyl]-6-cyclopentyl-3-(pyridin-2- ylmethyl)dihydro-2H-pyran-2,4(3H)-dione.
Figure imgf000334_0001
The title compound was prepared analogously to Example B(80) where 2- (chloromethyl)pyridine hydrochloride was substituted in place of 3-(chloromethyl)pyridine hydrochloride in that example.
Η NMR (CDClj): δ 1.30-1.80 (bm, 8H), 1.97 (m, 3H), 2.37 (m, 2H), 2.57 (m, 3H), 2.69 (s, IH), 2.75 (s, IH), 3.87 (s, 3H), 6.83 (d, 7= 8.32 Hz, IH), 6.97 (d, 7= 1.92 Hz, IH), 7.12 (s, IH), 7.26 (s, IH), 7.43 (d, 7 = 7.68 Hz, IH), 7.74 (t, 7= 7.68 Hz, IH), 8.40 (d, 7= 4.80 Hz, IH). Exact Mass: Calcd, 441.95; Found, 441.17.
Example B(82): 6-[2-(3-chloro-4-methoxyphenyl)ethyl]~6-cyclopentyl-3-(pyridin-4- ylmethyl)dihydro-2W-pyran-2,4(3H)-dione.
Figure imgf000334_0002
The title compound was prepared analogously to Example B(80) where 4-
(chloromethyl)pyridine hydrochloride was substituted in place of 3-(chloromethyl)pyridine hydrochloride in that example.
Η NMR (CDC13): δ 1.25-1.80 (bm, 8H), 1.97 (m, 3H), 2.33 (m, 2H), 2.52 (m, 3H), 2.77 (d, 7= 16.95 Hz, IH), 3.74 (s, IH), 3.83 (s, 3H), 6.80 (d, 7= 8.32 Hz, IH), 6.93 (m, IH), 7.06 (s, IH), 7.39 (bs, 2H), 8.50 (bs, 2H). Example B(83): 6-[2-(3-chloro-4-methoxyphenyl)ethyl]-6-cyclopentyl-3-(imidazo[1 ,2- a]pyrimidin-2-ylmethyl)dihydro-2W-pyran-2,4(3H)-dione.
Figure imgf000335_0001
Potassium carbonate (35.4mg, 0.256mmol) was added to a solution of 6-[2-(3-chloro-4- methoxyphenyl)ethyl]-6-cyclopentyldihydro-2H-pyran-2,4(3/-/)-dione (30mg, 0.085mmol), 2- (chloromethyl)imidazo[1 ,2-a]pyrimidine (17.2mg, 0.103mmol) and sodium iodide (5 crystals) in acetone (40ml). The reaction mixture was stirred at reflux for 24hrs, after which time the mixture was acidified to pH = 3 and the product was extracted with ethyl acetate (3 x 25ml). The combined organics were washed with brine (30ml), dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated in vacuo and purified by prep HPLC to afford the title compound as a white solid (8.8mg).
'H NMR (CDC13): δ 1.40-1.88 (bm, 11H), 2.24 (m, 2H), 2.48-2.59 (b , 3H), 3.79 (s, 3H), 4.03 (d, 7= 14.08 Hz, IH), 4.18 (d, 7= 14.08 Hz, IH), 6.94 (d, 7= 1.60 Hz, 2H), 7.03 (d, 7= 1.60 Hz, 2H), 8.08 (s, IH), 8.82 (bs, IH), 8.85 (bs, IH). Exact Mass: Calcd, 481.97; Found, 481.18.
Example B(84): 6-[2-(3-chloro-4-methoxyphenyl)ethyl]-6-cyclopentyl-3-[(1 -methyl-1 H- benzimidazol-2-yl)methyl]dihydro-2W-pyran-2,4(3H)-dione.
Figure imgf000335_0002
6-[2-(3-chloro-4-methoxyphenyl)ethyl]-6-cyclopentyldihydro-2H-pyran-2,4(3H)-dione (127mg, 0.362mmol) was dissolved in a mixture of dimethoxy ethylene glycol (1.8ml) and water (1.8ml). The solution was heated to 80°C. Sodium carbonate (42.2mg, 0.398mmol) was then added to the mixture followed by 2-(chloromethyl)-1 -methyl-1 H-benzimidazole (42.2mg, 0.398mmol). The reaction mixture was stirred at 80°C for 5hrs, after which time the mixture was acidified to pH 5 and the product was extracted with ethyl acetate (3 x 25ml). The combined organics were washed with brine (30ml), dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated in vacuo and purified by prep HPLC to afford the title compound as a white solid (13.5mg). 'HNMR (CDCl3): δ 1.30-1.80 (bm, HH), 2.22 (m, IH), 2.50 (t, 7= 8.29 Hz, 2H), 2.92 (d, J= 8.10 Hz, 2H), 3.78 (s, 3H), 4.01 ( s, 3H), 4.26 (d, 7= 7.35 Hz, IH), 6.87 (d, 7= 2.26 Hz, IH), 6.90 ( s, IH), 7.00 (d, 7= 2.07 Hz, 2H), 7.44 (m, 3H), 7.54 (m, IH), 7.84 (m, IH). Exact Mass: Calcd, 495.01; Found, 494.20.
Example B(85): 6-[2-(3-chloro-4-methoxyphenyl)ethyl]-6-cyclopentyl-3-(quinolin-2- ylmethyl)dihydro-2W-pyran-2,4(3r/)-dione.
Figure imgf000336_0001
The title compound was prepared analogously to Example B(84), where 2- (chloromethyl)quinoline hydrochloride was substituted in place of 2-(chloromethyl)-1 -methyl-1 H- benzimidazole in that example.
'H NMR (CDC13): δ 1.44-1.80 (bm, 8H), 2.20 (m, 3H), 2.72 (m, 2H), 3.01 (m, 2H), 3.21 (m, IH), 3.40 (m, IH), 3.72 (d, 7= 4.10 Hz, IH), 3.89 (s, 3H), 6.91 (m, IH), 7.17 (m, 2H), 7.36 (m, 3H), 7.82 (t, 7= 8.66 Hz, 2H), 8.09 (bs, IH). Exact Mass: Calcd, 492.01; Found, 491.19.
Example B(86): 6-Cyclopentyl-6-[2-(2,4-dimethoxy-phenyl)-ethyl]-4-hydroxy-3-[2-(3-methyl- isoxazol-5-yl)-acetyl]-5,6-dihydro-pyran-2-one.
Figure imgf000337_0001
To a solution of 6-cyclopentyl-6-[2-(2,4-dimethoxy-phenyl)-ethyl]-dihydro-pyran-2, 4-dione (52 mg, 0.15 mmol) from Step 2 below, triethylamine (0.075 mL, 0.68 mmol) and (3-Methyl- isoxazol-5-yl)-acetic acid (0.027 g, 0.196 mmol) in CH2CI2 (1.5 mL) were added DMAP (1 mg), and EDC (37 mg, 0.196 mmol). The reaction was stirred at room temperature for 18 hours, and then diluted with CH2CI2. The organic was washed with water, and the layers were separated. The organic layer was dried under vacuum, and then purified by preparatory HPLC to give the desired compound (26.2 mg, 37% yield). 1H NMR (CDCI3) δ: 1.47 - 1.75 (m, 8H), 1.85 - 1.91 (m, 2H), 2.21 (s, 3H), 2.26 - 2.32 (m, 1H), 2.48 - 2.53 (m, 2H), 2.71 (d, 7 = 18.09 Hz, 1H), 2.86 (d, 7 = 18.09 Hz, 1H), 3.69 (s, 3H), 3.71 (s, 3H), 4.40 - 4.57 (m, 2H), 6.00 (s, 1H), 6.31 - 6.36 (m, 2H), 6.91 (d, 7 = 7.91 Hz, 1 H).
Step 1 : 3-[2-(2,4-dimethoxyphenyl)ethyl]-1-cyclopentylpropan-1-one
Figure imgf000337_0002
A solution of 2,4-dimethoxybenzaldehyde (10.27 g, 45 mmol) and methyl cyclopentyl ketone (6.06 g, 54 mmol) in anhydrous ethanol (81 mL) was treated with 5 M NaOH (aq) (18 mL, 90 mmol) and the mixture stirred at room temperature for 18 h. The volatiles were removed in vacuo. The residue was extracted with ether (100 mL) and the extract washed with water (3 x 60 mL), then with brine. The ethereal solution was dried over MgS04, filtered, and concentrated in vacuo, affording the intermediate chalcone in a crude yield of 14.63 g. The crude intermediate (14.52 g) was dissolved in 110 mL ethyl acetate, treated with platinum oxide (5 mole%) and stirred over 1 atm of H2 at room temperature overnight. The Pt was filtered through a fine fritted funnel and the black residue washed with ethyl acetate. The filtrate was concentrated in vacuo to give a yellowish resin. The resin was chromatographed using silica gel and 6:1 hexanes/ethyl acetate, yielding 6.02 g (41%) of the ketone as a colorless oil.
'H NMR (CDCl3): δ 1.48-1.81 (m, 8H), 2.67 (m, 2H), 2.80 (m, 3H), 3.76 (s, 3H), 3.75 (s, 3H), 6.37 (dd, 1 H, 7= 8.1, 2.1 Hz), 6.41 (d, IH, 7= 2.1 Hz), 7.00 (d, IH, J= 8.1 Hz). MS(APCI) calcd for Cι6H22θ3: 262.2; found (M+H : 263.1.
Step 2: 6-[2-(2,4-dimethoxyphenyl)ethyl]-6-cyclopentyldihydro-2W-pyran-2,4(3W)-dione.
Figure imgf000338_0001
Methylacetoacetate (1.63 mL, 15.1 mmol) was dissolved in dry THF (42 mL) and cooled to 0 °C. NaH (60% in mineral oil, 0.604 g, 15.1 mmol) were carefully added and the reaction mixture was stirred for 20 min. A solution of BuLi in hexanes (1.6 M, 9.44 mL, 15.1 mmol) was added dropwise and the resulting mixture was stirred an additional 20 min. A solution of 3-(2,4- dimethoxyphenyl)-1-cyclopentylpropan-1-one (2.33 g, 7.55 mmol) from Step 1 above in THF (37 mL) was added dropwise. After stirring 1 h, the reaction mixture was quenched with saturated aq NH CI (100 mL) and extracted with Et20 (600 mL). The organic phase was dried over MgS0 and evaporated. The residue was then stirred overnight in a mixture of 0.1 M NaOH (370 mL) and THF (37 mL). After the addition of an aq solution of 10% aq KHS04 (50 mL) the resulting mixture was stirred 30 min and then extracted with Et20 (600 mL). The organic phase was washed with brine, dried over MgS04 and evaporated. The residue was purified by flash column chromatography (50% EtOAc in hexanes) to give the product (1.54 g, 52%) as a white foam.
Η NMR (CDCI3) δ 1.43 (m, 2 H), 1.78 (m, 8 H), 2.33 (m, IH), 2.58 (m, 2H), 2.78 (s, 2H), 3.43 (s, 2H), 3.78 (s, 6H), 6.37 (s, IH), 6.47 (s, IH), 6.93 (d, IH, 7= 7.93 Hz). MS (APCI) calcd for C20H26O5: 346.2; found (M+l): 347.0.
Example B(87): 6-[2-(3-Chloro-4-methoxy-phenyl)-ethyl]-6-cyclopentyl-4-hydroxy-3-(2- pyridin-2-yl-acetyl)-5,6-dihydro-pyran-2-one.
Figure imgf000339_0001
The target compound was synthesized analogously to Example B(86), substituting py rid i n-2-yl-acetic acid (22 mg, 0.16 mmol) in place of (3-methyl-isoxazol-5-yl)-acetic acid and 6- [2-(3-Chloro-4-methoxy-phenyl)-ethyl]-6-cyclopentyl-dihydro-pyran-2,4-dione (63 mg, 0.123 mmol) from Step 2 below in place of 6-cyclopentyl-6-[2-(2,4-dimethoxy-phenyl)-ethyl]-dihydro- pyran-2, 4-dione. Yield = 32 mg, 55% yield.
'H NMR (CDCl3) δ: 1.41 - 1.74 (m, 8H), 1.92 - 1.98 (m, 2H), 2.40 (p, 7= 8.00 Hz, IH), 2.56 - 2.62 (m, 2H), 2.69 (d, 7= 17.27 Hz, IH), 2.87 (d, 7== 17.27 Hz, IH), 3.88 (s, 3H), 4.40 (s, 2H), 6.84 (d, 7= 8.32 Hz, IH), 6.96 (d, 7= 8.32 Hz, IH), 7.12 (s, IH), 7.27 (s, IH), 7.67 (d, 7= 6.72 Hz, IH), 8.51 (d, 7= 4.80 Hz, IH), 8.58 (s, IH).
Step 1 : 3-(3-Chloro-4-methoxy-phenyl)-1-cyclopentyl-propan-1-one.
Figure imgf000339_0002
To a magnetically stirring solution of 4-bromo-2-chloroanisole (0.50 g, 2.61 mmol) and 1-
Cyclopentyl-2-propen-1-ol (1.5 eq, 0.49 g, 3.88 mmol) in anhydrous N-methylpyrrolidinone (3.0 mL), under argon at room temperature, was added sodium bicarbonate (1.2 eq, 0.26 g, 3.10 mmol) followed by dichlorobis (triphenylphosphine) palladium (II) (0.02 eq, 36.7 mg, 0.05 mmol). The resulting mixture was heated to 140 °C in an oil bath and maintained for 4 hours. The resulting dark reaction mixture was cooled to room temperature and poured into water (50 mL) and extracted with EtOAc (2 X 25 mL). The organics were washed with water (50 mL) and brine (50 mL) then dried over Na2S04, filtered and concentrated. The crude residue was purified by flash chromatography (1% through 10% EtOAc in Hexanes) to yield the intermediate ketone as a slightly yellow oil (0.49 g, 79%). Step 2: 6-[2-(3-Chloro-4-methoxy-phenyl)-ethyl]-6-cyclopentyl-dihydro-pyran-2,4-dione.
Figure imgf000340_0001
The title compound was prepared analogously to Example B(86), Step 2 substituting 3-
(3-chloro-4-methoxy-phenyl)-1-cyclopentyl-propan-1-one from Step 1 above in place of 3-(2,4- dimethoxyphenyl)-1 -cyclopentylpropan-1 -one.
Η NMR (CDC13): δ 1.41-1.86 (brm, 8H), 1.96 (m, 2H), 2.29 (t, 7= 7.6 Hz, IH), 2.61 (t, 7= 8.6 Hz, 2H), 2.81 (s, 2H), 3.40 (s, 2H), 3.89, (s, 3H), 6.45 (d, 7= 8.5 Hz, IH), 7.0 (d, 7= 8.5 Hz, IH), 7.15 (brs, IH). ESIMS (MH+): 351.8
Example B(88): 3-Acetyl-6-[2-(3-chloro-4-methoxy-phenyl)-ethyl]-6-cyclopentyl-4~hydroxy- 5,6-dihydro-pyran-2-one.
Figure imgf000340_0002
The target compound was synthesized analogously to Example B(87), substituting acetic acid (0.009 mL, 0.155 mmol) in place of pyridin-2-yl-acetic acid. Yield = 18.4 mg, 38% yield, Η NMR (CDCI3) δ: 1.57 - 1.77 (m, 8H), 1.94 - 2.00 (m, 2H), 2.35 (p, 7= 8.64 Hz, IH), 2.59 - 2.64 (m, 5H), 2.68 - 2.90 (m, 2H), 3.87 (s, 3H), 6.84 (d, 7= 8.32 Hz, IH), 7.00 (d, 7= 8.64 Hz, IH), 7.16 (s, IH).
Example B(89): 7-[(6-Cyclopentyl-6-{2-[4-(difluoromethyl)-3-fluorophenyl]ethyl}-4- hydroxy-2-oxo-5,6-dihydro-2H-pyran-3-yl)methyl]-3-methyl-5W-[1,3]thiazolo[3,2- a]pyrimidin-5-one
Figure imgf000341_0001
The title compound was prepared as described in Example B(54) where 6-Cyclopentyl-6- {2-[4-(difluoromethyI)-3-fluorophenyl]ethyl}-dihydro-2H-pyran-2,4(3H)-dione (described in Step 3 of Example B(69)) was used in place of 6-[2-(5-Chloro-2,4-dimethoxyphenyl)ethyl]-6- cyclopentyldihydro-2/-/-pyran-2,4(3H)-dione and 7-(ChIoromethyl)-3-methyl-5H-[1 ,3]thiazolo[3,2- a]pyrimidin-5-one (prepared according to a reported procedure: Doria, G.; Passarotti, C; Sala, R.; Magrini, R.; Sberze, P.; Tibolla, M.; Cesarani, R.; Arcari, G.; Castello, R.; Toti, D. Farmaco Ed. Sci. 1985, 40, 885) was used in place of 6-Hydroxy-8-mercaptopurine monohydrate. Η NMR (300 MHz, DMSO-D6) δ 1.55 (m, 8 H) 1.94 (m, 2 H) 2.33 (m, 1 H) 2.44 (d, 7=1.7 Hz, 2 H) 2.58 (s, 3 H,) 2.58 (1 H buried under singlet) 2.71 (d, 7=18.0 Hz, 1 H) 3.38 (dd, 7=15.0, 6.0 Hz, 2 H) 5.77 (s, 1 H) 6.90 (m, 1 H) 7.10 (m, 3 H) 7.27 (s, 1 H) 7.44 (t, 7=7.74 Hz, 1 H). MS (APCI) calcd for C27H27F3N204S: 532.16; found (M + H1") 533.0.
Example B(90): 6-[2-(5-chloro-2,4-dimethoxyphenyl)ethyl]-6-cyclopentyl-4-hydroxy-3- (imidazo[1,2-a]pyrimidin-2-ylmethyl)-5,6-dihydro-2H-pyran-2-one
Figure imgf000341_0002
The title compound was prepared as described in Example B(54) where 2- (Chloromethyl)imidazo[1,2-a]pyrimidine (described below) was used in place of 6-Hydroxy-8- mercaptopurine monohydrate with the exception that it was purified on a Phenomenex Synergi 4u Hydro-RP 21.2 ID x 150 mm column using a gradient of A: H2O/0.05% TFA, B: CAN/0.05% TFA. The gradient consisted of 5-40% of B for 6 minutes, then 40-70% of B for 9 minutes at a flow of 30 mL/min and collection of fractions using UV at 260 nm.
Η NMR (300 MHz, DMSO-D6) d 1.55 (m, 8 H) 1.79 (m, 2 H) 2.25 (m, 1 H) 2.43 (m, 2 H) 2.45 (IH, overlapped with DMSO) 2.67 (d, 7=17.56 Hz, 1 H) 3.60 (s, 2 H) 3.67 (s, 3 H) 3.77 (s, 3 H) 6.62 (s, 1 H) 6.93 (dd, 7=6.80, 4.15 Hz, 1 H) 7.04 (s, 1 H) 7.44 (s, 1 H) 8.37 (dd, 7=4.15, 1.89 Hz, 1 H) 8.77 (dd, 7=6.80, 1.89 Hz, 1 H). MS (APCI) calcd for C27H3oClN3θ5: 511.19; found (M + H ) 512.0.
Step 1 : 2-(chloromethyl)imidazo[1 ,2-a]pyrimidine
Figure imgf000342_0001
A solution of 2-Aminopyridine (19.02 g, 0.2 mol) in anhydrous DME (70 mL) was added to 1 ,3-dichloroacetone (25.39 g, 0.2 mol) to form a slurry in a 250-mL 3-necked round bottomed flask outfitted with a reflux condenser and a N2 line. The mixture heated at 65 °C for 18 h, warmed to 80 °C for 3 h and allowed to cool back to room temperature over 2 h. The DME was removed in vacuo and H20 was added to dissolve the resulting solid. Saturated NaHC03 was added to basify the solution to a pH to 8 and ethyl acetate was used to extract the product (3 x 300 mL). Both phases were stored in the freezer overnight. The organic phase was dried over Na2S04, filtered and concentrated to give an orange solid. The aqueous layer was extracted again with ethyl acetate (2 x 200 mL), then CH2CI2 (2 x 200 mL) and these organic layers were dried over Na2S04, filtered and concentrated to an orange solid. The two solids were combined and dissolved in hot 5-10% MeOH in CH2CI2, and allowed to cool. The resulting orange crystals were filtered and washed with cold CH2CI2. A small amount of ether was added to the mother liquor and scratched and put in the freezer. The resulting solid was filtered cold and washed with cold ether. The two batches of solid were combined and dried in the vacuum oven to yield 4.93 g (14%) of the desired product.
Η NMR (CDC13) d 4.78 (s, 2 H) 6.87 (dd, 7=6.6 Hz, 7=4.3 Hz, 1 H) 7.61 (s, 1 H) 8.45 (d, 7=6.8 Hz 1 H) 8.53 (d, 7=1.9 Hz, 1 H). MS (APCI) calcd for C7H6C1N3: 167.60; found (M + H1") 168.0.
Example B(91): 6 W-[4-(2-{2-cyclopentyl-5-[(5,7-dimethyl[1,2,4]triazolo[1,5-a]pyrimidin-2- yl)methyl]-4,6-dioxotetrahydro-2H-pyran-2-yl}ethyl)-2-ethylphenyl]-/V- methylmethanesulfonamide
Figure imgf000343_0001
The title compound was prepared analogously to Example B(31), where {4-[2-(2- cyclopentyl-4,6-dioxotetrahydro-2AV-pyran-2-yl)ethyl]-2-ethylphenyl}-Λ/- methylmethanesulfonamide (described in Example A(87)) was substituted in place of 6-[2-(3- chloro-4-isopropoxyphenyl)ethyl]-6-cyclopentyldihydro-2H-pyran-2,4(3/-/)-dione in the final step of that example.
Η NMR (CDC13): δ 1.20 (t, J = 7.54 Hz, 3H), 1.40-1.80 (brm, 8H), 2.59 (m, 2H), 2.62 (m, 2H), 2.67 (m, 5H), 2.79 (m, 5H), 2.95 (m, 5H), 3.20 (m, 5H), 6.54 (d, J = 2.07 Hz, IH), 6.95 (s, IH), 6.98 (d, J = 2.07 Hz, IH), 7.07 (m, IH). Anal. Calcd. For QSOHJ SNSS: C, 61.94; H, 6.75, N, 12.04. Found: C, 61.64; H, 6.46, N, 12.13.
Example B(92): 2-[4-(2-{2-cyclopentyl-4-hydroxy-5-[(1 -methyl-1 W-indol-5-yl)methyl]-6-oxo- 3,6-dihydro-2r -pyran-2-yl}ethyl)-2-fluorophenyl]-2-methylpropanenitrile
Figure imgf000343_0002
The title compound was prepared analogously to Example B(75), where 1 -methyl-1 H- indole-5-carbaldehyde was substituted in place of 5,7-Dimethyl-[1,2,4]triazolo[1,5-G]pyrimidine- 2-carbaldehyde in the final step of that example.
Η NMR (DMSO-D6, 300 MHz) δ (ppm): 1.20-1.60 (m, 8 H), 1.69 (s, 6 H), 1.80-1.89 (m, 2 H), 2.27-2.36 (m, 1 H), 2.45-2.55 (m, 1 H), 2.74-2.80 (m, 1 H), 3.32 (s, 2 H), 3.50-3.68 (m, 2 H), 3.73 (s, 3 H), 6.24 (d, 7=3.01 Hz, 1 H), 6.78 (dd, 7=8.10, 0.94 Hz, 1 H), 6.95-7.05 (m, 2 H), 7.16-7.26 (m, 3 H), 7.32 (s, 1 H). HRMS calcd for
Figure imgf000344_0001
(M+ET): 512.2705. Found: 512.2710.
Example B(93): 2-(4-{2-[2-cyclopentyl-4-hydroxy-6-oxo-5-(1W-pyrazol-4-ylmethyl)-3,6- dihydro-2r-pyran-2-yl]ethyl}-2-fluorophenyl)-2-methylpropanenitrile
Figure imgf000344_0002
The title compound was prepared analogously to Example B(75), where 1 H-pyrazole-4- carbaldehyde was substituted in place of 5,7-Dimethyl-[1,2,4]triazolo[1,5-D]pyrimidine-2- carbaldehyde in the final step of that example.
Η NMR (300 MHz, DMSO-D6) δ (ppm) 1.25-1.65 (m, 8 H), 1.71 (s, 6 H), 1.85-1.91 (m, 2 H), 2.28-2.35 (m, 1 H), 2.54-2.60 (m, 3 H), 2.66-2.72 (m, 1 H), 3.29-3.34 (m, 2 H), 6.97 (d, 7=8.10 Hz, 1 H), 7.08 (dd, 7=13.19, 1.13 Hz, 1 H), 7.35 (m, 3 H). Anal. Calcd for C26H3oN3θ3F.0.5H20: C, 67.80; H, 6.79; N, 9.12. Found: C, 67.98; H, 6.63; N, 9.22.
Example B(94): 6-Cyclopentyl-3-(5,7-dimethyl-[1 ,2,4]triazolo[1 ,5-a]pyrimidin-2-ylmethyl)-4- hydroxy-6-[2-(4-hydroxy-3-isopropyl-phenyl)-ethyl]-5,6-dihydro-pyran-2-one
Figure imgf000345_0001
The title compound was prepared by coupling 6-Cyclopentyl-6-[2-(4-hydroxy-3-isopropyl- phenyl)-ethyl]-dihydro-pyran-2,4-dione (Example A(93): ) to 5,7-Dimethyl-[1,2,4]triazolo[1,5- D]pyrimidine-2-carbaldehyde using the Me2NHBH3 method described in the synthesis of Example B(31).
Η NMR (DMSO- ): d 1.23 (t, 6H, 7 = 5.6 Hz), 1.45-1.87 (br m, 8H), 2.14 (m, IH), 2.24 (m, IH), 2.50 - 2.71 (m, 10H), 2.88 (d, IH, 7= 17.0 Hz), 3.26 (m, IH), 3.84 (d, IH, 7= 16.0 Hz), 3.94 (d, IH, 7= 16.0 Hz), 6.78 (d, IH, 7 = 8.1 Hz), 6.94 (d, IH, 7 = 8.1 Hz), 7.00 (s, IH), 7.16 (s, IH), 9.11 (s, IH), 11.00 (br s, IH). ESIMS: (M + H)+ 505.25.
Example B(95): 6-[2-(3-Chloro-4-hydroxy-phenyl)-ethyl]-6-cyclopentyl-3-(5,7-dimethyl- [1,2,4]triazolo[1,5-a]pyrimidin-2-ylmethyl)-4-hydroxy-5,6-dihydro-pyran-2-one
Figure imgf000345_0002
The title compound was prepared by coupling 6-[2-(3-Chloro-4-hydroxy-phenyl)-ethyl]-6- cyclopentyl-dihydro-pyran-2, 4-dione (Example A(95))) to 5,7-Dimethyl-[1,2,4]triazolo[1,5- D]pyrimidine-2-carbaldehyde using the Me2NHBH3 method described in the synthesis of Example B(31).
Η NMR
Figure imgf000345_0003
d 1.32-1.63 (br m, 8H), 2.02 (m, 2H), 2.34 - 2.50 (m, 10H), 2.72 (d, IH, 7 = 17.4 Hz), 3.65 (d, IH, 7 = 16.0 Hz), 3.76 (d, IH, 7 = 16.0 Hz), 6.81 (d, IH, 7 = 8.3 Hz), 6.96-6.99 (m, 2H), 7.07 (s, IH), 9.82 (s, IH), 10.85 (br s, IH). Anal. Calcd. For C26H29N4O4Cl«0.2 H20: C, 62.38; H, 5.92; N, 11.19. Found: C, 62.35; H, 5.96; N, 10.98. Example B(96): 6-Cyclopentyl-3-(5,7-dimethyl-[1 ,2,4]triazolo[1 ,5-a]pyrimidin-2-ylmethyl)-6-
[2-(3-ethyl-4-methoxy-phenyl)-ethyl]-4-hydroxy-5,6-dihydro-pyran-2-one
Figure imgf000346_0001
The title compound was prepared by coupling 6-Cyclopentyl-6-[2-(3-ethyl-4-methoxy- phenyl)-ethyl]-dihydro-pyran-2,4-dione (Example A(96)) to 5,7-Dimethyl-[1 ,2,4]triazolo[1 ,5- D]pyrimidine-2-carbaldehyde using the Me2NHBH3 method described in the synthesis of Example B(31).
Η NMR (DMSO- ): d 1.06 (t, 3H, 7 = 7.5 Hz), 1.40-1.70 (br m, 8H), 2.08 (m, 2H), 2.45 - 2.54 (m, 12H), 2.76 (d, IH, 7 = 17.0 Hz), 3.68 - 3.85 (m, 5H), 6.81 (d, IH, 7= 8.3 Hz), 6.94 (s, IH), 7.00 - 7.04 (m, 2H). ESIMS: (M + H)+ 505.20.
Example B(97): 6-[2-(3-Chloro-5-ethyl-4-methoxy-phenyl)-ethyl]-6-cyclopentyl-3-(5,7- dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-ylmethyl)-4-hydroxy-5,6-dihydro-pyran-2-one.
Figure imgf000346_0002
5,7-Dimethyl-[l,2,4]triazolo[l,5-a]pyrimidine-2-carbaldehyde (0.1 lg, 0.63mmol) was added to a solution of6-[2-(3-Chloro-5-ethyl-4-methoxy-phenyl)-ethyl]-6-cyclopentyl-dihydro-pyran-2,4-dione (0.2g, 0.53 mmol) in MeOH (5 mL). The reaction mixture was stirred for 15mins and then treated with borane- dimethylamine complex (47mg, 0.80mmoL). After 15 hours the reaction mixture was quenched with IN HCl and extracted with 10% MeOH in CH2C12. The combined organic layers were concentrated and purified by prep HPLC to give the product (50mg, 17% yield). Η NMR (400 MHz, OMSO-d6): δ 0.98 (t, 7=7.6 Hz, 3 H), 1.27-1.59 (br m, 8 H), 2.00 (m, 2 H), 2.33-2.49 (m, 12 H), 2.62 (d, 7=17.0 Hz, 1 H), 3.59 (d, 7=16.2 Hz, 1 H), 3.61 (s, 3 H), 3.69 (d, 7=16.2 Hz, 1 H), 6.91 (s, 1 H), 6.92 (s, 1 H), 7.00 (s, 1 H). MS: C29H36N404C1 (M + H+) 539.15. Step 4: Preparation of compound 6-[2-(3-Chloro-5-ethyl-4-methoxy-phenyl)-ethyl]-6- cyclopentyl-dihydro-pyran-2,4-dione.
Figure imgf000347_0001
Methyl acetoacetate (1.11 mL, 10.2mmol) was added to a cooled 0 °C suspension of NaH
(0.4 g, 10.2 mmol, 60% dispersion in mineral oil) in THF (15ml). After 30 min n-BuLi (4.08mL, 10.2mmol, 2.5M in hexanes) was added. The resulting dianion was stirred for an additional 30 min and then treated with a solution of 3-(3-Chloro-5-ethyl-4-methoxy-phenyl)-1-cyclopentyl- propan-1-one (1.0g, 3.4mmol) in THF (3ml). After stirring for 4h at 0°C, the reaction mixture was quenched with 1 HCl and extracted with EtOAc. The organic layers were washed with brine, dried over Na2S0 and concentrated to a yellow oil that was used without further purification.
The oil was dissolved in methanol (10mL), treated with potassium carbonate (1.4g, 10.2 mmol), and refluxed under N2for 90min. The reaction mixture was partitioned between 1N HCl and EtOAc. The organic layers were washed with brine, dried over Na2S04 and concentrated to a yellow oil that was purified by silica gel chromatography (0% to 30% EtOAc in hexanes) to give the title compound as a gum (0.25 g, 20% yield). 'HNMR (400 MHz, CDC13) δ: 1.21 (t, 7=7.6 Hz, 3 H) 1.42-1.78 (m, 8 H), 1.92 (m, 2 H), 2.27 (m, 1 H), 2.57-2.69 (m, 4 H), 2.76 (m, 2 H), 3.43 (s, 2 H), 3.81 (s, 3 H), 6.85 (s, 1 H), 6.99 (s, 1 H).
Step 3: Preparation of compound 3-(3-Chloro-5-ethyl-4-methoxy-phenyl)-1-cyclopentyl- propan-1-one.
Figure imgf000347_0002
A mixture of 5-bromo-1-chloro-3-ethyl-2-methoxy-benzene (2g, δmmol), 1-Cyclopentyl-2- propen-1-ol (1.31g, 10.4mmol), dichlorobis (triphenylphosphine) palladium (II) (110 mg, 0.16 mmol), and sodium bicarbonate (0.81 g, 9.6 mmol) in N-methylpyrrolidinone (15mL) was heated to 140°C under N2 for 5h. The reaction mixture was partitioned between 1N HCl and EtOAc. The organic layer was washed with saturated NaHC03, brine, dried over Na2S04 and concentrated to a black oil. The oil was purified by flash column chromatography (0% to 10% EtOAc in hexanes) to give the desired product (1.9g, 82%). 'HNMR (400 MHz, CDC13): δ 1.20 (t, 7=7.6 Hz, 3 H), 1.53- 1.81 (m, 8 H), 2.65 (q, 7=7.6 Hz, 2 H), 2.74 (m, 2 H), 2.79-2.87 (m, 3 H), 3.81 (s, 3 H), 6.90 (s, 1 H), 7.03 (m, 1 H).
Step 2: Preparation of compound 5-Bromo-1-chloro-3-ethyl-2-methoxy-benzene.
Figure imgf000348_0001
Potassium carbonate (3.9g, 28mmol) followed by methyl iodide (0.58mL, 9.3mmol) were added to a solution of 4-bromo-2-chloro-6-ethyl-phenol (2.2g, 9.3mmol) in DMF (10mL). The mixture was stirred for 20 hours and then partitioned between 1N HCl and EtOAc. The organic layers were washed with saturated NaHC03, brine, dried over Na2S0 and concentrated. The crude yellow oil was purified by flash column chromatography (0% to 3% EtOAc in hexanes) to give the desired product (2.1g, 91%)' 'HNMR (400 MHz, CDC13): δ 1.22 (t, 7=7.6 Hz, 3 H), 2.66 (q, 7=7.6 Hz, 2 H), 3.82 (s, 3 H), 7.22 (s, 1 H), 7.37 (s, 1 H).
Step 1 : Preparation of compound 4-Bromo-2-chloro-6-ethyl-phenol.
Figure imgf000348_0002
Sodium hydroxide (1.2g, 30mmol) and hydrazine monohydrate (1.75mL, 36mmol) were added to a solution of 5'-bromo-3'-chloro-2'-hydroxyacetophenone (3g, 12mmol) dissolved in triethylene glycol (15mL). The reaction mixture was heated to 160°C for 72 hours and then partitioned between 1N HCl and EtOAc. The organic layer was washed with saturated NaHC03, brine, dried over Na2S0 and concentrated. The residue was purified by flash silica gel chromatography (0% to 10% EtOAc in hexanes) to give the title compound (2.34 g, 83%). Η
NMR (400 MHz, CDC13): δ 1.22 (t, 7=7.6 Hz, 3 H), 2.65 (q, 7=7.6 Hz, 2 H), 5.55 (s, 1 H), 7.17 (s, 1 H), 7.31 (s, l H).
Example B(98): 6-Cyclopentyl-3-(5,7-dimethyl-[1 ,2,4]triazolo[1 ,5-a]pyrimidin-2-y lmethyl)-6- [2-(5-ethyl-2-methoxy-phenyl)-ethyl]-4-hydroxy-5,6-dihydro-pyran-2-one.
Figure imgf000349_0001
The title compound was prepared analogously to Example B(97), where 2-bromo-4-ethyl- phenol (from step 1 below) was substituted in place of 4-Bromo-2-chloro-6-ethyl-phenol in that example. 'HNMR (400 MHz, OMSO-d6) δ: 1.16 (t, 7=7.58 Hz, 3 H), 1.46-1.77(m, 8 H), 2.00 (m, IH), 2.16 (m, 1 H), 2.45-2.63 (m, 12 H), 2.80 (d, 7=17.2 Hz, 1 H), 3.71 (s, 3 H), 3.76 (d, 7=16.2 Hz, 1 H), 3.86 (d, 7=16.4 Hz, 1 H), 6.85 (d, 7=8.3 Hz, 1 H), 6.99 (s, IH), 7.03 (d, 7=8.3 Hz, 1 H), 7.08 (s, IH). MS: CasBπK (M + H*) 505.25.
Step 1: Preparation of compound 2-Bromo-4-ethyl-phenol.
Figure imgf000349_0002
Bromine (11.6mL, 0.23mol) was added slowly to a cooled 0°C of 4-ethylphenol (25g, 0.21 mol) dissolved in CH2CI2 (125mL). After the addition was complete the reaction mixture was stirred for 5 mins and then quenched with 1N NaOH. The reaction mixture was diluted with H20 and the layers separated. The organic layer was concentrated to an orange oil. Purification by flash column chromatography (0% to 5% EtOAc in hexanes) gave the title compound as a clear oil (42g, 98%). Η NMR (400 MHz, CDC13): δ 1.20 (t, 7=7.6 Hz, 3 H), 2.58 (q, 7=7.5 Hz, 2 H), 5.36 (s, 1 H), 6.93 (d, 7=8.3 Hz, 1 H), 7.03 (d, 7=8.3 Hz, 1 H), 7.28 (s, 1 H).
Example B(99): 6-Cyclopentyl-3-(5,7-dimethyl-[1 ,2,4]triazolo[1 ,5-a]pyrimidin-2-ylmethyl)-6- [2-(4-ethoxy-3-ethyl-phenyl)-ethyl]-4-hydroxy-5,6-dihydro-pyran-2-one.
Figure imgf000349_0003
The title compound was prepared analogously to Example B(97), where 4-Bromo-1- ethoxy-2-ethyl-benzene (from step 2 below) was substituted in place of 5-Bromo-1-ch!oro-3-ethyl- 2-methoxy-benzene in that example. Η NMR (400 MHz, DMSO-rf6): δ 0.90 (t, 7=7.3 Hz, 3 H), 1.16 (t, 7=7.1 Hz, 3 H), 1.23-1.53 (br m, 8 H), 1.92 (m, 2 H), 2.22-2.42 (m, 12 H), 2.64 (d, 7=17.4 Hz, 1 H), 3.56 (d, 7=16.2 Hz, 1 H), 3.66 (d, 7=16.2 Hz, 1 H), 3.82 (d, 7=7.3 Hz, 2 H), 6.63 (d, 7=8.3 Hz, 1 H), 6.77 (s, 1 H), 6.82 (d, 7=8.3 Hz, 1 H), 6.88 (s, 1 H), 10.67 (s, IH). Anal. Calcd. For C3oH38N404: C, 68.63; H, 7.30; N 10.67. Found: C, 68.73; H, 7.22; N, 10.60.
Step 2: Preparation of compound 4-Bromo-1-ethoxy-2-ethyl-benzene.
Figure imgf000350_0001
Potassium carbonate (3.3g, 23.6mmol) followed by iodoethane (0.63mL, 7.9mmol) were added to a solution of 4-bromo-2-ethyl-phenol (1.6g, 7.9mmol) in DMF (10mL). The mixture was stirred for 20 hours and then partitioned between 1 N HCl and EtOAc. The organic layers were washed with saturated NaHC03, brine, dried over Na2S04and concentrated. The crude yellow oil was purified by flash column chromatography (hexanes) to give the desired product (1.3 g, 72%). 'HNMR (400 MHz, CDC13): δ 1.18 (t, 7=7.3 Hz, 3 H), 1.41 (t, 7=7.1 Hz, 3 H), 2.60 (q, 7=7.6 Hz, 2 H), 3.99 (q, 7=7.1 Hz, 2 H), 6.68 (d, 7=8.1 Hz, 1 H), 7.24 (m, 2 H).
Step 1: Preparation of compound 4-Bromo-2-ethyl-phenol.
Figure imgf000350_0002
A solution of tetrabutyl ammonium tribromide (19.7g, 41 mmol) in CHCI3(100mL) was added to a stirred solution of 2-ethylphenol (5g, 41 mmol) dissolved in CHCI3 (150mL). The reaction mixture was stirred for 2 hrs and then quenched with 5% solution of sodium thiosulfate (150 mL). The biphasic mixture was stirred for 30 mins and then the layers were separated. The organic layer was washed with 1 N HCl, saturated NaHC03, brine, dried over Na2S04 and concentrated. The crude residue was purified by flash column chromatography (0 - 10% EtOAc in hexanes) to give the desired product (8.1 g, 98%). 'HNMR (400 MHz, CDC13): δ 1.22 (t, 7=7.5 Hz, 3 H), 2.60 (q, 7=7.5 Hz, 2 H), 6.64 (d, 7=8.5 Hz, 1 H), 7.17 (dd, 7=8.5, 2.5 Hz, 1 H), 7.24 (d, 7=2.5 Hz, I H). Example B(100): 6-[2-(3-Chloro-5-ethyl-4-hydroxy-phenyl)-ethyl]-6-cyclopentyl-3-(5,7- dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-ylmethyl)-4-hydroxy-5,6-dihydro-pyran-2-one.
Figure imgf000351_0001
The title compound was prepared analogously to Example B(97), where 6-[2-(3-Chloro-5- ethyl-4-hydroxy-phenyl)-ethyI]-6-cyclopentyI-dihydro-pyran-2,4-dione (Example 8) was substituted in place of 6-[2-(3-Chloro-5-ethyl-4-methoxy-phenyl)-ethyl]-6-cyclopentyl-dihydro-pyran-2,4-dione. 'HNMR (400 MHz, OMSO-d6) δ: 1.12 (t, 7=7.3 Hz, 3 H), 1.46-1.75(m, 8 H), 2.14 (m, 2H), 2.44-2.64 (m, 12 H), 2.83 (d, 7=17.4 Hz, 1 H), 3.78 (d, 7=16.2 Hz, 1 H), 3.88 (d, 7=16.2 Hz, 1 H), 6.94 (s, 1 H), 7.05 (s, 1 H), 7.10 (s, 1 H), 6.86 (s, 1 H), 10.90 (s, 1 H). Anal. Calcd. For C28H33N404C1.H20: C, 61.93; H, 6.50; N 10.32. Found: C, 62.02; H, 6.29; N, 10.13.
Example B(101): 6-[2-(3-Chloro-5-ethyl-4-hydroxy-phenyl)-ethyl]-6-cyclopentyl-dihydro- pyran-2,4-dione.
Figure imgf000351_0002
Trifluoroacetic acid (0.07mL, 0.88mmol) was added to a solution of 6-{2-[3-Chloro-5- ethyl-4-(2-methoxy-ethoxymethoxy)-phenyl]-ethyl}-6-cyclopentyl-dihydro-pyran-2, 4-dione (0.2g, 0.44mmol) dissolved in CH2CI2 (4mL). The reaction mixture was stirred for 2 hours at room temperature and then partitioned between H20 and EtOAc. The organic extracts were washed with brine, dried over Na2S04and concentrated to an oil. The oil was purified by flash column chromatography (0% to 30% EtOAc in hexanes) to give the title compound as a solid. (0.12g, 75%). Η NMR (400 MHz, CDC13): δ 1.21 (t, 7=7.6 Hz, 3 H), 1.58-173 (br m, 8 H), 1.92 (m, 2 H), 2.26 (m, 1 H), 2.57 (m, 2 H), 2.65 (q, 7=7.6 Hz, 2 H), 2.76 (s, 2 H), 3.43 (s, 2 H), 5.47 (s, 1 H), 6.81 (s, 1 H), 6.95 (s, 1 H). MS: C20H24O4Cl (M - H) 363.10. Step 2: Preparation of compound 6-{2-[3-Chloro-5-ethyl-4-(2-methoxy-ethoxymethoxy)- phenyl]-ethyl}-6-cyclopentyl-dihydro-pyran-2,4-dione.
Figure imgf000352_0001
The title compound was prepared analogously to Example B(97) where 5-bromo-1- chloro-3-ethyl-2-(2-methoxy-ethoxymethoxy)-benzene (from step 1 below) was substituted in place of 5-bromo-1-chloro-3-ethyl-2-methoxy-benzene in that example. 'HNMR (400 MHz, CDC13): δ 1.21 (t, 7=7.6 Hz, 3 H), 1.32-180 (br m, 8 H), 1.92 (m, 2 H), 2.26 (m, 1 H), 2.59 (m, 2 H), 2.69 (q, 7=7.6 Hz, 2 H), 2.76 (s, 2 H), 3.40 (s, 3 H), 3.43 (s, 2 H), 3.61 (m, 2 H), 3.98 (m, 2 H), 5.14 (s, 2 H), 6.86 (s, 1 H), 7.00 (s, 1 H).
Step 1: Preparation of compound 5-Bromo-1-chloro-3-ethyl-2-(2-methoxy-ethoxymethoxy)- benzene.
Figure imgf000352_0002
A solution of 4-Bromo-2-chloro-6-ethyl-phenol dissolved in THF (10mL) was added to a cooled 0°C suspension of NaH (0.43 g, 10.8 mmol, 60% dispersion in mineral oil) in THF (20ml). After the addition was complete the reaction mixture was warmed up to room temperature and stirred for 30 mins. 2-Methoxyethoxymethyl chloride (1.34mL, 11.7mmol) was added and the reaction was stirred for 15 hours. The reaction mixture was quenched with 1N HCl and extracted with EtOAc. The organic layers were washed with brine, dried over Na2S04 and concentrated to a yellow oil. Purification by flash column chromatography (0% to 10% EtOAc in hexanes) gave the title compound as a clear oil (2.4g, 76%). Η NMR (400 MHz, CDC13): δ 1.21 (t, 7=7.3 Hz, 3 H), 2.70 (q, 7=7.6 Hz, 2 H), 3.40 (s, 3 H), 3.61 (m, 2 H), 3.98 (m, 2 H), 5.15 (s, 2 H), 7.24 (s, 1 H), 7.37 (s, 1 H).
Example B(102): 6-CyclopentyI-3-(5,7-dimethyl-[1 ,2,4]triazolo[1 ,5-a]pyrimidin-2-ylmethyl)-6- [2-(3-ethyl-4-isopropoxy-phenyl)-ethyl]-4-hydroxy-5,6-dihydro-pyran-2-one.
Figure imgf000353_0001
The title compound was prepared analogously to Example B(97) where 4-Bromo-2-ethyl- 1-isopropoxy-benzene (from step 1 below) was substituted in place of 5-Bromo-1-chloro-3-ethyl- 2-methoxy-benzene of that example. Η NMR (400 MHz, DMSO-cf6) δ: 1.00 (t, 7=7.6 Hz, 3 H), 1.20 (d, 7=6.1 Hz, 6 H), 1.34-1.63(m, 8 H), 2.03 (m, 2 H), 2.40-2.51 (m, 12 H), 2.72 (d, 7=17.7 Hz, 1 H), 3.66 (d, 7=16.2 Hz, 1 H), 3.77 (d, 7=16.2 Hz, 1 H), 4.46 (m, 1 H), 6.76 (d, 7=8.3 Hz, 1 H) 6.88 (s, 1 H), 6.92 (d 7=8.1 Hz, 1 H), 6.99 (s, 1 H), 10.81 (s, 1 H). MS: C31H40N4O4 (M + H+) 533.30.
Step 1 : Preparation of compound 4~Bromo-2-ethyl-1 -isopropoxy-benzene.
Figure imgf000353_0002
Potassium carbonate (3.1g, 22.4mmol) followed by 2-iodopropane (0.75mL, 7.5mmol) were added to a solution of 4-bromo-2-ethyl-phenol (1.5g, 7.5mmol ) in DMF (10mL). The mixture was heated at 60°C for 20 hours and then partitioned between 1 N HCl and EtOAc. The organic layers were washed with saturated NaHC03, brine, dried over Na2S0 and concentrated. The crude yellow oil was purified by flash column chromatography (hexanes) to give the desired product (1.35g, 75%). Η NMR (400 MHz, CDC13): δ 1.16 (t, 7=7.6 Hz, 3 H), 1.32 (d, 7=6.1 Hz, 6 H), 2.58 (q, 7=7.6 Hz, 2 H), 4.49 (m, 1 H), 6.70 (d, 7=8.6 Hz, 1 H), 7.23 (m, 2 H).
Example B(103): 6-Cyclopentyl-3-(5,7-dimethyl-[1 ,2,4]triazolo[1 ,5-a]pyrimidin-2-ylmethyl)-6- [2-(2-fluoro-4-methoxy-phenyl)-ethyl]-4-hydroxy-5,6-dihydro-pyran-2-one.
Figure imgf000353_0003
The title compound was prepared analogously to Example B(97) where 1-Cyclopentyl-3-
(2-fluoro-4-methoxy-phenyl)-propan-1-one was substituted in place of 3-(3-chloro-5-ethyl-4- methoxy-phenyl)-1-cyclopentyl-propan-1-one in that example. 'HNMR (400 MHz, OMSO-d6) δ: 1.16-1.54 (m, 8 H), 1.83 (m, 2 H), 2.20-2.35 (m, 10 H), 2.56 (d, 7=17.4 Hz, 1 H), 3.49 (d, 7=16.2 Hz, 1 H), 3.51 (s, 3 H), 3.59 (d, 7=16.2 Hz, 1 H), 6.82 (m, 2 H), 6.82 (s, 1 H), 7.03 (t, 7=8.6 Hz, 1 H), 10.81 (s, 1 H). Anal. Calcd. For C27H3iN404F: C, 65.57; H, 6.32; N 11.33. Found: C, 65.53; H, 6.34; N, 11.34.
Step 2: Preparation of compound 1-Cyclopentyl-3-(2-fluoro-4-methoxy-phenyl)-propan-1- one.
Figure imgf000354_0001
Ba(OH)2 (0.2g, 1.2mmol) was added to a solution of 2-fluoro-4-methoxy benzaldehyde
(0.91 g, 5.9mmol) and 1-Cyclopentyl-ethanone (1g, 8.9mmol) dissolved in EtOH (10mL). The reaction mixture was stirred together for 20 hours and then partitioned between 1 N HCl and EtOAc. The organic layer was washed with saturated NaHC03, brine, dried over Na2S04and concentrated. Flash column chromatography (0% to 10% EtOAc in hexanes) gave 1-cyclopentyl- 3-(2-fluoro-4-methoxy-phenyl)-propenone as a yellow oil contaminated with some unreacted aldehyde.
The crude oil was dissolved in EtOH and 10 wt % Pd/C (0.25g, Degussa type) was added. The mixture was stirred under a balloon of H2 for 30 mins and then filtered through a pad of celite washing with EtOAc. The filtrate was concentrated and purified by flash column chromatography (0% to 20% EtOAc in hexanes) to give the title compound as an oil (0.57g, 39%). Η NMR (400 MHz, CDC13): δ 1.53-1.80 (m, 8 H), 2.73 (m, 2 H), 2.84 (m, 3 H), 3.77 (s, 3 H), 6.56-6.62 (m, 2 H), 7.08 (t, 1 H).
Step 1: Preparation of compound 1-Cyclopentyl-ethanone.
Figure imgf000354_0002
Cyclopentylmagnesium bromide (250mL, O.δmol, 2M sol in THF) was added to a cooled - 78°C solution of acetic anhydride (39 mL, 0.42mol) dissolved in THF (100mL). The reaction mixture was stirred for 2 hours. The reaction was quenched with saturated NH4CI and extracted with ether. The organic layers were washed with brine, dried over Na2S0 and concentrated to a black oil. Vacuum distillation gave the product as a yellow oil (16g, 33% yield) 'H MR (CDC13): δ 1.55 - 1.84 (br m, 8H), 2.16 (s, 3H), 2.87 (m, IH).
Example B(104): 6-Cyclopentyl-3-(5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2~ylmethyl)-6- {2-[3-ethyl-4-(2-hydroxy-ethoxy)-phenyl]-ethyl}-4-hydroxy-5,6-dihydro-pyran-2-one
Figure imgf000355_0001
This compound was prepared analogously to example C(112), except that 6- Cyclopentyl-6-{2-[3-ethyl-4-(2-hydroxy-ethoxy)-phenyl]-ethyl}-dihydro-pyran-2,4-dione was used in place of 2-[4-(2-Cyclopentyl-4,6-dioxo-tetrahydro-pyran-2-ylmethoxy)-2-fluoro-phenyl]-2- methyl-propionitrile The result was a white solid. 1H NMR (300 MHz, CDCI3): δ: 1.20 (t, 7 = 7.5 Hz, 3H), 1.52-1.81 (m, 9H), 2.04 (m, 2H), 2.39 (m, 1H), 2.62 (m, 10H), 2.79 (s, 3H), 4.05 (d, 7 = 15.5 Hz, 1H), 4.25 (m, 4H),4.12 (d, 7 = 15.5 Hz, 1H), 6.84 (s, 1H), 6.98 (m, 3H).
Example B(105): 6-Cyclopentyl-3-(5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-ylmethyl)-6- [2-(3-fluoro-4-hydroxy-phenyl)-ethyl]-4-hydroxy-5,6-dihydro-pyran-2-one
Figure imgf000355_0002
This compound was prepared analogously to example C(112), except that 6-
Cyclopentyl-6-[2-(3-fluoro-4-hydroxy-phenyl)-ethyl]-dihydro-pyran-2,4-dione was used in place of 2-[4-(2-Cyclopentyl-4,6-dioxo-tetrahydro-pyran-2-ylmethoxy)-2-fluoro-phenyl]-2-methyl- propionitrile. The result was a white solid. Η NMR (CDC13): δ: 1.44-1.92 (brm, 8H), 2.05 (m, 2H), 2.35 (m, IH) 2.44-2.88 (m, 11H), 4.05 (s, 2H), 6.85 (s, IH), 6.99 (m, 2H), 7.15 (d, 7= 7.5 Hz, IH).
Example B(106): [4-(2-{2-cyclopentyl-5-[(5,7-dimethyl[1,2,4]triazolo[1,5-a]pyrimidin-2- yl)methyl]-4-hydroxy-6-oxo-3,6-dihydro-2H-pyran-2-yl}ethyl)-2-fluorophenoxy]acetonitrile
Figure imgf000356_0001
The title compound was prepared analogously to Example A(131), where {4-[2-(2- cyclopentyl-4,6-dioxotetrahydro-2H-pyran-2-yl)ethyl]-2-fluorophenoxy}acetonitrile (from step 3 below) was substituted in place of 6-cyclopentyl-6-[2-(3-fluoro-4-{methyl[methyl(dimethylene)-6- sulfanyl]amino} phenyl) ethyl] dihydro-2H-pyran-2,4(3H)-dione. 'HNMR (CDC13): δ 1.40-2.24 (brm, 7H), 2.0-2.18 (m, 5H), 2.63 (s, 3H); 2.74 (m, 5H), 3.20 (m, 2H), 4.00(s, 2H); 4.74 (s, 2H); 6.77-7.10 (m, 4H).
Step 3: {4-[2-(2-cyclopentyl-4,6-dioxotetrahydro-2H-pyran-2-yl)ethyl]-2- fluorophenoxy}acetonitrile
Figure imgf000356_0002
Methyl acetoacetate (3.2mL, 29.4mmol) was added to a cooled 0 °C suspension of NaH (1.17 g, 29.4 mmol, 60% dispersion in mineral oil) in THF (50ml). After 30 min n-BuLi (11.7mL, 29.4mmol, 2.5M in hexanes) was added. The resulting dianion was stirred for an additional 30 min and then treated with a solution of [4-(3-Cyclopentyl-3-oxo-propyl)-2-fluoro-phenoxy]- acetonitrile (2.7g, 9.8mmol ) in THF (30ml). After stirring for 4h at 0 °C, the reaction mixture was quenched with 1 N HCl and extracted with EtOAc. The organic layers were washed with brine, dried over Na2S04 and concentrated to a yellow oil that was used without further purification. The oil was dissolved in toluene (10mL) and treated with Otera catalyst (100mg). The reaction mixture was heated to 80°C under N2for 30min. The reaction mixture was concentrated and crystallized from CH2CI2 to give the title compound (0.2 g, 24% yield). MS (APCI): 358 (M-H).
Step 2: [4-(3-Cyclopentyl-3-oxo-propyl)-2-fluoro-phenoxy]-acetonitrile
Figure imgf000357_0001
A mixture of (4-bromo-2-fluorophenoxy)acetonitrile (2.5g, 10.8mmol ), 1-Cyclopentyl-2- propen-1-ol (2.0g, 16.2mmol), dichlorobis (triphenylphosphine) palladium (II) (151 mg, 0.22 mmol), and sodium bicarbonate (1.08 g, 12.9 mmol) in N-methylpyrrolidinone (20mL) was heated to 140 °C under N2 for 5 hours. The reaction mixture was partitioned between 1 N HCl and EtOAc. The organic layer was washed with saturated NaHC03, brine, dried over Na2S0 and concentrated to a black oil. The oil was purified by flash column chromatography (Hexanes to 10% EtOAc in hexanes) to give the desired product (2.7g, 93%). Η NMR (CDC13): δ 1.52-1.83 (m, 8H), 2.75 (m, 2H), 2.85 (m, 3H), 4.80 (s, 2H), 6.92-7.06 (m, 3H).
Step 1 : Preparation of (4-bromo-2-fluorophenoxy)acetonitrile
Figure imgf000357_0002
Bromoacetonitrile (1.81ml, 0.026M) was added to a solution of 4-bromo-2-fluorophenol (5.0g, 0.026M) and potassium carbonate (3.54g, 0.026M) in DMF (50ml). The reaction was stirred for 12hours and then partitioned between diethyl ether (200ml) and water (200ml). The organics were separated, dried over magnesium sulfate, filtered and concentrated in vacuuo to afford the title compound as a yellow oil (6.0 g). 1H NMR (CDCI3): δ 4.84 (s, 2H), 7.03-7.10 (m, 2H), 7.21 (m, 1H).
Example B(107): 6-Cyclopentyl-6-[2-(3-cyclopropyl-4-methoxy-phenyl)-ethyl]-3-(5,7- dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-ylmethyl)-4-hydroxy-5,6-dihydro-pyran-2-one
Figure imgf000358_0001
This compound was prepared analogously to example C (112), except that 6- Cyclopentyl-6-[2-(3-cycIopropyl-4-methoxy-phenyl)-ethyl]-dihydro-pyran-2,4-dione was used in place of 2-[4-(2-Cyclopentyl-4,6-dioxo-tetrahydro-pyran-2-ylmethoxy)-2-fluoro-phenyl]-2-methyl- propionitrile The result was a white solid. 1H NMR (300 MHz, CDCI3): δ: 0.61 (m, 2 H), 0.88 (m, 2 H), 1.55 (m, 8 H), 1.97 (m, 2 H), 2.11 (m, 1 H), 2.36 (m, 1 H), 2.57 (m, 5 H), 2.67 (s, 3 H), 2.79 (s, 3 H), 3.82 (s, 3 H), 4.08(m, 2 H), 6.59 (s, 1 H), 6.73 (d, 7 = 8.3 Hz, 1 H), 6.84 (s, 1 H), 6.89 (d, 7 = 8.3 Hz, 1 H).
Example B(108): 6-Cyclopentyl-6-[2-(3,5-dichloro-4-ethoxy-phenyl)-ethyl]-dihydro-pyran- 2,4-dione
Figure imgf000358_0002
The title compound was prepared analogously to Example B(97), where 5-Bromo-1,3- dichloro-2-ethoxy-benzene was substituted in place of 5-Bromo-1-chloro-3-ethyl-2-methoxy- benzene. 1H NMR (400MHz, CDCI3): δ 1.45 (t, 7 = 7.0 Hz, 3H), 1.49-1.76 (m, 8H), 1.87-1.98 (m, 2H), 2.22-2.31 (m, 1H), 2.57-2.64 (m, 2H), 2.75 (d, 7 = 6 Hz, 2H), 3.44 (s, 2H), 4.07 (q, 7 = 7 Hz, 2H), 7.07 (s, 2H). ESIMS (M+H)+:400.
Step 1: 4-bromo-2,6-dichlorophenyl ethyl ether
Figure imgf000359_0001
The title compound was prepared analogously to step 2 in Example A(125), where 5-
Bromo-1 , 3-dichloro-phenol was substituted in place of 4-bromo-2-ethyl-phenol in that example. 1H NMR (400MHz, CDCI3): δ 1.46 (t, 7 = 7.0 Hz, 3H), 4.10 (q, 7 = 7 Hz, 2H), 7.09 (s, 2H).
Example B(109): 4-{3-[2-Cyclopentyl-5-(5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2- ylmethyl)-4-hydroxy-6-oxo-3,6-dihydro-2H-pyran-2-yl]-propionylamino}-piperidine-1- carboxylic acid tert-butyl ester.
Figure imgf000359_0002
The title compound was prepared analogously to Example B(97), where 4-(4-
Cyclopentyl-4-oxo-butyrylamino)-piperidine-1 -carboxylic acid ferf-butyl ester (from step 2 below) was substituted in place of 3-(3-chloro-5-ethyl-4-methoxy-phenyl)-1-cyclopentyl-propa-1-one in step 4 of that example. 1H NMR (400MHz, DMSO-d6): δ 1.34 (s, 9H), 1.35-1.61 (m, 18H), 1.97- 2.15 (m, 4H), 2.49 (s, 3H), 2.59 (s, 3H), 3.64-3.76 (m, 5H), 7.03 (s, 1H), 7.79 (d, 7 = 7.5, 1H). ESIMS (M+H)+: 597.
Step 2: 4-(4-Cyclopentyl-4-oxo-butyrylamino)-piperidine-1 -carboxylic acid tert-butyl ester
Figure imgf000360_0001
The title compound was prepared analogously to step 4 from Example B(97), where 4-(4- Cyclopentyl-4-oxo-butyrylamino)-piperidine-1 -carboxylic acid tert-butyl ester (described in step 1 below) was substituted in place of 5-bromo-1-chloro-3-ethyl-2-methoxy-benzene in step 3 of that example. 1H NMR (400MHz, DMSO-d6): δ 1.24-1.42 (m, 8H), 1.45 (s, 9H), 1.59-2.32 (m, 4H), 2.62 (d, 7 = 16 Hz, 1H), 2.71 (d, 7 = 16 Hz, 1H), 2.80-2.84 (s, 9H), 3.39 (d, 7 = 18 Hz, 1H), 3.56 (d, 7 = 18 Hz, 1H), 3.86 (m, 2H). MS(ESI):435 (MH-).
Step 1: 4-(4-Cyclopentyl-4-oxo-butyrylamino)-piperidine-1-carboxylic acid tert-butyl ester
Figure imgf000360_0002
To a stirred solution of 4-Amino-piperidine-1 -carboxylic acid tert-butyl ester (0.3g, 1.49 mmol) in anhydrous CH2CI2 under argon and cooled to 0 °C, were added 4-Cyclopentyl-4-oxo- butyric acid (0.31 g, 1.79 mmol), EDC.HCI (0.35 g, 1.79 mmol), HOBt (0.24 g, 1.79 mmol), and TEA (0.25 mL, 1.79 mmol). The resulting solution was stirred at 25 °C overnight. CH2CI2 was evaporate and the residue was partitioned between EtOAc and 1N HCl. The organic layer was washed with H20, brine and dried over Na2S04. The solvent was removed in vacuo and the residue was purified by flash column chromatography (80% EtOAc in hexanes) to provide the desired product (0.37 g, 71%) as a white solid. 1H NMR (400MHz, CDCI3): δ 1.24-1.32 (m, 2H), 1.45 (s, 9H), 1.60-1.85 (m, 11H), 2.41 (t, 7 = 6.4 Hz, 2H), 2.79-3.04 (m, 5H), 3.85-4.13 (m, 2H), 5.65 (s, 1H). MS(ESI):351 (MH-).
Example B(110): 6-Cyclopentyl-6-[2-(3-ethyl-4-hydroxy-phenyl)-ethyl]-4-hydroxy-3-(5- methyl-1 H-imidazol-4-ylmethyl)-5,6-dihydro-pyran-2-one.
Figure imgf000361_0001
The title compound was prepared analogously to Example A(126),where 4-methyl-5- imidazol carboxaldehyde was substituted in place of 6-Methyl-[1,2,4]triazolo[1,5-a]pyrimidine-2- carbaldehyde of that example. 1H NMR (400MHz, DMSO-d6): δ 1.09 (t, 7 = 7.4 Hz, 3H), 1.30-1.60 (m, 8H), 1.80-1.85 (m, 2H), 2.09 (s, 3H), 2.22-2.31 (m, 1H), 2.38-2.57 (m, 5H), 2.71 (d, 7 = 16 Hz, 1H), 3.46 (m, 2H), 6.64-6.72 (m, 3H), 6.79 (s, 1H), 8.43 (s, 1H). Anal. Calcd. For C25H32N204-1 HCI 0.25 H20: C, 64.51; H, 7.25; N, 6.02. Found: C, 64.22; H, 7.31; N, 5.91. MS(ESI):425.2 (M+H)+.
Example B(111): 6-Cyclopentyl-6-[2-(3-ethyl-4-hydroxy-phenyl)-ethyl]-3-(2-ethyl-5-methyl- 1H-imidazol-4-ylmethyl)-4-hydroxy-5,6-dihydro-pyran-2-one.
Figure imgf000362_0001
The title compound was prepared analogously to Example A(30),where 2-ethyl-5-formyl- 4-methylimidazole carboxaldehyde was substituted in place of 6-Methyl-[1 ,2,4]triazolo[1,5- a]pyrimidine-2-carbaldehyde of that example. 1H NMR (400MHz, DMSO-d6): δ 1.15 (t, 7 = 7.4 Hz, 3H), 1.25 (t, 7 = 7.6 Hz, 3H ), 1.40-1.75 (m, 8H), 1.80-1.9 (m, 2H), 2.17 (s, 3H), 2.25-2.35 (m, 1H), 2.44-2.64 (m, 6H), 2.74 (q, 7 = 7.4 Hz, 2H), 3.46 (d, 7 = 4.5 Hz, 2H), 6.70-6.81 (m, 3H), 6.87 (s, 1H). Anal. Calcd. For C27H36N204'1 H20: C, 68.91; H, 8.14; N, 5.95. Found: C, 69.89; H, 7.91; N, 6.05. MS(ESI):453.2 (MH+).
Example B(112): 6-Cyclopentyl-3-(5,7-dimethyl-[1 ,2,4]triazolo[1 ,5-a]pyrimidin-2-ylmethyl)-4- hydroxy-6-{2-[4-(1-hydroxy-ethyl)-phenyl]-ethyl}-5,6-dihydro-pyran-2-one.
Figure imgf000362_0002
OH
The title compound was prepared analogously to Example B(97), where 6-Cyclopentyl-6- {2-[4-(1-hydroxy-ethyl)-phenyl]-ethyl}-dihydro-pyran-2,4-dione (from step 2 below) was substituted in place of 6-[2-(3-Chloro-5-ethyl-4-methoxy-phenyl)-ethyl]6-cyclopentyl-dihydro-pyran-2,4-dione of that example. 1H NMR (400MHz, DMSO-d6): δ 1.17 (d, 7 = 6.4 Hz, 3H), 1.37-1.56 (m, 8H), 1.96-2 (m, 2H), 2.35-2.44 (m, 10H), 2.67 (d, 7 = 17 Hz, 1H), 3.59 (d, 7 = 16 Hz, 1H), 3.71 (d, 7 = 16 Hz, 1H), 4.50-4.55 (m, 1H), 4.93 (d, 7 = 4.1 Hz, 1H), 6.92 (s, 1H), 7.03 (d, 7 = 8.1 Hz, 2H), 7.10 (d, 7 = 8.1 Hz, 2H), 10.73 (brs, 1H). Anal. Calcd. For C28H34N404: C, 68.55; H, 6.99; N, 11.42. Found: C, 68.70; H, 7.10; N, 11.52. MS(ESI):491.2 (M+H)+.
Step 2: 6-Cyclopentyl-6-{2-[4-(1-hydroxy-ethyl)-phenyl]-ethyl}-dihydro-pyran-2,4-dione.
Figure imgf000363_0001
OH
The title compound was prepared analogously to step 4 from Example B(97), where (R)1-
(4-Bromo-phenyl)-ethanol (described in step 1 below) was substituted in place of 5-bromo-1- chloro-3-ethyl-2-methoxy-benzene in step 3 of that example. H NMR (400MHz, CDCI3): δ 1.48 (d, 7 = 6.4 Hz, 3H), 1.52-1.79 (m, 8H), 1.95 (q, 7 = 17, 8.5Hz, 2H), 2.26-2.32 (m, 1H), 2.68 (t, 7 = 8.5 Hz, 2H), 2.78 (s, 2H), 3.42 (s, 2H), 4.88 (q, 7 = 13, 6.4Hz, 1H), 7.13 (d, 7 = 8.1 Hz, 2H), 7.31 (d, 7 = 8.1 Hz, 2H). Anal. Calcd. For C20H26O4O.5H2O: C, 70.77; H, 8.02. Found: C, 70.37; H, 7.95. ESIMS (MH-): 329.
Step 1: (R)1-(4-Bromo-phenyl)-ethanol
Figure imgf000363_0002
0H
The title compound was prepared as described in the following reference: Tetrahedron 2001, 57, 5027-5038.
Example B(113): 6-[2-(4-Chloro-3-ethyl-phenyl)-ethyl]-6-cyclopentyl-3-(5,7-dimethyl- [1 ,2,4]triazolo[1 ,5-a]pyrimidin-2-ylmethyl)-4-hydroxy-5,6-dihydro-pyran-2-one
Figure imgf000364_0001
The title compound was prepared analogously to Example B(97) where 4-bromo-1- chloro-2-ethyl-benzene (from step 4 below) was substituted in place of 5-bromo-1-chloro-3-ethyl- 2-methoxy-benzene in step 3 of that example. 1H NMR (400 MHz, DMSO-cf6): δ 1.21 (t, 7=7.3 Hz, 3 H), 1.49-1.80 (br m, 8 H), 2.22 (m, 2 H), 2.54-2.77 (m, 12 H), 2.87 (d, 7=17.7 Hz, 1 H), 3.80 (d, 7=16.0 Hz, 1 H), 3.93 (d, 7=16.1 Hz, 1 H), 7.15 (s, 1H), 7.22 (dd, 7=8.1, 2.0 Hz, 1 H), 7.27 (s, 1H), 7.38 (d, 7=8.1 Hz, 1 H). Anal. Calcd. For C28H33N403O.5H20: C, 64.91; H, 6.62; N 10.82. Found: C, 64.93; H, 6.59; N, 10.50.
Step 4: 4-Bromo-1-chloro-2-ethyl-benzene
Figure imgf000364_0002
Sodium hydroxide (0.39g, 9.6mmol) and hydrazine monohydrate (0.56mL, 11.5 mmol) were added to a solution of 1-(5-Bromo-2-chloro-phenyl)-ethanone (0.9g, 3.85 mmol) dissolved in triethylene glycol (5mL). The reaction mixture was heated to 170°C for 24 hours and then partitioned between 1N HCl and EtOAc. The organic layer was washed with brine, dried over Na2S0 and concentrated. The residue was purified by flash silica gel chromatography (0% to 5% EtOAc in hexanes) to give the title compound (0.52 g, 62%). 1H NMR (400 MHz, CDCI3): δ 1.23 (t, 7=7.6 Hz, 3 H), 2.72 (q, 7=7.6 Hz, 2 H), 7.19 (d, 7=8.6 Hz, 1 H), 7.25 (dd, 7=8.3, 2.3 Hz, 1 H), 7.36 (d, 7=2.5 Hz, 1 H).
Step 3: 1-(5-Bromo-2-chloro-phenyl)-ethanone
Figure imgf000364_0003
Pyridinium dichromate (2.6g, 6.94 mmol) was added to a solution of 1-(5-bromo-2-chloro- phenyl)-ethanol (1.09 g, 4.6 mmol) in CH2CI2 (20 mL). The reaction was stirred for 15 hours and then more pyridinium dichromate (2.6g, 6.94 mmol) was added. After another 24 hours celite was added and the mixture was stirred for 20 mins. The reaction mixture was filtered through a pad of celite washing with ether. The filtrate was concentrated to a brown oil. The residue was purified by flash silica gel chromatography (0% to 10% EtOAc in hexanes) to give the title compound as a clear oil (0.92 g, 85%). 1H NMR (400 MHz, CDCI3): δ 2.64 (s, 3H), 7.29 (d, 7=8.6 Hz, 1 H), 7.51 (dd, 7=8.6, 2.3 Hz, 1 H), 7.66 (d, 7=2.3 Hz, 1 H).
Step 2: 1-(5-Bromo-2-chloro-phenyl)-ethanol
Figure imgf000365_0001
Methyl lithium (11.6mL, 16.3 mmol, 1.4M in ether) was added to a cooled -78°C solution of 5-bromo-2-chloro-benzaldehyde (2.75g, 12.5 mmol) dissolved in THF (40mL). The reaction mixture was stirred for 15 hours and then quenched with saturated NH CI and extracted with EtOAc. The organic extracts were washed with 1N HCl, brine, dried over Na2S0 and concentrated to an oil. The oil was purified by flash column chromatography (0% to 10% EtOAc in hexanes) to give the title compound as a solid (2.63g, 91%). H NMR (400 MHz, CDCI3): δ 6.32 (d, 7=6.3 Hz, 3 H), 2.00 (d, 7=3.8 Hz, 1 H), 5.24 (m, 1 H), 7.19 (d, 7=8.6 Hz, 1 H), 7.33 (dd, 7=8.6, 2.5 Hz, 1 H), 7.75 (d, 7=2.5 Hz, 1 H).
Step 1: 5-Bromo-2-chloro-benzaldehyde
Figure imgf000365_0002
Pyridinium dichromate (3.82 g, 10.2 mmol) was added to a solution of 5-bromo-2- chlorobenzylalcohol (1.5g, 6.8 mmol) in CH2CI2 (30 mL). The reaction was stirred for 5 hours and then celite was added. The mixture was stirred for 20 mins and then filtered through a pad of celite washing with ether. The filtrate was concentrated to a brown oil. The residue was purified by flash silica gel chromatography (0% to 10% EtOAc in hexanes) to give the title compound as a clear oil (1.28g, 86%). 1H NMR (400 MHz, CDCI3): δ 7.35 (d, 7=8.6 Hz, 1 H), 7.65 (dd, 7=8.3, 2.5 Hz, 1 H), 8.04 (d, 7=2.5 Hz, 1 H), 10.41 (s, 1 H).
Example B(114): 6-Cyclopentyl-3-(5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-ylmethyl)-6- {2-[3-fluoro-4-(1-hydroxy-ethyl)-phenyl]-ethyl}-4-hydroxy-5,6-dihydro-pyran-2-one
Figure imgf000366_0001
The title compound was prepared analogously to Example B(97) where 6-Cyclopentyl-6- {2-[3-fluoro-4-(1-hydroxy-ethyl)-phenyl]-ethyl}-dihydro-pyran-2,4-dione (from step 4 below) was substituted in place of 6-[2-(3-Chloro-5-ethyl-4-methoxy-phenyl)-ethyl]6-cyclopentyl-dihydro- pyran-2,4-dione of that example. 1H NMR (400MHz, DMSO-d6): δ 1.41 (d, 7 = 6.4 Hz, 3H), 1.57- 1.8 (m, 8H), 2.20-2.25 (m, 2H), 2.58-2.74 (m, 10H), 2.90 (d, 7 = 17 Hz, 1H), 3.82 (d, 7 = 16 Hz, 1H), 3.94 (d, 7 = 16 Hz, 1H), 5.0-5.08 (m, 1H), 5.29-5.33 (m, 1H), 7.06 (d, 7 = 11.5 Hz, 1H), 7.16 (s, 1H), 7.19 (d, 7 = 7.70 Hz, 1H), 7.50-7.56 (m, 1H), 11.0 (s, 1H). Anal. Calcd. For C28H33N4O4F'0.25H2O: C, 65.54; H, 6.58; N, 10.92. Found: C, 65.47; H, 6.56; N, 10.73. MS(ESI): 508.2 (M+H)+.
Example B(115) 6-Cyclopentyl-6-{2-[3-fluoro-4-(1-hydroxy-ethyl)-phenyl]-ethyl}-dihydro- pyran-2,4-dione (
Figure imgf000366_0002
The title compound was prepared analogously to step 4 from Example B(97), where (R) 1-(4-Bromo-2-fluoro-phenyl)-ethanol (described in step 3 below) was substituted in place of 5- bromo-1-chloro-3-ethyl-2-methoxy-benzene in step 3 of that example. 1H NMR (400MHz, CDCI3): δ 1.50 (d, 7 = 6.4 Hz, 3H), 1.52-1.88 (m, 8H), 1.91-1.98 (m, 2H), 2.22-2.32 (m, 1H), 2.64-2.69 (m, 2H), 2.77 (s, 2H), 3.43 (s, 2H), 5.16 (q, 7 = 13, 6.4Hz, 1H), 6.82 (dd, 7 = 11 , 1.5 Hz, 1H), 6.94 (dd, 7 = 7.9, 1.5 Hz, 1H), 7.4 (t, 7 = 7.9Hz, 1 H). Anal. Calcd. For C20H25FO4-0.5H2O: C, 67.21; H, 7.33. Found: C, 67.15; H, 7.14. ESIMS (MH-): 349.
Step 3: (R) 1-(4-Bromo-2-fluoro-phenyl)-ethanol
Figure imgf000367_0001
An oven dried 500 mL flask, was charged under nitrogen with (S) -2-methyl-CBS- oxazaborolidine 1M in toluene (5.02 mL) and dissolved in CH2CI2 (250 mL). Me2-BH3 (30 mL, 60.27 mmol) was then added and cooled to -30 °C and reaction stirred for 15 minutes. (1-(4- Bromo-2-fluoro-phenyl)-ethanone (10.9 g, 50.23 mmol) from step 2 below was dissolved in CH2CI2 (10 mL) and slowly added via addition funnel to the previous solution. The resulting reaction was stirred at 25 °C overnight. The solution was carefully quenched with MeOH, the solvent was removed in vacuo and the residue was purified by flash column chromatography (20% EtOAc in hexanes) to provide the desired product (9 37 g, 90%) as a clear oil. 1H NMR (400MHz, CDCi3): δ 1.49 (d, 7 = 6.6 Hz, 3H), 5.15 (q, 7 = 12, 6.4Hz, 1H), 7.15-7.45 (m, 3H).
Step 2: 1-(4-Bromo-2-fluoro-phenyl)-ethanone
Figure imgf000367_0002
4-Bromo-2-fluoro-thiobenzoic acid S-pyridin-2-yl ester (39 g, 124.94 mmol) from step 1 below was dissolved in THF (500 mL) and cooled to -78 °C. MeMgBr 3.0 M solution (45 mL, 137.43 mmol) was added and reaction stirred 1 hour at -78 °C. The resulting reaction mixture was poured into NaHC03 (100 mL) and extracted with EtOAC. The combined organics were washed with water (100mL) and brine (100 mL) then dried over Na2S0 , filtered and concentrated. The crude residue was purified by flash chromatography (10% EtOAc in Hexanes) to yield the intermediate ketone as a colorless oil (20g, 74%). H NMR (CDCI3): δ 2.63 (d, 3H, 7 = 5.1 Hz, 3H), 7.37 (dd, 7 = 8.8, 1.9 Hz, 1H), 7.37 (s, 1H), 7.77 (7, 7 = 8.8 Hz, 1H). ESIMS (MH+): 218.2.
Step 1: -Bromo-2-fluoro-thiobenzoic acid S-pyridin-2-yl ester
Figure imgf000368_0001
Aldrithiol-2 (30.18 g, 137 mmol followed by triphenylphosphine (36 g, 137 mmol were added to a solution of 4-bromo-2-fluorobenzoic acid (25 g, 114.16 mmol in CH2CL2 (570 mL) cooled to 0 °C. The resulting mixture was stirred 4 hours at room temperature. The CH2CI2 was then evaporated and residue was purified by flash column chromatography (20% EtOAc in hexanes) to give the product (35 g, 100%) as a pale yellow oil). 1H NMR (CDCI3) δ 7.33-7.44 (m, 3H), 7.71-7.83 (m, 3H), 8.67-8.71 (m, 1H). ESIMS (MH+): 313.1
Example B(116): 3-(6-Chloro-[1,2,4]triazolo[1,5-a]pyrimidin-2-ylmethyl)-6-cyclopentyl-6-{2- [3-fluoro-4-(1-hydroxy-ethyl)-phenyl]-ethyl}-4-hydroxy-5,6-dihydro-pyran-2-one
Figure imgf000368_0002
The title compound was prepared analogously to Example B(97) where where 6-Chloro- [1,2,4]triazolo[1,5-a]pyrimidine-2-carbaldehyde was substituted in place of 5,7-Dimethyl- [1 ,2,4]triazolo[1 ,5-a]pyrimidine-2-carbaldehyde and 6-Cyclopentyl-6-{2-[3-fluoro-4-(1-hydroxy- ethyl)-phenyl]-ethyl}-dihydro-pyran-2,4-dione (Example B(115) (was substituted in place of 6-[2- (3-Chloro-5-ethyl-4-methoxy-phenyl)-ethyl]6-cyclopentyl-dihydro-pyran-2,4-dione of that example. 1H NMR (400MHz, DMSO-d6): δ 1.13 (d, 7 = 6.4 Hz, 3H), 1.23-1.60 (m, 8H), 1.81-1.91 (m, 2H), 2.21-2.25 (m, 1H), 2.40-2.46 (m 3H), 2.6 (d, 7 = 16 Hz, 1H), 3.14 (s, 1H), 3.58 (d, 7 = 16 Hz, 1H), 3.68 (d, 7 = 16 Hz, 1H), 4.78-4.80 (m, 1H), 5.02 (d, 7 = 5 Hz, 1H), 6.75 (d, 7 = 10 Hz, 1H), 6.85 (d, 7 = 7.7 Hz, 1H), 7.23 (t, 7 = 7.70 Hz, 1H), 8.70 (d, 7 = 2.5 Hz, 1H), 9.4 (d, 7 = 2.5 Hz, 1H). Anal. Calcd. For C26H28CIFN4O4-0.5H2O: C, 59.60; H, 5.58; N, 10.69. Found: C, 59.67; H, 5.44; N, 10.65. MS (ESI): 515.2 (M+H)+.
Example B(117): 6-Cyclopentyl-6-[2-(2,4-dimethoxy-phenyl)-ethyl]-3-(5,7-dimethyl- [1,2,4]triazolo[1,5-a]pyrimidin-2-ylmethyl)-4-hydroxy-5,6-dihydro-pyran-2-one
Figure imgf000369_0001
The title compound was prepared analogously to Example B(97) where 1-Bromo-2,4- dimethoxy-benzene was substituted in place of 5-bromo-1-chloro-3-ethyl-2-methoxy-benzene in step 3 of that example. 1H NMR (400MHz, DMSO-d6): δ 1.52-1.89 (m, 8H), 2.06-2.26 (m, 3H), 2.59-2.70 (m, 9H), 2.95 (d, 7 = 16 Hz, 1H), 3.49 (s, 2H), 3.82 (s, 3H), 3.88 (s, 3H), 6.55-6.62 (m, 2H), 7.18-7.21 (m, 2H), 11 (s, 1H). Anal. Calcd. For C28H34N405: C, 66.39; H, 6.76; N, 11.06. Found: C, 66.18; H, 6.76; N, 10.74. MS (ESI): 507 (M+H)+.
Example B(118): 6-Cyclopentyl-6-[2-(2,4-dimethoxy-phenyl)-ethyl]-4-hydroxy-3-(6-methyl- [1,2,4]triazolo[1,5-a]pyrimidin-2-ylmethyl)-5,6-dihydro-pyran-2-one
Figure imgf000369_0002
The title compound was prepared analogously to Example B(97) where 6-Methyl- [1,2,4]triazolo[1,5-a]pyrimidine-2-carbaldehyde was substituted in place of 5,7-Dimethyl- [1 ,2,4]triazolo[1 ,5-a]pyrimidine-2-carbaldehyde and 6-Cyclopentyl-6-[2-(2,4-dimethoxy-phenyl)- ethyl]-4-hydroxy-5,6-dihydro-pyran-2-one was substituted in place of 6-[2-(3-Chloro-5-ethyl-4- methoxy-phenyl)-ethyl]6-cyclopentyl-dihydro-pyran-2, 4-dione of that example.. 1H NMR (400MHz, DMSO-d6): δ 1.36-1.72 (m, 8H), 1.93-2.02 (m, 2H), 2.35 (s, 3H), 2.42-2.58 (m, 2H), 2.76 (d, 7 = 16 Hz, 1H), 3.34 (s, 6H), 3.69 (s, 2H), 3.73 (s, 2H), 6.46 (dd, 7 = 8, 2.5 Hz, 1H), 6.49 (d, 7 = 2.5 Hz, 1H), 7.03 (d, 7 = 8.3 Hz, 1H), 6.70 (d, 7 = 2.5 Hz, 1H), 8.85-8.87 (m, 1H), 10.8 (s, 1H). Anal. Calcd. For C27H32N405: .1H20: C, 63.51; H, 6.71 ; N, 10.97. Found: C, 63.50; H, 6.70; N, 10.87. MS (ESI): 493 (M+H)+.
Example B(119): 3-(6-Chloro-[1,2,4]triazolo[1,5-a]pyrimidin-2-ylmethyl)-6-cyclopentyl-6-[2- (2,4-dimethoxy-phenyl)-ethyl]-4-hydroxy-5,6-dihydro-pyran-2-one
Figure imgf000370_0001
The title compound was prepared analogously to Example B(97), where 6-Chloro- [1,2,4]triazolo[1,5-a]pyrimidine-2-carbaldehyde was substituted in place of 5,7-Dimethyl- [1 ,2,4]triazolo[1 ,5-a]pyrimidine-2-carbaldehyde and 6-Cyclopentyl-6-[2-(2,4-dimethoxy-phenyl)- ethyf]-4-hydroxy-5,6-dihydro-pyran-2-one was substituted in place of 6-[2-(3-Chloro-5-ethyl-4- methoxy-phenyl)-ethyl]6-cyclopentyl-dihydro-pyran-2,4-dione of that example. 1H NMR (400MHz, DMSO-d6): δ 1.51-1.73 (m, 9H), 1.92-1.98 (m, 2H), 2.38-2.58 (m, 3H), 2.79 (d, 7 = 16 Hz, 1H), 3.71 (s, 2H), 3.73 (s, 6H), 6.40-6.5 (m, 2H), 7.03 (d, 7 = 8 Hz, 1H), 8.89 (d, 7 = 2.6 Hz, 1 H), 9.52 (d, 7 = 2.6 Hz, 1 H), 10.9 (s, 1 H). Anal. Calcd. For C26H29CIN4O5.0.25H2O: C, 60.35; H, 5.75; N, 10.83. Found: C, 60.40; H, 5.65; N, 10.74. MS (ESI): 513 (M+H)+.
Example B(120): 6-Cyclopentyl-3-(5,7-dimethyl-[1 ,2,4]triazolo[1 ,5-a]pyrimidin-2-ylmethyl)-4- hydroxy-6-{2-[3-(1-hydroxy-ethyl)-4-methoxy-phenyl]-ethyl}-5,6-dihydro-pyran-2-one
Figure imgf000370_0002
The title compound was prepared analogously to Example B(97) where 6-Cyclopentyl-6- {2-[3-(1-hydroxy-ethyl)-4-methoxy-phenyl]-ethyl}-dihydro-pyran-2,4-dione (from step 2 below) was substituted in place of 6-[2-(3-Chloro-5-ethyl-4-methoxy-phenyl)-ethyl]6-cyclopentyl-dihydro- pyran-2,4-dione of that example. 1H NMR (400MHz, DMSO-d6): δ 1.18-1.24 (m, 3H), 1.37-1.74 (m, 8H), 2.00-2.2 (m, 2H), 2.4-2.83 (m, 9H), 3.75 (s, 3H), 3.75-3.85 (m, 2H), 4.63 (d, 7 = 6 Hz, 1H), 4.93 9 (s, 2H), 6.82 (d, 7 = 8.3 Hz, 1H), 7.05-7.07 (m, 3H), 7.25 (s, 1H), 10.9 (s, 1H). MS (ESI): 521.2 (M+H)+.
Example B(121) 6-Cyclopentyl-6-{2-[3-(1-hydroxy-ethyl)-4-methoxy-phenyl]-ethyl}-dihydro- pyran-2,4-dione (
Figure imgf000371_0001
The title compound was prepared analogously to step 4 from Example B(97) where (R) 1- (5-Bromo-2-methoxy-phenyl)-ethanol (described in step 1 below) was substituted in place of 5- bromo-1-chloro-3-ethyl-2-methoxy-benzene in step 3 of that example. 1H NMR (400MHz, CDCI3): δ 1.6-2.28 (m, 16H), 2.6-2.69 (m, 2H), 2.74 (d, 7 = 7.6 Hz, 2H), 3.41 (d, 7 = 4.8 Hz, 2H), 3.70-3.71 (m, 1H), 3.84 (s, 2H), 6.80 (d, J = 8.9, 1H), 7.01 (d, 7 = 8.0Hz, 1H), 7.12 (s, 1H). ESIMS (MH-): 361.2.
Step 1: (R) 1-(5-Bromo-2-methoxy-phenyl)-ethanol
Figure imgf000371_0002
An oven dried 500 mL flask, was charged under nitrogen with (S) -2-methyl-CBS- oxazaborolidine 1M in toluene (2,18mL) and dissolved in CH2CI2 (100 mL). Me2-BH3 (13.10 mL, 26.20 mmol) was then added and cooled reaction to -30 °C then stirred for 15 minutes. 5- Bromo-2-methoxyacetophenone (5 g, 21.83 mmol) was dissolved in CH2CI2 (10 mL) and slowly added via addition funnel to the previous solution. The resulting reaction was stirred at -30 °C for 1 hour. The solution was carefully quenched with MeOH, the solvent was removed in vacuo and the residue was purified by flash column chromatography (20% EtOAc in hexanes) to provide the desired product (5 g, 100%) as a clear oil. 1H NMR (400MHz, CDCI3): δ 1.47 (d, 7 = 6.41 Hz, 3H), 2.44 (d, 7 = 5Hz, 1H), 3.84 (s, 3H), 5.03-5.11 (m, 1H), 6.74 (d, 7 = 8.7Hz, 1H), 7.33 (dd, 7 = 8.7, 2.5 Hz, 1H), 7.48 (d, 7 = 2.5 Hz, 1H).
Example B(122): 6-{2-[3-Chloro-4-(2-methyl-[1 ,3]dioxolan-2-yl)-phenyl]-ethyl}-6- cyclopentyl-3-(5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-ylmethyl)-4-hydroxy-5,6- dihydro-pyran-2-one
Figure imgf000372_0001
The title compound was prepared analogously to Example B(97) where Example B(123) ( 6-Cyclopentyl-6-{2-[3-fluoro-4-(1-hydroxy-ethyl)-phenyl]-ethyl}-dihydro-pyran-2, 4-dione (below) was substituted in place of 6-[2-(3-Chloro-5-ethyl-4-methoxy-phenyl)-ethyl]6-cyclopentyl-dihydro- pyran-2,4-dione of that example. 1H NMR (400MHz, DMSO-d6): δ 1.5-1.7 (m, 9H) 2.20-2.22 (m, 2H), 2.49-2.90 (m, 10 H), 3.39 (s, 3H), 3.70-3.74 (m, 2H), 3.78 (d, 7 = 16 Hz, 1H), 3.90 (d, 7 = 16 Hz, 1H), 4.04-4.07 (m, 2H), 7.13 (s, 1H), 7.32 (s, 1H), 7.36 (d, 7 = 8 Hz, 1H), 7.61 (d, 7 = 8 Hz, 1H), 10.9 (s, 1H). Anal. Calcd. For C3oH35CIN405: C, 63.54; H, 6.22; N, 9.88. Found: C, 63.27; H, 6.27; N, 9.56. MS (ESI): 567.2 (M+H)+.
Example B(123): 6-{2-[3-Chloro-4-(2-methyl-[1 ,3]dioxolan-2~yl)-phenyl]-ethyl}-6- cyclopentyl-dihydro-pyran-2,4-dione (
Figure imgf000372_0002
The title compound was prepared analogously to step 4 from Example B(97) where 2-
(4-Bromo-2-chloro-phenyl)-2-methyl-[1 ,3]dioxolane (described in step 3 below) was substituted in place of 5-bromo-1-chloro-3-ethyl-2-methoxy-benzene in step 3 of that example. 1H NMR (CDCI3-d6): δ 1.57-1.73 (m, 8H), 1.78 (s, 3H), 1.91-1.98 (m, 2H), 2.2-2.3 (m, 1H), 2.62-2.68 (m, 2H), 2.77 (d, 7 = 2.2 Hz, 2H), 3.43 (s, 2H), 3.75-3.79 (m, 2H), 4.04-4.09 (m, 2H), 7.01 (dd, 7 = 7.9, 1.8 Hz, 1H), 7.17 (d, 7 = 1.8 Hz, 1H), 7.55 (d, 7 = 7.9 Hz, 1H). ESIMS (MNa+): 429.1
Step 3: 2-(4-Bromo-2-chloro-phenyl)-2-methyl-[1,3]dioxolane.
Figure imgf000372_0003
1-(4-Bromo-2-chloro-phenyl)-ethanone (from step 2 below) (1.86 g, 5.66 mmol), below was dissolved in ethylene glycol (5 mL). Triethylorthoformate (0.71 g, 4.79 mmol), and tosic acid (0.02g) were added and reaction was stirred under nitrogen for 24 hours at room temperature. The resulting reaction mixture was poured into NaHC03 (10 mL) and extracted with EtOAC. The combined organics were washed with water (10mL) and brine (10 mL) then dried over Na2S0 , filtered and concentrated. The crude residue was purified by flash chromatography (5% EtOAc in
Hexanes) to yield the intermediate ether as a colorless oil (0.69 g, 58%). 1H NMR (CDCI3): δ 1.77 (s, 3H), 3.74-3.79 (m, 2H), 4.04-4.09 (m, 2H), 7.37 (dd, 7 = 8.5, 1.9 Hz, 1H), 7.52 (d, 7 = 8.5 Hz, 1 H), 7.55 (d, 7 = 1.9 Hz, 1 H). ESIMS (MH+): 278.2.
Step 2: 1-(4-Bromo-2-chloro-phenyl)-ethanone
Figure imgf000373_0001
The title compound was prepared analogously to Step 2 from Example X(X): 6-
Cyclopentyl-3-(5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-ylmethyl)-6-{2-[3-fluoro-4-(1-hydroxy- ethyl)-phenyl]-ethyl}-4-hydroxy-5,6-dihydro-pyran-2-one where 4-Bromo-2-chloro-thiobenzoic acid S-pyridin-2-yl ester (described in step 1 below) was substituted in place of 4-Bromo-2-fluoro- thiobenzoic acid S-pyridin-2-yl ester. 1H NMR (CDCI3) .δ2.64 (s, 3H), 7.46-7.48 (m,2H), 7.61 (s, 1H). ESIMS (MH+): 234.1
Step 1: 4-Bromo-2-chloro-thiobenzoic acid S-pyridin-2-yl ester
Figure imgf000373_0002
The title compound was prepared analogously to Step 1 from Example X(X): 6- Cyclopentyl-3-(5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-ylmethyl)-6-{2-[3-fluoro-4-(1-hydroxy- ethyl)-phenyl]-ethyl}-4-hydroxy-5,6-dihydro-pyran-2-one where 4-bromo-2-chlorobenzoic acid was substituted in place of 4-bromo-2-fluorobenzoic acid. of that example. 1H NMR (CDCI3) ,δ7.34- 7.38 (m, 1H), 7.53 (dd, 7 = 8.3, 1.7 Hz, 1H), 7.67-7.85 (m,4H), 8.68 (d, 7 = 5.6 Hz, 1H). ESIMS (MH+): 329.1 Example B(124): 6-[2-(4-Acetyl-3-chloro-phenyl)-ethyl]-6-cyclopentyl-3-(5,7-dimethyl-
Figure imgf000374_0001
The title compound was prepared in the following way: Example B(122) 6-{2-[3-Chloro-4- (2-methyl-[1,3]dioxolan-2-yl)-phenyl]-ethyl}-6-cyclopentyl-3-(5,7-dimethyl-[1,2,4]triazolo[1,5- a]pyrimidin-2-ylmethyl)-4-hydroxy-5,6-dihydro-pyran-2-one (0.138 g, 0.24 mmol), was dissolved in acetone (8 mL). Amberlyst-13 (0.23g) was added from top and reaction was stirred under nitrogen for 72 hours at room temperature. The resulting reaction mixture was filtered through fritted funnel to remove the amberlyst and the resultant filtrate was diluted with EtOAC and washed with water (10mL) and brine (10 mL) then dried over Na2S0 , filtered and concentrated. The resultant solid was recrystallized from MeOH to yield the product as a white solid (0.05 g, 41%). 1H NMR (400MHz, DMSO-d6): δ 1.5-1.7 (m, 9H) 2.20-2.22 (m, 2H), 2.49-2.90 (m, 10 H), 3.39 (s, 3H), 3.78 (d, 7 = 16 Hz, 1H), 3.90 (d, 7 = 16 Hz, 1H), 7.13 (s, 1H), 7.32 (s, 1H), 7.36 (d, 7 = 8 Hz, 1H), 7.61 (d, 7 = 8 Hz, 1H), 10.9 (s, 1H). MS (ESI): 523 (M+H)+.
Example B(125): 1-(2-Chloro-4-{2-[2-cyclopentyl-4-hydroxy-5-(6-methyl-[1,2,4]triazolo[1,5- a]pyrimidin-2-ylmethyl)-6-oxo-3,6-dihydro-2H-pyran-2-yl]-ethyl}-phenyl)- cyclopropanecarbonitrile
Figure imgf000374_0002
The title compound was prepared analogously to Example B(97) (where 1-(2-Chloro-4-{2- [2-cyclopentyl-5-(5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-ylmethyl)-4-hydroxy-6-oxo-3,6- dihydro-2/-/-pyran-2-yl]-ethyl}-phenyl)-cyclopropanecarbonitrile was substituted in place of 6-[2-(3- Chloro-5-ethyl-4-methoxy-phenyl)-ethyl]-6-cyclopentyl-dihydro-pyran-2,4-dione in that example and 6-Chloro-[1,2,4]triazolo[1,5-a]pyrimidine-2-carbaldehyde in place of the 5,7-Dimethyl- [1,2,4]triazolo[1,5-a]pyrimidine-2-carbaldehyde in that example. 1H NMR (400 MHz, CDCI3) δ: 1.38-1.42 (m, 2H), 1.47-1.73 (m, 8H), 1.73-1.77 (m, 2H), 2.01-2.21 (m, 2H)), 2.39-2.50 (m, 1H), 2.56 (d, 7 = 16 Hz, 1H), 2.63-2.69 (m, 2H), 2.80 (d, 7 = 16 Hz, 1H ), 3.3 (s, 3H), 3.75 (d, 7 = 16 Hz, 1H), 3.85 (d, 7 = 16 Hz, 1H), 7.29 (dd, 7 = 8, 1.6 Hz, 1H), 7.43-7.45 (m, 2H), 8.74 (d, 7 = 2.3 Hz, 1H), 9.01 (dd, 7 = 2.3, 1,1 Hz, 1H), 10.9 (s, 1H). C29H30CIN5O3.0.25: C, 64.68; H, 6.08; N, 13.00. Found: C, 64.78; H, 5.74; N, 12.65. MS (ESI): 532.2(M+H+).
Example B(126): 1 -(2-Chloro-4-{2-[5-(6-chloro-[1 ,2,4]triazolo[1 ,5-a]pyrimidin-2-ylmethyl)-2- cyclopentyl-4-hydroxy-6-oxo-3,6-dihydro-2H-pyran-2-yl]-ethyl}-phenyl)- cyclopropanecarbonitrile
Figure imgf000375_0001
The title compound was prepared analogously to Example B(97), 1-(2-Chloro-4-{2-[2- cyclopentyl-5-(5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-ylmethyl)-4-hydroxy-6-oxo-3,6- dihydro-2/-/-pyran-2-yl]-ethyl}-phenyl)-cyclopropanecarbonitrile was substituted in place of 6-[2- (3-Chloro-5-ethyl-4-methoxy-phenyl)-ethyl]-6-cyclopentyl-dihydro-pyran-2,4-dione in that example and 6-Methyl-[1,2,4]triazolo[1,5-a]pyrimidine-2-carbaldehyde in place of the 5,7-Dimethyl- [1,2,4]triazolo[1,5-a]pyrimidine-2-carbaldehyde in that example. 1H NMR (400 MHz, CDCI3) δ: 1.16-1.18 (m, 2H), 1.19-1.5 (m, 8H), 1.51-1.53 (m, 2H), 1.86-1.89 (m, 2H)), 2.16-2.29 (m, 1H), 2.35-2.47 (m, 3H), 2.59 (d, 7 = 17 Hz, 1H ), 3.56 (d, 7 = 16 Hz, 1H), 3.65 (d, 7 = 16 Hz, 1H), 7.08 (d, 7 = 7.8, 1 Hz, 1H), 7.20-7.23 (m, 2H), 8.70 (d, 7 = 2.5 Hz, 1H), 9.41 (d, 7 = 2.5, 1,1 Hz, 1H), 10.7 (s, 1H). C28H27CI2N5O3.0.25: C, 60.38; H, 4.98; N, 12.57. Found: C, 60.30; H, 4.80; N, 12.53. MS (ESI): 552.2(M+H+).
Example C(1): 6-Cyclopentyl-6-[2-(3-fluoro-4-isopropoxy-phenyl)-ethyl]-4-hydroxy-3- (quinolin-8-ylsulfanyl)-5,6-dihydro-pyran-2-one.
Figure imgf000375_0002
The title compound was prepared analogously to Example C(4), where Quinoline-8-thiol was substituted in place of 5-Pyridin-4-yl-4H-[1 ,2,4]triazole-3-thiol.
'H Ni R CCDC ): δ 1.33 (d, 7= 6.1 Hz, 6H)1.39-1.74 (brm, 8H), 1.88 (m, 2H), 2.36 (m, IH), 2.53 (m, 2H), 2.74 (d, 7= 18 Hz IH), 2.92 (m, 2H), 4.42 (m, IH), 6.81 (d, 7= 8.4 Hz IH), 6.93 (d, 7= 7.8 Hz IH), 7.01 (s, IH), 7.54-7.60 (m, 2H), 7.92 (d, 7= 8.1 Hz IH), 8.33 (d, 7= 8.1 Hz IH), 8.51 (d, 7= 7.8Hz IH), 8.97 (s, IH). Anal. Calcd. For C30H32FNO4S: C, 69.07; H, 6.18; N, 2.69. Found: C, 69.22; H, 6.08; N, 2.86.
Example C(2): 3-(5-Chloro-1-isopropyl-1-benzoimidazol-2-ylsulfanyl)-6-cyclopentyI-6-[2-(3- fluoro-4-isopropoxy-phenyl)-ethyl]-4-hydroxy-5,6-dihydro-pyran-2-one.
Figure imgf000376_0001
The title compound was prepared analogously to Example C(4), where 5-Chloro-1-isopropyl-1H- benzoimidazole-2-thiol was substituted in place of 5-Pyridin-4-yl-4H-[1 ,2,4]triazole-3-thiol. ESIMS (MH+): 588.3
Example C(3): 6-[2-(3-Chloro-4-methoxy-phenyl)-ethyl]-6-cyclopentyl-4-hydroxy-3- (quinolin-8-ylsulfanyl)-5,6-dihydro-pyran-2-one.
Figure imgf000377_0001
The title compound was prepared analogously to Example C(4), where Quinoline-8-thiol was substituted in place of 5-Pyridin-4-yl-4H-[1 ,2,4]triazole-3-thiol.
1H NMR (CDCI3): δ 1.25-1.74 (brm, 8H), 1.88 (m, 2H), 2.36 (m, 1H), 2.53 (m, 2H), 2.74 (d, 7 = 18 Hz 1H), 2.92 (m, 2H), 3.86 (s, 3H), 6.79 (d, 7 = 8.4 Hz 1H), 6.91 (d, 7 = 7.8 Hz 1H), 7.01 (s, 1H), 7.56-7.61 (m, 2H), 7.90 (d, 7 = 8.1 Hz 1H), 8.33 (d, 7 = 8.1 Hz 1H), 8.47 (d, 7 = 7.8Hz 1H), 8.97 (s, 1H). Anal. Calcd. For C28H28CIN04S: C, 65.94; H, 5.53; N, 2.75. Found: C, 65.68; H, 5.22; N, 2.85.
Figure imgf000377_0002
Example C(4): 6-(2-Cyclohex-1 -enyl-ethyl)-6-cyclopentyl-4-hydroxy-3-(5-pyridin-4-yl-4H- [1 ,2,4]triazol-3-ylsulfanyl)-5,6-dihydro-pyran-2-one.
A solution of 3-Chloro-6-(2-cyclohex-1-enyl-ethyl)-6-cyclopentyl-4-hydroxy-5,6-dihydro- pyran-2-one (150mg, 0.46 mmol, from Step 1 below), 5-Pyridin-4-yl-4H-[1,2,4]triazole-3-thiol (82mg, 0.46 mmol), and triethylamine (64 DL, 0.46 mmol) dissolved in DMF (5mL) was heated to 55°C under N2for 8h. The resulting mixture was concentrated and purified by Prep HPLC to give the title compound (58mg, 27%) as a pale yellow solid. 1HNMR (DMSO-t/6): δ 1.62-1.82 (m, 12H), 2.03 -2.11 (m, 8H),2.51 (m, IH), 2.87 (d, IH, 7= 17.5 Hz), 3.11 (d, IH, 7= 17.5 Hz), 5.55 (s, IH), 8.01 (d, 2H, 7= 5.8 Hz), 8.84 (d, 2H, 7= 5.8 Hz). ESIMS: MH1" 467.15
Figure imgf000378_0001
Step 1 : 3-Chloro-6-(2-cyclohex-1-enyl-ethyl)-6-cyclopentyl-4-hydroxy-5,6-dihydro-pyran-2- one.
Methyl-2-chloroacetoacetate (1.12g, 7.42mmol) was added to a cooled -40 °C suspension of NaH (0.3 g, 7.42 mmol, 60% dispersion in mineral oil) in THF (15ml). After 20 min n-BuLi (3.0mL, 7.42mmol, 2.5M in hexanes) was added. The resulting dianion was stirred for an additional 30 min and then treated with a solution of 3-Cyciohex-1-enyl-1-cyclopentyl-propan-1- one (0.51 g, 2.47mmol,) in THF (10ml). After stirring for 2 h at -40 °C, the reaction mixture was quenched with saturated NH CI and extracted with EtOAc. The organic layers were washed with brine, dried with Na2S0 and concentrated to a yellow oil that was used without further purification.
The oil was dissolved in toluene (8mL), treated with bis(dibutylchlorotin)oxide (0.61 g, 1.1 mmol), and heated to 100°C under N2for 1h. The resulting mixture was concentrated and purified by silica gel chromatography to give the title compound (0.31 g, 38% yield).
'H NMR CCDCls): δ 1.41-1.72 (m, 12H), 1.75 - 2.0 (m, 8H), 2.31 (m, IH), 2.63 (d, IH, 7= 17.8 Hz), 2.85 (d, IH, 7= 17.8 Hz), 5.40 (s, IH), 6.47 (br s, IH). ESIMS: MH+ 325.20
Example C(5): 3-(5-Chloro-1-isopropyl-1H-benzoimidazol-2-ylsulfanyl)-6-(2-cyclohex-1- enyl-ethyl)-6-cyclopentyl-4-hydroxy-5,6-dihydro-pyran-2-one.
Figure imgf000378_0002
The title compound was prepared analogously to example C(4), where 5-Chloro-1- isopropyl-1H-benzoimidazole-2-thiol was substituted in place of 5-Pyridin-4-yl-4H-[1,2,4]triazole- 3-thiol.
'HNMR(DMSO-c ): δ 1.50-1.67 (m, 18H), 1.91 - 1.98 (m, 7H),2.16 (m, 1H), 2.37 (m, 1H), 2.59 (d, 1 H, 7= 17.5 Hz), 2.92 (d, IH, 7= 17.5 Hz), 4.14 (m, IH), 5.43 (s, IH), 8.67 (d, IH, 7= 8.7 Hz), 7.32 (s, IH), 7.66 (d, IH, 7= 8.7 Hz). Anal. Calcd. For CΛNASCIO.S H20: C, 64.61; H, 6.89; N, 5.38. Found: C, 64.57; H, 6.97; N, 5.18.
Figure imgf000379_0001
Example C(6): 6-[2-(3-Chloro-4-methoxy-phenyl)-ethyl]-6-cyclopentyl-4-hydroxy-3-(5- hydroxy-4-isopropyl-4H-[1,2,4]triazol-3-ylsulfanyl)-5,6-dihydro-pyran-2-one.
The title compound was prepared analogously to example C(40), where 4-lsopropyl-5- mercapto-4H-[1 ,2,4]triazol-3-ol was substituted in place of 5-chloro-1 -isopropyl-1 H- benzimidazole-2-thiol.
1HNMR (DMSO-c 6): δ 1.50 (d, 6H, 7= 6.8 Hz) 1.42-1.67 (br m, 9H), 1.96 (m, 2H), 2.40 (m, IH), 2.51 (m, IH), 2.73 (d, IH, 7= 17.7 Hz), 2.90 (d, IH, 7= 17.7 Hz), 3.82 (s, 3H), 4.33 (m, IH), 7.08 (m, 2H), 7.26 (s, IH), 11.60 (s, IH), 12.31 (br s, IH). Anal. Calcd. For C24H28N306C1S: C, 55.22; H, 5.41, N, 8.05. Found: C, 55.02; H, 5.42, N, 8.17.
Example C(7): 6-Cyclopentyl-3-(5,7-dimethyl-[1 ,2,4]triazolo[1 ,5-a]pyrimidin-2-ylsulfanyl)-6- [2-(3-fluoro-4-isopropoxy-phenyl)-ethyl]-4-hydroxy-5,6-dihydro-pyran-2-one.
Figure imgf000379_0002
The title compound was prepared analogously to example C(64), where 5,7-Dimethyl-
[1 ,2,4]triazolo[1 ,5-a]pyrimidine-2-thiol was substituted in place of 5-chloro-1 -methyl-1 H- benzimidazole-2-thiol.
*H NMR (DMSO- ): δ 1.26 (d, 6H, 7= 6.0 Hz), 1.44-1.73 (br m, 9H), 2.21 (m, 2H), 2.39 (s, 3H), 2.53 (s,
3H), 2.58 (m, 2H), 2.71 (d, IH, 7= 17.6 Hz), 2.90 (d, IH, 7= 17.6 Hz), 4.53 (s, IH), 7.04 - 7.13 (m, 4H).
Anal. Calcd. For C2sH33N4O4FS«0.4 AcOH: C, 61.26; H, 6.18; N, 9.92. Found: C, 61.33; H, 6.40, N, 9.70.
Example C(8): 6-Cyclopentyl-6-[2-(3-fluoro-4-isopropoxy-phenyl)-ethyl]-4-hydroxy-3-(4- hydroxy-phenylsulfanyl)-5,6-dihydro-pyran-2-one.
Figure imgf000380_0001
The title compound was prepared analogously to example C(64), where 4-Mercapto- phenol was substituted in place of 5-chloro-1 -methyl-1 /-/-benzimidazole-2-thiol. Η NMR (DMSO- ): δ 1.34(d, 6H, 7= 6.0 Hz) 1.43-1.76 (br m, 8H), 1.97 (m, 2H), 2.38 (m, IH), 2.59 (m, 3H), 2.90 (d, IH, 7= 17.9 Hz), 4.48 (m, IH), 6.70 (d, 2H, 7= 7.8 Hz), 6.80 (m, 3H), 7.25 (d, 2H, 7= 7.8 Hz). Anal. Calcd. For C27H3105FS «0.8 H20: C, 64.73; H, 6.56. Found: C, 64.54; H, 6.46.
Example C(9): 6-Cyclopentyl-6-[2-(3-fluoro-4-isopropoxy-phenyl)-ethyl]-4-hydroxy-3-(5- methyl-[1,3,4]thiadiazol-2-ylsulfanyl)-5,6-dihydro-pyran-2-one.
Figure imgf000380_0002
The title compound was prepared analogously to example C(64), where 5-Methyl- [1 ,3,4]thiadiazole-2-thiol was substituted in place of 5-chloro-1 -methyl-1 /-/-benzimidazole-2-thiol. Η NMR (DMSO-tfe): δ 1.31 (d, 6H, 7= 5.8 Hz) 1.39-1.76 (br m, 9H), 2.05 (m, 2H), 2.46 (m, IH), 2.62 (m, 3H), 2.65 (m, IH), 2.78 (d, IH, 7= 17.9 Hz), 3.00 (d, IH, 7= 17.9 Hz), 4.59 (m, IH), 6.99 (d, IH, 7= 8.5 Hz), 7.10 (s, IH), 7.12 (d, IH, 7= 8.5 Hz). Anal. Calcd. For C24H29N2O4FS2 «0.5 H20: C, 57.46; H, 6.03; N, 5.58. Found: C, 57.43; H, 5.88; N, 5.54.
Example C(10): 5-{6-Cyclopentyl-6-[2-(3-fluoro-4-isopropoxy-phenyl)-ethyl]-4-hydroxy-2- oxo-5,6-dihydro-2H-pyran-3-ylsulfanyl}-4-methyl-4H-[1 ,2,4]triazole-3-carboxylic acid methyl ester.
Figure imgf000381_0001
The title compound was prepared analogously to example C(64), where 5-Mercapto-4- methyl-4H-[1,2,4]triazole-3-carboxylic acid methyl ester was substituted in place of 5-chloro-1- methyl-1H-benzimidazole-2-thiol.
'HNMR (DMSO-rf6): δ 1.31 (d, 6H, 7= 6.0Hz) 1.37-1.74 (br m, 9H), 2.05 (m, 2H), 2.46 (m, IH), 2.59 (m, IH), 2.74 (d, IH, 7= 17.6 Hz), 2.97 (d, IH, 7= 17.7 Hz), 3.85 (s, 3H), 3.94 (s, 3H), 4.58 (m, IH), 6.99 - 7.15 (m, 3H). Anal. Calcd. For C26H32N3O6FS-0.3 H20: C, 57.93; H, 6.10; N, 7.80. Found: C, 57.89; H, 6.08; N, 7.64.
Example C(11): 6-Cyclopentyl-6-[2-(3-fluoro-4-isopropoxy-phenyl)-ethyl]-4-hydroxy-3- (pyrimidin-2-ylsulfanyI)-5,6-dihydro-pyran-2-one.
Figure imgf000381_0002
The title compound was prepared analogously to example C(64), where Pyrimidine-2- thiol was substituted in place of 5-chloro-1 -methyl-1 /-/-benzimidazole-2-thiol lH NMR (OMSO-d6): δ 1.27 (d, 6H, 7= 6.0Hz) 1.37-1.74 (br m, 9H), 2.20 (m, 2H), 2.60 (m, 2H), 2.73 (d, IH, 7= 17.6 Hz), 2.94 (d, IH, 7= 17.6 Hz), 4.56 (m, IH), 6.95 (d, IH, 7= 8.3 Hz), 7.06 (m, 2H), 7.14 (t, IH, 7= 4.7 Hz), 8.40 (d, 2H, 7= 4.8 Hz). Anal. Calcd. For C25H29N2O4FS-0.3 H20: C, 62.82; H, 6.24; N, 5.86. Found: C, 62.76; H, 6.25; N, 5.75.
Example C(12): 6-Cyclopentyl-6-[2-(3-fluoro-4-isopropoxy-phenyl)-ethyl]-4-hydroxy-3-(5- hydroxy-4-isopropyl-4H-[1,2,4]triazol-3-ylsulfanyl)-5,6-dihydro-pyran-2-one.
Figure imgf000382_0001
The title compound was prepared analogously to example C(64), where 4-lsopropyl-5- mercapto-4H-[1 ,2,4]triazol-3-ol was substituted in place of 5-chloro-1 -methyl-1 H-benzimidazole-2- thiol
!H NMR (DMSO- ): δ 1.27 (d, 6H, 7= 6.0Hz), 1.39 (d, 6H, 7= 7.0Hz), 1.45-1.66 (br m, 9H), 1.96 (m, 2H), 2.4 (m, IH), 2.54 (IH), 2.73 (d, IH, 7= 17.8 Hz), 2.88 (d, IH, 7= 17.7 Hz), 4.33 (m, IH), 4.54 (m, IH), 6.90 (d, IH, 7= 8.3 Hz), 7.02 - 7.11 (m, 2H). Anal. Calcd. For C26H34N305FSO.3 H20: C, 59.48; H, 6,64; N, 8.00. Found: C, 59.58; H, 6.64; N, 7.99.
Example C(13): 6-Cyclopentyl-6-{2-[4-(3,5-dimethyl-isoxazol-4-yl)-phenyl]-ethyl}-3-(5,7- dimethyl-[1,2,4]triazolot1,5-a]pyrimidin-2-ylsulfanyl)-4-hydroxy-5,6-dihydro-pyran-2-one.
Figure imgf000382_0002
The title compound was prepared from 3-Chloro-6-cyclopentyl-6-{2-[4-(3,5-dimethyl- isoxazol-4-yl)-phenyl]-ethyl}-4-hydroxy-5,6-dihydro-pyran-2-one from Step 2 and 5,7-Dimethyl- [1,2,4]triazolo[1,5-a]pyrimidine-2-thiol using the coupling method described in Example C(4), *H NMR (DMSO-tf6): δ 1.44-1.75 (br m, 9H), 2.21 (s, 3H), 2.34 (s, 3H), 2.38 (s, 3H), 2.59 (s, 3H), 2.65 -2.79 (m, 3H), 2.97 (d, IH, 7= 17.0 Hz), 3.17 (s, 2H), 7.02 (s, IH), 7.29 (d, 2H, 7= 8.1 Hz), 7.40 (d, 2H, 7= 8.1 Hz). Anal. Calcd. For C30H33N5O4S«0.75 AcOH: C, 62.56; H, 6.00; N, 11.58. Found: C, 62.66; H, 5.98; N, 11,56.
Figure imgf000383_0001
Step 1: 1-Cyclopentyl-3-[4-(3,5-dimethyl-isoxazol-4-yl)-phenyl]-propan-1-one.
The title compound was prepared as described in Step 1 of Example A(82), where 4-(4- Bromo-phenyl)-3,5-dimethyl-isoxazole from Step 1 of Example A(18), was substituted for 2- Bromopyridine.
Step 2: 3-Chloro-6-cyclopentyl-6-{2-[4-(3,5-dimethyl-isoxazol-4-yl)-phenyl]-ethyl}-4- hydroxy-5,6-dihydro-pyran-2-one.
Figure imgf000383_0002
The title compound was prepared as described in Step 1 of Example C(4),where 1- Cyclopentyl-3-[4-(3,5-dimethyl-isoxazol-4-yl)-phenyl]-propan-1-one was substituted for 3- Cyclohex-1 -enyl-1 -cyclopentyl-propan-1 -one )
Example C(14): 3-(5-Chloro-1 -methyl-1 H-benzoimidazol-2-ylsulfanyl)-6-cyclopentyl-6-{2- [4-(3,5-dimethyl-isoxazol-4-yl)-phenyl]-ethyl}-4-hydroxy-5,6-dihydro-pyran-2-one.
Figure imgf000384_0001
The title compound was prepared analogously to example C(13) where 5-Chloro-1- methyl-1H-benzoimidazole-2-thiol was substituted in place of 5,7-Dimethyl-[1,2,4]triazolo[1,5- a]pyrimidine-2-thiol.
Η NMR (CDCI3): δ 1.27 - 1.74 (br m, 9H), 2.09 (m, 2H), 2.25 (s, 3H), 2.38 (s, 3H), 2.39 (m, IH), 2.70 (m, 3H), 3.93 (s, 3H), 7.14 (d, 2H, 7= 8.1 Hz), 7.21 (d, 2H, 7= 8.1 Hz), 7.26 - 7.34 (m, 2H), 7.55 (s, IH). Anal. Calcd. For C3ιH32N3O4SCl«0.7 H20: C, 63.03; H, 5.70; N, 7.11. Found: C, 63.01; H, 5.75; N, 6.97.
Example C(15): 3-(5-Chloro-1-isopropyl-1H-benzoimidazol-2-ylsulfanyl)-6-ethyl-4-hydroxy- 6-[2-(4-methoxy-phenyl)-ethyl]-5,6-dihydro-pyran-2-one.
Figure imgf000384_0002
The title compound was prepared from 3-Chloro-6-ethyl-4-hydroxy-6-[2-(4-methoxy- phenyl)-ethyl]-5,6-dihydro-pyran-2-one from Step 1 and 5-Chloro-1-isopropyl-1H- benzoimidazole-2-thiol using the coupling method described in Example C(4), Η NMR (CDCI3): δ 0.96 (t, 3H, 7= 7.5 Hz), 1.69 (d, 6H, 7= 7.0 Hz), 1.85 (m, 2H), 1.98 (m, 2H), 2.59 (m, 2H), 2,71 (s, 2H), 3.78 (s, 3H), 5.16 (m, IH), 6.81 (d, 2H, J= 8.5 Hz), 7.06 (d, 2H, 7= 8.5 Hz), 7.28 (d, 2H, 7= 8.9 Hz), 7.48 (d, IH, 7= 8.9 Hz), 7.59 (s, IH). ESIMS: MH+501.10, 503.10, MH" 4.99.10, 501.10.
Step 1 : 3-Chloro-6-ethyl-4-hydroxy-6-[2-(4-methoxy-phenyl)-ethyl]-5,6-dihydro-pyran-2-one.
Figure imgf000385_0001
The title compound was prepared as described in Step 1 of Example C(4),where 1-(4- Methoxy-phenyl)-pentan-3-one (from Step 2 of Example A(23)) was substituted in place of cyclohex-1 -enyl-1 -cyclopentyl-propan-1 -one.
Figure imgf000385_0002
Example C(16): 3-(5,7-Dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-ylsulfanyl)-6-ethyl-4- hydroxy-6-[2-(4-methoxy-phenyl)-ethyl]-5,6-dihydro-pyran-2-one.
The title compound was prepared analogously to Example C(15) where 5,7-Dimethyl- [1,2,4]triazolo[1 ,5-a]pyrimidine-2-thiol was substituted in place of 5-Chloro-1-isopropyl-1H- benzoimidazole-2-thiol.
ΗNMR(CDC13): δ 1.01 (t, 3H, 7= 7.4 Hz), 1.97 (m, 2H), 2.10 (m, 2H), 2.62 (s, 3H), 2.63 (s, 3H), 2. (m, 2H), 2.83 (s, 2H),3.78 (s, 3H), 6.76 (s, IH), 6.82 (d, 2H, 7= 8.5 Hz), 7.12 (d, 2H, 7= 8.5 Hz). Anal. Calcd. For C23H26N404SO.6H20: C, 59.36; H, 5.89; N, 12.04. Found: C, 59.26; H, 5.76; N, 11.52.
Example C(17): 6-Cyclopentyl-3-(5,7-dimethyl-[1,2,4]triazolo[1,5-apyrimidin-2-ylsulfanyl)-4- hydroxy-6-methyl-5,6-dihydro-pyran-2-one.
Figure imgf000385_0003
The title compound was prepared from 3-Chloro-6-cyclopentyl-4-hydroxy-6-methyl-5,6- dihydro-pyran-2-one (described in Step 2 below ) and 5,7-Dimethyl-[1 ,2,4]triazolo[1 ,5- a]pyrimidine-2-thιol using the coupling method described in Example C(4).1HNMR (CDC13): δ 1.54 (s, 3H), 1 ,55 - 2.32 (br m, 9H), 2.59 (m 1 H), 2.64 (s, 3H), 2.71 (s, 3H), 2.96 (m, 1 H), 6.77 (s, 1H). ESIMS: MH+375.10, MH- 373.10.
Step l: 1-Cyclopentyl-ethanone.
Figure imgf000386_0001
Cyclopentylmagnesium bromide (5mL, 10mmol, 2M soln in THF) was added to a cooled ■ 78°C solution of acetic anhydride (O.δmL, 8.33mmol) dissolved in THF (20mL). The reaction mixture was stirred for 60 min. The reaction was quenched with saturated NH4CI and extracted with EtOAc. The organic layers were washed with brine, dried over Na2S04 and concentrated to a yellow oil. The residue was purified by silica gel chromatography (hexanes) to give the title compound as an oil (0.5g, 54%). 'HNMRCCDC ): δ 1.55 - 1.84 (br m, 8H), 2.16 (s, 3H), 2.87 (m, 1H).
Step 2: 3-Chloro-6-cyclopentyl-4-hydroxy-6-methyl-5,6-dihydro-pyran-2-one.
Figure imgf000386_0002
The title compound was prepared as described in Step 1 of Example C(4),where 1- Cyclopentyl-ethanone (from Step 1 ) was substituted in place of cyclohex-1-enyl-1-cyclopentyl- propan-1-one. ESIMS: MH+ 231.10, MH" 230.10
Example C(18): 3-(5,7-Dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-ylsulfanyl)-6,6-diethyl-4- hydroxy-5,6-dihydro-pyran-2-one.
Figure imgf000387_0001
The title compound was prepared from 3-Chloro-6,6-diethyl-4-hydroxy-5,6-dihydro-pyran- 2-one (from Step 1 ) and 5,7-Dimethyl-[1,2,4]triazolo[1,5-a]pyrimidine-2-thiol using the coupling method described in Example 0(4).^ NMR (CDC13): δ 0.97 (t, 6H, 7= 7.5 Hz), 1.85 (m, 2H)5 1.94 (m, 2H), 2.63 (s, 3H), 2.71 (s, 3H), 2.78 (s, 2H), 6.78 (s, IH). Anal. Calcd. For C16H20N4O3S«0.5H2O: C, 53.76; H, 5.92; N, 15.68. Found: C, 53.96; H, 5.84; N, 15.37.
Step 1 : 3-Chloro-6,6-diethyl-4-hydroxy-5,6-dihydro-pyran-2-one.
Figure imgf000387_0002
The title compound was prepared as described in Step 1 of Example C(4),where 3- pentanone was substituted in place of cyclohex-1-enyl-1-cyclopentyl-propan-1-one.
Example C(19): 3-(5-Chloro-1 -isopropyl-1 H-benzoimidazol-2-y!sulfanyl)-6,6-diethyl-4- hydroxy-5,6-dihydro-pyran-2-one.
Figure imgf000387_0003
The title compound was prepared analogously to Example 0(18) where 5-Chloro-1- isopropyl-1 H-benzoimidazole-2-thiol was substituted in place of 5,7-Dimethyl-[1 ,2,4]triazolo[1 ,5- aJpyrimidine^-thiol.'H MR^DCls): δ 0.91 (t, 6H, 7= 7.4 Hz), 1.68 (d, 6H, J= 7.0 Hz), 1.69- 1.85 (m, 4H), 2.64 (s, 2H); 5.16 (m, IH), 6.34 (br s, IH), 7.28 (d, IH, 7= 8.9 Hz), 7.48 (d, IH, 7= 8.9 Hz), 7.59 (s, IH). Anal. Calcd. For C19H23N203SC1O.2H20: C, 57.26; H, 5.92; N, 7.03. Found: C, 57.31; H,5.89; N, 7.02.
Example C(20): 3-(5-Chloro-1 -isopropyl-1 H-benzoimidazol-2-ylsulfanyl)-6-ethyl-4-hydroxy- 6-methyl-5,6-dihydro-pyran-2-one.
Figure imgf000388_0001
The title compound was prepared from 3-Chloro-6-ethyl-4-hydroxy-6-methyl-5,6-dihydro- pyran-2-one (from Step 1 ) and 5-Chloro-1 -isopropyl-1 H-benzoimidazole-2-thiol using the coupling method described in Example C(4).
'HNMR (CDC13): δ 0.95 (t, 3H, 7= 7.5 Hz), 1.41 (s, 3H), 1.68 (d, 6H, 7= 7.0 Hz), 1.75 (in, 2H), 2.52 (d, IH, 7= 17.1 Hz), 2.74 (d, IH, 7= 17.1 Hz), 6.97 (m, IH), 6.56 (br s, IH), 7.28 (d, IH, 7= 8.9 Hz), 7.48 (d, IH, 7= 8.9 Hz), 7.60 (s, IH). Anal. Calcd. For C18H21N203SC1O.1H20: C, 56.49; H, 5.58; N, 7.32. Found: C, 56.32; H,5.56; N, 7.17.
Figure imgf000388_0002
Step 1 : 3-Chloro-6-ethyl-4-hydroxy-6-methyl-5,6-dihydro-pyran-2-one.
The title compound was prepared as described in Step 1 of Example C(4),where 2- butanone was substituted in place of cyclohex-1-enyl-1-cyclopentyl-propan-1-one.
Example C(21): 3-(5,7-Dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-ylsulfanyl)-6-ethyl-4- hydroxy-6-methyl-5,6-dihydro-pyran-2-one.
Figure imgf000388_0003
The title compound was prepared analogously to Example C(20) where 5,7-DimethyI- [1,2,4]triazolo[1,5-a]pyrimidine-2-thiol was substituted in place of 5-Chloro-1 -isopropyl-1 H- benzoimidazole-2-thiol. 'HNMR (CDC13): δ 1.01 (t, 3H, 7= 7.4 Hz), 1.54 (s, 3H , 1.87 (m, 2H), 2.63 (s, 3H), 2.68 (d, 1H, 7= 17.5 Hz), 2.71 (s, 3H), 2.90 (d, IH, 7= 17.5 Hz), 6.78 (m, IH). Anal. Calcd. For Cι5H18N403SO.4AcOH: C, 52.94; H, 5.51; N, 15.63. Found: C, 52.63; H,5.43; N, 15.92.
Example C(22): 6-[2-(3-Chloro-4-methoxy-phenyl)-ethyl]-6-cyclopentyl-3-(5-phenyl-4H- [1 ,2,4]triazol-3-ylsulfanyl)-dihydro-pyran-2,4-dione.
Figure imgf000389_0001
The title compound was prepared analogously to Example C(4),where 3-Chloro-6-[2-(3- chloro-4-methoxy-phenyl)-ethyl]-6-cyclopentyl-4-hydroxy-5,6-dihydro-pyran-2-one Step 1 of example C(40), was substituted in place of 3-Chloro-6-(2-cyclohex-1-enyl-ethyl)-6-cyclopentyl-4- hydroxy-5,6-dihydro-pyran-2-one and 5-Phenyl-1H-1,2,4-triazole-3-thiol was substituted in place of 5-Pyridin-4-yl-4H-[1 ,2,4]triazole-3-thiol of that example.
'HNMR (DMSO-d6): δ 1.53-1.85 (m, 10H), 2.17-2.34 (m, IH), 2.69-2.75 (m 2H), 2.95 (d, 7= 17.0, IH), 3.08 (d, 7 = 17.0 Hz, IH), 3.90 (s, 3H), 7.08 (d, 7 = 8.4 Hz, IH) 7.22-7.26 (m, IH), 7.40 (d, 7 = 2.0 Hz, IH), 7.40-7.53 (m, 4H), 7.91-7.94 (m, 2H), 12.0 (brs, IH); Anal. Calcd. For C27H28ClN3O4S-1.0 HCl- 1.0 H20: C, 55.86; H, 5.38, N, 7.24; Found: C, 55.75; H, 5.17, N, 7.17. ESIMS (MH+): 527
Example C(23): 6-[2-(3-Chloro-4-methoxy-phenyl)-ethyl]-6-cyclopentyl-3-[5-(4-hydroxy- phenyl)-4H-[1,2,4]triazol-3-ylsulfanyl]-dihydro-pyran-2,4-dione.
Figure imgf000390_0001
The title compound was prepared analogously to Example C(4),where 3-Chloro-6-[2-(3- chloro-4-methoxy-phenyl)-ethyl]-6-cyclopentyl-4-hydroxy-5,6-dihydro-pyran-2-one example C(40), was substituted in place of 3-Chloro-6-(2-cyclohex-1-enyl-ethyl)-6-cyclopentyl-4-hydroxy-5,6- dihydro-pyran-2-one and 4H-3-mercapto-5-(4-hydroxyphenyl)[1 ,2,4]-triazole was substituted in place of 5-Pyridin-4-yl-4H-[1 ,2,4]triazole-3-thiol of that example.
'H NMR (DMSO-d6): δ 1.47-1.76 (m, 10H), 2.04-2.23 (m, IH), 2.58-2.64 (m 2H), 2.83 (d, 7 = 17.0, IH), 2.94 (d, 7= 17.0 Hz, IH), 3.81 (s, 3H), 6.76 (d, 7= 8.7 Hz, IH) 6.98 (d, 7= 8.5 Hz, 2H), 7.13 (dd, 7= 8.5, 2.0 Hz, IH), 7.29 (d, 7 = 2.0 Hz, IH), 7.65 (d, 7 = 8.7 Hz, 2H), 9.88 (s, IH), 12.0 (brs, IH); Anal. Calcd. For C27H28ClN3O5S-1.0 HCl- 1.0 H20: C, 54.36; H, 5.24, N, 7.04; Found: C, 54.38; H, 5.02, N, 7.24. ESIMS (MH+): 543
Example C(24): 6-Cyclopentyl-6-[2-(3-fluoro-4-isopropoxy-phenyl)-ethyl]-4-hydroxy-3-(5- phenyl-4H-[1 ,2,4]triazol-3-ylsulfanyl)-5,6-dihydro-pyran-2-one.
Figure imgf000390_0002
The title compound was prepared analogously to Example C(4), where 3-Chloro-6-[2-(3- chloro-4-isopropoxy-phenyl)-ethyl]-6-cyclopentyl-4-hydroxy-5,6-dihydro-pyran-2-one from Step 1 of example C(64), was substituted in place of 3-Chloro-6-(2-cyclohex-1-enyl-ethyl)-6-cyclopentyl- 4-hydroxy-5,6-dihydro-pyran-2-one, and 5-Phenyl-1 H-1 ,2,4-triazoie-3-thiol was substituted in place of 5-Pyridin-4-yl-4H-[1 ,2,4]triazole-3-thiol of that example. Η NMR (DMSO-d6): δ 1.24 (d, 7 = 6.0 Hz, 6H), 1.39-1.73 (m, 10H), 1.97-2.00 (m, IH), 2.58-2.62 (m 2H), 2.81 (d, 7 = 17.0, IH), 2.96 (d, 7 = 17.0 Hz, IH), 4.46-4.54 (m, IH), 6.91-7.09 (m, 3H), 7.38-7.41 (m, 3H), 7.82-7.84 (m, 2H), 14.2 (brs, IH); Anal. Calcd. For C29H32FN304S: C, 64.79; H, 6.0, N, 7.82; Found: C, 64,52; H, 6.16, N, 7.75. ESIMS (MH+): 538.
Example C(25): 6-[2-(3-Chloro-4-isopropoxy-phenyl)-ethyl]-3-(5-chloro-1 -isopropyl-1 H- benzoimidazol-2-ylsulfanyl)-6-cyclopentyl-4-hydroxy-5,6-dihydro-pyran-2-one.
Figure imgf000391_0001
The title compound was prepared analogously to Example C(4), where 3-Chloro-6-[2-(3- chloro-4-isopropoxy-phenyl)-ethyl]-6-cyclopentyi-4-hydroxy-5,6-dihydro-pyran-2-one (from Step 1 below) was substituted in place of 3-Chloro-6-(2-cyclohex-1-enyl-ethyl)-6-cyclopentyl-4-hydroxy-
5,6-dihydro-pyran-2-one and 5-Chloro-1-isopropyl-2-mercapto benzimidazole was substituted in place of 5-Pyridin-4-yl-4H-[1 ,2,4]triazole-3-thiol of that example.
Η NMR (DMSO-d6): δ 1.13 (d, 7 = 6.1 Hz, 6H), 1.41 (d, 7= 7.1 Hz, 6H), 1.42-1.8 (m, 10H), 2.08-2.13 (m, IH), 2.43-2.54 (m 3H), 2.79 (d, 7= 17.0, IH), 4.44-4.48 (m, IH), 4.63-4.69 (m, IH), 6.89-6.91 (m,
2H), 6.95-7.00 (m, 2H), 7.14 (s, IH), 7.49 (d, 7= 8.6 Hz, IH), 12.0 (brs, IH); Anal. Calcd. For
C31H36Cl2N2O4S-1.0 AcOH: C, 59.72; H, 6.07, N, 4.22; Found: C, 59.50; H, 6.16, N, 4.33. ESIMS (MH+):
604.
Step 1: 3-Chloro-6-[2-(3-chloro-4-isopropoxy-phenyl)-ethyl]-6-cyclopentyl-4-hydroxy-5,6- dihydro-pyran-2-one.
Figure imgf000392_0001
The pyrone intermediate, was prepared analogously to Example C(4),where 3-(3-Chloro- 4-isopropoxy-phenyl)-1-cyclopentyl-propan-1-one (from Step 2 below) was substituted in place of 3-Cyclohex-1-enyl-1-cyclopentyl-propan-1-one in Step 1 of that example.
Step 2: 3-(3-Chloro-4-isopropoxy-phenyl)-1-cyclopentyl-propan-1-one.
Figure imgf000392_0002
The ketone intermediate, was prepared analogously to Example A(27), .where 4-Bromo- 2-chloro-1-isopropoxy-benzene (from Step 3 below) was substituted in place of 3-Cyclohex-1- enyl-1-cyclopentyl-propan-1-one in Step 1 of that example.
Step 3: 4-Bromo-2-chloro-1-isopropoxy-benzene
Figure imgf000392_0003
The intermediate bromide, was prepared analogously to Step 1 in Example A(52), where 4-Bromo-2-chloro-phenol was substituted in place of 4-bromo-2-fluorophenol and 2-iodopropane instead of methyl D-bromobutyrate of that example.
Example C(26): 3-(5-Chloro-1 H-benzoimidazol-2-ylsulfanyl)-6-[2-(3-chloro-4-isopropoxy- phenyl)-ethyl]-6-cyclopentyl-4-hydroxy-5,6-dihydro-pyran-2-one.
Figure imgf000393_0001
The title compound was prepared analogously to Example C(4), where 3-Chloro-6-[2-(3- chloro-4-isopropoxy-phenyl)-ethyl]-6-cyclopentyl-4-hydroxy-5,6-dihydro-pyran-2-one was substituted in place of 3-Chloro-6-(2-cyclohex-1-enyl-ethyl)-6-cyclopentyl-4-hydroxy-5,6-dihydro- pyran-2-one and 5-Chloro-benzimidazole-2-thiol was substituted in place of 5-Pyridin-4-yl-4H-
[1 ,2,4]triazole-3-thiol of that example.
Η NMR (DMSO-d6): δ 1.34 (d, 7 = 6.1 Hz, 6H), 1.41-1.82 (m, 10H), 2.07-2.14 (m, IH), 2.55-2.88 (m, 4H), 3.4 (brs, IH), 4.44-4.48 (m, IH), 6.81-6.91 (m, 2H), 7.13-7.39 (m, 4H), 12.0 (brs, IH); ESIMS (MH+)
(C28H30Cl2N2O4S): 562.
Example C(27): 6-(2-Cyclohexyl-ethyl)-6-cyclopentyl-4-hydroxy-3-(5-pyridin-4-yl-4H- [1,2,4]triazol-3-ylsulfanyl)-5,6-dihydro-pyran-2-one.
Figure imgf000393_0002
The title compound was prepared analogously to Example C(4), where 3-Cyclohexyl-1- cyclopentyl-propan-1-one from Step 2 of Example A(44), was substituted in place of 3-Cyclohex- 1-enyl-1-cyclopentyl-propan-1-one in Step 1 of that example.
Η NMR (CDC13): δ 0.5-3.4 (m, 28H), 7.84 (d, 7 = 6.0, 2H), 8.66 (d, 7 = 6.0, 2H); Anal. Calcd. For C25H32 N403S: C, 64.08; H, 6.88, N, 11.96; Found: C, 64.30; H, 6.68, N = 11.90. ESIMS (MH+): 345
Example C(28): 6-Cyclopentyl-6-(2-cyclopentyl-ethyl)-4-hydroxy-3-(5-pyridin-4-yl-4H- [1,2,4]triazol-3-ylsulfanyl)-5,6-dihydro-pyran-2-one.
Figure imgf000394_0001
The title compound was prepared analogously to Example C(4),where 3-Chloro-6- cyclopentyl-6-(2-cyclopentyl-ethyl)-4-hydroxy-5,6-dihydro-pyran-2-one (from Step 2 below) was substituted in place of 3-Chloro-6-(2-cyclohex-1-enyl-ethyl)-6-cyclopentyl-4-hydroxy-5,6-dihydro- pyran-2-one of that example. Η NMR (DMSO-d6): δ 0.96-1.86 (m, 21H), 2.24-2.26 (m, IH), 2.61 (d, 7 = 17.0, IH), 2.90 (d, 7 = 17.0, IH), 3.31 (brs, IH), 7.80-7.88 (m, 2H), 8.61-8.71 (m, 2H), 14.0 (brs, IH); Anal. Calcd. For C24H30 N403S: C, 63.41; H, 6.65, N, 12.32; Found: C, 63.20; H, 6.90, N, 12.60. ESIMS (MH+): 454
Step: 1: 4-Cyclopentyl-1-cyclopentyl-butan-1-one:
Figure imgf000394_0002
The title compound was prepared analogously to Example A(44), where 3-cyclopentyl propionic acid was substituted in place of 3-cyclohexylpropionic acid in Step 1 of that example. 'HNMR (DMSO-d6): δ O.79-0.91 (m, 2H), 1.11-1.24 (m, 5H), 1.55-1.88 (m, 12H), 2.41 (t, 7 = 7.4, 2H), 2.81-2.91 (m, IH). Step 2: 2-Chloro-5-cyclopentyl-5-(2-cyclopentyl-ethyl)-3-hydroxy-cyclohex-2-enone.
Figure imgf000395_0001
The title compound was prepared analogously to Example C(4),where 4-Cyclopentyl-1- cyclopentyl-butan-1-one from Step 1 above was substituted in place of 3-Cyclohex-1-enyl-1- cyclopentyl-propan-1 -one of that example.
Η NMR (CDC13): δ 0.86-1.73 (m, 23H), 2.24-2.31 (m, IH), 2.62 (d, 7= 17, IH), 2.83 (d, 7= 17, IH). ESIMS (MH+): 311.
Example C(29): 3-(5-Chloro-1 -isopropyl-1 H-benzoimidazol-2-ylsulfanyl)-6-cyclopentyl-6-(2- cyclopentyl-ethyl)-4-hydroxy-5,6-dihydro-pyran-2-one.
Figure imgf000395_0002
The title compound was prepared analogously to Example C(4),where 3-Chloro-6- cyclopentyl-6-(2-cyclopentyl-ethyl)-4-hydroxy-5,6-dihydro-pyran-2-one from Step 2 of example C(28) was substituted in place of 3-Chloro-6-(2-cyclohex-1-enyl-ethyl)-6-cyclopentyl-4-hydroxy- 5,6-dihydro-pyran-2-one and 5-Chloro-1-isopropyl-2-mercapto benzimidazole was substituted in place of 5-Pyridin-4-yl-4H-[1 ,2,4]triazole-3-thiolof that example.
Η NMR (DMSO-d6): δ 0.84-2.28 (m, 28H), 2.31 (d, 7= 17.0, IH), 2.66 (d, 7= 17.0, IH), 3.96 (brs, IH), 4.55-4.67 (m, IH), 6.93 (d, 7= 8.5, IH), 7.12 (s, IH), 7.46 (d, 7= 8.5, IH); Anal. Calcd. For C27H35C1N203S: C, 64.46; H, 7.01, N, 5.57; Found: C, 64.85; H, 7.30, N, 5.76. ESIMS (MH+): 504.
Example C(30): 6-(3-Cyclohexyl-propyl)-6-cyclopentyl-4-hydroxy-3-(5-pyridin-4-yl-4H- [1,2,4]triazol-3-ylsulfanyl)-5,6-dihydro-pyran-2-one.
Figure imgf000396_0001
The title compound was prepared analogously to Example C(4),where 3-Chloro-6-(3- cyclohexyl-propyl)-6-cyclopentyl-4-hydroxy-5,6-dihydro-pyran-2-one (described in Step 2 below) was substituted in place of 3-Chloro-6-(2-cyclohex-1-enyl-ethyl)-6-cyclopentyl-4-hydroxy-5,6- dihydro-pyran-2-one of that example.
'H NMR (DMSO-d6): δ 0.5-1.86 (m, 25H), 2.08-2.10 (m, IH), 2.42 (d, 7= 17.0, IH), 2.71 (d, 7= 17.0, IH), 3.11 (brs, IH), 7.61 (d, 7 = 5.8, 2H), 8.43 (d, 7 = 4.5, 2H), 11.71 (brs, IH); Anal. Calcd. For C26H34N4O3S-0.5 AcOH-0.75 H20: C, 61.63; H, 7.18, N, 10.65; Found: C, 61.55; H, 7.06, N, 10.98. ESIMS (MH+): 483.
Step 1: 4-Cyclohexyl-1-cyclopentyl-butan-1-one.
Figure imgf000396_0002
The title compound was prepared analogously to Example A(44), where cyclohexanebutyric acid was substituted in place of 3-cyclohexylpropionic acid in Step 1 of that example.
Η NMR (DMSO-d6): δ 0.79-0.91 (m, 2H), 1.11-1.27 (m, 7H), 1.55-1.85 (m, 14H), 2.41 (t, 7 = 7.4, 2H), 2.81-2.91 (m, IH).
Step 2: 3-Chloro-6-(3-cyclohexyl-propyl)-6-cyclopentyl-4-hydroxy-5,6-dihydro-pyran-2-one.
Figure imgf000397_0001
The title compound was prepared analogously to Example C(4),where 4-Cyclohexyl-1- cyclopentyl-butan-1-one from Step 1 above was substituted in place of 3-Cyclohex-1-enyl-1- cyclopentyl-propan-1-one of that example.
Η NMR (CDC13): δ 0.86-1.75 (m, 26H), 2.27-2.32 (m, 1H), 2.61 (d, 7= 17, IH), 2.83 (d, 7= 17, IH). ESIMS (MH+): 341.
Example C(31): 3-(5-Chloro-1-isopropyl-1H-benzoimidazol-2-ylsulfanyl)-6-(3-cyclohexyl- propyl)-6-cyclopentyl-4-hydroxy-5,6-dihydro-pyran-2-one.
Figure imgf000397_0002
The title compound was prepared analogously to Example C(4),where 3-Chloro-6-(3- cyclohexyl-propyl)-6-cyclopentyl-4-hydroxy-5,6-dihydro-pyran-2-one (described in Step 2 of example C(30) was substituted in place of 3-Chloro-6-(2-cyclohex-1-enyl-ethyl)-6-cyclopentyl-4- hydroxy-5,6-dihydro-pyran-2-one and 5-Chloro-1-isopropyl-2-mercapto benzimidazole was substituted in place of 5-Pyridin-4-yl-4H-[1 ,2,4]triazole-3-thiolof that example. Η NMR (DMSO-d6): δ 0.63-1.39 (m, 23H), 1.38 (d, 7= 6.9, 6H), 1.70-1.73 (m, 2H), 2.14-2.20 (m, IH), 2.39 (d, 7= 17.0, IH), 2.71 (d, 7= 17.0, IH), 4.58-4.67 (m, IH), 6.96 (dd, 7= 8.6, 2.1, IH), 7.17 (d, 7 = 2.1, IH), 7.49 (d, 7 = 8.6, IH) 12.9 (brs, IH); Anal. Calcd. For C29H39ClN2O3S-0.5 H20: C, 64.48; H, 7.46, N, 5.19; Found: C, 64.69; H, 7.30, N, 5.15. ESIMS (MH+): 532.
Example C(32): 6-(4-Cyclohexyl-butyl)-6-cyclopentyl-4-hydroxy-3-(5-pyridin-4-yl-4H- [1,2,4]triazol-3-ylsulfanyl)-5,6-dihydro-pyran-2-one.
Figure imgf000398_0001
The title compound was prepared analogously to Example C(4),where 3-Chloro-6-(4- cyclohexyl-butyl)-6-cyclopentyl-4-hydroxy-5,6-dihydro-pyran-2-one (from Step 2 below) was substituted in place of 3-Chloro-6-(2-cyclohex-1-enyl-ethyl)-6-cyclopentyl-4-hydroxy-5,6-dihydro- pyran-2-one of that example
Η NMR (DMSO-d6): δ 0.87-1.75 (m, 27H), 2.13-2.16 (m, IH), 2.49 (d, 7= 17.0, IH), 2.78 (d, 7= 17.0, IH), 3.27 (brs, IH), 7.70 (d, 7= 6.0, 2H), 8.50 (d, 7 = 5.3, 2H), 13.9 (brs, IH); Anal. Calcd. For C27H36N403S-1.5 H20: C, 61.93; H, 7.51, N, 10.70; Found: C, 62.22; H, 7.30, N, 10.87. ESIMS (MH+): 497.
Step 1: 5-Cyclohexyl-1-cyclopentyl-pentan-1-one.
Figure imgf000398_0002
The title compound was prepared analogously to Example A(44), where cyclohexanepentanoic acid was substituted in place of 3-cyclohexylpropionic acid in Step 1 of that example. Η NMR (DMSO-d6): δ 0.79-0.91 (m, 2H), 1.11-1.85 (m, 23H), 2.40 (t, 7 = 7., 2H), 2.8-2.90 (m, IH).
Step 2: 3-Chloro-6-(3-cyclohexyl-propyl)-6-cyclopentyl-4-hydroxy-5,6-dihydro-pyran-2-one.
Figure imgf000398_0003
The title compound was prepared analogously to Example C(4),where 5-CycIohexyl-1- cyclopentyl-pentan-1-one from Step 1 above was substituted in place of 3-Cyclohex-1-enyl-1- cyclopentyl-propan-1 -one of that example.
'HNMR (CDC13): δ 0.86-1.80 (m, 28H), 2.25-2.31 (m, IH), 2,6 (d, 7 = 17, 1H), 2.85 (d, 7= 17, IH). ESIMS (MH+): 355
Example C(33): 6-(4-Cyclohexyl-butyl)-6-cyclopentyl-4-hydroxy-3-(5-pyridin-4-yl-4H- [1,2,4]triazol-3-ylsulfanyl)-5,6-dihydro-pyran-2-one.
Figure imgf000399_0001
The title compound was prepared analogously to Example C(4),where 3-Chloro-6-(4- cyclohexyl-butyl)-6-cyclopentyl-4-hydroxy-5,6-dihydro-pyran-2-one (described in Step 2 of example C(32) was substituted in place of 3-Chloro-6-(2-cyclohex-1-enyl-ethyl)-6-cyclopentyl-4- hydroxy-5,6-dihydro-pyran-2-one and 5-Chloro-1-isopropyl-2-mercapto benzimidazole was substituted in place of 5-Pyridin-4-yl-4H-[1 ,2,4]triazole-3-thiolof that example.
Η NMR (DMSO-d6): δ 0.73-1.36 (m, 23H), 1.43 (d, 7= 7.4, 6H), 1.49-1.55 (m, 2H), 1.84-1.88 (m, 2H), 2.18-2.23 (m IH), 2.41 (d, 7= 17.0, IH), 2.77 (d, 7= 17.0, IH), 4.65-4.74 (m, IH), 7.02 (dd, 7= 8.6, 1.9, IH), 7.22 (d, 7= 1.9, IH), 7.54 (d, 7= 8.6, IH), 12.9 (brs, IH); Anal. Calcd. For C30H41ClN2O3S-1.25 H20: C, 63.47; H, 7.72, N, 4.93; Found: C, 63.27; H, 7.44, N, 4.80. ESIMS (MH+): 546.
Example C(34): 3-[(4-tert-butyl-4W-1 ,2,4-triazol-3-yl)thio]-6-[2-(3-chloro-4- methoxyphenyl)ethyl]-6-cyclopentyl-4-hydroxy-5,6-dihydro-2H-pyran-2-one.
Figure imgf000400_0001
The title compound was prepared analogously to Example C(40), , where 4-fert-butyl-4H-1 ,2,4- triazole-3-thiol was substituted in place of 5-chloro-1 -isopropyl-1 H-benzimidazole-2-thiol. Η NMR (300 MHz, DMSO-d6) δ ppm 1.58 (m, 1 H), 1.79 (m, 6 H), 1.89 (s, 9 H), 1.90 (m, 2 H), 2.24 (m, 1 H), 2.38 (m, 1 H), 2.68 (m, 1 H), 2.80 (m, 2 H), 2.84 (d, 7=17.3 Hz, 1 H), 3.13 (d,.7=17.3 Hz, 1 H), 4.05 (s, 3 H), 7.26 (d, 7=8.4 Hz, 1 H), 7.51 (dd, 7=8,4, 2.1 Hz, 1 H), 7.58 (d, 7=2.1 Hz, 1 H), 8.82 (s, 1 H). Anal. Calcd. For C25H32C1N304S: C, 59.33; H, 6.37; N, 8.30; S, 6.34. Found: C, 59.07; H, 6.46; N, 8.13; S, 6.18.
Example C(35): 6-[2-(3-chloro-4-methoxyphenyl)ethyl]-6-cyclopentyl-3-[(4-ethyl-4H-1 ,2,4- triazol-3-yl)thio]-4-hydroxy-5,6-dihydro-2H-pyran-2-one.
Figure imgf000400_0002
The title compound was prepared analogously to Example C(40), , where 4-ethyl-4H- 1,2,4-triazole-3-thioi was substituted in place of 5-chloro-1 -isopropyl-1 H-benzimidazole-2-thiol.
Η NMR (300 MHz, DMSO-d6) δ ppm 1.24 (m, 1 H), 1.26 (t, 7=7.3 Hz, 3 H), 1.49 (m, 7 H), 1.90 (m, 2 H), 2.29 (m, 1 H), 2.43 (m, 2 H), 2.56 (d, 7=17.5 Hz, 1 H), 2.80 (d, 7=17.5 Hz, 1 H), 3.73 (s, 3 H), 3.97 (q, 7=7.3 Hz, 2 H), 6.94 (d, 7=8.5 Hz, 1 H), 7.11 (dd, 7=8.5, 2.1 Hz, 1 H), 7.21 (d, 7=2.1 Hz, 1 H), 8.54 (s, 1 H). Anal. Calcd. For C23H28C1N304S: C, 57.79; H, 5.90; N, 8.79; S, 6.71. Found: C, 57.62; H, 5.93; N, 8.69; S, 6.65. Example C(36): 6-[2-(3-chloro-4-methoxyphenyl)ethyl]-6-cycIopentyl-4-hydroxy-3-[(4- isopropyl-4H-1,2,4-triazol-3-yl)thio]-5,6-dihydro-2H-pyran-2-one.
Figure imgf000401_0001
The title compound was prepared analogously to Example C(40), , where 4-isopropyl-4/-/- 1 ,2,4-triazole-3-thiol was substituted in place of 5-chloro-1 -isopropyl-1 H-benzimidazole-2-thiol. Η NMR (300 MHz, DMSO-D6) δ ppm 1.43 (d, 7=6.6 Hz, 3 H), 1.44 (d, 7=6.6 Hz, 3 H), 1.48 (m, 8 H), 1.99 (m, 2 H), 2.39 (m, 1 H), 2.53 (m, 2 H), 2.65 (d, 7=17.5 Hz, 1 H), 2.89 (d, 7=17.5 Hz, 1 H), 3.82 (s, 3 H), 4.59 (dq, 7=6.6, 6.6 Hz, 1 H), 6.51 (s, 1 H), 7.03 (d, 7=8.4 Hz, 1 H), 7.20 (dd, 7=8.4, 2.2 Hz, 1 H), 7.30 (d, 7=2.2 Hz, 1 H), 8.76 (s, 1 H). Anal. Calcd. For C24H3oClN304S: C, 58.59; H, 6.15; N, 8.54; S, 6.52. Found: C, 58.35; H, 6.29; N, 8.29; S, 6.27.
Example C(37): 6-[2-(3-chloro-4-methoxyphenyl)ethyl]-6-cyclopentyl-4-hydroxy-3-[(4- phenyl-4H-1,2,4-triazol-3-yl)thio]-5,6-dihydro-2H-pyran-2-one.
Figure imgf000401_0002
The title compound was prepared analogously to Example C(40), , where 4-phenyl-4H- 1 ,2,4-triazole-3-thiol was substituted in place of 5-chloro-1 -isopropyl-1 H-benzimidazole-2-thiol. Η NMR (300 MHz, CDCL3) δ ppm 1.37 (m, 1 H), 1.63 (m, 8 H), 2.00 (m, 2 H), 2.35 (m, 1 H), 2.60 (m, 2 H), 2.91 (d, 7=17.8 Hz, 1 H), 3.10 (d, 7=17.8 Hz, 1 H), 3.85 (s, 3 H), 6.82 (d, 7=8.4 Hz, 1 H), 7.02 (dd, 7=8.4, 2.1 Hz, 1 H), 7.15 (d, 7=2.1 Hz, 1 H), 7.60 (m, 5 H), 8.27 (s, 1 H). Anal. Calcd. For C27H28C1N304S: C, 61.65; H, 5.36; N, 7.99; S, 6.10. Found: C, 61.53; H, 5.41; N, 7.74; S, 5.92.
Example C(38): 6-[2-(3-chloro-4-methoxyphenyl)ethyl]-6-cyclopentyl-4-hydroxy-3-[(1- methyl-1H-tetrazol-5-yl)thio]-5,6-dihydro-2H-pyran-2-one.
Figure imgf000402_0001
The title compound was prepared analogously to Example C(40), , where 1 -methyl-1 H- tetrazole-5-thiol was substituted in place of 5-chloro-1 -isopropyl-1 /-/-benzimidazole-2-thiol. 'HNMR (300 MHz, CDCL3) δ ppm 1.36 (s, 1 H), 1.59 (m, 8 H), 2.00 (dd, 7=11.0, 5.4 Hz, 2 H), 2.35 (s, 1 H), 2.59 (dd, 7=11.0, 6.0 Hz, 2 H), 2.90 (d, 7=17.9 Hz, 1 H), 3.09 (d, 7=17.9 Hz, 1 H), 3.87 (s, 3 H), 4.25 (s, 3 H), 6.83 (d, 7=8.5 Hz, 1 H), 6.98 (dd, 7=8.5, 2.1 Hz, 1 H), 7.14 (d, 7=2.1 Hz, 1 H). Anal. Calcd. For C21H25CΪN4O4S.0.1H2O: C, 54.03; H, 5.44; N, 12.00; S, 6.87. Found: C, 53.90; H, 5.45; N, 11.74; S, 6.75.
Example C(39): 6-[2-(3-chloro-4-methoxyphenyl)ethyl]-6-cyclopentyl-3-[(1-ethyl-1H- tetrazol-5-yl)thio]-4-hydroxy-5,6-dihydro-2H-pyran-2-one.
Figure imgf000402_0002
The title compound was prepared analogously to Example C(40), , where 1 -et yl-1 H- tetrazole-5-thiol was substituted in place of 5-chloro-1 -isopropyl-1 H-benzimidazoIe-2-thiol. Η NMR (400 MHz, CDCL3) δ ppm 1.34 (m, 1 H), 1.59 (m, 8 H), 1.63 (t, 7=7.3 Hz, 3 H), 1.99 (m, 2 H), 2.36 (m, 1 H), 2.59 (m, 2 H), 2.90 (d, 7=17.9 Hz, 1 H), 3.10 (d, 7=17.9 Hz, 1 H), 3.87 (s, 3 H), 4.65 (q, 7=7.3 Hz, 2 H), 6.83 (d, 7=8.3 Hz, 1 H), 6.99 (dd, 7=8.3, 2.3 Hz, 1 H), 7.14 (d, 7=2.3 Hz, 1 H). Anal. Calcd. For C22H27C1N404S: C, 55.16; H, 5.68; N, 11.70; S, 6.69. Found: C, 55.22; H, 5.64; N, 11.48; S, 6.54.
Figure imgf000403_0001
Step 1 : 2-Chloro-7-(3-chloro-4-methoxy-phenyl)-5-cyclopentyl-5-hydroxy-3-oxo-heptanoic acid methyl ester.
Methyl-2-chloroacetoacetate (2.5g, 16.9mmol) was added to a cooled 0 °C suspension of
NaH (0.68 g, 16.9 mmol, 60% dispersion in mineral oil) in THF (30ml). After 15 min the solution was cooled to -40 °C and n-Buϋ (10.6mL, 16.9mmol, 1.6M in hexanes) was added. The resulting dianion was stirred for an additional 30 min and then treated with a solution of 3-(3- Chloro-4-methoxy-phenyl)-1-cyclopentyl-propan-1-one (1.5g, 5.6mmol, compound was prepared analogously to Step 1 of Example A(82), where 4-bromo-2-chloro-1-methoxybenzene was substituted in place of 2-Bromopyridine) in THF (10ml). After stirring for 1 h at -40 °C, the reaction mixture was quenched with saturated NH CI and extracted with EtOAc. The organic layers were washed with brine, dried with Na2S04 and concentrated to an orange oil that was used without further purification.
Step 2: 3-Chloro-6-[2-(3-chloro-4-methoxy-phenyl)-ethyl]-6-cyclopentyl-4-hydroxy-5,6- dihydro-pyran-2-one.
Figure imgf000403_0002
A solution of 2-Chloro-7-(3-chloro-4-methoxy-phenyl)-5-cyclopentyl-5-hydroxy-3-oxo- heptanoic acid methyl ester (2.33g, 5.6 mmol, from Step 1), and bis(dibutylchlorotin)oxide (1.38g, 2.5 mmol), dissolved in toluene (18 mL) were heated at reflux for 30mins. The resulting mixture was concentrated and purified by silica gel chromatography to give the title compound (1.57 g, 75% yield, two Steps).
'HNMR(CDC13): δ 1.36-1.79 (br m, 8H), 2.02 (m, 2H), 2.41 (m, IH), 2.65 (m, 3H), 2.89 (d, 1H, 7= 17.7 Hz), 3.88 (s, 3H), 6.47 (br s, IH), 6.85 (d, IH, 7= 8.4 Hz), 7.01 (dd, IH, 7= 8.4, 2.1 Hz), 7.16 (d, IH, 7= 2.1 Hz).
Example C(40): 3-[(5-chloro-1 -isopropyl-1 H-benzimidazol-2-yl)thio]-6-[2-(3-chloro-4- methoxyphenyl)ethyl]-6-cyclopentyl-4-hydroxy-5,6-dihydro-2H-pyran-2-one.
Figure imgf000404_0001
A solution of 3-chloro-6-[2-(3-chloro-4-methoxyphenyl)ethyl]-6-cyclopentyl-4-hydroxy-5,6- dihydro-2/-/-pyran-2-one (300 mg, 0.78 mmol), 5-chloro-1 -isopropyl-1 H-benzimidazole-2-thiol (181 mg, 0.80 mmol) and Et3N ( 0.1 mL, 0.80 mmol) was stirred at 55 °C for 5 hrs. The mixture was concentrated and purified by prep HPLC to obtain 50 mg product (11% yield). Η NMR (300 MHz, DMSO-D6) δ: 1.49-1.61 (m, 14 H) 2.23-2.30 (m, 2 H) 2.57-2.66 (m, 4 H) 2.91-2.96 (m, 1 H), 3.81 (s, 3 H) 4.73-4.79 (m, 1 H) 6.93 (d, 7=2.07 Hz, 1 H), 7.03 (d, 7=8.48 Hz, 1 H), 7.09 (dd, 7=8.57, 2.17 Hz, 1 H), 7.12-7.16 (m, 1 H), 7.28 (d, 7=1.88 Hz, 1 H), 7.62 (d, 7=8.67 Hz, 1 H). ESI-MS calcd for C29H32C12N204S: 574.1. Found (M+V ): 575.0. Anal. Calcd for C29H32C12N204S: C, 60.52; H, 5.60; N, 4.87. Found: C, 60.51; H, 5.74; N, 4.58.
Example C(41): 6-[2-(3-chloro-4-methoxyphenyl)ethyl]-6-cyclopentyl-4-hydroxy-3-[(1- methyl-1H-benzimidazol-2-yl)thio]-5,6-dihydro-2tø-pyran-2-one.
Figure imgf000405_0001
The title compound was prepared analogously to Example C(40), where 1 -methyl-1 H- benzimidazole-2-thiol was substituted in place of 5-chloro-1 -isopropyl-1 -/-benzimidazole-2-thiol. 'HNMR (300 MHz, DMSO-D6) δ: 1.51-1.70 (m, 8 H), 2.02-2.08 (m, 2 H), 2.35-2.43 (m, 1 H), 2.55-2.60 (m, 3 H), 2.75-2.80 (m, 1 H), 3.81 (s, 6 H), 7.02 (d, 7=8.48 Hz, 1 H), 7.10-7.13 (m, 1 H), 7.25-7.34 (m, 4 H), 7.39 (d, 7=8.10 Hz, 1 H), 7.62 (d, 7=7.35 Hz, 1 H). ESI-MS calcd for C27H29C1N204S: 512.2. Found (M+H+): 513.0. Anal. Calcd for C27H29ClN2O4S.0.6H2O: C, 61.68; H, 5.76; N, 5.10; S, 5.84. Found: C, 61.71; H, 5.75; N, 5.16; S, 5.85.
Example C(42): 6-[2-(3-chloro-4-methoxyphenyl)ethyl]-6-cyclopentyl-3-{[5-(2-furyl)-4- methyl-4H-1,2,4-triazol-3-yl]thio}-4-hydroxy-5,6-dihydro-2W-pyran-2-one.
Figure imgf000405_0002
The title compound was prepared analogously to Example C(40), where 5-(2-furyl)-4- methyl-4/-/-1,2,4-triazole-3-thiol was substituted in place of 5-chloro-1 -isopropyl-1 H- benzimidazole-2-thiol.
'HNMR (300 MHz, DMSO-D6) δ: 1.17-1.45 (m, 8 H) 1.67-1.74 (m, 2 H), 2.08-2.16 (m, 2 H), 2.29-2.32 (m, 1 H), 2.39-2.45 (m, 1 H), 2.61-2.67 (m, 1 H), 3.54 (s, 3 H), 3.56 (s, 3 H), 6.49 (dd, 7=3.39, 1.88 Hz, 1 H), 6.75 (d, 7=8.48 Hz, 1 H), 6.83 (d, 7=3.39 Hz, 1 H), 6.89 (dd, 7=8.48, 2.07 Hz, 1 H), 7.05 (d, 7=2.07 Hz, 1 H), 7.70-7.72 (m, 1 H). ESI-MS calcd for C26H28CΪN305S: 529.1. Found (M+H+): 530.0. Anal. Calcd for C26H28ClN3O5S.0.2 HOAc: C, 58.50; H, 5.36; N, 7.75; S, 5.92. Found: C, 58.34; H, 5.32; N, 7.81; S, 5.92.
Example C(43): 6-[2-(3-chloro-4-methoxyphenyl)ethyl]-6-cyclopentyl-4-hydroxy-3-(1tø- imidazo[4,5-ό]pyridin-2-ylthio)-5,6-dihydro-2H-pyran-2-one.
Figure imgf000406_0001
The title compound was prepared analogously to Example C(40), , where 1/-/- imidazo[4,5-b]pyridine-2-thiol was substituted in place of 5-chloro-1 -isopropyl-1 H-benzimidazole- 2-thiol.
Η NMR (300 MHz, DMSO-D6) δ: 1.38-1.75 (m, 8 H), 2.05-2.11 (m, 2 H), 2.40-2.45 (m, 1 H), 2.57-2.63 (m, 2 H), 2.69-2.75 (m, 1 H), 2.93-2.99 (m, 1 H), 3.81 (s, 3 H), 7.05 (d, 7=8.48 Hz, 1 H), 7.13 (dd, 7=7.91, 4.90 Hz, 1 H), 71.8-7.22 (m, 1 H), 7.31 (d, 7=2.07 Hz, 1 H), 7.67 (dd, 7=7.82, 1.22 Hz, 1 H), 8.19 (dd, 7=4.90, 1.32 Hz, 1 H). ESI-MS calcd for C25H25C1N304S: 499.1. Found (M+H+): 500.00. Anal. Calcd. For C25H26ClN3O4S.1.0 HOAc: C, 57.90; H, 5.40; N, 7.50; S, 5.73. Found, C, 57.99; H, 5.37; N, 7.29; S, 6.04.
Example C(44): 6-[2-(3-chloro-4-methoxyphenyl)ethyl]-6-cyclopentyl-4-hydroxy-3-[(1- isopropyl-1H-benzimidazol-2-yl)thio]-5,6-dihydro-2H-pyran-2-one.
Figure imgf000406_0002
The title compound was prepared analogously to Example C(40), where 1 -isopropyl-1 H- benzimidazole-2-thioi was substituted in place of 5-chloro-1 -isopropyl-1 H-benzimidazole-2-thiol. Η NMR (300 MHz, DMSO-D6) δ: 1.45-1.70 (m, 14 H), 2.04-2.10 (m, 2 H), 2.37-2.43 (m, 1 H), 2.55-2.60 (m, 2 H), 2.71-2.76 (m, 1 H), 3.81 (s; 3 H), 4.89-4.92 (m, 1 H), 7.02 (d, 7=8.48 Hz, 1 H), 7.11-7.14 (m, 1 H), 7.19-7.22 (m, 2 H), 7.25 (d, 7=1.88 Hz, 1 H), 7.29-7.32 (m, 1 H), 7.71-7.74 (m, 1 H). ESI-MS calcd for C29H33C1N204S: 540.2. Found (M+H*) 541.1. Anal. Calcd. For C29H33ClN204S.1.5HOAc: C, 60.89; H, 6.23; N, 4.44. Found: C, 61.02; H, 6.34; N, 4.82.
Figure imgf000407_0001
Example C(45): 3-(1 ,3-benzothiazol-2-ylthio)-6-[2-(3-chloro-4-methoxyphenyl)ethyl]-6- cyclopentyl-4-hydroxy-5,6-dihydro-2H-pyran-2-one.
The title compound was prepared analogously to Example C(40), where 1 ,3- benzothiazole-2-thiol was substituted in place of 5-chloro-1 -isopropyl-1 /-/-benzimidazole-2-thiol. 'H NMR (300 MHz, DMSO-D5) δ: 1.39-1.73 (m, 8 H), 2.11-2.16 (m, 2 H), 2.43-2.45 (m, 1 H), 2.62-2.67 (m, 2 H), 2.80-2.86 (m, 1 H), 2.99-3.05 (m, 1 H), 3.83 (s, 3 H), 7.07 (d, 7=8.48 Hz, 1 H), 7.16-7.19 (m, 1 H), 7.28-7.34 (m, 2 H), 7.37-7.43 (m, 1 H), 7.66 (d, 7=7.54 Hz, 1 H), 7.79-7.82 (m, 1 H). ESI-MS calcd for C26H25C1N04S2: 515.1. Found (M+FT): 516.2. Anal. Calcd for C26H26C1N04S2: C, 60.51; H, 5.08; N, 2.71. Found: C, 60.30; H, 5.24; N, 2.71.
Figure imgf000407_0002
Example C(46): 6-[2-(3-chloro-4-methoxyphenyl)ethyl]-6-cyclopentyl-4-hydroxy-3-(1 H- imidazo[4,5-c]pyridin-2-ylthio)-5,6-dihydro-2H-pyran-2-one.
The title compound was prepared analogously to Example C(40), where 1/-/-imidazo[4,5- c]pyridine-2-thiol was substituted in place of 5-chloro-1 -isopropyl-1 /-/-benzimidazole-2-thiol. 'HNMR (300 MHz, DMSO-D6) δ: 1.45-1.68 (m, 8 H), 1.93-1.99 (m, 2 H), 2.35-2.40 (m, 2 H), 2.54-2.60 (m, 2 H), 2.70-2.72 (m, 1 H), 3.80 (s, 3 H), 7.03 (d, 7=8.48 Hz, 1 H), 7.10-7.12 (m, 1 H), 7.22 (d, 7=2.07 Hz, 1 H), 7.70 (d, 7=6.41 Hz, 1 H), 8.34 (d, 7=6.40 Hz, 1 H), 8.83 (s, 1 H). ESI-MS calcd for C25H26C1N304S: 499.1. Found (M+H+): 500.0. Anal. Calcd. For C25H26ClN3O4S.0.9H2O: C, 58.16; H, 5.43; N, 8.14; S, 6.21. Found: C, 58.29; H, 5.41; N, 8.10; S, 5.94.
Example C(47): 6-[2-(3-chloro-4-methoxyphenyl)ethyl]-6-cyclopentyl-4-hydroxy-3- ([I.SlthiazoloIδ^-blpyridin^-ylthioJ-δ.δ-dihydro^H-pyran-Σ-one.
Figure imgf000408_0001
The title compound was prepared analogously to Example C(40), where [1 ,3]thiazolo[5,4- J ]pyridine-2-thiol was substituted in place of 5-chloro-1 -isopropyl-1 H-benzimidazole-2-thiol. Η NMR (300 MHz, DMSO-D5) δ: 1.37-1.76 (m, 8 H), 2.04-2.14 (m, 2 H), 2.60-2.65 (m, 2 H), 2.81-3.02 (m, 3 H), 3.82 (s, 3 H), 7.05 (d, 7=8.48 Hz, 1 H), 7.16 (m, 1 H), 7.30 (d, 7=1.88 Hz, 1 H), 7.45 (dd, 7=8.29, 4.71 Hz, 1 H), 8.00 (dd, 7=8.29, 1.51 Hz, 1 H), 8.43 (dd, 7=4.62, 1.41 Hz, 1 H). ESI-MS calcd for C25H25C1N204S2: 516.1. Found (M+H+): 517.0. Anal. Calcd for C25H25CIN204S2: C, 58.07; H, 4.87; N, 5.42; S, 12.40. Found: C, 57.71; H, 4.87; N, 5.40; S, 12.13.
Example C(48): 6-[2-(3-chloro-4-methoxyphenyl)ethyl]-6-cyclopentyl-4-hydroxy-3-[(1 - phenyl-1H-benzimidazol-2-yl)thio]-5,6-dihydro-2H-pyran-2-one.
Figure imgf000408_0002
The title compound was prepared analogously to Example C(40), where 1-phenyl-1H- benzimidazole-2-thiol was substituted in place of 5-chloro-1 -isopropyl-1 H-benzimidazole-2-thiol. Η NMR (300 MHz, DMSO-D6) δ: 1.41-1.73 (m, 8 H), 2.20-2.29 (m, 2 H), 2.60-2.74 (m, 3 H), 2.89-2.93 (m, 2 H), 3.83 (s, 3 H), 7.06 (d, 7=8.59 Hz, 1 H), 7.13-7.21 (m, 6 H), 7.32 (d, 7=2.02 Hz, 1 H), 7.59-7.60 (m, 2 H), 7.63-7.68 (m, 2 H). ESI-MS calcd for C32H31C1N204S: 574.2. Found (M+H1): 575.2. Anal. Calcd. For C32H3ιClN2O4S.0.2H2O: C, 66.41; H, 5.47; N, 4.84; S, 5.54. Found: C, 66.34; H, 5.43; N, 4.93; S, 5.44.
Example C(49): 3-[(5-chloro-1tf-benzimidazol-2-yl)thio]-6-[2-(3-chloro-4- methoxyphenyl)ethyl]-6-cyclopentyl-4-hydroxy-5,6-dihydro-2H-pyran-2-one.
Figure imgf000409_0001
The title compound was prepared analogously to Example C(40), where 5-chloro-1/-/- benzimidazole-2-thiol was substituted in place of 5-chloro-1 -isopropyl-1 H-benzimidazole-2-thiol. Η NMR (300 MHz, DMSO-D6) δ: 1.36-1.71 (s, 8 H), 2.05-2.13 (m, 2 H), 2.38-2.43 (m, 1 H), 2.56-2.72 (m, 3 H), 2.86-2.93 (m, 1 H), 3.81 (s, 3 H), 7.03 (d, 7=8.48 Hz, 1 H), 7.10-7.15 (m, 2 H), 7.24-7.35 (m, 3 H). ESI-MS calcd for C26H26C12N204S: 532.10. Found (M+H+): 533.00. Anal. Calcd. For C26H26Cl2N2O4S.1.0H2O: C, 56.62; H, 5.12; N, 5.08; S, 5.81. Found: C, 56.89; H, 5.01; N, 5.35; S, 5.55.
Example C(50): 6-[2-(3-chloro-4-methoxyphenyl)ethyl]-6-cyclopentyl-4-hydroxy-3-[(5- pyridin-4-yl-4W-1,2,4-triazol-3-yl)thio]-5,6-dihydro-2H-pyran-2-one.
Figure imgf000409_0002
The title compound was prepared analogously to Example C(40), where 5-pyridin-4-yl- 4H-1 ,2,4-triazole-3-thiol was substituted in place of 5-chloro-1 -isopropyl-1 H-benzimidazole-2- thiol.
'HNMR (300 MHz, DMSO-D6) δ: 1.30-1.68 (m, 8 H), 1.82-2.10 (s, 2 H), 2.31-2.40 (m, 1 H), 2.47-2.52 (m, 2 H), 2.69-2.75 (m, 1 H), 2.86-2.93 (m, 1 H), 3.71 (s, 3 H), 6.90 (d, 7=8.48 Hz, 1 H), 7.02-7.06 (m, 1 H), 7.19 (d, 7=1.88 Hz, 1 H), 7.64 (d, 7=4.71 Hz, 2 H), 8.48 (d, 7=4.71 Hz, 2 H). ESI-MS calcd for C26H27C1N404S: 526.1. Found (M+H+): 517.2. Anal. Calcd. For C26H27ClN4O4S.0.4HOAc: C, 58.41; H, 5.23; N, 10.17; S, 5.82. Found: C, 58.33; H, 5.57; N, 10.02; S, 5.76. Example C(51 ): 6-[2-(3-chloro-4-methoxyphenyl)ethyl]-6-cyclopentyl-4-hydroxy-3-[(5- pyridin-4-yl-1,3,4-oxadiazol-2-yl)thio]-5,6-dihydro-2H-pyran-2-one.
Figure imgf000410_0001
The title compound was prepared analogously to Example C(40), where 5-pyridin-4-yl- 1 ,3,4-oxadiazoie-2-thiol was substituted in place of 5-chloro-1 -isopropyl-1 H-benzimidazole-2-thiol. 'HNMR (300 MHz, DMSO-D6) δ: 1.26-1.62 (m, 8 H), 1.92-1.98 (m, 2 H), 2.26-2.31 (m, 1 H), 2.41-2.50 (m, 2 H), 2.64-2.70 (m, 1 H), 2.84-2.90 (m, 1 H), 3.65 (s, 3 H), 6.85 (d, 7=8.48 Hz, 1 H), 7.02 (dd, 7=8.48, 2.07 Hz, 1 H), 7.15 (d, 7=2.07 Hz, 1 H), 7.60 (d, 7=5.84 Hz, 2 H), 8.58 (s, 2 H). ESI-MS calcd for C26H26C1N305S: 527.1. Found (M+H : 528.1. Anal. Calcd. For C26H26C1N305S: C, 59.14; H, 4.96; N, 7.96; S, 6.07. Found: C, 59.13; H, 5.22; N, 7.62; S, 5.79.
Example C(52): 6-[2-(3-chloro-4-methoxyphenyl)ethyl]-6-cyclopentyl-3-[(5-fluoro-1 H- benzimidazol-2-yl)thio]-4-hydroxy-5,6-dihydro-2H-pyran-2-one.
Figure imgf000410_0002
The title compound was prepared analogously to Example C(40), where 5-fluoro-1H- benzimidazole-2-thiol was substituted in place of 5-chloro-1 -isopropyl-1 H-benzimidazole-2-thiol. 'H MR (300 MHz, DMSO-D6) δ: 1.41-1.70 (m, 8 H), 2.05-2.09 (m, 2 H), 2.39-2.44 (m, 1 H), 2.56-2.61 (m, 2 H), 2.63-2.67 (m, 1 H), 2.87-2.91 (m, 1 H), 3.75-3.83 (m, 3 H), 6.95-7.01 (m, 1 H), 7.03 (d, 7=8.59 Hz, 1 H), 7.10-7.15 (m, 2 H), 7.27-7.28 (m, 1 H), 7.31-7.35 (m, 1 H). ESI-MS calcd for C26H26C1FN204S: 516.1. Found (M+H*): 517.1. Anal. Calcd. For C26H25ClFN2O4S.0.9H2O: C, 58.47; H, 5.22; N, 4.91; S, 5.61. Found: C, 58.84; H, 5.01; N, 4.64; S, 5.27. Example C(53): 6-[2-(3-chloro-4-methoxyphenyl)ethyl]-6-cyclopentyl-4-hydroxy-3-[(5- methyl-1W-benzimidazol-2-yl)thio]-5,6-dihydro-2W-pyran-2-one.
Figure imgf000411_0001
The title compound was prepared analogously to Example C(40), where 5-methyl-1rV- benzimidazole-2-thiol was substituted in place of 5-chloro-1-isopropyl-1W-benzimidazole-2-thiol. Η NMR (300 MHz, DMSO-D6) δ: 1.43-1.69 (m, 8 H), 1.94-1.99 (m, 2 H), 2.35-2.37 (m, 1 H), 2.40 (s, 3 H), 2.52-2.60 (m, 3 H), 2.70-2.76 (m, 1 H), 3.80 (s, 3 H), 7.02 (d, 7=8.67 Hz, 1 H), 7.09 (d, 7=1.88 Hz, 1 H), 7.12 (brs, 1 H), 7.24 (d, 7=2.07 Hz, 1 H), 7.26 (brs, 1 H), 7.36 (d, 7=8.29 Hz, 1 H). ESI-MS calcd for C27H29C1N204S: 512.2. Found (M+H*): 513.0. Anal. Calcd. For C27H29ClN2O4S.0.9HOAc: C, 60.99; H, 5.79; N, 4.94; S, 5.65. Found: C, 61.13; H, 5.81; N, 4.88; S, 5.59.
Example C(54): 6-[2-(3-chloro-4-methoxyphenyl)ethyl]-6-cyclopentyl-4-hydroxy-3-[(4- methyl-1W-benzimidazol-2-yl)thio]-5,6-dihydro-2W-pyran-2-one.
Figure imgf000411_0002
The title compound was prepared analogously to Example C(40), where 4-methyl-1tt- benzimidazole-2-thiol was substituted in place of 5-chloro-1 -isopropyl-1 H-benzimidazole-2-thiol. Η NMR (300 MHz, DMSO-D6) δ: 1.44-1.68 (m, 8 H), 1.95-2.00 (m, 2 H), 2.36-2.39 (m, 1 H), 2.42 (s, 3 H), 2.45-2.47 (m, 1 H), 2.53-2.59 (m, 2 H), 2.71-2.75 (m, 1 H), 3.80 (s, 3 H), 7.00-7.06 (m, 2 H), 7.09-7.15 (m, 2 H), 7.24-7.27 (m, 2 H). ESI-MS calcd for C27H29C1N204S: 512.2. Found (M+H*): 513.1. Anal. Calcd. For C27H29C1N204S. OH20: C, 61.06; H, 5.88; N, 5.28; S, 6.04. Found: C, 60.89; H, 5.71; N, 5.17; S, 5.86.
Example C(55): 2-({6-[2-(3-chloro-4-methoxyphenyl)ethyl]-6-cyclopentyl-4-hydroxy-2-oxo- 5,6-dihydro-2W-pyran-3-yl}thio)-1W-benzimidazole-5-carbonitrile
Figure imgf000412_0001
The title compound was prepared analogously to Example C(40), where 2-mercapto-1H- benzimidazole-5-carbonitrile was substituted in place of 5-chloro-1 -isopropyl-1 H-benzimidazole-2- thiol.
'H NMR (300 MHz, DMSO-D6) δ: 1.54-1.74 (m, 8 H), 2.11-2.17 (m, 2 H), 2.42-2.45 (m, 1 H), 2.57-2.63 (m, 2 H), 2.70-2.76 (m, 1 H), 2.94-3.00 (m, 1 H), 3.82 (s, 3 H), 7.04 (d, 7=8.48 Hz, 1 H), 7.14-7.17 (m, 1 H), 7.29 (d, 7=2.07 Hz, 1 H), 7.42-7.49 (m, 2 H), 7.69 (s, 1 H). ESI-MS calcd for C27H26CΪN304S: 523.1. Found (M+FT): 524.1. Anal. Calcd. For C27H26CΪN3O4S.0.4H2O: C, 61.04; H, 5.09; N, 7.91. Found: C, 61.27; H, 5.42; N, 7.90.
Example C(56): 2-({6-[2-(3-chloro-4-methoxyphenyl)ethyl]-6-cyclopentyl-4-hydroxy-2-oxo- 5,6-dihydro-2H-pyran-3-yl}thio)nicotinonitrile
Figure imgf000412_0002
The title compound was prepared analogously to Example C(40), where 2- mercaptonicotinonitrile was substituted in place of 5-chloro-1 -isopropyl-1 H-benzimidazole-2-thiol. Η NMR (300 MHz, DMSO-D6) δ: 1.43-1.78 (m, 8 H), 2.04-2.10 (m, 2 H), 2.40-2.45 (m, 1 H), 2.63-2.69 (m, 2 H), 2.78-3.00 (m, 2 H), 3.81 (s, 3 H), 7.06 (d, 7=8.48 Hz, 1 H), 7.15-7.19 (m, 1 H), 7.31 (d, 7=1.88 Hz, 1 H), 7.52 (dd, 7=8.19, 4.43 Hz, 1 H), 8.18 (dd, 7=8.19, 1.41 Hz, 1 H), 8.82 (dd, 7=4.43, 1.41 Hz, 1 H). ESI-MS calcd for C25H25C1N204S: 484.1. Found (M+HT): 485.0. Anal. Calcd. For C25H25ClN2O S.0.4 H20: C, 61.00; H, 5.28; N, 5.69; S, 6.51. Found: C, 60.90; H, 5.15; N, 5.87; S, 6.66.
Example C(57): 6-[2-(3-chloro-4-methoxyphenyl)ethyl]-3-[(5-chloro-1 -methyl-1 H- benzimidazol-2-yl)thϊo]-6-cyclopentyl-4-hydroxy-5,6-dihydro-2H-pyran-2-one.
Figure imgf000413_0001
The title compound was prepared analogously to Example C(40), where 5-chloro-1- methyl-1H-benzimidazole-2-thiol was substituted in place of 5-chloro-1 -isopropyl-1 H- benzimidazole-2-thiol.
Η NMR (300 MHz, DMSO-D6) δ: 1.39-1.70 (m, 8 H), 2.21-2.27 (m, 2 H), 2.42-2.46 (m, 1 H), 2.55-2.70 (m, 3 H), 2.93-2.99 (m, 1 H), 3.73 (s, 3 H), 3.82 (s, 3 H), 7.01-7.04 (m5 2 H), 7.13-7.20 (m, 2 H), 7.29 (d, 7=2.07 Hz, 1 H), 7.49 (d, 7=8.48 Hz, 1 H). ESI-MS calcd for C27H28C12N204S: 546.1. Found (M+H+): 547.0. Anal. Calcd. For C27H28Cl2N2O4S.0.4HOAc: C, 58.42; H, 5.22; N, 4.90; S, 5.61. Found: 58.25; H, 5.12; N, 4.88; S, 5.46.
Example C(58): 6-[2-(3-chloro-4-methoxyphenyl)ethyl]-6-cyclopentyl-4-hydroxy-3-[(4- hydroxy-1H-benzimidazol-2-yl)thio]-5,6-dihydro-2H-pyran-2-one.
Figure imgf000413_0002
The title compound was prepared analogously to Example C(40), where 2-mercapto-1/7- benzimidazol-4-ol was substituted in place of 5-chloro-1 -isopropyl-1 /-/-benzimidazole-2-thiol. 'HNMR (300 MHz, DMSO-D6) δ: 1.26-1.55 (m, 8 H), 1.77-1.80 (m, 2 H), 2.19-2.27 (m, 1 H), 2.39-2.45 (m, 3 H), 2.54-2.60 (m, 1 H), 3.66 (s, 3 H), 6.54 (d, 7=7.35 Hz, 1 H), 6.77 (d, 7=7.91 Hz, 1 H), 6.86-6.97 (m, 3 H), 7.09 (d, 7=2.07 Hz, 1 H). HRMS calcd. For C26H28C1N205S (M+H+): 515.1402. Found: 515.1381.
Example C(59): 6-[2-(3-chloro-4-methoxyphenyl)ethyl]-6-cyclopentyl-3-[(5-ethoxy-1H- benzimidazol-2-yl)thio]-4-hydroxy-5,6-dihydro-2H-pyran-2-one.
Figure imgf000414_0001
The title compound was prepared analogously to Example C(40), where 5-ethoxy-1 H- benzimidazole-2-thiol was substituted in place of 5-chloro-1 -isopropyl-1 -/-benzimidazole-2-thiol. Η NMR (300 MHz, DMSO-D5) δ: 1.33 (t, 7=6.97 Hz, 3 H), 1.41-1.68 (m, 8 H), 1.93-1.99 (m, 7=17.33 Hz, 2 H), 2.34-2.44 (m, 2 H), 2.54-2.60 (m, 2 H), 2.71-2.77 (m, 1 H), 3.80 (s, 3 H), 4.02 (q, 7=6.91 Hz, 2 H), 6.88 (dd, 7=8.76, 2.35 Hz, 1 H), 6.94 (d, 7=2.26 Hz, 1 H), 7.02 (d, 7=8.48 Hz, 1 H), 7.09-7.12 (m, 1 H), 7.24 (d, 7=1.88 Hz, 1 H), 7.36 (d, 7=8.67 Hz, 1 H). ESI-MS calcd for C28H3ιClN205S: 542.2. Found (M+H+): 543.1. Anal. Calcd. For C28H31ClN2O5S.0.4HOAc: C, 60.99; H, 5.79; N, 4.94; S, 5.65. Found: C, 61.05; H, 5.82; N, 4.62; S, 5.41.
Example C(60): 6-[2-(3-chloro-4-methoxyphenyl)ethyl]-6-cyclopentyl-3-[(5,6-dichloro-1- methyl-1H-benzimidazol-2-yl)thio]-4-hydroxy-5,6-dihydro-2H-pyran-2-one.
Figure imgf000414_0002
The title compound was prepared analogously to Example C(40), where 5,6-dichloro-1- methyl-1H-benzimidazole-2-thiol was substituted in place of 5-chloro-1-isopropyI-1H- benzimidazole-2-thiol.
'HNMR (300 MHz, DMSO-D6) δ: 1.37-1.74 (m, 8 H), 2.26-2.32 (m, 2 H), 2.41-2.45 (m, 1 H), 2.57-2.63 (m, 2 H), 2.67-2.73 (m, 1 H), 2.98-3.03 (m, 1 H), 3.73 (s, 3 H), 3.82 (s, 3 H), 7.03 (d, 7=8.48 Hz, 1 H), 7.08 (s, 1 H), 7.15 (d, 7=8.48 Hz, 1 H), 7.28 (d, 7=1.70 Hz, 1 H), 7.85 (s, 1 H). ESI-MS calcd for C27H27C13N204S: 580.1. Found (M+H1): 581.0. Anal. Calcd. For C27H27Cl3N2O4S.0.3H2O: C, 55.21; H, 4.74; N, 4.77; S, 5.46. Found: C, 55.22; H, 4.76; N, 4.89; S, 5.20. Example C(61): 3-[(5-chloro-6-fluoro-1H-benzimidazol-2-yl)thio]-6-[2-(3-chloro-4- methoxyphenyl)ethyl]-6-cyclopentyl-4-hydroxy-5,6-dihydro-2H-pyran-2-one.
Figure imgf000415_0001
The title compound was prepared analogously to Example C(40), where 5-chloro-6- fluoro-1H-benzimidazole-2-thiol was substituted in place of 5-chloro-1 -isopropyl-1 H- benzimidazole-2-thiol.
'HNMR (300 MHz, DMSO-D6) δ: 1.40-1.71 (m, 8 H), 2.13-2.18 (m, 2 H), 2.40-2.45 (m, 1 H), 2.56-2.62 (m, 2 H), 2.70-2.76 (m, 1 H), 2.95-3.01 (m, 1 H), 3.81 (s, 3 H), 7.04 (d, 7=8.48 Hz, 1 H), 7.13-7.16 (m, 1 H), 7.25 (d, 7=9.61 Hz, 1 H), 7.29 (d, 7=1.88 Hz, 1 H), 7.37 (d, 7=6.78 Hz, 1 H). ESI-MS calcd for C26H25C12FN204S: 550.1. Found (M+H*): 551.0. Anal. Calcd. For C26H25Cl2FN2O4S.0.3H2O: C, 56.08; H, 4.63; N, 5.03; S, 5.76. Found: C, 56.08; H, 4.86; N, 5.17; S, 5.80.
Example C(62): 6-[2-(3-chloro-4-methoxyphenyl)ethyl]-3-{[7-chloro-5-(trifluoromethyl)-1 H- benzimidazol-2-yl]thio}-6-cyclopentyl-4-hydroxy-5,6-dihydro-2H-pyran-2-one.
Figure imgf000415_0002
The title compound was prepared analogously to Example C(40), where 7-chloro-5- (trifluoromethyl)-1/-/-benzimidazole-2-thiol was substituted in place of 5-chloro-1 -isopropyl-1 H- benzimidazole-2-thiol.
Η NMR (300 MHz, DMSO-D6) δ: 1.42-1.68 (m, 8 H), 1.92-1.96 (m, 2 H), 2.32-2.37 (m, 1 H), 2.53-2.66 (m, 3 H), 3.07-3.15 (m, 1 H), 3.79 (s, 3 H), 7.00 (d, 7=8.48 Hz, 1 H), 7.07-7.11 (m, 1 H), 7.22 (d, 7=2.07 Hz, 1 H), 7.42 (d, 7=1.13 Hz, 1 H), 7.56 (s, 1 H). ESI-MS calcd for C27H25C12F3N204S: 600.1. Found (M+FT): 610.0. Anal. Calcd. For C27H25Cl2F3N2O4S.1.0H2O: C, 52.35; H, 4.39; N, 4.52; S, 5.18. Found: C, 52.06; H, 4.64; N, 4.80; S, 4.82, Example C(63): 6-[2-(5-chloro-2,4-dimethoxyphenyl)ethyl]-3-[(5-chloro-1 -methyl-1 H- benzimidazol-2-yl)thio]-6-cyclopentyl-4-hydroxy-5,6-dihydro-2H-pyran-2-one.
Figure imgf000416_0001
The title compound was prepared analogously to Example C(40), where 3-chloro-6-[2-(5- chloro-2,4-dimethoxyphenyl)ethyl]-6-cyclopentyl-4-hydroxy-5,6-dihydro-2H-pyran-2-one was substituted in place of 3-chloro-6-[2-(3-chloro-4-methoxyphenyl)ethyl]-6-cyclopentyl-4-hydroxy- 5,6-dihydro-2/-/-pyran-2-one and 5-chloro-1 -methyl-1 H-benzimidazole-2-thioI was substituted in place of 5-chloro-1 -isopropyl-1 H-benzimidazole-2-thiol.
Η NMR (300 MHz, DMSO-D6) δ: 1.37-1.71 (m, 8 H), 2.07-2.19 (m, 2 H), 2.35-2.42 (m, 1 H), 2.57-2.72 (m, 3 H), 2.83-2.88 (m, 1 H), 3.71 (s, 3 H), 3.75 (s, 3 H), 3.86 (s, 3 H), 6.71 (s, 1 H), 7.01 (d, 7=1.70 Hz, 1 H), 7.13 (s, 1 H), 7.16 (d, 7=2.07 Hz, 1 H), 7.45 (d, 7=8.67 Hz, 1 H). ESI-MS calcd for C28H30Cl2N2O5S: 576.1. Found (M+H+): 577.1. Anal. Calcd. For C28H3oCl2N205S.1.0H20: C, 56.47; H, 5.42; N, 4.70; S, 5.38. Found: C, 56.86; H, 5.24; N, 5.05; S, 5.20.
Example C(64): 6-[2-(3-chloro-4-isopropoxyphenyl)ethyl]-3-[(5-chloro-1-methyl-1W- benzimidazol-2-yl)thio]-6-cyclopentyl-4-hydroxy-5,6-dihydro-2H-pyran-2-one.
Figure imgf000416_0002
The title compound was prepared analogously to Example C(40), where 3-chloro-6- cyclopentyl-6-[2-(3-fluoro-4-isopropoxyphenyl)ethyl]-4-hydroxy-5,6-dihydro-2/-/-pyran-2-one, where 4-bromo-2-fluoro-1-isopropoxybenzene was) was substituted in place of 3-chloro-6-[2-(3- chloro-4-methoxyphenyl)ethyl]-6-cyclopentyl-4-hydroxy-5,6-dihydro-2H-pyran-2-one and 7-chloro- 5-(trifluoromethyl)-1H-benzimidazole-2-thiol was substituted in place of 5-chloro-1 -isopropyl-1 H- benzimidazole-2-thiol.
'H NMR (300 MHz, DMSO-D6) δ: 1.26 (d, 7=6.03 Hz, 6 H), 1.43-1.71 (m, 8 H), 2.16-2.22 (m, 2 H), 2.39- 2.42 (m, 1 H), 2.53-2.69 (m, 3 H), 2.70-2.75 (m, 1 H), 3.70 (s, 3 H), 4.50-4.58 (m, 1 H), 6.93-6.96 (m, 1 H), 7.02-7.08 (m, 2 H), 7.11-7.15 (m, 2 H), 7.41-7.44 (m, 1 H). ESI-MS calcd for C29H32C12N204S: 558.2. Found (M+KT): 559.1. Anal. Calcd. For C29H32Cl2N2O4S.1.0H2O: C, 60.35; H, 5.94; N, 4.85; S, 5.56. Found: C, 60.46; H, 5.95; N, 4.74; S, 5.52.
Step 1: Methyl 2-chloro-5-cyclopentyl-7-(3-fluoro-4-isopropoxyphenyl)-5-hydroxy-3- oxoheptanoate
Figure imgf000417_0001
Methyl-2-chloroacetoacetate (2.0 mL, 16.2mmol) was added to a cooled 0 °C suspension of NaH (0.65 g, 16.2 mmol, 60% dispersion in mineral oil) in THF (54 mL). After 15 min the solution was cooled to -40 °C and n-BuLi (10. OmL, 16.2 mmol, 1.6M in hexanes) was added. The resulting dianion was stirred for an additional 30 min and then treated with a solution of 1- cyclopentyl-3-(3-fluoro-4-isopropoxyphenyl)propan-1-one (1.5g, 5.4 mmol, compound was prepared analogously to Step 1 of Example A(82), where 4-(bromo)-2-fluoro-1- isopropoxybenzene was substituted in place of 2-Bromopyridine) in THF (10ml). After stirring for 1 h at -40 °C, the reaction mixture was quenched with saturated NH4CI and extracted with EtOAc. The organic layers were washed with brine, dried with Na2S04 and concentrated to an orange oil that was used without further purification.
Step 2: 3-chloro-6-cyclopentyl-6-[2-(3-fluoro-4-isopropoxyphenyl)ethyl]-4-hydroxy-5,6- dihydro-2H-pyran-2-one.
Figure imgf000418_0001
A solution of methyl 2-chloro-5-cyclopentyl-7-(3-fluoro-4-isopropoxyphenyl)-5-hydroxy-3- oxoheptanoate (1.74 g, 4.1 mmol), and bis(dibutylchlorotin)oxide (1.38 g, 2.5 mmol), dissolved in toluene (20 mL) were heated at reflux for 30mins. The resulting mixture was concentrated and purified by silica gel chromatography to give the title compound (0.80 g, 50% yield, two Steps). Η NMR (300 MHz, CDC13): δ 1.33 (d, 7= 6.03 Hz, 6H), 1.45-1.80 (m, 10 H), 1.99-2.05 (m, 2 H), 2.34- 2.44 (m, 1 H), 2.59-2.66 (m, 2 H), 4.44-4.52 (m, 1 H), 6.78-6.91 (m, 3 H).
Example C(65): 6-[2-(3-chloro-4-methoxyphenyl)ethyl]-6-cyclopentyl-4-hydroxy-3-(9H- purin-8-ylthio)-5,6-dihydro-2H-pyran-2-one.
Figure imgf000418_0002
The title compound was prepared analogously to Example C(40), where 9/-/-purine-8-thiol was substituted in place of 5-chloro-1 -isopropyl-1 H-benzimidazole-2-thiol.
'HNMR (300 MHz, DMSO-D6) δ: 1.37-1.68 (m, 8 H), 2.04-2.10 (m, 2 H), 2.38-2.43 (m, 1 H), 2.55-2.60 (m, 2 H), 2.69-2.75 (m, 1 H), 2.93-2.98 (m, 1 H), 3.78 (s, 3 H), 7.03 (d, 7=8.48 Hz, 1 H), 7.15-7.19 (m, 1 H), 7.28 (d, 7=1.88 Hz, 1 H), 8.62 (s, 1 H), 8.72 (s, 1 H). ESI-MS calcd for C24H25C1N404S: 500.1. Found (M+H+): 501.1. Anal. Calcd. For C24H25C1N404S.1.2H20: C, 55.15; H, 5.28; N, 10.72; S, 6.14. Found: C, 54.92; H, 5.28; N, 11.16; S, 6.01.
Example C(66): 6-[2-(3-chloro-4-methoxyphenyl)ethyl]-6-cyclopentyl-4-hydroxy-3- (quinolin-2-ylthio)-5,6-dihydro-2H-pyran-2-one.
Figure imgf000419_0001
The title compound was prepared analogously to Example C(40), where quinoiine-2-thiol was substituted in place of 5-chloro-1 -isopropyl-1 H-benzimidazole-2-thiol. Η NMR (300 MHz, DMSO-D6) δ: 1.33-1.64 (m, 8 H), 1.91-2.03 (m, 2 H), 2.13-2.20 (m, 1 H), 2.38-2.49 (m, 2 H), 2.55-2.61 (m, 1 H), 2.73-2.79 (m, 1 H), 3.59 (s, 3 H), 6.81 (d, 7=8.48 Hz, 1 H), 6.92-6.95 (m, 1 H), 7.02-7.08 (m, 3 H), 7.19-7.22 (m, 2 H), 7.59-7.62 (m, 1 H), 7.87 (d, 7=8.85 Hz, 1 H). ESI-MS calcd for C28H28C1N04S: 509.1. Found (M+H1): 510.1. Anal. Calcd. For C28H28ClNO4S.0.5H2O: C, 64.79; H, 5.63; N, 2.70; S, 6.18. Found: C, 64.52; H, 5.66; N, 2.68; S, 6.07.
Example C(67): 6-[2-(3-chIoro-4-methoxyphenyl)ethyl]-6-cyclopentyl-4-hydroxy-3-(7H- purin-2-ylthio)-5,6-dihydro-2r/-pyran-2-one.
Figure imgf000419_0002
The title compound was prepared analogously to Example C(40), where 7 V-purine-2-thiol was substituted in place of 5-chloro-1 -isopropyl-1 H-benzimidazole-2-thiol. 'HNMR (300 MHz, DMSO-D6) δ: 1.43-1.71 (m, 8 H), 2.18-2.29 (m, 2 H), 2.60-2.76 (m, 4 H), 2.88-2.94 (m, 1 H), 3.82 (m, 3 H), 7.03-7.36 (m, 3 H), 8.39-8.74 (m, 2 H). ESI-MS calcd for C24H25C1N404S: 500.1. Found (M+H÷): 501.1. Anal. Calcd. For C24H25ClN4O4S.0.7H2O: C, 56.12; H, 5.18; N3 10.91; S, 6.24. Found: C, 55.87; H, 5.26; N, 10.73; S, 6.14.
Example C(68): 6-[2-(3-chloro-4-methoxyphenyl)ethyl]-6-cyclopentyl-4-hydroxy-3- (quinazolin-4-ylthio)-5,6-dihydro-2H-pyran-2-one.
Figure imgf000420_0001
The title compound was prepared analogously to Example C(40), where quinazoline-4- thiol was substituted in place of 5-chloro-1 -isopropyl-1 H-benzimidazole-2-thiol. 'HNMR (300 MHz, DMSO-D6) δ: 1.42-1.77 (m, 8 H), 2.25-2.35 (m, 2 H), 2.61-2.77 (m, 4 H), 2.96-3.02 (m, 1 H), 3.83 (m, 3 H), 7.07-7.10 (m, 1 H), 7.16-7.20 (m, 1 H), 7.30 (s, 1 H), 7.71-7.76 (m, 1 H), 7.90-7.99 (m, 1 H), 8.21 (d, 7=8.29 Hz, 1 H), 8.49 (s, 1 H). HRMS calcd. For C27H28C1N204S (M+H+): 511.1453. Found: 511.1443.
Example C(69): 6-Cyclopentyl-6-{2-[4-(difluoromethyl)-3-fluorophenyl]ethyl}-3-[(5,7- dimethyl[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)thio]-4-hydroxy-5,6-dihydro-2H-pyran-2-one.
Figure imgf000420_0002
A mixture of 3-chloro-6-cyclopentyl-6-{-[4-(difluoromethyl)-3-fluorophenyl]ethyl}dihydro- 2H-pyran-2,4(3H)-dione (200 mg, 0.514 mmol), from Step 1, below, and 5,7- dimethyl[1 ,2,4]triazolo[1,5-a]pyrimidine-2-thiol (93 mg, 0.514 mmol) in DMF (4 mL) was treated with triethylamine (52 mg, 0.514 mmol, 1 equiv). The mixture stirred and heated at 55 °C for 4 h. The reaction was cooled to room temperature, and the DMF removed in vacuo. Water and ethyl acetate were added to the resinous material, resulting in the precipitation of a solid. This was filtered, washed with ether, and allowed to air dry, affording 186 mg (68%) of the title product. 'HNMR (DMF-d7) δ 1.81-2.00 (m, 8H) 2.56-2.62 (m, 2H) 2.71 (s, 3H) 2.76 (s, 3H) 2.80 (m, 1H) 3.07(m, 2H) 3.14 (d, 7=6 Hz, IH) 3.32 (d, 7=18 Hz, IH) 7.40 (t, 7=57 Hz, IH), 7.24 (s, IH) 7.66 (m, 2H) 7.84 (m, IH,). MS (APCI) calcd for C26H27F303S: 532.58; MS found; (M + H+ 533.1. Anal. Calc'd for C26H27F303S: C, 58.64; H, 5.11; N, 10.52; S, 6.02. Found : C, 58.26, 58.33; H, 5.25, 5.14; N, 10.69, 10.61; S, 5.78, 5.79. Step 1 : 3-chloro-6-cyclopentyl-6-{-[4-(difluoromethyl)-3-fluorophenyl]ethyl}dihydro-2H- pyran-2,4(3H)-dione.
Figure imgf000421_0001
To a slurry of NaH (450 mg, 18.65 mmol) in dry THF (6 mL) at -40 °C under nitrogen was added a cold solution of methyl 2-chloroacetoacetate (2.67g, 17.76 mmol) in 20 mL dry THF (20 mL) at such a rate that the temperature was maintained within 5 °C of -40 °C. When the addition was complete, the mixture was stirred at this temperature for an additional 30 min, then cooled to -70 °C with a dry ice/acetone bath. Cold n-BuLi (9 mL, 2.08 M, 18.65 mmol) was slowly added via syringe, maintaining the temperature at -70 °C. The mixture was stirred for an additional 45 min at this temperature. A solution of 1-cyclopentyl-3-[4-(difluoromethyl)-3-fluorophenyl]propan- 1-one (4 g, 14.8 mmol) in dry THF (20 mL) was added slowly via an addition funnel. The reaction was allowed to stir at -70 °C for 45 min, then warmed to room temperature. After stirring for 2 h, the mixture was quenched with 4M aqueous NH4CI (9.35 mL, 37.3 mmol), stirred for 5 min, then concentrated in vacuo. The oily residue was treated with water and extracted with CH2CI2 (3 x 50 mL). The extract was dried over Na2S04, filtered and concentrated to a orange resin. Purification by column chromatography on silica gel and a gradient of 10% ethyl acetate/hexanes to 100% ethyl acetate afforded 3.5 g (8.32 mmol, 56%) of methyl 2-chloro-5-cyclopentyl-7-[4- (difluoromethyl)-3-fluorophenyl]-5-hydroxy-3-oxoheptanoate. This hydroxyester intermediate was dissolved in toluene (20 mL), treated with bis(dibutylchlorotin)oxide (2.07 g, 3.75 mmol, 0.45 equiv), and the mixture refluxed for 1 h. The solution was cooled to room temperature, the solvent removed in vacuo, and the resin filtered through a plug of silica gel, eluting with 5% MeOH/ethyl acetate. The fractions containing the product were evaporated and recrystallized from ethyl ether, affording 437 mg (13.5% yield) of the title product.
Example C(70): 8-({6-[2-(5-chloro-2,4-dimethoxyphenyl)ethyl]-6-cyclopentyl-4-hydroxy-2- oxo-5,6-dihydro-2H-pyran-3-yl}thio)-1,7-dihydro-6f -purin-6-one.
Figure imgf000422_0001
A solution of 3-chlora-6-[2-(5-chloro-2,4-dimethoxyphenyl)ethyl]6-cyclopentyldihydro-2H- pyran-2,4(3H)-dione in anhydrous DMF (0.5 M, 160 μL, 0.08 mmol) was delivered by electronic pipette to a reaction vessel. To this was added a solution of 6-hydroxy-8-mercaptopurine monohydrate in anhydrous DMF (0.5M, 160 μL, 0.08 mmol, 1 equiv), and a solution of triethylamine in DMF (1M, 80 μL, 0.08 mmol, 1 equiv). The reaction mixture was heated at 55 +/- 5°C for 16 h. The solvent was evaporated and the residue dissolved in DMSO to make a final concentration of 0.0572 M, and the product purified by HPLC using a Pecke Hi-Q 5 μm, 20 x 100 mm column with a 5-90% CH3CN/0.05% TFA gradient. A run time of 8.1 min, a flow rate of 30.0 mL/min, and a monitoring wavelength at 260 nm were used.
Η NMR (500 MHz, DMSO-d6, WET suppression of DMSO [2.5 ppm] and H20 [3.35 ppm]) δ 1.55-1.70 (m, 8 H) 1.91 (m, 2 H) 2.35 (m, 1 H) 2.63 (m, 1 H) 2.50-2.60 (m, 2H) 2.75 (d, 7=17.6 Hz, IH) 2.98 (d, 7=17.6 Hz, 1 H) 3.80 (s, 3 H) 3.84 (s, 3 H) 6.71 (s, 1 H) 7.20 (s, 1 H) 7.88 (s, IH) 12.14 (s, 1 H). MS (APCI) calcd for C25H27C1N406S: 546.13; found [M+l]: 547.1.
Example C(71): 6-[2-(5-Chloro-2,4-dimethoxyphenyl)ethyl]-6-cyclopentyl-4-hydroxy-3-[(5- phenyl-1H-1,2,4-triazol-3-yl)thio]-5,6-dihydro-2H-pyran-2-one.
Figure imgf000422_0002
The title compound was prepared as described in Example C(70),where 3-phenyl-1 ,2,4- triazole-5-thiol was used in place of 6-hydroxy-8-mercaptopurine monohydrate. Η NMR (500 MHz, DMSO-d6, WET suppression of DMSO [2.5 ppm] and H20 [3.35 ppm]) δ 1.55-1.74 (m, 8 H) 1.90 (m, IH) 2.35 (s, 1 H) 2.62 (m, 1 H) 2.70 (d, 7=17.9 Hz, 1 H) 2.80 (d, 7=17.6 Hz, 2 H) 2.89 (d, 7=17.9 Hz, 1 H) 3.70 (s, 3 H) 3.78 (s, 3 H) 6.64 (s, 1 H) 7.15 (s, 2 H) 7.32 (d, J=5 Hz, IH) 7.70 (s IH) 7.78 (s, IH). MS (APCI) calcd for C2SH30ClN3O5S: 556.08; found M: 556.
Example C(72): 6-[2-(5-Chloro-2,4-dimethoxyphenyl)ethyl]-6-cyclopentyl-4-hydroxy-3-[(1- methyl-1H-tetrazol-5-yl)thio]-5,6-dihydro-2H-pyran-2-one.
Figure imgf000423_0001
The title compound was prepared as described in Example C(70),where 5-mercapto-1- methyltetrazole was used in place of 6-hydroxy-8-mercaptopurine monohydrate. 'H NMR (500 MHz, DMSO-d6, WET suppression of DMSO [2.5 ppm] and H20 [3.35 ppm]) δ 1.50-1.69 (m, 8 H) 1.92 (m, 2 H) 2.37 (m, 1 H) 2.50 (m, IH) 2.63 (m, 1 H) 2.72 (d, 7=17.9 Hz, 1 H) 2.93 (d, 7=17.9 Hz, 1 H) 3.77 (s, 3 H) 3.84 (s, 3 H) 3.97 (s, 3 H) 6.71 (s, 1 H) 7.18 (s, 1 H). MS (APCI) calcd for C22H27C1N405S: 494.99; found M = 495.1.
Example C(73): 6-[2-(5-Chloro-2,4-dimethoxyphenyl)ethyl]-3-[(5-chloro-1-isopropyl-1W- benzimidazol-2-yl)thio]-6-cyclopentyl-4-hydroxy-5,6-dihydro-2H-pyran-2-one.
Figure imgf000423_0002
The title compound was prepared as described in Example C(70), where 5-chloro-1- isopropyl-2-mercaptobenzimidazole was used in place of 6-hydroxy-8-mercaptopurine monohydrate.
'H NMR (500 MHz, DMSO-d6, WET suppression of DMSO [2.5 ppm] and H20 [3.35 ppm]) δ 1.56 (s, 3 H) 1.57 (s, 3 H) 1.60-1.74 (m, 8 H) 2.13 (m, 1 H) 2.29 (m, 1 H) 2.35 (m, 1 H) 2.50 (m, IH) 2.63 (m, 1 H) 2.74 (d, 7=17.3 Hz, 1 H) 2.97 (d, 7=17.3 Hz, 1H)3.74 (s, 3 H) 3.86 (s, 3 H) 4.80 (m, 1 H) 6.71 (s, 1 H) 6.91 (s, 1 H) 7.11 (dd, 7=8.65, 2.06 Hz, 1 H) 7.16 (s, 1 H) 7.63 (d, 7=8.79 Hz, 1 H). MS (APCI) calcd for C30H34Cl2N2O5S: 605.58; found M = 605.0
Example C(74): 6-[2-(5-chloro-2,4-dimethoxyphenyl)ethyl]-6-cyclopentyl-4-hydroxy-3-{[4- hydroxy-6-(trifluoromethyl)pyrimidin-2-yl]thio}-5,6-dihydro-2H-pyran-2-one.
Figure imgf000424_0001
The title compound was prepared as described in Example C(70),where 4-hydroxy-6- (trifluoromethyl)pyrimidine-2-thiol was used in place of 6-hydroxy-8-mercaptopurine monohydrate. Η NMR (500 MHz, DMSO-d6, WET suppression of DMSO [2.5 ppm] and H20 [3.35 ppm]) δ 1.52-1.68 (m, 8 H) 1.84 (m, 1 H) 2.02 (m, 1 H) 2.35 (s, 1 H) 2.50 (m, IH, overlap with dmso) 2.63 (s, 1 H) 2.80-2.88 (m, 2 H) 3.77 (s, 3 H) 3.83 (s, 3 H) 6.52 (s, 1 H) 6.70 (s, 1 H) 7.12 (s, 1 H). MS (APCI) calcd for C25H26C1F3N206S: 575.00; found M = 575.0
Example C(75): 6-[2-(5-chloro-2,4-dimethoxyphenyl)ethyl]-6-cyclopentyl-4-hydroxy-3-[(5- pyridin-3-yl-4H-1,2,4-triazol-3-yl)thio]-5,6-dihydro-2H-pyran-2-one.
Figure imgf000424_0002
The title compound was prepared as described in Example C(70),where 5-(3-pyridinyl)- 4H-1 ,2,4-triazole-3-thiol was used in place of 6-hydroxy-8-mercaptopurine monohydrate. 'H NMR (500 MHz, DMSO-d6, WET suppression of DMSO [2.5 ppm] and H20 [3.35 ppm]) δ 1.55-1.73 (m, 8 H) 1.92 (m, 1 H) 2.11 (m, 1 H) 2.35 (m, 1 H) 2.50 (m,lH, buried under dmso peak) 2.81 (d, 7=17.6 Hz, 1 H) 3.46 (m, 2 H) 3.71 (s, 3 H) 3.78 (s, 3 H) 6.61 (s, 1 H) 7.12 (s, 1 H) 7.38 (m, 1 H) 8.08 (m, 1 H) 8.59 (d, 7=5.2 Hz, 1 H) 9.02 (s, 1 H). MS (APCI) calcd for C27H29C1N405S: 557.07; found M = 557.0 Example C(76): 3-[(5-amino-1 -methyl-1 H-benzimidazol-2-yl)thio]-6-[2-(5-chloro-2,4- dimethoxyphenyl)ethyl]-6-cyclopentyl-4-hydroxy-5,6-dihydro-2H-pyran-2-one.
Figure imgf000425_0001
The title compound was prepared as described in Example C(70),where 5-Amino-1- methyl-1H-benzimidazole-2-thiol was used in place of 6-hydroxy-8-mercaptopurine monohydrate. 'HNMR (500 MHz, DMSO-d6) WET suppression of DMSO [2.5 ppm] and H20 [3.35 ppm]) δ 1.60 (m, 8 H) 1.88 (m, 2 H) 2.62 (m, 1 H) 2.79 (d, 7=17.86 Hz, 1 H) 3.78 (m, 1 H) 6.71 (s, 1 H) 6.88 (m, 1 H) 7.12 (s, 1 H) 7.48 (d, 7=8.79 Hz, 1 H). MS (APCI) calcd for C28H32CιN305S: 558.09; found M = 558.1
Step 1: 6-amino-1/7-benzimidazole-2-thiol
Figure imgf000425_0002
Λ/ -methylbenzene-1 ,2,4-triamine (Le Bris, M. T. Bull. Soc. Chim Fr 1976, 5, 921) (10.91 g, 40 mmol) in EtOH (75 mL) and H20 (12 mL) and potassium o-ethyl dithiocarbonate (10.47 g, 64.01 mmol) were placed in a 250 mL 3-necked round bottomed flask, outfitted with a mechanical overhead stirrer and N2 flow. The resulting suspension was stirred for 15 min at room temperature.K2C03 (8.36 g, 60.50 mmol) was added to the pot and the reaction mixture refluxed for 18 h. Warm water (150 mL, 80°C) was added to the reaction mixture along with an 8:5 acetic acid/water solution (27 mL) to bring the pH to δ.The reaction mixture was allowed to cool to room temperature over 2 h and then was suction filtered. The filtrate (filtrate A) was concentrated to half the volume (250 mL to 125 mL) by heating, then allowed to cool to room temperature over the weekend. The solid obtained from the filtration was dissolved in 8% NaOH (50 mL) and filtered to remove any undissolved solids. This filtrate was brought to pH 5 by the addition of glacial acetic acid and stirred for 1.5 h at room temperature. The solution was filtered and washed with water to give Filtrate B. Filtrate A formed a sticky black solid on the bottom and sides of the flask. The liquid (Filtrate A) was decanted off and the solid was dissolved in 8% NaOH (150 mL) and filtered to remove any undissolved solids. The filtrate (Filtrate C) was acidified to pH 5 using glacial acetic acid (25 mL) and stirred at room temperature for 2 h. It was filtered again and washed with water, then concentrated to half its volume (225 mL to 115 mL).
Filtrates A, B and C were combined and concentrated by heating. The solution was suction filtered and washed with H20 (30 mL). A dark violet solid was obtained and dried in a vacuum oven affording 1.25 g (15.8%) of the desired product.
Η NMR (DMSO-d6) d 3.53 (s, 3H); 5.03 (broad s, 2H); 6.94 (s, IH); 6.43-6.46 (d, 7=9 Hz, IH); 6.98-7.01 (d, 7=9 Hz, IH); 12.23 (broad s, IH). MS (APCI) calcd for C8H9N3S: 179.2; found (M + H+) 180.0.
Example C(77): 6-[2-(5-chloro-2,4-dimethoxyphenyl)ethyl]-6-6cyclopentyl-4-hydroxy-3-[(5- pyridin-3-yl-1W-imidazol-2-yl)thio]-5,6-2H-pyran-2-one.
Figure imgf000426_0001
The title compound was prepared as described in Example C(70),where 5-pyridin-3-yl- 1/-/-imidazole-2-thiol was used in place of 6-hydroxy-8-mercaptopurine monohydrate. Η NMR (500 MHz, DMSO-d6, WET suppression of DMSO-h6 (2.5 ppm) and H20 (3.35 ppm) peak areas) δ 1.40-1.71 (m, 8 H) 1.91 (m, IH)) 2.02 (m, 1 H) 2.36 (m, 1 H) 2.49 (m, IH, overlap with dmso) 2.62 (m, 1 H) 2.72 (d, 7=17.6 Hz, 1 H) 2.94 (d, 7=17.9 Hz, 1 H) 3.72 (s, 3 H) 3.79 (s, 3 H) 6.61 (s, 1 H) 7.08 (s, 1 H) 7.58 (m, 1 H) 7.95 (s, 1 H) 8.23 (m., 1 H) 8.54 (d, 7=4.67 Hz, 1 H) 8.92 (s, 1 H). MS (APCI) calcd for C28H3oClN3θ5S: 556.08; found M = 556.1
Example C(78): 6-[2-(5-chloro-2,4-dimethoxyphenyl)ethyl]-6-cyclopentyl-4-hydroxy-3[(3- methylpyrazin-2-yl)thio]-5,6-dihydro-2H-pyran-2-one.
Figure imgf000427_0001
The title compound was prepared as described in Example C(70),where 3- methyIpyrazine-2-thiol was used in place of 6-hydroxy-8-mercaptopurine monohydrate. Η NMR (500 MHz, DMSO-d6, WET suppression of DMSO-h6 (2.5 ppm) and H20 (3.35 ppm) peak areas) d 1.54-1.71 (m, 8 H) 2.05 (m, 1 H) 2.18 (m, 1 H) 2.35 (m, 1 H) 2.50 (m, IH, overlap with dmso) 2.63 (m, 1 H) 2.75 (d, 7=17.6 Hz, 1 H) 2.95 (d, 7=17.3 Hz, 1 H) 3.30 (s, 3H, overlap with H20) 3.74 (s, 3 H) 3.86 (s, 3 H) 6.72 (s, 1 H) 7.10 (s, 1 H) 7.84 (d, 7=2.20 Hz, 1 H) 8.11 (d, 7=2.75 Hz, 1 H). MS (APCI) calcd for C25H29C1N205S: 505.03; found M = 505.0
Step l: 3-methylpyrazine-2-thiol
Figure imgf000427_0002
Sodium hydrogen sulfide dihydrate (139.7 g, 1.58 mol), 2-chloro-3,(5),(6)-methylpyrazine (with 80% of 3-methyl isomer) (65.0 g, 0.51 mol) and 1 ,3-propanediol (300 mL) were added to a 3-L round bottomed flask, which was equipped with a magnetic stir bar, a condenser and a thermometer. The reaction mixture was heated for 1.5 h at 110-130°C. After cooling to room temperature, the inorganic salt was filtered and washed with methanol (200 mL). The combined filtrate was concentrated in vacuo, (10-20 mmHg/ 140-120°C). Water (200 mL) was added to the residue and aqueous NaOH was used to adjust from pH 1 to pH 14. Insoluble material was filtered and the filtrate was adjusted to pH 5-6. The yellow solid was filtered, washed with water (2 x 100 mL) and lyophilized to yield 44 of a mixture of isomers of the desired product, of which contained 80% of the 3-methyl isomer. The mixture was dissolved in 4 L of hot isopropanol/ethanol (1:1). Upon cooling to room temperature, the yellow crystallized impurity was filtered. After evaporating the filtrate under reduced pressure, the desired product was obtained as a yellow solid. (25.0 g, 39% yield, 85% pure)
Η NMR (DMSO-d6): d 2.5 (s, 3H) 7.54 (s, IH) 7.71 (d, 7=3.0 Hz, IH) 14.15 (broad s, IH). MS (APCI) calcd for C5H6N2S: 126.03; found (M + H+): 127.0 Example C(79): 6-[2-(5-chloro-2,4-dimethoxyphenyl)ethyl]-6-cyclopentyl-4-hydroxy-3-{[5-
(3-methoxyphenyl)-4-methyl-4W-1,2,4-triazol-3-yl]thio}-5,6-dihydro-2W-pyran-2-one.
Figure imgf000428_0001
The title compound was prepared as described in Example C(70),where 5-(3-methoxyphenyl)-4- methyl-4H-1 ,2,4-triazole-3-thiol was used in place of 6-hydroxy-8-mercaptopurine monohydrate. Η NMR (500 MHz, DMSO-d6, WET suppression of DMSO-h6 (2.5 ppm) and H20 (3.35 ppm) peak areas) δ 1.53-1.74 (m, 8 H) 1.91 (m,Hz, 2 H) 2.35 (m, 1 H) 2.50 (m, lH,overlap with dmso) 2.63 (m, 1 H) 2.70 (d, 7=17.9 Hz, 1 H) 2.92 (d, 7=17.6 Hz, 1 H) 3.67 (s, 3 H) 3.77 (s, 3 H) 3.80 (s, 3 H) 3.83 (s, 3 H) 6.69 (s, 1 H) 7.11 (m, 1 H) 7.20 (s, 2 H) 7.45 (t, 7=8.2 Hz, 1 H). MS (APCI) calcd for C3oH34ClN306S: 600.13; found M = 600.1
Example C(80): 6-[2-(5-chloro-2,4-dimethoxyphenyl)ethyl]-6-cyclopentyl-4-hydroxy-3-[(5- hydroxy-4-isopropyl-4H-1,2,4-triazol-3-yl)thio]-5,6-dihydro-2H-pyran-2-one.
Figure imgf000428_0002
The title compound was prepared as described in Example C(70),where 4-isopropyl-5- mercapto-4H-1 ,2,4-triazol-3-ol was used in place of 6-hydroxy-8-mercaptopurine monohydrate. Η NMR (500 MHz, DMSO-d6, WET suppression of DMSO-h6 (2.5 ppm) and H20 (3.35 ppm) peak areas) δ 1.35 (s, 3 H) 1.37 (s, 3 H) 1.54-1.69 (m, 8 H) 1.80 (m, 1 H) 1.91 (m, 1 H) 2.062.34 (m, 1 H) 2.50 (m, IH, overlap with dmso) 2.63 (m, 1 H) 2.74 (d, 7=15.0 Hz, 1 H) 2.85 (d, 7=15.0 Hz, 1 H) 3.77 (s, 3 H) 3.84 (s, 3 H) 4.31 (m, 1 H) 6.70 (s, 1 H) 7.13 (s, 1 H) 11.52 (s, 2 H). MS (APCI) calcd for C25H32C1N306S: 538.06; found M = 538.1 Example C(81): 6-[2-(5-chlor-2,4-dimethoxyphenyl)ethyl]-6-cyclopentyl-4-hydroxy-3-{[5-(4- hydroxyphenyl)-4r -1,2,4-triazol-3-yl]thio}-5,6-dihydro-2H-pyran-2-one.
Figure imgf000429_0001
The title compound was prepared as described in Example C(70),where 4H-mercapto- 5(4-hydroxyphenyl)-[1,2,4]triazole was used in place of 6-hydroxy-8-mercaptopurine monohydrate.
Η NMR (500 MHz, DMSO-d6, WET suppression of DMSO-h5 (2.5 ppm) and H20 (3.35 ppm) peak areas) δ 1.50-1.72 (m, 8 H) 1.89 (m, 2 H) 2.35 (m, 1 H) 2.50 (m, IH, overlap with dmso) 2.63 (m, 1 H) 2.79 (d, 7=17.9 Hz, 1 H) 3.73 (s, 3 H) 3.81 (s, 3 H) 6.66 (s, 1 H) 6.70 (s, 1 H) 6.72 (s, 1 H) 7.14 (s, 1 H) 7.56 (s, 2 H). MS (APCI) calcd for C2SH3oClN3θ6S: 572.08; found M = 572.2
Figure imgf000429_0002
Example C(82): 6-[2-(5-chloro-2,4-dimethoxyphenyl)ethyl]-6-cyclopentyl-4-hydroxy-3-[(5- methyl[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)thio]-5,6-dihydro-2H-pyran-2-one.
The title compound was prepared as described in Example C(70), where 5- methyl[1 ,2,4]triazoIo[1,5-a]pyrimidine-2-thiol was used in place of 6-hydroxy-8-mercaptopurine monohydrate. Η NMR (500 MHz, DMSO-d6, WET suppression of DMSO-h6 (2.5 ppm) and H20 (3.35 ppm) peak areas) δ 1.55-1.73 (m, 8 H) 2.03 (m, 1 H) 2.11 (m, 1 H) 2.35 (m, 1 H) 2.56 (m, 1 H) 2.62 (m, 1 H) 2.75 (d, 7=17.6 Hz, 1 H) 2.95 (d, 7=17.6 Hz, 1 H) 3.75 (s, 2 H) 3.84 (s, 3 H) 6.69 (s, 1 H) 7.10 (d, 7=6.9 Hz, 1 H) 7.19 (s, 1 H) 8.69 (d, 7=6.9 Hz, 1 H). MS (APCI) calcd for C26H29C1N405S: 545.06; found M = 545.2
Step 1 : 4-methyl-2-methylsulfanyl-pyrimidine
Figure imgf000430_0001
Based on a reported procedure (Ishizumi, K.; Kojima, A.; Antoku, F. Chem Pharm Bull 1991, 39, 2288). Sodium hydroxide (92.5 g, 2.31 mol) was added to a suspension of 2-mercapto-4-methyl pyrimidine hydrochloride (150 g, 0.93 mol) in water (1.5 L). Methyl iodide (78.9 ml, 1.39 mol) was rapidly added to the clear solution (solution temp. < 20 °C). After overnight stirring, diethyl ether (400 mL), the organic layer was separated and the aqueous layer was extracted with diethyl ether (4*200 ml) all organic layers were combined, washed with 5% aq. NaOH solution (100 ml), brine (200 ml, 2 times), and dried (MgS0 ), concentrated in vacuo to afford 119.3 g of crude material (95% pure by NMR) which was used in the next step without purification. Η NMR (CDC13, 300 MHz) δ, ppm: 2.46 (s, 3H), 2.56 (s, 3H), 6.82 (d, 7=5 Hz, IH,), 8.37 (d, 7=5 Hz IH).
Step 2: (4-methyl-pyrimidin-2-yl)-hydrazine
Figure imgf000430_0002
Based on a reported procedure (Vanderhaeghe, Claesen, Bull. Soc. Chim. Belg. 1959, 68, 30). Hydrazine monohydrate (334.7 ml, 6.90 mmol) was added in one portion to a solution of 4-Methyl-2-methylsulfanyl-pyrimidine (357.9 g, 2.55 mol) in abs. EtOH (890 ml). The resulting mixture was refluxed for 50 h, then hydrazine monohydrate (200 ml) was added and refluxing was continued for 50 h (the reaction was monitored by 1H NMR). Then it was cooled to 0°C to crystallize and 213 g of crude product was isolated by filtration. Recrystallization from ethanol gave the title compound (184.7 g, 59%) as a white solid. Η NMR (CDClj, 300 MHz) δ, ppm: 2.40 (s, 3H), 4.00 (broad, 2H), 6.512 (d, IH, 5 Hz), 7.03 (broad, IH), 8.24 (d, IH, 5 Hz).
Step 3: Sodium 7-methyl-1H-[1,2,4]triazolo[4,3-a]pyrimidine-3-thiolate
Figure imgf000431_0001
The title compound was prepared by a modification or a reported procedure (Shirakawa, K. Yakugaku Zasshi 1960, 80, 1542. A solution of (4-Methyl-pyrimidin-2-yl)-hydrazine (140 g, 1.13 mol), sodium hydroxide (45 g, 1.13 mol) and carbon disulfide (67.7 ml, 1.13 mol) in 50% aqueous ethanol (900 ml) was refluxed for 6 hours. The resulting mixture was cooled to ambient temperature and 54.7 g the yellow solid formed was isolated (54.7 g). It was recrystallized from 50% aqueous ethanol and dried at 40°C/1 Torr for 10 hours to give 44 g (18%) of sodium 5- methyl-1 H-[1 ,2,4]triazolo[4,3-a]pyrimidine-3-thiolate, 85% pure by ELSD and 1H NMR.
The initial mother liquid was kept at 0 °C for 2 days. The crystallized orange solid was isolated by filtration, dried for 10 h at 40 °C/1 Torr to give 68.1 g (27%) of the title compound, sodium 7- methyl-1H-[1,2,4]triazolo[4,3-a]pyrimidine-3-thiolate, used in Step 4, below. H NMR (DMSO- 6, 300 MHz) δ, ppm: 2.44 (s, 3H), 6.60 (d, 1H, 7 Hz), 8.29 (d, 1H, 7 Hz).
Step 4: 5-methyl[1 ,2,4]triazolo[1 ,5-a]pyrimidine-2-thiol
Figure imgf000431_0002
The title compound was synthesized from 7-methyl-1 H-[1 ,2,4]triazolo[4,3-a]pyrimidine-3-thiolate (from Step 3, above) using the procedure described for the synthesis of 7- methyl[1,2,4]triazolo[1,5-a]pyrimidine-2-thiol [Step 2 in the AG-101578 example], to give the crude product in 77% yield. Two recrystallizations from 50% aqueous ethanol provided 99% pure (1H NMR and ELSD) material in 46% yield. 1H NMR (DMSO- /6, 300 MHz) δ, ppm: 2.58 s, 3H), 7.34 (d, 1H, 7 Hz), 8.99 (d, 1H, 7 Hz), 14.10 (broad, 1 H)."'
Figure imgf000432_0001
Example C(83): 6-[2-(5-chloro-2,4-dimethoxyphenyl)ethyl]-6-cyclopentyl-3-({5-
[dimethylamino)methyl]-4-methyl-4H-1,2,4-triazol-3-yl}thio)-4-hydroxy-5,6-dihydro-2H- pyran-2-one.
The title compound was prepared as described in Example C(70),where 5- [(dimethylamino)methyl]-4-methyl-4H-1 ,2,4-triazole-3-thiol was used in place of 6-hydroxy-8- mercaptopurine monohydrate. 1H NMR (500 MHz, DMSO-d6, WET suppression of DMSO-h6 (2.5 ppm) and H20 (3.35 ppm) peak areas) d ppm 1.59 (m, 8 H) 1.91 (m, 2 H) 2.36 (m, 1 H) 2.62 (m, 1 H) 2.73 (d, 7=17.58 Hz, 1 H) 2.86 (s, 9 H) 2.91 (d, 7=17.86 Hz, 1 H) 3.63 (s, 1 H) 3.80 (d, 7=3.02 Hz, 1 H) 3.84 (s, 1 H) 4.52 (s, 3 H) 6.71 (s, 1 H) 7.20 (s, 1 H). MS (APCI) calcd for C2sH35CIN405S: 551.10; found M = 551.2
Step 1 : 5-[(dimethylamino)methyl]-4-methyl-4H-1 ,2,4-triazole-3-thiol
Figure imgf000432_0002
N,N-dimethylglycine hydrazide hydrochloride (50 g, 0.263 mol) was stirred for 5 min in EtOH (525 mL). To this suspension was added Cs2C03 (62.5 g, 0.192 mol) and the mixture was stirred at room temperature for 15 min. Methyl isothiocyanate (19.25 g, 0.263 mol) in EtOH (270 mL) was added to the pot and the reaction mixture was brought to reflux. The reflux condenser was removed and the EtOH was allowed to evaporate under atmospheric pressure (oil bath temperature 105-110°C) over 3h to give a purple paste. The reaction was removed from heat and allowed to sit at room temperature overnight (18 h), during which time the paste became a solid. The solid was mixed with CH2CI2 (1.5 L) and filtered. The organic filtrate was concentrated under reduced pressure to give 31 g of a crude yellow oil. The oil was purified by column chromatography through silica gel, eluting with 4:1 CH2CI2/MeOH to afford 15.3 g (34.9%) of the desired product. Η NMR (DMSO-d6) d 2.17 (s, 6H) 3.46 (s, 5H) 13.57 (s, IH). MS (APCI) calcd for C6H12N4S: 172.25; found (M-H+) 171.1.
Example C(84): 6-[2-(5-chloro-2,4-dimethoxyphenyl)ethyl]-6-cyclopentyl-4-hydroxy-3- ([1 ,2,4]triazolo[1 ,5-a]pyrimidin-2-ylthio-5,6-dihydro-2H-pyran-2-one.
Figure imgf000433_0001
The title compound was prepared as described in Example C(70),where [1 ,2,4]triazolo[1 ,5-a]pyrimidine-2-thiol was used in place of 6-hydroxy-8-mercaptopurine monohydrate.
Η NMR (500 MHz, DMSO-d6) WET suppression of DMSO-h6 (2.5 ppm) and H20 (3.35 ppm) peak areas) δ 1.55-1.72 (m, 8 H) 2.08 (m, 2 H) 2.35 (m, 1 H) 2.50 (m, IH, overlap with dmso) 2.63 (m, 1 H) 2.78 (d, 7=17.9 Hz, 1 H) 2.96 (d, 7=17.6 Hz, 1 H) 3.76 (s, 3 H) 3.85 (s, 3 H) 6.70 (s, IH) 7.20 (m, 1 H, overlap) 7.21 (s, 1 H) 7.22 (m, 1 H, overlap) 8.75 (dd, 7=4.4, 1.7 Hz, 1 H) 8.87 (dd, 7=6.9, 1.7 Hz, 1 H). MS (APCI) calcd for C25H27C1N405S : 531.03 ; found M = 531.1
Step 1 : [1 ,2,4]triazolo[1 ,5-a]pyrimidine-2-thiol
Figure imgf000433_0002
The title compound was prepared from malonodialdehyde bis(dimethylacetal) and 3- amino-5-mercapto-1 ,2,4-triazole as previously described by M. Kϋnstlinger and E. Breitmaier in Synthesis, 1983, 44-47.
'H NMR (DMSO-d6) d 7.07 (dd, 7=6.8, =3.8, 1 H) 8.63 (d, 7=6.8, 1 H) 8.76 (s, 1 H). MS (APCI) calcd for C5H4N4S: 152.18; found (M = H1") 153.0.
Example C(85): 6-[-(5-chloro-2,4-dimethoxyphenyl)ethyl]-6-cyclopentyl-4-hydroxy-3-[(4- methyl-5-pyridin-3-yl-4W-1,2,4-triazol-3-yl)thio]-5,6-dihydro-2W-pyran-2-one.
Figure imgf000434_0001
The title compound was prepared as described in Example C(70),where 4-methyl-5-(3- pyridyl)-4/-/-1 ,2,4-triazole-3-thiol was used in place of 6-hydroxy-8-mercaptopurine monohydrate. Η NMR (500 MHz, DMSO-d6, WET suppression of DMSO-h6 (2.5 ppm) and H20 (3.35 ppm) peak areas) d ppm 1.52-1.69 (m, 8 H) 1.92 (m,2 H) 2.37 (m, 1 H) 2.5 (m, 1 H, overlap with dmso) 2.62 (m, 1 H) 2.73 (d, 7=17.6 Hz, 1 H) 2.94 (d, 7=17.9 Hz, 2 H) 3.70 (s, attenuation due to proximity to H20 peak) 3.8 (s, attenuation due to proximity to H20 peak) 6.70 (s, 1 H) 7.21 (s, 1 H) 7.59 (dd, 7=7.7, 4.7 Hz, 1 H) 8.12 (d, 7=8.5 Hz, 1 H) 8.73 (d, 7=4.1 Hz, 1 H) 8.89 (s, 1 H). MS (APCI) calcd for C28H31C1N405S: 571.09; found M = 571.1
Example C(86): 6-[2-(5-chloro-2,4-dimethoxyphenyl)ethyl]-6-cyclopentyl-4-hydroxy-3-{[5- methyl-4-(2-morpholin-4-ylethyl)-4H-1,2,4-triazol-3-yl]thio}-5,6-dihydro-2H-pyran-2-one.
Figure imgf000434_0002
The title compound was prepared as described in Example C(70),where 5-methyl-4-(2- morpholin-4-y!ethyl)-4/-/-1 ,2,4-triazole-3-thiol was used in place of 6-hydroxy-8-mercaptopurine monohydrate.
Η NMR (500 MHz, DMSO-d6) WET suppression of DMSO-h6 (2.5 ppm) and H20 (3.35 ppm) peak areas) d ppm 1.50 (m, 9 H) 1.83 (m, 2 H) 2.33 (m, 2 H) 2.42 (m, 1 H) 2.63 (m, 1 H) 2.78 (d, 7=16.5 Hz, 1 H) 3.27 (s, 4 H) 3.42 (s, 3 H) 3.53 (m, 3 H) 3.82 (d, 7=15.0 Hz, 1 H) 4.45 (m, 2 H) 6.71 (s, 2 H) 7.13 (s, 1 H). MS (APCI) calcd for C29H39C1N406S: 607.17; found M = 607.1 Step 1 : 5-methyl-4-(2-morpholin-4-ylethyl)-4W-1 ,2,4-triazole-3-thiol
Figure imgf000435_0001
The title compound was prepared by a modification of a procedure reported for related compounds: Henichart, J. P.; Bernier, J. L Synthesis 1980, 4, 311. Acetic hydrazide (3.7 g, 50 mmol) in ethanol (50 mL) was placed in a 200 mL 3-necked round bottomed flask outfitted with a magnetic stir bar and a reflux condenser. 2-morpholinoethyl isothiocyanate (8.61 g, 500 mmol) in ethanol (50 mL) was added to the pot. The mixture was refluxed, under N2, for 6 h. The reaction was cooled to room temperature and the solvent removed on the rotovap. The resulting resin was dissolved in minimal ethanol and ether. A white solid precipitated out, was filtered and washed with cold ether. The filtrate, containing uncyclized intermediate, was concentrated and dissolved in xylenes. The mixture was refluxed under N2 for 8 h, then allowed to sit at room temperature, under N2. for 48 h. A white solid formed, was filtered and washed with cold ether. The first and second batches of white solid were combined to yield 7.33 g (64%) of the desired product.
Η NMR (DMSO-d6): d 2.33 (s, 3H) 2.41 (m, 4H) 2.55 (m, 2H) 3.52 (m, 4H) 3.99 (t, 2H, J = 6) 13.41 (s, IH). MS (APCI) calcd for C9H16N4OS: 228.32; found (M + ET) 229.1.
Example C(87): 6-[2-(5-chloro-2,4-dimethoxyphenyl)ethyl]-6-cyclopentyl-4-hydroxy-3-[(6- methyl[1 ,2,4]triazolo[1 ,5-a]pyrimidin-2-yl)thio]-5,6-dihydro-2W-pyran-2-one.
Figure imgf000435_0002
The title compound was prepared as described in Example C(70),where 6- methyl[1,2,4]triazolo[1,5-a]pyrimidine-2-thiol in place of 6-hydroxy-8-mercaptopurine monohydrate.
Η NMR (500 MHz, DMSO-d6, WET suppression of DMSO-h6 (2.5 ppm) and H20 (3.35 ppm) peak areas) d 1.40-1.74 (m, 8 H) 2.09 (m, 1 H) 2.18 (m, 1 H) 2.29 (s, 3 H) 2.35 (m, 1 H) 2.63 (m, 1 H) 2.69 (m, 1 H) 2.75 (d, 7=17.6 Hz, 1 H) 2.86 (m, 1 H) 2.98 (d, 7=17.9 Hz, 1 H) 3.75 (s, 2 H) 3.85 (m, 3 H) 6.70 (s, 1 H) 7.19 (s, 1 H) 8.48 (s, 1 H) 8.64 (d, 7=2.2 Hz, 1 H). MS (APCI) calcd for C26H29C1N405S: 545.06; found M
= 545.2
Stepl : 6-methyl[1 ,2,4]triazolo[1 ,5-a]pyrimidine-2-thiol
Figure imgf000436_0001
The title compound was prepared from 3-ethoxymethacrolein and 3-amino-5-mercapto- 1 ,2,4-triazole as previously described by M. Kϋnstlinger and E. Breitmaier in Synthesis, 1983, 44- 47.
Η NMR (DMSO-dβ) d 2.31 (s, 1 H) 8.45 (s, 1 H) 8.68 (s, 1 H). MS (APCI) calcd for CfiH6N4S: 166.21; found (M + H+) 167.0.
Example C(88): 6-[2-(5-chloro-2,4-dimethoxyphenyl)ethyl]-6-cyclopentyl-3-[(4,5-dimethyl- 4W-1 ,2,4-triazol-3-yl)thio]-4-hydroxy-5,6-dihydro-2H-pyran-2-one.
Figure imgf000436_0002
The title compound was prepared as described in Example C(70), where 4,5-dimethyl-4/-/- 1 ,2,4-triazole-3-thiol was used in place of 6-hydroxy-8-mercaptopurine monohydrate. Η NMR (500 MHz, DMSO-d6, WET suppression of DMSO-h6 (2.5 ppm) and H20 (3.35 ppm) peak areas) δ 1.48-1.65 (m, 8 H) 1.84 (m, 3 H) 2.18 (m, 1 H) 2.32 (m, 2H) 2.38 (s, 3 H) 2.61 (d, 7=17.9 Hz, 1 H) 2.82 (d, 7=17.3 Hz, IH) 3.56 (s, attenuation due to proximity to H20 peak) 3.78 (s, attenuation due to proximity to H20 peak) 3.84 (s, 3H) 6.71 (s, IH) 7.12 (s, IH). MS (APCI) calcd for C24H3oClN3θ5S: 508.04; found M = 508.1
Step 1: 4,5-dimethyl-4H-1,2,4-triazole-3-thiol:
Figure imgf000437_0001
Acetic hydrazide (7.4 g, 100 mmol) in ethanol (75 mL) was placed in a 200 mL 3-necked round bottomed flask outfitted with a magnetic stir bar and a reflux condenser. Methyl isothiocyanate (7.3 g, 100 mmol) in ethanol (75 mL) was added to the pot. The mixture was refluxed, under N2, for 6 h. The reaction was cooled to room temperature and the solvent removed on the rotovap. The resulting wet solid was triturated with ether and filtered to give a sticky, yellow solid. This solid was triturated with hot CH2CI2/ethyl acetate (1:1), which afforded a white solid of the uncyclized intermediate. The solid and all liquids associated with the reaction were combined, dissolved in ethanol. Aqueous NaOH (1 M, 50 mL) was added and the mixture refluxed under N2 for 1 h. Acetic acid was used to acidify to a pH of 4-5.The mixture was then cooled on an ice bath to facilitate precipitation. White solid formed, was filtered and washed with ether. (repeated the crystallization process three times with mother liquors). Combined all solids collected and chromatographed through silica gel, eluting with 1-4% MeOH/ethyl acetate. The collected fractions were concentrated, washed with ether and filtered to yield 5.02 g (38.9%) of the desired product.
Η NMR (DMSO-d6): d 2.27 (s, 3H) 3.37 (s, 3H) 13.36 (broad s, IH). MS (APCI) calcd for C4H7N3S: 129.18; found (M + H ) 130.0.
Example C(89): methyl 5-({6-[2-(5-chloro-2,4-dimethoxyphenyl)ethyl]-6-cyclopentyl-4- hydroxy-2-oxo-5,6-dihydro-2H-pyran-3-yl}thio)-4-methyl-4H-1,2,4-triazole-3-carboxylate
Figure imgf000437_0002
The title compound was prepared as described in Example C(70),where methyl 5- mercapto-4-methyl-4H-1 ,2,4-triazole-3-carboxylate was used in place of 6-hydroxy-8- mercaptopurine monohydrate.
Η NMR (500 MHz, DMSO-d6, WET suppression of DMSO-h6 (2.5 ppm) and H20 (3.35 ppm) peak areas) d 1.51-1.67 (m, 8 H) 1.88 (m, 2 H) 2.36 (m, 1 H) 2.5 (m, IH, overlap with dmso) 2.63 (m, 1 H) 2.73 (d, 7=17.6 Hz, 1 H) 2.90 (d, 7=17.6 Hz, 1 H) 3.77 (s, 3 H) 3.81 (s, 3 H) 3.85 (s, 3 H) 3.87 (s, 3 H) 6.70 (s, 1 H) 7.16 (s, 1 H). MS (APCI) calcd for C25H30ClN3O7S: 552.05; found M = 552.1
Step 1: methyl hydrazino(oxo)acetate
Figure imgf000438_0001
This compound was prepared as described: Smuszkovicz, J.; Greig, M. E. J. Med Pharm. Chem. 1961, 4, 259). From 1.08 mol of dimethyl oxalate, 51.7 g (44%) of the title product was obtained. Η NMR (DMSO-d6) d 3.75 (s, 3H) 4.63 (broad s, 2H) 10.24 (broad s, IH). MS (APCI) calcd for C3H6N203: 118.09; found (M + H+) 119.1
Step 2: methyl 5-mercapto-4-methyl-4W-1,2,4-triazole-3-carboxylate
Figure imgf000438_0002
Methyl isothiocyanate (24 g, 0.328 mol) in MeOH (100 mL) was added to a stirred solution of methyl hydrazino(oxo)acetate (35 g, 0.296 mol) in MeOH (350 mL) and the reaction mixture refluxed for 24 h. TLC (MeOH/CH2CI2, 1 :9) indicated no starting material present, intermediate product appeared on TLC as a single spot, Rf = 0.44. Cs2C03 (24 g, 0.74 mol) was added to the hot reaction mixture, cautiously, as the reaction was exothermic. The reaction mixture was cooled down to room temperature and then filtered. The filtrate was concentrated to wet yellow paste. The paste was triturated with CH2CI2 and filtered. The solid material was dried in the vacuum oven at 30°C to afford 43.1 g of product. The mother liquor was concentrated, then triturated with cold CH2CI2 and filtered and dried in the vacuum oven at 30°C to give an additional 6 g of product. The two batches were combined to yield 49.1 g (95.8%) of desired product. 1H NMR (DMSO-d6) d 3.63 (s, 3H) 3.84 (s, 3H) 13.83 (broad s, 1H). MS (APCI) calcd for C5H7N302S: 173.19; found (M + H+) 174.0
Example C(90): 6-[2-(5-chloro-2,4-dimethoxyphenyl)ethyl]-6-cyclopentyl-4-hydroxy-3-{[4- methyl-5-(2-morpholin-4-ylethyl)-4H-1,2,4-triazol-3-yl]thio}-5,6-dihydro-2H-pyran-2-one.
Figure imgf000439_0001
The title compound was prepared as described in Example C(70), where methyl-5-(2- morpholin-4-ylethyl)-4H-1 ,2,4-triazole-3-thiol was used in place of 6-hydroxy-8-mercaptopurine monohydrate.
Η NMR (500 MHz, DMSO-dfi, WET suppression of DMSO-h6 (2.5 ppm) and H20 (3.35 ppm) peak areas) d 1.46-1.66 (m, 12 H) 1.88 (dd, 7=9.8, 6.7 Hz, 4 H) 2.34 (m, 1 H) 2.50 (m, IH, overlap with dmso) 2.63 (m, 1 H) 2.69 (d, 7=17.9 Hz, 2 H) 2.87 (d, 7=17.6 Hz, 2 H) 3.16 (t, 7=7.55 Hz, 2 H) 3.80 (s, attenuation due to proximity to H20 peak) 3.82 (m, 2 H) 3.84 (s, 6 H) 6.71 (s, 1 H) 7.19 (s, 1 H). MS (APCI) calcd for C29H39ClN4OfiS: 607.17; found M = 607.1
Step 1: 3-morpholin-4-ylpropanohydrazide
Figure imgf000439_0002
Hydrazine (64.1 g, 2 mol) was added dropwise, over 8-10 min, to methyl 3- morpholinopropionate (35 g, 0.202 mol) and the reaction mixture was refluxed for 16 h. The excess hydrazine was removed under reduced pressure and the material was dried in vacuo at room temperature for 16 h to give the crude product as an oil. The 1H NMR showed the presence of hydrazine, so the crude material was dried using a lyophilizer. Then the oil was refluxed in benzene/water (using a Dean-Stark distilling receiver). The benzene was then removed under reduced pressure, and the product was triturated with petroleum ether. After sitting in petroleum ether at room temperature for 16 h, the oil solidified. The petroleum ether was decanted and the solid was dried under house vacuum at room temperature to give the desired product (21.5 g, 61.4%), which was used without further purification.
Step 2: 4-methyl-5-(2-morpholin-4-ylethyl)-4H-1 ,2,4-triazole-3-thiol
Figure imgf000440_0001
Prepared according to a procedure reported for related compounds: Henichart, J. P. et al. 7. Het Chem. 1977, 14, 615. Methyl isothiocyanate (9.08 g, 0.124 mol) in EtOH (50 mL) was added at room temperature to a stirred solution of 3-morpholin-4-ylpropanohydrazide (21.5 g, 0.124 mol) in EtOH (200 mL). The mixture was refluxed for 8 h, then removed from heat and stirred at room temperature for 16 h. The EtOh was removed under reduced pressure to give the crude material as a yellow oil. The oil was purified by column chromatography through silica gel, eluting with CH2CI2/MeOH to afford the title compound. (6 g, 21.2%)
Η NMR (DMSO-d6) d 2.42 (m, 4H) 2.64 (m, 2H) 2.85 (m, 2H; 3.43 (s, 3H) 3.55 (m, 4H) 13.47 (s, IH). MS (APCI) calcd forC9Hι6N4OS: 228.32; found (M-H+) 227.1.
Example C(91): 3 6-[2-(3-chlor-4-methoxyphenyl)ethyl]-6-cyclopentyl-4-hydroxy-3-[(6- hydroxy-7W-purin-8-yl)thio]-5,6-dihydro-2H-pyran-2-one.
Figure imgf000440_0002
The title compound was prepared as described in Example C(70), where 3-chloro-6-[2-(3- chloro-4-methoxyphenyl)ethyl]-6-cyclopentyldihydro-2H-pyran-2,4(3H)-dione was used in place of 3-chloro-6-[2-(5-chloro-2,4-dimethoxyphenyl)ethyl]6-cyclopentyldihydro-2H-pyran-2,4(3H)-dione. Η NMR (500 MHz, DMSO-d6, WET suppression of DMSO-h6 (2.5 ppm) and H20 (3.35 ppm) peak areas) δ 1.54-1.69 (m, 9 H) 2.03 (m, 2 H) 2.35 (m, 1 H) 2.58 (m, 1 H) 2.63 (m, Hz, 1 H) 2.76 (d, 7=17.6 Hz, 1 H) 2.96 (d, 7=15.0 Hz, 1 H) 3.80 (s, 3 H) 7.05 (d, 7=8.5 Hz, 1 H) 7.24 (dd, 7=8.5, 17 Hz, 1 H) 7.30 (d, 7=1.7 Hz, 1 H) 7.90 (d, 7=3.6 Hz, 1 H) 12.15 (broad s, 2H). MS (APCI) calcd for C24H25C1N405S: 517.00; found M = 517.1
Example C(92): 6-[2-(3-chloro-4-methoxyphenyl)ethyl]-6-cyclopentyl-4-hydroxy-3-[(5- pyridin-3-yl-4H-1,2,4-triazol-3-yl)thio]-5,6-dihydro-2W-pyran-2-one.
Figure imgf000441_0001
The title compound was prepared as described in Example C(70), where 3-chloro-6-[2-(3- chloro-4-methoxyphenyl)ethyl]-6-cyclopentyldihydro-2/-/-pyran-2,4(3H)-dione was used in place of 3-chloro-6-[2-(5-chloro-2,4-dimethoxyphenyl)ethyl]6-cyclopentyldihydro-2H-pyran-2,4(3H)-dione and 5-(3-pyridinyl)-4H-1 ,2,4-triazole-3-thiol was used in place of 6-hydroxy-8-mercaptopurine monohydrate.
Η NMR (500 MHz, DMSO-d6, WET suppression of DMSO-h6 (2.5 ppm) and H20 (3.35 ppm) peak areas) δ 1.53-1.69 (m, 8 H) 2.03 (m, 1 H) 2.11 (m, 1 H) 2.35 (m, 1 H) 2.57 (m, 1 H) 2.63 (m, 1 H) 2.82 (d, 7=17.6 Hz, 1 H) 2.96 (d, 7=15.0 Hz, 1 H) 3.77 (s, 3 H) 6.95 (d, 7=8.5 Hz, 1 H) 7.09 (d, J = 8.5 Hz, IH) 7.23 (d, 7=1.4 Hz, 1 H) 7.41 (m, 1 H) 8.13 (s, 1 H) 8.60 (d, 7=4.1 Hz, 1 H) 9.03 (s, 1 H). MS (APCI) calcd for C26H27C1N404S: 527.04; found M = 527.0
Example C(93): ethyl 2-({6-[2-(5-chloro-2,4-dimethoxyphenyl)ethyl]-6-cyclopentyl-4- hydroxy-2-oxo-5,6-dihydro-2H-pyran-3-yl}thio)[1 ,2,4]triazolo[1 ,5-a]pyrimidine-6-carboxylate
Figure imgf000441_0002
The title compound was prepared as described in Example C(70), where ethyl 2- mercapto[1,2,4]triazolo-[1,5-a]pyrimidine-6-carboxylate was used in place of 6-hydroxy-8- mercaptopurine monohydrate.
Η NMR (500 MHz, DMSO-d6, WET suppression of DMSO-h6 (2.5 ppm) and H20 (3.35 ppm) peak areas) d 1.34 (t, 7=7.14 Hz, 3 H) 1.55-1.74 (m, 8 H) 2.07 (m, 1 H) 2.16 (m, 1 H) 2.35 (m, 1 H) 2.5 (m, IH, overlap with dmso) 2.63 (m, 1 H) 2.78 (d, 7=17.6 Hz, 1 H) 2.98 (d, 7=17.6 Hz, 1 H) 3.72 (s, 3 H) 3.82 (s, 3 H) 4.37 (q, 7=7.1 Hz, 2 H) 6.67 (s, 1 H) 7.19 (s, 1 H) 9.09 (d, 7=2.2 Hz, 1 H) 9.22 (d, 7=2.2 Hz, 1 H). MS (APCI) calcd for C28H3IC1N407S: 603.09; found M = 603.1 Step 1 : ethyl 2-mercapto[1 ,2,4]triazolo-[1 ,5-a]pyrimidine-6-carboxylate
Figure imgf000442_0001
The title compound was prepared by reaction of (ethoxycarbonyl)malonialdehyde with 3- amino-5-mercapto-1 ,2,4-triazole as previously described by M. Kϋnstlinger and E. Breitmaier in Synthesis, 1983, 44-47. H NMR (DMSO-d6) d 1.35 (t, 7=6.99, 1 H) 4.39 (q, 7=6.80, 1 H) 9.10 (s, 1 H) 9.55 (s, 1H). MS (APCI) calcd for C8H8N402S: 224.24; found (M + H+) 225.0.
Example C(94): ethyl 2-({6-[2-(3-chloro-4-methoxyphenyl)ethyl]-6-cyclopentyl-4-hydroxy- 2-oxo-5,6-dihydro-2W-pyran-3-yl}thio)[1,2,4]triazolo[1,5-a]pyrimidine-6-carboxylate
Figure imgf000442_0002
The title compound was prepared as described in Example C(70), where 3-chloro-6-[2-(3- chloro-4-methoxyphenyl)ethyl]-6-cyclopentyldihydro-2/-/-pyran-2,4(3/-/)-dione was used in place of
3-chloro-6-[2-(5-chloro-2,4-dimethoxyphenyl)ethyl]6-cyclopentyldihydro-2/-/-pyran-2,4(3H)-dione and ethyl 2-mercapto[1 ,2,4]triazolo-[1 ,5-a]pyrimidine-6-carboxylate was used in place of 6- hydroxy-8-mercaptopurine monohydrate.
'HNMR (500 MHz, DMSO-d6, WET suppression of DMSO-h6 (2.5 ppm) and H20 (3.35 ppm) peak areas) δ 1.34 (t, 7=7.1 Hz, 3H) 1.55-1.74 (m, 8 H) 2.07 (m, 1 H) 2.22 (m, 2 H) 2.63 (d, 7=8.2 Hz, 2 H)
2.75 (d, 7=17.6 Hz, 2 H) 3.00 (d, 7=15.0 Hz, 1 H) 3.81 (s 3 H) 4.38 (m, 2 H) 7.06 (t, 7=8.8 Hz, 1 H) 7.25 (s,
1 H) 7.27 (s, 1 H) 7.30 (m, 1 H) 9.13 (s, 1 H) 9.26 (s, 1 H). MS (APCI) calcd for C27H29C1N406S: 573.07; found M = 573.1
Example C(95): 6-[2-(3-chloro-4-methoxyphenyl)ethyl]-6-cyclopentyl-4-hydroxy-3-[(7- methyl[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)thio]-5,6-dihydro-2W-pyran-2-one.
Figure imgf000443_0001
The title compound was prepared as described in Example C(70), where 3-chloro-6-[2-(3- chloro-4-methoxyphenyl)ethyl]-6-cyclopentyldihydro-2H-pyran-2,4(3H)-dione was used in place of 3-chloro-6-[2-(5-chloro-2,4-dimethoxyphenyl)ethyl]6-cyclopentyldihydro-2H-pyran-2,4(3H)-dione and 7-methyl[1,2,4]triazolo[1 ,5-a]pyrimidine-2-thioI was used in place of 6-hydroxy-8- mercaptopurine monohydrate.
IH NMR (500 MHz, DMSO-d6, WET suppression of DMSO-h6 (2.5 ppm) and H20 (3.35 ppm) peak areas) d 1.53-1.73 (m, 8 H) 2.14 (m, 1 H) 2.24 (m, 1 H) 2.35 (m, IH) 2.50 (m, 1 H, overlap with dmso) 2.62 (m, 1 H) 2.80 (d, 7=17.9 Hz, 1 H) 2.96 (d, 7=20.0 Hz, 1 H) 3.80 (s, 3 H) 7.03 (d, 7=8.2 Hz, 1 H) 7.15 (d, 7=4.7 Hz, 1 H) 7.22 (dd, 7=8.4, 2.06 Hz, 1 H) 7.29 (d, 7=1.9 Hz, 1 H) 8.63 (d, 7=4.7 Hz, 1 H). MS (APCI) calcd for C25H27C1N404S; 515.03; found M = 515.0
Step 1: Sodium 5-methyl-1H-[1,2,4]triazolo[4,3-a]pyrimidine-3-thiolate
Figure imgf000443_0002
The title compound was prepared by a modification or a reported procedure (Shirakawa, K. Yakugaku Zasshi 1960, 80, 1542. A solution of (4-Methyl-pyrimidin-2-yl)-hydrazine (140 g, 1.13 mol), sodium hydroxide (45 g, 1.13 mol) and carbon disulfide (67.7 ml, 1.13 mol) in 50% aqueous ethanol (900 ml) was refluxed for 6 hours. The resulting mixture was cooled to ambient temperature and 54.7 g the yellow solid formed was isolated (54.7 g). It was recrystallized from 50% aqueous ethanol and dried at 40°C/1 Torr for 10 hours to give 44 g (18%) of sodium 5- methyl-1H-[1,2,4]triazolo[4,3-a]pyrimidine-3-thiolate, 85% pure by ELSD and 1H NMR.
The initial mother liquid was kept at 0 °C for 2 days. The crystallized orange solid was isolated by filtration, dried for 10 h at 40 °C/1 Torr to give 68.1 g (27%) of the title compound, sodium 7- methyl-1 H-[1,2,4]triazolo[4,3-a]pyrimidine-3-thiolate. 1H NMR (DMSO-cfe, 300 MHz) δ, ppm: 2.44 (s, 3H), 6.60 (d, 1H, 7 Hz), 8.29 (d, 1H, 7 Hz).
Step 2: 7-methyl[1,2,4]triazolo[1,5-a]pyrimidine-2-thiol
Figure imgf000444_0001
A solution of sodium 5-methyl-1H-[1,2,4]triazolo[4,3-a]pyrimidine-3-thiolate from Step 3 (56 g, 0.25 mol) and pyridine (50 ml) in water (169 ml) was heated at reflux for 60 hours (the reaction was monitored by 1H NMR). After the disappearance of starting material the reaction mixture was evaporated to dryness, dissolved in water (100 ml) and acidified with acetic acid (23 ml). The solid was filtered, washed with water and dried for 4 h at 40 °C/1 Torr to give 42 g (84%) of desired product, 95% pure by 1H NMR and ELSD. 1H NMR (DMSO-d6, 300 MHz) δ, ppm: 2.68 (s, 3H), 7.34 (d, 1 H, 3 Hz), 8.56 (d, 1H, 3 Hz).
Example C(96): 6-[2-(3-chloro-4-methoxyphenyl)ethyl]-6-cyclopentyl-4-hydroxy-3-[(4- methyl-5-pyridin-3-yl-4H-1,2,4-triazol-3-yl)thio-5,6-dihydro-2r/-pyran-2-one.
Figure imgf000444_0002
The title compound was prepared as described in Example C(70), where 3-chloro-6-[2-(3- chloro-4-methoxyphenyl)ethyI]-6-cyclopentyldihydro-2/-/-pyran-2,4(3H)-dione was used in place of 3-chloro-6-[2-(5-chloro-2,4-dimethoxyphenyl)ethyl]6-cyclopentyldihydro-2/-/-pyran-2,4(3H)-dione and 4-methyl-5-(3-pyridyi)-4H-1,2,4-triazole-3-thiol was used in place of 6-hydroxy-8- mercaptopurine monohydrate.
IH NMR (500 MHz, DMSO-d6, WET suppression of DMSO-h6 (2.5 ppm) and H20 (3.35 ppm) peak areas) δ 1.52-1.69 (m, 8 H) 2.03 (m, 1 H) 2.09 (m, 1 H) 2.36 (m, 1 H) 2.50 (m, IH, overlap with dmso) 2.63 (m, 1 H) 2.73 (d, 7=17.6 Hz, 1 H) 2.95 (d, 7=17.6 Hz, 1 H) 3.71 (s, 3 H) 3.80 (s, 3 H) 7.01 (d, 7=8.5 Hz, 1 H) 7.18 (dd, 7=8.2, 1.9 Hz, 1 H) 7.32 (d, 7=1.9 Hz, 1 H) 7.61 (dd, 7=7.6, 4.8 Hz, 1 H) 8.14 (d, 7=8.2 Hz, 1 H) 8.74 (d, 7=5.00 Hz, 1 H) 8.91 (s, 1 H). MS (APCI) calcd for C27H29C1N404S: 541.07; found M = 541.1
Example 0(97): 6-[2-(3-chloro-4-methoxyphenyl)ethyl]-6-cyclopentyl-3-({5-
[(dimethylamino)methyl]-4-methyl-4H-1,2,4-triazol-3-yl}thio)-4-hydroxy-5,6-dihydro-2H- pyran-2-one.
Figure imgf000445_0001
The title compound was prepared as described in Example C(70),where 3-chloro-6-[2-(3- chloro-4-methoxyphenyl)ethyl]-6-cyclopentyldihydro-2/-/-pyran-2,4(3H)-dione was used in place of 3-chloro-6-[2-(5-chloro-2,4-dimethoxyphenyl)ethyl]6-cyclopentyldihydro-2H-pyran-2,4(3H)-dione and 5-[(dimethylamino)methyl]-4-methyl-4H-1 ,2,4-triazole-3-thiol, as described in Step 1 of Example C(83), was used in place of 6-hydroxy-8-mercaptopurine monohydrate. Η NMR (500 MHz, DMSO-d6, WET suppression of DMSO-h6 (2.5 ppm) and H20 (3.35 ppm) peak areas) δ 1.50-1.69 (m, 8 H) 2.02 (m, 2 H) 2.35 (m, IH) 2.50 (m, 1 H, overlap with dmso) 2.63 (m, 1 H) 2.72 (d, 7=18.1 Hz, 1 H) 2.87 (s, 6 H) 2.92 (d, 7=15.0 Hz, 1 H) 3.63 (s, 3 H) 3.80 (s, 3 H) 4.53 (s, 2 H) 7.01 (d, 7=8.5 Hz, 1 H) 7.18 (dd, 7=8.4, 2.1 Hz, 1 H) 7.31 (d, 7=1.9 Hz, 1 H). MS (APCI) calcd for C25H33C1N404S: 521.08; found M = 521.2
Example C(98): 6-[2-(3-chloro-4-methoxyphenyl)ethyl]-6-cyclopentyl-4-hydroxy-3-[(6- methyl[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)thio]-5,6-dihydro-2H-pyran-2-one.
Figure imgf000445_0002
The title compound was prepared as described in Example C(70),where 3-chloro-6-[2-(3- chloro-4-methoxyphenyl)ethyl]-6-cyclopentyldihydro-2/-/-pyran-2,4(3H)-dione was used in place of 3-chloro-6-[2-(5-chloro-2,4-dimethoxyphenyl)ethyl]6-cyclopentyldihydro-2H-pyran-2,4(3H)-dione and 6-methyl[1,2,4]triazolo[1,5-a]pyrimidine-2-thiol was used in place of 6-hydroxy-8- mercaptopurine monohydrate.
'H NMR (500 MHz, DMSO-d6, WET suppression of DMSO-h6 (2.5 ppm) and H20 (3.35 ppm) peak areas) δ 1.52-1.69 (m, 8 H) 2.22 (m, 2 H) 2.30 (s, 3 H) 2.35 (m, IH) 2.50 (m, 1 H, overlap with dmso) 2.62 (m, 1 H) 2.73 (d, 7=17.6 Hz, 1 H) 2.98 (d, 7=17.9 Hz, 1 H) 3.81 (s, 3 H) 7.06 (d, 7=8.2 Hz, 1 H) 7.24 (dd, 7=8.5, 1.9 Hz, 1 H) 7.30 (d, 7=1.9 Hz, 1 H) 8.55 (d, 7=1.1 Hz, 1 H) 8.67 (d, 7=2.2 Hz, 1 H). MS (APCI) calcd for C25H27C1N404S: 515.03; found M = 515.0
Example C(99): 6-[2-(3-chloro-4-methoxyphenyl)ethyl]-6-cyclopentyl-3-[(4,5-dimethyl-4H- 1,2,4-triazol-3-yl)thio]-4-hydroxy-5,6-dihydro-2W-pyran-2-one.
Figure imgf000446_0001
The title compound was prepared as described in Example C(70), where 3-chloro-6-[2-(3- chloro-4-methoxyphenyl)ethyl]-6-cyclopentyldihydro-2H-pyran-2,4(3H)-dione was used in place of
3-chloro-6-[2-(5-chloro-2,4-dimethoxyphenyl)ethyl]6-cyclopentyldihydro-2H-pyran-2,4(3/-/)-dione and 4,5-dimethyl-4H-1,2,4-triazole-3-thiol,as shown in Example C(88), Step 1, was used in place of 6-hydroxy-8-mercaptopurine monohydrate.
Η NMR (500 MHz, DMSO-d6, WET suppression of DMSO-h6 (2.5 ppm) and H20 (3.35 ppm) peak areas) δ 1.49-1.64 (m, 8 H) 1.92 (m, 2 H) 2.33 (m, 1 H) 2.37 (s, 3 H) 2.50 (m, 2H, overlap with dmso) 2.62 (d,
7=15 Hz, 1 H) 2.80 (d, 7=17.6 Hz, 1 H) 3.55 (s, attenuation due to proximity to H20 peak) 3.80 (s, 3 H)
7.02 (d, 7=8.5 Hz, 1 H) 7.12 (dd, 7=8.5, 1.9 Hz, 1 H) 7.24 (d, 7=1.9 Hz, 1 H). MS (APCI) calcd for
C23H28C1N304S: 478.01; found M = 478.1
Example C(100): methyl 5-({6-[2-(3-chloro-4-methoxyphenyl)ethyl]-6-cyclopentyl-4- hydroxy-2-oxo-5,6-dihydro-2W-pyran-3-yl}thio)-4-methyl-4r -1,2,4-triazole-3-carboxylate
Figure imgf000447_0001
The title compound was prepared as described in Example C(70),where 3-chloro-6-[2-(3- chloro-4-methoxyphenyl)ethyl]-6-cyclopentyldihydro-2 7-pyran-2,4(3/-/)-dione was used in place of 3-chloro-6-[2-(5-chIoro-2,4-dimethoxyphenyl)ethyl]6-cyclopentyldihydro-2/-/-pyran-2,4(3/-/)-dione and methyl 5-mercapto-4-methyl-4H-1,2,4-triazoIe-3-carboxylate,as shown in Example 21, Step 2, was used in place of 6-hydroxy-8-mercaptopurine monohydrate.
'H NMR (500 MHz, DMSO-d6, WET suppression of DMSO-h6 (2.5 ppm) and H20 (3.35 ppm) peak areas) δ 1.50-1.70 (s, 8 H) 1.98 (m, 2 H) 2.35 (m, 1 H) 2.50 (m, IH, overlap with dmso) 2.63 (m, 1 H) 2.71 (d, 7=18.1 Hz, 1 H) 2.90 (d, 7=17.6 Hz, 1 H) 3.81 (s, 3 H) 3.81 (s, 3 H) 3.88 (s, 3 H) 7.02 (d, 7=8.2 Hz, 1 H) 7.15 (dd, 7=8.2, 1.9 Hz, 1 H) 7.27 (d, 7=1.9 Hz, 1 H). MS (APCI) calcd for C24H28C1N306S: 522.02; found M = 522.1
Example C(101): 6-[2-(3-chloro-4-methoxyphenyl)ethyl]-6-cyclopentyl-4-hydroxy-3-[(1- methyl-1 W-imidazol-2-yl)thio]-5,6-dihydro-2W-pyran-2-one.
Figure imgf000447_0002
The title compound was prepared as described in Example C(70),where 3-chloro-6-[2-(3- chloro-4-methoxyphenyl)ethyl]-6-cyclopentyldihydro-2/-/-pyran-2,4(3H)-dione was used in place of 3-chloro-6-[2-(5-chloro-2,4-dimethoxyphenyl)ethyl]6-cyclopentyldihydro-2H-pyran-2,4(3/-/)-dione and 2-mercapto-1-methylimidazole was used in place of 6-hydroxy-8-mercaptopurine monohydrate.
'HNMR (500 MHz, DMSO-d6) WET suppression of DMSO-h6 (2.5 ppm) and H20 (3.35 ppm) peak areas) δ 1.48-1.65 (m, 8 H) 1.86 (m, 2 H) 3.72 (s, 3 H) 3.80 (s, 3 H) 7.04 (m, 2 H) 7.19 (d, 7=1.7 Hz, 1 H) 7.46 (s, 1 H) 7.58 (s, 1 H). MS (APCI) calcd for C23H27C1N204S: 462.99; found 463.1 Example C(102): 6-[2-(3-chloro-4-methoxyphenyl)ethyl]-6-cyclopentyl-4-hydroxy-3-[(4- methyl-4H-1,2,4-triazol-3-yl)thio]-5,6-dihydro-2H-pyran-2-one.
Figure imgf000448_0001
The title compound was prepared as described in Example C(70) where 3-chloro-6-[2-(3- chloro-4-methoxyphenyl)ethyl]-6-cyclopentyldihydro-2 7-pyran-2,4(3H)-dione was used in place of 3-chloro-6-[2-(5-chloro-2,4-dimethoxyphenyl)ethyl]6-cyclopentyldihydro-2/-/-pyran-2,4(3H)-dione and 4-methyl-4H-1 ,2,4-triazole-3-thiol was used in place of 6-hydroxy-8-mercaptopurine monohydrate.
Η NMR (500 MHz, DMSO-d6, WET suppression of DMSO-h6 (2.5 ppm) and H20 (3.35 ppm) peak areas) δ 1.48-1.65 (m, 8 H) 1.96 (m, 2 H) 2.65 (d, 7=15.1 Hz, 1 H) 2.87 (d, 7=17.7 Hz, 1 H) 3.16 (s, 1 H) 3.64 (s, 3 H) 3.80 (s, 3 H) 7.02 (d, 7=8.8 Hz, 1 H) 7.16 (dd, 7=8.5, 2.20 Hz, 1 H) 7.27 (d, 7=1.9 Hz, 1 H) 8.56 (s, 1 H). MS (APCI) calcd for C22H26C1N304S: 463.98; found M = 464.9
Example C(103): 6-[2-(3-chloro-4-methoxyphenyl)ethyl]-6-cyclopentyl-4-hydroxy-3-(1H- imidazol-2-ylthio)-5,6-dihydro-2W-pyran-2-one.
Figure imgf000448_0002
The title compound was prepared as described in Example C(70),where 3-chloro-6-[2-(3- chloro-4-methoxyphenyl)ethyl]-6-cyclopentyldihydro-2/-/-pyran-2,4(3/-/)-dione was used in place of 3-chloro-6-[2-(5-chloro-2,4-dimethoxyphenyl)ethyl]6-cyclopentyldihydro-2/-/-pyran-2,4(3/-/)-dione and 2-mercaptoimidazole was used in place of 6-hydroxy-8-mercaptopurine monohydrate. Η NMR (500 MHz, DMSO-d6) WET suppression of DMSO-h6 (2.5 ppm) and H20 (3.35 ppm) peak areas) δ 1.50-1.64 (m, 8 H) 1.89 (m, 2 H) 2.71 (d, 7=15.0 Hz, 1 H) 3.80 (s, 3 H) 7.03 (d, 7=8.5 Hz, 1 H) 7.08 (d, 7=5.0 Hz, 1 H) 7.21 (d, 7=1.9 Hz, 1 H) 7.46 (s, 2 H). MS (APCI) calcd for C22H25C1N204S: 448.97; found M = 449.0
Example C(104): 6-[2-(3-chloro-4-methoxyphenyl)ethyl]-6-cyclopentyl-4-hydroxy-3-[(5- pyridin-4-yl-1,3,4-oxadiazol-2-yl)thio]-5,6-dihydro-2H-pyran-2-one.
Figure imgf000449_0001
The title compound was prepared as described in Example C(70),where 3-chloro-6-[2-(3- chloro-4-methoxyphenyl)ethyl]-6-cyclopentyldihydro-2 -/-pyran-2,4(3/-/)-dione was used in place of 3-chloro-6-[2-(5-chloro-2,4-dimethoxyphenyl)ethyl]6-cyclopentyldihydro-2H-pyran-2,4(3AV)-dione and 5-(4-pyridyl)-1 ,3,4-oxadiazole-2-thiol was used in place of 6-hydroxy-8-mercaptopurine monohydrate.
Η NMR (500 MHz, DMSO-d6, WET suppression of DMSO-h5 (2.5 ppm) and H20 (3.35 ppm) peak areas) δ 1.53-1.70 (m, 8 H) 2.09 (m, 2 H, overlap) 2.82 (d, 7=18.1 Hz, 1 H) 3.00 (d, 7=18.1 Hz, 1 H) 3.78 (s, 3 H) 6.97 (d, 7=8.5 Hz, 1 H) 7.13 (dd, 7=8.4, 2.1 Hz, 1 H) 7.27 (d, 7=1.9 Hz, 1 H) 7.73 (d, 7=5.5 Hz, 2 H) 8.71 (d, 7=5.8 Hz, 2 H). MS (APCI) calcd C26H26C1N305S: 528.03; found M = 528.1
Example C(105): 2-({6-[2-(3-chloro-4-methoxyphenyI)ethyl]-6-cyclopentyl-4-hydroxy-2- oxo-5,6-dihydro-2W-pyran-3-yl}thio)-4,6-dimethylnicotinonitrile
Figure imgf000449_0002
The title compound was prepared as described in Example C(70),where 3-chloro-6-[2-(3- chloro-4-methoxyphenyl)ethyl]-6-cyclopentyldihydro-2f/-pyran-2,4(3/-/)-dione was used in place of 3-chloro-6-[2-(5-chloro-2,4-dimethoxyphenyl)ethyl]6-cyclopentyldihydro-2 -/-pyran-2,4(3/-/)-dione and 4,6-dimethyl-2-mercaptonicotinonitrile was used in place of 6-hydroxy-8-mercaptopurine monohydrate.
'H NMR (500 MHz, DMSO-d6, WET suppression of DMSO-h6 (2.5 ppm) and H20 (3.35 ppm) peak areas) δ 1.53-1.71 (m, 8 H) 2.01 (s, 3 H) 2.06 (m, 2 H) 2.34 (m, 1 H) 2.37 (s, 3 H) 2.58 (m, 2 H) 2.83 (d,
7=17.9 Hz, 1 H) 2.93 (d, 7=15.0 Hz, 1 H) 3.80 (s, attenuation due to proximity to H20 peak) 6.98 (s, 1 H)
7.02 (d, 7=8.2 Hz, 1 H) 7.11 (d, 7=5.0 Hz, 1 H) 7.23 (d, 7=1.9 Hz, 1 H). MS (APCI) calcd for
C27H29C1N204S: 513.06; found M = 513.1
Example C(106): 6-[2-(3-chloro-4-methoxyphenyl)ethyl]-6-cyclopentyl-4-hydroxy-3-[(4- phenyl-1,3-thiazol-2-yl)thio]-5,6-dihydro-2H-pyran-2-one.
Figure imgf000450_0001
The title compound was prepared as described in Example C(70),where 3-chloro-6-[2-(3- chloro-4-methoxyphenyl)ethyl]-6-cyclopentyldihydro-2H-pyran-2,4(3H)-dione was used in place of 3-chloro-6-[2-(5-chloro-2,4-dimethoxyphenyl)ethyl]6-cyclopentyldihydro-2f/-pyran-2,4(3H)-dione and 2-mercapto-4-phenylthiazole was used in place of 6-hydroxy-8-mercaptopurine monohydrate.
Η NMR (500 MHz, DMSO-d6, WET suppression of DMSO-h6 (2.5 ppm) and H20 (3.35 ppm) peak areas) δ 1.53-1.71 (m, 8 H) 2.05 (m, 2 H, overlap) 2.35 (m, 1 H) 2.50 (m, 1 H, overlap with dmso) 2.61 (m, 1 H) 2.84 (d, 7=17.3 Hz, 1 H) 2.95 (d, 7=20.0 Hz, 1 H) 3.80 (s, 3 H) 7.03 (d, 7=8.5 Hz, 1 H) 7.13 (dd, 7=8.4, 2.1
Hz, 1 H) 7.28 (d, 7=1.9 Hz, 1 H) 7.32 (d, 7=7.1 Hz, 1 H) 7.38 (t, 7=7.4 Hz, 2 H) 7.85 (d, 7=7.7 Hz, 3 H).
MS (APCI) calcd for C28H28C1N04S2: 542.12; found M = 542.0
Example C(107): 6-[2-(3-chloro-4-methoxyphenyl)ethyl]-6-cyclorpentyl-4-hydroxy-3- [(pyridin-2-ylmethyl)thio]-5,6-dihydro-2H-pyran-2-one.
Figure imgf000451_0001
The title compound was prepared as described in Example C(70),where 3-chloro-6-[2-(3- chloro-4-methoxyphenyl)ethyl]-6-cyclopentyldihydro-2H-pyran-2,4(3/-/)-dione was used in place of 3-chloro-6-[2-(5-chloro-2,4-dimethoxyphenyl)ethyl]6-cyclopentyIdihydro-2H-pyran-2,4(3/-/)-dione and pyridine-2-methanethiol was used in place of 6-hydroxy-8-mercaptopurine monohydrate. Η NMR (500 MHz, DMSO-d5, WET suppression of DMSO-h6 (2.5 ppm) and H20 (3.35 ppm) peak areas) δ 1.47-1.58 (m, 8 H) 1.80 (m, 2 H) 2.23 (m, 1 H) 2.66 (d, 7=20.6 Hz, 1 H) 3.80 (s, 3 H) 3.96 (m, 2 H) 7.03 (d, 7=8.2 Hz, 1 H) 7.07 (d, 7=5.0 Hz, 1 H) 7.21 (d, 7=1.9 Hz, 1 H) 7.34 (s, 1 H) 7.49 (d, 7=7.1 Hz, 1 H) 7.84 (s, 1 H) 8.44 (s, 1 H). MS (APCI) calcd for C25H28C1N04S: 474.02; found M = 474.1
Example C(108): 6-[2-(3-chloro-4-methoxyphenyl)ethyl]-6-cyclopentyl-3-[(2,3- dichlorophenyl)thio]-4-hydroxy-5,6-dihydro-2H-pyran-2-one.
Figure imgf000451_0002
The title compound was prepared as described in Example C(70),where 3-chloro-6-[2-(3- chloro-4-methoxyphenyl)ethyl]-6-cyclopentyldihydro-2H-pyran-2,4(3K)-dione was used in place of 3-chloro-6-[2-(5-chloro-2,4-dimethoxyphenyl)ethyl]6-cyclopentyldihydro-2H-pyran-2,4(3H)-dione and 2,3-dichlorothiophenol was used in place of 6-hydroxy-8-mercaptopurine monohydrate. MS (APCI) calcd for C25H25C1304S: 527.89; found M = 529.0.
Example 0(109): 6-[2-(3-Chloro-4-methoxy-phenyl)-ethyl]-6-cyclopentyl-4-hydroxy-3-(2- pyridin-2-yl-ethylsulfanyl)-5,6-dihydro-pyran-2-one.
Figure imgf000452_0001
The title compound was prepared analogously to Example F(7), Step 6, substituting 3- chloro-6-[2-(3-chloro-4-methoxy-phenyl)-ethyl]-6-cycIopentyl-dihydro-pyran-2,4-dione (0.201 g, 0.52 mmol, described below) in place of 3-chloro-6-cyclopentyl-6-[4-(3-hydroxy-phenyl)-but-3- ynyl]-dihydro-pyran-2,4-dione, and 2-Pyridin-2-yl-ethanethiol in place of 2-mercaptothiazole. Yield: 12.6 mg, 5% yield.
'H NMR (CDC13) δ: 1.48 - 1.73 (m, 8H), 1.92 - 1.98 (m, 2H), 2.34 (p, 7= 8.32 Hz, IH), 2,56 - 2.62 (m, 4H), 2.80 - 3.01 (m, 4H), 3.80 (s, 3H), 6.76 (d, 7= 8.32 Hz, IH), 6.95 (dd, 71 = 8.48 Hz, 72 = 2.08 Hz, IH), 7.09 (d, 7= 2.24 Hz, IH), 7.41 - 7.48 (m, 2H), 7.93 (t, 7= 7.52 Hz, IH), 8.52 (d, 7= 5.12 Hz, IH).
Figure imgf000452_0002
Step 1 : 2-Chloro-7-(3-chloro-4-methoxy-phenyl)-5-cyclopentyl-5-hydroxy-3-oxo-heptanoic acid methyl ester.
Methyl-2-chloroacetoacetate (2.5g, 16.9mmol) was added to a cooled 0 °C suspension of NaH (0.68 g, 16.9 mmol, 60% dispersion in mineral oil) in THF (30ml). After 15 min the solution was cooled to -40 °C and n-BuLi (10.6mL, 16.9mmol, 1.6M in hexanes) was added. The resulting dianion was stirred for an additional 30 min and then treated with a solution of 3-(3- Chloro-4-methoxy-phenyl)-1-cyclopentyl-propan-1-one (1.5g, 5.6mmol, prepared from Heck route) in THF (10ml). After stirring for 1 h at -40 °C, the reaction mixture was quenched with saturated NH4CI and extracted with EtOAc. The organic layers were washed with brine, dried with Na2S04 and concentrated to an orange oil that was used without further purification.
Step 2: 3-Chloro-6-[2-(3-chloro-4-methoxy-phenyl)-ethyl]-6-cyclopentyl-4-hydroxy-5,6- dihydro-pyran-2-one.
Figure imgf000453_0001
A solution of 2-Chloro-7-(3-chloro-4-methoxy-phenyl)-5-cyclopentyl-5-hydroxy-3-oxo- heptanoic acid methyl ester (2.33g, 5.6 mmol, from Step 1 below), and bis(dibutylchlorotin)oxide (1.38g, 2.5 mmol), dissolved in toluene (18 mL) were heated at reflux for 30mins. The resulting mixture was concentrated and purified by silica gel chromatography to give the title compound (1.57 g, 75% yield, two Steps). Η NMR (CDC13): δ 1.36-1.79 (br m, 8H), 2.02 (m, 2H), 2.41 (m, IH), 2.65 (m, 3H), 2.89 (d, IH, 7= 17.7 Hz), 3.88 (s, 3H), 6.47 (br s, IH), 6.85 (d, IH, 7= 8.4 Hz), 7.01 (dd, IH, 7= 8.4, 2.1 Hz), 7.16 (d, IH, 7= 2.1 Hz).
Section C: Compounds with oxygen.
Scheme 3
Figure imgf000454_0001
Figure imgf000454_0002
Example C(110): 2-[4-(2-Cyclopentyl-4,6-dioxo-tetrahydro-pyran-2-ylmethoxy)-2-fluoro- phenyl]-2-methyl-propionitrile
Figure imgf000454_0003
Sodium hydride (60%) (0.49 g, 12.3 mmol) was magnetically stirred in dry THF (33 mL) and cooled to 0 °C. The mixture was then treated with Methyl acetoacetate (1.34 mL, 12.3 mmol) dropwise over 15 min. The reaction was allowed to stir for 30 min at 0 °C. To the resulting clear solution was added nBuLi (1.6M in Hexanes) (7.71 mL, 12.3 mmol). The reaction was then allowed to stir for 30 min at 0 °C. To the yellow solution was added 2-[4-(2-Cyclopentyl-2-oxo- ethoxy)-2-fluoro-phenyl]-2-methyl-propionitrile (1.19g, 4.1 mmol) as a solution in dry THF (15 mL). The result was stirred at 0 °C for 15 min and then at room temperature for 90 min. The solution was next poured into 0.5N HCl (100 mL) and extracted with EtOAc (2X 50 mL). The organics were concentrated and the residue dissolved in MeOH (33 mL) and treated with K2C03 (1.5 g). The mixture was heated to 65 °C and maintained for 1 hr. The reaction was cooled and poured into 0.5N HCl (100 mL) and extracted with EtOAc (2X 50 mL). The organics were dried over Na2S0 , filtered and concentrated. The residue was purified by flash chromatography (silica gel) eluting with CH2CI2 through 1% MeOH in CH2CI2 to yield the title compound as a white solid (1.21g, 79%). 1H NMR (300 MHz, DMSO-d6) δ: 1.55 (m, 8 H), 1.69 (s, 6 H), 2.37 (m, 1 H), 2.62 (s, 2 H), 3.33 (s, 2 H), 4.10 (m, 2 H), 6.87 (m 2 H), 7.34 (m 1 H). Step 4: Preparation of compound 2-[4-(2-Cyclopentyl-2-oxo-ethoxy)-2-fluoro-phenyl]-2- methyl-propionitrile
Figure imgf000455_0001
Potassium carbonate (3.1 g, 22 mmol) was added to a solution of 2-(2-Fluoro-4-hydroxy- phenyl)-2-methyl-propionitrile (1.0 g, 6.0 mmol) and 2-Chloro-1 -cyclopentyl-ethanone (3.3 g, 22 mmol) in DMF (20 mL). The mixture was stirred at room temperature for 16 hours. The mixture was poured into water (100 mL) and extracted with EtOAc (2X 50 mL). The organics were washed with brine (100 mL), dried over Na2S04, filtered and concentrated. The residue was purified by flash column chromatography (0-15 % EtOAc in hexanes) to give the product (1.2 g, 75% yield) as a clear oil. 1H NMR (300 MHz, CDCI3) δ: 1.57-1.93 (m, 14 H), 3.10 (m, 1 H), 4.64 (s, 2 H), 6.65 (d, 7=9.6 Hz, 2 H), 7.37 (t, 7=8.9 Hz, 1 H).
Step 3: Preparation of compound 2-(2-Fluoro-4-hydroxy-phenyl)-2-methyl-propionitrile
Figure imgf000455_0002
To a solution of 2-(2-Fluoro-4-methoxy-phenyl)-2-methyl-propionitrile (1.5 g, 7.8 mmol) in
CH2CI2 (75 mL) at -78 °C was added Boron tribromide (1M solution in CH2CI2) (16 mL, 16 mmol). The solution was allowed to warm to room temperature and stir for 48 hours. The reaction was quenched with 0.5N HCl (50 mL) and poured into water (100 mL). The organic layer was separated and the aqueous was extracted with CH2CI2 (50mL). The combined organics were washed with water (100 mL), dried over Na2S04, filtered and concentrated. The resulting oil was used without further purification.
Step 2: Preparation of compound 2-(2-Fluoro-4-methoxy-phenyl)-2-methyl-propionitrile
Figure imgf000456_0001
A solution of (2-Fluoro-4-methoxy-phenyl)-acetonitrile (5 g, 30 mmol) and lodomethane (6.03 mL, 97 mmol) in DMSO (30 mL) was added dropwise over 2 hours to a stirring solution of KOH (7.47 g, 133 mmol) in water (4 mL) and DMSO (20 mL) at 0 °C. The solution was allowed to warm to room temperature and stirred for 4 hours. The reaction was poured into water (100 mL) and extracted with EtOAc (2X 50 mL). The organics were washed with water (100 mL) and brine (100 mL), dried over Na2S04, filtered and concentrated. The residue was purified by flash column chromatography (0-10 % EtOAc in hexanes) to give the product (4.76 g, 82% yield) as a clear oil. 1H NMR (300 MHz, CDCI3) δ: 1.82 (s, 6 H), 3.85 (s, 3 H), 6.64 (d, 7=9.6 Hz, 2 H), 7.42 (m, 1 H).
Step 1 : Preparation of compound (2-Fluoro-4-methoxy-phenyl)-acetonitrile
Figure imgf000456_0002
To a mixture of 1-Bromomethyl-2-fluoro-4-methoxy-benzene (4.5 g, 21 mmol) and Tetrabutylammonium iodide (0.66 g, 2.1 mmol) in CH2CI2 (50 mL) was added a solution potassium cyanide (4.0 g, 60 mmol) in water (50 mL). The resulting biphasic mixture was stirred vigorously for 8 hours. The reaction was poured into water (100 mL) and extracted with CH2CI2 (2X 50 mL). The organics were washed with water (100 mL) and brine (100 mL), dried over Na S04, filtered and concentrated. The residue was purified by flash column chromatography (10-30 % EtOAc in hexanes) to give the product (2.6 g, 75% yield) as a clear oil. 1H NMR (300 MHz, CDCI3) δ: 3.66 (s, 2 H), 3.82 (s, 3 H), 6.69 (m, 2 H), 7.31 (m, 1 H).
Example C(111): 2-{4-[2-Cyclopentyl-4-hydroxy-5-(6-methyl-[1,2,4]triazolo[1,5-a]pyrimidin- 2-ylmethyl)-6-oxo-3,6-dihydro-2H-pyran-2-ylmethoxy]-2-fluoro-phenyl}-2-methyl- propionitrile
Figure imgf000457_0001
A solution of 2-[4-(2-Cyclopentyl-4,6-dioxo-tetrahydro-pyran-2-ylmethoxy)-2-fluoro- phenyl]-2-methyl-propionitrile (200 mg, 0.54 mmol) in anhydrous MeOH (4.0 mL) was treated with 6-Methyl-[1,2,4]triazolo[1,5-a]pyrimidine-2-carbaldehyde (140 mg, 0.86 mmol), followed by borane-dimethylamine complex (47 mg, 0.8 mmol) at room temperature. The reaction was stirred for 5 hours before it was quenched by the addition of 0.5N HCl (25 mL). The mixture was extracted with 10% MeOH in CH2CI2 (3 x 10 mL) and the combined organic layers were washed with brine, dried over Na2S04, filtered and concentrated. The residue was purified by crystallization from EtOAc/Hexanes to give the product as a white solid (91 mg, 32% yield). 1H NMR (300 MHz, DMSO-d6) δ: 1.67 (m, 8 H), 1.70 (s, 6 H), 2.38 (s, 3 H), 2.55 (m, 1 H), 2.77 (m, 2 H), 3.77 (m, 2 H), 4.12 (m, 1 H), 4.44 (m, 1 H), 6.97 (m 2 H), 7.35 (m, 1 H), 8.69 (s, 1 H), 9.03 (s, 1 H), 10.98 (brs, 1 H).
Example C(112): 2-{4-[2-Cyclopentyl-5-(5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2- ylmethyl)-4-hydroxy-6-oxo-3,6-dihydro-2H-pyran-2-ylmethoxy]-2-fluoro-phenyl}-2-methyl- propionitrile
Figure imgf000457_0002
This compound was prepared analogously to example C (111 ), except that 5,7-Dimethyl-
[1,2,4]triazolo[1,5-a]pyrimidine-2-carbaldehyde was used in place of 6-Methyl-[1,2,4]triazoIo[1,5- a]pyrimidine-2-carbaldehyde. The result was a white solid. 1H NMR (300 MHz, DMSO-d6) δ: 1.64 (m, 8 H), 1.70 (s, 6 H), 2.50 (1, 1 H), 2.57 (s, 3 H), 2.63 (s, 3 H), 2.79 (m, 2 H), 3.77 (m, 2 H), 4.12 (brs, 1 H), 4.50 (m, 1 H), 6.95 (m 3 H), 7.35 (m, 1 H), 10.95 (brs, 1 H).
Example D(1): 6-[2-(3-Chloro-4-methoxy-phenyl)-ethyl]-6-cyclopentyl-4-hydroxy-3- (methyl-phenyl-amino)-5,6-dihydro-pyran-2-one.
Figure imgf000458_0001
To a refluxing solution of N-methylaniline (0.115 mL, 1.1 mmol) and rhodium (II) acetate (9.4 mg) in toluene (1.6 mL) was added 6-[2-(3-chloro-4-methoxy-phenyl)-ethyl]-6-cyclopentyl-3- diazo-dihydro-pyran-2,4-dione (0.080 g, 0.213 mmol) from Step 1 below over 1 hour. The reaction was stirred at reflux for three more hours. The reaction was concentrated by rotary evaporation, and then purified by preparatory HPLC to give the desired product (28 mg, 29% yield). 'H NMR (CDC13) δ: 1.48 - 1.78 (m, 8H), 1.92 - 2.07 (m, 2H), 2.38 (p, 7= 8.10 Hz, IH), 2.51 - 2.63 (m, 3H), 2.90 (d, 7= 17.90 Hz, IH), 3.10 (s, 3H), 3.82 (s, 3H), 6.77 - 6.81 (m, 2H), 6.86 (t, 7= 7.44 Hz, IH), 6.94 (dd, 71 = 8.38 Hz, 72 = 1.98 Hz, IH), 7.10 (d, 7= 2.07 Hz), 7.18 - 7.23 (m, 2H), 7.29 (s, IH).
Step 1 : 6-[2-(3-Chloro-4-methoxy-phenyl)-ethyl]-6-cyclopentyl-3-diazo-dihydro-pyran-2,4- dione.
Figure imgf000458_0002
To a solution of 6-[2-(3-chloro-4-methoxy-phenyl)-ethyl]-6-cyclopentyl-dihydro-pyran-2,4- dione (0.500 g, 1.44 mmol) from Example B(87), and sodium dihydrogen phosphate (0.26 g, 2.16 mmol) in DMF (6 mL) was added 4-acetamidobenzenesulfonyl azide (0.52 g, 2.16 mmol). The reaction was stirred for 4 hours, and then concentrated by rotary evaporation. The crude material was purified by flash chromatography to yield the desired compound (0.537 g, 100% yield). MS (ESI): 373 (M+H).
Example D(2): 6-[2-(3-Chloro-4-methoxy-phenyl)-ethyl]-6-cyclopentyl-4-hydroxy-3- phenoxy-5,6-dihydro-pyran-2-one.
Figure imgf000459_0001
The target compound was synthesized analogously to Example D(1), substituting phenol (56 mg, 0.598 mmol) in place of N-methylaniline. Yield 12.3 mg, 23% yield. Η NMR (CDCla) δ: 1.49 - 1.79 (m, 8H), 1.96 - 2.18 (m, 2H), 2.46)p, J= 8.32 Hz, IH), 2.54 (d, 7= 17.91 Hz, IH), 2.63 (t, 7= 8.32 Hz, 2H), 2.92 (d, 7= 17.59 Hz, IH), 3.82 (s, 3H), 6.79 (d, 7= 8.32 Hz, IH), 6.88 (d, 7= 8.00 Hz, 2H), 6.95 -7.02 (m, 2H), 7.13 (d, 7= 1.92 Hz, IH), 7.21 - 7.29 (m, 2H).
Example D(3): 6-Cyclopentyl-6-{2-[5-ethyl-4-(2-methoxy-ethoxymethoxy)-2-methyl-phenyl]- ethyl}-dihydro-pyran-2,4-dione
Figure imgf000459_0002
Methyl acetoacetate (0.36mL, 3.4 mmol) was added to a cooled -40 °C solution of LDA
(prepared from n-BuLi (4.2 ml, 6.71 mmol, 1.6 M in hexanes) and diisoproplyamine (0.94 mL, 6.71 mmol)) in THF (6 mL). The mixture was stirred for 30 mins and then treated with a solution of 1-cyclopentyl-3-[5-ethyl-4-(2-methoxy-ethoxymethoxy)-2-methyl-phenyl]-propan-1-one (0.39g, 1.1 mmol) in THF (3ml). After stirring for 6h, the reaction mixture was partitioned between 1N HCl and EtOAc. The organic layers were washed with brine, dried over Na2S04 and concentrated to a yellow oil that was purified by flash column chromatography (10 - 25% EtOAc in hexanes) to give a clear oil (0.33g, 65%).
The oil (0.33g, 0.71 mmol) was dissolved in methanol (5 mL), treated with potassium carbonate (0.29g, 2.1 mmol), and refluxed under N2 for 60min. The reaction mixture was partitioned between 1 N HCl and EtOAc. The organic layers were washed with brine, dried over Na2S04 and concentrated to a yellow oil that was purified by silica gel chromatography (20% to 40% EtOAc in hexanes) to give the title compound as an oil (0.21 g, 69% yield). 1H NMR (400 MHz, CDCI3): δ 1.16 (t, 7=7.6 Hz, 3 H), 1.51-1.91 (br m, 10 H), 2.23 (s, 3 H), 2.32 (m, 1 H), 2.57 (m, 4 H), 2.79 (s, 2 H), 3.39 (s, 3 H), 3.42 (s, 2 H), 3.57 (m, 2 H), 3.82 (m, 2 H), 5.25 (s, 2 H), 6.83 (s, 1 H), 6.91 (s, 1 H). C25H36θ6 (M + H)+ 433.30.
Step 5: 1 -Cyclopentyl-3-[5-ethyl-4-(2-methoxy-ethoxymethoxy)-2-methy l-phenyl]-propan-1 - one
Figure imgf000460_0001
A mixture of 1-cyclopentyl-3-[5-ethyl-4-(2-methoxy-ethoxymethoxy)-2-methyl-phenyI]- propenone(0.75g, 2.2 mmol) and 5 % wt Pd/BaS04 (0.15g) in THF (10 mL) was stirred under a balloon of H2 for 30 mins. The reaction mixture was filtered through a pad of celite washing with EtOAc. The filtrate was concentrated and purified by flash column chromatography (0% to 15% EtOAc in hexanes) to give the title compound as an oil (0.39g, 52%). 1H NMR (400 MHz, CDCI3): δ 1.16 (t, 7=7.6 Hz, 3 H), 1.54-1.84 (br m, 8 H), 2.25 (s, 3 H), 2.58 (q, 7=7.6 Hz, 2 H), 2.68 (m, 2 H), 2.82 (m, 3 H), 3.39 (s, 3 H), 3.57 (m, 2 H), 3.83 (m, 2 H), 5.26 (s, 2 H), 6.89 (s, 1 H), 6.91 (s, 1 H).
Step 4: 1-Cyclopentyl-3-[5-ethyl-4-(2-methoxy-ethoxymethoxy)-2-methyl-phenyl]- propenone
Figure imgf000460_0002
Ba(OH)2 (0.18g, 1.1 mmol) was added to a solution of 5-ethyl-4-(2-methoxy- ethoxymethoxy)-2-methyl-benzaldehyde (0.87g, 3.5 mmol) and 1 -cyclopentyl-ethanone (0.59g, 5.3 mmol) dissolved in EtOH (7mL). The reaction mixture was stirred together for 24 hours and then partitioned between 1N HCl and EtOAc. The organic layer was washed with saturated NaHC03, brine, dried over Na2S04 and concentrated to an oil. Flash column chromatography (0% to 10% EtOAc in hexanes) gave the title compound as a clear oil (0.78g, 65%). 1H NMR (400 MHz, CDCI3): δ 1.20 (t, 7=7.6 Hz, 3 H), 1.54-1.91 (br m, 8 H), 2.41 (s, 3 H), 2.62 (q, 7=7.6 Hz, 2 H), 3.18 (m, 1 H), 3.39 (s, 3 H), 3.57 (m, 2 H), 3.83 (m, 2 H), 5.30 (s, 2 H), 6.65 (d, 7=15.9 Hz, 1 H), 6.94 (s, 1 H), 7.41 (s, 1 H), 7.84 (d, 7=15.9 Hz, 1 H).
Step 3: 5-Ethyl-4-(2-methoxy-ethoxymethoxy)-2-methyl-benzaldehyde
Figure imgf000461_0001
A solution of 5-ethyl-4-hydroxy-2-methyl-benzaldehyde (0.9g, 5.5mmol) dissolved in THF (10mL) was added to a cooled 0°C suspension of NaH (0.29 g, 7.2 mmol, 60% dispersion in mineral oil) in THF (5ml). After the addition was complete the reaction mixture was warmed up to room temperature and stirred for 30 mins-. 2-Methoxyethoxymethyl chloride (0.82 mL, 7.1 mmol) was added and the reaction was stirred for 4 hours. The reaction mixture was quenched with 1 N HCl and extracted with EtOAc. The organic layers were washed with brine, dried over Na2S0 and concentrated to a yellow oil. Purification by flash column chromatography (10% to 20% EtOAc in hexanes) gave the title compound as a clear oil (0.89g, 65%). 1H NMR (400 MHz, CDCI3): δ 1.21 (t, 7=7.3 Hz, 3 H), 2.63 (m, 5 H), 3.39 (s, 3 H), 3.57 (m, 2 H), 3.84 (m, 2 H), 5.37 (s, 2 H), 6.95 (s, 1 H), 7.62 (s, 1 H), 10.15 (s, 1 H).
Step 2: 5-Ethyl-4-hydroxy-2-methyl-benzaldehyde
Figure imgf000461_0002
Titanium(IV) chloride (11 mL, 11 mmol, 1M in CH2CI2) followed by dichloromethyl methyl ether (1.04g, 9.1 mmol) was added to a cooled 0°C solution of 2-ethyl-5-methyl-phenol (0.75g, 5.5 mmol) The reaction mixture was stirred for 30 mins and then warmed up to rt and stirred for another 30 mins. The mixture was poured into ice and extracted with EtOAc. The organic layers were washed with satd NaHC03, brine, dried over Na2S04 and concentrated to a purple oil. Purification by flash column chromatography (0% to 10% EtOAc in hexanes) gave the title compound as an oil (0.45g, 50%). 1H NMR (400 MHz, CDCI3): δ 1.26 (t, 7=7.6 Hz, 3 H), 2.60 (s, 3 H), 2.65 (q, 7=7.6 Hz, 2 H), 5.37 (s, 1H), 6.62 (s, 1 H), 7,62 (s, 1 H), 10.11 (s, 1 H).
Step 1 : 2-Ethyl-5-methyl-phenol
Figure imgf000462_0001
A mixture of 1-(2-hydroxy-4-methyl-phenyl)-ethanone (5g, 33.3mmol) and 10 wt % Pd/C
(2g, Degussa type) in MeOH (50 mL) was stirred under a balloon of H2 for 24 hours. The reaction mixture was filtered through a pad of celite washing with EtOAc. The filtrate was concentrated to a clear oil (4.5g, 99%). 1H NMR (400 MHz, CDCI3): δ 1.23 (t, 7=7.6 Hz, 3 H), 2.27 (s, 3 H), 2.59
(q, 7=7.6 Hz, 2 H), 4.68 (s, 1H), 6.59 (s, 1 H), 6.71 (d, 7=7.7 Hz, 1 H), 7.01 (d, 7=7.7 Hz, 1 H).
Example D(4): 6-Cyclopentyl-6-[2-(2,3-dihydro-benzofuran-5-yl)-ethyl]-3-(5,7-dimethyl- [1 ,2,4]triazolo[1 ,5-a]pyrimidin-2-ylmethyl)-4-hydroxy-5,6-dihydro-pyran-2-one
Figure imgf000462_0002
The title compound was prepared analogously to Example A(123) where 6-cyclopentyl-6- [2-(2,3-dihydro-benzofuran-5-yl)-ethyl]-dihydro-pyran-2,4-dione (Example D(5)) was substituted in place of 6-cyclopentyl-6-[2-(3-ethyl-5-fluoro-4-hydroxy-phenyl)-ethyl]-dihydro-pyran-2,4-dione. 1H NMR (400 MHz, DMSO-d6): δ 1.39-1.69 (br m, 8 H), 2.05-2.11 (m, 2 H), 2.39 (m, 1 H), 2.49-2.55 (m, 9 H), 2.75 (d, 7=17.6 Hz, 1 H), 3.11 (t, 7=8.8 Hz, 2 H), 3.70 (d, 7=16.2 Hz, 1 H), 3.82 (d, 7=16.2 Hz, 1 H), 4.48 (t, 7=8.8 Hz, 2 H), 6.62 (d, 7=8.1 Hz, 1 H), 6.92 (d, 7=6.6 Hz, 1 H), 7.04 (s, 1 H), 7.07 (s, 1 H). Anal. Calcd. For C21H32N4O O.4H2O: C, 67.83; H, 6.67; N 11.30. Found: C, 67.86; H, 6.74; N, 11.40. Example D(5): 6-Cyclopentyl-6-[2-(2,3-dihydro-benzofuran-5-yl)-ethyl]-dihydro-pyran-2,4- dione
Figure imgf000463_0001
The title compound was prepared analogously to Example D(1) where 2,3-dihydro- benzofuran-5-carbaldehyde was substituted in place of 5-ethyl-4-(2-methoxy-ethoxymethoxy)-2- methyl-benzaldehyde in step 4 of that example. 1H NMR (400 MHz, CDCI3) δ: 1.51-180 (br m, 8 H), 1.76-2.01 (m, 2 H), 2.28 (m, 1 H), 2.60 (t, 7=8.6 Hz, 2 H), 2.76 (s, 2 H), 3.17 (t, 7=8.6 Hz, 2 H), 3.42 (s, 2 H), 4.55 (t, 7=8.8 Hz, 2 H), 6.70 (d, 7=8.1 Hz, 1 H), 6.87 (d, 7=9.6 Hz, 1 H), 6.97 (s, 1 H). Anal. Calcd. For C20H24O4: C, 73.15; H, 7.37. Found: C, 72.88; H, 7.35.
Example D(6): 6-Cyclopentyl-6-{2-[5-ethyl-2-fluoro-4-(2-methoxy-ethoxymethoxy)-phenyl]- ethyl}-dihydro-pyran-2,4-dione
Figure imgf000463_0002
The title compound was prepared analogously to Example D(1) where 1-(4-fluoro-2- hydroxy-phenyl)-ethanone was substituted in place of 1-(2-hydroxy-4-methyl-phenyl)-ethanone in step 1 of that example. 1H NMR (400 MHz, CDCI3): δ 1.15 (t, 7=7.6 Hz, 3 H), 1.44-1.96 (br m, 10 H), 2.31 (m, 1 H), 2.53-2.67 (m, 4 H), 2.77 (s, 2 H), 3.39 (s, 3 H), 3.43 (s, 2 H), 3.56 (m, 2 H), 3.81 (m, 2 H), 5.24 (s, 2 H), 6.06 (m, 2 H).
Example D(7): 6-Cyclopentyl-6-{2-[5-ethyl-2-(2-methoxy-ethoxymethoxy)-phenyl]-ethyl}- dihydro-pyran-2,4-dione
Figure imgf000463_0003
The title compound was prepared analogously to Example D(1) where 5-ethyl-2-(2- methoxy-ethoxymethoxy)-benzaldehyde (from step 1 below) was substituted in place of 5-ethyl-4- (2-methoxy-ethoxymethoxy)-2-methyl-benzaldehyde in step 4 of that example. 1H NMR (400 MHz, CDCI3): δ 1.15 (t, 7=7.6 Hz, 3 H), 1.44-1.98 (br m, 10 H), 2.35 (m, 1 H), 2.56 (q, 7=7.6 Hz, 2 H), 2.56 - 2.70 (m, 2H), 2.74 (d, 7=16.2 Hz, 1 H), 2.56 (d, 7=16.2 Hz, 1 H), 3.38 (s, 3H), 3.43 (s, 2H), 3.56 (m, 2H), 3.80 (m, 2 H), 5.25 (s, 2H), 6.91 (d, 7=2.1 Hz, 1 H), 6.99 (dd, 7=8.4, 2.1 Hz, 1 H), 7.04 (d, 7=8.4 Hz, 1 H).
Step 1 : 5-Ethyl-2-(2-methoxy-ethoxymethoxy)-benzaldehyde
Figure imgf000464_0001
CHCI3 (10 mL) was slowly added to a suspension of 4-ethyl phenol (30g, 0.25 mol) in 10N NaOH (150 mL). After the vigorous reaction died down, the mixture was stirred for 20 mins and then additional CHCI3 (20mL) was added very slowly. The reaction was cooled to 0°C and let stand for 2 hrs. The reaction mixture was acidified with 12 N HCl, diluted with water and then extracted with CH2CI2. The organics were concentrated to a brown oil (17.3g).
The oil was dissolved in THF (50mL) and added to a cooled 0°C suspension of NaH (5.76 g, 0.14 mol, 60% dispersion in mineral oil) in THF (100ml). After the addition was complete the reaction mixture was warmed up to room temperature and stirred for 1 hr. Methoxyethoxymethyl chloride (17.1 mL, 0.15 mmol) was added and the reaction was stirred for 20 hours. The reaction mixture was quenched with 1N HCl and extracted with EtOAc. The organic layers were washed with 1N NaOH, brine, dried over Na2S0 and concentrated to a brown oil. Purification by flash column chromatography (0% to 10% EtOAc in hexanes) gave the title compound as a yellow oil (10.8g, 18%). 1H NMR (400 MHz, CDCI3): δ 1.22 (t, 7=7.6 Hz, 3 H), 2.63 (q, 7=7.6 Hz, 2 H), 3.38 (s, 3H), 3.57 (m, 2H), 3.87 (m, 2H), 5.38 (s, 2H), 7.19 (d, 7=8.5 Hz, 1 H), 7.37 (dd, 7=8.3, 2.3 Hz, 1 H), 7.67 (d, 7=2.5 Hz, 1 H), 10.47 (s, 1H).
Example D(8): 6-[2-(2-Benzyloxy-5-ethyl-phenyl)-ethyl]-6-cyclopentyl-dihydro-pyran-2,4- dione
Figure imgf000465_0001
The title compound was prepared analogously to Example D(1) where 2-benzyloxy-5- ethyl-benzaldehyde (from step 2 below) was substituted in place of 5-ethyl-4-(2-methoxy- ethoxymethoxy)-2-methyl-benzaldehyde in step 4 of that example. 1H NMR (400 MHz, CDCI3): δ 1.20 (t, 7=7.8 Hz, 3 H), 1.33-1.70 (br m, 8 H), 1.87 (m, 1 H), 1.99 (m, 1 H), 2.27 (m, 1 H), 2.54- 2,74 (m, 6 H), 3.27 (s, 2 H), 5.01 (s, 2 H), 6.83 (d, 7=8.1 Hz, 1 H), 6.93 (s, 1 H), 7.01 (d, 7=8.1 Hz, 1 H), 7.34-7.40 (m, 5 H). MS (ESI): 421.10 (M+H+)
Step 2: 2-Benzyloxy-5-ethyl-benzaldehyde
Figure imgf000465_0002
n-BuLi (7.56 mL, 18.9 mmol, 2.5M in hexanes) followed by DMF (5.5 mL) were added to a cooled -78°C solution of 1-benzyloxy-2-bromo-4-ethyl-benzene (5g, 17.2 mmol) in THF (40 mL). The reaction was stirred at -78°C for 1 hr and then warmed up to rt. After 2 hrs the reaction was quenched with 1N HCl and extracted with EtOAc. The organic layers were washed with brine, dried over Na2S0 and concentrated to a yellow oil. Purification by flash column chromatography (0% to 5% EtOAc in hexanes) gave the title compound as a clear oil (3.6 g, 87%). 1H NMR (400 MHz, CDCI3): δ 1.22 (t, 7=7.8 Hz, 3 H), 2.62 (q, 7=7.8 Hz, 2 H), 5.17 (s, 2 H), 6.97 (d, 7=8.6 Hz, 1 H), 7.33-7.45 (m, 6 H), 7.69 (s, 1 H), 10.54 (s, 1 H).
Step 1: 1-Benzyloxy-2-bromo-4-ethyl-benzene
Figure imgf000465_0003
Potassium carbonate (21.6g, 0.16 mol) followed by benzyl bromide (6.2 mL, 52 mmol) were added to a solution of 4-bromo-2-ethyl-phenol (1.6g, 7.9mmol, from step 1 of Example B(98)) in DMF (75mL). The mixture was stirred for 20 hours and then partitioned between 1N HCl and EtOAc. The organic layers were washed with brine, dried over Na2S04 and concentrated. The crude yellow oil was purified by flash column chromatography (hexanes) to give the desired product (13.1 g, 87%). 1H NMR (400 MHz, CDCI3): δ 1.20 (t, 7=7.6 Hz, 3 H), 2.56 (q, 7=7.8 Hz, 2 H), 5.13 (s, 2 H), 6.84 (d, 7=8.3 Hz, 1 H), 7.04 (dd, 7=8.3, 2.3 Hz, 1 H), 7.32 (m, 1 H), 7.38 (m, 3 H), 7.47 (d, 7=7.9 Hz, 2 H).
Example E(1): 3-[4-(2-Cyclopentyl-4,6-dioxo-tetrahydro-pyran-2-ylethynyl)-phenyl]-3-oxo- propionitrile
Figure imgf000466_0001
The title compound was prepared analogously to example A(75), where the hydrogenation of the triple bond Step was omitted. Yield 48 mg, 32%.
'HNMR (CDCI3): δ 1.35 to 1.71 (bm, 8H), 2.34 (m, IH), 2.66 (d, 7= 17.8 Hz, IH), 2.87 (d, 7= 17.4 Hz, IH), 3.36 (d, 7= 20.2 Hz, IH), 3.75 (d, 7= 19.8 Hz, IH), 3.93 (s, 2H), 7.41 (d, 7= 8.3 Hz, 2H), 7.76 (d, 7= 8.6 Hz, 2H). ESIMS (M+Na+): 372.13
Example E(2): 3-[5-(2-Cyclopentyl-4,6-dioxo-tetrahydro-pyran-2-ylethynyl)-thiophen-2-yl]-3- oxo-propionitrile
Figure imgf000466_0002
The title compound was prepared analogously to Example A(86), , where 3-(5-Bromo- thiophen-2-yl)-isoxazole was substituted in place of. 1-(4-Bromo-phenyl)-cyclopropanecarboxylic acid methyl ester in Step 3 of that example, and the hydrogenation of the triple bond Step was omitted (Note that the isoxazole opens to the cyanomethyl ketone during the Sonogashira coupling Step). Yield 30 mg, 35%.
Η NMR (CDC13): δ 1.35 to 1.68 (bm, 8H), 2.33 (m, IH), 2.65 (d, 7= 17.7 Hz, IH), 2.87 (d, 7= 17.4 Hz,
IH), 3.37 (d, 7= 20.2 Hz, IH), 3.70 (d, 7= 20.0 Hz, IH), 3.83 (s, 2H), 7.52 (m, 2H). ESIMS (M+Na+):
378.09.
Example E(3): [3-(2-Cyclopentyl-4,6-dioxo-tetrahydro-pyran-2-ylethynyl)-phenyl]- acetonitrile
Figure imgf000467_0001
The title compound was prepared analogously to example A(86), , where (3-Bromo- phenyl)-acetonitrile was substituted in place of. 1-(4-Bromo-phenyl)-cyclopropanecarboxylic acid methyl ester in Step 3 of that example, and the hydrogenation of the triple bond Step was omitted.
'H NMR (CDCI3): δ 1.44 to 1.72 (bm, 8H), 2.82 (m, IH), 3.79 (d, 7= 17.4 Hz, IH), 2.87 (d, 7= 17.4 Hz, IH), 3.35 (d, 7= 20.0 Hz, IH), 3.61 (s, 2H), 3.81 (d, 7= 20.2 Hz, IH), 7.13 (s, IH), 7.24 (bm, 4H). ESIMS (M+Na+): 344.14
Example F(1): 6-Cyclopentyl-6-[4-(4-hydroxy-2,5-dimethyl-phenyl)-but-3-ynyl]-dihydro- pyran-2,4-dione.
Figure imgf000467_0002
To 5-cyclopentyl-5-hydroxy-9-(4-hydroxy-2,5-dimethyl-phenyl)-3-oxo-non-8-ynoic acid methyl ester (60 mg, 0.155 mmol) from Step 2 below was added NaOH (0.3 M in MeOH, 1 mL, 0.31 mmol). The solution was stirred overnight, and then quenched with 1 N HCl (5 mL). The solution was extracted with 4 x 10 mL CH2CI2. The organic layer was dried over Na2S04, and then the solids were removed by filtration. After concentrating the mother liquor, the resulting oil was purified by flash chromatography to yield the desired product (54 mg, 98% yield). Η NMR (CDC13) δ: 1.35 - 1.75 (m, 8H), 1.93 - 1.99 (m, 3H), 2.10 (s, 3H), 2.23 (s, 3H), 2.51 (t, 7= 7.33 Hz, 2H), 2.69 (d, 7= 16.17 Hz, IH), 2.83 (d, 7= 16.18 Hz, IH), 3.37 (s, 2H), 4.66 (s, IH), 6.52 (s, IH), 7.05 (s, IH). MS (ESI): 353 (M-H).
Step 1 : 1-Cyclopentyl-5-(4-hydroxy-2,5-dimethyl-phenyl)-pent-4-yn-1-one.
Figure imgf000468_0001
A solution of 1-cyclopentyl-pent-4-yn-1-one (0.33 g, 2.2 mmol) from example F(7), Step 2, 4-iodo-2,5-dimethyl-phenoI (0.54 g, 2.2 mmol), copper (I) iodide (33 mg, 0.18 mmol), trans- dichlorobis(triphenylphosphine)palladium (II) (63 mg, 0.09 mmol), and diisopropylamine (2.2 mL) in DMF (2.2 mL) was heated to 100 °C for 30 minutes. The reaction was cooled to room temperature and diluted with 10 mL of EtOAc. The resulting slurry was filtered, and the mother liquor was concentrated to a black oil. The oil was then purified by flash chromatography to give the desired product (112 mg, 19% yield). 'H NMR (CDCI3) δ: 1.58 - 1.84 (m, 8H), 2.15 (s, 3H), 2.29 (s, 3H), 2.68 - 2.70 (m, 2H), 2.75 - 2.79 (m, 2H), 2.90 (p, 7= 8.08 Hz, IH), 6.57 (s, IH), 7.10 (s, IH).
Step 2: 5-Cyclopentyl-5-hydroxy-9-(4-hydroxy-2,5-dimethyl-phenyl)-3-oxo-non-8-ynoic acid methyl ester.
Figure imgf000468_0002
To a freshly prepared solution of LDA (1 M, 2.2 mL, 2.2 mmol) cooled to 0 °C was added methyl acetoacetate (0.12 mL, 1.1 mmol) dissolved in THF (1 mL). After stirring for 30 minutes, 1-cyclopentyl-5-(4-hydroxy-2,5-dimethyl-phenyl)-pent-4-yn-1-one (0.10 g, 0.37 mmol) from Step 1 above dissolved in THF (1 mL) was added. The reaction was stirred for 1 hour, and then warmed to room temperature. After quenching with 10 mL saturated ammonium chloride, the layers were separated. The aqueous layer was extracted with 2 x 15 mL CH2CI2l and the organic layers were combined. After drying over Na2S04, and filtering to remove the solids, the mother liquor was concentrated to an oil. Flash chromatography of the oil gave the desired product (69 mg, 48% yield). MS (ESI): 385 (M-H).
Example F(2): 3-[4-(2-Cyclopentyl-4,6-dioxo-tetrahydro-pyran-2-yl)-but-1 -ynyl]- benzenesulfonamide.
Figure imgf000469_0001
The desired product was prepared analogously to example F(1 ), substituting 5- cyclopentyl-5-hydroxy-3-oxo-9-(3-sulfamoyl-phenyl)-non-8-ynoic acid methyl ester (80 mg, 0.19 mmol) from Step 2 below in place of 5-cyclopentyl-5-hydroxy-9-(4-hydroxy-2,5-dimethyl-phenyl)- 3-oxo-non-8-ynoic acid methyl ester. Yield: 17 mg, 23%. 'H NMR (CDC13) δ: 1.43 - 1.74 (m, 8H), 1.93 -2.05 (m, 2H), 2.20 (p, 7= 8.59 Hz, IH), 2.52 (t, 7= 7.45 Hz, 2H), 2.70 (d, 7= 16.17 Hz, IH), 2.80 (d, 7= 16.17 Hz, IH), 3.39 (s, 2H), 4.82 (s, 2H), 7.38 (t, 7= 7.83 Hz, IH), 7.50 (d, 7= 8.84 Hz, IH), 7.76 (d, 7= 7.83 Hz, IH), 7.90 (t, 7= 1.52 Hz, IH). MS (ESI): 388 (M- H).
Step 1: 3-(5-Cyclopentyl-5-oxo-pent-1-ynyl)-benzenesulfonamide.
Figure imgf000470_0001
The desired product was prepared analogously to example F(1), Step 1 substituting 3- bromo-benzenesulfonamide (400 mg, 2.7 mmol) in place of 4-iodo-2,5-dimethyl-phenol. Yield: 0.556 g, 67%.
Η NMR (CDC13) δ: 1.66 - 1.96 (m, 8H), 2.77 (t, 7= 6.82 Hz, 2H), 2.88 (t, 7= 6.82 Hz, 2H), 2.99 (p, 7= 7.96 Hz, IH), 5.01 (s, IH), 5.09 (s, IH), 7.52 (t, 7= 7.83 Hz, IH), 7.79 - 7.82 (m, IH), 7.94 - 7.97 (m, IH), 8.17 (t, 7= 1.89 Hz, IH).
Step 2: 5-Cyclopentyl-5-hydroxy-3-oxo-9-(3-sulfamoyl-phenyl)-non-8-ynoic acid methyl ester
Figure imgf000470_0002
The desired product was prepared analogously to example A(86), Step 2, substituting 3-
(5-cyclopentyl-5-oxo-pent-1-ynyl)-benzenesulfonamide (200 mg, 0.66 mmol) from Step 1 above in place of 1-cyclopentyl-5-(4-hydroxy-2,5-dimethyl-phenyl)-pent-4-yn-1-one. Yield: 89 mg, 32%. MS (ESI): 420 (M-H).
Example F(3): 6-Cyclopentyl-6-[4-(2-methylsulfanyl-phenyl)-but-3-ynyl]-dihydro-pyran-2,4- dione.
Figure imgf000471_0001
The desired product was prepared analogously to example F(1), substituting 5- cyclopentyl-5-hydroxy-9-(2-methylsulfanyl-phenyl)-3-oxo-non-8-ynoic acid methyl ester (43 mg, 0.11 mmol) from Step 2 below in place of 5-cyclopentyl-5-hydroxy-9-(4-hydroxy-2,5-dimethyl- phenyl)-3-oxo-non-8-ynoic acid methyl ester. Yield: 38 mg, 97%.
1H NMR (CDCI3) δ: 1.41 - 1.69 (m, 8H), 1.94 - 2.01 (m, 2H), 2.13 - 2.18 (m, 1H), 2.36 (s, 3H), 2.55 (t, 7 = 7.45 Hz, 2H), 2.67 (d, 7 = 16.17 Hz, 1H), 2.87 (d, 7 = 16.17 Hz, 1H), 3.34 (d, 7 = 8.84 Hz, 2H), 6.93 - 7.01 (m, 2H), 7.14 - 7.16 (m, 1H), 7.24 (d, 7 = 6.32 Hz, 1H). MS (ESI): 355 (M- H).
Step 1: 1-Cyclopentyl-5-(2-methylsulfanyl-phenyl)-pent-4-yn-1-one.
Figure imgf000471_0002
The desired product was prepared analogously to example F(1), Step 1, substituting 2- bromothioanisole (0.58 g, 2.8 mmol) in place of 4-iodo-2,5-dimethyl-phenoi. Yield: 63 mg, 8.3%. MS (APCI): 273 (M+H).
Step 2: 5-Cyclopentyl-5-hydroxy-9-(2-methylsulfanyl-phenyl)-3-oxo-non-8-ynoic acid
Figure imgf000472_0001
The desired product was prepared analogously to example F(1), Step 2, substituting 1- Cyclopentyl-5-(2-methylsulfanyl-phenyl)-pent-4-yn-1-one (60 mg, 0.22 mmol) from Step 1 above in place of 1-cyclopentyl-5-(4-hydroxy-2,5-dimethyl-phenyl)-pent-4-yn-1-one. Yield: 43 mg, 50%.
MS (ESI): 387 (M-H).
Example F(4): 6-Cyclopentyl-6-[4-(2-trifluoromethoxy-phenyl)-but-3-ynyl]-dihydro-pyran- 2,4-dione.
Figure imgf000472_0002
The desired product was prepared analogously to example F(1), substituting 5- cyclopentyl-5-hydroxy-3-oxo-9-(2-trifluoromethoxy-phenyl)-non-8-ynoic acid methyl ester (72 mg, 0.17 mmol) from Step 2 below in place of 5-cyclopentyl-5-hydroxy-9-(4-hydroxy-2,5-dimethyl- phenyl)-3-oxo-non-8-ynoic acid methyl ester. Yield: 25 mg, 37%.
1H NMR (CDCI3) δ: 1.33 - 1.73 (m, 8H), 1.89 - 2.06 (m, 2H), 2.14 - 2.23 (m, 1H), 2.55 (t, 7 = 7.58 Hz, 2H), 2.69 (d, 7 = 16.17 Hz, 1H), 2.84 (d, 7 = 16.17 Hz, 1H), 3.37 (s, 2H), 7.15 - 7.21 (m, 2H), 7.23 - 7.27 (m, 1 H), 7.38 - 7.44 (m, 1 H). MS (ESI): 393 (M-H).
Step 1 : 1 -cyclopentyl-5-(2-trif luoromethoxy-phenyl)-pent-4-y n-1 -one.
Figure imgf000472_0003
The desired product was prepared analogously to example F(1), Step 1, substituting 1- lodo-2-trifluoromethoxy-benzene (0.80 g, 2.8 mmol) in place of 4-iodo-2,5-dimethyl-phenol. Yield: 0.247 g, 28%.
1H NMR (CDCI3) δ: 1.80 - 2,05 (m, 8H), 2.70 - 3.12 (m, 5H), 7.40 - 7.45 (m, 2H), 7.49 - 7.53 (m,1H), 7.64 - 7.69 (m, 1H).
Step 2: 5-cyclopentyl-5-hydroxy-3-oxo-9-(2-trifluoromethoxy-phenyl)-non-8-ynoic acid methyl ester.
Figure imgf000473_0001
The desired product was prepared analogously to example F(1), Step 2, substituting 1- cyclopentyl-5-(2-trifluoromethoxy-phenyl)-pent-4-yn-1-one (200 mg, 0.65 mmol) from Step 1 above in place of 1-cyclopentyl-5-(4-hydroxy-2,5-dimethyl-phenyl)-pent-4-yn-1-one. Yield: 72 mg, 26%.
MS (ESI): 425 (M-H).
Example F(5): 6-Cyclopentyl-6-[4-(4-fluoro-phenyl)-but-3-ynyl]-dihydro-pyran-2,4-dione
Figure imgf000473_0002
The desired product was prepared analogously to example F(1), substituting 5- cyclopentyl-9-(4-fluoro-phenyl)-5-hydroxy-3-oxo-non-8-ynoic acid methyl ester (400 mg, 1.1 mmol) from Step 2 below in place of 5-cyclopentyl-5-hydroxy-9-(4-hydroxy-2,5-dimethyl-phenyl)- 3-oxo-non-8-ynoic acid methyl ester. Yield: 190 mg, 53%. MS (ESI): 327 (M-H).
Step 1 : 1 -Cyclopentyl-5-(4-fluoro-phenyl)-pent-4-yn-1 -one
Figure imgf000474_0001
The desired product was prepared analogously to example F(1), Step 1, substituting 1- fluoro-4-iodo-benzene (0.38 mL, 3.3 mmol) in place of 4-iodo-2,5-dimethyl-phenol. Yield: 0.415 g, 51%.
1H NMR (CDCI3) δ: 1.44 - 1.74 (m, 8H), 2.52 - 2.58 (m, 2H), 2.66 (t, 7 = 6.95 Hz, 2H), 2.79 (p, 7 = 7.96 Hz, 1H), 6.85 (t, 7 = 8.84 Hz, 2H), 7.22 (ddd, 71 = 11.81 Hz, 72 = 5.24 Hz, 73 = 2.65 Hz, 2H).
Step 2: 5-Cyclopentyl-9-(4-fluoro-phenyl)-5-hydroxy-3-oxo-non-8-ynoic acid methyl ester.
Figure imgf000474_0002
The desired product was prepared analogously to example F(1), Step 2, substituting 1- cycIopentyl-5-(4-fluoro-phenyl)-pent-4-yn-1-one (300 mg, 1.23 mmol) from Step 1 above in place of 1-cyclopentyl-5-(4-hydroxy-2,5-dimethyl-phenyl)-pent-4-yn-1-one. The crude product was used directly without purification.
MS (ESI): 359 (M-H).
Example F(6): 6-Cyclopentyl-6-(4-p-tolyl-but-3-ynyl)-dihydro-pyran-2,4-dione.
Figure imgf000475_0001
The desired product was prepared analogously to example F(1), substituting 5- cyclopentyl-5-hydroxy-3-oxo-9-p-tolyl-non-8-ynoic acid methyl ester (400 mg, 1.1 mmol) from Step 2 below in place of 5-cyclopentyl-5-hydroxy-9-(4-hydroxy-2,5-dimethyl-phenyl)-3-oxo-non-8- ynoic acid methyl ester. Yield: 180 mg, 50%.
MS (ESI): 323 (M-H).
Step 1: 1-Cyclopentyl-5-p-tolyl-pent-4-yn-1-one.
Figure imgf000475_0002
The desired product was prepared analogously to example F(1), Step 1, substituting 4- iodotoluene (0.727 g, 3.3 mmol) in place of 4-iodo-2,5-dimethyl-phenol. Yield: 0.412 g, 52%.
1H NMR (CDCI3) δ: 1.49 - 1.79 (m, 8H), 2.26 (s, 3H), 2.57 - 2.61 (m, 2H), 2.69 - 2.73 (m, 2H), 2.84 (p, 7 = 8.08 Hz, 1 H), 7.01 (d, 7 = 7.83 Hz, 2H), 7.19 (d, 7 = 8.34 Hz, 2H).
Step 2: 5-Cyclopentyl-5-hydroxy-3-oxo-9-p-tolyl-non-8-ynoic acid methyl ester.
Figure imgf000476_0001
The desired product was prepared analogously to example F(1), Step 2, above substituting 1-cyclopentyl-5-p-tolyl-pent-4-yn-1-one (300 mg, 1.23 mmol) from Step 1 above in place of 1-cyclopentyl-5-(4-hydroxy-2,5-dimethyl-phenyl)-pent-4-yn-1-one. The crude product was used directly without purification.
MS (ESI): 355 (M-H).
Example F(7): 6-Cyclopentyl-4-hydroxy-6-[4-(3-hydroxy-phenyl)-but-3-ynyl]-3-(thiazol-2- ylsulfanyl)-5,6-dihydro-pyran-2-one.
Figure imgf000476_0002
To a solution of 3-chloro-6-cyclopentyl-6-[4-(3-hydroxy-phenyl)-but-3-ynyl]-dihydro-pyran- 2,4-dione (216 mg, 0.6 mmol) from Step 5 below and 2-mercaptothiazole (141 mg, 1.2 mmol) in DMF (6 mL) was added triethylamine (0.15 mL, 1.2 mmol). The reaction was stirred at 50 °C for 2.5 hours and then quenched with 10 mL of saturated ammonium chloride. The mixture was further acidified to a pH of 1-2 with 1 N HCl. To this mixture was added 10 mL CH2CI2 and the layers were separated. The aqueous was extracted with 2 x 10 mL CH2CI2, and the organic layers were combined. After drying the organic layer over MgS0 , the solids were filtered away and the liquid was concentrated to an oil. The oil was chromatographed on silica to yield the desired product (28 mg, 11 % yield).
Η NMR (CDC13) δ: 1.09 - 1.58 (m, 8H), 1.93-2.05 (m, 3H), 2.58-2.82 (m, 4H), 6.59 (d, 7= 6.82 Hz, 2H), 6.65 (d, 7= 7.58 Hz, IH), 6.96-7.00 (m, IH), 7.32 (d, 7= 3.28 Hz, IH), 7.46 (d, 7= 3.28 Hz, IH). MS (ESI): 440 (M-H). Step 1 : Pent-4-ynethioic acid S-pyridin-2-yl ester.
Figure imgf000477_0001
To a solution of 4-pentynoic acid (9.27 g, 94.5 mmol) dissolved in CH2CI2 (125 mL) was added triphenylphosphine (32.2 g, 123 mmol) and 2,2'-dithiodipyridine (26 g, 118 mmol) and stirred at room temperature for 2 hours. The reaction was concentrated by rotary evaporation, and then chromatographed to yield the desired product (17.9 g, 99% yield).
MS (ESI): 192 (M+H). Step 2: 1-cyclopentyl-pent-4-yn-1-one.
Figure imgf000477_0002
To a solution of pent-4-ynethioic acid S-pyridin-2-yl ester (17.9 g, 94 mmol), dissolved in THF (900 mL) cooled to -78 °C was added cyclopentylmagnesium bromide (2.0 M, 94 mL, 188.5 mmol). The reaction was stirred for 15 minutes, and then warmed to -50 °C. The reaction was poured into 500 mL 1 N HCl and the layers were separated. The aqueous layer was extracted with 2 x 200 mL diethyl ether and the organic layers were combined. The organics were then washed with 300 mL of 1 N NaOH. The organic layer was dried over Mg S0 , and the solids were removed by filtration. The solvent was removed by rotary evaporation to give the desired compound (14.0 g, 99 % yield).
1H NMR (CDCI3) δ: 1.54 - 1.87 (m, 8H), 1.94 (t, 7 = 2.65 Hz, 1H), 2.45 (dt, 71 = 7.33 Hz, 72 = 2.78 Hz, 2H), 2.71 (t, 7 = 7.58 Hz, 2H), 2.87 (p, 7 = 7.96 Hz, 1H).
Step 3: 2-Chloro-5-cyclopentyl-5-hydroxy-3-oxo-non-8-ynoic acid methyl ester.
Figure imgf000478_0001
A slurry of NaH (3.2 g, 60 % suspension in mineral oil, 80 mmol) in dry THF (250 mL) was cooled to -40 °C. Methyl-2-chloroacetoacetate (9.74 mL.,80 mmol) was added slowly. The reaction was stirred until all gas evolution had ceased, and then butyl lithium (2.5 M, 32 mL, 80 mmol) was added. The reaction was stirred for 10 minutes, and then 1-cyclopentyl-pent-4-yn-1- one (4.0 g, 27 mmol) from Step 2 above, was added as a solution in 20 mL THF. The reaction was stirred 1 hour, and then warmed to room temperature. The reaction was quenched with 1 N HCl (200 mL) and the layers were separated. The aqueous layer was extracted with CH2CI2 and the organic layers were combined. The organic layer was washed with water, and then concentrated by rotary evaporation. The crude product was purified by chromatography to yield the pure product (6.345 g, 78% yield). MS (ESI): 298 (M-H), 300 (M+2-H).
Step 4: 6-But-3-ynyl-3-chloro-6-cyclopentyl-dihydro-pyran-2,4-dione.
Figure imgf000478_0002
A slurry of 2-chloro-5-cyclopentyl-5-hydroxy-3-oxo-non-8-ynoic acid methyl ester (6.0 g, 20 mmol) from Step 3 above and K2C03 (11 g, 80 mmol) in methanol (100 mL) was stirred at 50 °C for 1.5 hours. The reaction was concentrated by rotary evaporation, and then re-dissolved in ethyl acetate. The solution was washed with water, and then saturated Na2C03. The organic layer was dried over sodium sulfate. After removing the solids by filtration, the organic layer was concentrated by rotary evaporation to yield the desired product (5.24 g, 97% yield). MS (ESI): 267 (M-H), 269 (M+2-H). Step 5: 3-Chloro-6-cyclopentyl-6-[4-(3-hydroxy-phenyl)-but-3-ynyl]-dihydro-pyran-2,4- dione.
Figure imgf000479_0001
A solution of 6-but-3-ynyl-3-chloro-6-cyclopentyl-dihydro-pyran-2,4-dione (200 mg, 0.66 mmol) from Step 4 above, 3-iodophenol (145 mg, 0.66 mmol), bis(triphenylphosphine)palladium (II) dichloride (18 mg, 0.026 mmol), and copper (I) iodide (10 mg, 0.052 mmol) in DMF (0.66 mL) and diisopropylamine (0.66 mL) was sonicated for 1 minute and then heated to 90 °C for 20 minutes. The reaction was cooled to room temperature, and then diluted with 10 mL CH2CI2. The reaction was then neutralized to a pH of 4 with 6 N HCl and the layers were separated. The aqueous layer was extracted with 3 x 10 mL CH2CI2 and the organic layers were combined, and then dried over sodium sulfate. After filtering the solids, the organic layer was concentrated to a dark oil, which was used without further purification. MS (ESI): 359 (M-H), 361 (M+2-H).
Example G(1): 6-[2-(3-chloro-4-methoxyphenyl)ethyl]-6-cyclopentyl-4-(pyridin-3- ylmethoxy)-5,6-dihydro-2H-pyran-2-one.
Figure imgf000480_0001
The title compound was prepared analogously to Example B(78),, where 3- (chloromethyl)pyridine hydrochloride was substituted in place of benzyl bromide in that example. Η NMR (CDC13): δ 1.41-1.70 (bm, 8H), 2.02 (m, 3H), 2.44 (m, 2H), 2.63 (m, 2H), 3.87 (s, 3H), 4.96 (s, 2H), 5.30 (s, IH), 6.83 (d, 7= 8.64 Hz, IH), 7.02 (d, 7= 8.64 Hz, IH), 7.17 (s, IH), 7.36 (t, 7= 4.80 Hz, IH), 7.72 (d, 7= 7.68 Hz, IH), 8.65 (s, 2H).
Example G(2): 6-[2-(3-Chloro-4-methoxy-phenyl)-ethyl]-6-cyclopentyl-4-(pyridin-2- ylmethoxy)-5,6-dihydro-pyran-2-one.
Figure imgf000480_0002
The target compound was isolated out of the same reaction that was used for Example
B(81).
Η NMR (CDCI3) ?: 1.57 - 1.80 (m, 8H), 1.89 - 20.4 (m, 2H), 2.39 - 2.50 (m, 2H), 2.60 - 2.66 (m, 2H), 2.74 -2.80 (d, 7= 17.27 Hz, IH), 3.87 (s, 3H), 5.28 (s, IH), 6.84 (d, 7= 8.32 Hz, IH), 6.99 - 7.03 (m, IH), 7.24 - 7.30 (m, IH), 7.38 (d, 7= 8.00 Hz, IH), 7.74 (tt, 71 = 7.26 Hz, 72 = 7.26 Hz, 73 = 1.76 Hz, IH), 8.61 (d, 7= 3.84 Hz, IH). Example G(3): 6-[2-(3-Chloro-4-methoχy-phenyl)-ethyI]-6-cyclopentyl-4-methoxy-5,6- dihydro-pyran-2-one.
Figure imgf000481_0001
To a solution of 6-[2-(3-Chloro-4-methoxy-phenyl)-ethyl]-6-cyclopentyl-dihydro-pyran-2,4- dione (60 mg, 0.17 mmol) from Example B(87), dissolved in DMF (1.5 mL), were added DBU (0.028 mL, 0.188 mmol) and iodomethane (0.011 mL, 0.17 mmol). The reaction was stirred at room temperature overnight, and then was quenched with water. The reaction was extracted with EtOAc, and the organic layers were combined. After washing with saturated NaCl, the organic layer was dried over Na2S0 . The solids were removed by filtration, and the liquid was concentrated by rotary evaporation. Purification by preparatory HPLC gave the desired product (8.2 mg, 13% yield).
'H NMR (CDC13) δ: 1.47 - 1.69 (m, 8H), 1.89 - 1.95 (m, 2H), 2.25 - 2.35 (m, 2H), 2.52 - 2.63 (m, 3H), 3.67 (s, 3H), 3.80 (s, 3H), 6.77 (d, 7= 8.32 Hz, IH), 6.94 (dd, 71 = 8.32 Hz, 72 = 2.24 Hz, IH), 7.09 (d, 7= 1.92 Hz, IH).
Example H(1 ): N-[2-(2-Cyclopentyl-4,6-dioxo-tetrahydro-pyran-2-yl)-ethyl]-3-f uran-2-yl- propionamide.
Figure imgf000481_0002
A solution of 6-(2-Amino-ethyl)-6-cyclopentyl-dihydro-pyran-2,4-dione (90 mg, 0.4 mmol) from Step 5 below, TEA (0.22 mL, 1.6 mmol), 3-furan-2-yl-propionic acid (67 mg, 0.48 mmol) and HATU (182 mg, 0.48 mmol) in DMF (2 mL) was stirred at room temperature overnight. The reaction was purified directly by preparatory HPLC to yield the desired product (26 mg, 19% yield). Η NMR (CDCI3) δ: 1.27 - 3.47 (m, 21H), 6.94 (s, IH), 6.19 (s, IH), 7.22 (s, IH). MS (ESI): 346 (M-H).
Step 1: (3-Chloro-1-cyclopentyl-propan-1-one.
Figure imgf000482_0001
A solution of cyclopentanecarbonyl chloride (10 g, 75 mmol) and AICI3 (11.1 g, 83 mmol) in CH2CI2 (100 mL) was cooled to -10 °C. A solution of vinyltrimethylsilane (12 mL, 75 mmol) in CH2CI2 (50 mL) was added drop wise over 30 minutes. The reaction was stirred for 20 additional minutes, and then poured over 200 g of ice. The layers were separated, and the aqueous layer was extracted with CH2CI2. The organic layers were combined and washed with saturated NaHC03. The organic was then dried over Na2S0 , the solids were filtered away, and the product was purified by distillation (7.17 g, 60 %). Η NMR (CDCI3) δ: 1.43 - 1.70 (m, 8H), 2.69-2.80 (m, 3H), 3.61 (t, 7= 6.57 Hz, 2H).
Step 2: (3-Cyclopentyl-3-oxo-propyl)-carbamic acid tert-butyl ester
Figure imgf000482_0002
To a solution of 3-chloro-1-cyclopentyl-propan-1-one (2.913 g, 18.1 mmol) from Step 1 above in DMF (40 mL) was added sodium azide (1.77 g, 27.2 mmol). The reaction was heated to 70 °C for 3 hours. The reaction was cooled to room temperature, and then diluted with 100 mL of ethyl acetate and 100 mL of water. The layers were separated, and the aqueous was extracted with 2 x 50 mL of ethyl acetate. The organic layer was then washed with 2 x 50 mL of water. The organic layer was dried over sodium sulfate, filtered, and concentrated to an oil. The oil was then dissolved in ethanol (75 mL) and TFA was added (3 mL). To this solution was added 10 % Pd/C (300 mg). The slurry was stirred under a hydrogen atmosphere for 2 hours. The solids were removed by filtration, and the organic was concentrated by rotary evaporation to a black oil. The black oil was dissolved in THF (100 mL) and TEA (7.5 mL) and di-ferf-butyl pyrocarbonate (1 M in THF, 40 mL, 40 mmol) were added. The reaction was stirred at room temperature for 18 hours, and then concentrated by rotary evaporation. The crude oil was purified by flash chromatography to yield the product (1.677 g, 38%).
'H MR (CDCl3) δ: 1.43 (s, 9H), 1.56-1.84 (m, 8H), 2.68 (t, 7= 5.65 Hz, 2H), 2.85 (p, 7= 5.65 Hz, IH), 3.36 (q, 7= 6.03, 2H). Step 3: 7-tert-Butoxycarbonylamino-5-cyclopentyl-5-hydroxy-3-oxo-heptanoic acid methyl ester.
Figure imgf000483_0001
The desired product was prepared analogously to example F(1), Step 2 replacing 1- cyclopentyl-5-(4-hydroxy-2,5-dimethyl-phenyl)-pent-4-yn-1-one, from Step 2 above with (3- cyclopentyl-3-oxo-propyl)-carbamic acid tert-butyl ester (1,6 g, 6.6 mmol) described in Step 2 above. Yield: 1.36 g, 58 %. MS (ESI): 356 (M-H).
Step 4: [2-(2-Cyclopentyl-4,6-dioxo-tetrahydro-pyran-2-yl)-ethyl]-carbamic acid tert-butyl ester.
Figure imgf000483_0002
To 7-tert-butoxycarbonylamino-5-cyclopentyl-5-hydroxy-3-oxo-heptanoic acid methyl ester (1.36 g, 3.8 mmol) from Step 3 above dissolved in MeOH (50 mL) was added a NaOH solution (2.8 M, 2.7 mL, 7.6 mmol). The reaction was stirred at room temperature for 18 hours. The reaction was then quenched with acetic acid (0.44 mL, 7.7 mmol) and concentrated by rotary evaporation to an oil. The oil was dissolved in CH2CI2 and washed with water. The organic layer was separated, and dried over Na2S0 . The solids were removed by filtration, and the liquid was concentrated to yield the product (1.061 g, 86 % yield). MS (ESI): 324 (M-H).
Step 5: 6-(2-Amino-ethyl)-6-cyclopentyl-dihydro-pyran-2,4-dione.
Figure imgf000484_0001
A solution of [2-(2-cyclopentyl-4,6-dioxo-tetrahydro-pyran-2-yl)-ethyl]-carbamic acid tert- butyl ester (1.0 g, 2.8 mmol) from Step 4 above in 10 % TFA / CH2CI2 was stirred at room temperature for 20 minutes. The reaction was concentrated by rotary evaporation and used as is without further purification. MS (ESI): 224 (M-H).
Example H(2): Furan-2-carboxylic acid [2-(2-cyclopentyl-4,6-dioxo-tetrahydro-pyran-2-yl)- ethyl]-amide.
Figure imgf000484_0002
The desired product was prepared analogously to Example H(1), substituting 2-furanoic acid (54 mg, 0.48 mmol) in place of 3-furan-2-yl-propionic acid. Yield: 28 mg, 22%. 'H NMR (CDCl3) δ: 1.46 - 3.29 (m, 21H), 6.62 (s, IH), 7.20 (s, IH), 7.58 (s, IH). MS (ESI): 318 (M-H).
Example H(3): } N-[3-(2-Cyclopentyl-4,6-dioxo-tetrahydro-pyran-2-yl)-propyl]-3-furan-2-yl- propionamide.
Figure imgf000484_0003
The desired product was prepared analogously to example H(1) substituting 6-(3-Amino- propyl)-6-cyclopentyl-dihydro-pyran-2,4-dione (62 mg, 0.26 mmol) in place of 36-(2-Amino-ethyl)- 6-cyclopentyl-dihydro-pyran-2,4-dione. Yield: 12 mg, 13%.
Η NMR (CDC13) δ: 1.10 - 1.47 (m, 8H), 2.09 - 2.39 (m, 8H), 2.55 - 2.66 (m, 3H), 2.74 - 2.94 (m, 4H), 5.68 (s, IH), 5.93 (s, IH), 6.96 (s, IH). MS (ESI): 360 (M-H). Example H(4): N-{2-[2-Cyclopentyl-5-(5,7-dimethyl-[1 ,2,4]triazolo[1 ,5-a]pyrimidin-2- ylsulfanyl)-4-hydroxy-6-oxo-3,6-dihydro-2H-pyran-2-yl]-ethyl}-3-furan-2-yl-propionamide
Figure imgf000485_0001
The desired product was prepared analogously to example F(7), substituting N-[2-(5- chIoro-2-cyclopentyl-4,6-dioxo-tetrahydro-pyran-2-yl)-ethyl]-3-furan-2-yl-propionamide from Step 3 below in place of 3-chloro-6-cyclopentyl-6-[4-(3-hydroxy-phenyl)-but-3-ynyl]-dihydro-pyran-2,4- dione and 5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidine-2-thiol in place of 2-mercaptothiazole. Yield: 11 mg, 8%. MS (ESI): 524 (M-H). Step l: 3-Amino-1-cyclopentyl-propan-1-one.
Figure imgf000485_0002
The desired product was prepared analogously to example H(1), Step 5, substituting (3- Cyclopentyl-3-oxo-propyl)-carbamic acid tert-butyl ester (described in Step 2 of example H(1) ) in place of [2-(2-cyclopentyl-4,6-dioxo-tetrahydro-pyran-2-yl)-ethyl]-carbamic acid tert-butyl ester. MS (ESI): 142 (M+H).
Step 2: N-(3-Cyclopentyl-3-oxo-propyl)-3-furan-2-yl-propionamide.
Figure imgf000485_0003
The desired product was prepared analogously to example H(1), substituting 3-amino-1- cyclopentyl-propan-1-one (0.874 g, 6.2 mmol) from Step 1 above in place of 6-(2-Amino-ethyl)-6- cyclopentyl-dihydro-pyran-2,4-dione. Yield: 0.901 g, 55%.
1H NMR (CDCI3) δ: 1.33 - 1.60 (m, 8H), 2.24 (t, 7 = 7.58 Hz, 2H), 2.42 - 2.48 (m, 3H), 2.73 (t, 7 = 7.45 Hz, 2H), 3.24 (q, 7 = 6.06 Hz, 2H), 5.78 (d, 7 = 3.79 Hz, 1H), 6.03 (d, 7 = 6.03 Hz, 1H), 7.06 (d, 7 = 2.53 Hz, 1H).
Step 3: N-[2-(5-Chloro-2-cyclopentyl-4,6-dioxo-tetrahydro-pyran-2-yl)-ethyl]-3-furan-2-yl- propionamide.
Figure imgf000486_0001
The desired product was prepared analogously to example F(1), Step 2, substituting N- (3-cyclopentyl-3-oxo-propyl)-3-furan-2-yl-propionamide (300 mg, 1.1 mmol) from Step 2 above in place of 1-cyclopentyl-5-(4-hydroxy-2,5-dimethyl-phenyl)-pent-4-yn-1-one and methyl 2- chloroacetoacetate (0.7 mL, 5.7 mmol) in place of methyl acetoacetate. Yield: 103 mg, 14%.
MS (ESI): 380 (M-H), 382 (M+2-H).
Example H(5): 3-Cyclopentyl-5-(3-furan-2-yl-propionylamino)-3-hydroxy-pentanoic acid
Figure imgf000486_0002
A solution of NaOH (0.3 M. 1-6 mL, 0.49 mmol) was added to 3-cyclopentyl-5-(3-furan-2- yl-propionylamino)-3-hydroxy-pentanoic acid ethyl ester (86 mg, 0.245 mmol) from Step 1 below and stirred at room temperature until complete by HPLC. The reaction was diluted with 10 mL CH2CI2, and washed with 10 mL saturated NH CI. The aqueous layer was extracted with 2 x 10 mL CH2CI2, and the organic layers were combined. After concentrating by rotary evaporation, the residue was purified by flash chromatography to give the desired compound (29 mg, 37% yield).
1H NMR (CDCI3) δ: 1.39 - 1.75 (m, 8H), 2.00-2.09 (m, 2H), 2.39-2.52 (m, 5H), 2.90 (t, 7 = 7.45 Hz, 2H), 3.29 - 3.40 (m, 2H), 5.96 (s, 1H), 6.2 (s, 1H), 6.31 (br, 1H), 7.23 (s, 1H). MS (ESI): 322 (M-H).
Step 1: 3-Cyclopentyl-5-(3-furan-2-yl-propionylamino)-3-hydroxy-pentanoic acid ethyl ester.
Figure imgf000487_0001
To a solution of LDA (1.0 M. 1- nnL, 1.1 mmol) cooled to -78 °C was added EtOAc (0.1 mL, 1.1 mmol). After stirring for 30 minutes, a solution of N-(3-cyclopentyl-3-oxo-propyl)-3-furan- 2-yl-propionamide (100 mg, 0.38 mmol; described in Step 2 of example H(4)) dissolved in 3 mL THF was added. The reaction was stirred for 2 hours and then allowed to warm to -40 °C. The reaction was quenched with 10 mL saturated NH4CI, and the layers were separated. The aqueous layer was extracted with 3 x 10 mL CH2CI2, and the organic layers were combined. After concentrating the organic layers by rotary evaporation, the product was purified by flash chromatography (86 mg, 64% yield). MS (ESI): 350 (M-H).
Example 1(1 ): 6-cyclopentyl-6-[(pyrimidin-2-ylthio)methyl]dihydro-2W-pyran-2,4(3H)-dione.
Figure imgf000487_0002
The title compound was prepared analogously to Example A(6), where pyrimidine-2-thiol was substituted in place of p-methoxythiophenol in Step 2 of that example. 'HNMR (CDCl3): δ 1.6-2.0 (brm, 8H), 2.48 (m, IH), 2.66 (s, IH), 2.86 (s, IH), 3.66 (s, IH), 3.43 (s, 2H), 3.70-3.74 (m, 2H), 3.78 (d, J= 7.54 Hz, IH), 7.03 (t, 7= 4.90 Hz, IH), 8.50, (d, 7= 4.71 Hz, 2H). Anal. Calcd. For Ci5Hι8N203S: C, 58.80; H, 5.92; N, 9.14. Found: C, 58.95; H, 6.04; N, 9.20.
Example 1(2): 6-cyclopentyl-6-{[(2-furylmethyl)thio]methyl}dihydro-2H-pyran-2,4(3A7)-dione.
Figure imgf000488_0001
The title compound was prepared analogously to Example A(6), where 2- furylmethanethiol was substituted in place of p-methoxythiophenol in Step 2 of that example. Η NMR (CDC13): δ 1.31-175 (brm, 8H), 2.25 (m, IH), 2.68 (m, 2H), 2.86-2.88 (m, 2H), 3.72 (s, IH), 3.75 (s, IH), 6.22 (d, 7 = 1.88 Hz, IH), 6.32 (t, 7= 1.88 Hz, IH), 7.38, (s, IH). Anal. Calcd. For C16H20O4S: C, 62.31; H, 6.54. Found: C, 62.54; H, 6.37.
Example 1(3): 6-cyclopentyl-6-{[(6-ethoxy-1 ,3-benzothiazol-2-yl)thio]methyl}dihydro-2H- pyran-2,4(3H)-dione.
Figure imgf000488_0002
The title compound was prepared analogously to Example A(6), where 6-ethoxy-1,3- benzothiazole-2-thiol was substituted in place of p-methoxythiophenol in Step 2 of that example. LCMS : 404, M-ve on APCI. Rf : 0.3; 98:2, DCM : MeOH, developed with anisaldehyde. Anal. Calcd. For C2oH23S204N: C, 59.24; H, 5.72; N, 3.45. Found: C, 56.50; H, 6.04; N, 3.63.
Example l(4): 6-cyclopentyl-6-{[(4-isopropylphenyl) thio]methyl}dihydro-2H-pyran-2,4(3H)- dione.
Figure imgf000489_0001
The title compound was prepared analogously to Example A(6),where 4- isopropylbenzenethiol was substituted in place of p-methoxythiophenol in Step 2 of that example. Η NMR (CDC13): δ 1.00 (m, IH), 1.23 (d, 7= 6.97Hz), 6H), 1.44-1.70 (brm, 8H), 1.94 (m, IH), 2.67 (m, 2H), 2.77 (s, 2H), 3.42 (s, 2H), 7.07, (d, 7 = 8.10 Hz, 2H), 7.15 (d, 7= 8.10 Hz, 2H). Anal. Calcd. For C20H26O3S: C, 69.33; H, 7.56. Found: C, 69.55; H, 7.70.
General scheme for resolution of 6-(2-cyclopentyl-2-hydroxybut-3-ynyl)-2,2-dimethyl-4W- 1,3-dioxin-4-one Precursors.
Figure imgf000489_0002
Enantiomer B, Enantiomer A Enantiomer A ee 92%, 46%, ee 96%, 42% ee 95.5%
Enantiomers A and B of 6-(2-cyclopentyl-2-hydroxybut-3-ynyl)-2,2-dimethyl-4 7-1,3-dioxin- 4-one (absolute stereochemistry not known)
Figure imgf000490_0001
Enantiomer A Enantiomer B
Step 1 : 1 -cyclopentyl-1 -[(2,2-dimethyl-4-oxo-4H-1 ,3-dioxin-6-yl)methyl]prop-2-ynyl ethyl oxalate
Figure imgf000490_0002
To a solution of racemic 6-(2-cyclopentyl-2-hydroxybut-3-ynyl)-2,2-dimethyl-4/-/-1,3- dioxin-4-one (10 g, 37.9 mmol) in CH2CI2(200 ml) was added triethylamine (3.0 eqv, 113.7 mmol) at 0 °C. Then ethyl chlorooxoacetate (3.0 eqv, 113.7 mmol) in CH2CI2 (10 ml) was added dropwise over a 30-minute period under argon. The solution was allowed to stir overnight at room temperature. After removal of solvent, the crude product was purified using a flash column (heptane: EtOAc, 3:1) to afford the desired oxalate (13.5 g, >95%). API-MS: [M+Na+]: 387; Η NMR (CDC13, 300 MHz) δ: 5.27 (s, IH), 4.33 (dq, 7= 2.5 and 7.5 Hz, 2H), 2.67 (s, 2H), 2.64 ( , IH), 1.65 (s, 6H), 1.40-1.80 (m, 6H), 1.36 (dt, J = 3.0 and 7.2 Hz, 3H). 13C NMR (CDC13, 75 MHz) δ: 171.47, 165.83, 163.62, 161.84, 107.31, 97.74, 83.33, 79.21, 77.58, 63.48, 46.65, 42.82, 28.62, 28.62, 28.44, 25.28, 14.54, 14.44, 12.89. Step 2: Enantiomer B of 6-(2-cyclopentyl-2-hydroxybut-3-ynyl)-2,2-dimethyl-4r/-1,3-dioxin- 4-one.
Figure imgf000491_0001
Enantiomer B, Enantiomer A ee 92%, 46%, ee 96%, 42%
To a 250 ml three-necked flask equipped with a pH electrode was added 72 ml of phosphate buffer (pH 4.0, 0.5M) and Candida rugosa lipase (5 g, Amano AY). The mixture was stirred vigorously and then the oxalate (6 g) in 18 ml of acetonitrile was added. The reaction mixture was allowed to stir at 23 °C and the pH was kept at 4.0 using a pH titrator. The reaction was monitored with HPLC and stopped after 50% conversion (<20 hrs). The mixture was extracted by MTBE (x3) and the combined organic layer was dried over MgS04. After removal of the solvent, the crude product was separated carefully by silica-gel chromatography, using heptane/EtOAC (5:1, 2:1), which afforded 2.6 g of the oxalate (43% yield, 96% ee) and 2.0 g of product (enantiomer B: 46% yield, 92% ee). 'HNMR (300 MHz, CDC13) δ: 1.45-1.80 (m, 8 H), 1,72 (s, 3 H), 1.74 (s, 3 H), 2.13-2.18 (m, 1 H), 2.49 (s, 1 H), 2.56 (s, IH), 2.58 (s, 2 H), 5.43 (s, 1 H).
Step 3: Enantiomer A of 6-(2-cyclopentyl-2-hydroxybut-3-ynyl)-2,2-dimethyl-4H-1,3-dioxin- 4-one.
Figure imgf000492_0001
Enantiomer A ee 95.5%
To the optically pure oxalate (2.5 g, 15.1 mmol) in 50 ml of MeOH was added K2C03 (2.0 g). The mixture was stirred at 23 °C for 8h. After complete conversion, the mixture was neutralized with 1 N HCl at cold temperature. The aqueous solution was extracted with MTBE (x3) and the organic layer was washed with brine and dry over MgS04. After removal of MTBE, 1.75 g of the desired product (enantiomer A) was produced with 95.5% ee and 96% yield. Η NMR (300 MHz, CDC13) δ: 1.45-1.80 (m, 8 H), 1,72 (s, 3 H), 1.74 (s, 3 H), 2.13-2.18 (m, 1 H), 2.49 (s, 1 H), 2.56 (s, IH), 2.58 (s, 2 H), 5.43 (s, 1 H).
Example J(1): 6-cyclopentyl-6-[2-(3~fluoro-4-isopropoxyphenyl)ethyl]dihydro-2H-pyran- 2,4(3H)-dione (Enantiomer A)
Figure imgf000492_0002
The title compound was prepared analogously to Example A(64), , where Enantiomer A (described above) of 6-(2-cyclopentyl-2-hydroxybut-3-ynyl)-2,2-dimethyl-4H-1 ,3-dioxin-4-one was substituted in place of the racemic material.
Η NMR (300 MHz, CDC13) δ: 71.34 (d, 7=6.03 Hz, 6 H), 1.61-1.77 (m, 8 H), 1.89-1.97 (m, 2 H), 2.24- 2.29 (m, 1 H), 2.61 (t, 7=8.38 Hz, 2 H), 2.76 (s, 2 H), 3.43 (s, 2 H), 4.44-4.52 (m, 1 H), 6.79-6.92 (m, 3 H). HRMS calcd for C2ιH2804F (M+H1): 363.1966. Found: 363.1980. Example J(2): 6-cyclopentyl-6-[2-(3-fluoro-4-isopropoxyphenyl)ethyl]dihydro-2W-pyran- 2,4(3H)-dione (Enantiomer B)
Figure imgf000493_0001
The title compound was prepared analogously to Example A(64), where Enantiomer B (described above) of 6-(2-cyclopentyl-2-hydroxybut-3-ynyl)-2,2-dimethyl-4H-1,3-dioxin-4-one was substituted in place of the racemic material.
'H MR (300 MHz, CDC13) δ: 1.34 (d, 7=6.03 Hz, 6 H), 1.61-1.77 (m, 8 H), 1.89-1.97 (m, 2 H), 2.24-2.29 (m, 1 H), 2.61 (t, 7=8.38 Hz, 2 H), 2.76 (s, 2 H), 3.43 (s, 2 H), 4.44-4.52 (m, 1 H), 6.79-6.92 (m, 3 H). ESIMS calcd for C21H2704F: 362.2. Found (M+Na4): 385.1.
Example J(3): 6-cyclopentyl-3-[(5,7-dimethyl[1 ,2,4]triazolo[1 ,5-a]pyrimidin-2-yl)methyl]-6- [2-(3-fluoro-4-isopropoxyphenyl)ethyl]-4-hydroxy-5,6-dihydro-2tø-pyran-2-one (Enantiomer A)
Figure imgf000493_0002
The title compound was prepared analogously to Example B(31), where Enantiomer A of 6-cyclopentyl-6-[2-(3-fluoro-4-isopropoxyphenyl)ethyl]dihydro-2H-pyran-2,4(3H)-dione was substituted in place of 6-[2-(3-chloro-4-isopropoxyphenyl)ethyl]-6-cyclopentyldihydro-2/-/-pyran- 2,4(3H)-dione.
'HNMR (300 MHz, CDC13) δ: ?1.32 (d, 7=6.03 Hz, 6 H), 1.50-1.80 (m, 8 H), 1.95-2.01 ( , 2 H), 2.33- 2.41 (m, 1 H), 2.56-2.62 (m, 3 H), 2.66 (s, 3 H), 2.71-2.73 (m, 1 H), 2.79 (s, 3 H), 4.09 (s, 2 H), 4.41-4.50 (m, 1 H), 6.78-6.88 (m, 4 H). HRMS calcd for C29H36N404F ( +rf : 523.2715. Found: 523.2708. Example J(4): 6-cyclopentyl-3-[(5,7-dimethyl[1 ,2,4]triazolo[1 ,5-a]pyrimidin-2-yl)methyl]-6- [2-(3-fluoro-4-isopropoxyphenyl)ethyl]-4-hydroxy-5,6-dihydro-2H-pyran-2-one (Enantiomer B)
Figure imgf000494_0001
The title compound was prepared analogously to Example B(31), where Enantiomer B of 6-cyclopentyl-6-[2-(3-fluoro-4-isopropoxyphenyl)ethyl]dihydro-2/-/-pyran-2,4(3H)-dione was substituted in place of 6-[2-(3-chloro-4-isopropoxyphenyl)ethyl]-6-cyclopentyldihydro-2H-pyran- 2,4(3H)-dione.
'H NMR (300 MHz, CDC13) δ:?1.32 (d, 7=6.03 Hz, 6 H), 1.50-1.80 (m, 8 H), 1.95-2.01 (m, 2 H), 2.33-2.41 (m, 1 H), 2.56-2.62 (m, 3 H), 2.66 (s, 3 H), 2.71-2.73 (m, 1 H), 2.79 (s, 3 H), 4.09 (s, 2 H), 4.41-4.50 (m, 1 H), 6.78-6.88 (m, 4 H). HRMS calcd for C29H36N404F (M+H1"): 523.2715. Found: 523.2699.
Example J(5): 6-Cyclopentyl-6-[2-(3-ethyl-phenyl)-ethyl]-dihydro-pyran-2,4-dione (Enantiomer A)
Figure imgf000494_0002
The title compound was prepared analogously to Example A(64), where 1-Bromo-3-ethyl- benzene was substituted in place of 4-bromo-2-fluoro-1 -isopropylbenzene in that example, and Enantiomer A of 6-(2-cyclopentyl-2-hydroxybut-3-ynyl)-2,2-dimethyl-4H-1 ,3-dioxin-4-one was used in place of the racemic alkyne. Η NMR (CDCI3): δ 1.23 (t, 3H, 7= 7.6 Hz), 1.50-1.83 (br m, 8H), 1.91 - 2.05 (m, 2H), 2.29 (m, IH), 2.59 - 2.68 (m, 4H) 2.27, (s, 2H), 3.42 (s, 2H), 6.96 (m, 2H), 7.06 (d, IH, 7= 7.01 Hz), 7.21 (t, IH, 7= 8.0 Hz). ESIMS: MH+ 315.20, MH" 313.20.
Example J(6): 6-Cyclopentyl-6-[2-(3-ethyl-phenyl)-ethyl]-dihydro-pyran-2,4-dione (Enantiomer B)
Figure imgf000495_0001
The title compound was prepared analogously to Example A(64), where 1-Bromo-3-ethyl- benzene was substituted in place of 4-bromo-2-fluoro-1 -isopropylbenzene of that example and
Enantiomer B of 6-(2-cyclopentyl-2-hydroxybut-3-ynyl)-2,2-dimethyl-4/-/-1 ,3-dioxin-4-one was used in place of the racemic alkyne.
Η NMR (CDC13): δ 1.23 (t, 3H, 7= 7.6 Hz), 1.50-1.83 (br m, 8H), 1.91 -2.05 (m, 2H), 2.29 (m, IH),
2.59 - 2.68 (m, 4H) 2.27, (s, 2H), 3.42 (s, 2H), 6.96 (m, 2H), 7.06 (d, IH, 7= 7.01 Hz), 7.21 (t, IH, 7= 8.0 Hz). ESIMS: MH^IS^O, MH" 313.20..
Example J(7): 6-Cyclopentyl-3-(5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-ylmethyl)-6- [2-(3-ethyl-phenyl)-ethyl]-4-hydroxy-5,6-dihydro-pyran-2-one (Enantiomer A)
Figure imgf000495_0002
The title compound was prepared by coupling 6-Cyclopentyl-6-[2-(3-ethyl-phenyl)-ethyl]- dihydro-pyran-2,4-dione (Enantiomer A) (Example J(6) ) to 5,7-Dimethyl-[1,2,4]triazolo[1,5- ?]pyrimidine-2-carbaldehyde using the Me2NHBH3 method described in the synthesis of Example B(31), . 1H NMR (DMSO-de): δ 1.18 (t, 3H, 7 = 7.6 Hz), 1.46-1.76 (br m, 8H), 2.18 (m, 2H), 2.48 - 2.67 (m, 12H), 2.85 (d, 1H, 7 = 17.4 Hz), 3.78 (d, 1H, 7 = 16.3 Hz), 3.91 (d, 1H, 7 = 16.3 Hz), 7.08 (m, 4H), 7.22 (t, 1H, 7 = 7.6 Hz), 10.91 (s, 1H). C28H34N4θ3 (M + H)+ 475.20.
Example J(8): 6-Cyclopentyl-3-(5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-ylmethyl)-6- [2-(3-ethyl-phenyl)-ethyl]-4-hydroxy-5,6-dihydro-pyran-2-one (Enantiomer B)
Figure imgf000496_0001
1H NMR (DMSO-d6): δ 1.18 (t, 3H, 7 = 7.6 Hz), 1.46-1.76 (br m, 8H), 2.18 (m, 2H), 2.48 - 2.67 (m, 12H), 2.85 (d, 1H, 7 = 17.4 Hz), 3.78 (d, 1H, 7 = 16.3 Hz), 3.91 (d, 1H, 7 = 16.3 Hz), 7.08 (m, 4H), 7.22 (t, 1H, 7 = 7.6 Hz), 10.91 (s, 1H). C28H34N403 (M + H)+ 475.20.
The title compound was prepared by coupling 6-Cyclopentyl-6-[2-(3-ethyl-phenyl)-ethyl]- dihydro-pyran-2,4-dione (Enantiomer B) (Example J(7) ) to 5,7-Dimethyl-[1 ,2,4]triazolo[1 ,5- ?]pyrimidine-2-carbaldehyde using the Me2NHBH3 method described in the synthesis of Example B(31), .
The compounds of the present invention are potent inhibitors of Hepatitis C virus, in particular HCV replication, and even in more particular, HCV RNA-dependent RNA-polymerase. The compounds are all adapted to therapeutic use as anti-HCV agents in mammals, particularly in humans. The active compound may be applied as a sole therapy or may involve one or more other antiviral substances, for example those selected from, for example, HCV inhibitors such as interferon alphacon-1, natural interferon, interferon beta-1a, interferon omega, interferon gamma- lb, interleukin-10, BILN 2061 (serine protease), amantadine (Symmetrel), thymozine alpha-1, viramidine; HIV inhibitors such as nelfinavir, delavirdine, indinavir, nevirapine, ritonavir, saquinavir, and tenofovir. Such conjoint treatment may be achieved by way of the simultaneous, sequential or separate dosing of the individual components of the treatment. The in vitro activity of the compounds of formula 1 may be determined by the following procedure.
The compounds described herein were tested for activity with HCV polymerase. Recombinant HCV polymerase was tested for its ability to perform primer/template-directed transcription in assays that contained 30 mM tris-HCI pH 7.2, 10 mM MgCI2, 20 mM NaCl, 1mM Dithiothreitol (DTT), 0.05% Tween-20, 1% glycerol, 5 pmoles biotin-dG12 (primer), 0.5 pmoles poly(rC)300 (template), 1 μM GTP, 0.1-0.3 uCi α-32P-GTP, and 2.5 pmoles (0.15 μg) HCV polymerase protein in a final volume of 75 μL. Reactions were initiated by addition of enzyme and incubated 30 minutes at 30°C. Reactions were stopped by addition of 33 mM EDTA, and polynucleotide products were collected by filtration through Diethylaminoethyl (DE) Filtermat papers (Wallac). Unincorporated triphosphate was removed by washing the filters with 5% dibasic sodium phosphate. The filters were counted in a Packard Tri-Lux Microbeta scintillation counter (Packard Bioscience, Meriden, CT). Compounds to be tested were added at various concentrations, e.g., 1μm to 50 μm, from stocks in 10% DMSO-water (final DMSO is 1% in reaction).
IC50 values were estimated from the primary cpm data (collected in triplicate) using the formula: cpm (l)= cpm (no inhibitor)(1- ([l]/([l] + IC50))). An IC50 value represents the concentration (in μM) of a compound that provides 50% inhibition of polymerase-directed transcription in the above assay. A percent inhibition value is expressed for a compound where it was impractical to calculate an IC50 value with available data. If the IC50 estimated by the above equation was less than 200 nM, it was recalculated using the following equation, which takes into account the enzyme concentration (30 nM) in the assay: cpm(l) = cpm(no inhibitor)(1-((((l+IC50+30e-9)- sqrt(((l+IC50+30e-9)2)-4 x 30e-9 x l)))/((2) (30e-9))). Curve fitting was performed using the program KaleidaGraph (Synergy Software, Reading, Pennsylvania). Inhibition concentration (!C50) data as determined for exemplary compounds of the invention are presented in Table 1 below.
TABLE 1
Figure imgf000497_0001
Figure imgf000498_0001
Figure imgf000499_0001
Figure imgf000500_0001
Figure imgf000501_0001
Figure imgf000502_0001
Figure imgf000503_0001
Figure imgf000504_0001
Figure imgf000505_0001
Figure imgf000506_0001
Figure imgf000507_0001
Figure imgf000508_0001
Figure imgf000509_0001
Figure imgf000510_0001
Figure imgf000511_0001
Figure imgf000512_0001
Figure imgf000513_0001
Figure imgf000514_0001
Example J(8 0.014
The examples and preparations provided above further illustrate and exemplify the compounds of the present invention and methods of preparing such compounds. It is to be understood that the scope of the present invention is not limited in any way by the scope of the following examples and preparations.

Claims

We claim:
A compound of formula (1)
Figure imgf000516_0001
or a pharmaceutically acceptable salt, solvate or prodrug thereof, wherein:
W-Z is -C(=0)-C(-R3)(H)- or-C(-OR6)=C(-R3')-; each R1 is independently selected from hydrogen, C C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, (C3-C10) cycloalkyl, 4- to 10-membered heterocyclic, and C6-C10 aryl, wherein the foregoing R1 groups, except H, are optionally substituted by 1 to 4 substituents selected from R4;
R2 is selected from the group of R1 substituents, -(CR8R9)t(C6-C10 aryl), -(CR8R9)t(4-10 membered heterocyclic), -(CR8R9)qC(O)(CR8R9)t(C6-C10 aryl), -(CR8R9)qC(O)(CR8R9)t(4-10 membered heterocyclic), -(CR8R9)tO(CR8R9)q(C6-C10 aryl), -(CR8R9)tO(CR8R9)q(4-10 membered heterocyclic), -(CR8R9)qSOn(CR8R9)t(C6-C10 aryl), and -(CR8R9)qSOn(CR8R9)t(4-10 membered heterocyclic), wherein q and t are each independently an integer from 0 to 5, n is an integer from 0 to 2, the alkyl, aryl and heterocyclic moieties of said R2 groups are optionally substituted by 1 to 5 R4 groups, and with the proviso that R2 is not H;
R3 is hydrogen, -OR6, -SR6, -NR6R7, and the group of R2 substituents;
R3' is selected from the group of R3 substituents except R3' is not H; each R4 is independently selected from halo, cyano, nitro, trifluoromethoxy, trifluoromethyl, azido, C C10 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, -C(0)R6, -C(0)OR6, -OC(0)R6, -NR6C(0)R7, -NR6C(0)NR7, -C(0)NR6R7, -NR6R7, -NR6OR7, -S02NR6R7, -NR6S02R7, -(CR8R9)t(C6-C10 aryl)(wherein t is an integer from 0 to 5), -(CR8R9)t(4-10 membered heterocyclic)(wherein t is an integer from 0 to 5), C3-C10 cycloalkyl, R6-0-, R6-SOn- (wherein n is an integer from 0 to 2), and oxo (=0), and wherein the alkyl, aryl, and heterocyclic moieties of said R4 groups are optionally substituted by 1 to 4 substituents selected from R5; each R5 is independently selected from halo, trifluoromethyl, trifluoromethoxy, cyano, C C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, -OR8, C3-C10 cycloalkyl, C6-C10 aryl, 4- to 10-membered heterocyclic, oxo (=0), -C(0)R6, -C(0)OR6, -OC(0)R6, -NR6C(0)R6, -NR6C(0)NR7, -C(0)NR6R7, -NR6R7, -NR6OR7, -NR6S02R7 and -S02NR6R7, wherein the alkyl, aryl and heterocyclic moieties of the foregoing R5 groups are optionally substituted by 1 to 3 R10; each R6 and R7 is independently selected from H, C C6 alkyl, C3-C10 cycloalkyl, -(CR8R9)t(C6-C10 aryl), and -(CR8R9)t(4-10 membered heterocyclic), wherein t is an integer from 0 to 5, 1 or 2 ring carbon atoms of the heterocyclic group are optionally substituted with an oxo (=0) moiety, and the alkyl, aryl and heterocyclic moieties of the foregoing R6 and R7 groups are optionally substituted with 1 to 3 halo, cyano, trifluoromethyl, trifluoromethoxy, C C6 alkyl, C C6 alkoxy, C2-C6 alkenyl, C2-C6 alkynyl, -(CR8R9)t(C6-C 0 aryl), and -(CR8R9)t(4-10 membered heterocyclic), wherein t is an integer from 0 to 5; each R8 and R9 is independently selected from H and C C4 alkyl; and each R10 is independently selected from halo, cyano, trifluoromethyl, trifluoromethoxy, -C(0)0-R6, -OR6, -C(0)(CR8R9)pC(0)0R6, wherein p is an integer from 1 to 5, C C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, and -NR6R7.
2. A compound of formula (2)
Figure imgf000517_0001
or a pharmaceutically acceptable salt, prodrug or solvate thereof, wherein:
W-Z is -C(-OR6)=C(-R3')-;
R1 is cyclopentyl;
R2 is -(CR8R9)t(C6-C10 aryl) or -(CR8R9)t(4-10 membered heterocyclic), wherein t is an integer from 0 to 5, and the aryl and heterocyclic moieties of said R2 groups are optionally substituted by 1 to 5 R4 groups, and with the proviso that R2 is not H;
Rd is hydrogen, -ORb, -SR , -NR°R\ and the group of R^ substituents; each R4 is independently selected from halo, cyano, nitro, trifluoromethoxy, trifluoromethyl, azido, CrC10 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, -C(0)R6, -C(0)OR6, -OC(0)R6, -NR6C(0)R7, -NR6C(0)NR7, -C(0)NR6R7, -NR6R7, -NR6OR7, -S02NR6R7, -NR8S02R7, -(CR8R9)t(C6-C10 aryl)(wherein t is an integer from 0 to 5), -(CR8R9)t(4-10 membered heterocyclic)(wherein t is an integer from 0 to 5), C3-C10 cycloalkyl, R6-0-, R6-SOn- (wherein n is an integer from 0 to 2), and oxo (=0), and wherein the alkyl, aryl, and heterocyclic moieties of said R4 groups are optionally substituted by 1 to 4 substituents selected from R5; each R5 is independently selected from halo, trifluoromethyl, trifluoromethoxy, cyano, C C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, -OR8, C3-Cι0 cycloalkyl, C6-C10 aryl, 4- to 10-membered heterocyclic, oxo (=0), -C(0)R6, -C(0)OR6, -OC(0)R6, -NR6C(0)R6, -NR6C(0)NR7, -C(0)NR6R7, -NR6R7, -NR60R7, -NR6S02R7and -S02NR6R7, wherein the alkyl, aryl and heterocyclic moieties of the foregoing Rs groups are optionally substituted by 1 to 3 R10; each R6 and R7 is independently selected from H, Cι-C6 alkyl, C3-Cι0 cycloalkyl, - (CR8R9)t(C6-C10 aryl), and -(CR8R9)t(4-10 membered heterocyclic), wherein t is an integer from 0 to 5, 1 or 2 ring carbon atoms of the heterocyclic group are optionally substituted with an oxo (=0) moiety, and the alkyl, aryl and heterocyclic moieties of the foregoing R6 and R7 groups are optionally substituted with 1 to 3 halo, cyano, trifluoromethyl, trifluoromethoxy, C C6 alkyl, C C6 alkoxy, C2-C6 alkenyl, C2-C6 alkynyl, (CR8R9),(C6-C10 aryl), and -(CR8R9)t(4-10 membered heterocyclic), wherein t is an integer from 0 to 5; each R8 and R9 is independently selected from H and Cι-C alkyl; and each R10 is independently selected from halo, cyano, trifluoromethyl, trifluoromethoxy, - C(0)0-R6, -OR6, -C(0)(CR8R9)pC(0)OR6, wherein p is an integer from 1 to 5, d-Cβ alkyl, C2-C6 alkenyl, C2-C6 alkynyl, and NR6R7.
A compound of formula (3)
Figure imgf000518_0001
or a pharmaceutically acceptable salt, prodrug or solvate thereof, wherein:
W-Z is -C(=0)-C(-R 3J\)(H)-; R1 is cyclopentyl;
R2 is -(CR8R9)t(C6-Cιo aryl) or -(CR8R9)t(4-10 membered heterocyclic), wherein t is an integer from 0 to 5, and the aryl and heterocyclic moieties of said R2 groups are optionally substituted by 1 to 5 R4 groups, and with the proviso that R2 is not H; R3 is hydrogen; each R4 is independently selected from halo, cyano, nitro, trifluoromethoxy, trifluoromethyl, azido, C C10 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, -C(0)R6, -C(0)OR6, -OC(0)R6, -NR6C(0)R7, -NR6C(0)NR7, -C(0)NR6R7, -NR6R7, -NR6OR7, -S02NR6R7, -NR6S02R7, -(CR8R9)t(C6-C10 aryl)(wherein t is an integer from 0 to 5), -(CR8R9)t(4-10 membered heterocyclic)(wherein t is an integer from 0 to 5), C3-C10 cycloalkyl, R6-0-, R6-SOn- (wherein n is an integer from 0 to 2), and oxo (=0), and wherein the alkyl, aryl, and heterocyclic moieties of said R4 groups are optionally substituted by 1 to 4 substituents selected from R5; each R5 is independently selected from halo, trifluoromethyl, trifluoromethoxy, cyano, C C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, -OR8, C3-C10 cycloalkyl, C6-C10 aryl, 4- to 10-membered heterocyclic, oxo (=0), -C(0)R6, -C(0)OR6, -OC(0)R6, -NR6C(0)R6, -NR6C(0)NR7, -C(0)NR6R7, -NR6R7, -NR6OR7, -NR6S02R7 and -S02NR6R7, wherein the alkyl, aryl and heterocyclic moieties of the foregoing R5 groups are optionally substituted by 1 to 3 R10; each R6 and R7 is independently selected from H, C C6 alkyl, C3-C10 cycloalkyl, -(CR8R9)t(C6-C10 aryl), and -(CR8R9)t(4-10 membered heterocyclic), wherein t is an integer from 0 to 5, 1 or 2 ring carbon atoms of the heterocyclic group are optionally substituted with an oxo (=0) moiety, and the alkyl, aryl and heterocyclic moieties of the foregoing R6 and R7 groups are optionally substituted with 1 to 3 halo, cyano, trifluoromethyl, trifluoromethoxy, C C6 alkyl, C C6 alkoxy, C2-C6 alkenyl, C2-C6 alkynyl, (CR8R9)t(C6-C10 aryl), and -(CR8R9)t(4-10 membered heterocyclic), wherein t is an integer from 0 to 5; each R8 and R9 is independently selected from H and C C4 alkyl; and each R10 is independently selected from halo, cyano, trifluoromethyl, trifluoromethoxy, - C(0)0-R6, -OR6, -C(0)(CR8R9)pC(0)OR6, wherein p is an integer from 1 to 5, C C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, and NR6R7.
4, A compound chosen from:
6-Cyclopentyl-3-(5,7-dimethyl-[1 ,2,4]triazolo[1 ,5-a-pyrimidin-2-ylmethyl)-6-[2-(3-fluoro-4-methoxy- phenyl)-ethyl]-4-hydroxy-5,6-dihydro-pyran-2-one;
6-[2-(3-tert-Butyl-phenyl)-ethyl]-6-cyclopentyl-3-(5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2- ylmethyl)-4-hydroxy-5,6-dihydro-pyran-2-one; 6-Cyclopentyl-3-(5,7-dimethyl-[1l2,4]triazolo[1,5-a]pyrimidin-2-ylmethyl)-6-[2-(3-ethyl-4-hydroxy- phenyl)-ethyl]-4-hydroxy-5,6-dihydro-pyran-2-one;
6-[2-(3-tert-Butyl-4-hydroxy-phenyl)-ethyl]-6-cyclopentyl-3-(5,7-dimethyl-[1 ,2,4]triazolo[1 ,5- a]pyrimidin-2-ylmethyl)-4-hydroxy-5,6-dihydro-pyran-2-one; 6-[2-(3-Chloro-4-isopropoxy-phenyl)-ethyl]-6-cyclopentyl-3-(5,7-dimethyl-[1 ,2,4]triazolo[1,5- a]pyrimidin-2-ylmethyl)-4-hydroxy-5,6-dihydro-pyran-2-one;
6-Cyclopentyl-6-[2-(3,5-dichloro-4-ethoxy-phenyl)-ethyl]-3-(5,7-dimethyl-[1,2,4]triazolo[1,5- a]pyrimidin-2-ylmethyl)-4-hydroxy-5,6-dihydro-pyran-2-one; 6-cyclopentyl-3-[(5,7-dimethyl [1 ,2,4]triazolo[1 ,5-a]pyrimidin-2-yl)methyl]-6-[2-(3- isopropylphenyl)ethyl]dihydro-2H-pyran-2,4(3/-/)-dione;
7-({6-[2-(5-Chloro-2,4-dimethoxyphenyl)ethyl]-6-cyclopentyl-4-hydroxy-2-oxo-5,6-dihydro-2H- pyran-3-yl}methyl)-3-methyl-5/-/-[1,3]thiazolo[3,2-a]pyrimidin-5-one;
2-(4-{2-[2-Cyclopentyl-5-(5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-ylmethyl)-4-hydroxy-6-oxo- 3,6-dihydro-2H-pyran-2-yl]-ethyl}-2-fluoro-phenyl)-2-methyl-propionitrile;
1-(4-{2-[2-Cyclopentyl-5-(5,7-dimethyl-[1,2,4]triazoIo[1,5-a]pyrimidin-2-ylmethyl)-4-hydroxy-6-oxo-
3,6-dihydro-2H-pyran-2-yl]-ethyl}-2-fluoro-phenyl)-cyclopropanecarbonitrile;
6-[2-(5-chloro-2,4-dimethoxyphenyl)ethyl]-6-cyclopentyl-4-hydroxy-3-(imidazo[1,2-a]pyrimidin-2- ylmethyl)-5,6-dihydro-2/-/-pyran-2-one; 6 Λ/-[4-(2-{2-cyclopentyl-5-[(5,7-dimethyl[1 ,2,4]triazolo[1 ,5-a]pyrimidin-2-yl)methyl]-4,6- dioxotetrahydro-2/-/-pyran-2-yl}ethyl)-2-ethylphenyl]-Λ/-methylmethanesulfonamide;
2-[4-(2-{2-cyclopentyl-4-hydroxy-5-[(1-methyl-1H-indol-5-yl)methyl]-6-oxo-3,6-dihydro-2H-pyran-
2-yl}ethyl)-2-fluorophenyl]-2-methylpropanenitrile;
6-[2-(3-Chloro-4-hydroxy-phenyl)-ethyl]-6-cyclopentyl-3-(5,7-dimethyl-[1,2,4]triazolo[1,5- a]pyrimidin-2-ylmethyl)-4-hydroxy-5,6-dihydro-pyran-2-one;
6-Cyclopentyl-3-(5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-ylmethyl)-6-t2-(3-ethyl-4-methoxy- phenyl)-ethyl]-4-hydroxy-5,6-dihydro-pyran-2-one;
3-(5-Chloro-1-isopropyl-1-benzoimidazol-2-ylsulfanyl)-6-cyclopentyl-6-t2-(3-fluoro-4-isopropoxy- phenyl)-ethyl]-4-hydroxy-5,6-dihydro-pyran-2-one; 5-{6-Cyclopentyl-6-[2-(3-fluoro-4-isopropoxy-phenyl)-ethyl]-4-hydroxy-2-oxo-5,6-dihydro-2H- pyran-3-ylsulfanyl}-4-methyl-4H-[1 ,2,4]triazole-3-carboxylic acid methyl ester;
3-(5-Chloro-1-methyl-1H-benzoimidazol-2-ylsulfanyl)-6-cyclopentyl-6-{2-[4-(3,5-dimethyl-isoxazol-
4-yl)-phenyl]-ethyl}-4-hydroxy-5,6-dihydro-pyran-2-one;
6-[2-(3-chloro-4-methoxyphenyl)ethyl]-6-cyclopentyl-3-{[5-(2-furyl)-4-methyl-4H-1,2,4-triazol-3- yl]thio}-4-hydroxy-5,6-dihydro-2H-pyran-2-one;
6-[2-(3-chloro-4-methoxyphenyl)ethyl]-6-cyclopentyl-4-hydroxy-3-[(5-pyridin-4-yl-4H-1,2,4-triazol-
3-yl)thio]-5,6-dihydro-2H-pyran-2-one; 6-[2-(3-chloro-4-methoxyphenyl)ethyl]-3-[(5-chloro-1-methyl-1 -/-benzimidazol-2-yl)thio]-6- cyclopentyl-4-hydroxy-5,6-dihydro-2H-pyran-2-one;
6-[2-(5-chloro-2,4-dimethoxyphenyl)ethyl]-3-[(5-chloro-1-methyl-1H-benzimidazol-2-yl)thio]-6- cyclopentyl-4-hydroxy-5,6-dihydro-2H-pyran-2-one; 6-[2-(3-chloro-4-isopropoxyphenyl)ethyl]-3-[(5-chloro-1 -methyl-1 /-/-benzimidazol-2-yl)thio]-6- cyclopentyl-4-hydroxy-5,6-dihydro-2/-/-pyran-2-one;
8-({6-[2-(5-chloro-2,4-dimethoxyphenyl)ethyl]-6-cyclopentyl-4-hydroxy-2-oxo-5,6-dihydro-2H- pyran-3-yl}thio)-1,7-dihydro-6H-purin-6-one;
6-[2-(5-chlor-2,4-dimethoxyphenyl)ethyl]-6-cyclopentyl-4-hydroxy-3-{[5-(4-hydroxyphenyl)-4H- 1 ,2,4-triazol-3-yl]thio}-5,6-dihydro-2/-/-pyran-2-one; ethyl 2-({6-[2-(5-chloro-2,4-dimethoxyphenyl)ethyl]-6-cyclopentyl-4-hydroxy-2-oxo-5,6-dihydro-
2H-pyran-3-yl}thio)[1 ,2,4]triazolo[1,5-a]pyrimidine-6-carboxylate;
6-cyclopentyl-3-[(5,7-dimethyl[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-6-[2-(3-fluoro-4- isopropoxyphenyl)ethyl]-4-hydroxy-5,6-dihydro-2/-/-pyran-2-one; 6-Cyclopentyl-3-(5,7-dimethyl-[1 ,2,4]triazolo[1,5-a]pyrimidin-2-ylmethyl)-6-[2-(3-ethyl-phenyl)- ethyl]-4-hydroxy-5,6-dihydro-pyran-2-one;
6-Cyclopentyl-3-(5,7-dimethyl-t1,2,4]triazolo[1,5-a]pyrimidin-2-ylmethyl)-6-[2-(3-ethyl-phenyl)- ethyl]-4-hydroxy-5,6-dihydro-pyran-2-one;
2-[4-(2-{5-[(4-chloro-1 -methyl-1 /-/-pyrazol-3-yl)methyl]-2-cyclopentyl-4-hydroxy-6-oxo-3,6-dihydro- 2/-/-pyran-2-yl}ethyl)-2-fluorophenyl]-2-methylpropanenitrile;2-{4-[2-(2-Cyclopentyl-4,6-dioxo-5-
[1,2,4]triazolo[1,5-a]pyrimidin-2-ylmethyl-tetrahydro-pyran-2-yl)-ethyl]-2-fluoro-phenyl}-2-methyl- propionitrile;2-(4-{2-[2-Cyclopentyl-5-(6-methyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-ylmethyl)-4,6- dioxo-tetrahydro-pyran-2-yl]-ethyl}-2-fluoro-phenyl)-2-methyl-propionitrile;(+)-2-(4-{2-[2-
Cyclopentyl-5-(6-methyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-ylmethyl)-4,6-dioxo-tetrahydro-pyran-2- yl]-ethyl}-2-fluoro-phenyl)-2-methyl-propionitrile;(-)-2-(4-{2-[2-Cyclopentyl-5-(6-methyl-
[1,2,4]triazolo[1,5-a]pyrimidin-2-ylmethyl)-4,6-dioxo-tetrahydro-pyran-2-yl]-ethyl}-2-fluoro-phenyl)-
2-methyl-propionitrile;2-(4-{2-[5-(6-Chloro-t1,2,4]triazolo[1,5-a]pyrimidin-2-ylmethyl)-2-cyclopentyl-
4,6-dioxo-tetrahydro-pyran-2-yl]-ethyl}-2-fluoro-phenyi)-2-methyl-propionitrile;2-(4-{2-[2-
Cyclopentyl-5-(5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-ylmethyl)-4,6-dioxo-tetrahydro-pyran- 2-yl]-ethyl}-2-fluoro-phenyl)-2-ethyl-butyronitrile;1-(4-{2-[2-Cyclopentyl-5-(6-methyl-
[1,2,4]triazolo[1,5-a]pyrimidin-2-ylmethyl)-4,6-dioxo-tetrahydro-pyran-2-yi]-ethyl}-2-fluoro-phenyl)- cyclopropanecarbonitrile;1-(4-{2-[5-(6-Chloro-[1,2,4]triazolo[1,5-a]pyrimidin-2-ylmethyI)-2- cyclopentyl-4,6-dioxo-tetrahydro-pyran-2-yl]-ethyl}-2-fIuoro-phenyl)-cyclopropanecarbonitrile;6- Cyclopentyl-6-[2-(3-ethyl-4-hydroxy-phenyl)-ethyl]-4-hydroxy-3-(6-methyl-[1,2,4]triazolo[1,5- a]pyrimidin-2-ylmethyl)-5,6-dihydro-pyran-2-one;3-(6-Chloro-[1,2,4]triazolo[1,5-a]pyrimidin-2- ylmethyl)-6-cyclopentyl-6-[2-(3-ethyl-4-hydroxy-phenyl)-ethyl]-4-hydroxy-5,6-dihydro-pyran-2- one;6-cyclopentyl-3-[(5,7-diethyl[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-4-hydroxy-6-[2-(4- hydroxy-3-propylphenyl)ethyl]-5,6-dihydro-2/-/-pyran-2-one;6-cyclopentyl-3-[(5,7- diethyl[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-6-[2-(3-ethyl-4-hydroxyphenyl)ethyl]-4-hydroxy- 5,6-dihydro-2/-/-pyran-2-one;
Λ/-{2-[4-(2-{2-cyclopentyl-5-[(5,7-dimethyl[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-4-hydroxy-6- oxo-3,6-dihydro-2/-/-pyran-2-yl}ethyl)-2-ethylphenoxy]ethyl}acetamide; 2-(4-{2-[2-Cyclopentyi-5- 5,7-dimethyl- [1 ,2,4] triazolo[1 ,5-a]pyrimidin-2-ylmethyl]-4-hydroxy-6-oxo-3,6-dihydro-2H-pyran-2- yl}-ethyl)-2,6-difluoro-phenyl)-2-methyl-propionitrile;
2-(4-{2-[2-Cyclopentyl-4-hydroxy-5-(6-methyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-ylmethyl)-6-oxo-3,6- dihydro-2H-pyran-2-yl]-ethyl}-2,6-difluoro-phenyl)-2-methyl-propionitrile;2-(2-Chloro-4-{2-[2- cyclopentyl-5-(5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-ylmethyl)-4-hydroxy-6-oxo-3,6- dihydro-2H-pyran-2-yl]-ethyl}-phenyl)-2-methyl-propionitrile;
1-(2-Chloro-4-{2-[2-cyclopentyl-5-(5,7-dimethyl-[1 ,2,4]triazolo[1 ,5-a]pyrimidin-2-ylmethyl)-4- hydroxy-6-oxo-3,6-dihydro-2H-pyran-2-yl]-ethyl}-phenyl)-cyclopropanecarbonitrile;
6-Cyclopentyl-3-(5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-ylmethyl)-6-[2-(5-ethyl-4-hydroxy-2- methoxy-phenyl)-ethyl]-4-hydroxy-5,6-dihydro-pyran-2-one; (+)-2-(2-chloro-4-{2-[2-cyclopentyl-5-(5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-ylmethyl)-4- hydroxy-6-oxo-3,6-dihydro-2/-/-pyran-2-yl]-ethyl}-phenyl)-2-methyl-propionitrile;
(-)-2-(2-chloro-4-{2-[2-cyclopentyl-5-(5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-ylmethyl)-4- hydroxy-6-oxo-3,6-dihydro-2H-pyran-2-yl]-ethyl}-phenyl)-2-methyl-propionitrile;
(+)-2-(2-fluoro-4-{2-[2-cyclopentyl-5-(5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-ylmethyl)-4- hydroxy-6-oxo-3,6-dihydro-2H-pyran-2-yl]-ethyl}-phenyl)-2-methyl-propionitrile;
(-)-2-(2-fiuoro-4-{2-[2-cyclopentyl-5-(5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-ylmethyl)-4- hydroxy-6-oxo-3,6-dihydro-2/-/-pyran-2-yl]-ethyl}-phenyl)-2-methyl-propionitrile;
(+)-3-[(6-chloro[1,2,4]triazolo[1 ,5-a]pyrimidin-2-yl)methyl]-6-cyclopentyl-6-[2-(5-ethyl-4-hydroxy-2- methoxyphenyl)ethyl]-4-hydroxy-5,6-dihydro-2H-pyran-2-one; (-)-3-[(6-chloro[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-6-cyclopentyl-6-[2-(5-ethyl-4-hydroxy-2- methoxyphenyl)ethyl]-4-hydroxy-5,6-dihydro-2/-/-pyran-2-one
6-Cyclopentyl-3-(5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-ylmethyl)-6-[2-(5-ethyl-4-hydroxy-2- methoxy-phenyl)-ethyl]-4-hydroxy-5,6-dihydro-pyran-2-one; (-)-6-Cyclopentyl-3-(5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-ylmethyl)-6-[2-(5-ethyl-4- hydroxy-2-methoxy-phenyl)-ethyl]-4-hydroxy-5,6-dihydro-pyran-2-one;
6-[2-(3-Chloro-5-ethyl-4-methoxy-phenyl)-ethyl]-6-cyclopentyl-3-(5,7-dimethyl-[1,2,4]triazolo[1,5- a]pyrimidin-2-ylmethyl)-4-hydroxy-5,6-dihydro-pyran-2-one; 6-Cyclopentyl-3-(5,7-dimethyl-t1,2,4]triazolo[1,5-a]pyrimidin-2-ylmethyl)-6-[2-(5-ethyl-2-methoxy- phenyl)-ethyl]-4-hydroxy-5,6-dihydro-pyran-2-one;6-[2-(3-Ohloro-5-ethyl-4-hydroxy-phenyl)-ethyl]- 6-cyclopentyl-3-(5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-ylmethyl)-4-hydroxy-5,6-dihydro- pyran-2-one;6-Cyclopentyl-3-(5,7-dimethyl-[1,2,4]triazolo[1 ,5-a]pyrimidin-2-ylmethyl)-6-{2-[3-ethyl- 4-(2-hydroxy-ethoxy)-phenyl]-ethyl}-4-hydroxy-5,6-dihydro-pyran-2-one; 6-Cyclopentyl-6-[2-(3-cyclopropyl-4-methoxy-phenyl)-ethyl]-3-(5,7-dimethyl-[1,2,4]triazolo[1 ,5- a]pyrimidin-2-ylmethyl)-4-hydroxy-5,6-dihydro-pyran-2-one; and pharmaceutically acceptable salts, solvates and thereof.
5. A compound chosen from: 6-[2-(3-tert-Butyl-phenyl)-ethyl]-6-cyclopentyl-3-(5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2- ylmethyl)-4-hydroxy-5,6-dihydro-pyran-2-one;
6-Cyclopentyl-3-(5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-ylmethyl)-6-[2-(3-ethyl-4-hydroxy- phenyl)-ethyl]-4-hydroxy-5,6-dihydro-pyran-2-one;
6-[2-(3-Chloro-4-isopropoxy-phenyl)-ethyl]-6-cyclopentyl-3-(5,7-dimethyl-[1,2,4]triazolo[1,5- a]pyrimidin-2-ylmethyl)-4-hydroxy-5,6-dihydro-pyran-2-one;
6-Cyclopentyl-6-[2-(3,5-dichloro-4-ethoxy-phenyl)-ethyl]-3-(5,7-dimethyl-[1 ,2,4]triazolo[1 ,5- a]pyrimidin-2-ylmethyl)-4-hydroxy-5,6-dihydro-pyran-2-one;
7-({6-[2-(5-Chloro-2,4-dimethoxyphenyl)ethyl]-6-cyclopentyl-4-hydroxy-2-oxo-5,6-dihydro-2/7- pyran-3-yl}methyl)-3-methyl-5/7-[1,3]thiazolo[3,2-a]pyrimidin-5-one; 2-(4-{2-[2-Cyclopentyl-5-(5,7-dimethyI-[1,2,4]triazolot1,5-a]pyrimidin-2-ylmethyl)-4-hydroxy-6-oxo-
3,6-dihydro-2H-pyran-2-yl]-ethyl}-2-fluoro-phenyl)-2-methyl-propionitrile;
1-(4-{2-[2-Cyclopentyl-5-(5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-ylmethyl)-4-hydroxy-6-oxo-
3,6-dihydro-2H-pyran-2-yl]-ethyl}-2-fluoro-phenyl)-cycIopropanecarbonitrile;
6-[2-(5-chloro-2,4-dimethoxyphenyl)ethyl]-6-cyclopentyl-4-hydroxy-3-(imidazo[1 ,2-a]pyrimidin-2- ylmethyl)-5,6-dihydro-2/-/-pyran-2-one;
2-[4-(2-{2-cyclopentyl-4-hydroxy-5-[(1-methyl-1H-indol-5-yl)methyl]-6-oxo-3,6-dihydro-2/-/-pyran-
2-yl}ethyl)-2-fluorophenyl]-2-methylpropanenitrile; 6-Cyclopentyl-3-(5,7-dimethyl-t1,2,4]triazolo[1,5-a]pyrimidin-2-ylmethyl)-6-[2-(3-ethyl-4-methoxy- phenyl)-ethyl]-4-hydroxy-5,6-dihydro-pyran-2-one;
6-[2-(5-chloro-2,4-dimethoxyphenyl)ethyl]-3-[(5-chloro-1-methyl-1H-benzimidazol-2-yl)thio]-6- cyclopentyl-4-hydroxy-5,6-dihydro-2H-pyran-2-one;
6-cyclopentyl-3-t(5,7-dimethyl[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-6-[2-(3-fluoro-4- isopropoxyphenyl)ethyl]-4-hydroxy-5,6-dihydro-2H-pyran-2-one;
(+)-2-(2-fluoro-4-{2-[2-cyclopentyl-5-(5,7-dimethyl-[1,2,4]triazolo[1 ,5-a]pyrimidin-2-ylmethyl)-4- hydroxy-6-oxo-3,6-dihydro-2/-/-pyran-2-yl]-ethyl}-phenyl)-2-methyl-propionitriIe;
(-)-2-(2-fluoro-4-{2-[2-cyclopentyl-5-(5,7-dimethyl-[1,2,4]triazolo[1 ,5-a]pyrimidin-2-ylmethyl)-4- hydroxy-6-oxo-3,6-dihydro-2H-pyran-2-yl]-ethyl}-phenyl)-2-methyl-propionitrile;
(+)-2-(2-chloro-4-{2-[2-cyclopentyl-5-(5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-ylmethyl)-4- hydroxy-6-oxo-3,6-dihydro-2H-pyran-2-yl]-ethyl}-phenyl)-2-methyl-propionitrile;
(-)-2-(2-chloro-4-{2-t2-cyclopentyl-5-(5,7-dimethyl-[1,2,4]triazolo[1 ,5-a]pyrimidin-2-ylmethyl)-4- hydroxy-6-oxo-3,6-dihydro-2/-/-pyran-2-yl]-ethyl}-phenyl)-2-methyl-propionitrile;
(+)-3-[(6-chloro[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-6-cyclopentyl-6-[2-(5-ethyl-4-hydroxy-2- methoxyphenyl)ethyl]-4-hydroxy-5,6-dihydro-2H-pyran-2-one; );
(-)-3-[(6-chloro[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-6-cyclopentyl-6-[2-(5-ethyl-4-hydroxy-2- methoxyphenyl)ethyl]-4-hydroxy-5,6-dihydro-2H-pyran-2-one; and pharmaceutically acceptable salts, solvates and prodrugs thereof.
6. A compound of formula (4),
Figure imgf000524_0001
wherein:
R1 is cyclopentyl; R3 is -(CR8R9)t(C6-C10 aryl) or -(CR8R9)t(4-10 membered heterocyclic), wherein t is an integer from 0 to 5, and the aryl and heterocyclic moieties of said R3 groups are optionally substituted by 1 to 5 R4 groups; each R4 is independently chosen from halo, C C10 alkyl, and R6-0-, and each C Cι0 alkyl may be optionally substituted by at least one substituent chosen from halo, trifluoromethyl, trifluoromethoxy, Cι-C 0 alkyl, and cyano;
R6 is hydrogen or CrC10 alkyl;
R8 and R9 are independently chosen from hydrogen and C C10 alkyl; z is an integer from 1 to 5; and y is an integer from 0 to 5.
7. A compound according to claim 6, wherein:
R3 is -(CH2)t([1,2,4]triazolo[1l5-a]pyrimidyl), optionally substituted by 1 to 3 R4 groups; and t is an integer from 1-3.
8. A compound of formula (5),
Figure imgf000525_0001
wherein: R4a, R4 , and R4c are independently chosen from halo and CrC10 alkyl;
R d, R4e, and R4f are independently chosen from halo, R6-0-, and Cι-C10 alkyl, wherein said C Cιo alkyl is optionally substituted with at least one substituent chosen from halo and cyano; and
R6 is C C10 alkyl or hydrogen.
9. A compound of formula (6),
Figure imgf000526_0001
wherein R is halo
10. A compound according to claim 9, wherein R is chosen from fluoro and chloro
11. A compound of formula (9),
Figure imgf000526_0002
wherein:
R ■>4a is halo or C C 0 alkyl; R R ,, RR440c,, aanndd RR44dd aarree iinnddeependently chosen from CrC10 alkyl and R6-0-; and R6 is hydrogen or methyl.
12. A compound according to claim 11 , wherein: R4a is fluorine or chlorine; R4b is -OCH3; R4c is -OH; and R4d is -CH2CH3.
13. A method of inhibiting Hepatitis C virus in a mammal, comprising administering to the mammal a Hepatitis C virus-inhibiting amount of a compound according to any one of claims 1- 12.
14. A method of inhibiting Hepatitis C virus polymerase, comprising contacting said polymerase with a Hepatitis C virus polymerase-inhibiting amount of a compound according to any one of claims 1-12.
15. A medicament, comprising an effective amount of a compound according to any one of claims 1-12 and a pharmaceutically acceptable carrier.
PCT/IB2004/000493 2003-02-21 2004-02-09 Inhibitors of hepatitis c virus rna-dependent rna polymerase, and compositions and treatments using the same WO2004074270A2 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
EP04709301A EP1597246A2 (en) 2003-02-21 2004-02-09 Inhibitors of hepatitis c virus rna-dependent rna polymerase, and compositions and treatments using the same
JP2006502472A JP3940430B2 (en) 2003-02-21 2004-02-09 Hepatitis C virus RNA-dependent RNA polymerase inhibitor and compositions and treatments using the same
BR0407699-0A BRPI0407699A (en) 2003-02-21 2004-02-09 Hepatitis C virus-dependent rna polymerase inhibitors and compositions and treatments using them
CA002516235A CA2516235A1 (en) 2003-02-21 2004-02-09 Inhibitors of hepatitis c virus rna-dependent rna polymerase, and compositions and treatments using the same
MXPA05007133A MXPA05007133A (en) 2003-02-21 2004-02-09 Inhibitors of hepatitis c virus rna-dependent rna polymerase, and compositions and treatments using the same.
AU2004213247A AU2004213247A1 (en) 2003-02-21 2004-02-09 Inhibitors of Hepatitis C virus RNA-dependent rna polymerase, and compositions and treatments using the same
IS7896A IS7896A (en) 2003-02-21 2005-06-16 Hepatitis C virus ribosuric acid-dependent ribosuric acid conjugation enzymes, and the combinations and treatments that use them.

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US44908803P 2003-02-21 2003-02-21
US60/449,088 2003-02-21
US47235503P 2003-05-20 2003-05-20
US60/472,355 2003-05-20

Publications (3)

Publication Number Publication Date
WO2004074270A2 true WO2004074270A2 (en) 2004-09-02
WO2004074270A3 WO2004074270A3 (en) 2004-12-23
WO2004074270B1 WO2004074270B1 (en) 2005-03-17

Family

ID=32912318

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2004/000493 WO2004074270A2 (en) 2003-02-21 2004-02-09 Inhibitors of hepatitis c virus rna-dependent rna polymerase, and compositions and treatments using the same

Country Status (15)

Country Link
US (3) US7148226B2 (en)
EP (1) EP1597246A2 (en)
JP (1) JP3940430B2 (en)
AR (1) AR044749A1 (en)
AU (1) AU2004213247A1 (en)
BR (1) BRPI0407699A (en)
CA (1) CA2516235A1 (en)
IS (1) IS7896A (en)
MX (1) MXPA05007133A (en)
NL (1) NL1025544C2 (en)
PA (1) PA8596001A1 (en)
PE (1) PE20050289A1 (en)
TW (1) TW200426143A (en)
UY (1) UY28192A1 (en)
WO (1) WO2004074270A2 (en)

Cited By (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006018725A1 (en) * 2004-08-18 2006-02-23 Pfizer Inc. Inhibitors of hepatitis c virus rna-dependent rna polymerase, and compositions and treatments using the same
WO2006097817A1 (en) 2005-03-17 2006-09-21 Pfizer Japan Inc. N- (n-sulfonylaminomethyl) cyclopropanecarboxamide derivatives useful for the treatment of pain
WO2006120252A2 (en) * 2005-05-12 2006-11-16 Tibotec Pharmaceuticals Ltd. Pyrido[2,3-d]pyrimidines useful as hcv inhibitors, and methods for the preparation thereof
WO2007010350A1 (en) * 2005-07-19 2007-01-25 Pfizer Products Inc. Synthesis of therapeutic diphenyl ethers
WO2007128086A2 (en) * 2006-05-05 2007-11-15 Katholieke Universiteit Leuven Novel viral replication inhibitor
WO2009023179A2 (en) * 2007-08-10 2009-02-19 Genelabs Technologies, Inc. Nitrogen containing bicyclic chemical entities for treating viral infections
WO2010018131A1 (en) 2008-08-11 2010-02-18 Smithkline Beecham Corporation Purine derivatives for use in the treatment of allergic, inflammatory and infectious diseases
US7977342B2 (en) 2004-09-30 2011-07-12 Tibotec-Virco Virology Bvba HCV inhibiting bi-cyclic pyrimidines
WO2011098451A1 (en) 2010-02-10 2011-08-18 Glaxosmithkline Llc Purine derivatives and their pharmaceutical uses
WO2011098452A1 (en) 2010-02-10 2011-08-18 Glaxosmithkline Llc 6-amino-2-{ [ (1s)-1-methylbutyl] oxy}-9-[5-(1-piperidinyl)-7,9-dihydro-8h-purin-8-one maleate
US8030318B2 (en) 2005-03-25 2011-10-04 Tibotec Pharmaceuticals Ltd. Fused bicyclic inhibitors of HCV
EP2494991A1 (en) 2007-05-04 2012-09-05 Vertex Pharmaceuticals Incorporated Combination therapy for the treatment of HCV infection
WO2013004551A1 (en) 2011-07-01 2013-01-10 Bayer Intellectual Property Gmbh Hydroxymethylaryl-substituted pyrrolotriazines as alk1 inhibitors
WO2013175397A1 (en) 2012-05-22 2013-11-28 Actelion Pharmaceuticals Ltd New process for the preparation of 2-cyclopentyl-6-methoxy-isonicotinic acid
WO2015052226A1 (en) * 2013-10-11 2015-04-16 F. Hoffmann-La Roche Ag Thiazolopyrimidinones as modulators of nmda receptor activity
US9090671B2 (en) 2008-06-06 2015-07-28 Scynexis, Inc. Macrocyclic peptides
WO2015124591A1 (en) 2014-02-20 2015-08-27 Glaxosmithkline Intellectual Property (No.2) Limited Pyrrolo[3,2] pyrimidine derivatives as inducers of human interferon
US9290502B2 (en) 2005-05-12 2016-03-22 Janssen Sciences Ireland Uc Pteridines useful as HCV inhibitors and methods for the preparation thereof
EP3000813A1 (en) 2008-08-11 2016-03-30 GlaxoSmithKline LLC Purine derivatives for use in the treatment of allergic, inflammatory and infectious diseases
WO2016075661A1 (en) 2014-11-13 2016-05-19 Glaxosmithkline Biologicals Sa Adenine derivatives which are useful in the treatment of allergic diseases or other inflammatory conditions
WO2017055147A1 (en) 2015-09-28 2017-04-06 Syngenta Participations Ag Pesticidally active heterocyclic derivatives with sulphur containing substituents
WO2017093933A1 (en) 2015-12-03 2017-06-08 Glaxosmithkline Intellectual Property Development Limited Cyclic purine dinucleotides as modulators of sting
WO2017175147A1 (en) 2016-04-07 2017-10-12 Glaxosmithkline Intellectual Property Development Limited Heterocyclic amides useful as protein modulators
WO2017175156A1 (en) 2016-04-07 2017-10-12 Glaxosmithkline Intellectual Property Development Limited Heterocyclic amides useful as protein modulators
EP3246030A1 (en) 2008-08-11 2017-11-22 GlaxoSmithKline LLC Novel adenine derivatives
WO2019069270A1 (en) 2017-10-05 2019-04-11 Glaxosmithkline Intellectual Property Development Limited Modulators of stimulator of interferon genes (sting)
WO2019069269A1 (en) 2017-10-05 2019-04-11 Glaxosmithkline Intellectual Property Development Limited Modulators of stimulator of interferon genes (sting) useful in treating hiv
US10280165B2 (en) 2015-04-15 2019-05-07 Genentech, Inc. Pyridopyrimidinones and methods of use thereof
WO2019152911A1 (en) 2018-02-02 2019-08-08 Steven Albert Everett Novel small molecule drug conjugates of gemcitabine derivatives
WO2019152955A1 (en) 2018-02-02 2019-08-08 Steven Albert Everett Small molecule drug conjugates of gemcitabine monophosphate
WO2019219820A1 (en) 2018-05-16 2019-11-21 Ctxt Pty Limited Substituted condensed thiophenes as modulators of sting
US10588894B2 (en) 2017-06-21 2020-03-17 SHY Therapeutics LLC Compounds that interact with the Ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease
WO2020232378A1 (en) 2019-05-16 2020-11-19 Silicon Swat, Inc. Benzo[b][1,8]naphthyridine acetic acid derivatives and methods of use
WO2020232375A1 (en) 2019-05-16 2020-11-19 Silicon Swat, Inc. Oxoacridinyl acetic acid derivatives and methods of use
US10870657B2 (en) 2015-12-22 2020-12-22 SHY Therapeutics LLC Compounds for the treatment of cancer and inflammatory disease
WO2021009365A1 (en) 2019-07-18 2021-01-21 Ctxt Pty Limited Benzothiophene, thienopyridine and thienopyrimidine derivatives for the modulation of sting
WO2021009362A1 (en) 2019-07-18 2021-01-21 Ctxt Pty Limited Benzothiophene, thienopyridine and thienopyrimidine derivatives for the modulation of sting
WO2024028169A1 (en) 2022-08-01 2024-02-08 Nerviano Medical Sciences S.R.L. Novel specifically substituted thiophenolic compounds

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1485093B1 (en) * 2002-03-12 2010-11-03 Merck Sharp & Dohme Corp. Di-aryl substituted tetrazole modulators of metabotropic glutamate receptor-5
NZ527142A (en) 2003-07-23 2006-03-31 Douglas Pharmaceuticals Ltd A stable suspension formulation
US7807838B2 (en) * 2005-08-24 2010-10-05 Pfizer Inc. Methods for the preparation of HCV polymerase inhibitors
WO2007035816A2 (en) * 2005-09-20 2007-03-29 Dr. Reddy's Laboratories Ltd. Paroxetine compositions
CN101711174A (en) 2007-05-04 2010-05-19 卡迪欧梅制药公司 Controlled release oral formulations of ion channel modulating compounds and related methods for preventing arrhythmia
RU2571662C2 (en) 2009-03-25 2015-12-20 Эббви Инк. Antiretroviral compounds and use thereof
US8957254B2 (en) 2009-07-06 2015-02-17 Solvay Sa Process for chemical synthesis from an alkenone made from a halogenated precursor
WO2011159920A1 (en) * 2010-06-17 2011-12-22 Concert Pharmaceuticals, Inc. [5,6]-dihydro-2h-pyran-2-one derivatives
JP6250394B2 (en) 2010-08-19 2017-12-20 バック・インスティテュート・フォー・リサーチ・オン・エイジング Method for treating mild cognitive impairment (MCI) and related disorders
CN114105745A (en) * 2020-08-28 2022-03-01 广东东阳光药业有限公司 Siponimod intermediate and preparation method thereof
CN114234210A (en) * 2021-12-23 2022-03-25 南通万达锅炉有限公司 Petrochemical waste liquid integration incineration boiler
CN115784977A (en) * 2023-02-06 2023-03-14 淄博新农基作物科学有限公司 Synthesis process of 2-chloro-3-trifluoromethylpyridine

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5840751A (en) * 1993-11-19 1998-11-24 Warner-Lambert Company 5,6-dihydropyrone derivatives as protease inhibitors and antiviral agents
WO2000015634A2 (en) * 1998-09-11 2000-03-23 Warner-Lambert Company Hiv protease inhibitors
EP1256628A2 (en) * 2001-05-10 2002-11-13 Agouron Pharmaceuticals, Inc. Hepatitis c virus (hcv) ns5b rna polymerase and mutants thereof
WO2003095441A1 (en) * 2002-05-10 2003-11-20 Pfizer Inc. Inhibitors of hepatitis c virus rna-dependent rna polymerase, and compositions and treatments using the same

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3786063A (en) 1971-05-24 1974-01-15 Universal Oil Prod Co Thiazolethiosulfonates
US3904667A (en) * 1972-04-06 1975-09-09 Du Pont 4-Halo-2,5-dialkyl-benzeneacetonitriles
CA1140049A (en) 1977-12-22 1983-01-25 Dke J.E. Helgstran Pharmaceutical preparations from derivatives of hydroxycarbonylphosphonic acid
US4326058A (en) 1979-02-05 1982-04-20 Sumitomo Chemical Company, Limited Organo-phosphoric esters and their production and use
US4489077A (en) 1983-03-23 1984-12-18 Warner-Lambert Company 3-Isoxa-zolyl-2H-1,2-benzothiazine-3-carboxamide, 1,1-dioxides
US6174868B1 (en) 1992-09-10 2001-01-16 Isis Pharmaceuticals, Inc. Compositions and methods for treatment of hepatitis C virus-associated diseases
US5846964A (en) 1993-07-19 1998-12-08 Tokyo Tanabe Company Limited Hepatitis C virus proliferation inhibitor
CA2176041A1 (en) 1993-11-19 1995-05-26 Edmund Lee Ellsworth 5,6-dihydropyrone derivatives as protease inhibitors and antiviral agents
AU689158B2 (en) 1993-11-19 1998-03-26 Parke, Davis & Company 5,6-dihydropyrone derivatives as protease inhibitors and antiviral agents
US5504104A (en) 1993-11-19 1996-04-02 Warner-Lambert Company Tricyclic pyrone derivatives as protease inhibitors and antiviral agents
US6005103A (en) 1993-11-19 1999-12-21 Warner-Lambert Company Pyrone derivatives as protease inhibitors and antiviral agents
US5834506A (en) 1996-11-01 1998-11-10 Warner-Lambert Company Dihydropyrones with improved antiviral activity
DE19933767B4 (en) 1999-07-19 2013-10-31 Volkswagen Ag Fastening arrangement for a windshield wiper system on a vehicle body
US6512006B1 (en) 1999-12-09 2003-01-28 Warner-Lambert Company HIV protease inhibitors
ATE337309T1 (en) * 2002-04-01 2006-09-15 Pfizer PYRANONE AND PYRANDIONE INHIBITORS OF THE RNA-DEPENDENT RNA POLYMERASE OF THE HEPATITIS C VIRUS

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5840751A (en) * 1993-11-19 1998-11-24 Warner-Lambert Company 5,6-dihydropyrone derivatives as protease inhibitors and antiviral agents
WO2000015634A2 (en) * 1998-09-11 2000-03-23 Warner-Lambert Company Hiv protease inhibitors
EP1256628A2 (en) * 2001-05-10 2002-11-13 Agouron Pharmaceuticals, Inc. Hepatitis c virus (hcv) ns5b rna polymerase and mutants thereof
WO2003095441A1 (en) * 2002-05-10 2003-11-20 Pfizer Inc. Inhibitors of hepatitis c virus rna-dependent rna polymerase, and compositions and treatments using the same

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
F.E. BOYER ET. AL.: "5,6-Dihydropyran-2-ones Possessing Various Sulfonyl Functionalitites: Potent Nonpeptidic Inhibitors of HIV Protease." JOURNAL OF MEDICINAL CHEMISTRY, vol. 43, no. 5, 2000, pages 843-58, XP002250770 *
J.V.N. VARA PRASAD ET. AL.: "Nonpeptidic HIV protease inhibitors. 6-Alkyl-5,6-dihydropyran-2-ones possessing achiral 3-(4-amino/carboxamide-2-t-butyl, 5-methylphenylthio) moiety. Antiviral activities and pharmacokinetic properties." BIOORGANIC AND MEDICINAL CHEMISTRY LETTERS, 1999, pages 1481-6, XP004169615 *

Cited By (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7622605B2 (en) 2004-08-18 2009-11-24 Pfizer Inc. Inhibitors of hepatitis C virus RNA-dependent RNA polymerase, and compositions and treatments using the same
KR100851178B1 (en) * 2004-08-18 2008-08-08 화이자 인코포레이티드 Inhibitors of hepatitis c virus rna-dependent rna polymerase, and compositions and treatments using the same
US7151105B2 (en) 2004-08-18 2006-12-19 Agouron Pharmaceuticals, Inc. Inhibitors of Hepatitis C virus RNA-dependent RNA polymerase, and compositions and treatments using the same
WO2006018725A1 (en) * 2004-08-18 2006-02-23 Pfizer Inc. Inhibitors of hepatitis c virus rna-dependent rna polymerase, and compositions and treatments using the same
AP2313A (en) * 2004-08-18 2011-10-31 Pfizer Inhibitors of hepatitis C virus RNA-dependent RNA ploymerase, and compositions and treatments using the same.
EA012605B1 (en) * 2004-08-18 2009-10-30 Пфайзер Инк. Inhibitors of hepatitis c virus rna-dependent rna polymerase, and compositions and methods for treatment using the same
US7977342B2 (en) 2004-09-30 2011-07-12 Tibotec-Virco Virology Bvba HCV inhibiting bi-cyclic pyrimidines
WO2006097817A1 (en) 2005-03-17 2006-09-21 Pfizer Japan Inc. N- (n-sulfonylaminomethyl) cyclopropanecarboxamide derivatives useful for the treatment of pain
US8030318B2 (en) 2005-03-25 2011-10-04 Tibotec Pharmaceuticals Ltd. Fused bicyclic inhibitors of HCV
WO2006120252A2 (en) * 2005-05-12 2006-11-16 Tibotec Pharmaceuticals Ltd. Pyrido[2,3-d]pyrimidines useful as hcv inhibitors, and methods for the preparation thereof
US9708328B2 (en) 2005-05-12 2017-07-18 Janssen Sciences Ireland Uc Pteridines useful as HCV inhibitors and methods for the preparation thereof
WO2006120252A3 (en) * 2005-05-12 2007-02-22 Tibotec Pharm Ltd Pyrido[2,3-d]pyrimidines useful as hcv inhibitors, and methods for the preparation thereof
US9290502B2 (en) 2005-05-12 2016-03-22 Janssen Sciences Ireland Uc Pteridines useful as HCV inhibitors and methods for the preparation thereof
US8022077B2 (en) 2005-05-12 2011-09-20 Tibotec Pharmaceuticals Ltd. Pyrido[2,3-d]pyrimidines useful as HCV inhibitors, and methods for the preparation thereof
US9951075B2 (en) 2005-05-12 2018-04-24 Janssen Sciences Ireland Uc Pteridines useful as HCV inhibitors and methods for the preparation thereof
WO2007010350A1 (en) * 2005-07-19 2007-01-25 Pfizer Products Inc. Synthesis of therapeutic diphenyl ethers
WO2007128086A3 (en) * 2006-05-05 2008-01-24 Univ Leuven Kath Novel viral replication inhibitor
WO2007128086A2 (en) * 2006-05-05 2007-11-15 Katholieke Universiteit Leuven Novel viral replication inhibitor
EP2494991A1 (en) 2007-05-04 2012-09-05 Vertex Pharmaceuticals Incorporated Combination therapy for the treatment of HCV infection
WO2009023179A2 (en) * 2007-08-10 2009-02-19 Genelabs Technologies, Inc. Nitrogen containing bicyclic chemical entities for treating viral infections
WO2009023179A3 (en) * 2007-08-10 2009-08-06 Genelabs Tech Inc Nitrogen containing bicyclic chemical entities for treating viral infections
US9090671B2 (en) 2008-06-06 2015-07-28 Scynexis, Inc. Macrocyclic peptides
EP3246030A1 (en) 2008-08-11 2017-11-22 GlaxoSmithKline LLC Novel adenine derivatives
WO2010018131A1 (en) 2008-08-11 2010-02-18 Smithkline Beecham Corporation Purine derivatives for use in the treatment of allergic, inflammatory and infectious diseases
EP3000813A1 (en) 2008-08-11 2016-03-30 GlaxoSmithKline LLC Purine derivatives for use in the treatment of allergic, inflammatory and infectious diseases
WO2011098451A1 (en) 2010-02-10 2011-08-18 Glaxosmithkline Llc Purine derivatives and their pharmaceutical uses
WO2011098452A1 (en) 2010-02-10 2011-08-18 Glaxosmithkline Llc 6-amino-2-{ [ (1s)-1-methylbutyl] oxy}-9-[5-(1-piperidinyl)-7,9-dihydro-8h-purin-8-one maleate
WO2013004551A1 (en) 2011-07-01 2013-01-10 Bayer Intellectual Property Gmbh Hydroxymethylaryl-substituted pyrrolotriazines as alk1 inhibitors
WO2013175397A1 (en) 2012-05-22 2013-11-28 Actelion Pharmaceuticals Ltd New process for the preparation of 2-cyclopentyl-6-methoxy-isonicotinic acid
WO2015052226A1 (en) * 2013-10-11 2015-04-16 F. Hoffmann-La Roche Ag Thiazolopyrimidinones as modulators of nmda receptor activity
US10647731B2 (en) 2013-10-11 2020-05-12 Genentech, Inc. Thiazolopyrimidinones and methods of use thereof
RU2703273C2 (en) * 2013-10-11 2019-10-16 Ф. Хоффманн-Ля Рош Аг Thiazolopyrimidinones as modulators of nmda receptor activity
EP3415519A1 (en) * 2013-10-11 2018-12-19 F. Hoffmann-La Roche AG Thiazolopyrimidinones as modulators of nmda receptor activity
US9988400B2 (en) 2013-10-11 2018-06-05 Genentech, Inc. Thiazolopyrimidinones and methods of use thereof
CN105612162A (en) * 2013-10-11 2016-05-25 豪夫迈·罗氏有限公司 Thiazolopyrimidinones as modulators of NMDA receptor activity
WO2015124591A1 (en) 2014-02-20 2015-08-27 Glaxosmithkline Intellectual Property (No.2) Limited Pyrrolo[3,2] pyrimidine derivatives as inducers of human interferon
WO2016075661A1 (en) 2014-11-13 2016-05-19 Glaxosmithkline Biologicals Sa Adenine derivatives which are useful in the treatment of allergic diseases or other inflammatory conditions
US10280165B2 (en) 2015-04-15 2019-05-07 Genentech, Inc. Pyridopyrimidinones and methods of use thereof
WO2017055147A1 (en) 2015-09-28 2017-04-06 Syngenta Participations Ag Pesticidally active heterocyclic derivatives with sulphur containing substituents
WO2017093933A1 (en) 2015-12-03 2017-06-08 Glaxosmithkline Intellectual Property Development Limited Cyclic purine dinucleotides as modulators of sting
EP3366691A1 (en) 2015-12-03 2018-08-29 GlaxoSmithKline Intellectual Property Development Limited Cyclic purine dinucleotides as modulators of sting
US11560390B2 (en) 2015-12-22 2023-01-24 SHY Therapeutics LLC Compounds for the treatment of cancer and inflammatory disease
US10870657B2 (en) 2015-12-22 2020-12-22 SHY Therapeutics LLC Compounds for the treatment of cancer and inflammatory disease
EP4032885A1 (en) 2016-04-07 2022-07-27 GlaxoSmithKline Intellectual Property Development Limited Heterocyclic amides useful as protein modulators
WO2017175147A1 (en) 2016-04-07 2017-10-12 Glaxosmithkline Intellectual Property Development Limited Heterocyclic amides useful as protein modulators
WO2017175156A1 (en) 2016-04-07 2017-10-12 Glaxosmithkline Intellectual Property Development Limited Heterocyclic amides useful as protein modulators
US11541041B1 (en) 2017-06-21 2023-01-03 SHY Therapeutics LLC Compounds that interact with the Ras superfamily for the treatment of cancers, inflammatory diseases, Rasopathies, and fibrotic disease
US10588894B2 (en) 2017-06-21 2020-03-17 SHY Therapeutics LLC Compounds that interact with the Ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease
US11026930B1 (en) 2017-06-21 2021-06-08 SHY Therapeutics LLC Compounds that interact with the Ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease
US11213515B1 (en) 2017-06-21 2022-01-04 SHY Therapeutics LLC Compounds that interact with the Ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease
US10933054B2 (en) 2017-06-21 2021-03-02 SHY Therapeutics LLC Compounds that interact with the Ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease
US10940139B2 (en) 2017-06-21 2021-03-09 SHY Therapeutics LLC Compounds that interact with the Ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease
US11000515B2 (en) 2017-06-21 2021-05-11 SHY Therapeutics LLC Compounds that interact with the Ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease
WO2019069270A1 (en) 2017-10-05 2019-04-11 Glaxosmithkline Intellectual Property Development Limited Modulators of stimulator of interferon genes (sting)
WO2019069269A1 (en) 2017-10-05 2019-04-11 Glaxosmithkline Intellectual Property Development Limited Modulators of stimulator of interferon genes (sting) useful in treating hiv
WO2019152911A1 (en) 2018-02-02 2019-08-08 Steven Albert Everett Novel small molecule drug conjugates of gemcitabine derivatives
WO2019152955A1 (en) 2018-02-02 2019-08-08 Steven Albert Everett Small molecule drug conjugates of gemcitabine monophosphate
WO2019219820A1 (en) 2018-05-16 2019-11-21 Ctxt Pty Limited Substituted condensed thiophenes as modulators of sting
US11613525B2 (en) 2018-05-16 2023-03-28 Ctxt Pty Limited Substituted condensed thiophenes as modulators of sting
WO2020232375A1 (en) 2019-05-16 2020-11-19 Silicon Swat, Inc. Oxoacridinyl acetic acid derivatives and methods of use
WO2020232378A1 (en) 2019-05-16 2020-11-19 Silicon Swat, Inc. Benzo[b][1,8]naphthyridine acetic acid derivatives and methods of use
WO2021009362A1 (en) 2019-07-18 2021-01-21 Ctxt Pty Limited Benzothiophene, thienopyridine and thienopyrimidine derivatives for the modulation of sting
WO2021009365A1 (en) 2019-07-18 2021-01-21 Ctxt Pty Limited Benzothiophene, thienopyridine and thienopyrimidine derivatives for the modulation of sting
WO2024028169A1 (en) 2022-08-01 2024-02-08 Nerviano Medical Sciences S.R.L. Novel specifically substituted thiophenolic compounds

Also Published As

Publication number Publication date
AR044749A1 (en) 2005-10-05
IS7896A (en) 2005-06-16
NL1025544A1 (en) 2004-08-24
US20040224960A1 (en) 2004-11-11
US20060189681A1 (en) 2006-08-24
BRPI0407699A (en) 2006-02-07
WO2004074270A3 (en) 2004-12-23
US7473790B2 (en) 2009-01-06
AU2004213247A1 (en) 2004-09-02
PE20050289A1 (en) 2005-04-29
US7148226B2 (en) 2006-12-12
PA8596001A1 (en) 2004-09-16
MXPA05007133A (en) 2005-08-29
JP3940430B2 (en) 2007-07-04
WO2004074270B1 (en) 2005-03-17
CA2516235A1 (en) 2004-09-02
JP2006518370A (en) 2006-08-10
UY28192A1 (en) 2004-09-30
TW200426143A (en) 2004-12-01
EP1597246A2 (en) 2005-11-23
NL1025544C2 (en) 2006-05-09
US20050176701A1 (en) 2005-08-11

Similar Documents

Publication Publication Date Title
US7473790B2 (en) Inhibitors of hepatitis C virus RNA-dependent RNA polymerase, and compositions and treatments using the same
AU2008213767B2 (en) [1,2,3] triazolyl substituted quinolines and coumarins as inhibitors of leukotriene biosynthesis
JP6422438B2 (en) 4-Heteroaryl-substituted benzoic acid compounds and their use as RORγT inhibitors
CA2600727C (en) Thiadiazole substituted coumarin derivatives and their use as leukotriene biosynthesis inhibitor
MX2007001129A (en) Compounds and compositions as modulators of steroid hormone nuclear receptors.
TWI808305B (en) Substituted bicyclic compounds as farnesoid x receptor modulators
US7115658B2 (en) Inhibitors of hepatitis C virus RNA-dependent RNA polymerase
EP3704106A1 (en) Alkene compounds as farnesoid x receptor modulators
AU2009201867A1 (en) Compounds and compositions as LXR modulators
EP1934205A1 (en) Substituted quinolines as inhibitors of leukotriene biosynthesis
JP7476216B2 (en) Substituted Bicyclic Compounds as Farnesoid X Receptor Modulators - Patent application
KR20210129119A (en) Substituted Amide Compounds Useful as Farnesoid X Receptor Modulators

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
B Later publication of amended claims

Effective date: 20041201

WWE Wipo information: entry into national phase

Ref document number: 2825/DELNP/2005

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 200505229

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: PA/a/2005/007133

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 2004213247

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 169969

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: P20050685A

Country of ref document: HR

WWE Wipo information: entry into national phase

Ref document number: 541646

Country of ref document: NZ

WWP Wipo information: published in national office

Ref document number: 2004213247

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2516235

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2006502472

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2004709301

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2004213247

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: 2004709301

Country of ref document: EP

ENP Entry into the national phase

Ref document number: PI0407699

Country of ref document: BR